<SEC-DOCUMENT>0000906709-22-000014.txt : 20220805
<SEC-HEADER>0000906709-22-000014.hdr.sgml : 20220805
<ACCEPTANCE-DATETIME>20220804213553
ACCESSION NUMBER:		0000906709-22-000014
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220805
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		221138386

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nktr-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:29a4b4dc-8cca-4a2c-8b00-1653a7b25685,g:4140688d-8727-4745-9ca5-400c87633167,d:140383c8fcb34877b7aa2512bcb00b00--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:nktr="http://www.nektar.com/20220630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nktr-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80L2ZyYWc6YmMyMGE0ZmEwYjVjNDdjM2EwZjllNzc1MDNjMjA2YjcvdGFibGU6NDg3NzZiNjk5Y2MxNDhkYTk5ODMzM2ExZWE3YTMxODcvdGFibGVyYW5nZTo0ODc3NmI2OTljYzE0OGRhOTk4MzMzYTFlYTdhMzE4N18yLTEtMS0xLTMwNTUy_80de16ce-8abf-435e-808c-8a22aff7ecbe">false</ix:nonNumeric><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80L2ZyYWc6YmMyMGE0ZmEwYjVjNDdjM2EwZjllNzc1MDNjMjA2YjcvdGFibGU6NDg3NzZiNjk5Y2MxNDhkYTk5ODMzM2ExZWE3YTMxODcvdGFibGVyYW5nZTo0ODc3NmI2OTljYzE0OGRhOTk4MzMzYTFlYTdhMzE4N180LTEtMS0xLTMwNTUy_c00ae5d7-f2df-45dc-99dc-9584dea2f118">2022</ix:nonNumeric><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80L2ZyYWc6YmMyMGE0ZmEwYjVjNDdjM2EwZjllNzc1MDNjMjA2YjcvdGFibGU6NDg3NzZiNjk5Y2MxNDhkYTk5ODMzM2ExZWE3YTMxODcvdGFibGVyYW5nZTo0ODc3NmI2OTljYzE0OGRhOTk4MzMzYTFlYTdhMzE4N181LTEtMS0xLTMwNTUy_5671b4d6-cfc7-4515-a253-4c62ac66f9a6">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80L2ZyYWc6YmMyMGE0ZmEwYjVjNDdjM2EwZjllNzc1MDNjMjA2YjcvdGFibGU6NDg3NzZiNjk5Y2MxNDhkYTk5ODMzM2ExZWE3YTMxODcvdGFibGVyYW5nZTo0ODc3NmI2OTljYzE0OGRhOTk4MzMzYTFlYTdhMzE4N184LTEtMS0xLTMwNTUy_0e06e235-4a21-4f75-8c51-fd9e18f9cd5c">0000906709</ix:nonNumeric><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80L2ZyYWc6YmMyMGE0ZmEwYjVjNDdjM2EwZjllNzc1MDNjMjA2YjcvdGFibGU6NDg3NzZiNjk5Y2MxNDhkYTk5ODMzM2ExZWE3YTMxODcvdGFibGVyYW5nZTo0ODc3NmI2OTljYzE0OGRhOTk4MzMzYTFlYTdhMzE4N185LTEtMS0xLTMwNTUy_4efc2c62-fb9c-4282-b390-0f58dda6f9f6">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ia518ccd858fb499086a0d1804fb52ded_D20220101-20220630" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTM5_574175bf-cc3f-4a3a-8666-7dacd922de94">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="id2f38983ece7482091edcf1be3b8181d_D20210101-20211231" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTM5_b6cfd8b2-81fb-4e7c-b623-4b4795c2fc57">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nktr-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e3b25b44f741e29bebfd8f823ae5ab_I20220729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5776247877d44fa1a76a034a60ca9a45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iab10c83366854752a16f76890719307a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i841d22063d474fa5b3b392a4925ca344_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id98ac0fa001e4daab8a52e2248b1146c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9530c36c4b448839ff7ef902cfd13dc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa02756dcbe4a1a871ce1cb0480648d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i957bd179292a4a5f8bea0ec87a04ddac_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e6059c3a6a244129de957ee89ff70fc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82df606601154dc1ad7096a861539bf7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51c7b009052b4c3db8cb98c20f670ac9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a6d564c98e44ea1bb8b4ec60494b8bb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134972093bfc48989eb2da3ed230985f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib60cd739b0c941a290a478c66b5d7ae8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c832ade51b45958d331545ae3e5dc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i207702fa8b624c6685cbfa6fc0824271_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e9a5d5deddf468b87ac44df66d21b86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93c37c43548a4597827bc1c98a494182_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec541b07f4024b509da17efe3def4f82_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19adf3d7365740b8858300248f7a335e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a50cc46191d4f39bb966fafeb0e21e3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icafc13b8f8e341f385a8e18d347395f3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa6f15b9c6c42eb988d570abd03ec38_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic71c4e96623541daac88b34839da139e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b44eabefa5748f3b2039c96188a4ea4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13345764e6d142fba76c8c33e9ce581f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id81e115f70424914b18921a48b6334c6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9463547a4e54c51a8dae165b31e8443_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d42324a1f854a268dd508881663f4b2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e5f79481a6422383f5010e8d560526_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c21ab7235041cd9295a6a01131a511_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia46078182c6d4bf9b8244c13bb5ada0c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id92ad17e88394b29b2c99010d4cfde2b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d89fcb27e2e40da9712016c38d184da_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0352e962dc144389a178d00a7ff496fb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c2e13b9ea7a4dcf8081838f1ac66a94_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bfcf4e2d4804d659adca4c109ad23d1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i332b83a475bf4c03a2f3b3c3d925e70a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6abdeb335de487c9793e2cad1674f4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e39b9fd4534db1890613d6cbab71a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida61f606d16e4a479dbd86a2a2078bcb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if034602e638345f8a92708bdd04f4ae4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a11ce6ef2f4211a0e058edcf0f297a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16f9f7814fe344ab965d049b1bf8498d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf30f1f3976425f9ae1a9658814d0a2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24276f68c0f648ce93afcce8e8ccb424_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b081e4b21eb44e3937cc738e930511a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i947f1c275a9b45f0a3c9254c3b4831ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d041e6febc8402f9919661245a523c4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47859d4a9c7d444ea3fc5298c02e72eb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021df6170fef4aa0940cfaf057de5391_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6863c3c60a704766bc19dbf81c2dcb5b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i741af916cbcf43e186ee1732ed353f02_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b2f1f3796c48159ef8f2ec154733e9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5340ad5b6f0045e68f5d19b34ed7b610_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db06ec5739d430ab6e1129243313c23_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93db7cc57e114d759dc91e2753b81b55_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e75a96d7ae4fb5941842c8f737bbc8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2b9522e14ad475e9d048da16aa5b505_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1443f9bb2a2a449b8e75120a43351e1e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6844748a7747471187efa284c70c9b40_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2fb960f7e2be4ba7b0f30d51ecbfb755_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8729a4959d1742a08e7c7a9e6181f0a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia518ccd858fb499086a0d1804fb52ded_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f38983ece7482091edcf1be3b8181d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66e409cb85994a9abd0992f91c81602e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b4fb75e85ef4d1da810d56d536e5949_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0737ddba317b4605a758d1342bb280e1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd6d6cf71b0b4e4cb1bd7a9a8a889eaa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63723a98759b4da988fffbbea0791b9d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f239069b834dec8cbd03936544ce8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5873fdec0d5484a8a91ad052ca94c7b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id98fd41da4fd448aa47ed43c6f62a705_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie76220fe2fa146ab81b848b799537428_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c9aa8ae8ab44df7bce7acd7e0dd79d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b0f9be97ef3499ea6911ba085621ae3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8ed5efbb1774febb2171044acdc2732_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice3a2c19d2b5444eaed3f904cc22980b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id459719606054ed78ab057269952a7b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i751eb150d22f4b73820c3eb0fdd04e8d_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b68ac442765412db42b3953906b0388_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95ace3aff3a44be7928b81e09398f163_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icde60c2bb5d4479b97cd2cd805d5a6bb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6ef03c0e8b845309927dbe4dfbda529_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a1586d1667c4181ab22d8c15f8e9bca_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21c1fe452b344cea3b108885a4d4a8b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57c770143f6e43cc8285c4e87e608f39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec257d9c2a4f4ca29ba184473f2f37bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id755a03fdc2b4e99b02634a338a1d47e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fd48c3f03db4bea80b8a4775bd85320_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c3682511cdc470e8b31f4be9255bc51_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ffcae4931614a41b546c5604b6e9e1a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07faaf6c80274e79b161089c13725a99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80ddb5385d944743a6830e905272b6dc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if11fbbe66ec44a33844d1df024a81f34_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f61ce40f5741b1bd39e0dce462d66f_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i434d1fce8cc349169ce2249b32af62e5_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b4e6c90ab19450e859fb50421c353c0_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i689d7549c612490aa4442f5f5348ccf0_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4bfcb6279024241948e7bd08d4d1b15_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie055df71b6fe4ad78a3fae8b679f8f1b_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5048bfc963648bd9dd0de98c3c9f77f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i545e1ec1c15e497d8d84331994a8de35_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cb09da3230846e4ab889acaf256b09a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a74c1627d594a4e9983b68d9cb5016a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55a25cbb90084904aaa526c771ddf88f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2710a7259237431b952f8e9e2f6ca813_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b66ce62bc84a1e8198557985db717e_D20170723-20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-23</xbrli:startDate><xbrli:endDate>2017-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i709e2f46181a4b05a3abc2e27c2e31e3_I20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ed1fb4aeaf4781a0044453513572b1_D20170723-20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-23</xbrli:startDate><xbrli:endDate>2017-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c14708c9dc14478a8d5ecaefcbb0ee5_D20170723-20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-23</xbrli:startDate><xbrli:endDate>2017-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60d7ddcd1e843edacbce13b2a891386_D20170723-20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-23</xbrli:startDate><xbrli:endDate>2017-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e937e61c4a04a74b304ed91d94164d3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i615612becd454568aed79f306f2b522e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>nktr:employee</xbrli:measure></xbrli:unit><xbrli:context id="ic87a58d05dff437199600e83c801a439_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2f06c20fdeb4692aecab09bd5ba73dc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac52ca5498ce49769a17fcd39f41a8fe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30a2d694cc3e4307a91fcd4094b87e05_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3a1676fb6a54c20884fa6fd60c2e2c7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26bb03096c94a0cb77035930f749cab_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0541e02c0b140788f808cb99a415cce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaeb6b4f62ff443a849137f15836e9cf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce6c1dda32f4aad9544682d143fc875_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i497fa308a3a645399b2e66b525053f40_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1540676709064b73bec30295a78b402b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a99a4cd3e9046998329b115338a1fcf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbf30fbd9d0b453c90b68fbde9485002_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d93efed2f4445efbb3ddeb1f2270dee_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575b5f648bf14d37af112b07599ee280_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90314768134649a19db482bb55a94126_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic166b3669ca64e7781374dbce5ce7ae2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79e0f4b9899445bfb9f7c130223aa7e0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib642b7862a8f41ebaf418619e6c1e3a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73b2d39f16fe45808af4224f9bb7e64a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cdb1245c2a242b295b7228ac4ac5bfd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278bdb80843a4d15829b02b5f7e5db58_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4699c5afe4c64c4dab6ccd99e97a4420_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1e3d5e8c9da41acba432436d90e144e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2392ef5c8b944214b18e26ee24b8b8f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i597b24d94a354403bcb197617d6325c3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcf4331b31d34c4b8595b0bf92ffe39c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13e1155ab7ba47dfa1bb5c48d087629a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie29cf24f92e945298307779be936b4b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0c160117d32471bba70bb96f864292d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3143ddecf7734d3da635d16bd5e504a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8529e0af2b847e992427d335aa69816_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ecfd9df5834d09abbc58af261ebf32_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c21bdadf59b4c48a135191cd5c2ec54_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27d1141edbfe4feb8e6950e0879e5c18_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb0b12b5faa4aaba9bdc2b06745202f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6659ab393074492bbe414ddb56231ee4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecfbea4ad565429885a50c6fba0cc5b8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cecbd4c604b48409676aa9a35884b89_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34088cc50d6948ccbe3650a776356dc9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3fe74ae0994a9b8a3cb73f23feba72_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib91712b5e54b4334b079f6d3036b9a32_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f2c5502b65c4bc38990dea8219187f9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id493f1b7c27c408ea3daa0171ccfbdbd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa4c735c57bc4b3cbe3c2e99a3d9895e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34db7c40bdc449ff8d949f1f5970651c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58da4c5a8eb049b2ae0fe612bc3870d4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9af591eefe4df68e2c4f1f5bd76bca_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e718894f1c9465093719bbd74467c63_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9172d4dea5534ee5a60b8140527f533b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd2b36e57d474f11a75428893dd08b02_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5070c46f774b5ba4d6c3752a1c61f0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i140383c8fcb34877b7aa2512bcb00b00_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjU5_e27a9ff5-0d69-42cd-a929-3b8df74f4e56">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6YWEwNDczNTJlNjM0NGQyNWFlZjFlNTZmNjI5YjY3ZTgvdGFibGVyYW5nZTphYTA0NzM1MmU2MzQ0ZDI1YWVmMWU1NmY2MjliNjdlOF8wLTAtMS0xLTMwNTUy_b9232417-d1d1-4e3b-abd7-cdddee9016fb">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yNjY_c7eb90ce-f581-4e70-914a-466f5ff09587">June&#160;30, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6NzE1YWExMjNkZjYwNDAyYmI0ZWU5NDFmZmU0MzgzNWYvdGFibGVyYW5nZTo3MTVhYTEyM2RmNjA0MDJiYjRlZTk0MWZmZTQzODM1Zl8wLTAtMS0xLTMwNTUy_849aebed-99cc-4d10-ae44-539aa8d4a50b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjU2_3930c1e5-2dc1-4f89-98c9-cdb721a078a2">0-24006</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjYw_d831eb3d-a949-4cb9-b62f-ffacaaadc718">NEKTAR THERAPEUTICS</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.034%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6MDRlOGY4MzZjMjkxNDRkOGI4NTU5MGJkYzIzZjAzMTkvdGFibGVyYW5nZTowNGU4ZjgzNmMyOTE0NGQ4Yjg1NTkwYmRjMjNmMDMxOV8wLTAtMS0xLTMwNTUy_9408f402-20d4-4046-b0eb-d9996c61b4e5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6MDRlOGY4MzZjMjkxNDRkOGI4NTU5MGJkYzIzZjAzMTkvdGFibGVyYW5nZTowNGU4ZjgzNmMyOTE0NGQ4Yjg1NTkwYmRjMjNmMDMxOV8wLTItMS0xLTMwNTUy_cdfeccca-b11a-434a-9f68-473479c7bf95">94-3134940</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjU3_c6ad1ecc-23a5-44eb-a07c-0357fe674786">455 Mission Bay Boulevard South</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjYx_2cf5a1dd-4402-43c7-9cba-bca2031c43c7">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjYy_b3287541-fbff-4d41-8758-8ca626e2b9b1">California</ix:nonNumeric> <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjYz_697492f3-5fbc-4fdd-a400-4421cbdbc291">94158</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjY0_52189eae-acde-4278-9ba7-19672b6a494a">415</ix:nonNumeric>-<ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjY1_706587f4-a21d-429c-9cf5-d541e6335319">482-5300</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6M2YzYzg1YmExZjE0NDFiYzgzMzNkMTI2ZmQ0YTIwYTcvdGFibGVyYW5nZTozZjNjODViYTFmMTQ0MWJjODMzM2QxMjZmZDRhMjBhN18yLTAtMS0xLTMwNTUy_e5e618fd-56aa-45bd-bebb-fb52f2db4589">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6M2YzYzg1YmExZjE0NDFiYzgzMzNkMTI2ZmQ0YTIwYTcvdGFibGVyYW5nZTozZjNjODViYTFmMTQ0MWJjODMzM2QxMjZmZDRhMjBhN18yLTEtMS0xLTMwNTUy_76bc7a11-5d1c-4173-8f6b-2e15b1bb9369">NKTR</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6M2YzYzg1YmExZjE0NDFiYzgzMzNkMTI2ZmQ0YTIwYTcvdGFibGVyYW5nZTozZjNjODViYTFmMTQ0MWJjODMzM2QxMjZmZDRhMjBhN18yLTItMS0xLTMwNTUy_4cd819ca-fe9b-4710-ae55-b5fa217740bf">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjY2_19913785-0053-4553-a534-276064232d66">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjU4_11f7fd39-f7ee-4f25-ac27-0deae14e20c9">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6OGVjYTJkOTY5M2RiNGVkOGFkNWVjMDJjNjVmN2E0YTUvdGFibGVyYW5nZTo4ZWNhMmQ5NjkzZGI0ZWQ4YWQ1ZWMwMmM2NWY3YTRhNV8wLTAtMS0xLTMwNTUy_65ab7958-be63-497e-ac08-233401b13652">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6OGVjYTJkOTY5M2RiNGVkOGFkNWVjMDJjNjVmN2E0YTUvdGFibGVyYW5nZTo4ZWNhMmQ5NjkzZGI0ZWQ4YWQ1ZWMwMmM2NWY3YTRhNV8yLTYtMS0xLTMwNTUy_05a3e35a-7571-40e3-a889-d5e6ee2e5f1c">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6OGVjYTJkOTY5M2RiNGVkOGFkNWVjMDJjNjVmN2E0YTUvdGFibGVyYW5nZTo4ZWNhMmQ5NjkzZGI0ZWQ4YWQ1ZWMwMmM2NWY3YTRhNV80LTItMS0xLTMwNTUy_cee88d5b-1e9e-4a15-94cc-b4e4a504e979">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV82MDQ3MzEzOTU1MDM3_ad55be6e-ded3-4a3b-85ee-b6742e1eae2e">&#9746;</ix:nonNumeric></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value, was <ix:nonFraction unitRef="shares" contextRef="ia4e3b25b44f741e29bebfd8f823ae5ab_I20220729" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjQ4_242640bf-1161-4271-ab2a-7351857249d1">187,404,772</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n July&#160;29, 2022.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_13">Summary of Risks</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_13">4</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_16">PART I: FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_19">Condensed Consolidated Financial Statements &#8212; Unaudited:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_22">Condensed Consolidated Balance Sheets &#8212; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_22">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_22">, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_25">Condensed Consolidated Statements of Operations for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_25">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_25">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_25">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_28">Condensed Consolidated Statements of Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_28">and s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_28">ix </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_28">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_28">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_28">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_31">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_31"> an</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_31">d six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_31"> months ended</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_31"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_31">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_31">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_34">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_34">six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_34"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_34">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_34">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_70">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_70">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Item 3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_82">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_82">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_85">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_85">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_85">33</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_88">PART II: OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_91">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_91">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_91">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_94">Item 1A.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_94">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_94">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_97">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_97">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_97">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_100">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_100">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_100">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_103">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_103">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_103">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_106">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_106">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_106">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_109">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_109">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_109">55</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_112">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i140383c8fcb34877b7aa2512bcb00b00_112">57</a></span></div></td></tr></table></div><div style="text-indent:-9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this Quarterly Report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements related to our strategic reorganization and cost restructuring plans, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates and our future research and development plans, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of our collaboration arrangements, commercialization activities and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part I, Item&#160;1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, the &#8220;Company,&#8221; &#8220;Nektar,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nektar brand and product names, including but not limited to Nektar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_13"></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risks</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time, and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks to our business are more fully described below in Item IA in this Form 10-Q, which risks include, among others:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Research and Development Efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">clinical drug development is a lengthy and uncertain process and we may not be able to generate and develop successful drug candidates for commercial use;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on the success of NKTR-358 and NKTR-255 and our business will be significantly harmed if either NKTR-358 or NKTR-255 do not continue to advance in clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the outcomes from competitive oncology and immunology therapy clinical trials, and the discovery and development of new potential oncology and immunology therapies could have a material and adverse impact on the value of our pipeline;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significant competition for our polymer conjugate chemistry technology platforms and our products and drug candidates could make our technologies, drug products or drug candidates obsolete or uncompetitive;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">preliminary and interim data from our clinical studies are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical trials for any of our drug candidates could be delayed for a variety of reasons. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Financial Condition and Capital Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are implementing a strategic reorganization plan focused on prioritizing key research and development efforts, as well as a cost restructuring plan, and our business will be significantly harmed if either of these plans is unsuccessful; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our revenue is exclusively derived from our collaboration agreements. If we are unable to establish and maintain collaboration partnerships with attractive commercial terms, including significant development milestones and research and development cost-sharing, our business, results of operations and financial condition could suffer; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we expect to continue to incur substantial net losses from operations and may not achieve or sustain profitability in the future. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Collaboration Partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on Eli Lilly and Company, our collaboration partner for NKTR-358, our lead drug candidate, to initiate, properly conduct and prioritize clinical trials for NKTR-358 and to perform important additional development and commercialization activities, and our business will be significantly harmed if our partner&#8217;s actions deprioritize or otherwise harm the prospects of NKTR-358; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the operations of our collaboration partners have been affected by the COVID-19 pandemic in the past, and it is possible that the COVID-19 pandemic will affect the operations of our collaboration partners in the future, which would cause delays in initiating or completing one or more clinical trials involving our drug candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to the COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic. While the COVID-19 pandemic has not had a material adverse effect on our current operations, the ongoing challenges associated with the pandemic, including the emergence of new variants of the coronavirus and resurgences in the number and rates of infections, and shortages in raw materials and equipment and other supply chain disruptions, could have a material negative impact on our business and our clinical trial timelines.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Supply and Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, our business, financial condition and results of operations could be harmed; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause delays, loss of revenue and contract liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we or our partners may not obtain regulatory approval for our drug candidates on a timely basis, or at all;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required, which may not be available to us on commercially reasonable terms; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">from time to time, we are involved in legal proceedings and may incur substantial litigation costs and liabilities that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above-mentioned risks, our business is subject to a number of additional risks faced by businesses generally. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I: FINANCIAL INFORMATION</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_19"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Condensed Consolidated Financial Statements&#8212;Unaudited:</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_22"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMy0xLTEtMS0zMDU1Mg_dcd163d5-54a1-44b7-a656-e987ac93e282">77,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMy0zLTEtMS0zMDU1Mg_c4f9d1cb-70ab-4443-b687-e88b7c87bfff">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNC0xLTEtMS0zMDU1Mg_ee93cde0-5e8d-4dfe-a339-d89091c9c5d9">541,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNC0zLTEtMS0zMDU1Mg_de700be2-6bf3-457c-8c38-71d8775de90e">708,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNS0xLTEtMS0zMDU1Mg_6de34cd1-f2b4-49f7-b754-15275321291e">10,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNS0zLTEtMS0zMDU1Mg_5917ebc4-8a06-41d8-957e-6da0229f3260">22,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNi0xLTEtMS0zMDU1Mg_7a907a61-df8f-46ef-9771-b859c5ba82a7">16,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNi0zLTEtMS0zMDU1Mg_f91f0336-69f0-4bbd-8883-6faad5154476">15,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNy0xLTEtMS0zMDU1Mg_6fcf7335-8b01-4d95-96b4-b4de7867cf5f">19,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNy0zLTEtMS0zMDU1Mg_471915c3-8a8d-4497-a978-673cd548135c">23,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfOC0xLTEtMS0zMDU1Mg_47db0078-b318-4058-aea4-60440636ca36">665,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfOC0zLTEtMS0zMDU1Mg_28ad6e77-7f22-431f-b860-e8dc84418674">795,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfOS0xLTEtMS0zMDU1Mg_ff8578ff-e41d-429a-9029-23510ca96f13">8,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfOS0zLTEtMS0zMDU1Mg_1d2c509b-9021-4604-a566-07e6bacbbe6e">64,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTAtMS0xLTEtMzA1NTI_fbd6dfa1-2d16-403c-843e-07350ceaa411">39,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTAtMy0xLTEtMzA1NTI_6a99fb72-dc51-4382-bcf2-cdcb84e295cf">60,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTEtMS0xLTEtMzA1NTI_bd87f6fd-94a8-4421-b495-8eb2a4090c63">68,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTEtMy0xLTEtMzA1NTI_aeb09127-3326-409a-8ace-1ac5343d14b7">117,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTItMS0xLTEtMzA1NTI_675461d7-04e9-4899-8c50-ac7b8994bae8">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTItMy0xLTEtMzA1NTI_97988f5b-7051-4415-8fa3-fdbbc137d3ea">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTMtMS0xLTEtMzA1NTI_0ff46da2-a725-4cf2-b5a8-2f60264df902">2,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTMtMy0xLTEtMzA1NTI_84450b41-1a34-4a92-b65b-69b8f2fba0ad">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTQtMS0xLTEtMzA1NTI_e5daaba4-8b00-4e1a-9d6d-6e1a00663094">861,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTQtMy0xLTEtMzA1NTI_a75f7054-665f-41f3-88ed-fe0f91bacfd3">1,117,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTctMS0xLTEtMzA1NTI_5337cc1a-c1cc-4475-96ba-72f676a86314">12,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTctMy0xLTEtMzA1NTI_d3b290f0-43d7-489a-841c-6f92a37584c4">9,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTgtMS0xLTEtMzA1NTI_6d54e137-b9e3-4e56-b22f-79a74dfa6752">30,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTgtMy0xLTEtMzA1NTI_35afd38e-29ad-4eab-894e-2c67490d3320">15,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued clinical trial expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="nktr:AccruedClinicalTrialExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTktMS0xLTEtMzA1NTI_26a6a34c-07da-4c88-bd48-2b7398b3ccc8">29,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="nktr:AccruedClinicalTrialExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTktMy0xLTEtMzA1NTI_1ba566bc-257f-42dd-bd72-0d57ff94f96f">26,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjAtMS0xLTEtMzA1NTI_ce809f16-018e-4ee5-aeb7-03895b5781a1">13,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjAtMy0xLTEtMzA1NTI_99db9cc6-d9e7-423b-9760-018c4ea56aa8">15,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjEtMS0xLTEtMzA1NTI_4ad2c85b-547d-4d4a-bbfa-f1df05ce1a33">20,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjEtMy0xLTEtMzA1NTI_30fd90ea-f2e4-47b4-8f40-21701578b730">17,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjItMS0xLTEtMzA1NTI_7a14245f-2245-489b-8299-44fc0f6ac322">104,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjItMy0xLTEtMzA1NTI_2e5c8dde-f2a2-41c3-af04-8dcb4c206daf">85,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjMtMS0xLTEtMzA1NTI_7565ce8c-1354-459c-acee-921c3431dfe5">119,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjMtMy0xLTEtMzA1NTI_544e207c-2a72-4aef-ac6a-b39789b4c1a5">125,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjQtMS0xLTEtMzA1NTI_952debfd-a12d-4705-8bd9-71ef49b7b545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjQtMy0xLTEtMzA1NTI_60fe333c-4dd7-4b70-adfc-08b20165a8ec">27,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities related to the sales of future royalties, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjUtMS0xLTEtMzA1NTI_6d80247d-1a13-46c6-a6ef-7a53db5017a0">176,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjUtMy0xLTEtMzA1NTI_444691ca-e175-4681-b3f9-3f8615e28c4c">195,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjYtMS0xLTEtMzA1NTI_0ad0926e-8e21-4628-8995-98f049c5f9ee">2,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjYtMy0xLTEtMzA1NTI_aa4ea691-7173-4979-915d-42c3a348117d">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjctMS0xLTEtMzA1NTI_a6c28877-dae2-4f0b-a749-cda3c0364923">403,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjctMy0xLTEtMzA1NTI_67c82a0b-fca5-412d-9885-bc0e18c6c7f0">437,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjgtMS0xLTEtMzA1NTI_9cba38e4-84db-471e-b5e0-fb6c377e86cb"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjgtMy0xLTEtMzA1NTI_6391881b-9b17-46e0-9253-462cba33cb36"></ix:nonFraction>Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV8yMQ_78e6db7d-534b-468d-a510-dfd37b451f73"><ix:nonFraction unitRef="usdPerShare" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV8yMQ_97b0e455-0cb0-4e15-8486-02673684c988">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV8zNQ_2798f712-b8e7-42ba-9c3c-535f17c64dad"><ix:nonFraction unitRef="shares" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV8zNQ_2c359ca9-a4ba-4a79-9d0d-0832df3a19c1">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV81Nw_1fc04ece-6ffc-4be8-8d11-b1ca12a3826e"><ix:nonFraction unitRef="shares" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="INF" name="nktr:PreferredStockShareDesignated" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV81Nw_3d677712-d5b7-40e8-ac8e-60a1fe88a7d3"><ix:nonFraction unitRef="shares" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="INF" name="nktr:PreferredStockShareDesignated" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV81Nw_54e30853-9a85-4e80-9152-0d3baad556cb"><ix:nonFraction unitRef="shares" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV81Nw_fe7c4b4f-cb2c-45fc-bbab-95252598c5fa">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares designated or outstanding at June 30, 2022 or December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMS0xLTEtMzA1NTI_6fdd578a-90b4-4cdc-94da-5bae9a795850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMy0xLTEtMzA1NTI_dd0b9f07-1e1a-4e1a-bbfc-5bf5fa8ebc83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF8xOA_b05c0ddd-5f0f-41c1-88aa-7332f1e6c96c"><ix:nonFraction unitRef="usdPerShare" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF8xOA_df717e02-f832-4132-8c0f-0905e2445efa">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF8zMg_4d39ee6e-2303-41d1-88e5-faf3820c416d"><ix:nonFraction unitRef="shares" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF8zMg_645421e7-5653-4a35-a406-0effd4035cdf">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF81NA_ed948156-60b5-4060-a2a7-e6475e96326c">187,405</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF82OA_d8fd9694-e40c-4455-ab53-0632a89ac84d">185,468</ix:nonFraction> shares outstanding at June 30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMS0xLTEtMzA1NTI_6f505fb4-7b8b-414d-9cc4-db3663809b1e">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMy0xLTEtMzA1NTI_81d93896-41af-46ad-ab7f-02e0ac8b6920">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital in excess of par value</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzItMS0xLTEtMzA1NTI_2527e7a9-4291-4b6e-b458-9e94096dd74e">3,549,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzItMy0xLTEtMzA1NTI_944af5a8-18ab-4c45-b056-159a34387da9">3,516,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzMtMS0xLTEtMzA1NTI_fae4df6e-244b-4f5c-8471-c2197681d210">8,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzMtMy0xLTEtMzA1NTI_4b11cc99-a1e6-4bfb-b174-5409b3e1652f">4,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzQtMS0xLTEtMzA1NTI_cc36f779-a5ac-4fc1-b0b2-662d15fce412">3,082,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzQtMy0xLTEtMzA1NTI_35e49a24-8d2d-4ea9-b1c1-491bf4b72a95">2,832,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzUtMS0xLTEtMzA1NTI_c1a7001b-1a8b-4224-8435-f54d687b1337">458,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzUtMy0xLTEtMzA1NTI_aa93c94e-b1c5-41aa-b666-7397fa4280b2">679,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzYtMS0xLTEtMzA1NTI_548dbe7b-ffc7-412e-b247-8b2adfa0edd0">861,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzYtMy0xLTEtMzA1NTI_1cd03fdb-7ef2-4c8b-9b6b-c0da4bfe148c">1,117,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share information)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab10c83366854752a16f76890719307a_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMy0xLTEtMS0zMDU1Mg_f90e137b-a902-4181-a193-d244d50f5674">5,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841d22063d474fa5b3b392a4925ca344_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMy0zLTEtMS0zMDU1Mg_77e18abb-b763-4499-ae06-6272644e15ca">7,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id98ac0fa001e4daab8a52e2248b1146c_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMy01LTEtMS0zMDg0NA_4d343171-a04c-49c0-ad11-e68336775aa9">11,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9530c36c4b448839ff7ef902cfd13dc_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMy03LTEtMS0zMDg0NA_e8d466ba-876b-4a4c-a3f6-5ab0dcc140a4">12,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa02756dcbe4a1a871ce1cb0480648d_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNC0xLTEtMS0zMDU1Mg_dbd7ca35-f921-43e3-902e-2f5e898fc132">16,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957bd179292a4a5f8bea0ec87a04ddac_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNC0zLTEtMS0zMDU1Mg_56f2d597-20fc-4d4f-89d0-5e5a86f6e784">20,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6059c3a6a244129de957ee89ff70fc_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNC01LTEtMS0zMDg0NA_5557ad72-37db-432f-91a2-a843cde7ab22">33,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82df606601154dc1ad7096a861539bf7_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNC03LTEtMS0zMDg0NA_c5ff6273-bf68-4191-b2ed-4ff5e2a87507">39,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7b009052b4c3db8cb98c20f670ac9_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNS0xLTEtMS0zMDU1Mg_633c7635-43a4-42db-99f7-2582f5326448">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6d564c98e44ea1bb8b4ec60494b8bb_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNS0zLTEtMS0zMDU1Mg_fe05a08c-50ea-4f14-9d9d-53d8c6dbcb57">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i134972093bfc48989eb2da3ed230985f_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNS01LTEtMS0zMDg0NA_6edd588d-cb48-48d2-881e-f6b42bee9b75">1,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib60cd739b0c941a290a478c66b5d7ae8_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNS03LTEtMS0zMDg0NA_0a021325-6c76-4bae-8f01-291dbc862962">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNi0xLTEtMS0zMDU1Mg_3cf2abc6-493e-4eac-8df2-86458c84e49e">21,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNi0zLTEtMS0zMDU1Mg_3b87a048-d05b-4fa2-9b49-25541daefee6">28,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNi01LTEtMS0zMDg0NA_79e11a23-9331-4e9b-af94-02e45a0bddf7">46,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNi03LTEtMS0zMDg0NA_97b58364-50b1-4249-a33e-d03305359ed3">51,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating costs and expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOC0xLTEtMS0zMDU1Mg_6ea798c9-4c1f-48b5-a3ae-f47c901d66d2">5,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOC0zLTEtMS0zMDU1Mg_b6607496-37de-4839-ad17-c007f803cc52">7,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOC01LTEtMS0zMDg3NA_9b3fdeaf-bfdf-492a-9e29-472d4a831b71">10,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOC03LTEtMS0zMDg3NA_9a89ec78-3863-4f23-8dab-cc170116dd28">13,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOS0xLTEtMS0zMDU1Mg_b70bba5b-5d16-4c44-9873-54acdb61ca91">42,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOS0zLTEtMS0zMDU1Mg_29cf8813-9a5f-4e0b-a44b-63f9ec27eb41">101,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOS01LTEtMS0zMDg3NA_60c51cc5-9197-427e-adcd-2592de8b9f1a">149,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOS03LTEtMS0zMDg3NA_a34ab3e9-012e-46d2-8830-928d27adb861">196,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTAtMS0xLTEtMzA1NTI_04827bd5-c532-4469-94cc-d77793411bed">20,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTAtMy0xLTEtMzA1NTI_7827055a-dc0b-4255-94da-cb69201f420f">29,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTAtNS0xLTEtMzA4NzQ_20d6bf77-451d-4db3-820c-ffa3808b51bf">47,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTAtNy0xLTEtMzA4NzQ_f8ce5a2a-aace-4984-b1d8-753545692766">61,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTEtMS0xLTEtMzA1NTI_78f6443b-5d68-4d31-9920-b56aa576c72a">106,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTEtMy0xLTEtMzA1NTI_f97c82a7-9d37-464e-b0a8-797432914783">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTEtNS0xLTEtMzA4NzQ_784b74da-b555-4b12-8d19-1ffe44478357">107,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTEtNy0xLTEtMzA4NzQ_4e92ce63-c929-4fb8-9226-e960572bb9ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTItMS0xLTEtMzA1NTI_54dcced9-6fdd-4695-bb9e-e36b73a89bcb">174,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTItMy0xLTEtMzA1NTI_7753823b-1a03-406d-b925-1a30f393582a">138,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTItNS0xLTEtMzA4ODY_f940a333-cce1-42f6-be08-7aa0e3a95095">315,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTItNy0xLTEtMzA4ODY_4d50f9b2-e274-4641-bb10-71b66a546eb4">271,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTMtMS0xLTEtMzA1NTI_c5c1101b-cf62-476d-b68e-5a98c92e22b4">152,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTMtMy0xLTEtMzA1NTI_518b3346-6f69-4cfd-b918-2390f8a734d7">110,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTMtNS0xLTEtMzA4ODY_d5c15c45-d098-403b-8254-1682ef484b2e">269,396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTMtNy0xLTEtMzA4ODY_0bb6ac6a-bb99-4d02-9ccd-42373da8cc5a">219,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income (expense):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTUtMS0xLTEtMzA1NTI_79d03c49-9678-4163-8f36-ee11ac576bf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTUtMy0xLTEtMzA1NTI_38df5220-d4e4-41e1-806b-a2e4f1397959">2,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTUtNS0xLTEtMzA5MTc_52c81acb-0ca6-4c55-b08f-c6f77aabdd21">33,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTUtNy0xLTEtMzA5MTc_18552a5e-3cbc-483b-9696-2b21bd29cd80">4,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liabilities related to the sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTYtMS0xLTEtMzA1NTI_c6ae1263-fd1b-4b8e-885a-2295d9580bc5">7,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTYtMy0xLTEtMzA1NTI_efe53f33-4875-4e23-b37b-5a7d327d35af">13,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTYtNS0xLTEtMzA5MTc_1670922b-8380-4049-a98f-7ad0c6767f0c">14,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTYtNy0xLTEtMzA5MTc_b9f8bcdd-8c42-4fd8-ad5e-8d46b5ee761e">26,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTctMS0xLTEtMzA1NTI_8edf2522-3501-4372-b42d-0d7b9f82b81a">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTctMy0xLTEtMzA1NTI_cf4f8c3a-1e8d-4dba-86b6-5d05b2329aea">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTctNS0xLTEtMzA5MjQ_14d34ae6-0f58-43e4-9956-0acf800edfd3">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTctNy0xLTEtMzA5MjQ_c015b718-c40f-4420-ba5f-40f337fb9672">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-operating income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTgtMS0xLTEtMzA1NTI_89b64abe-7628-418b-93df-38db0624693d">6,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTgtMy0xLTEtMzA1NTI_4c10f9df-0909-499f-8362-eaccc39b9d2e">14,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTgtNS0xLTEtMzA5MzM_a7023557-11f3-457e-b4c9-985a847d71af">20,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTgtNy0xLTEtMzA5MzM_ea7a810c-ef32-4928-b798-f1f7bf4ddd71">28,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTktMS0xLTEtMzA1NTI_b7ff777d-9616-48d2-adac-babd423a1def">158,968</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTktMy0xLTEtMzA1NTI_d4615117-d801-4ed0-a9d6-a9269fe9b032">125,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTktNS0xLTEtMzA5MzM_d7286771-1272-4f87-93a8-f699464cf768">249,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTktNy0xLTEtMzA5MzM_7fcca9a6-9214-4837-b876-df9e57ca0bcb">248,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjAtMS0xLTEtMzA1NTI_d6b82b25-d7c4-4e55-9a54-c7103a5c939f">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjAtMy0xLTEtMzA1NTI_92f99c93-877c-4295-a77c-9f5c2ad52b48">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjAtNS0xLTEtMzA5MzM_81f6883d-614f-489a-b648-acce8fce05a7">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjAtNy0xLTEtMzA5MzM_6a40b781-0d47-4afc-8d2f-a493b16bad95">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjEtMS0xLTEtMzA1NTI_ab1417ff-daa6-4a3c-8fed-3e0333aa30c6">159,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjEtMy0xLTEtMzA1NTI_4b7516bc-01c9-46c9-8b6f-85938ed37a4c">125,519</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjEtNS0xLTEtMzA5MzM_42db699f-24c4-403e-a77e-4f37d531cf40">249,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjEtNy0xLTEtMzA5MzM_8d9bcf09-1909-46cb-b6de-517c132cfee8">248,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtMS0xLTEtMzA1NTI_3128f977-28b1-4c77-aa84-f32aba0e43b6"><ix:nonFraction unitRef="usdPerShare" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtMS0xLTEtMzA1NTI_c26928c6-5d4f-4553-8be0-b986b0eb1b23">0.85</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtMy0xLTEtMzA1NTI_a6c56bed-bdaa-48fb-940b-f3da31533e92"><ix:nonFraction unitRef="usdPerShare" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtMy0xLTEtMzA1NTI_fe17880a-cbbe-4bdc-963d-b35b6e89577a">0.69</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtNS0xLTEtMzA5NDM_24d2f03e-61aa-46ac-98e8-674ddeb00df6"><ix:nonFraction unitRef="usdPerShare" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtNS0xLTEtMzA5NDM_a1793020-00b6-4c54-bfb4-3beb980ca5dc">1.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtNy0xLTEtMzA5NDM_34672dfc-7315-4b46-80ac-aed0c81df9f9"><ix:nonFraction unitRef="usdPerShare" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtNy0xLTEtMzA5NDM_7f1e6dac-95ca-494c-b511-6c2432a8a5b8">1.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in computing basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtMS0xLTEtMzA1NTI_9bc9ebf4-fe87-48c6-b4a5-f1a2d53ed7e5"><ix:nonFraction unitRef="shares" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtMS0xLTEtMzA1NTI_fde463f0-37b1-42da-9fb4-403cf73ef182">186,800</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtMy0xLTEtMzA1NTI_911d45e6-2556-4bad-a3b4-ba83478f8a70"><ix:nonFraction unitRef="shares" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtMy0xLTEtMzA1NTI_b1486c95-76d1-4245-8e95-1506b8894199">182,698</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtNS0xLTEtMzA5NTA_02cf4277-918c-48a2-928a-9c5101678749"><ix:nonFraction unitRef="shares" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtNS0xLTEtMzA5NTA_392cf590-1876-4f4f-9333-4ad595236a0f">186,323</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtNy0xLTEtMzA5NTA_22db53a2-b591-457d-bbef-0c58b59aa2e9"><ix:nonFraction unitRef="shares" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtNy0xLTEtMzA5NTA_fef81653-e4c2-4e90-bb08-da6009861971">182,038</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfMi0xLTEtMS0zMDU1Mg_16b7afcf-2ad8-44d9-a755-ef992d0629d0">159,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfMi0zLTEtMS0zMDU1Mg_6616d01e-37a5-46bf-a2aa-e6de339bc3d5">125,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfMi00LTEtMS0zMTAzMw_f4276e00-6cca-413d-af95-78b8244f0b9c">249,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfMi02LTEtMS0zMTAzMw_be3276cf-5b99-4df2-95fb-e859aadec3c7">248,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNC0xLTEtMS0zMDU1Mg_b4398460-b9f6-412e-a99c-c5f942ba27f9">988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNC0zLTEtMS0zMDU1Mg_dd4a7146-c835-4aac-a305-b75290bd7d6b">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNC01LTEtMS0zMTA0Ng_a9d637da-0ae3-49a2-a98d-ae701bb727af">3,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNC03LTEtMS0zMTA0Ng_83c8bbbe-0721-4bf5-bbd1-bfd21a0eadb2">830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNS0xLTEtMS0zMDU1Mg_af1077fc-b75a-4db7-8f23-7a8563ec61e2">671</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNS0zLTEtMS0zMDU1Mg_ced8818a-790e-4fb0-b1f8-c797c002d331">215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNS01LTEtMS0zMTA0Ng_5cdfdf3e-fb63-4d33-8771-ce99ec192b37">955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNS03LTEtMS0zMTA0Ng_b9776085-a47a-4e91-af75-448b9b8386d3">275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNi0xLTEtMS0zMDU1Mg_d3567cac-e00c-49a4-a8d0-082241ca17b0">1,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNi0zLTEtMS0zMDU1Mg_576d746f-9b50-4a9d-81bb-852d616ee650">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNi01LTEtMS0zMTA0Ng_9098930a-e725-49d8-b497-05956462b633">4,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNi03LTEtMS0zMTA0Ng_f216393b-bf31-4379-9f2c-575c8d8ca785">1,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNy0xLTEtMS0zMDU1Mg_a0820572-8181-404c-a417-529d65c971b2">160,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNy0zLTEtMS0zMDU1Mg_66a5239e-7f94-42cd-87bc-38e6c476b6f9">125,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNy01LTEtMS0zMTA0Ng_3e33bd70-e3fc-42c9-a601-640dd0152f5e">253,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNy03LTEtMS0zMTA0Ng_35dafbd0-5707-4941-9fcd-63222a58c2a4">249,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6c832ade51b45958d331545ae3e5dc3_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS0xLTEtMS0zMDU1Mg_d9f2e287-f2a7-4907-99d3-dbd81474dcfd">180,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6c832ade51b45958d331545ae3e5dc3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS0zLTEtMS0zMDU1Mg_89e5eb60-c353-4770-b627-350141b0a93b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207702fa8b624c6685cbfa6fc0824271_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS01LTEtMS0zMDU1Mg_948d5ca0-fe5a-4e08-a338-4c37983d2ff4">3,388,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e9a5d5deddf468b87ac44df66d21b86_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS03LTEtMS0zMDU1Mg_1b12c503-8704-4126-8b24-04230a69b834">2,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93c37c43548a4597827bc1c98a494182_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS05LTEtMS0zMDU1Mg_911b11f3-4885-47ea-83ce-ab0ad49d838c">2,309,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec541b07f4024b509da17efe3def4f82_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS0xMS0xLTEtMzA1NTI_0a5e88fe-fa0d-41de-82da-3a3f29e7c0ff">1,077,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19adf3d7365740b8858300248f7a335e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMi0xLTEtMS0zMDU1Mg_fce0ccbb-a991-4095-8c6f-0133d3a4a5fb">2,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a50cc46191d4f39bb966fafeb0e21e3_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMi01LTEtMS0zMDU1Mg_bbb135c0-34fa-4539-ab5b-4e26c741e30f">17,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc13b8f8e341f385a8e18d347395f3_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMi0xMS0xLTEtMzA1NTI_029720c6-f92f-4341-a339-d3cf21fe90d9">17,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a50cc46191d4f39bb966fafeb0e21e3_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMy01LTEtMS0zMDU1Mg_dd80a55c-32ef-4265-8cdc-2143cd0536bf">23,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafc13b8f8e341f385a8e18d347395f3_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMy0xMS0xLTEtMzA1NTI_046cead0-daa4-4196-871f-23eab8ff5655">23,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafa6f15b9c6c42eb988d570abd03ec38_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNC03LTEtMS0zMDU1Mg_8b74b527-428a-4575-9dc8-ac859d1b02ab">826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic71c4e96623541daac88b34839da139e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNC05LTEtMS0zMDU1Mg_779c2085-b61d-47e8-9c6e-388348a79653">122,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icafc13b8f8e341f385a8e18d347395f3_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNC0xMS0xLTEtMzA1NTI_e3c87811-943c-4bf9-ad25-439670e70f09">123,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b44eabefa5748f3b2039c96188a4ea4_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS0xLTEtMS0zMDU1Mg_06c1cc11-ba7e-429f-b8f8-f4c0a4fbf00f">182,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44eabefa5748f3b2039c96188a4ea4_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS0zLTEtMS0zMDU1Mg_1c83bb2d-511b-413d-bcfe-3d22e0843e0b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13345764e6d142fba76c8c33e9ce581f_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS01LTEtMS0zMDU1Mg_4434b9ab-3dc0-40a7-ae91-c4bf605b8848">3,429,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id81e115f70424914b18921a48b6334c6_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS03LTEtMS0zMDU1Mg_4a8f19cf-2552-4849-9df8-2056b29b85fc">3,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9463547a4e54c51a8dae165b31e8443_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS05LTEtMS0zMDU1Mg_5bca68e9-c3cd-4b9a-8a4a-40cffb19da3a">2,432,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d42324a1f854a268dd508881663f4b2_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS0xMS0xLTEtMzA1NTI_7322324b-0b3a-40ab-84a9-7aefd7b9cfa9">994,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0e5f79481a6422383f5010e8d560526_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNi0xLTEtMS0zMTA5Nw_7485969a-f421-40cd-9c87-9e59a7d81be8">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c21ab7235041cd9295a6a01131a511_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNi01LTEtMS0zMTA5Nw_a46743d1-2a16-4519-8692-c3c48785d588">12,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNi0xMS0xLTEtMzEwOTc_ab607331-0018-47cb-9456-0ea1596dc194">12,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c21ab7235041cd9295a6a01131a511_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNy01LTEtMS0zMTA5Nw_be64ec23-4833-4d0c-baa0-4c5f9ad58666">23,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNy0xMS0xLTEtMzEwOTc_f4c37870-3af7-47b5-b24c-f57f99c17cfd">23,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia46078182c6d4bf9b8244c13bb5ada0c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOC03LTEtMS0zMTA5Nw_a987286f-89e2-4586-a73e-6b3474d1c976">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id92ad17e88394b29b2c99010d4cfde2b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOC05LTEtMS0zMTA5Nw_ddcad5ea-a345-4734-8db3-dea47ce82405">125,519</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOC0xMS0xLTEtMzEwOTc_33663d71-3581-4964-a77d-763efb0d5fc6">125,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d89fcb27e2e40da9712016c38d184da_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS0xLTEtMS0zMTA5Nw_a2dc8282-4c2d-41f0-9275-e051e4d687c6">183,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d89fcb27e2e40da9712016c38d184da_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS0zLTEtMS0zMTA5Nw_c30a45e0-9884-4c4c-be01-3b633c22da19">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0352e962dc144389a178d00a7ff496fb_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS01LTEtMS0zMTA5Nw_236d219e-8579-47d3-b3f5-b2ec905c7031">3,466,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c2e13b9ea7a4dcf8081838f1ac66a94_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS03LTEtMS0zMTA5Nw_f13909ec-db55-4642-a955-96d91dc1061d">3,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bfcf4e2d4804d659adca4c109ad23d1_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS05LTEtMS0zMTA5Nw_d53193c8-2514-4198-920d-cf1bf6e3d7ba">2,557,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i332b83a475bf4c03a2f3b3c3d925e70a_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS0xMS0xLTEtMzEwOTc_328506b2-99f4-46f2-91ac-27537a18b661">904,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6abdeb335de487c9793e2cad1674f4e_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS0xLTEtMS0zMDU1Mg_e0e27040-2a85-4e6c-9e78-90cb3e4dc6db">185,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6abdeb335de487c9793e2cad1674f4e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS0zLTEtMS0zMDU1Mg_5bdaa61e-2632-4863-a399-96d4c5cbca93">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e39b9fd4534db1890613d6cbab71a7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS01LTEtMS0zMDU1Mg_1523ba40-49f9-4936-a6de-3ae97c263036">3,516,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida61f606d16e4a479dbd86a2a2078bcb_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS03LTEtMS0zMDU1Mg_921eba21-2268-4338-a544-2a72f4310e0c">4,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if034602e638345f8a92708bdd04f4ae4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS05LTEtMS0zMDU1Mg_86943c55-2542-477c-a176-c2b6e015dea9">2,832,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS0xMS0xLTEtMzA1NTI_044af9d2-ab76-4927-9531-08cc7fa4e9be">679,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74a11ce6ef2f4211a0e058edcf0f297a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMi0xLTEtMS0zMDU1Mg_524a10f5-9ea5-495e-82a6-cbf08c1fbb0f">806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f9f7814fe344ab965d049b1bf8498d_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMi01LTEtMS0zMDU1Mg_458f252b-8295-4164-aaae-3315b9ba1abf">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf30f1f3976425f9ae1a9658814d0a2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMi0xMS0xLTEtMzA1NTI_08729052-d43a-4671-aa09-057415830019">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f9f7814fe344ab965d049b1bf8498d_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMy01LTEtMS0zMDU1Mg_7129b87e-d4dd-4113-8a4a-d496c5ce830e">20,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf30f1f3976425f9ae1a9658814d0a2_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMy0xMS0xLTEtMzA1NTI_17459d81-a986-4fe2-8ac0-6ab1b14870ee">20,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24276f68c0f648ce93afcce8e8ccb424_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNC03LTEtMS0zMDU1Mg_46411152-886f-4cfa-825d-54aa9357ad0e">2,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b081e4b21eb44e3937cc738e930511a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNC05LTEtMS0zMDU1Mg_f0c56ddd-cce1-4d97-8158-869ff2a1695c">90,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf30f1f3976425f9ae1a9658814d0a2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNC0xMS0xLTEtMzA1NTI_4daf565a-ca88-4f26-a80b-b99557aaedd5">92,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i947f1c275a9b45f0a3c9254c3b4831ff_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS0xLTEtMS0zMDU1Mg_989f9c68-7947-4c1a-a452-dca72d7093af">186,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947f1c275a9b45f0a3c9254c3b4831ff_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS0zLTEtMS0zMDU1Mg_c9a54d81-6af9-46c2-8895-411316eeb581">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d041e6febc8402f9919661245a523c4_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS01LTEtMS0zMDU1Mg_036183e1-9635-45d7-a3eb-fc2b3181f1c4">3,537,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47859d4a9c7d444ea3fc5298c02e72eb_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS03LTEtMS0zMDU1Mg_bdd66494-2770-4b3d-a860-7d1c92066cbe">6,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i021df6170fef4aa0940cfaf057de5391_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS05LTEtMS0zMDU1Mg_245d0714-8270-409b-92b3-dc45d8946658">2,923,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6863c3c60a704766bc19dbf81c2dcb5b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS0xMS0xLTEtMzA1NTI_c70c866f-7b6a-42ba-95ce-1cffc0a33d85">607,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i741af916cbcf43e186ee1732ed353f02_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNi0xLTEtMS0zMTEyMw_5f0dee10-93db-4cc7-84b5-4fbacaf953f4">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73b2f1f3796c48159ef8f2ec154733e9_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNi01LTEtMS0zMTEyMw_c9621658-95f0-4b38-938b-61440127b64b">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNi0xMS0xLTEtMzExMjM_f0c24947-175a-4460-b03c-ff6320618ef2">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73b2f1f3796c48159ef8f2ec154733e9_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNy01LTEtMS0zMTEyMw_c2e5ef2b-d075-4433-9d5f-dc23e3cb494f">11,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNy0xMS0xLTEtMzExMjM_7f88a1cf-f5d3-46b9-a01f-4810d7ad9a00">11,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5340ad5b6f0045e68f5d19b34ed7b610_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOC03LTEtMS0zMTEyMw_1e7567bf-ff43-4c52-b160-551ca95c2726">1,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5db06ec5739d430ab6e1129243313c23_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOC05LTEtMS0zMTEyMw_7a5e7537-1569-456b-93a6-bedccfe74405">159,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOC0xMS0xLTEtMzExMjM_26a96814-30ce-4135-ab01-4415243209fe">160,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93db7cc57e114d759dc91e2753b81b55_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS0xLTEtMS0zMTEyMw_3cece348-1cf9-4344-809c-b11d4f916f8c">187,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93db7cc57e114d759dc91e2753b81b55_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS0zLTEtMS0zMTEyMw_d16f81fc-4232-4599-838b-78fbf2d05d91">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e75a96d7ae4fb5941842c8f737bbc8_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS01LTEtMS0zMTEyMw_812bded5-3de9-41a1-93cf-e41ed31b1b97">3,549,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2b9522e14ad475e9d048da16aa5b505_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS03LTEtMS0zMTEyMw_55a917c3-1e4a-4d97-88de-3cfe0aa1283d">8,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1443f9bb2a2a449b8e75120a43351e1e_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS05LTEtMS0zMTEyMw_f0d7bdfd-ac95-4ef7-9bef-f5474b6ed03b">3,082,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS0xMS0xLTEtMzExMjM_77cf48df-2793-4be8-a7f6-3aeb82e1a08f">458,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMy0xLTEtMS0zMDU1Mg_156d3cd2-ec7b-42a0-8018-aecd53406133">249,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMy0zLTEtMS0zMDU1Mg_cd5c6ce2-bdbd-4968-8f51-76ef47f0f295">248,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNS0xLTEtMS0zMDU1Mg_7fb04e0b-e4e6-425f-b4e3-8ec1dde5a2cd">33,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNS0zLTEtMS0zMDU1Mg_e980d1c6-f290-4e19-b605-fd6d520ca118">39,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on liabilities related to the sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNi0xLTEtMS0zMDU1Mg_428fd31f-7e28-453b-8635-da2717aa86d8">14,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNi0zLTEtMS0zMDU1Mg_1b6aadbd-9315-40ae-a79e-af858850b3be">26,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNy0xLTEtMS0zMDU1Mg_48dc8591-f0c7-4938-b5ef-f951d668b1de">33,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNy0zLTEtMS0zMDU1Mg_029e8144-0484-4058-b9ab-3ea73df38460">4,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfOC0xLTEtMS0zMDU1Mg_db36d27a-2c9c-4a40-852c-a50bb3b178e4">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfOC0zLTEtMS0zMDU1Mg_ec2b8fc6-cb8f-4d61-8e05-7479288ee394">5,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfOS0xLTEtMS0zMDU1Mg_e0cc3fca-0c48-4b23-9d03-662f96749573">32,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfOS0zLTEtMS0zMDU1Mg_f6418d02-0dcd-47d3-be5b-879b04fcf0c4">47,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTAtMS0xLTEtMzA1NTI_be88672e-5e77-4db5-8c6e-8c55cf193b8a">7,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTAtMy0xLTEtMzA1NTI_5c7948f1-ec08-42a4-926e-2233b1626e66">7,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTEtMS0xLTEtMzQwOTU_fb251e96-0ebf-4973-9f13-8349a5802977">57,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTEtMy0xLTEtMzQwOTU_7b6c4afd-3ec0-4101-99ab-0b85af98cb3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums (discounts), net and other non-cash transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTEtMS0xLTEtMzA1NTI_bc6720f0-a2f9-423c-be93-fe8957cfb72f">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTEtMy0xLTEtMzA1NTI_c7566f73-f6a7-482d-ac51-daad58f8539c">4,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTMtMS0xLTEtMzA1NTI_4fb3371d-0aaa-4cb0-b52b-58cd51e18db6">12,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTMtMy0xLTEtMzA1NTI_e5e8c9b2-90bb-424e-b210-f8f3a333894a">10,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTQtMS0xLTEtMzA1NTI_dfad6bf1-5f2b-40a4-bd7e-9074e27fd91d">1,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTQtMy0xLTEtMzA1NTI_958e7390-f212-4613-9a24-22b80b422aa8">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTUtMS0xLTEtMzA1NTI_ede55972-29ac-4576-9fbf-bdab30ff4b46">1,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTUtMy0xLTEtMzA1NTI_b5f5a4e2-11dd-45c3-ba20-bc1181d3aa94">2,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTYtMS0xLTEtMzA1NTI_b54a7b98-1bb0-4833-af66-ebea19e9a57c">7,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTYtMy0xLTEtMzA1NTI_108b96fc-e519-4a85-a8d7-453c8e4f5b02">11,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTctMS0xLTEtMzA1NTI_78e50e1b-aaed-4afd-8368-7bcd4072077a">2,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTctMy0xLTEtMzA1NTI_67596fc3-b179-44d9-acc3-fd56e1109e40">2,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTgtMS0xLTEtMzA1NTI_7f5f8977-c702-46bf-9805-7cf4a9d1c613">14,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTgtMy0xLTEtMzA1NTI_79b2fb3f-8cc9-4932-ad8c-6ef3a8696da6">14,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTktMS0xLTEtMzA1NTI_d8441658-3577-48a7-8866-840121d7d7c9">1,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTktMy0xLTEtMzA1NTI_28666c86-8f62-4471-bbad-2b5851ecaefe">4,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjAtMS0xLTEtMzA1NTI_fc36820f-2e32-4759-80e2-159b5e465f3c">163,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjAtMy0xLTEtMzA1NTI_de4204a5-0107-4924-b6a9-c45a7e199a48">159,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjItMS0xLTEtMzA1NTI_0c1e1f74-a4ee-4d68-bd8f-f482e341db10">247,014</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjItMy0xLTEtMzA1NTI_08fd4b10-41f0-4bf6-b5ec-f00db8416071">527,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjMtMS0xLTEtMzA1NTI_dd2b3b71-9f56-4fb4-bf13-16017a2e055a">466,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjMtMy0xLTEtMzA1NTI_26549be6-5ff6-41de-a21f-a4c4e21fe39c">612,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjQtMS0xLTEtMzA1NTI_25dc7080-6c79-4c08-ba81-3362c98a5d8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjQtMy0xLTEtMzA1NTI_f94a5c7e-a76d-4c82-979c-0187c8a4867a">5,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjUtMS0xLTEtMzA1NTI_8b32bb62-0341-4b72-8225-e4ecd57eec8a">4,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjUtMy0xLTEtMzA1NTI_7e9c604e-693c-429e-90dd-9e8639435a9e">6,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjYtMS0xLTEtMzA1NTI_36909e45-de09-4d07-a830-0fa4ef0566e0">214,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjYtMy0xLTEtMzA1NTI_9daa42e2-f6e1-4c22-abf7-1fda2e138713">83,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjgtMS0xLTEtMzA1NTI_9e26ded8-f46a-405f-8316-6f62b82d07a1">655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjgtMy0xLTEtMzA1NTI_e9334e01-dfda-4c87-b04e-5f6853dd1d1e">28,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjktMS0xLTEtMzA1NTI_b539a882-48e0-4437-830e-e79b945e70df">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjktMy0xLTEtMzA1NTI_04c96094-adcc-44a9-9b1a-dd967fb00a2f">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzAtMS0xLTEtMzA1NTI_1f9e242c-252a-454f-b71b-fbade7d42b50">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzAtMy0xLTEtMzA1NTI_53207339-4cb4-41be-9bf0-dae27bf9099d">30,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzEtMS0xLTEtMzA1NTI_1ef704b2-d8eb-4a70-b42b-3334530288ca">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzEtMy0xLTEtMzA1NTI_b621ef39-1842-43f1-9cd4-bde8e2dad1c3">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzItMS0xLTEtMzA1NTI_2cef1a6e-5644-4140-99e3-164e64560ee9">52,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzItMy0xLTEtMzA1NTI_e2d896ca-64cb-40d9-a5b4-154c0b18fbe2">46,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzMtMS0xLTEtMzA1NTI_f6402ad5-1539-494c-bf5b-5a7f4363324b">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec541b07f4024b509da17efe3def4f82_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzMtMy0xLTEtMzA1NTI_e485d6c3-5e08-462f-9a24-ae11cb0b5424">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzQtMS0xLTEtMzA1NTI_aff60e5c-f855-4bf6-a2b3-d77d3e8cb955">77,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i332b83a475bf4c03a2f3b3c3d925e70a_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzQtMy0xLTEtMzA1NTI_616f2a7c-c927-4b75-a1ab-28c48cf1bdc3">152,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset recognized in exchange for lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzYtMS0xLTEtMzA1NTI_911126f9-a62d-426a-80cf-48a395210849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzYtMy0xLTEtMzA1NTI_7afc0b09-0d42-4cc6-95f0-15b5bb01f140">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June&#160;30, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8212; <ix:nonNumeric contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3MTM_a24122d3-34d9-4019-a60c-6a9beab99b62" continuedAt="i99813f0b3acc4f879e9d9b7209b5963e" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i99813f0b3acc4f879e9d9b7209b5963e" continuedAt="i3e32a173304d4e7ab4252811c3e92611"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="nktr:OrganizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3MjY_09f22e6f-ee68-49ff-b5cf-da6c64c16f86" continuedAt="i1b2b6c2ebd514533acea12107f0cd4fa" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We (individually or with a partner) are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in oncology and immunology.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1b2b6c2ebd514533acea12107f0cd4fa">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</ix:continuation> As of June&#160;30, 2022, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-5" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTAyNA_136b38be-1db2-4713-aa04-76d92cf4f341">628.2</ix:nonFraction> million in cash and investments in marketable securities.</span></div><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3MTk_e68328d5-687d-400e-bbf0-0cd349a99327" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Bempegaldesleukin Program and the Restructuring Plan</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans for the Company&#8217;s future:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 14, 2022, BMS and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 7 for additional information on our BMS Collaboration Agreement.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we decided to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 4 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, subject to activities required for an orderly wind down of the studies, there will be no ongoing clinical development activities of bempegaldesleukin.    </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the Restructuring Plan), which were reviewed and approved by our Board of Directors on April 14, 2022. Pursuant to the Restructuring Plan, on April 26, 2022, our duly authorized officers implemented certain strategic, operational and organizational steps, including the prioritization of key Phase 2 development programs to advance our early stage research pipeline. In addition, we announced our plan to reduce our workforce by approximately <ix:nonFraction unitRef="number" contextRef="i6844748a7747471187efa284c70c9b40_D20220401-20220430" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfNDAxNg_054c1d37-a98c-440d-a472-dedaffd996e7">70</ix:nonFraction>% and to close our research facility in India.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and expect to incur significant costs resulting from these decisions and plans. See Note 8 for additional information on the effect on our Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><ix:continuation id="i3e32a173304d4e7ab4252811c3e92611" continuedAt="i16625f3448bc41cd9c6189b6b5a5af0c"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3MTY_663f0d25-0bc4-46fe-a32c-7fd6ff0a099d" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three and six months ended June&#160;30, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2021 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 filed with the SEC on March 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3MTU_bcd6ab24-1a4c-4eec-9759-5037436989b5" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3Mjg_1ea8ec61-0a9d-4297-8730-8caa2f79227b" continuedAt="i5996b470429e4c77a130a58718849c7a" escape="true">Significant Concentrations</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5996b470429e4c77a130a58718849c7a" continuedAt="iefc704c01deb439db8b49ff1cdc911be">Our customers are primarily pharmaceutical companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements.</ix:continuation> As of June&#160;30, 2022 and December&#160;31, 2021, our accounts receivable includes $<ix:nonFraction unitRef="usd" contextRef="i2fb960f7e2be4ba7b0f30d51ecbfb755_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfODQxMg_8196590a-9a40-4580-b56b-e2c5d6e36d21">7.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8729a4959d1742a08e7c7a9e6181f0a3_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfODQxOQ_bdb879ab-ddde-4ff0-ab5d-5eeecee10623">21.4</ix:nonFraction>&#160;million, respectively, for unbilled net expense reimbursements from BMS. The remaining accounts receivable relate primarily to product sales. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have <ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTY0OTI2NzQ2NDQ4OA_11c1a750-11cf-4ef3-b5ff-52336a3ad929"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTY0OTI2NzQ2NDQ4OA_22d8c169-1d30-4205-84d6-5d0bca59c37d"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTY0OTI2NzQ2NDQ4OA_7d063a50-8ca5-4502-9a5e-256459ce5875"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTY0OTI2NzQ2NDQ4OA_a94fe1f7-7701-419e-b828-83e4db9d2b54">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t experienced credit losses from our accounts receivable. We have not recorded reserves for credit losses for the three and six months ended June&#160;30, 2022 and 2021, nor have recorded such an allowance as of June&#160;30, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iefc704c01deb439db8b49ff1cdc911be" continuedAt="i79c9c9d11b1c4f2084a0922175f7da58">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><ix:continuation id="i16625f3448bc41cd9c6189b6b5a5af0c"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i79c9c9d11b1c4f2084a0922175f7da58">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</ix:continuation></span></div><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTY0OTI2NzQ4MDY5NQ_22a44aaf-ec28-4a14-a77f-24f93320faec" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual employee termination benefits provided that the obligations result from services already rendered based on vested rights to such benefits when the payment of benefits becomes probable and the amount can be reasonably estimated,</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn, </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract termination costs when we cancel the contract in accordance with its terms, and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 for additional information on the severance expense that we recognized for employees terminated in connection with our reduction-in-force.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjE5OTAyMzMxMjQ3Ng_09c0610c-1326-48e6-9bc9-e3778ef0faab" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Asset Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. See Note 8 for additional information regarding the impairment charge we recorded in connection with our leased facilities and certain property and equipment.</span></div></ix:nonNumeric></ix:continuation><div id="i140383c8fcb34877b7aa2512bcb00b00_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8212; <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfODYw_0155fffc-903d-44b5-aed5-3fc6724132ba" continuedAt="i55474837f0744c338fca188f1541e284" escape="true">Cash and Investments in Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i55474837f0744c338fca188f1541e284" continuedAt="i2fc95255d1954ac5b65c5a54c8712502"><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfODU0_e0f44ed9-c952-4854-bb81-fce19bd4b626" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfMi0xLTEtMS0zMDU1Mg_3d8ae68e-ece7-4156-9ddd-00ca930291c9">77,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfMi0zLTEtMS0zMDU1Mg_03669afa-0dd5-4492-b25b-4281c57ee901">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfMy0xLTEtMS0zMDU1Mg_c9bd8a1c-fc97-4d80-98ec-d2a47da420a9">541,771</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfMy0zLTEtMS0zMDU1Mg_da03a5bf-538e-4d72-b080-37dc066acb5a">708,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfNC0xLTEtMS0zMDU1Mg_b8514ad4-a325-44fe-b608-1b96dff1a0cc">8,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfNC0zLTEtMS0zMDU1Mg_c8e0f097-3b4e-4849-bc68-7a5ea1c6a2b4">64,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfNS0xLTEtMS0zMDU1Mg_ef480b9a-ba5e-44c5-bdf4-d531e5fadfa3">628,244</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfNS0zLTEtMS0zMDU1Mg_f826e0f5-6906-40c9-bb84-58f7b5f1ead6">798,783</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in liquid, high quality debt securities which are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="nktr:DebtInvestmentMaximumMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfMzk5_ac6e01cd-4b6b-47a1-9714-029b9740291f">two years</ix:nonNumeric> or less and maintain a weighted average maturity of <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="nktr:DebtInvestmentMaturityTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNDU0_d39d7a30-938d-4de3-971a-f234492ed947">one year</ix:nonNumeric> or less. As of June&#160;30, 2022 and December&#160;31, 2021, all of our long-term investments had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTM5_574175bf-cc3f-4a3a-8666-7dacd922de94"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTM5_b6cfd8b2-81fb-4e7c-b623-4b4795c2fc57">one</span></span> and <ix:nonNumeric contextRef="i66e409cb85994a9abd0992f91c81602e_D20210101-20211231" name="nktr:LongTermInvestmentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTQ2_8b91c342-db01-4db0-86c7-8f13c6041b88"><ix:nonNumeric contextRef="i2b4fb75e85ef4d1da810d56d536e5949_D20220101-20220630" name="nktr:LongTermInvestmentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTQ2_92bb9f8a-fa1c-45b0-9f23-466324216bba">two years</ix:nonNumeric></ix:nonNumeric>.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><ix:continuation id="i2fc95255d1954ac5b65c5a54c8712502"><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfODU2_83b35634-587e-4d3f-bab1-a39de9ee83e3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0737ddba317b4605a758d1342bb280e1_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMi00LTEtMS0zMDU1Mg_ff37acd6-8ed1-4402-b136-83bafcd0d3fc">141,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0737ddba317b4605a758d1342bb280e1_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMi02LTEtMS0zMDU1Mg_79e3da13-ca1a-4da9-b00f-245faa621211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0737ddba317b4605a758d1342bb280e1_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMi04LTEtMS0zMDU1Mg_5b2ee916-c2f3-42f1-a853-8277026b0250">1,505</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0737ddba317b4605a758d1342bb280e1_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMi0xMC0xLTEtMzA1NTI_c6441fbf-a7e6-4f65-bd4a-8559090f99ea">139,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6d6cf71b0b4e4cb1bd7a9a8a889eaa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMi0xMi0xLTEtMzA1NTI_97f96262-264b-414c-8093-7c88671d1545">278,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63723a98759b4da988fffbbea0791b9d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMy00LTEtMS0zMDU1Mg_d40a60d9-4dab-4dbe-a0cf-4140ae2629ae">415,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63723a98759b4da988fffbbea0791b9d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMy02LTEtMS0zMDU1Mg_855c8d52-b4b0-46d2-a782-a4e838c3377f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63723a98759b4da988fffbbea0791b9d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMy04LTEtMS0zMDU1Mg_73c2e891-aea0-4c2b-828b-efb11735641a">2,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63723a98759b4da988fffbbea0791b9d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMy0xMC0xLTEtMzA1NTI_598ac761-7c91-45f9-988a-e208fa0e1415">412,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f239069b834dec8cbd03936544ce8d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMy0xMi0xLTEtMzA1NTI_d381d43a-87ce-472b-9b3c-8dbe66008f3a">478,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5873fdec0d5484a8a91ad052ca94c7b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNC00LTEtMS0zMDU1Mg_cf8e610d-29d4-4e81-b896-82537b003aab">4,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5873fdec0d5484a8a91ad052ca94c7b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNC02LTEtMS0zMDU1Mg_f88b63a6-64bc-4a65-b69f-f8a0bcd5c8a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5873fdec0d5484a8a91ad052ca94c7b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNC04LTEtMS0zMDU1Mg_91cecd99-de08-4eba-9878-02279c98361b">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5873fdec0d5484a8a91ad052ca94c7b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNC0xMC0xLTEtMzA1NTI_bdb4024f-0d1d-4001-89ed-157f81392d95">4,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id98fd41da4fd448aa47ed43c6f62a705_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNC0xMi0xLTEtMzA1NTI_a36a2b6d-97d5-4e26-94d4-def7c98b7590">5,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie76220fe2fa146ab81b848b799537428_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNS00LTEtMS0zMDU1Mg_be09783b-3d9b-4677-9b0e-f7078bcf9454">561,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie76220fe2fa146ab81b848b799537428_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNS02LTEtMS0zMDU1Mg_c11365c7-c012-4755-bf73-64833c94e354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie76220fe2fa146ab81b848b799537428_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNS04LTEtMS0zMDU1Mg_64d4c13b-e667-4cd3-b813-212b913e9e18">3,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie76220fe2fa146ab81b848b799537428_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNS0xMC0xLTEtMzA1NTI_635017bb-8446-41c4-afb9-0b859bc0906f">557,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c9aa8ae8ab44df7bce7acd7e0dd79d4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNS0xMi0xLTEtMzA1NTI_c5c7c284-d896-4b84-8111-8a5eed8ee946">762,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0f9be97ef3499ea6911ba085621ae3_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNi0xMC0xLTEtMzA1NTI_c42ed84d-620c-449b-aa91-5241e1c13dc2">42,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ed5efbb1774febb2171044acdc2732_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNi0xMi0xLTEtMzA1NTI_ace8b1f0-1f40-4c09-aae1-909b30531f69">23,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice3a2c19d2b5444eaed3f904cc22980b_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNy0xMC0xLTEtMzA1NTI_ca1d3ce4-a788-46e2-9dc4-3f5d0f9279df">9,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id459719606054ed78ab057269952a7b5_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNy0xMi0xLTEtMzA1NTI_12f7c785-83b9-4fff-b96d-0d03c438d41b">10,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfOC0xMC0xLTEtMzA1NTI_c4539cc9-e98e-441f-bb37-f064a12010ce">18,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfOC0xMi0xLTEtMzA1NTI_6bf3bd37-9acf-4bdb-a670-97115afdc939">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfOS0xMC0xLTEtMzA1NTI_8c14b41b-735e-422c-b2ca-59be72f54808">628,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfOS0xMi0xLTEtMzA1NTI_b318a45b-67c3-41cb-ae85-eaa87ab531bc">798,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December&#160;31, 2021, our gross unrealized losses totaled $<ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfODAx_7d7ea293-fe4e-418f-8ba2-bd75668f1f02">0.7</ix:nonFraction>&#160;million, and our gross unrealized gains were insignificant.</span></div></ix:continuation><div id="i140383c8fcb34877b7aa2512bcb00b00_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8212; <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RleHRyZWdpb246NzY1ODM1ODY1NTdjNDQ3NThiNGY1ODhmMDIyZDgzZDVfODQy_172e3a10-99f9-437c-88bf-97b6a205d7ca" continuedAt="i78e7772ded13426c84b51bf4fe1289c6" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i78e7772ded13426c84b51bf4fe1289c6"><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RleHRyZWdpb246NzY1ODM1ODY1NTdjNDQ3NThiNGY1ODhmMDIyZDgzZDVfODQ0_d500e198-f701-4721-aab3-a605f385545e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMS0xLTEtMS0zMDU1Mg_a4814f80-a0d8-4a0d-9055-e4cdbd724add">2,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMS0zLTEtMS0zMDU1Mg_efcd7da9-884b-455a-80c8-c4abf8fcd27d">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMi0xLTEtMS0zMDU1Mg_d6c2e19c-fc39-4379-924c-633a933c7392">13,837</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMi0zLTEtMS0zMDU1Mg_075ea139-ad94-4e41-9faf-7b88fffa8f8a">9,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMy0xLTEtMS0zMDU1Mg_996d90b2-d0c9-490e-bb95-4e60f6cbf744">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMy0zLTEtMS0zMDU1Mg_8f00bd0a-f195-4389-97a5-68863d7d5b70">3,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfNC0xLTEtMS0zMDU1Mg_4fb8c3fa-8ffc-4ef0-be4a-e93b4b6ac77f">16,969</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfNC0zLTEtMS0zMDU1Mg_9ba6f4e8-1950-4304-ae19-eac07924e3c3">15,801</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RleHRyZWdpb246NzY1ODM1ODY1NTdjNDQ3NThiNGY1ODhmMDIyZDgzZDVfODQ2_0fcb9c71-9a43-4e3b-b200-d43b79d86561" escape="true">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</ix:nonNumeric></span></div></ix:continuation><div id="i140383c8fcb34877b7aa2512bcb00b00_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8212; <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="nktr:DevelopmentDerivativeLiabilityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RleHRyZWdpb246NGE1MzM0YzRjMzNkNDMxYTliYzVkMTM4OTE1ZjVlZDFfMzI2Ng_ee569094-dd8c-455c-9e5f-a6adb2aedfee" continuedAt="id047f9d562ab4d17942e7a3ccd47daeb" escape="true">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</ix:nonNumeric></span></div><ix:continuation id="id047f9d562ab4d17942e7a3ccd47daeb" continuedAt="i70c0e9b9283a4da2aad53ea59dd2f0da"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $<ix:nonFraction unitRef="usd" contextRef="i751eb150d22f4b73820c3eb0fdd04e8d_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementCommittedFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RleHRyZWdpb246NGE1MzM0YzRjMzNkNDMxYTliYzVkMTM4OTE1ZjVlZDFfMzAz_9e3761ee-0816-4e2e-bbd6-5e76dd362b33">150.0</ix:nonFraction>&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ has primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we are the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $<ix:nonFraction unitRef="usd" contextRef="i751eb150d22f4b73820c3eb0fdd04e8d_D20210212-20210212" decimals="-5" name="nktr:CollaborativeArrangementSuccessBasedPaymentsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RleHRyZWdpb246NGE1MzM0YzRjMzNkNDMxYTliYzVkMTM4OTE1ZjVlZDFfODE4_a039ab93-7e3f-4ce9-b069-e4786e9887ba">637.5</ix:nonFraction>&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin for the metastatic melanoma, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to $<ix:nonFraction unitRef="usd" contextRef="i6863c3c60a704766bc19dbf81c2dcb5b_I20220331" decimals="INF" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RleHRyZWdpb246NGE1MzM0YzRjMzNkNDMxYTliYzVkMTM4OTE1ZjVlZDFfNjU5NzA2OTc3MDcwMQ_ca78fbc6-23f9-408a-967a-7e51d45c205d">0</ix:nonFraction> as of March 31, 2022, and we recognized a corresponding gain in the Change in fair value of development derivative liability. As discussed in Note 1, on April 14, 2022, BMS and we decided to end the development for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and that all other ongoing studies in the bempegaldesleukin program would be discontinued. We also announced that SFJ and we agreed to discontinue the SCCHN Clinical Trial. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><ix:continuation id="i70c0e9b9283a4da2aad53ea59dd2f0da"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presented the SFJ Agreement as a Development derivative liability in our Condensed Consolidated Balance Sheets, which we remeasured to fair value at each reporting date. As SFJ conducted the SCCHN Clinical Trial, we recorded non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remitted funding to us to support our internal costs of conducting the trial, we also recorded a corresponding increase to the development derivative liability. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Condensed Consolidated Statements of Operations. </span></div><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RleHRyZWdpb246NGE1MzM0YzRjMzNkNDMxYTliYzVkMTM4OTE1ZjVlZDFfMzI2NQ_2dc01f81-8a36-4ce8-a980-13fb66d2263f" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the development derivative liability:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of March 31, 2022 and 2021, respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b68ac442765412db42b3953906b0388_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfMi00LTEtMS0zMDU1Mg_11035c1c-7111-4232-b2bf-5ef12dd4be5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ace3aff3a44be7928b81e09398f163_I20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfMi02LTEtMS0zMDU1Mg_424ec540-bfd2-4535-be9b-dacaa928c02a">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icde60c2bb5d4479b97cd2cd805d5a6bb_D20220401-20220630" decimals="-3" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfMy00LTEtMS0zMDU1Mg_f1727eb5-e054-43cc-8a30-e01acca67409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ef03c0e8b845309927dbe4dfbda529_D20210401-20210630" decimals="-3" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfMy02LTEtMS0zMDU1Mg_d1dd4b19-e70a-4c01-aec6-82c89e385ec9">3,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icde60c2bb5d4479b97cd2cd805d5a6bb_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNC00LTEtMS0zMDU1Mg_22e4781b-7811-496c-b21f-16a76d339c1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ef03c0e8b845309927dbe4dfbda529_D20210401-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNC02LTEtMS0zMDU1Mg_43f217a1-971d-4efb-8ebc-9c279bf0f0f4">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icde60c2bb5d4479b97cd2cd805d5a6bb_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNS00LTEtMS0zMDU1Mg_79d8310a-f623-49fa-b481-6a84461c2561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ef03c0e8b845309927dbe4dfbda529_D20210401-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNS02LTEtMS0zMDU1Mg_fbc4a288-9293-4c61-ad24-24617c7aa7a7">2,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1586d1667c4181ab22d8c15f8e9bca_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNi00LTEtMS0zMDU1Mg_b8cea9a2-280b-4dd5-9c6a-bf15e2a3296e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21c1fe452b344cea3b108885a4d4a8b_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNi02LTEtMS0zMDU1Mg_73de5abd-a8c6-4020-8360-3669f4ac5189">11,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c770143f6e43cc8285c4e87e608f39_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMS00LTEtMS0zMzkwMg_5eb49037-36a4-4f63-a8be-c2ff2aff7031">27,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec257d9c2a4f4ca29ba184473f2f37bd_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMS02LTEtMS0zMzkxMg_2a40840b-1920-4574-b938-ddc15357f893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id755a03fdc2b4e99b02634a338a1d47e_D20220101-20220630" decimals="-3" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMi00LTEtMS0zMzkwMg_bcddef3a-beb8-4a50-b813-dadbf164004c">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd48c3f03db4bea80b8a4775bd85320_D20210101-20210630" decimals="-3" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMi02LTEtMS0zMzkxMg_afe09693-71fb-41a8-98df-d35efc9d5555">5,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id755a03fdc2b4e99b02634a338a1d47e_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMy00LTEtMS0zMzkwMg_1620f034-1dd8-415a-b779-4c75e76ced45">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd48c3f03db4bea80b8a4775bd85320_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMy02LTEtMS0zMzkxMg_e60e1c61-a062-4a3e-b8e6-73156ab4f9ce">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id755a03fdc2b4e99b02634a338a1d47e_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfNC00LTEtMS0zMzkwMg_fb70df94-821e-40a0-9014-1609a2cb7b99">33,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd48c3f03db4bea80b8a4775bd85320_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfNC02LTEtMS0zMzkxMg_d5ff28e2-b59b-4a45-a5c1-41260632a984">4,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1586d1667c4181ab22d8c15f8e9bca_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfNS00LTEtMS0zNDA1MQ_6c2a3cfc-1aa4-4c39-aae2-67699b3c3aac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21c1fe452b344cea3b108885a4d4a8b_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfNS02LTEtMS0zNDA1NQ_681f087a-297d-42d3-819d-d47448d69657">11,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 &#8212; <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RleHRyZWdpb246NDhhZTA3NWYzM2JkNGU5NWEyNjlmZjVhOTFlYjA4NTJfMTY5MQ_4c7b8e4e-fd12-4cb1-a532-e3578d2dcf2b" continuedAt="icca579dc68104fe4843228fe6fd4c4e2" escape="true">Liabilities Related to Sales of Future Royalties</ix:nonNumeric></span></div><ix:continuation id="icca579dc68104fe4843228fe6fd4c4e2" continuedAt="i1d6dad0b8e41499385705b4f78e09c60"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="nktr:ScheduleOfPurchaseAndSaleAgreementTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RleHRyZWdpb246NDhhZTA3NWYzM2JkNGU5NWEyNjlmZjVhOTFlYjA4NTJfMTY5Mg_1a898fae-de5b-44c5-b5b0-2bc6bf5bdefe" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Drug</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty under Purchase and Sale Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Sold</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (naloxegol tablets) and  MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca AB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (certolizumab pegol)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Continuous Erythropoietin Receptor Activator)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F. Hoffmann-La Roche Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><ix:continuation id="i1d6dad0b8e41499385705b4f78e09c60"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our ongoing manufacturing obligations in both arrangements, we account for the proceeds as imputed debt (Royalty Obligations) and therefore continue to recognize these non-cash royalties as revenue. As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. Additionally, to the extent that the amount or timing of the royalty payments is materially different from our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the applicable Royalty Obligation. As of June 30, 2022, our imputed interest rates for the arrangements with RPI and HCR were <ix:nonFraction unitRef="number" contextRef="i7c3682511cdc470e8b31f4be9255bc51_I20220630" decimals="2" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RleHRyZWdpb246NDhhZTA3NWYzM2JkNGU5NWEyNjlmZjVhOTFlYjA4NTJfNjU5NzA2OTc2OTIxMA_b66cd3a9-b3e5-4d2b-bec8-71d1d960c1da">16</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9ffcae4931614a41b546c5604b6e9e1a_I20220630" decimals="2" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RleHRyZWdpb246NDhhZTA3NWYzM2JkNGU5NWEyNjlmZjVhOTFlYjA4NTJfNjU5NzA2OTc2OTIxOA_956c7920-d8c2-4e11-bf26-fa45026c6fde">15</ix:nonFraction>%, respectively.</span></div><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RleHRyZWdpb246NDhhZTA3NWYzM2JkNGU5NWEyNjlmZjVhOTFlYjA4NTJfMTY5Mw_4fce65a4-e47d-48ad-8bb3-a6f66de90b67" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account of each arrangement (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMi0xLTEtMS0zMDU1Mg_22658a73-38a8-4e13-97b3-68a2ac739047">124,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMi0zLTEtMS0zMDU1Mg_c2753cc8-1188-4475-9461-91557ad39874">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMi01LTEtMS0zMDU1Mg_c87f018c-dd35-4e4f-bfb7-a74441c918fc">274,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630" decimals="-3" sign="-" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMy0xLTEtMS0zMDU1Mg_c4f301f7-83c5-46e1-b45e-33d898b50b63">297,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630" decimals="-3" sign="-" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMy0zLTEtMS0zMDU1Mg_67d90f3c-9d99-41bd-9de8-48a65a0734fd">69,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630" decimals="-3" sign="-" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMy01LTEtMS0zMDU1Mg_3426c57d-85d6-4e5e-9fe2-eaf9e68f4a4d">367,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNC0xLTEtMS0zMDU1Mg_227f8abe-3772-46c8-8c01-e5d891365aea">229,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNC0zLTEtMS0zMDU1Mg_f7337315-d63d-4c44-a064-71a150508cb9">29,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNC01LTEtMS0zMDU1Mg_fc3fd73a-14e5-4fe1-8d09-a667f59b2aa0">259,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNS0xLTEtMS0zMDU1Mg_fe53bc28-6fa9-4cb9-b8f1-23093ba03b1c">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNS0zLTEtMS0zMDU1Mg_f4ea5f1c-7f2b-46e7-a504-0165f67d4d54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNS01LTEtMS0zMDU1Mg_78b1db04-9e64-48c0-a0d1-94363faa6b16">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNi0xLTEtMS0zMDU1Mg_782af0a0-1677-4092-b81b-849ceac61937">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNi0zLTEtMS0zMDU1Mg_84aaf2b5-965d-44c4-8e29-dafd625522e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNi01LTEtMS0zMDU1Mg_ec5806be-a761-43dd-9c8b-b2c1d857f7be">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3682511cdc470e8b31f4be9255bc51_I20220630" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNy0xLTEtMS0zMDU1Mg_97d94938-a46e-429b-814f-3ada27ac1ab3">69,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ffcae4931614a41b546c5604b6e9e1a_I20220630" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNy0zLTEtMS0zMDU1Mg_cfdb5b2d-6232-4a14-b053-fb4f902b2187">109,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNy01LTEtMS0zMDU1Mg_136c8acb-b16f-4fce-bd7d-a184571b7989">179,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3682511cdc470e8b31f4be9255bc51_I20220630" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOC0xLTEtMS0zMDU1Mg_eb74965a-ff4d-4257-98c7-a6547efed7ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ffcae4931614a41b546c5604b6e9e1a_I20220630" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOC0zLTEtMS0zMDU1Mg_e0f41bff-effa-46f7-b04e-9c6f449ba8f4">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOC01LTEtMS0zMDU1Mg_ed034880-42f6-4aab-8ed0-453803c9a9e5">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3682511cdc470e8b31f4be9255bc51_I20220630" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOS0xLTEtMS0zMDU1Mg_c454d56e-fb8a-4a41-b678-2fa441d0e6a7">69,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ffcae4931614a41b546c5604b6e9e1a_I20220630" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOS0zLTEtMS0zMDU1Mg_b03ee524-1b86-4d27-b887-1827d0c6efe0">107,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOS01LTEtMS0zMDU1Mg_9c64ba96-ec61-4aa0-9c8f-aad6adf8e62d">176,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Loss recognized from Settlement Agreement to resolve UCB&#8217;s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i140383c8fcb34877b7aa2512bcb00b00_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8212; <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81NS9mcmFnOmI0M2UzYmQyY2U0ZTQ0MzQ4MjBlYzcyZjlmOTg2N2MzL3RleHRyZWdpb246YjQzZTNiZDJjZTRlNDQzNDgyMGVjNzJmOWY5ODY3YzNfNjcyNQ_0db1f95c-f8ba-48f9-acda-b380d8d6a758" continuedAt="i4d842898e14944ec9fef075d18d2271c" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i4d842898e14944ec9fef075d18d2271c" continuedAt="i45b3c14e833445a984fb21aef4793165"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018, about the clinical trials of bempegaldesleukin. The Mulquin complaint was amended in May 2019. The defendants moved to dismiss and the court granted the motion without prejudice in July 2020. The Mulquin plaintiffs again amended their complaint and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice. The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument occurred on December 10, 2021. On May 19, 2022, the Ninth Circuit affirmed the district court's dismissal of all claims against the defendants. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A derivative action was also filed against certain of the Company&#8217;s current and former officers and directors, purportedly on the Company&#8217;s behalf. This derivative action is based on the allegations in the Mulquin action and on the premise that the Company&#8217;s officers and directors breached their fiduciary duties to the Company. The complaint for this derivative action was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF). Following a stay in the proceedings during the pendency of the appeal in the Mulquin action, the Company received an amended complaint on July 29, 2022, and the defendants will have until September 12, 2022 to respond to the amended complaint. Given the nature and status of the derivative action, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded <ix:nonFraction unitRef="usd" contextRef="i07faaf6c80274e79b161089c13725a99_I20211231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81NS9mcmFnOmI0M2UzYmQyY2U0ZTQ0MzQ4MjBlYzcyZjlmOTg2N2MzL3RleHRyZWdpb246YjQzZTNiZDJjZTRlNDQzNDgyMGVjNzJmOWY5ODY3YzNfNDU3MQ_37144bfd-9f6d-494f-af29-5f1a954fee31"><ix:nonFraction unitRef="usd" contextRef="i80ddb5385d944743a6830e905272b6dc_I20220630" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81NS9mcmFnOmI0M2UzYmQyY2U0ZTQ0MzQ4MjBlYzcyZjlmOTg2N2MzL3RleHRyZWdpb246YjQzZTNiZDJjZTRlNDQzNDgyMGVjNzJmOWY5ODY3YzNfNDU3MQ_f8831c74-26b1-46ce-b4c8-d137ec3fef98">no</ix:nonFraction></ix:nonFraction> liability for these matters in our Consolidated Balance Sheets at either June&#160;30, 2022 or December&#160;31, 2021. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><ix:continuation id="i45b3c14e833445a984fb21aef4793165" continuedAt="i8ae71f2b544b4a7fb8903a184a9ccfd7"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8ae71f2b544b4a7fb8903a184a9ccfd7">To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations.</ix:continuation> </span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8212; <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNzQ5NQ_7d685a2a-946a-4ffe-aaea-d45d38159b6d" continuedAt="i3c355c868c2f45e8a461f8ac9004c501" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i3c355c868c2f45e8a461f8ac9004c501" continuedAt="i79788e0c3e25494ebf75519e8feac2e2"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our collaboration agreements in the three and six months ended June&#160;30, 2022, other than as described below for our Strategic Collaboration Agreement with BMS and Note 4 regarding SFJ.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="number" contextRef="if11fbbe66ec44a33844d1df024a81f34_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMTg5OA_1d526572-081a-45e6-b033-ea56fda40e7c">67.5</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="ib0f61ce40f5741b1bd39e0dce462d66f_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMTkyMQ_d2406ce3-8e27-4161-ad44-46cf392f3779">32.5</ix:nonFraction>% to Nektar. The parties share costs for the manufacturing and commercialization of bempegaldesleukin, <ix:nonFraction unitRef="number" contextRef="i434d1fce8cc349169ce2249b32af62e5_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjAyNQ_4562dea7-69c1-44be-a5e8-e15b9f009332">35</ix:nonFraction>% of the costs to BMS and <ix:nonFraction unitRef="number" contextRef="i5b4e6c90ab19450e859fb50421c353c0_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjA1Mg_e698f168-6f51-4cd2-b605-b9a3640db0da">65</ix:nonFraction>% to Nektar. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i689d7549c612490aa4442f5f5348ccf0_D20180401-20180430" decimals="INF" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjE5NA_4e541515-17d7-4986-99d7-a604d788becf">1.0</ix:nonFraction>&#160;billion and purchased <ix:nonFraction unitRef="shares" contextRef="id4bfcb6279024241948e7bd08d4d1b15_I20180430" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjIxMQ_0245cd20-1a06-4562-9ecf-416fde07f86b">8,284,600</ix:nonFraction> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ie055df71b6fe4ad78a3fae8b679f8f1b_D20180401-20180430" decimals="-5" name="nktr:SaleOfStockConsiderationReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjMyNQ_3aba27e8-1962-4074-9c5b-1ed8720aa2f7">850.0</ix:nonFraction>&#160;million. In 2020, we received non-refundable milestone payments of $<ix:nonFraction unitRef="usd" contextRef="id5048bfc963648bd9dd0de98c3c9f77f_I20201231" decimals="INF" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjM4Nw_cdd502ab-84bc-409c-8aa0-d7804c397b98">50.0</ix:nonFraction>&#160;million in aggregate for the first patient, first visit in the registrational trials in muscle-invasive bladder cancer and adjuvant melanoma.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, on March 14, 2022, we announced our registrational trial in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the trials in metastatic melanoma and adjuvant melanoma. On April 14, 2022, we announced that our registrational trials in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided that these studies and all other ongoing studies in the program will be discontinued. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. However, without further development of bempegaldesleukin, we will no longer be eligible for the development, regulatory and sales milestones under the arrangement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><ix:continuation id="i79788e0c3e25494ebf75519e8feac2e2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognized BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. As discussed in Note 8, beginning in the three months ended June 30, 2022, we began reporting clinical trial, other third-party costs and employee costs for the bempegaldesleukin program in Restructuring, impairment and other costs of program. Accordingly, during the three months ended June 30, 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i545e1ec1c15e497d8d84331994a8de35_D20220101-20220630" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjE5OTAyMzI2NDg4MQ_56e7f53e-8523-44ea-9174-d46fdae284d9"><ix:nonFraction unitRef="usd" contextRef="i8cb09da3230846e4ab889acaf256b09a_D20220401-20220630" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjE5OTAyMzI2NDg4MQ_87c03267-3a0b-4491-b60c-50577b1393cc">7.6</ix:nonFraction></ix:nonFraction>&#160;million, as a reduction of such expense for the net reimbursement from BMS. During the six months ended June 30, 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i6a74c1627d594a4e9983b68d9cb5016a_D20220101-20220331" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDA1Mg_ccde7678-612e-4683-abd2-5232574eea36">24.9</ix:nonFraction>&#160;million as a reduction of research and development expense for the net reimbursement from BMS, reflecting the reimbursement recorded in the three months ended March 31, 2022. For the three and six months ended June 30, 2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="i55a25cbb90084904aaa526c771ddf88f_D20210401-20210630" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjE5OTAyMzI2NDg1MA_75b34390-af41-4845-9c8e-3c0b9c169e1f">24.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2710a7259237431b952f8e9e2f6ca813_D20210101-20210630" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjE5OTAyMzI2NDg2NQ_e07693d2-540f-4316-8eeb-e18ef620f580">51.4</ix:nonFraction>&#160;million, respectively, as a reduction of research and development expense for the net reimbursement from BMS. As of June&#160;30, 2022, we have recorded an unbilled receivable of $<ix:nonFraction unitRef="usd" contextRef="i2fb960f7e2be4ba7b0f30d51ecbfb755_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDI0MA_8196590a-9a40-4580-b56b-e2c5d6e36d21">7.4</ix:nonFraction>&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">): NKTR-358 </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop NKTR-358, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $<ix:nonFraction unitRef="usd" contextRef="i06b66ce62bc84a1e8198557985db717e_D20170723-20170723" decimals="INF" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDYxMw_1aa9ec69-c43a-4ed9-ba6e-f7b7bab6ecbd">150.0</ix:nonFraction>&#160;million and are eligible for up to $<ix:nonFraction unitRef="usd" contextRef="i709e2f46181a4b05a3abc2e27c2e31e3_I20170723" decimals="INF" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDY0Mw_23cb9299-93da-46e3-bfcd-e811e2a8aba5">250.0</ix:nonFraction>&#160;million in additional development and regulatory milestones. We are currently in Phase 1B and Phase 2 development, where we share costs with <ix:nonFraction unitRef="number" contextRef="ic5ed1fb4aeaf4781a0044453513572b1_D20170723-20170723" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDc3OQ_0d2cdcc4-e939-4339-8b3b-bb0810a7bd58">75</ix:nonFraction>% of the costs borne by Lilly and <ix:nonFraction unitRef="number" contextRef="i06b66ce62bc84a1e8198557985db717e_D20170723-20170723" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDgxNA_4785d94d-0d65-4f9e-bb6b-a6cff7d6babb">25</ix:nonFraction>% of the costs borne by us. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to <ix:nonFraction unitRef="number" contextRef="i4c14708c9dc14478a8d5ecaefcbb0ee5_D20170723-20170723" decimals="INF" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDk0Nw_4e596389-9eb3-446d-8016-4cf43fc6a465">25</ix:nonFraction>% of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the costs of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 development on an indication-by-indication basis in order for us to achieve the maximum royalty level under the Lilly Agreement, and further</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, we will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales.  Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by <ix:nonFraction unitRef="number" contextRef="id60d7ddcd1e843edacbce13b2a891386_D20170723-20170723" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNTUwOQ_31ba2324-84f7-4227-86fd-ade51f9d37c9">50</ix:nonFraction>% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by <ix:nonFraction unitRef="number" contextRef="id60d7ddcd1e843edacbce13b2a891386_D20170723-20170723" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNTc0NA_fcd2484d-49ff-4daf-b929-41549bd2d75e">75</ix:nonFraction>% if both conditions occur.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lilly Agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The Lilly Agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are entitled to significant development milestones under this arrangement, through June&#160;30, 2022, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 5, we have sold our rights to receive royalties from these other collaboration agreements. Our non-cash royalty revenue which totaled $<ix:nonFraction unitRef="usd" contextRef="ibaa02756dcbe4a1a871ce1cb0480648d_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNjU5NzA2OTc3NjE4Ng_552f5966-7aa8-43bf-8802-dc39c7303641">16.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2e6059c3a6a244129de957ee89ff70fc_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNjU5NzA2OTc3NjE5NA_8018bdfd-d45a-4bfc-a6b9-3b6bb173860d">33.8</ix:nonFraction>&#160;million for the three and six months ended June&#160;30, 2022 and totaled  $<ix:nonFraction unitRef="usd" contextRef="i957bd179292a4a5f8bea0ec87a04ddac_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNjU5NzA2OTc3NjI0MA_02ccf7cc-f1f5-4231-9fdd-677af2ea0f29">20.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i82df606601154dc1ad7096a861539bf7_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNjU5NzA2OTc3NjI0OA_a6938617-5ab2-4010-b789-041cb6ce760f">39.3</ix:nonFraction>&#160;million for the three and six months ended June 30, 2021, respectively, represents revenue for granting licenses which we had satisfied in prior periods.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $<ix:nonFraction unitRef="usd" contextRef="i4e937e61c4a04a74b304ed91d94164d3_I20220630" decimals="INF" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNzA0MQ_ce561293-edf4-4914-be7c-dc8712f4e68f">40.0</ix:nonFraction>&#160;million of regulatory milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.</span></div></ix:continuation><div id="i140383c8fcb34877b7aa2512bcb00b00_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 &#8212; <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfMjU3_2dc1e985-7573-4b91-aa79-e50b505eec40" continuedAt="i50f2a2d1dd5c4d23af42f55d132ddda7" escape="true">Restructuring, Impairment and Other Costs of Terminated Program</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i50f2a2d1dd5c4d23af42f55d132ddda7" continuedAt="i0f3a1743c4f14a65abb0b6098d546a37">As discussed in Note 1, because our registrational trials in bempegaldesleukin did not meet their primary endpoints, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors, and, during April 2022, we announced the Restructuring Plan to prioritize key Phase 2 development programs, to advance our early stage research pipeline and to reduce our workforce by approximately <ix:nonFraction unitRef="number" contextRef="i6844748a7747471187efa284c70c9b40_D20220401-20220430" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfNjU5NzA2OTc3MDM1NQ_054c1d37-a98c-440d-a472-dedaffd996e7">70</ix:nonFraction>% from approximately </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><ix:continuation id="i0f3a1743c4f14a65abb0b6098d546a37" continuedAt="ie604f8c4f99c4d8bbe032448d632e29a"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i615612becd454568aed79f306f2b522e_I20220331" decimals="0" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfMTY0OTI2NzQ2NjI0Nw_9ea6766e-4dc5-4c42-ac86-79fd8d05b40b">735</ix:nonFraction> to approximately <ix:nonFraction unitRef="employee" contextRef="ic87a58d05dff437199600e83c801a439_I20220430" decimals="0" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfMTY0OTI2NzQ2NjI1Mg_dd6668b5-f7d8-4ad1-8ec5-5a971c9bf5c1">225</ix:nonFraction> employees. In connection with these events, we reported the following costs in Restructuring, impairment and other costs of terminated program in the three months ended June 30, 2022:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Severance and related benefit costs pursuant to the Restructuring Plan;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impairment of right-of-use assets and property, plant and equipment resulting from the Restructuring Plan, primarily reflecting excess office and laboratory leased spaces in San Francisco, CA; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract termination and other costs associated with these plans. Previously, during the three months ended March 31, 2022, we recognized an initial $<ix:nonFraction unitRef="usd" contextRef="i6cf30f1f3976425f9ae1a9658814d0a2_D20220101-20220331" decimals="-5" name="us-gaap:LossOnContractTermination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfMTY0OTI2NzQ2NjI1Nw_50532fed-a1b1-4e2f-87ad-0b1abf3301bc">1.5</ix:nonFraction>&#160;million in cancellation fees related to certain manufacturing activities for bempegaldesleukin.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In prior periods, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin primarily in research and development expense. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfODc5NjA5MzA0NjYyNw_760e5161-3f21-49fa-9623-0db087a6dda9" continuedAt="iedff54fa96074b47ba3640e6018f8c93" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfMi01LTEtMS0zMTM2OA_146d788b-9a41-4f26-afdf-6f621bffa005">20,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfMi03LTEtMS0zMTM2OA_33c77449-0d15-4eb8-9f8a-76ecab957d59">20,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfMy01LTEtMS0zMTM2OA_ab3f8180-acfc-448d-bf6d-4fa8f3e058ea">27,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfMy03LTEtMS0zMTM2OA_4c5c6339-712f-4578-a51d-112749b6d066">27,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNS0yLTEtMS0zMzI0MQ_2a55b8f0-51b5-4997-bbb3-fb89e2d85ab8">57,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNS00LTEtMS0zMzI0Mw_06ffba70-3e9e-45c1-b37b-e1f01b2bbd8c">57,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:LossOnContractTermination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNC01LTEtMS0zMTM2OA_6c379e80-ed09-48e0-a3f1-44904866e0bc">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:LossOnContractTermination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNC03LTEtMS0zMTM2OA_193a8427-09ca-48ec-9e57-7269c695a20f">2,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNS01LTEtMS0zMTM2OA_a8f96a2d-f5c8-431f-9e13-2858e3008eb4">106,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNS03LTEtMS0zMTM2OA_a23e14a0-e3cf-4b49-9331-8b545ca38787">107,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program for the three and six months ended June 30, 2022 includes a reduction of $<ix:nonFraction unitRef="usd" contextRef="i545e1ec1c15e497d8d84331994a8de35_D20220101-20220630" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfNjU5NzA2OTc5MzAyNw_56e7f53e-8523-44ea-9174-d46fdae284d9"><ix:nonFraction unitRef="usd" contextRef="i8cb09da3230846e4ab889acaf256b09a_D20220401-20220630" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfNjU5NzA2OTc5MzAyNw_87c03267-3a0b-4491-b60c-50577b1393cc">7.6</ix:nonFraction></ix:nonFraction>&#160;million for the net reimbursement from BMS. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and Benefit Expense</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the reduction in force under our Restructuring Plan are entitled to receive severance payments and certain Company funded benefits. We recognized severance and benefit expense in full for employees who were notified of their termination in April 2022 and have no requirements for future service, and we are recognizing expense for employees who are required to render services to receive their severance and benefits over the service period ratably over the service period. This service period began in April 2022 and all will end during 2022. <ix:continuation id="iedff54fa96074b47ba3640e6018f8c93" continuedAt="i2c8409357fa446c3883315a87802a025">The following table provides details regarding the severance and other termination benefit expense and a reconciliation of such liability for the three months ended June 30, 2022, which we report within Accrued compensation on our Condensed Consolidated Balance Sheet (in thousands):</ix:continuation></span></div><div style="margin-top:9pt"><ix:continuation id="i2c8409357fa446c3883315a87802a025" continuedAt="ie98adaadac64494a867cc30511174c31"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">No service period</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service period required</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total severance and other termination benefits, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f06c20fdeb4692aecab09bd5ba73dc_I20220331" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMS0yLTEtMS0zMzYyOQ_852b4d19-2961-4c83-98ad-3e3290e20219">23,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac52ca5498ce49769a17fcd39f41a8fe_I20220331" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMS00LTEtMS0zMzYzMQ_f8300eb4-95c2-4907-a9b5-8dd4774a5c68">8,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615612becd454568aed79f306f2b522e_I20220331" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMS02LTEtMS0zMzYzMw_496a12ad-5716-479c-b185-c6089991416b">32,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f06c20fdeb4692aecab09bd5ba73dc_I20220331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMi0yLTEtMS0zMzYyOQ_94f1a750-bdbf-4b2e-a8c9-e40277a531a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac52ca5498ce49769a17fcd39f41a8fe_I20220331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMi00LTEtMS0zMzYzMQ_587bb617-379b-4956-8c02-d85a60f1adda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615612becd454568aed79f306f2b522e_I20220331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMi02LTEtMS0zMzYzMw_02986932-d2e2-4020-a8f4-e7ab398f7b6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a2d694cc3e4307a91fcd4094b87e05_D20220401-20220630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMy0yLTEtMS0zMzYyOQ_b7f6c54c-0c83-46b3-80c2-9c9c8dcb4fc3">23,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3a1676fb6a54c20884fa6fd60c2e2c7_D20220401-20220630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMy00LTEtMS0zMzYzMQ_10d35f9d-0735-429c-b037-f0a3fbbf9193">4,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26bb03096c94a0cb77035930f749cab_D20220401-20220630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMy02LTEtMS0zMzYzMw_5e4aa123-4e87-4329-8a7a-d7db905584cf">27,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a2d694cc3e4307a91fcd4094b87e05_D20220401-20220630" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNC0yLTEtMS0zMzYyOQ_9ac32293-214d-44e9-b60d-39c4817a5113">12,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3a1676fb6a54c20884fa6fd60c2e2c7_D20220401-20220630" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNC00LTEtMS0zMzYzMQ_77f8efac-34ec-471c-af65-5792977718e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia26bb03096c94a0cb77035930f749cab_D20220401-20220630" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNC02LTEtMS0zMzYzMw_8b2a5502-7ff2-4ab0-b00d-4c3564851167">12,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0541e02c0b140788f808cb99a415cce_I20220630" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNS0yLTEtMS0zMzYyOQ_f2327e08-f12a-4ed4-84f1-04af3f45f29b">10,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaeb6b4f62ff443a849137f15836e9cf_I20220630" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNS00LTEtMS0zMzYzMQ_fdcd03e1-e11a-41e8-8338-1174001e6ebe">4,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce6c1dda32f4aad9544682d143fc875_I20220630" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNS02LTEtMS0zMzYzMw_33a6ce7b-760f-4eaf-b0cb-268469bffc8d">14,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><ix:continuation id="ie604f8c4f99c4d8bbe032448d632e29a" continuedAt="ic2f656d1ef1d4be3923fbdd8e761fd32"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability as of June 30, 2022 for employees terminated with no requirements for future service primarily relates to final severance paid in July 2022. We may record adjustments to severance and benefit expense in future periods as our estimates of the costs of benefits change or when an employee terminates before the end of their requisite service period. However, we do not expect that such adjustments will have a material effect on our results of operations or financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Right-of-Use Assets and Property, Plant and Equipment</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our Restructuring Plan, we have consolidated our operations by exiting all of the office space from our leased facility at 360 Third St. and certain laboratory and office spaces at our leased facility at 455 Mission Bay Blvd. South, both in San Francisco, CA. We are seeking to sublease these spaces, while still maintaining sufficient office and laboratory space to allow our team to develop our proprietary programs. We have also terminated all research and development activities at our owned facility in India, which we plan to sell. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these plans, we reviewed each of our excess spaces for impairment as of May 31, 2022, when management had determined which spaces we would retain and which spaces we may sublease. As part of our impairment evaluation of each excess space, we separately compared the estimated undiscounted income for each sublease to the net book value of the related long-term assets, which include right-of-use assets and certain property, plant and equipment, primarily for leasehold improvements (collectively, sublease assets). We estimated sublease income using market participant assumptions, including the length of time to enter into a sublease and lease payments, which we evaluated using current real estate trends and market conditions. If such income exceeded the net book value of the related assets, we did not record an impairment charge. Otherwise, we recorded an impairment charge by reducing the net book value of the assets to their estimated fair value, which we determined by discounting the estimated sublease income using the estimated borrowing rate of a market participant subtenant, which we estimated to be 6.4%. For our India site, we recorded no impairment charge because the estimated net proceeds from the sale exceed the net book value of the site. We have classified the India facility as an asset held for sale as of June 30, 2022 and report this in other current assets in our Condensed Consolidated Balance Sheet. <ix:continuation id="ie98adaadac64494a867cc30511174c31" continuedAt="i97247592486e45e399b7ef7a17bf4fe5">Additionally, we recorded an impairment expense primarily for software which we plan to abandon and certain excess equipment based on the estimated income from selling such assets. We recorded impairment charges as follows (in thousands):</ix:continuation></span></div><div style="margin-top:9pt"><ix:continuation id="i97247592486e45e399b7ef7a17bf4fe5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease Right-of-Use Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of impaired facilities before write-off</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i497fa308a3a645399b2e66b525053f40_I20220630" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMS0xLTEtMS0zMzYzNQ_dfacee2e-7c1b-4b72-8699-6c0f89c16e3f">16,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1540676709064b73bec30295a78b402b_I20220630" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMS0zLTEtMS0zMzYzNw_c3f535d0-a287-4a58-965d-86d02f8b2289">70,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a99a4cd3e9046998329b115338a1fcf_I20220630" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMS01LTEtMS0zNDI0NQ_b6c41fa0-6d99-47c8-a306-c50c163ecda6">87,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Fair value of impaired facilities &#8212; Level 3 of Fair Value Hierarchy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbf30fbd9d0b453c90b68fbde9485002_I20220630" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMi0xLTEtMS0zMzYzNQ_b8725cba-b1d4-4893-bff0-939e1a55cc29">6,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d93efed2f4445efbb3ddeb1f2270dee_I20220630" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMi0zLTEtMS0zMzYzNw_d1b91211-f80d-406f-85ff-bcd91599a251">28,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i575b5f648bf14d37af112b07599ee280_I20220630" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMi01LTEtMS0zNDI0NQ_4f3e7d2c-eb0a-4a11-91cf-01362329f376">35,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment expense for facilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90314768134649a19db482bb55a94126_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMy0xLTEtMS0zMzYzNQ_a09a926d-2f10-4d35-a48c-d254b2161ca7">9,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic166b3669ca64e7781374dbce5ce7ae2_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMy0zLTEtMS0zMzYzNw_2e7b5c0c-55cd-440c-a5b5-f875f39b416c">42,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMy01LTEtMS0zNDI0NQ_54be68b2-8557-406c-987f-b4a39cb541ba">52,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of other property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90314768134649a19db482bb55a94126_D20220101-20220630" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfNC0xLTEtMS0zMzYzNQ_6963006d-74fe-4c7c-830a-c0f2e9e0c2ec">5,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfNC01LTEtMS0zNDI0NQ_70c8dc83-aab3-420d-848e-74d2a7af2756">5,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total impairment of right-of-use assets and property, plant and equipment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90314768134649a19db482bb55a94126_D20220101-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfNS0xLTEtMS0zMzYzNQ_5b24eab7-571b-4ca9-906d-987807db3470">14,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic166b3669ca64e7781374dbce5ce7ae2_D20220101-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfNS0zLTEtMS0zMzYzNw_657caad9-45cf-4c13-b096-069331da07cb">42,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfNS01LTEtMS0zMzYzOQ_cf56e42c-b620-48d5-9110-89cfcee52c2d">57,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfMTY0OTI2NzQ3MDY1OA_299d0f71-4b90-45dc-87be-f3adb6291460" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our property, plant and equipment as of June 30, 2022 and December 31, 2021, reflecting the effects of the impairment charges and held-for-sale reclassification.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e0f4b9899445bfb9f7c130223aa7e0_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMS0xLTEtMS0zNTg5Mg_bd00b37e-f7e5-4248-877e-851881d7db40">83,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib642b7862a8f41ebaf418619e6c1e3a2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMS0zLTEtMS0zNTgyMA_99f5ca82-2036-4f13-89f6-988bcaef2819">97,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73b2d39f16fe45808af4224f9bb7e64a_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMi0xLTEtMS0zNTg5Mg_529611be-66e2-4f40-bcda-264fb559b126">36,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdb1245c2a242b295b7228ac4ac5bfd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMi0zLTEtMS0zNTg5NA_b2c94b05-d540-4450-ac18-953b775b0b37">42,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278bdb80843a4d15829b02b5f7e5db58_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMy0xLTEtMS0zNTg5Mg_2e0b80c7-7560-4048-bcb0-fc7d07380e59">28,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4699c5afe4c64c4dab6ccd99e97a4420_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMy0zLTEtMS0zNTg5NA_1fd3927e-a70a-4a2e-86f3-35c0b48c638d">28,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e3d5e8c9da41acba432436d90e144e_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNC0xLTEtMS0zNTg5Mg_0bdf5439-2756-414f-8cb5-8030251104fd">23,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2392ef5c8b944214b18e26ee24b8b8f7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNC0zLTEtMS0zNTg5NA_28b28bc3-efbe-4e7c-a4ee-e4aff8a26346">22,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597b24d94a354403bcb197617d6325c3_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNS0xLTEtMS0zNTg5Mg_e31d9f32-a645-4a5e-ba9e-006b3a69824c">7,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf4331b31d34c4b8595b0bf92ffe39c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNS0zLTEtMS0zNTg5NA_6107b44b-4a31-4f3b-a943-3696e0b5987f">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e1155ab7ba47dfa1bb5c48d087629a_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNi0xLTEtMS0zNTg5Mg_3b4f901d-f19b-403a-979d-b6119b052fa0">179,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie29cf24f92e945298307779be936b4b8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNi0zLTEtMS0zNTg5NA_c221e975-45e9-4dbf-b15c-888ceed49b04">201,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13e1155ab7ba47dfa1bb5c48d087629a_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNy0xLTEtMS0zNTg5Mg_7fb0bdf0-510c-4861-b6b3-aa5c4bb4d98d">143,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie29cf24f92e945298307779be936b4b8_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNy0zLTEtMS0zNTg5NA_1cbdacc7-8e71-4660-81c4-582dd30c05be">148,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e1155ab7ba47dfa1bb5c48d087629a_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfOC0xLTEtMS0zNTg5Mg_d4b9a9af-93b3-46df-8531-46f67be225ad">36,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie29cf24f92e945298307779be936b4b8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfOC0zLTEtMS0zNTg5NA_20884252-e364-4847-84b2-134754b0bbff">53,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c160117d32471bba70bb96f864292d_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfOS0xLTEtMS0zNTg5Mg_93b23a6b-9f32-45ed-9672-13092582251b">3,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3143ddecf7734d3da635d16bd5e504a6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfOS0zLTEtMS0zNTg5NA_8002cdcc-48d6-479a-90a4-3194dd5965a5">7,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMTAtMS0xLTEtMzU4OTI_f86acf4c-94cc-461e-b9b8-7b1cce0596fe">39,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMTAtMy0xLTEtMzU4OTQ_079a3c82-14af-4719-add1-6603a7e25b2c">60,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic2f656d1ef1d4be3923fbdd8e761fd32">We may record adjustments to impairment expense in future periods as we enter into sublease or sale agreements or change our estimates when additional information becomes available to us.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_6597069767687"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 &#8212; <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGV4dHJlZ2lvbjpmMThhMjIxZTIwZGU0MWZhYjlhOWQ4OTRiY2ZiZDE5Y18yMTk5MDIzMjU1ODEy_e5d53ccb-5114-4aaa-9f39-1d7e00d3e02b" continuedAt="i4f6bc672ef7a4de6ae3b99094bfe62da" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i4f6bc672ef7a4de6ae3b99094bfe62da"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2022, the stockholders of Nektar approved an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by <ix:nonFraction unitRef="shares" contextRef="if8529e0af2b847e992427d335aa69816_I20220608" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGV4dHJlZ2lvbjpmMThhMjIxZTIwZGU0MWZhYjlhOWQ4OTRiY2ZiZDE5Y182NTk3MDY5NzY3NjQw_21f62a21-2266-44aa-a8a9-7d4d059b4ffe">5,000,000</ix:nonFraction> shares.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our Restructuring Plan, we recorded the benefit for the forfeitures of stock awards from employees who were terminated as part of our reduction-in-force during the three months ended June 30, 2022. <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGV4dHJlZ2lvbjpmMThhMjIxZTIwZGU0MWZhYjlhOWQ4OTRiY2ZiZDE5Y18yMTk5MDIzMjU1ODEz_aebf58a1-2f7a-4037-aec9-e3c265fe7fd2" continuedAt="ic8365bc57bf4478daa3dfe0f80da0ff4" escape="true">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</ix:nonNumeric></span><ix:continuation id="ic8365bc57bf4478daa3dfe0f80da0ff4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33ecfd9df5834d09abbc58af261ebf32_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8yLTEtMS0xLTMxODIw_ae92be32-fb5e-4e06-b635-e1c685a1f505">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c21bdadf59b4c48a135191cd5c2ec54_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8yLTMtMS0xLTMxODIw_284c3552-0bef-4228-b058-3d50c81aa41a">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27d1141edbfe4feb8e6950e0879e5c18_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8yLTUtMS0xLTMxODIw_eccf2979-687f-468a-ba4b-8029be8a17bf">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb0b12b5faa4aaba9bdc2b06745202f_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8yLTctMS0xLTMxODIw_28d6ca0f-db9e-46ed-821a-79978e4275c7">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6659ab393074492bbe414ddb56231ee4_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8zLTEtMS0xLTMxODIw_ff78b5ea-56d4-459d-a907-594293aeaa89">4,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfbea4ad565429885a50c6fba0cc5b8_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8zLTMtMS0xLTMxODIw_94469622-9482-447c-aff0-9ed513d3e0d1">13,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cecbd4c604b48409676aa9a35884b89_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8zLTUtMS0xLTMxODIw_24f27e81-4aff-4ac8-a6db-c85cc260d8bf">16,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34088cc50d6948ccbe3650a776356dc9_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8zLTctMS0xLTMxODIw_fca22ab0-dbf3-4cbe-ba0e-cd1bce56bf83">27,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3fe74ae0994a9b8a3cb73f23feba72_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV80LTEtMS0xLTMxODIw_a5da0c8a-e384-460d-9b8d-cbd5685d8350">4,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib91712b5e54b4334b079f6d3036b9a32_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV80LTMtMS0xLTMxODIw_9879a1a5-6310-4b0f-8be3-93c71309788b">9,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c5502b65c4bc38990dea8219187f9_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV80LTUtMS0xLTMxODIw_b0ac699b-b09f-4f83-9c0d-757e00ea71bf">13,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id493f1b7c27c408ea3daa0171ccfbdbd_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV80LTctMS0xLTMxODIw_b650dccb-0f60-4c3f-afbf-d6035ba9a2f0">18,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4c735c57bc4b3cbe3c2e99a3d9895e_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTEtMS0xLTMzNzY1_09ab1809-6f58-4144-a5db-86b29adea25b">922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34db7c40bdc449ff8d949f1f5970651c_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTMtMS0xLTMzNzY1_5db1a74c-fb00-4095-8ac1-c6c1993641aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58da4c5a8eb049b2ae0fe612bc3870d4_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTUtMS0xLTMzNzY1_b09e327c-ae21-4c10-b184-ffc25b5d7a52">922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9af591eefe4df68e2c4f1f5bd76bca_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTctMS0xLTMzNzY1_6985f39e-c74b-4995-9c9f-e2bfdc4c2b11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTEtMS0xLTMxODIw_c8c498ef-a0e9-410f-a01f-3c2fdeb76ecc">11,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTMtMS0xLTMxODIw_c08ef01d-f746-4eec-a6a5-d182f689d9a3">23,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTUtMS0xLTMxODIw_8ca73c24-917e-4699-9644-6d108aad1505">32,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTctMS0xLTMxODIw_06249410-23fb-48a2-88b7-d9a10e60beaa">47,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGV4dHJlZ2lvbjpmMThhMjIxZTIwZGU0MWZhYjlhOWQ4OTRiY2ZiZDE5Y18yMTk5MDIzMjU1ODE0_da206dca-0549-4ca0-be1b-57554f9ea4d7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards of our common stock as follows (shares in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8yLTEtMS0xLTMxODIw_00617f3c-ca53-454e-98dd-e64f05c34c4d">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8yLTMtMS0xLTMxODIw_c63de360-70c3-42d7-aad4-dafa93176e03">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8yLTUtMS0xLTMxODIw_7a43e46c-4b59-4f1c-a3a2-7e9f7ba8f996">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8yLTctMS0xLTMxODIw_092623e2-872f-4982-b1f7-df66415f7ab5">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8zLTEtMS0xLTMxODIw_6aad3c31-3ca5-45a4-bdc3-52b15d7c44ab">2.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8zLTMtMS0xLTMxODIw_52bd5e97-5dd0-4631-bdb9-3e02d073e24b">9.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8zLTUtMS0xLTMxODIw_4237cef2-a863-42a5-9707-1fbab9392877">3.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8zLTctMS0xLTMxODIw_834fd10f-40f2-44f9-a596-41bda29d170f">10.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e718894f1c9465093719bbd74467c63_D20220401-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl80LTEtMS0xLTMxODIw_185563f5-785e-4edb-813b-15b9b9c34d1b">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9172d4dea5534ee5a60b8140527f533b_D20210401-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl80LTMtMS0xLTMxODIw_3d4cf821-c99d-43eb-9ccb-dcd7d524f2fb">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd2b36e57d474f11a75428893dd08b02_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl80LTUtMS0xLTMxODIw_2e807c0d-eadb-4eec-85bd-347bfa739bdf">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f5070c46f774b5ba4d6c3752a1c61f0_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl80LTctMS0xLTMxODIw_e39361d1-f424-44b8-ba4b-a1e872fcc2b8">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e718894f1c9465093719bbd74467c63_D20220401-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl81LTEtMS0xLTMxODIw_38e7a5c8-b2f1-442b-a469-957fc9cd9144">3.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9172d4dea5534ee5a60b8140527f533b_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl81LTMtMS0xLTMxODIw_45d1f9e4-bf60-48ad-b847-17beafb30c01">18.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd2b36e57d474f11a75428893dd08b02_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl81LTUtMS0xLTMxODIw_d8be19d7-a8c7-48c3-a2bd-85f6af11f67f">6.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f5070c46f774b5ba4d6c3752a1c61f0_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl81LTctMS0xLTMxODIw_511a75d4-6eac-4a39-93de-01c13b4994fa">19.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl82LTEtMS0xLTMxODIw_8b949853-95ae-4db2-b967-03a35c1d1f34">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl82LTMtMS0xLTMxODIw_cd1f7886-cfc9-4683-a9c0-9c082eb14527">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl82LTUtMS0xLTMxODIw_a8f7c8d7-1490-45c0-b452-f53e83b49e88">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl82LTctMS0xLTMxODIw_20d3064c-6b54-4c5a-b079-bc507b708be1">3,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i140383c8fcb34877b7aa2512bcb00b00_64"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 &#8212; <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RleHRyZWdpb246MjgwYTQxMzFhZjY4NDliOGJlMTc5NmI4ZTgyM2Q2NmZfOTE4_da847aa1-0a0d-4118-950b-ca85ed8ceb8e" continuedAt="ie359e6722e6244eaada637681a3ff62c" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="ie359e6722e6244eaada637681a3ff62c"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. <ix:nonNumeric contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RleHRyZWdpb246MjgwYTQxMzFhZjY4NDliOGJlMTc5NmI4ZTgyM2Q2NmZfOTE5_4c49dc40-fec5-48f8-9d80-ae597f1c2a68" continuedAt="i0d031b37344d4d8ab57da25419e77484" escape="true">Potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i0d031b37344d4d8ab57da25419e77484"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RhYmxlOmQ0OGI2OWRmMDM2NjQyNDA4NjVkOTQzYjY1MTI0ODJjL3RhYmxlcmFuZ2U6ZDQ4YjY5ZGYwMzY2NDI0MDg2NWQ5NDNiNjUxMjQ4MmNfMi0xLTEtMS0zMDU1Mg_21ac27d6-054c-49fe-b9b2-b72ef01d21a8">20,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RhYmxlOmQ0OGI2OWRmMDM2NjQyNDA4NjVkOTQzYjY1MTI0ODJjL3RhYmxlcmFuZ2U6ZDQ4YjY5ZGYwMzY2NDI0MDg2NWQ5NDNiNjUxMjQ4MmNfMi0zLTEtMS0zMDU1Mg_b760e043-5e5b-4b08-96b4-962d3cb7486b">18,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RhYmxlOmQ0OGI2OWRmMDM2NjQyNDA4NjVkOTQzYjY1MTI0ODJjL3RhYmxlcmFuZ2U6ZDQ4YjY5ZGYwMzY2NDI0MDg2NWQ5NDNiNjUxMjQ4MmNfMi01LTEtMS0zMTQ3NA_7d903375-bfc3-4a73-a9c0-547d7e10aecb">21,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RhYmxlOmQ0OGI2OWRmMDM2NjQyNDA4NjVkOTQzYjY1MTI0ODJjL3RhYmxlcmFuZ2U6ZDQ4YjY5ZGYwMzY2NDI0MDg2NWQ5NDNiNjUxMjQ4MmNfMi03LTEtMS0zMTQ3NA_40f64452-1766-4ed0-9334-99b1a460bfab">18,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to those discussed in this section as well as factors described in Part II, Item&#160;1A &#8220;Risk Factors.&#8221;</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Direction of Our Business</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative new medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes potential therapies for oncology and immunology. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in new drug discovery and advancing our pipeline of drug candidates as we believe that this is the best strategy to build long-term stockholder value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we focus on developing medicines in immuno-oncology (I-O), which is a therapeutic approach based on targeting biological pathways that stimulate and sustain the body&#8217;s immune response in order to fight cancer. In the I-O area, we executed a broad clinical development program to develop bempegaldesleukin (previously referred to as NKTR-214) in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nivolumab) in collaboration with Bristol-Myers Squibb Company (BMS) under our Strategic Collaboration Agreement. We also conducted independent development work evaluating bempegaldesleukin in combination with other checkpoint inhibitors and agents with potential complementary mechanisms of action, including studies evaluating bempegaldesleukin combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab). In April 2022, we and BMS jointly announced that the companies would be ending the global clinical development program for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and discontinue all ongoing studies in our collaboration with BMS. We also decided to discontinue all studies of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as our studies of NKTR-262, which was being evaluated in combination with bempegaldesleukin. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we announced new strategic reorganization and cost restructuring plans (together, the Restructuring Plan) focused on prioritizing key research and development efforts that will be most impactful to the Company&#8217;s future, including our NKTR-255 and NKTR-358 programs and several core research programs.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of natural killer (NK) cells and induces survival of both effector and CD8+ memory T cells. Recombinant human IL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular cytotoxicity molecules as well as to enhance CAR-T therapies. We have initiated a Phase 1 dose escalation and expansion clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. We are also continuing our oncology clinical collaboration with Merck KGaA and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255 in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in the Phase II JAVELIN Bladder Medley study. We are also currently designing a Nektar-sponsored comparative study, which we aim to initiate in the second half of 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In immunology, NKTR-358 targets the underlying immune system imbalance in the body that occurs in patients with autoimmune disease. NKTR-358 is designed to optimally target the IL-2 receptor complex in order to stimulate proliferation and growth of regulatory T cells. NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of autoimmune diseases. In 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to develop and commercialize NKTR-358, pursuant to which we received an initial payment of $150.0 million and are eligible for up to an additional $250.0 million for development and regulatory milestones. We have completed our responsibilities for Phase 1 clinical development and certain drug product development and supply activities. We also share Phase 2 development costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to 25% of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the costs of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 development on an indication-by-indication basis in order for us to achieve the maximum royalty level under the Lilly Agreement, and further</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, we will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy patients. We also completed treatment of a Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with systemic lupus erythematosus (SLE). Lilly is conducting two Phase 1b studies in patients with psoriasis and atopic dermatitis, and based on positive interim Phase 1b results in atopic dermatitis announced in December 2021, Lilly is planning to initiate a Phase 2 study in atopic dermatitis. Lilly also initiated a Phase 2 study in SLE in October 2020 and a Phase 2 study in ulcerative colitis in March 2021. In April 2022, we announced that Lilly had informed us that an interim analysis in the Phase 2 study in ulcerative colitis led to the discontinuation of further development in this indication. Lilly also plans to initiate another Phase 2 study in another immune-mediated disease to potentially start in 2023. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically derived all of our revenue and substantial amounts of operating capital from our collaboration agreements. In addition to our collaborations with BMS and Lilly, we have received upfront and milestone payments under a number of other previous collaboration agreements, several of which have resulted in approved drugs, for which we may continue to manufacture the polymer reagents used in the production of the drug products and may be entitled to royalties for net sales of these approved drugs. As of December 31, 2020, however, we have sold the majority of our rights to receive royalties under these arrangements, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2012 Purchase and Sale Agreement: In 2012, we sold all of our rights to receive royalties from CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of Crohn&#8217;s disease and other autoimmune indications) and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of anemia associated with chronic kidney disease) under our collaborations with UCB Pharma and F. Hoffmann-La Roche Ltd, respectively, to RPI Finance Trust (RPI), an affiliate of Royalty Pharma for $124.0 million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2020 Purchase and Sale Agreement: In December 2020, we sold our rights, subject to a cap, to receive royalties from MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / MOEVNTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of opioid-induced constipation), ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a half-life extension product of Factor VIII) and other hemophilia products, under our arrangements with AstraZeneca AB, Baxalta, Inc. (a wholly owned-subsidiary of Takeda Pharmaceutical Company Ltd.), and Novo Nordisk A/S, respectively, for $150.0 million to entities managed by HealthCare Royalty Management (HCR) under a capped sale arrangement, such that all future royalties return to Nektar if HCR receives $210.0 million in royalties by December 31, 2025 (the 2025 Threshold) or $240.0 million if the 2025 Threshold is not met.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While in the near-term we continue to expect to generate substantially all of our revenue from collaboration arrangements, our long-term plan is to generate significant commercial revenue from proprietary products. Over the next several years, we plan to continue to make significant investments to advance our early drug candidate pipeline. We have several drug candidates in earlier stage clinical development or are being explored in research and that we are preparing to advance into clinical trials in future years. We are cultivating several research programs, including a collaboration with Biolojic Design to develop a unique bivalent antibody targeting TNFR2, as well as two Nektar-developed research programs focused in the areas of oncology and auto-immune disease. We believe that our substantial investment in research and development has the potential to create significant value if one or more of our drug candidates demonstrates positive clinical results, receives regulatory approval in one or more major markets and achieves commercial success.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the marketing efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market opportunities. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Item 1A &#8220;Risk Factors.&#8221; </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of the COVID-19 Pandemic</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to actively monitor the ongoing COVID-19 pandemic and applicable government recommendations in light of new developments. In particular, the emergence of new variants of the coronavirus and local resurgences in number and rates of infections, and the further spread of the virus may result in the return of prior restrictions or the institution of restrictions in the affected areas, which could have an adverse effect on our business, including our clinical trial timelines. Currently, our operations in research, manufacturing and maintenance that occur within our facilities are continuing in accordance with applicable guidelines and orders. Across all our locations, we have instituted a temporary work from home policy for office personnel who do not need to work on site to maintain productivity and we allow employees to voluntarily return to work on site with appropriate health and safety measures. The safety and well-being of our employees, and the patients and healthcare providers in our clinical trial programs, are of first and foremost importance to us. We believe that the safety measures we are taking and instructing our contractors to take in response to the COVID-19 pandemic meet or exceed the guidance and requirements issued from government and public health officials. We also continue to monitor our supply chains for any disruptions or constraints </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">caused by the COVID-19 pandemic. To date, we have not experienced any significant impacts on our supply, but ongoing global shortages in labor, raw materials and equipment could limit our ability to manufacture our products or to supply drug candidates for our clinical trials, or delay our research and development efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are currently engaged in the clinical testing of our drug candidates and the COVID-19 pandemic introduces challenges to our clinical development programs which are central to our business. The evolving situation around the COVID-19 pandemic, along with the resulting public health guidance measures that have been put into place, have thus far had varying impacts on the clinical testing of our drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the COVID-19 pandemic. Nektar&#8217;s Phase 1 clinical study of NKTR-255 in patients with relapsed/refractory hematologic malignancies has enrolled slower than anticipated due to the challenges caused by the COVID-19 pandemic.  While we are not currently aware of significant delays by our partners and collaborators caused by the COVID-19 pandemic on clinical trials involving our drug candidates; however, the fluidity of the COVID-19 pandemic precludes any firm estimates as to the ultimate effect this disease will have on clinical trials. Any current assessments of the effects of the COVID-19 pandemic on our clinical programs are difficult to predict and subject to change and, with regard to individual clinical trial sites within these studies, will likely vary by the geographic region in which they are located. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to mitigate the negative effects of the COVID-19 pandemic on our clinical trials (both in terms of clinical trial timelines and integrity of clinical study data), we have taken steps to help our clinical trial investigators and their teams continue to provide care and uninterrupted access to their patients. Although these steps may have the benefit of mitigating some of the negative effects of the COVID-19 pandemic, these measures may be insufficient to fully address all of the challenges posed by the pandemic.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to financing our near-term business needs, as set forth below in &#8220;Key Developments and Trends in Liquidity and Capital Resources,&#8221; we estimate we have working capital to fund our current business plans through at least the next twelve months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Developments and Trends in Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing. At June&#160;30, 2022, we had approximately $628.2 million in cash and investments in marketable securities.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_1050"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Three and Six Months Ended June&#160;30, 2022 and 2021</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,312&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,846&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,330&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,745)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,570)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as development or manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of products and services expected to be required to fulfill our performance obligations. Given the uncertainties in research and development collaborations, significant judgment is required to make these estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales decreased for the six months ended June&#160;30, 2022 as compared to the six months ended June&#160;30, 2021 primarily due to a decrease in product demand from our collaboration partners. We expect product sales for the full year of 2022 to be marginally lower than 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash Royalty Revenue Related to Sales of Future Royalties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our Non-cash royalty revenue, please see our discussion below in &#8220;Non-Cash Royalty Revenue and Non-Cash Interest Expense.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and Other Revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements and certain research and development activities. The level of license, collaboration and other revenue depends in part upon the estimated recognition period of the upfront payments allocated to continuing performance obligations, the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of research and development work, and entering into new collaboration agreements, if any. During the six months ended June&#160;30, 2022, we recognized $1.5 million for a license agreement, under which </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we are entitled to no further consideration. As a result of the recognition of this revenue in the six months ended June&#160;30, 2022, we expect license, collaboration and other revenue for 2022 to increase compared to 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties. See Item&#160;1A.&#160;Risk Factors for a discussion of the risks associated with the complex nature of our collaboration agreements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold and Product Gross Margin (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:49.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:49.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Percentage change represents an improvement in the gross margin.</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to manufacture and supply polymer reagents to support our proprietary drug candidates or our third-party collaborators where we have a strategic development and commercialization relationship or where we derive substantial economic benefit. We have elected to only enter into and maintain those manufacturing relationships associated with long-term collaboration agreements which include multiple sources of revenue, which we view holistically and in aggregate. We have a predominantly fixed cost base associated with our manufacturing activities. As a result, our product gross profit and margin are significantly impacted by the mix and volume of products sold in each period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product gross margin improved from the three and six months ended June&#160;30, 2021 to the three and six months ended June&#160;30, 2022 due to the mix of manufacturing orders from our customers. Product gross margin was negative for the six months ended June&#160;30, 2021. We have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the reagent, and we expect this situation to continue with this partner in future years. In addition to product sales to this partner, we also receive royalty revenue from this collaboration. In the three and six months ended June&#160;30, 2022 and 2021, the royalty revenue from this collaboration exceeded the related negative gross profit for this customer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect product gross margin to continue to fluctuate in future periods depending on the level and mix of manufacturing orders from our customers. We expect product gross profit to be negative in 2022 as a result of the collaborative arrangement described above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the expense reimbursement from our partners as a reduction to research and development expense, and we record our share of our partners&#8217; expenses as an increase to research and development expense. Under the BMS Collaboration Agreement, BMS generally bears 67.5% of development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 35% of costs for manufacturing bempegaldesleukin.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, BMS and we have decided to discontinue development of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will wind down the various clinical trials under the BMS Collaboration Agreement, and we have also decided to discontinue all other development of bempegaldesleukin. The cost sharing under the BMS Collaboration Agreement remains unchanged. Additionally, as discussed in Note 8 to our Condensed Consolidated Financial Statements, we have also implemented the Restructuring Plan to reduce our workforce by approximately 70%. As a result, beginning in the three months ended June 30, 2022, we report clinical trial expense, other third-party costs and employee costs for the bempegaldesleukin program, net of the reimbursement from BMS, within Restructuring, impairment and other costs of terminated program in our Condensed Consolidated Statement of Operations. Because we no longer report these expenses in research and development expense, research and development expense decreased significantly for the three and six months ended June&#160;30, 2022 as compared to the three and six months ended June&#160;30, 2021, respectively, and we expect this to continue for the remainder 2022 as compared to the same period in 2021. Additionally, during the three months ended June 30, 2022, we recorded $7.6&#160;million, as a reduction of Restructuring, impairment and other costs of terminated program for the net reimbursement from BMS. During the six months ended June 30, we recorded $24.9&#160;million as a reduction of research and development expense for the net reimbursement from BMS, reflecting the reimbursement we recorded in the three months ended March 31, 2022. For the three and six months ended June 30, 2021, we recorded $24.8&#160;million and $51.4&#160;million, respectively, as a reduction of research and development expense for the net reimbursement from BMS. Please see our discussion below in Restructuring, impairment and other costs of terminated program for additional information.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred research and development expense in the three and six months ended June&#160;30, 2022 and June&#160;30, 2021 for development costs and manufacturing activities for NKTR-255 and development costs for NKTR-358 as Lilly conducts its Phase 1B and Phase 2 studies, for which we are responsible for 25% of costs and Lilly is responsible for 75% of costs.&#160;We expect research and development expense for the development of NKTR-255 and NKTR-358 to increase for 2022 as compared to 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and amount of our future clinical trial expenses will vary significantly based upon our evaluation of ongoing clinical results and the structure, timing, and scope of additional clinical development programs and potential clinical collaboration partnerships (if any) for these programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our drug candidates that we plan to evaluate in clinical development during 2022 and beyond, we believe it is vitally important to continue our substantial investment in a pipeline of new drug candidates to continue to build the value of our drug candidate pipeline and our business. Our discovery research organization is identifying new drug candidates across a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We also plan from time to time to evaluate opportunities to in-license potential drug candidates from third parties to add to our drug discovery and development pipeline. We plan to continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for a given clinical study design;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll clinical study participants;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and location of sites included in the clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes);</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential for changing standards of care for the target patient population;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of producing supplies of the drug candidates needed for clinical trials and regulatory submissions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety and efficacy profile of the drug candidate;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the use of clinical research organizations to assist with the management of the trials;&#160;and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of, and the ability to secure, approvals from government health authorities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as the collaboration that we have already completed for NKTR-358, or clinical collaborations where we would share costs and operational responsibility with a partner. In certain situations, the clinical development program and process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,521&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,555&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,034)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,860&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,234&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,374)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense includes the cost of administrative staffing, commercial, finance and legal activities.  As discussed in Note 8 to our Condensed Consolidated Financial Statements, we have implemented a Restructuring Plan to reduce our workforce by approximately 70%. As a result of our Restructuring Plan, the commercial organization was eliminated and all other bempegaldesleukin-related commercialization activities ceased. Accordingly, general and administrative expense decreased for the three and six months ended June&#160;30, 2022 compared with the three and six months ended June&#160;30, 2021, and we expect this trend to continue for the full year of 2022 as compared to 2021. Beginning in the three months ended June 30, 2022, we report third-party costs and employee compensation costs for the bempegaldesleukin program and severance and benefit costs in Restructuring, impairment and other costs for terminated program. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Other Costs of Terminated Program (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,045&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,520&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 8 to our Condensed Consolidated Financial Statements, following the announcements in March and April 2022 that our registrational trials in bempegaldesleukin failed to meet their primary endpoints, on April 25, 2022, we announced strategic reorganization and cost restructuring plans (together, the Restructuring Plan) to prioritize key Phase 2 development programs, to advance our early stage research pipeline and to reduce our workforce by approximately 70% from approximately 735 to approximately 225 employees. In connection with these events, we reported the following costs in Restructuring, impairment and other costs of terminated program:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Severance and related benefit costs pursuant to the Restructuring Plan;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impairment of right-of-use assets and property, plant and equipment resulting from the Restructuring Plan, primarily reflecting excess office and laboratory leased spaces in San Francisco, CA; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract termination and other costs associated with these plans to discontinue development of bempegaldesleukin. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of Restructuring, impairment and other costs of terminated program, as further described and disclosed in Note 8 to our Condensed Consolidated Financial Statements (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,520&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to recognize expenses in future periods for the winddown of the bempegaldesleukin program and related costs, of which we expect to recognize a significant portion in 2022. The ultimate amount of expense will be affected by the timing to complete the full wind down of the clinical trials run by BMS and us and whether or not we are able to enter into subleases and, if we do enter into subleases, the economic terms of those subleases. We will revise our estimates for the costs to wind down these studies for the bempegaldesleukin program, the amount of severance and benefits paid to employees, and our assessment of impairment charges as new information becomes available to us in future periods.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in fair value of development derivative liability</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of development derivative liability (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,713)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of development derivative liability (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,312)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Percentage change represents a reduction of the expense or change to income.</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4 to our Condensed Consolidated Financial Statements, we remeasured the development derivative liability under our co-development agreement with SFJ to fair value at each reporting date. As discussed in Note 4, as of March 31, 2022, due to the results of the metastatic melanoma trial, we concluded that it was remote that SFJ and we would continue the clinical trial in head and neck cancer. Accordingly, we reduced the liability to $0 as of March 31, 2022 and recognized a corresponding gain in the change in fair value of development derivative liability. As a result of the decision to discontinue the clinical trial in head and neck cancer, we do not expect to record any future significant adjustments for the change in fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense recorded for the change in fair value for the three and six months ended June 30, 2021 primarily reflected the accretion of our obligation to potentially pay Success Payments to SFJ using our imputed borrowing rate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Cash Royalty Revenue and Non-Cash Interest Expense</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to the sales of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Increase) /<br/>Decrease<br/>2022 vs. 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to the sales of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,089)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,861&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to the sales of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Increase) /<br/>Decrease<br/>2022 vs. 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to the sales of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,628&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5 to our Condensed Consolidated Financial Statements, we recognize non-cash royalty revenue for the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue decreased for the three and six months ended June&#160;30, 2022 as compared to the three and six months ended June&#160;30, 2021. Non-cash interest expense decreased significantly for the&#160;three and six months ended June&#160;30, 2022 as compared to the three and six months ended June&#160;30, 2021 </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2012 Purchase and Sale Agreement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in the non-cash interest expense in 2022 resulted from the decrease in the interest rate from 48% in the three and six months ended June&#160;30, 2021 to 16% for the three six months ended June&#160;30, 2022 as a result of the revaluation of the liability, which we recognized in the three months ended December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To resolve UCB&#8217;s challenges to our patents and their resulting obligation to pay us royalties on net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which we had sold to RPI, RPI and UCB negotiated a reduction in the royalty term and decreased royalty rates over the remaining term, which was implemented through the Settlement Agreement between UCB and us. As a result of accounting for the Settlement Agreement as a debt modification during the three months ended December 31, 2021, we remeasured the liability to fair value using a discount rate of 16%. The Settlement Agreement and revaluation do not affect our cash flows, and the net income statement effect over the term of 2012 Purchase and Sale Agreement remains unchanged.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the term of this arrangement, the net proceeds of the transaction of $114.0 million, consisting of the original proceeds of $124.0 million, net of $10.0 million in payments from us to RPI, is amortized as the difference between the non-cash royalty revenue and the sum of the non-cash interest expense and the loss on the revaluation of the liability. To date, we have amortized $44.5 million of the net proceeds. We periodically assess future non-cash royalty revenues, and we may adjust the prospective effective interest rate based on our best estimates of future non-cash royalty revenue such that future non-cash interest expense will amortize the remaining $69.5 million of the net proceeds, since RPI receives all of the benefits of the increases in future royalties. There are a number of factors that could materially affect our estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, future interest rates could differ significantly, and we will adjust any such change in our estimated interest rate prospectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Purchase and Sale Agreement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have amortized $40.2 million of the proceeds. We periodically assess future non-cash royalty revenues, and we may adjust the prospective effective interest rate based on our best estimates of future non-cash royalty revenue such that future non-cash interest expense will amortize the remaining $109.8 million. Our current estimate of the imputed interest rate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reflects that our estimates of sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will result in meeting the 2025 Threshold. Because the 2025 Threshold of $210.0 million and the increase in the threshold to $240.0 million (if the 2025 Threshold is not timely achieved) limit the amount of royalties payable to HCR, the potential for the implicit interest rate to vary is more limited. Instead, we will receive the benefit of net sales if they exceed the threshold, but do not bear risk of loss or payments to HCR if royalties are less than expected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Other Income (Expense), net (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense) increased for the three months ended June 30, 2022 as compared to the three months ended June 30, 2020 but decreased for the six months ended June&#160;30, 2022 as compared to the six months ended June&#160;30, 2021. The year-to-date decrease was due to lower investment balances which have been utilized to fund our operations. We expect that our interest income and other income (expense), net will decrease for 2022 compared to 2021 for the same reason.</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_76"></div><div style="margin-top:9pt;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations primarily through revenue from upfront and milestone payments under our strategic collaboration agreements, royalties and product sales, as well as public and private placements of debt and equity securities. As of June&#160;30, 2022, we had approximately $628.2 million in cash and investments in marketable securities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing, which includes the payments for the winddown of the bempegaldesleukin program, as further disclosed in Note 8 to our Condensed Consolidated Financial Statements.   </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the clinical development of our drug candidates, including NKTR-358 and NKTR-255, will continue to require significant investment to continue to advance in clinical development with the objective of obtaining regulatory approval or entering into one or more collaboration partnerships. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursement from BMS, and a $150.0 million upfront payment from Lilly for our collaboration agreement for NKTR-358. In the future, we have the opportunity to receive up to $250.0 million in milestone payments under our collaboration with Lilly.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current business is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for NKTR-358 and NKTR-255, the sales levels for those products for which we are entitled to royalties, if and when they are approved, whether, when and on what terms we are able to enter into new collaboration transactions, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no credit facility or any other sources of committed capital. The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions. We may pursue various financing alternatives to fund the expansion of our business as appropriate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the short term, we do not anticipate that the effects of the COVID-19 pandemic will have a material effect on our results of operations or financial position since we do not generate significant cash flows from recurring revenues and our revenues are generally less affected by regulatory restrictions and guidelines that have been implemented in response to the pandemic. However, if delays caused by the COVID-19 pandemic in commencing and enrolling patients in our clinical trials or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those run by our partners result in a delay in completing these trials, our or our partner&#8217;s ability to file for regulatory approval and commercialize these products (if approved) and receive associated milestone payments may also be delayed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. To date we have not experienced any liquidity issues with respect to these securities. We believe that, even allowing for potential liquidity issues with respect to these securities and the effect of the COVID-19 pandemic or other conditions on the financial markets, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the Securities and Exchange Commission, which expires in March 2024. The 2021 Shelf Registration Statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which may be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities have been sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from operating activities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities for the six months ended June&#160;30, 2022 and 2021 totaled $163.4&#160;million and $160.0&#160;million, respectively. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, if any, will decrease for 2022 as compared to 2021 as a result of the various cost restructuring activities described above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from investing activities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 and 2021, the maturities and sales of our investments, net of purchases, totaled $219.4&#160;million and $89.6&#160;million, respectively, which we used to fund our operations. Our maturities and sales of investments, net of purchases was lower during the six months ended June 30, 2021 as compared to the six months ended June 30, 2022, because we purchased securities in early 2021, utilizing the $150.0 million in proceeds from the 2020 Purchase and Sale Agreement that were included in cash equivalents at December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $5.0 million and $6.2&#160;million for the purchase or construction of property, plant and equipment in the six months ended June&#160;30, 2022 and 2021, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received proceeds from issuance of common stock related to our employee option and stock purchase plans of $0.7 million and $28.5 million in the six months ended June&#160;30, 2022 and 2021, respectively. Additionally, during the six months ended June&#160;30, 2022 and 2021, we received $0.8 million and $1.5 million, respectively, from SFJ pursuant to our co-development agreement.</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation and presentation of financial statements in conformity with U.S.&#160;generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. See Note 1 and Note 8 to our Condensed Consolidated Financial Statements for our accounting policies and estimates related to the severance and benefits and the impairment of right-of-use assets and property, plant and equipment. Other than these accounting policies and estimates, there have been no material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.                Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks at June&#160;30, 2022 have not changed materially from those discussed in Item 7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2021 on file with the SEC.</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_85"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. However, there was no change in our internal control over financial reporting that occurred in the three months ended June&#160;30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Specifically, despite the fact that most of our office-based employees are working remotely due to the COVID-19 pandemic, we do not believe that our adjustments to how we work have materially impacted our internal controls over financial reporting. We continue to monitor and assess the potential impact of the COVID-19 pandemic, and the related regulatory and government guidance that have been issued in response to the pandemic, on our internal controls and strive to minimize the impact on our internal control design and operating effectiveness.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II: OTHER INFORMATION</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_91"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is hereby made to our disclosures in &#8220;Legal Matters&#8221; under Note 6 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q and the information under the heading &#8220;Legal Matters&#8221; is incorporated by reference herein.</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_94"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. The risks described below may not be the only ones relating to our company. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously disclosed in Item&#160;1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the success of drug candidates, including NKTR-358 and NKTR-255.&#160;If these drug candidates fail in clinical development our business will be significantly harmed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is highly dependent on the clinical success of our drug candidates, including NKTR-358 and NKTR-255. In general, most investigational drugs, including immunology and I-O drug candidates such as NKTR-358 and NKTR-255, respectively, do not become approved drugs. Accordingly, there is a very meaningful risk that our drug candidates will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals.&#160;Further, if Lilly, our collaboration partner for NKTR-358, delays the initiation or completion of one or more clinical trials for reasons outside of our control, or is not successful, it would materially harm our market valuation, prospects, financial condition and results of operations.&#160;For example, under our collaboration agreement with Lilly, we are eligible for up to $250.0 million in additional development and regulatory milestones, and a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. One or more clinical failures of our drug candidates would jeopardize and could result in reduced, delayed or eliminated revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, promising results from earlier trials may not predict similarly favorable outcomes in subsequent trials. For example, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational drug candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational drug candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our drug candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may experience delays in clinical trials of drug candidates. Our partner Lilly is conducting a Phase 2 study of NKTR-358 in patients with SLE as well as two Phase 1b studies in patients with psoriasis and atopic dermatitis.&#160;&#160;In addition, we have initiated a Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">squamous cell carcinoma or colorectal cancer. These and other clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our drug candidates could be delayed for a variety of reasons, including:</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in obtaining regulatory authorization to commence a clinical study;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching agreement with applicable regulatory authorities on a clinical study design;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">for drug candidates (such as NKTR-358) partnered with other companies, delays caused by our partner; </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by the COVID-19 pandemic (see also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in recruiting suitable patients to participate in a trial;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites dropping out of a trial due to the detriment of enrollment rates;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in manufacturing and delivery of sufficient supply of clinical trial materials;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory authorities policies or guidance applicable to our drug candidates; and</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by changing standards of care or new treatment options.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, results for the studies would be delayed, and consequently the regulatory approval process would be delayed which would also delay our ability to commercialize these drug candidates, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies, could have a material and adverse impact on the value of our I-O research and development pipeline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development of I-O therapies is a very competitive global segment in the biopharmaceutical industry attracting tens of billions of dollars of investment each year.&#160; Our clinical trial plans for NKTR-255 and other I-O therapy drug candidates face substantial competition from other I-O combination regimens already approved, and many more combination therapies that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As I-O combination therapies are relatively new approaches in cancer treatment and few have successfully completed late stage development, I-O drug development entails substantial risks and uncertainties that include rapidly changing standards of care, identifying contribution of component therapies, patient enrollment competition, evolving regulatory frameworks to evaluate combination regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of I-O drug candidates.&#160;</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The risk of clinical failure for any drug candidate remains high prior to regulatory approval and there can be no assurance that our product candidates will obtain regulatory approval.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a drug candidate may not predict the results that will be obtained in later phase clinical trials of the drug candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a drug candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary drugs and drug candidates could make our technologies, drugs or drug candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and drug candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories Ltd., SunBio Corporation, Laysan Bio, Inc., Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many competitors for our drug candidates currently in development. For NKTR-358, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC, Janssen, AstraZeneca, and Tizona Therapeutics), regulatory T cell therapies (Targazyme, Inc., Caladrius BioSciences, Inc., and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc., Celgene Corporation, GentiBio, Inc., ILTOO Pharma, Kyverna Therapeutics, Merck &amp; Co, through its acquisition of Pandion Therapeutics, and Roche). For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., Nkarta therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.). There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies uncompetitive or obsolete.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Collaboration Partners </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our collaboration partner to initiate, properly conduct and prioritize clinical trials for NKTR-358 and to perform important additional development and commercialization activities, and our business will be significantly harmed if their actions deprioritize or otherwise harm the prospects of our drug candidates. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on Lilly (through the Lilly Agreement) to initiate, properly conduct, and prioritize clinical trials and other development-related activities for NKTR-358.  Furthermore, we will rely on Lilly to perform specified commercialization activities for NKTR-358, pursuant to our collaboration agreement. In the event Lilly fails to initiate, properly conduct and prioritize their obligations under their applicable agreement with us, our business will be significantly harmed.  Even if the applicable agreement provides us with enforcement or other curative rights to address the harm caused by Lilly&#8217;s action (or failure to act), our efforts in pursuing a remedy would be costly and there is no guarantee that these efforts would succeed or be sufficient to fully address the harm.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for reasons outside of our control, the operations of our collaboration partners may be affected by the COVID-19 pandemic more than our operations, or our collaboration partners may adopt more restrictive procedures for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addressing the COVID-19 pandemic, either of which could delay initiating or completing one or more clinical trials involving our drug candidates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirement</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategic reorganization plan and cost restructuring plan may not be successful.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, we announced strategic reorganization and cost restructuring plans (together, the Restructuring Plan) to prioritize key research and development efforts that will impact the Company&#8217;s future business activities, including activities involving NKTR-358, NKTR-255 and several core research programs.  In connection with the  Restructuring Plan, we also announced cost restructuring measures aimed at ensuring we will have significant capital to fund key programs over a multi-year time horizon. There is no guarantee that the Restructuring Plan will achieve its intended benefits or that our post-restructuring focus will be sufficient for us to achieve success. For example, our cost restructuring efforts may not result in the anticipated savings or other economic benefits, or could result in total costs and expenses that are greater than expected, which would require us to seek potentially dilutive financing alternatives, disrupt or restrain the scope of our business activities, and would make it more difficult to attract and retain qualified personnel, each of which could have a material adverse effect on our business, financial condition and prospects.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreements with various pharmaceutical or biotechnology companies, our collaboration partner is generally solely responsible for:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">designing and conducting large scale clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">marketing and selling the drugs when and if they are approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaboration partners with commercial rights may choose to devote fewer resources to the development or marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of drug candidates or to litigation or arbitration proceedings;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may be unable to pay us as expected;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may respond to natural disasters or health epidemics, such as the COVID-19 pandemic, by ceasing all or some of their development responsibilities (including the responsibility to clinical develop our drug candidates).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly impair our access to capital necessary to fund our research and development efforts for our drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantial future capital requirements and there is a risk that we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had cash and investments in marketable securities valued at approximately $628.2 million. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, timing and outcomes of clinical studies and regulatory reviews of our drug candidates, particularly NKTR-358;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing, cost and results of our clinical development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our general and administrative expenses, capital expenditures and other uses of cash; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes concerning patents, proprietary rights, or license and collaboration agreements that could negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue to advance our drug candidates to later stage research and development, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is very difficult to estimate the commercial potential of drug candidates due to important factors such as safety and efficacy compared to other available treatments, including changing standards of care, third party payer reimbursement standards, patient and physician preferences, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic and biosimilar versions of our drug candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We may also depend on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our relationships with other companies for sales and marketing performance and the commercialization of drug candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If government and private insurance programs do not provide payment or reimbursement for our partnered drug or proprietary drugs, those drugs will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and markets in other countries, patients generally rely on third-party payers to reimburse all or part of the costs associated with their treatment. In both domestic and foreign markets, sales of our partnered and proprietary products that receive regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid in the U.S., managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a biologic candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. Further, due to the COVID-19 pandemic, millions of individuals have lost or will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our biologic candidates even if there is adequate coverage and reimbursement from third-party payers. It is unclear what effect, if any, the American Rescue Plan Act will have on the number of covered individuals.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payers tend to follow CMS to a substantial degree. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors payers consider in determining reimbursement are based on whether the product is (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any of our drug product candidates that are commercialized and, if reimbursement is available, the level of reimbursement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent federal legislation and actions by federal, state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face competition in the United States for our development candidates and investigational medicines, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act (MMA), contains provisions that call for the promulgation of regulations that expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these changes to U.S. importation laws will not take effect, unless and until the U.S. Secretary of Health and Human Services (HHS) certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September 23, 2020, the U.S. Secretary of HHS made such certification to Congress, and on October 1, 2020, FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the issuance of the final rule, several industry groups have filed federal lawsuits challenging multiple aspects of the final rule, and authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. On September 25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future biologic candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, from which we receive upfront fees, research and development reimbursement and funding, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any biologic candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2022, we reported a net loss of $249.5 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestones and other contingent payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary biologic candidates and the regulatory approval and market success of our biologic candidates. We may not be able to achieve and sustain profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for NKTR-358 and NKTR-255;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive necessary regulatory and marketing approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain or expand manufacturing at necessary levels;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achieve market acceptance of our partnered products;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive revenue or royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain sufficient funds to finance our activities.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected, directly or indirectly, by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, including both our own manufacturing operations as well as the manufacturing operations of third parties upon whom we rely. With respect to the ongoing COVID-19 pandemic, national, state and local governments in regions affected by the COVID-19 pandemic have implemented, and may continue to implement or reinstate safety precautions, including quarantines, border closures, increased border controls, travel restrictions, business closures and other measures.  These measures may disrupt normal business operations both in and outside areas affected by COVID-19 and may have significant negative impacts on our business. Even as these safety precautions are eased or reduced over time, there may be long lasting effects of these precautions on our business that may only be fully realized in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic. Throughout the pandemic we have modified our office policies to maintain productivity and safety of our employees. Although we believe these and the other safety measures we have taken in response to the COVID-19 pandemic have not substantially impacted our productivity, it is not certain that this will continue to be the case. Operating requirements may continually change due to the COVID-19 pandemic and we may experience unpredictability in our expenses, employee productivity and availability and employee work culture. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our clinical trials have been and may continue to be affected by the COVID-19 pandemic. Investigator recruitment, clinical site initiation, patient screening and patient enrollment may be delayed due to, for example, prioritization of hospital resources toward the COVID-19 pandemic. Some patients who are successfully enrolled in clinical trials involving our biologic candidates may not be able to comply with clinical trial protocols due to, for example, disrupted healthcare services, or health issues for suspected or confirmed COVID-19 status. Similarly, our ability to recruit and retain patients and principal investigators and site staff, all of whom may have heightened risk for COVID-19, could adversely impact our clinical trial operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays and disruptions experienced by our collaborators or other third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect clinical development or regulatory approvals of our biologic candidates. For example, due to recent supply chain disruptions, we have been monitoring our supply chains for any disruptions or constraints caused by the COVID-19 pandemic. To date, we have not experienced any supply impact. However, if we, our collaborators or any third parties which we rely on are adversely effected by any supply disruptions or shortages in raw materials and equipment caused by the COVID-19 pandemic, our ability to manufacture our products and to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supply drug candidates for our clinical trials could be negatively impacted, which could harm our business prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are implementing measures to maintain the integrity of our clinical trials, there is no guarantee that we will prevent all study protocol violations, missed study treatment visits, and other influences that jeopardize reliability and validity of our clinical trial data. If a regulatory authority determines our clinical trial data lacks integrity, there is no guarantee that we will have a remedy to correct or otherwise address the deficiency. Even if such a remedy is identified, the cost for implementing the remedy could be prohibitively expensive, time consuming, or both. As a consequence, a clinical study of our biologic candidate in which the integrity of the clinical study is questioned or doubted may require lengthy and costly remediation measures (such as, for example, over-enrolling patients into the study or repeating the study), thereby causing substantial harm to our business.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the COVID-19 pandemic could postpone necessary interactions with regulators regarding our drug candidates in development and could delay review or approval of our regulatory submissions. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapid development and fluidity of the COVID-19 pandemic results in a substantial number of individual variables that could cause a significant negative impact on our operations and our business, thereby precluding useful predictions as to how this pandemic will ultimately affect us. In particular, it is unclear how our business may be affected by the emergence of new variants of the coronavirus, such as the Delta and Omicron variants, and recent resurgences in number and rates of COVID-19 infections. Thus, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our clinical trial timelines, is subject to change. We do not yet know the full extent of potential impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material negative impact on our operations and our business. Furthermore, to the extent the ongoing COVID-19 pandemic adversely affects our operations and business, it may also heighten the other risks described in this &#8220;Risk Factors&#8221; section. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Supply and Manufacturing</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our contract manufacturers are not able to manufacture biologic substance or substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our contract manufacturing organizations (CMOs) are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#8217; clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#8217; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on CMOs to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of biologics involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. These risks and uncertainties are compounded by the COVID-19 pandemic wherein the facilities and employees responsible for manufacturing biologics for use in clinical trials may be negatively impacted such that there is an insufficient supply of study biologic drugs. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party CMOs required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our CMOs to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in response to the COVID-19 pandemic. Throughout the COVID-19 outbreak, there has been public concern over the availability and accessibility of critical medical products, and the CARES Act enhances FDA&#8217;s existing authority with respect to drug shortage measures. Under the CARES Act, we must have in place a risk management plan that identifies and evaluates the risks to the supply of approved drugs for certain serious diseases or conditions for each establishment </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">where the drug or API is manufactured. The risk management plan will be subject to FDA review during an inspection. If we experience shortages in the supply of our marketed products, our results could be materially impacted.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or biologic candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product according to the specifications previously submitted to or approved by the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop biologic candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our biologic candidate that such CMO owns independently. This would increase our reliance on such a CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our products or biologic candidates. In addition, in the case of the CMOs that supply our biologic candidates, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We purchase some of the starting material for biologics and biologic candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply, diminution in quality of raw materials supplied to us or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CMOs are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our CMOs for compliance with applicable regulatory requirements. Any failure to follow and document our or our CMOs&#8217; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial compliance with cGMP. Manufacturing delays, for us or our CMOs, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Business Operations</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third parties to conduct the clinical trials for our biologic candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our biologic candidates. We rely heavily on these parties for the successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our biologic candidates to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical trials could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future depends on the proper management of our current and future business operations and their associated expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy requires us to manage our business to provide for the continued development of our proprietary and partnered biologic candidates. Our strategy also calls for us to manage the capital necessary to fund key programs through value-enhancing data and other milestones. If we are unable to manage effectively our current operations, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other dilutive financing arrangements on unfavorable terms.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we rely on other pharmaceutical or biotechnology companies with established sales, marketing and distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenue we receive will depend upon the efforts of third parties, which may not be successful and over which we have little or no control. In the event that we market our products without a partner, we would be required to build, either internally or through third-party contracts, a sales and marketing organization and infrastructure, which would require a significant investment, and we may not be successful in building this organization and infrastructure in a timely or efficient manner. We would also incur substantial costs in building such capabilities before receiving regulatory approval of our products, which would have an adverse effect on our financial condition if our products are not ultimately approved.  </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must attract and retain experts in the areas of research, development (including clinical testing), manufacturing, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel.  Furthermore, as a result of our Restructuring Plan, our employees may experience distractions or decreases in employee morale and we may experience increased levels of employee attrition and turnover, which would adversely affect our business. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rising inflation rates have increased our operating costs and could negatively impact our operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inflation rates, particularly in the United States, have increased recently to levels not seen in decades. Increased inflation has resulted in increased operating costs. In addition, the United States Federal Reserve has raised, and is expected to again raise, interest rates in response to concerns about inflation.  Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners do not obtain regulatory approval for our biologic candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may not obtain regulatory approval for biologic candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Biologic candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a biologic candidate. In addition, undesirable side effects caused by our biologic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. For example, AstraZeneca is&#160;conducting a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to other treatments of opioid-induced constipation in patients with chronic, non-cancer pain and the results of this study could at some point in the future negatively impact the labeling, regulatory status, and commercial potential of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which could reduce our future royalties from sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of drug candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partner&#8217;s performance;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered biologic candidate development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">indemnity obligations for intellectual property infringement, product liability and certain other claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g., financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, we could be subject to substantial liabilities, which would harm our financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property licenses related to the development of our biologic candidates on a commercially reasonable basis, if at all.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent rights will be considered relevant to our or our collaboration partners&#8217; technology or biologic candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the sufficiency of the scope and adequacy of these licenses is very uncertain in view of the long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology to avoid a need to secure a license. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the biologic, which could significantly harm our business, results of operations, and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 310 U.S. and 1,200 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to opposition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, re-examinations or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire prior to the commercialization of the biologic. Moreover, even if a patent encompassing a biologic has not expired prior to the biologic's commercialization, the patent may only provide a short period of protection following the commercialization of products.&#160; In </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, our patents may be subject to post grant proceedings, such as or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examinations, before the U.S. Patent and Trademark Office (or equivalent proceedings in other jurisdictions), which could result in a loss of the patent and/or substantial cost to us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our biologic candidates.&#160;There can be no assurance that the patent applications for which we apply will actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&#160;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.&#160;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&#160;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our biologic candidates, if approved, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any biologic candidates for which we obtain marketing approval. Our future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. On December 2, 2020, the Office of Inspector General, or OIG, published further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. This rule (with exceptions) became effective January 19, 2021. Implementation of this change and new </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. We continue to evaluate what effect, if any, the rule will have on our business;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the U.S. federal False Claims Act (FCA), which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payers if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes, referred to as the &#8220;HIPAA All-Payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website, effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician assistants and nurse practitioners;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information, and also includes the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there  may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">additionally, state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts. These state-equivalent laws may also apply to our business practices, including, but not limited to, research, distribution, and sales or marketing arrangements. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including administrative, civil or criminal penalties, imprisonment, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to the normal functioning of the FDA and other government agencies could hinder their ability to perform and carry out important roles and activities on which the operation of our business relies, which could negatively impact our business. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. For example, the current five-year authorization of the Prescription Drug User Fee Act (PDUFA) and other user free programs from which the FDA receives significant funding is set to expire on September 30, 2022, and a failure by Congress to reauthorize PDUFA and other user fee programs by this date may cause a reduction in the responsiveness of the FDA generally. In the past, average review times at the agency have fluctuated, and this may continue in the future. In addition, government funding of other agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable. Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold due to the COVID-19 pandemic, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. In April 2021, the FDA issued guidance for industry formally announcing plans to employ remote interactive evaluations, suing risk management methods, to meet user fee commitments and goal dates. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be appropriate, FDA has stated that it generally intends to issue a complete response letter.  Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. Additionally, as of June 23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals. On July 16, 2020, the FDA noted that it is continuing to expedite oncology product development with its staff teleworking full-time. However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions the FDA is unable to complete such required inspections during the review period. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future shutdowns of other government agencies, such as the SEC, may also impact our business through review of our public filings and our ability to access the public markets. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies. Third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or biologic candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. For example, we are involved in ongoing litigation with Aether Therapeutics Inc., who in March 2020 filed a complaint against AstraZeneca, Nektar and Daiichi-Sanko, Inc. alleging that MOVANTIK&#174; infringes U.S. Patent Nos. 6,713,488, 8,748,448, 8,883,817 and 9,061,024. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partners against any claims. We are also regularly involved in opposition proceedings at the European Patent Office and in inter partes review and re-examination proceedings at the U.S. Patent and Trademark Office where third parties seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our biologic candidates and platform technologies.  If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain biologics or biologic candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we are involved in legal proceedings other than those related to intellectual property.  In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018, about the clinical trials of bempegaldesleukin. The Mulquin complaint was amended in May 2019. The defendants moved to dismiss and the court granted the motion without prejudice in July 2020. The Mulquin plaintiffs again amended their complaint and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice. The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument occurred on December 10, 2021. On May 19, 2022, the Ninth Circuit affirmed the district court's dismissal of all claims against the defendants. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A derivative action was also filed against certain of the Company&#8217;s current and former officers and directors, purportedly on the Company&#8217;s behalf. This derivative action is based on the allegations in the Mulquin action and on the premise that the Company&#8217;s officers and directors breached their fiduciary duties to the Company. The complaint for this derivative action was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF). Following a stay in the proceedings during the pendency of the appeal in the Mulquin action, the Company received an amended complaint on July 29, 2022, and the defendants will have until September 12, 2022 to respond to the amended complaint. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties. There is no guarantee that our insurance coverage for damages resulting from a litigation or the settlement thereof (including the Mulquin action and related shareholder derivative lawsuit) is sufficient, thereby resulting in substantial financial risk to the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of lawsuits and complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses for any of the legal proceedings we are currently involved in. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at June&#160;30, 2022.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found in violation of privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to many laws and regulations intended to protect the privacy and data of individuals participating in our clinical trials and our employees, among others. For example, with regard to individuals participating in our clinical trials, these laws and regulations govern the safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. In addition to federal laws and regulations in the United States, such as the HIPAA requirements relating to the privacy, security and transmission of individually identifiable health information, many state and foreign laws also govern the privacy and security of health information. These laws often differ from each other in significant ways, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has increased our compliance costs and may increase our potential liability. The CCPA has prompted a number of proposals for new federal and state privacy legislation. If passed, these proposals could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), and the implementing legislation of EU Member States, which became effective on May 25, 2018, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside of the EU and processing personal information of individuals located in the EU. The GDPR is wide-ranging in scope and imposes strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to, for example, (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, and (iii) ensuring the security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20 million or 4% of annual global revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are found liable for the inappropriate collection, storage, use or disclosure of protected information of individuals (such as employees and or clinical patients protected by any privacy or data protection law), we could be subject to reputational harm, monetary fines (such as those imposed by the GDPR and CCPA), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and the development of our biologic candidates could be delayed. In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a research-based biopharmaceutical company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations (including, but not limited to, the handling and disposal of both our hazardous and non-hazardous waste) is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk related to Investment and Securities</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial                                losses for investors and securities class action and shareholder derivative litigation. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. During the three months ended June&#160;30, 2022, based on closing prices on the NASDAQ Global Select Market, the closing price of our common stock ranged from $3.17 to $6.17 per share. In response to volatility in the price of our common stock in the past, plaintiffs&#8217; securities litigation firms have sought information from us and/or shareholders as part of their investigation into alleged securities violations and breaches of duties (among other corporate misconduct allegations). Following their investigations, plaintiffs&#8217; securities litigation firms have often initiated legal action, including the filing of class action lawsuits, derivative lawsuits, and other forms of redress. We expect our stock price to remain volatile and we continue to expect the initiation of legal actions by plaintiffs&#8217; securities litigation firms following share price fluctuations. A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch &#8211; in particular, data from clinical studies of bempegaldesleukin has had a significant impact on our stock price;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of outcomes from our clinical trials which can be difficult to predict particularly for clinical studies that have event-driven end points such as progression-free survival and overall survival;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by collaboration partners as to their plans or expectations related to biologic candidates and approved biologics in which we have a substantial economic interest;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding terminations or disputes under our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our results of operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products that may compete with our approved partnered products or products under development;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of changes in governmental regulation affecting us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation brought against us or third parties to whom we have indemnification obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of drug formulations developed by us or others;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financing needs and activities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a classified board of directors such that not all members of the board may be elected at one time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board to authorize the issuance of &#8220;blank check&#8221; preferred stock to increase the number of outstanding shares and thwart a takeover attempt;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on who may call a special meeting of stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We significantly rely on information technology systems, and any failure, inadequacy, interruption, breach, or security lapse of that technology within our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may result in a material disruption of our development programs and our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. Despite the implementation of security measures, our internal computer systems and those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to loss, damage, denial-of-service, unauthorized access, or misappropriation. Such cybersecurity breaches may be the result of unauthorized activity by our employees and contractors, as well as by third parties who use cyberattack techniques involving malware, hacking and phishing, among others. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of an increase in the number of employees adopting a remote working environment during the COVID-19 pandemic, which may be less secure and more susceptible to hacking attacks. Our information technology systems, and those of our partners, vendors, CROs, CMOs or other contractors or consultants are also vulnerable to natural disasters, terrorism, war and telecommunication and electrical failures. Any such compromise or disruption, no matter the origin, may cause an interruption of our operations. For instance, the loss of preclinical data or data from any clinical trial involving our biologic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, the loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information could compromise the commercial viability of one or more of our programs, which would negatively affect our business. Also, the costs to us to investigate and mitigate cybersecurity incidents could be significant.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. In the U.S., the rules dealing with federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, such changes have been made and changes are likely to continue to occur in the future. For example, on March 27, 2020, the CARES Act was signed into law and included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 pandemic, including temporary changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the EU may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 31, 2020, the U.K. ceased to be a member state of the EU, a process known as Brexit, and began a transition period, which expired on December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the U.K. and the EU agreed on a trade and cooperation agreement, under which the EU and the U.K. will now form two separate markets governed by two distinct regulatory and legal regimes. The trade and cooperation agreement covers the general objectives and framework of the relationship between the U.K. and the EU, including as it relates to trade, transport and visas. Under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the EU. Depending on the application of the terms of the trade and cooperation agreement, we, our collaboration partners and others could face new regulatory costs and challenges.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global economic and political conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions, including, for example, adverse global economic conditions resulting from the COVID-19 pandemic. See also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; In addition, our operations and performance may be affected by political or civil unrest or military action, terrorist activity, and unstable governments and legal systems. For example, in late February 2022, Russia commenced a military invasion of Ukraine, and the sustained conflict in Ukraine, including the potential effects of sanctions and retaliatory cyber-attacks on the world economy and markets, has contributed to increased market volatility and uncertainty.  In particular, sanctions imposed by the U.S., EU and other countries in response to the conflict between Russia and Ukraine and the potential response to such sanctions may have an adverse impact on our business, including our clinical trials, the financial markets and the global economy.  As the conflict in Ukraine continues, there can be no certainty regarding whether the U.S., EU or other governments will impose additional sanctions, or other economic or military measured relating to Russia.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of global economic and political conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. Our ability to conduct clinical trials in regions experiencing political or civil unrest could negatively affect clinical trial enrollment or the timely completion of a clinical trial. We believe the aforementioned economic conditions have led and could continue to lead to reduced demand for our and our collaboration partners&#8217; drug products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with rising international trade tensions or sanctions, our business may be adversely affected following new or increased tariffs that result in increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partners&#8217; drug products, affect our and our collaboration partners&#8217; ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by corporate citizenship and&#160;sustainability&#160;matters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increased focus from certain investors, employees, and other stakeholders concerning corporate citizenship and&#160;sustainability&#160;matters, which include environmental concerns and social investments. We could fail to meet, or be perceived </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to fail to meet, the expectations of these certain investors, employees and other stakeholders concerning corporate citizenship and sustainability matters, thereby resulting in a negative impact to our business. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If earthquakes or other catastrophic events strike, our business may be harmed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama and own and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, or terrorist event in any of these locations, our ability to manufacture and supply materials for biologic candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaboration partners and important vendors and suppliers to us or our collaboration partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes, tornadoes and pandemics any of which could harm our business (including, for example, by disrupting supply chains important to the success of our business), results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur.</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_97"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None, including no purchases of any class of our equity securities by us or any affiliate pursuant to any publicly announced repurchase plan in the three months ended June&#160;30, 2022.</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_100"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_103"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i140383c8fcb34877b7aa2512bcb00b00_106"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:9pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Exhibit Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Description of Documents</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.1(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.2(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.3(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">Certificate of Ownership and Merger of Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.4(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.5(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000121390020043821/ea132008ex3-1_nektartherap.htm">Amended and Restated Bylaws of Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(6) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr2022-06x30xexx101ar201.htm#i7b0c4c07e114409f9b9c3f6a9592b777_1">Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr2022-06x30xexx102north.htm">Employment Transition, Separation and Consultation Agreement, dated as of June 29, 2022, by and between Nektar Therapeutics and John Northcott.++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">31.1(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2022-06x30xexx311.htm#idd4b9035edaa4908be84c4b152aff4d2_1">Certification of Nektar Therapeutics&#8217; principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">31.2(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2022-06x30xexx312.htm#i425fa6fbf3444c50b0815e66d59c2082_1">Certification of Nektar Therapeutics&#8217; principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2022-06x30xexx321.htm#ib941c08443684a549b4e814f8722fd55_1">Section 1350 Certifications.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.SCH(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Schema Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.CAL(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.LAB(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.PRE(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.DEF(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">104(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">_____________________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       1. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               June 30, 1998.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       2. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.3 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               June 30, 2000.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       3.     Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               January 23, 2003.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       4. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.6 to Nektar Therapeutics&#8217; Annual Report on Form 10-K, for the year ended </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">                December 31, 2009.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       5. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               December 21, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       6.     Filed herewith.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Exhibit 32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i140383c8fcb34877b7aa2512bcb00b00_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i140383c8fcb34877b7aa2512bcb00b00_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JILLIAN B. THOMSEN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jillian B. Thomsen<br/>Senior&#160;Vice&#160;President,&#160;Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 4, 2022</span></td></tr></table></div><div style="margin-top:6pt;text-align:right"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>nktr2022-06x30xexx101ar201.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7b0c4c07e114409f9b9c3f6a9592b777_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="-sec-extract:summary;margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEKTAR THERAPEUTICS</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN</font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.5pt">PURPOSE OF PLAN</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The purpose of this Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) of Nektar Therapeutics, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.5pt">ELIGIBILITY</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Administrator (as such term is defined in Section&#160;3.1) may grant awards under this Plan only to those persons that the Administrator determines to be Eligible Persons. An &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eligible Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any person who is either&#58; (a)&#160;an officer (whether or not a director) or employee of the Corporation or one of its Subsidiaries&#59; (b)&#160;a director of the Corporation or one of its Subsidiaries&#59; or (c)&#160;an individual consultant or advisor who renders or has rendered bona fide services (other than services in connection with the offering or sale of securities of the Corporation or one of its Subsidiaries in a capital-raising transaction or as a market maker or promoter of securities of the Corporation or one of its Subsidiaries) to the Corporation or one of its Subsidiaries and who is selected to participate in this Plan by the Administrator&#59; provided, however, that a person who is otherwise an Eligible Person under clause (c)&#160;above may participate in this Plan only if such participation would not adversely affect either the Corporation&#8217;s eligibility to use Form S-8 to register under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the offering and sale of shares issuable under this Plan by the Corporation or the Corporation&#8217;s compliance with any other applicable laws. An Eligible Person who has been granted an award (a &#8220;participant&#8221;) may, if otherwise eligible, be granted additional awards if the Administrator shall so determine. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any corporation or other entity a majority of whose outstanding voting stock or voting power is beneficially owned directly or indirectly by the Corporation&#59; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Corporation. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.5pt">PLAN ADMINISTRATION</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">The Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Plan shall be administered by and all awards under this Plan shall be authorized by the Administrator. The &#8220;Administrator&#8221; means the Board or one or more committees appointed by the Board or another committee (within its delegated authority) to administer all or certain aspects of this Plan. Any such committee shall be comprised solely of one or more directors or such number of directors as may be required under applicable law. A committee may delegate some or all of its authority to another committee so constituted. The Board or a committee comprised solely of directors may also delegate, to the extent permitted by Section&#160;157(c) of the Delaware General Corporation Law and any other applicable law, to one or more officers of the Corporation, its powers under this Plan (a)&#160;to designate the officers and employees of the Corporation and its Subsidiaries who will receive grants of awards under this Plan, and (b)&#160;to determine the number of shares subject to, and the other terms and conditions of, such awards. The Board may delegate different levels of authority to different committees with administrative and grant authority under this Plan. Unless otherwise provided in the Bylaws of the Corporation or the applicable charter of any Administrator&#58; (a)&#160;a majority of the members of the acting Administrator shall constitute a quorum, and (b)&#160;the vote of a majority of the members present assuming the presence of a quorum or the unanimous written consent of the members of the Administrator shall constitute action by the acting Administrator.</font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With respect to awards previously intended to satisfy the requirements for performance-based compensation under Section&#160;162(m) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), this Plan shall be administered by a committee consisting solely of two or more outside directors (as this requirement is applied under Section&#160;162(m) of the Code)&#59; provided, however, that the failure to satisfy such requirement shall not affect the validity of the action of any committee otherwise duly authorized and acting in the matter. Award grants, and transactions in or involving awards, intended to be exempt under Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), must be duly and timely authorized by the Board or a committee consisting solely of two or more non-employee directors (as this requirement is applied under Rule 16b-3 promulgated under the Exchange Act). To the extent required by any applicable listing agency, this Plan shall be administered by a committee composed entirely of independent directors (within the meaning of the applicable listing agency). </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Powers of the Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Subject to the express provisions of this Plan, the Administrator is authorized and empowered to do all things necessary or desirable in connection with the authorization of awards and the administration of this Plan (in the case of a committee or delegation to one or more officers, within the authority delegated to that committee or person(s)), including, without limitation, the authority to&#58; </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">determine eligibility and, from among those persons determined to be eligible, the particular Eligible Persons who will receive an award under this Plan&#59; </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">grant awards to Eligible Persons, determine the price at which securities will be offered or awarded and the number of securities to be offered or awarded to any of such persons, determine the other specific terms and conditions of such awards consistent with the express limits of this Plan, establish the installments (if any) in which such awards shall become exercisable or shall vest (which may include, without limitation, performance and&#47;or time-based schedules), or determine that no delayed exercisability or vesting is required, establish any applicable performance targets, and establish the events of termination or reversion of such awards&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">approve the forms of award agreements (which need not be identical either as to type of award or among participants)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">construe and interpret this Plan and any agreements defining the rights and obligations of the Corporation, its Subsidiaries, and participants under this Plan, further define the terms used in this Plan, and prescribe, amend and rescind rules and regulations relating to the administration of this Plan or the awards granted under this Plan&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">cancel, modify, or waive the Corporation&#8217;s rights with respect to, or modify, discontinue, suspend, or terminate any or all outstanding awards, subject to any required consent under Section&#160;8.6.5&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.41pt">accelerate or extend the vesting or exercisability or extend the term of any or all such outstanding awards (in the case of options or stock appreciation rights, within the maximum ten-year term of such awards) in such circumstances as the Administrator may deem appropriate (including, without limitation, in connection with a termination of employment or services or other events of a personal nature) subject to any required consent under Section&#160;8.6.5&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">adjust the number of shares of Common Stock subject to any award, adjust the price of any or all outstanding awards or otherwise change previously imposed terms and conditions, in such circumstances as the Administrator may deem appropriate, in each case subject to Sections 4 and 8.6 (and subject to the no repricing provision below)&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">determine the date of grant of an award, which may be a designated date after but not before the date of the Administrator&#8217;s action (unless otherwise designated by the Administrator, the date of grant of an award shall be the date upon which the Administrator took the action granting an award)&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.97pt">determine whether, and the extent to which, adjustments are required pursuant to Section&#160;7 hereof and authorize the termination, conversion, substitution or succession of awards upon the occurrence of an event of the type described in Section&#160;7&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.97pt">acquire or settle (subject to Sections 7 and 8.6) rights under awards in cash, stock of equivalent value, or other consideration (subject to the no repricing provision below)&#59; and </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">determine the fair market value of the Common Stock or awards under this Plan from time to time and&#47;or the manner in which such value will be determined. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing and except for an adjustment pursuant to Section&#160;7.1 or a repricing approved by stockholders, in no case may the Administrator (1)&#160;amend an outstanding stock option or stock appreciation right to reduce the exercise price or base price of the award, (2)&#160;cancel, exchange, or surrender an outstanding stock option or stock appreciation right in exchange for cash or other awards for the purpose of repricing the award, or (3)&#160;cancel, exchange, or surrender an outstanding stock option or stock appreciation right in exchange for an option or stock appreciation right with an exercise or base price that is less than the exercise or base price of the original award. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Binding Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any action taken by, or inaction of, the Corporation, any Subsidiary, or the Administrator relating or pursuant to this Plan and within its authority hereunder or under applicable law </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shall be within the absolute discretion of that entity or body and shall be conclusive and binding upon all persons. Neither the Board nor any Board committee, nor any member thereof or person acting at the direction thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with this Plan (or any award made under this Plan), and all such persons shall be entitled to indemnification and reimbursement by the Corporation in respect of any claim, loss, damage or expense (including, without limitation, attorneys&#8217; fees) arising or resulting therefrom to the fullest extent permitted by law and&#47;or under any directors and officers liability insurance coverage that may be in effect from time to time.</font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Reliance on Experts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In making any determination or in taking or not taking any action under this Plan, the Administrator may obtain and may rely upon the advice of experts, including employees and professional advisors to the Corporation. No director, officer or agent of the Corporation or any of its Subsidiaries shall be liable for any such action or determination taken or made or omitted in good faith. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Delegation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Administrator may delegate ministerial, non-discretionary functions to individuals who are officers or employees of the Corporation or any of its Subsidiaries or to third parties. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.5pt">SHARES OF COMMON STOCK SUBJECT TO THE PLAN&#59; SHARE LIMITS </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Shares Available</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Subject to the provisions of Section&#160;7.1, the capital stock that may be delivered under this Plan shall be shares of the Corporation&#8217;s authorized but unissued Common Stock and any shares of its Common Stock held as treasury shares. For purposes of this Plan, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the common stock of the Corporation and such other securities or property as may become the subject of awards under this Plan, or may become subject to such awards, pursuant to an adjustment made under Section&#160;7.1. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Share Limits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Subject to Section&#160;7.1, the maximum number of shares of Common Stock that may be delivered pursuant to awards granted to Eligible Persons under this Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share Limit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is equal to&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:57.6pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">39,200,000 shares of Common Stock, less&#160;</font></div><div style="padding-left:57.6pt;text-align:justify"><font><br></font></div><div style="padding-left:57.6pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">The number of any shares subject to awards granted under the Corporation&#8217;s 2012 Performance Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2012 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) on or after March&#160;31, 2017. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:30.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued in respect of any &#8220;Full-Value Award&#8221; granted under this Plan shall be counted against the foregoing Share Limit as 1.5 shares for every one share issued in connection with such award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Full-Value Award Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). (For example, if a stock bonus of 100 shares of Common Stock is granted under this Plan, 150 shares shall be charged against the Share Limit in connection with that award.) For this purpose, a &#8220;Full-Value Award&#8221; means any award under this Plan that is not a stock option grant or a stock appreciation right grant. </font></div><div style="margin-top:9pt;text-align:justify;text-indent:30.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following limits also apply with respect to awards granted under this Plan&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">&#160;The maximum number of shares of Common Stock that may be delivered pursuant to options qualified as incentive stock options granted under this Plan is 39,200,000 shares. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">The maximum number of shares of Common Stock subject to options and stock appreciation rights that are granted during any calendar year to any individual under this Plan is 3,000,000 shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">Additional limits with respect to performance-based awards are set forth in Section&#160;5.2.2.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">The aggregate value of cash compensation and the grant date fair value (computed in accordance with generally accepted accounting principles) of shares of Common Stock that may be paid or granted during any calendar year to any non-employee director shall not exceed $1,200,000 for existing non-employee directors and $2,200,000 for new non-employee directors. </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each of the foregoing numerical limits is subject to adjustment as contemplated by Section&#160;4.3, Section&#160;7.1, and Section&#160;8.10. </font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Awards Settled in Cash, Reissue of Awards and Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Except as provided in the next sentence, shares that are subject to or underlie awards granted under this Plan or the 2012 Plan, the Corporation&#8217;s 2008 Equity Incentive Plan, the Corporation&#8217;s 2000 Non-Officer Equity Incentive Plan, or the Corporation&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2000 Equity Incentive Plan (collectively, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Prior Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), which expire or for any reason are cancelled or terminated, are forfeited, fail to vest, or for any other reason are not paid or delivered under this Plan or a Prior Plan shall again be available for subsequent awards under this Plan (with any such shares increasing the Share Limit based on the Full-Value Award Ratio specified in Section&#160;4.2 or, with respect to awards granted under a Prior Plan, the Full-Value Award Ratio as specified in such Prior Plan). Shares that are exchanged by a participant or withheld by the Corporation as full or partial payment in connection with any award under this Plan, as well as any shares exchanged by a participant or withheld by the Corporation or one of its Subsidiaries to satisfy the tax withholding obligations related to any award, shall not be available for subsequent awards under this Plan. To the extent that an award granted under this Plan or a Prior Plan is settled in cash or a form other than shares of Common Stock, the shares that would have been delivered had there been no such cash or other settlement shall again be available for subsequent awards under this Plan (with any such shares increasing the Share Limit based on the Full-Value Award Ratio specified in Section&#160;4.2 or, with respect to awards granted under a Prior Plan, the Full-Value Award Ratio as specified in such Prior Plan). In the event that shares of Common Stock are delivered in respect of a dividend equivalent right granted under this Plan, the number of shares delivered with respect to the award shall be counted against the share limits of this Plan (including, for purposes of clarity, the limits of Section&#160;4.2 of this Plan). (For purposes of clarity, if 1,000 dividend equivalent rights are granted and outstanding when the Corporation pays a dividend, and 50 shares are delivered in payment of those rights with respect to that dividend, 75 shares (after giving effect to the Full-Value Award premium counting rules) shall be counted against the share limits of this Plan). To the extent that shares of Common Stock are delivered pursuant to the exercise of a stock appreciation right or stock option granted under this Plan, the number of underlying shares as to which the exercise related shall be counted against the applicable share limits under Section&#160;4.2, as opposed to only counting the shares issued. (For purposes of clarity, if a stock appreciation right relates to 100,000 shares and is exercised at a time when the payment due to the participant is 15,000 shares, 100,000 shares shall be charged against the applicable share limits under Section&#160;4.2 with respect to such exercise.) Refer to Section&#160;8.10 for application of the foregoing share limits with respect to assumed awards.</font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Reservation of Shares&#59; No Fractional Shares&#59; Minimum Issue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Corporation shall at all times reserve a number of shares of Common Stock sufficient to cover the Corporation&#8217;s obligations and contingent obligations to deliver shares with respect to awards then outstanding under this Plan (exclusive of any dividend equivalent obligations to the extent the Corporation has the right to settle such rights in cash). No fractional shares shall be delivered under this Plan. The Administrator may pay cash in lieu of any fractional shares in settlements of awards under this Plan. The Administrator may from time to time impose a limit (of not greater than 100 shares) on the minimum number of shares that may be purchased or exercised as to awards granted under this Plan unless (as to any particular award) the total number purchased or exercised is the total number at the time available for purchase or exercise under the award. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.5pt">AWARDS</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Type and Form of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Administrator shall determine the type or types of award(s) to be made to each selected Eligible Person. Awards may be granted singly, in combination or in tandem. Awards also may be made in combination or in tandem with, in replacement of, as alternatives to, or as the payment form for grants or rights under any other employee or compensation plan of the Corporation or one of its Subsidiaries. The types of awards that may be granted under this Plan are (subject, in each case, to the no repricing provisions of Section&#160;3.2)&#58;</font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A stock option is the grant of a right to purchase a specified number of shares of Common Stock during a specified period as determined by the Administrator. An option may be intended as an incentive stock option within the meaning of Section&#160;422 of the Code (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ISO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or a nonqualified stock option (an option not intended to be an ISO). The award agreement for an option will indicate if the option is intended as an ISO. Each option, or portion thereof, that is not an ISO, shall be a nonqualified stock option.&#160;&#160;&#160;&#160;The maximum term of each option (ISO or nonqualified) shall be eight (8)&#160;years. The per share exercise price for each option shall be not less than 100% of the fair market value of a share of Common Stock on the date of grant of the option. When an option is exercised, the exercise price for the shares to be purchased shall be paid in full in cash or such other method permitted by the Administrator consistent with Section&#160;5.5. </font></div><div style="padding-left:61.2pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Additional Rules Applicable to ISOs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To the extent that the aggregate fair market value (determined at the time of grant of the applicable option) of stock with respect to which ISOs first become exercisable by a participant in any calendar year exceeds $100,000, taking into account both Common Stock subject to ISOs under this Plan and stock subject to ISOs under all other plans of the Corporation or one of its Subsidiaries (or any parent or predecessor corporation to the extent required by and within the meaning of Section&#160;422 of the Code and the regulations promulgated thereunder), </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:61.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">such options shall be treated as nonqualified stock options. In reducing the number of options treated as ISOs to meet the $100,000 limit, the most recently granted options shall be reduced first. To the extent a reduction of simultaneously granted options is necessary to meet the $100,000 limit, the Administrator may, in the manner and to the extent permitted by law, designate which shares of Common Stock are to be treated as shares acquired pursuant to the exercise of an ISO. ISOs may only be granted to employees of the Corporation or one of its subsidiaries (for this purpose, the term &#8220;subsidiary&#8221; is used as defined in Section&#160;424(f) of the Code, which generally requires an unbroken chain of ownership of at least 50% of the total combined voting power of all classes of stock of each subsidiary in the chain beginning with the Corporation and ending with the subsidiary in question). There shall be imposed in any award agreement relating to ISOs such other terms and conditions as from time to time are required in order that the option be an &#8220;incentive stock option&#8221; as that term is defined in Section&#160;422 of the Code. No ISO may be granted to any person who, at the time the option is granted, owns (or is deemed to own under Section&#160;424(d) of the Code) shares of outstanding Common Stock possessing more than 10% of the total combined voting power of all classes of stock of the Corporation, unless the exercise price of such option is at least 110% of the fair market value of the stock subject to the option and such option by its terms is not exercisable after the expiration of five years from the date such option is granted. </font></div><div style="padding-left:61.2pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Stock Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A stock appreciation right or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is a right to receive a payment, in cash and&#47;or Common Stock (as specified in the applicable award agreement), equal to the excess of the fair market value of a specified number of shares of Common Stock on the date the SAR is exercised over the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">base price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of the award, which base price shall be set forth in the applicable award agreement and shall be not less than 100% of the fair market value of a share of Common Stock on the date of grant of the SAR. The maximum term of a SAR shall be eight (8)&#160;years. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Other Awards&#59; Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The other types of awards that may be granted under this Plan include&#58; (a)&#160;stock bonuses, restricted stock, performance stock, stock units, phantom stock or similar rights to purchase or acquire shares, whether at a fixed or variable price or ratio related to the Common Stock, upon the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions, or any combination thereof&#59; (b)&#160;any similar securities with a value derived from the value of or related to the Common Stock and&#47;or returns thereon&#59; or (c)&#160;cash awards. Dividend equivalent rights may be granted as a separate award or in connection with another award under this Plan&#59; provided, however, that dividend equivalent rights may not be granted in connection with a stock option or SAR granted under this Plan. Notwithstanding anything in the Plan or an award agreement to the contrary, any dividends and&#47;or dividend equivalents as to the unvested portion of an award (including, without limitation, a restricted stock award) will be subject to termination and forfeiture to the same extent as the corresponding portion of the award to which they relate. </font></div><div style="padding-left:61.2pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Performance-Based Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The grant, vesting, exercisability or payment of performance-based awards shall depend on the degree of achievement of one or more performance goals relative to a pre-established targeted level or levels using one or more of the Business Criteria set forth below (on an absolute or relative (including, without limitation, relative to the performance of other companies or upon comparisons of any of the indicators of performance relative to other companies) basis) for the Corporation on a consolidated basis or for one or more of the Corporation&#8217;s subsidiaries, segments, divisions or business units, or any combination of the foregoing. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The specific performance goals for performance-based awards may be, on an absolute or relative basis, established based on one or more of the following business criteria (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) as selected by the Administrator in its sole discretion&#58; earnings per share&#59; cash flow (which means cash and cash equivalents derived from either net cash flow from operations or net cash flow from operations, financing and investing activities)&#59; working capital&#59; stock price&#59; total stockholder return&#59; revenue&#59; gross profit&#59; operating income&#59; net earnings (before or after interest, taxes, depreciation and&#47;or amortization)&#59; gross margin&#59; operating margin&#59; net margin&#59; return on equity or on assets or on net investment&#59; cost containment or reduction&#59; regulatory submissions or approvals&#59; manufacturing production&#59; completion of strategic partnerships&#59; research milestones&#59; any other measure selected by the Administrator or any combination thereof. As applicable, these terms are used as applied under generally accepted accounting principles or in the financial reporting of the Corporation or of its Subsidiaries. The applicable performance goals may be applied on a pre- or post-tax basis and may be adjusted to include or exclude determinable components of any performance goal, including, without limitation, foreign exchange gains and losses, asset write-downs, acquisitions and divestitures, change in fiscal year, unbudgeted capital expenditures, special charges such as restructuring or impairment charges, debt refinancing costs, extraordinary or noncash items, unusual, infrequently occurring, nonrecurring or one-time events affecting the Corporation or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:61.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">its financial statements or changes in law or accounting principles (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Adjustment Events&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). The applicable performance measurement period may not be less than three months nor more than 10 years. </font></div><div style="padding-left:61.2pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Form of Payment&#59; Maximum Performance-Based Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Grants or awards under this Section&#160;5.2 may be paid in cash or shares of Common Stock or any combination thereof. The maximum number of shares of Common Stock which may be subject to performance-based awards (including performance-based awards payable in shares of Common Stock and performance-based awards payable in cash where the amount of cash payable upon or following vesting of the award is determined with reference to the fair market value of a share of Common Stock at such time) that are granted to any one participant in any one calendar year shall not exceed 3,000,000 shares, either individually or in the aggregate, subject to adjustment as provided in Section&#160;7.1&#59; provided that this limit shall not apply to Options and SARs (which are covered by the limit of Section&#160;4.2(b)). The aggregate amount of compensation to be paid to any one participant in respect of all performance-based awards payable only in cash (excluding cash awards covered by the preceding sentence where the cash payment is determined with reference to the fair market value of a share of Common Stock upon or following the vesting of the award) and granted to that participant in any one calendar year shall not exceed $5,000,000. </font></div><div style="padding-left:61.2pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Certification of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Before any performance-based award is paid under this Section&#160;5.2, the Administrator must certify in writing that the performance target(s) and any other material terms of the Performance-Based Award were in fact timely satisfied. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Reservation of Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Administrator will have the discretion to determine the restrictions or other limitations of the individual awards granted under this Section&#160;5.2 including the authority to reduce awards, payouts or vesting or to pay no awards, in its sole discretion, if the Administrator preserves such authority at the time of grant by language to this effect in its authorizing resolutions or otherwise. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Award Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Each award shall be evidenced by either (1)&#160;a written award agreement in a form approved by the Administrator and executed by the Corporation by an officer duly authorized to act on its behalf, or (2)&#160;an electronic notice of award grant in a form approved by the Administrator and recorded by the Corporation (or its designee) in an electronic recordkeeping system used for the purpose of tracking award grants under this Plan generally (in each case, an &#8220;award agreement&#8221;), as the Administrator may provide and, in each case and if required by the Administrator, executed or otherwise electronically accepted by the recipient of the award in such form and manner as the Administrator may require. The Administrator may authorize any officer of the Corporation (other than the particular award recipient) to execute any or all award agreements on behalf of the Corporation. The award agreement shall set forth the material terms and conditions of the award as established by the Administrator consistent with the express limitations of this Plan. Notwithstanding anything contained herein to the contrary, the Administrator may approve an award agreement that, upon the termination of a participant&#8217;s employment or service, provides that, or may, in its sole discretion based on a review of all relevant facts and circumstances, otherwise take action regarding an award agreement such that (i)&#160;any or all outstanding stock options and SARs shall become exercisable in part or in full, (ii)&#160;all or a portion of the restriction or vesting period applicable to any outstanding award shall lapse, (iii)&#160;all or a portion of the performance measurement period applicable to any outstanding award shall lapse and (iv)&#160;the performance goals applicable to any outstanding award (if any) shall be deemed to be satisfied at the target, maximum or any other interim level.</font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Deferrals and Settlements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Payment of awards may be in the form of cash, Common Stock, other awards or combinations thereof as the Administrator shall determine, and with such restrictions as it may impose. The Administrator may also require or permit participants to elect to defer the issuance of shares or the settlement of awards in cash under such rules and procedures as it may establish under this Plan. The Administrator may also provide that deferred settlements include the payment or crediting of interest or other earnings on the deferral amounts, or the payment or crediting of dividend equivalents where the deferred amounts are denominated in shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Consideration for Common Stock or Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The purchase price for any award granted under this Plan or the Common Stock to be delivered pursuant to an award, as applicable, may be paid by means of any lawful consideration as determined by the Administrator, including, without limitation, one or a combination of the following methods&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:8pt">services rendered by the recipient of such award&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:8pt">cash, check payable to the order of the Corporation, or electronic funds transfer&#59;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:8pt">notice and third party payment in such manner as may be authorized by the Administrator&#59; </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:8pt">the delivery of previously owned shares of Common Stock&#59; </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:8pt">&#160;by a reduction in the number of shares otherwise deliverable pursuant to the award&#59; or </font></div><div style="margin-bottom:5pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:8pt">subject to such procedures as the Administrator may adopt, pursuant to a &#8220;cashless exercise&#8221; with a third party who provides financing for the purposes of (or who otherwise facilitates) the purchase or exercise of awards. </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In no event shall any shares newly-issued by the Corporation be issued for less than the minimum lawful consideration for such shares or for consideration other than consideration permitted by applicable state law. Shares of Common Stock used to satisfy the exercise price of an option shall be valued at their fair market value on the date of exercise. The Corporation will not be obligated to deliver any shares unless and until it receives full payment of the exercise or purchase price therefor and any related withholding obligations under Section&#160;8.5 and any other conditions to exercise or purchase have been satisfied. </font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Definition of Fair Market Value.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> For purposes of this Plan, &#8220;fair market value&#8221; shall mean the closing price (in regular trading) for a share of Common Stock on the NASDAQ Stock Market (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for the date in question or, if no sales of Common Stock were reported on the Market on that date, the closing price (in regular trading) for a share of Common Stock on the Market for the next preceding day on which sales of Common Stock were reported on the Market. The Administrator may, however, provide with respect to one or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">more</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> awards that the fair market value shall equal the closing price (in regular trading) for a share of Common Stock on the Market on the last trading day preceding the date in question or the average of the high and low trading prices of a share of Common Stock on the Market for the date in question or the most recent trading day. If the Common Stock is no longer listed or is no longer actively traded on the Market as of the applicable date, the fair market value of the Common Stock shall be the value as reasonably determined by the Administrator for purposes of the award in the circumstances. The Administrator also may adopt a different methodology for determining fair market value with respect to one or more awards if a different methodology is necessary or advisable to secure any intended favorable tax, legal or other treatment for the particular award(s) (for example, and without limitation, the Administrator may provide that fair market value for purposes of one or more awards will be based on an average of closing prices (or the average of high and low daily trading prices) for a specified period preceding the relevant date).</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:6.6pt">Transfer Restrictions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.7.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Limitations on Exercise and Transfer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Unless otherwise expressly provided in (or pursuant to) this Section&#160;5.7 or required by applicable law&#58; (a)&#160;all awards are non-transferable and shall not be subject in any manner to sale, transfer, anticipation, alienation, assignment, pledge, encumbrance or charge&#59; (b)&#160;awards shall be exercised only by the participant&#59; and (c)&#160;amounts payable or shares issuable pursuant to any award shall be delivered only to (or for the account of) the participant. </font></div><div style="padding-left:61.2pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.7.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Exceptions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Administrator may permit awards to be exercised by and paid to, or otherwise transferred to, other persons or entities pursuant to such conditions and procedures, including limitations on subsequent transfers, as the Administrator may, in its sole discretion, establish in writing. Any permitted transfer shall be subject to compliance with applicable federal and state securities laws and shall not be for value (other than nominal consideration, settlement of marital property rights, or for interests in an entity in which more than 50% of the voting interests are held by the Eligible Person or by the Eligible Person&#8217;s family members). </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.7.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Further Exceptions to Limits on Transfer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The exercise and transfer restrictions in Section&#160;5.7.1 shall not apply to&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">transfers to the Corporation (for example, in connection with the expiration or termination of the award)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">the designation of a beneficiary to receive benefits in the event of the participant&#8217;s death or, if the participant has died, transfers to or exercise by the participant&#8217;s beneficiary, or, in the absence of a validly designated beneficiary, transfers by will or the laws of descent and distribution&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">subject to any applicable limitations on ISOs, transfers to a family member (or former family member) pursuant to a domestic relations order if approved or ratified by the Administrator&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">if the participant has suffered a disability, permitted transfers or exercises on behalf of the participant by his or her legal representative&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">the authorization by the Administrator of &#8220;cashless exercise&#8221; procedures with third parties who provide financing for the purpose of (or who otherwise facilitate) the exercise of awards consistent with applicable laws and the express authorization of the Administrator. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">International Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> One or more awards may be granted to Eligible Persons who provide services to the Corporation or one of its Subsidiaries outside of the United States. Any awards granted to such persons may be granted pursuant to the terms and conditions of any applicable sub-plans, if any, appended to this Plan and approved by the Administrator. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.5pt">EFFECT OF TERMINATION OF EMPLOYMENT OR SERVICE ON AWARDS </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Administrator shall establish the effect of a termination of employment or service on the rights and benefits under each award under this Plan and in so doing may make distinctions based upon, inter alia, the cause of termination and type of award. If the participant is not an employee of the Corporation or one of its Subsidiaries and provides other services to the Corporation or one of its Subsidiaries, the Administrator shall be the sole judge for purposes of this Plan (unless a contract or the award otherwise provides) of whether the participant continues to render services to the Corporation or one of its Subsidiaries and the date, if any, upon which such services shall be deemed to have terminated. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Events Not Deemed Terminations of Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Unless the express policy of the Corporation or one of its Subsidiaries, or the Administrator, otherwise provides, the employment relationship shall not be considered terminated in the case of (a)&#160;sick leave, (b)&#160;military leave, or (c)&#160;any other leave of absence authorized by the Corporation or one of its Subsidiaries, or the Administrator&#59; provided that, unless reemployment upon the expiration of such leave is guaranteed by contract or law or the Administrator otherwise provides, such leave is for a period of not more than three months (or such other period of time as required by applicable law). In the case of any employee of the Corporation or one of its Subsidiaries on an approved leave of absence, continued vesting of the award while on leave from the employ of the Corporation or one of its Subsidiaries may be suspended until the employee returns to service, unless the Administrator otherwise provides or applicable law (including Section&#160;409A of the Code) otherwise requires. In no event shall an award be exercised after the expiration of the term set forth in the applicable award agreement. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Effect of Change of Subsidiary Status.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> For purposes of this Plan and any award, if an entity ceases to be a Subsidiary of the Corporation a termination of employment or service shall be deemed to have occurred with respect to each Eligible Person in respect of such Subsidiary who does not continue as an Eligible Person in respect of the Corporation or another Subsidiary that continues as such after giving effect to the transaction or other event giving rise to the change in status unless the Subsidiary that is sold, spun-off or otherwise divested (or its successor or a direct or indirect parent of such Subsidiary or successor) assumes the Eligible Person&#8217;s award(s) in connection with such transaction. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.5pt">ADJUSTMENTS&#59; ACCELERATION </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Adjustments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Subject to Section&#160;7.2, upon (or, as may be necessary to effect the adjustment, immediately prior to)&#58; any reclassification, recapitalization, stock split (including a stock split in the form of a stock dividend) or reverse stock split&#59; any merger, combination, consolidation, or other reorganization&#59; any spin-off, split-up, or similar extraordinary dividend distribution in respect of the Common Stock&#59; or any exchange of Common Stock or other securities of the Corporation, or any similar, unusual or extraordinary corporate transaction in respect of the Common Stock&#59; then the Administrator shall equitably and proportionately adjust (1)&#160;the number and type of shares of Common Stock (or other securities) that thereafter may be made the subject of awards (including the specific share limits, maximums and numbers of shares set forth elsewhere in this Plan), (2)&#160;the number, amount and type of shares of Common Stock (or other securities or property) subject to any outstanding awards, (3)&#160;the grant, purchase, or exercise price (which term includes the base price of any SAR or similar right) of any outstanding awards, and&#47;or (4)&#160;the securities, cash or other property deliverable upon exercise or payment of any outstanding awards, in each case to the extent necessary to preserve (but not increase) the level of incentives intended by this Plan and the then-outstanding awards. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise expressly provided in the applicable award agreement, upon (or, as may be necessary to effect the adjustment, immediately prior to) any event or transaction described in the preceding paragraph or a sale of all or substantially all of the business or assets of the Corporation as an entirety, the Administrator shall equitably and proportionately adjust the performance standards applicable to any then-outstanding performance-based awards to the extent necessary to preserve (but not increase) the level of incentives intended by this Plan and the then-outstanding performance-based awards. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">It is intended that, if possible, any adjustments contemplated by the preceding two paragraphs be made in a manner that satisfies applicable U.S. legal, tax (including, without limitation and as applicable in the circumstances, Section&#160;424 of the Code and Section&#160;409A of the Code) and accounting (so as to not trigger any charge to earnings with respect to such adjustment) requirements. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without limiting the generality of Section&#160;3.3, any good faith determination by the Administrator as to whether an adjustment is required in the circumstances pursuant to this Section&#160;7.1, and the extent and nature of any such adjustment, shall be conclusive and binding on all persons. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Change in Control&#8212;Assumption and Termination of Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Upon the occurrence of a Change in Control, then the Administrator may make provision for a cash payment in settlement of, or for the termination, assumption, substitution or exchange of any or all outstanding share-based awards or the cash, securities or property deliverable to the holder of any or all outstanding share-based awards, based upon, to the extent relevant under the circumstances, the distribution or consideration payable to holders of the Common Stock upon or in respect of such Change in Control. Upon the occurrence of a Change in Control, then, unless the Administrator has made a provision for the substitution, assumption, exchange or other continuation or settlement of the award or (unless the Administrator has provided for the termination of the award) the award would otherwise continue in accordance with its terms in the circumstances&#58; (1)&#160;unless otherwise provided in the applicable award agreement, each then-outstanding option and SAR shall become fully vested, all shares of restricted stock then outstanding shall fully vest free of restrictions, and each other award granted under this Plan that is then outstanding shall become payable to the holder of such award&#59; and (2)&#160;each award shall terminate upon the Change in Control&#59; provided that the holder of an option or SAR shall be given reasonable advance notice of the impending termination and a reasonable opportunity to exercise his or her outstanding vested options and SARs (after giving effect to any accelerated vesting required in the circumstances) in accordance with their terms before the termination of such awards (except that in no case shall more than ten days&#8217; notice of the impending termination be required and any acceleration of vesting and any exercise of any portion of an award that is so accelerated may be made contingent upon the actual occurrence of the Change in Control). </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Administrator may adopt such valuation methodologies for outstanding awards as it deems reasonable in the event of a cash or property settlement and, in the case of options, SARs or similar rights, but without limitation on other methodologies, may base such settlement solely upon the excess (if any) of the per share amount payable upon or in respect of such Change in Control over the exercise or base price of the award. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to applicable law, in the event of a Change in Control, the Administrator may take such action contemplated by this Section&#160;7.2 prior to such Change in Control (as opposed to on the occurrence of such Change in Control) to the extent that the Administrator deems the action necessary to permit the participant to realize the benefits intended to be conveyed with respect to the underlying shares. Without limiting the generality of the foregoing, the Administrator may deem an acceleration to occur immediately prior to the Change in Control and, in such circumstances, will reinstate the original terms of the award if an event giving rise to an acceleration does not occur. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without limiting the generality of Section&#160;3.3, any good faith determination by the Administrator pursuant to its authority under this Section&#160;7.2 shall be conclusive and binding on all persons. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Other Acceleration Rules.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Administrator may override the provisions of Section&#160;7.2 by express provision in the award agreement and may accord any Eligible Person a right, subject to Section&#160;409A of the Code, to refuse any acceleration, whether pursuant to the award agreement or otherwise, in such circumstances as the Administrator may approve. The portion of any ISO accelerated in connection with an event referred to in Section&#160;7.2 (or such other circumstances as may trigger accelerated vesting of the award) shall remain exercisable as an ISO only to the extent the applicable $100,000 limitation on ISOs is not exceeded. To the extent exceeded, the accelerated portion of the option shall be exercisable as a nonqualified stock option under the Code. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Definition of Change in Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> With respect to a particular award granted under this Plan, a &#8220;Change in Control&#8221; shall be deemed to have occurred as of the first day, after the date of grant of the particular award, that any one or more of the following conditions shall have been satisfied&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">The acquisition by any individual, entity or group (within the meaning of Section&#160;13(d)(3) or 14(d)(2) of the Exchange Act (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than 30% of either (1)&#160;the then-outstanding shares of common stock of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Company Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or (2)&#160;the combined voting power of the then-outstanding voting securities of the Corporation entitled to vote generally in the election of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Company Voting Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that, for purposes of this clause (a), the following acquisitions shall not constitute a Change in Control Event&#59; (A)&#160;any acquisition directly from the Corporation, (B)&#160;any acquisition by the Corporation, (C)&#160;any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Corporation or any affiliate of the Corporation or a successor, or (D)&#160;any acquisition by any entity pursuant to a transaction that complies with Sections (c)(1), (2)&#160;and (3)&#160;below&#59; </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">Individuals who, as of the Effective Date, constitute the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incumbent Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) cease for any reason to constitute at least a majority of the Board&#59; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by the Corporation&#8217;s stockholders, was approved by a vote of at least two-thirds of the directors then comprising the Incumbent Board (including for these purposes, the new members whose election or nomination was so approved, without counting the member and his predecessor twice) shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">Consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving the Corporation or any of its Subsidiaries, a sale or other disposition of all or substantially all of the assets of the Corporation, or the acquisition of assets or stock of another entity by the Corporation or any of its Subsidiaries (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), in each case unless, following such Business Combination, (1)&#160;all or substantially all of the individuals and entities that were the beneficial owners of the Outstanding Company Common Stock and the Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the entity resulting from such Business Combination (including, without limitation, an entity that, as a result of such transaction, owns the Corporation or all or substantially all of the Corporation&#8217;s assets directly or through one or more subsidiaries (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)) in substantially the same proportions as their ownership immediately prior to such Business Combination of the Outstanding Company Common Stock and the Outstanding Company Voting Securities, as the case may be, (2)&#160;no Person (excluding any entity resulting from such Business Combination or a Parent or any employee benefit plan (or related trust) of the Corporation or such entity resulting from such Business Combination or Parent) beneficially owns, directly or indirectly, more than 30% of, respectively, the then-outstanding shares of common stock of the entity resulting from such Business Combination or the combined voting power of the then-outstanding voting securities of such entity, except to the extent that the ownership in excess of 30% existed prior to the Business Combination, and (3)&#160;at least a majority of the members of the board of directors or trustees of the entity resulting from such Business Combination or a Parent were members of the Incumbent Board at the time of the execution of the initial agreement or of the action of the Board providing for such Business Combination&#59; or </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">Approval by the stockholders of the Corporation of a complete liquidation or dissolution of the Corporation other than in the context of a transaction that does not constitute a Change in Control under clause (c)&#160;above. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.5pt">OTHER PROVISIONS</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Compliance with Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Plan, the granting and vesting of awards under this Plan, the offer, issuance and delivery of shares of Common Stock, and&#47;or the payment of money under this Plan or under awards are subject to compliance with all applicable federal and state laws, rules and regulations (including but </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">not limited to state and federal securities law and federal margin requirements) and to such approvals by any listing, regulatory or governmental authority as may, in the opinion of counsel for the Corporation, be necessary or advisable in connection therewith. The person acquiring any securities under this Plan will, if requested by the Corporation or one of its Subsidiaries, provide such assurances and representations to the Corporation or one of its Subsidiaries as the Administrator may deem necessary or desirable to assure compliance with all applicable legal and accounting requirements. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">No Rights to Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No person shall have any claim or rights to be granted an award (or additional awards, as the case may be) under this Plan, subject to any express contractual rights (set forth in a document other than this Plan) to the contrary. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">No Employment&#47;Service Contract.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Nothing contained in this Plan (or in any other documents under this Plan or in any award) shall confer upon any Eligible Person or other participant any right to continue in the employ or other service of the Corporation or one of its Subsidiaries, constitute any contract or agreement of employment or other service or affect an employee&#8217;s status as an employee at will, nor shall interfere in any way with the right of the Corporation or one of its Subsidiaries to change a person&#8217;s compensation or other benefits, or to terminate his or her employment or other service, with or without cause. Nothing in this Section&#160;8.3, however, is intended to adversely affect any express independent right of such person under a separate employment or service contract other than an award agreement. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Plan Not Funded.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Awards payable under this Plan shall be payable in shares or from the general assets of the Corporation, and no special or separate reserve, fund or deposit shall be made to assure payment of such awards. No participant, beneficiary or other person shall have any right, title or interest in any fund or in any specific asset (including shares of Common Stock, except as expressly otherwise provided) of the Corporation or one of its Subsidiaries by reason of any award hereunder. Neither the provisions of this Plan (or of any related documents), nor the creation or adoption of this Plan, nor any action taken pursuant to the provisions of this Plan shall create, or be construed to create, a trust of any kind or a fiduciary relationship between the Corporation or one of its Subsidiaries and any participant, beneficiary or other person. To the extent that a participant, beneficiary or other person acquires a right to receive payment pursuant to any award hereunder, such right shall be no greater than the right of any unsecured general creditor of the Corporation. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Tax Withholding. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon any exercise, vesting, or payment of any award, or upon the disposition of shares of Common Stock acquired pursuant to the exercise of an ISO prior to satisfaction of the holding period requirements of Section&#160;422 of the Code, or upon any other tax withholding event with respect to any award, the Corporation or one of its Subsidiaries shall have the right at its option to&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt">require the participant (or the participant&#8217;s personal representative or beneficiary, as the case may be) to pay or provide for payment of at least the minimum amount of any taxes which the Corporation or one of its Subsidiaries may be required to withhold with respect to such award event or payment&#59; or </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt">deduct from any amount otherwise payable in cash (whether related to the award or otherwise) to the participant (or the participant&#8217;s personal representative or beneficiary, as the case may be) the minimum amount of any taxes which the Corporation or one of its Subsidiaries may be required to withhold with respect to such award event or payment. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In any case where a tax is required to be withheld in connection with the delivery of shares of Common Stock under this Plan, the Administrator may in its sole discretion (subject to Section&#160;8.1) require or grant (either at the time of the award or thereafter) to the participant the right to elect, pursuant to such rules and subject to such conditions as the Administrator may establish, that the Corporation reduce the number of  shares to be delivered by (or otherwise reacquire) the appropriate number of shares, valued in a consistent manner at their fair market value or at the sales price in accordance with authorized procedures for cashless exercises, necessary to satisfy the applicable withholding obligation on exercise, vesting or payment. Shares of Common Stock to be delivered or withheld may not have an aggregate Fair Market Value in excess of the amount determined by applying the minimum statutory withholding rate (or, if permitted by the Corporation, such other rate as will not cause adverse accounting consequences under generally accepted accounting principles then in effect). Any fraction of a share of Common Stock which would be required to satisfy such an obligation shall be disregarded and the remaining amount due shall be paid in cash by the holder. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:3.6pt"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Effective Date, Termination and Suspension, Amendments. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Effective Date. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Plan is effective as of March&#160;28, 2017, the date of its approval by the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). This Plan shall be submitted for and subject to stockholder approval no later than twelve months after the Effective Date. Upon such stockholder approval, no further awards shall be granted under any Prior Plan. Unless earlier terminated by the Board, this Plan shall terminate at the close of business on the day before the tenth anniversary of the Effective Date. After the termination of this Plan either upon such stated expiration date or its earlier termination by the Board, no additional awards may be granted under this Plan, but previously granted awards (and the authority of the Administrator with respect thereto, including the authority to amend such awards) shall remain outstanding in accordance with their applicable terms and conditions and the terms and conditions of this Plan.</font></div><div style="padding-left:61.2pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Board Authorization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Board may, at any time, terminate or, from time to time, amend, modify or suspend this Plan, in whole or in part. No awards may be granted during any period that the Board suspends this Plan. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Stockholder Approval.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To the extent then required by applicable law or any applicable listing agency or required under Sections 422 or 424 of the Code to preserve the intended tax consequences of this Plan, or deemed necessary or advisable by the Board, any amendment to this Plan shall be subject to stockholder approval. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Amendments to Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Without limiting any other express authority of the Administrator under (but subject to) the express limits of this Plan, the Administrator by agreement or resolution may waive conditions of or limitations on awards to participants that the Administrator in the prior exercise of its discretion has imposed, without the consent of a participant, and (subject to the requirements of Sections 3.2 and 8.6.5) may make other changes to the terms and conditions of awards. Any amendment or other action that would constitute a repricing of an award is subject to the limitations set forth in Section&#160;3.2. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Limitations on Amendments to Plan and Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No amendment, suspension or termination of this Plan or amendment of any outstanding award agreement shall, without written consent of the participant, affect in any manner materially adverse to the participant any rights or benefits of the participant or obligations of the Corporation under any award granted under this Plan prior to the effective date of such change. Changes, settlements and other actions contemplated by Section&#160;7 shall not be deemed to constitute changes or amendments for purposes of this Section&#160;8.6. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Privileges of Stock Ownership.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Except as otherwise expressly authorized by the Administrator, a participant shall not be entitled to any privilege of stock ownership as to any shares of Common Stock not actually delivered to and held of record by the participant (subject to the last sentence of Section&#160;5.1.4). Except as expressly required by Section&#160;7.1 or otherwise expressly provided by the Administrator, no adjustment will be made for dividends or other rights as a stockholder for which a record date is prior to such date of delivery.</font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Governing Law&#59; Construction&#59; Severability. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Choice of Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Plan, the awards, all documents evidencing awards and all other related documents shall be governed by, and construed in accordance with the laws of the State of Delaware. </font></div><div style="padding-left:61.2pt;text-align:justify"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.8.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If a court of competent jurisdiction holds any provision invalid and unenforceable, the remaining provisions of this Plan shall continue in effect. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.8.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:2.7pt">Plan Construction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.31pt;text-decoration:underline">Rule 16b-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. It is the intent of the Corporation that the awards and transactions permitted by awards be interpreted in a manner that, in the case of participants who are or may be subject to Section&#160;16 of the Exchange Act, qualify, to the maximum extent compatible with the express terms of the award, for exemption from matching liability under Rule 16b-3 promulgated under the Exchange Act. Notwithstanding the foregoing, the Corporation shall have no liability to any participant for Section&#160;16 consequences of awards or events under awards if an award or event does not so qualify. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.74pt;text-decoration:underline">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. It is intended that the provisions of the Plan comply with, or be exempt from, Section&#160;409A of the Code, and all provisions of the Plan shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section&#160;409A of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Code. If, at the time of a participant&#8217;s &#8220;separation from service&#8221; (within the meaning of Section&#160;409A of the Code), (i) such participant shall be a specified employee (within the meaning of Section&#160;409A of the Code and using the identification methodology selected by the Corporation from time to time) and (ii)&#160;the Corporation shall make a good faith determination that an amount payable pursuant to an award constitutes deferred compensation (within the meaning of Section&#160;409A of the Code) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Section&#160;409A of the Code in order to avoid taxes or penalties under Section&#160;409A of the Code, then the Corporation shall not pay such amount on the otherwise scheduled payment date but shall instead pay it on the first business day after such six-month period. Such amount shall be paid without interest, unless otherwise determined by the Administrator, in its sole discretion, or as otherwise provided in any applicable award agreement between the Corporation and the relevant participant. Notwithstanding any provision of the Plan to the contrary, in light of the uncertainty with respect to the proper application of Section&#160;409A of the Code, the Corporation reserves the right to make amendments to any award as the Corporation deems necessary or desirable to avoid the imposition of taxes or penalties under Section&#160;409A of the Code. In any case, a participant shall be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on such participant or for such participant&#8217;s account in connection with an award (including any taxes and penalties under Section&#160;409A of the Code), and neither the Corporation nor any of its affiliates shall have any obligation to indemnify or otherwise hold such participant harmless from any or all of such taxes or penalties. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Captions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Captions and headings are given to the sections and subsections of this Plan solely as a convenience to facilitate reference. Such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> shall not be deemed in any way material or relevant to the construction or interpretation of this Plan or any provision thereof. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Stock-Based Awards in Substitution for Stock Options or Awards Granted by Other Corporation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Awards may be granted to Eligible Persons in substitution for or in connection with an assumption of employee stock options, SARs, restricted stock or other stock-based awards granted by other entities to persons who are or who will become Eligible Persons in respect of the Corporation or one of its Subsidiaries, in connection with a distribution, merger or other reorganization by or with the granting entity or an affiliated entity, or the acquisition by the Corporation or one of its Subsidiaries, directly or indirectly, of all or a substantial part of the stock or assets of the employing entity. The awards so granted need not comply with other specific terms of this Plan, provided the awards reflect only adjustments giving effect to the assumption or substitution consistent with the conversion applicable to the Common Stock in the transaction and any change in the issuer of the security. Any shares that are delivered and any awards that are granted by, or become obligations of, the Corporation, as a result of the assumption by the Corporation of, or in substitution for, outstanding awards previously granted by an acquired company (or previously granted by a predecessor employer (or direct or indirect parent thereof) in the case of persons that become employed by the Corporation or one of its Subsidiaries in connection with a business or asset acquisition or similar transaction) shall not be counted against the Share Limit or other limits on the number of shares available for issuance under this Plan. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:6.6pt">Non-Exclusivity of Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Nothing in this Plan shall limit or be deemed to limit the authority of the Board or the Administrator to grant awards or authorize any other compensation, with or without reference to the Common Stock, under any other plan or authority. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:1.6pt">No Corporate Action Restriction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The existence of this Plan, the award agreements and the awards granted hereunder shall not limit, affect or restrict in any way the right or power of the Board or the stockholders of the Corporation to make or authorize&#58; (a)&#160;any adjustment, recapitalization, reorganization or other change in the capital structure or business of the Corporation or any Subsidiary, (b)&#160;any merger, amalgamation, consolidation or change in the ownership of the Corporation or any Subsidiary, (c)&#160;any issue of bonds, debentures, capital, preferred or prior preference stock ahead of or affecting the capital stock (or the rights thereof) of the Corporation or any Subsidiary, (d)&#160;any dissolution or liquidation of the Corporation or any Subsidiary, (e)&#160;any sale or transfer of all or any part of the assets or business of the Corporation or any Subsidiary, or (f)&#160;any other corporate act or proceeding by the Corporation or any Subsidiary. No participant, beneficiary or any other person shall have any claim under any award or award agreement against any member of the Board or the Administrator, or the Corporation or any employees, officers or agents of the Corporation or any Subsidiary, as a result of any such action. </font></div><div style="padding-left:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:1.6pt">Other Company Benefit and Compensation Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Payments and other benefits received by a participant under an award made pursuant to this Plan shall not be deemed a part of a participant&#8217;s compensation for purposes of the determination of benefits under any other employee welfare or benefit plans or arrangements, if any, provided by the Corporation or any Subsidiary, except where the Administrator expressly otherwise provides or authorizes in writing. Awards under this Plan may be made </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in addition to, in combination with, as alternatives to or in payment of grants, awards or commitments under any other plans or arrangements of the Corporation or its Subsidiaries. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:1.6pt">Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The awards granted under this Plan are subject to the terms of the Corporation&#8217;s recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of awards or any shares of Common Stock or other cash or property received with respect to the awards (including any value received from a disposition of the shares acquired upon payment of the awards). </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>nktr2022-06x30xexx102north.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4b1c65eaf7f946719d550dfc5f394c18_1"></div><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="margin-bottom:18pt;text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYMENT TRANSITION, SEPARATION AND CONSULTATION AGREEMENT</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Employment Transition, Separation and Consultation Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into between Nektar Therapeutics, a Delaware corporation, defined to include its affiliated companies (including subsidiaries), employees, officers, directors, managers, agents, and shareholders, successors, assigns, and representatives (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JOHN NORTHCOTT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(hereafter &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">you</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">your</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (collectively with the Company, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">April 25, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (your &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Notice Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you were provided notice that your last day of employment with the Company will be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">June 30, 2022 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="padding-left:67.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> pursuant to the terms of this Agreement, the Parties intend to separate from their employment relationship, and further intend to have you provide consulting services to the Company for a limited time to ensure the orderly transition of your duties and for the Company to receive the benefit of your executive leadership in helping guide the Company in it restructuring efforts, which Agreement also contemplates the execution of a standard release to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that you may have against the Company and&#47;or any of the Released Parties, as defined in the standard release, including, but not limited to, any and all claims arising out of or in any way related to your employment with or separation from the Company&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Transition Services and Compensation During the Transition Period.</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a) &#160;&#160;&#160;&#160;Transition Services During the Transition Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  From the Notice Date through the Separation Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Transition Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you will continue to carry out those duties assigned to you by your manager, with the understanding that those duties will include efforts to provide for the orderly transition of your duties and to help guide the Company in its restructuring efforts using your executive leadership.  During the Transition Period, you shall continue to abide by that certain employment agreement, dated as of December 4, 2019, by and between you and the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as well as all of the Company&#8217;s policies and procedures in effect from time to time, and continue to perform all employment duties requested by your manager in good faith to the best of your abilities.  Your employment with the Company during the Transition Period will continue and the compensation and benefits you receive during the Transition Period are not dependent upon you signing this Agreement.  Your employment during the Transition Period does not alter your status as an at-will employee and does not constitute a guarantee of employment for any duration.  Either you or the Company </font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="-sec-extract:summary;margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidential       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;JOHN NORTHCOTT</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may terminate your employment with the Company at any time, with or without advance notice, for any reason, provided, however, if you resign or otherwise terminate your employment with the Company prior to the Separation Date, you will not be eligible for the consideration set forth in Section 1 of the Standard Release (as defined below).</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;Compensation and Benefits During the Transition Period.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the Transition Period, you will be paid at your current semi-monthly base compensation in accordance with the Company&#8217;s normal payroll practices (which is subject to the usual, required deductions and withholdings).  Accordingly, subject to the other provisions in this Agreement, you shall be entitled through the Separation Date to the same rights, benefits, equity, salary, and vesting of equity awards, under any employee benefit or compensation plan or program sponsored by Company or any of its parent, subsidiary or affiliated entities as (as such benefit, plan or program may be amended from time to time) that you were eligible for immediately prior to the Notice Date.  You will not, however, be entitled to any cash bonuses (such as the annual bonus) or any further grants of performance equity awards (e.g., grants of stock options or restricted stock units) pursuant to the 2022 Performance Review Process (and any subsequent year&#8217;s performance review process) or other compensation or benefits following your Separation Date, except as provided by this Agreement.  </font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Separation from the Company.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;Date and Time of Separation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At 11&#58;59 p.m. Pacific Time on the Separation Date your employment in any capacity for the Company will terminate.  Following the Separation Date, you shall not be authorized to transact any business on behalf of the Company unless authorized to do so in writing by an officer of the Company.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Payment of Salary and Expenses on Your Separation Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  On your Separation Date, the Company will pay you a total of (i) all accrued and unpaid salary through the Separation Date, and (ii) an amount equal to your effective hourly rate multiplied by the number of hours of accrued, but unused, paid time off (collectively, (i) and (ii), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  In the event that you have a negative paid time off balance, you agree that an amount (as calculated in the same manner used above in Section 2(b)(ii)) will be deducted from the Accrued Obligations, to the extent permitted by applicable law.  You further agree that, by the Separation Date, you will submit your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement.  The Company will reimburse you for these expenses pursuant to its regular business practice.  In connection with the Separation Date, you and the Company will enter into a standard release (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Standard Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; the form of which shall be in substantial accordance with the &#8220;Standard Release&#8221; attached hereto as Exhibit A) which will include an acknowledgement and representation that, upon receiving the Accrued Obligations, you will have received all salary, wages, eligible bonuses, accrued vacation and paid time off, and all other benefits and compensation due to you through the Separation Date.    </font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c) &#160;&#160;&#160;&#160;Older Worker Benefit Protection Act Disclosure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In accordance with the Older Worker Benefit Protection Act (OWBPA), the Company discloses to you the Company&#8217;s OWBPA Disclosure attached hereto and incorporated herein as Attachment A.  You acknowledge and agree the Company provided you with the following&#58; (i)&#160;information that describes the group of individuals to whom the Company is offering severance benefits in exchange for a release of claims&#59; (ii) information regarding the </font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="-sec-extract:summary;margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidential       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;JOHN NORTHCOTT</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eligibility factors for inclusion in that group&#59; (iii) information regarding the time limits applicable to that offer&#59; (iv) information regarding the job titles and ages of all individuals to whom the Company is offering a severance payment in exchange for a release of claims&#59; and (v) information regarding the ages of all individuals to whom the Company did not offer a severance payment in exchange for a release of claims but who were in the same job classifications or organizational unit as any individual covered in the group described in (iv) as required by the OWBPA.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Employee Acknowledgements.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree, acknowledge and affirm, as of and through the date of your signature to this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Signature Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58; (a) you received all earned salary, accrued paid time off, and all other earned compensation and benefits due to you through the Signature Date as a result of services you performed for the Company&#59; (b) you reported to the Company any and all work-related injuries incurred during your employment&#59; (c) the Company properly provided any leave of absence because of your or a family member&#8217;s health condition, and you have not been subjected to any improper treatment, conduct or actions due to a request for or taking such leave&#59; (d) you provided the Company with written notice of any and all concerns regarding suspected ethical and compliance issues or violations on the part of the Company or any Released Party&#59; (e) you have not solicited or assisted (except as provided in the Agreement or under applicable law) in any way an existing or former Company employee or shareholder in bringing an action or claim against the Company&#59; (f) you have not filed and do not have pending any complaints, charges or lawsuits against any Released Party with any governmental agency or any court, and that you will not initiate or encourage any such actions in any manner contrary to the terms of this Agreement&#59; and (g) you have not raised a claim, including but not limited to, unlawful discrimination&#59; harassment&#59; sexual harassment, abuse, assault, or other criminal conduct&#59; failure to prevent an act of workplace harassment or discrimination&#59; or retaliation in a court or government agency proceeding, in an alternative dispute resolution forum, or through the Company&#8217;s internal complaint process, involving any Released Party.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consulting Services.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160; Consulting Services and Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Immediately effective upon the Separation Date you will serve as an independent contractor to the Company to provide estimated and projected valuations of business and product opportunities, and to perform such other tasks as may be reasonably requested by the Company&#8217;s Chief Executive Officer or his designee (such services, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consulting Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  You agree to begin providing the Consulting Services immediately following the Separation Date through December 31, 2022, or such earlier date as you or the Company determine (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consulting Services Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Generally, during the Consulting Services Term, you are expected to be available upon reasonable notice for consultation by phone and email during regular business hours. During the Consulting Services Term, you will have no authority to represent the Company to third parties or to bind the Company to any contractual obligations, whether written, oral or implied, or represent that you have such authority, unless authorized to do so in writing by an officer of the Company. During the Consulting Services Term, you shall continue to abide by all of the Company's policies and procedures in effect from time to time and perform duties requested of you in good faith to the best of your abilities.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;Consideration and Fee Reimbursement during the Consulting Services Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> During the Consulting Services Term, the Company will compensate you with a monthly retainer of twenty thousand dollars ($20,000.00) per month (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Monthly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="-sec-extract:summary;margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidential       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;JOHN NORTHCOTT</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) regardless of the number of hours of Consulting Services you provide to the Company.  You will record the hours of Consulting Services you provide to the Company in any given month against the Monthly Retainer at the rate of $335.00 per hour.  The Parties agree that the total number of hours of Consulting Services you provide during the Consulting Services Term shall not exceed twenty percent (20%) of the total number of hours of services you provided in a thirty six-month period as an employee of the Company prior to the Separation Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consulting Services Ceiling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  So long as the Consulting Services Ceiling at the end of the Consulting Services Term will not be exceeded, for each hour of Consulting Services that you provide to the Company in excess of sixty (60) hours per calendar month (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Excess Hour</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you will be compensated at an hourly rate of $335.00 per Excess Hour.  You will also be reimbursed for reasonable out-of-pocket travel costs and other expenses that are approved in advance by email or writing by Company's Chief Operating Officer or his designee. Any approved air travel during the Consulting Services Term may be ticketed in business class.  All required Company travel time during the Consulting Services Term shall be billed to the Company at $250.00 per hour calculated from portal-to-portal. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;Invoices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  After each complete calendar month during the Consulting Services Term, you shall provide to the Company on or before the seventh (7th) calendar day of the immediately following month an invoice for payment of (i) the Monthly Retainer, and (ii) your Excess Hours for such month, which shall be invoiced at $335.00 per Excess Hour (with the understanding that the Consulting Services Ceiling cannot be exceeded by the end of the Consulting Services Term).  In addition, you shall provide to the Company within seven (7) days after the end of each calendar month during the Consulting Services Term a true and correct invoice for any pre-approved reasonable out-of-pocket travel costs and other expenses incurred during the prior month. The Company shall pay each invoice within thirty (30) business days of receiving such invoice from you. You shall submit each invoice and direct all communications to the Company&#8217;s Senior Vice President, Human Resources (or such other person as delegated by the Senior Vice President, Human Resources).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;Independent Contractor Status.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> It is the express intention of you and the Company that, during the Consulting Services Term, you shall be an independent contractor, and shall be classified by the Company as such for all purposes, and shall not be an officer, employee, agent, joint venturer, or partner of the Company. Accordingly, you shall not be entitled to earn or accrue during the Consulting Services Term any bonus, salary, benefits sponsored by the Company or any of its parent, subsidiary or affiliated entities at any time, including, but not limited to health, dental, vision, 401(k), or other employee welfare benefits, and you shall be solely responsible for your insurance, taxes, fees, licenses, costs, equipment, expenses, and providing your own office space, if necessary, to perform your duties as a consultant. Nothing in this Agreement shall be interpreted or construed as creating or establishing an employment relationship between you and the Company at any time after the Separation Date. You will receive a Form 1099 for services performed for the Company during the Consulting Services Term.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)&#160;&#160;&#160;&#160;Equity and Change of Control From July 1, 2022 Through to December 31, 2022.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to this Section 4(e), after the Separation Date (including during the Consulting Services Term), you will not continue to vest in your equity awards, although your right to exercise vested and outstanding stock </font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="-sec-extract:summary;margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidential       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;JOHN NORTHCOTT</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">options as of the Separation Date, pursuant to your equity award notices and agreements issued to you thereunder (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Award Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), will continue during the Consulting Services Term and the post-termination exercise period as set forth in further detail in Section 4(e)(ii) below.  Notwithstanding anything to the contrary, with regard to the treatment of your outstanding and unvested equity awards (as those awards existed immediately prior to your Separation Date) from July 1, 2022, through to December 31, 2022, if (i) a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (as that term is defined in Section 3.5 of the Nektar Therapeutics Amended and Restated Change of Control Severance Benefit Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">CIC Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)) occurs and such Change of Control transaction closes during the period commencing on July 1, 2022 through December 31, 2022, and (ii) at least two (2) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Officer Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (as that term is defined in the CIC Plan) who each report directly to the Company&#8217;s Chief Executive Officer and are each involuntarily terminated within three months following the closing of such Change of Control (not to exceed March 31, 2023) and such involuntary terminations each qualify as a Covered Termination (as that term is defined in the CIC Plan), then such outstanding and unvested equity awards (as those awards existed immediately prior to the Separation Date) shall be treated in the same manner as the outstanding and unvested equity awards held by those Officer Participants who were subject to the Covered Termination.  For the avoidance of doubt, any termination or other forfeiture of the unvested portion of your equity awards that would otherwise occur upon the Separation Date will be delayed to effect the terms of this Section 4(e)(i) and such termination or forfeiture of such unvested equity awards will subsequently automatically occur if any vesting pursuant to this subsection does not occur, which in all cases cannot be later than March 31, 2023. Further, you acknowledge and agree that any unvested stock options and unvested restricted stock units held by you (after giving effect to any acceleration of vesting provided herein), shall be forfeited immediately and no later than April 1, 2023.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)&#160;&#160;&#160;&#160;Provisions Concerning Exercise Period After the Consulting Services Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding anything to the contrary in the applicable equity incentive plan (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Equity Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Award Agreements, your right immediately following the Consulting Services Term to exercise vested stock options shall end on the earlier of (i) June 30, 2023, or (ii) the expiration of the term of your stock options. Except as set forth in this Agreement, your stock options and restricted stock units (if any) continue to remain subject to all other terms and conditions of the applicable Equity Plans and Award Agreements.  </font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)&#160;&#160;&#160;&#160;Equity and No Change of Control by January 1, 2023.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event no Change of Control (and the closing of such Change of Control) has occurred by January 1, 2023, you acknowledge and agree that any unvested stock options and unvested restricted stock units held by you on December 31, 2022 shall be forfeited immediately effective as of January 1, 2023.</font></div><div style="padding-left:108pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Confidentiality of this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as permitted by the terms of this Agreement and applicable laws, the provisions of this Agreement shall be held in strictest confidence by you and shall not be publicized or disclosed in any manner whatsoever by you at any time to any person other than your lawyer or accountant, a governmental agency, or your immediate family without the prior written consent of an officer of the Company, except as necessary in any legal proceedings directly related to the provisions and terms of this </font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="-sec-extract:summary;margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidential       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;JOHN NORTHCOTT</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement, to prepare and file income tax forms, or as required by court order after reasonable notice to the Company.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;Proprietary Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You acknowledge access to and receipt of confidential business and proprietary information regarding the Company and its partners during the time of your employment with the Company.  This information may be in a variety of paper and electronic forms.  You agree not to make any such information known to any member of the public and to comply with all applicable ethical responsibilities related to client confidences and secrets.  You further agree to maintain and not destroy any such information in your possession, and to return to the Company prior to the Separation Date all confidential and proprietary information and all other Company property (other than Personal IT Equipment so long as you sign the Standard Release and it becomes effective), as well as all copies or excerpts of any property, files or documents obtained as a result of employment with the Company, except those items that the Company specifically agrees in writing to permit you to retain. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Return of Company Property.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Other than your facility badge, any parking garage badges, and (so long as you sign the Standard Release and it becomes effective) Personal IT Equipment, you agree that, by the Separation Date, you will return to the Company all Company documents (and all copies thereof whether in physical or electronic format) and other Company property in your possession or control, including, but not limited to&#58; Company files, email, electronic messages, notes, memoranda, correspondence, agreements, draft documents, notebooks, logs, drawings, records, plans, proposals, reports, forecasts, financial information, sales and marketing information, research and development information, personnel information, specifications, computer-recorded information, tangible property, credit cards, and keys&#59; and any materials of any kind that contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part).  If you have used any personal computer, server, or electronic system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, you agree to provide the Company with a computer-useable copy of such information and then permanently delete and expunge such Company confidential or proprietary information from those systems.  You agree to provide the Company access to your system as requested to verify that the necessary copying and&#47;or deletion has been completed.  You agree not to retain any paper or electronic copies of any Company documents or data (including but not limited to email and electronic messages) other than this Agreement and other documents evidencing your employment relationship with the Company.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8. &#160;&#160;&#160;&#160;Non-Disparagement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Except as permitted by the terms of this Agreement and applicable laws, you agree not to make statements to clients, customers, partners, or suppliers of the Company that are any way disparaging or negative towards any of the Released Parties.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Entire Agreement&#59; Modification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement is governed by California law.  This Agreement constitutes the complete and only agreement between you and the Company on these subjects.  In entering this Agreement, you are not relying on any promise or representation, written or oral, other than those expressly contained in this Agreement.  Any prior agreements between or directly involving you and the Company are superseded by this Agreement, except for your Equity Plans, and Award Agreements.  This Agreement may not be modified except in a writing signed by both you and a Senior Vice President of the Company (other than yourself).  This Agreement shall bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Released Parties, their heirs, successors and assigns.  </font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="-sec-extract:summary;margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidential       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;JOHN NORTHCOTT</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any determination that a provision of this Agreement is invalid or unenforceable, in whole or in part, will not affect any other provision of this Agreement, and the provision in question shall be modified by the court so as to be rendered enforceable in accordance with the intent of the parties to the extent possible. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The headings in this Agreement are provided for reference only and shall not affect the substance of this Agreement.  This Agreement may be signed in counterparts.  This Agreement may be executed by electronic means and such signatures shall be deemed to bind each Party with the same force and effect as a handwritten signature.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="-sec-extract:summary;margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidential       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;JOHN NORTHCOTT</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If this Agreement is acceptable to you, please sign below and return the original to Human Resources no later than Thursday, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">June 30, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company&#8217;s offer to enter this Agreement will automatically expire if we do not receive your executed Agreement by the aforementioned time period.  </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I acknowledge and agree that I have read and understand this Agreement, am signing this Agreement knowing I could be waiving valuable rights, and acknowledge that this Agreement is final and binding.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JOHN NORTHCOTT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Position&#58; SVP &#38; Chief Commercial Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John Northcott&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dated (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Signature Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58; 6&#47;29&#47;2022</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nektar Therapeutics</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Howard W. Robin&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dated&#58; 6&#47;29&#47;2022</font></div><div style="margin-bottom:24pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Howard W. Robin<br>President and Chief Executive Officer </font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="-sec-extract:summary;margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidential       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;JOHN NORTHCOTT</font></div><div><font><br></font></div></div></div><div id="i4b1c65eaf7f946719d550dfc5f394c18_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STANDARD RELEASE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This standard release (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Standard Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into between Nektar Therapeutics, a Delaware corporation, defined to include its affiliated companies (including subsidiaries), employees, officers, directors, managers, agents, and shareholders, successors, assigns, and representatives (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JOHN NORTHCOTT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(hereafter &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">you</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">your</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (collectively with the Company, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and is supplemental to that certain Employment Transition, Separation and Consultation Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) entered into by you and the Company on                             .  </font></div><div><font><br></font></div><div style="padding-left:67.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, You and the Company entered into an Employment Transition, Separation and Consultation Agreement, to, among other things, provide for the orderly transition of your duties&#59;</font></div><div><font><br></font></div><div style="padding-left:67.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties wish to provide for the releases as set forth herein with immediate effect upon the Separation Date (as that term is defined in the Agreement)&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows&#58; </font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consideration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In exchange for your promises in this Standard Release, you understand the Company is offering you&#58; (a) severance&#59; (b) COBRA payments&#59; (c) outplacement services&#59; and any other consideration specifically set forth below.  You acknowledge and agree that the consideration given under this Standard Release is in addition to anything of value to which you already were entitled and would not have been provided to you if you had not entered into this Standard Release.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Although the Company will calculate any deductions and withholdings based on the Company&#8217;s understanding of applicable law using the information the Company has in its payroll system at the time of disbursing any consideration provided to you under this Standard Release, you acknowledge and agree that you are solely responsible for your personal tax liability associated with such consideration.&#160;</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;Severance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to applicable deductions and withholdings and so long as you have not resigned prior to the Separation Date and otherwise have successfully completed the Transition Period (as that term is defined in the Agreement), and within thirty (30) days of the Standard Release becoming effective (provided, that such date shall be no later than March 15, 2023), the Company will pay you, in a lump sum, the amount of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$921,206.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) calculated as the sum of (i)  your annual base pay of $695,250.00 and (ii) $225,956.25, which corresponds to your bonus target of fifty percent (50%) of your annual base pay ($695,250.00) multiplied by the expected pay-out percentage used by the Company for its GAAP financial statements in the previous quarter, which was sixty-five percent (65%) for the first quarter of 2022.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i4b1c65eaf7f946719d550dfc5f394c18_7"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COBRA Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are eligible for and meet all requirements for timely election of COBRA coverage, the Company will pay for certain premiums for your group medical, dental, employee assistance program (EAP) and vision plan COBRA coverage from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">July 1, 2022 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">June 30, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; provided, however, that the Company may cease paying the premiums for such continuation coverage at any time you become eligible for similar group coverage (medical, dental, or vision, as applicable) from another employer.  No provision of the Agreement or this Standard Release will affect the continuation coverage rules under COBRA, except that the Company&#8217;s payment of COBRA premiums, if any, will be credited as payment by you for purposes of payments required for COBRA coverage.  If the Company determines that it cannot pay such premiums to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above, and such payments to you shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates. </font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;Career Transition Services.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To assist you in your job search, the Company will pay for up to six (6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months of career transition services to be provided by the Company&#8217;s outplacement services provider, provided that you must initiate your request for these services no earlier than one (1) month before, and no later than three (3) months after, your Separation Date. </font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d) &#160;&#160;&#160;&#160;Transfer of Title to Personal Information Technology Equipment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the Company&#8217;s standard process for removing access to the Company&#8217;s electronic communications, applications and file storage systems, the Company will assign to you any Company-issued mobile phone, laptop computer, tablet, monitor, printer, keyboard, headset, speaker, desk, chair and mouse, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in each case, currently in your possession at your residence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Personal IT Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  In accepting the ownership of this Personal IT Equipment, you agree to remove and destroy (and otherwise not use) any Company confidential and proprietary content, as well as any third-party confidential and proprietary content.  You further agree you are solely responsible for using any Personal IT Equipment in accordance with applicable laws and regulations, and you will dispose of any Personal IT Equipment in accordance with manufacturer recommendations, as well as local, state and federal regulations. </font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that you are not entitled and will not be provided the above consideration if you do not enter into this Standard Release and the Standard Release becoming effective.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Employee Acknowledgements.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree and acknowledge that as of the Separation Date&#58; (a) you received all earned salary, accrued paid time off, and all other earned compensation and benefits due to you through the Separation Date as a result of services you performed for the Company&#59; (b) you reported to the Company any and all work-related injuries incurred during your employment&#59; (c) the Company properly provided any leave of absence because of your or a family member&#8217;s health condition, and you have not been subjected to any improper treatment, conduct or actions due to a request for or taking such leave&#59; (d) you provided the Company with written notice of any and all concerns regarding suspected ethical and compliance issues or violations on the part of the Company or any Released Party&#59; (e) you have not solicited or assisted (except as provided in the Agreement, this Standard Release or under applicable law), in any way an existing or former Company employee or shareholder in bringing an action or claim against the Company&#59; (f) you confirm that you have not filed and do not have pending any complaints, charges or lawsuits against any Released Party with any governmental agency or any court, and you agree that you will not initiate or encourage any such </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;padding-left:216pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.705%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">actions in any manner contrary to the terms of this Standard Release&#59; and (g) you affirm that you have not raised a claim, including but not limited to, unlawful discrimination&#59; harassment&#59; sexual harassment, abuse, assault, or other criminal conduct&#59; failure to prevent an act of workplace harassment or discrimination&#59; or retaliation in a court or government agency proceeding, in an alternative dispute resolution forum, or through the Company&#8217;s internal complaint process, involving the Released Parties.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge your continued obligations to maintain as confidential all confidential and proprietary information of the Company under Section 4 of your Employee Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Release.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">General Release.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In exchange for the consideration recited in Section 1 of the Standard Release, you, personally and for your heirs, executors, administrators, successors and assigns, hereby agree to forever and fully release and discharge the Company and its subsidiaries, successors, predecessors and affiliates, and its and their respective current and former partners, members, directors, officers, employees, stockholders, shareholders, agents, attorneys, predecessors, insurers, affiliates and assigns (each, a &#8220;Released Party,&#8221; and together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), from any and all claims, demands, actions, causes of action, suits, damages, losses, expenses, liabilities, and obligations, in each case, of every kind and nature, and both known and unknown, individually or as part of a group action, that exist, can arise out of or are in any way related to events, acts, conduct, or omissions occurring at any time during your employment and&#47;or separation of employment with the Company, through to and including the Standard Release Signature Date.  This general release includes, but is not limited to, any rights or claims arising under the California Constitution&#59; California statutory and common law (including contract law, employment law and tort law)&#59; the California Fair Employment and Housing Act&#59; the California Labor Code (including Labor Code section 132A), the Age Discrimination in Employment Act (ADEA)&#59; Title VII of the of the Civil Rights Act of 1964&#59; the Americans with Disabilities Act&#59; the Employee Retirement Income Security Act (ERISA)&#59; the Worker Adjustment and Retraining Notification Act (WARN), federal and state family leave statutes&#59; and any and all other federal, state and local laws, statutes, executive orders, regulations and common law&#59; any claim for any loss, cost, damage or expense arising out of any dispute over the non-withholding or other tax treatment of any of the proceeds received by you as a result of this Standard Release&#59; any and all claims for attorney&#8217;s fees and costs&#59; and any and all claims relating to, or arising from your right to purchase, or actual purchase of shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law.  You and the Company agree that this is a compromise settlement of all such claims and therefore, this Standard Release does not constitute any admission of liability on the part of the Company.     </font></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are releasing all rights under Section 1542 of the California Civil Code.  Section 1542 provides as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.   </font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You intend these consequences even as to claims for damages that may exist as of the date this Standard Release is executed that you do not know exist and which if known, would materially affect your decision to execute this Standard Release, regardless of </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;padding-left:216pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.705%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whether the lack of knowledge is the result of ignorance, oversight, error, negligence or any other cause. </font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Exclusions from General Release.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The above release does not waive claims&#58; (i)&#160;for unemployment or workers&#8217; compensation benefits, (ii)&#160;for vested rights under ERISA-covered employee benefit plans as applicable on the Standard Release Signature Date, (iii)&#160;that may arise after the Standard Release Signature Date, (iv) for indemnification under California Labor Code section 2802, or (v) which cannot be released by private agreement.  </font></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Confidentiality of this Standard Release.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as permitted by the terms of this Standard Release and applicable laws, the provisions of this Standard Release shall be held in strictest confidence by you and shall not be publicized or disclosed in any manner whatsoever by you at any time to any person other than your lawyer or accountant, a governmental agency, or your immediate family without the prior written consent of an officer of the Company, except as necessary in any legal proceedings directly related to the provisions and terms of this Standard Release, to prepare and file income tax forms, or as required by court order after reasonable notice to the Company.  </font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Retaliation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; Nevertheless, nothing in this Standard Release prohibits you from reporting an event that you reasonably and in good faith believes is a violation of law to the relevant law-enforcement agency (such as the SEC, EEOC, or DOL), from testifying truthfully under oath in any court, arbitration or administrative agency proceeding, from providing truthful information in the course of a government investigation or from cooperating in an investigation conducted by such a government agency.&#160; This may include disclosure of trade secret or confidential information within the limitations permitted by the 2016 Defend Trade Secrets Act (DTSA).&#160; You are hereby provided notice that under the&#160;DTSA, (1) no individual will be held criminally or civilly liable under federal or state trade secret law for the disclosure of a trade secret (as defined in the Economic Espionage Act) that (A) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney&#59; and made solely for the purpose of reporting or investigating a suspected violation of law&#59; or, (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal so that it is not made public&#59; and, (2) an individual who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Voluntary Waiver and Release, Acknowledgement of Waiver of Claims, Advice of Counsel, Consideration, Revocation and Other Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acknowledge you are waiving and releasing rights you have under the law and that this waiver and release is executed knowingly and voluntarily without any coercion, duress or undue influence.  You acknowledge that the consideration given for this Standard Release is in addition to anything of value to which you were already entitled.  You further acknowledge notice in writing that&#58;  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;&#160;your waiver and release of rights under this Standard Release are voluntary and deliberate, and that you are acting of your own free will in executing this Standard Release and you had an opportunity to ask questions concerning this Standard Release&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) &#160;&#160;&#160;&#160;through this Standard Release, you are releasing the Released Parties from any and all claims, that you may have against any of the Released Parties&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;&#160;your waiver and release, as set forth in this Standard Release, do not apply to any rights or claims that may arise after the date you sign this Standard Release&#59;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;padding-left:216pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.705%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;&#160;the Company hereby advises you that, before signing this Standard Release, you should consult with an attorney, although you may choose voluntarily not to do so&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;you have had at least forty-five (45) days to consider whether to sign this Standard Release, although you may choose voluntarily to sign it earlier&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;&#160;changes to this Standard Release, whether material or immaterial, do not restart the running of the forty-five (45) day consideration period&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) &#160;&#160;&#160;&#160;you may challenge the knowing and voluntary nature of this release under any applicable federal, state, or local agency charged with the enforcement of any employment laws, such as under the Older Workers Benefit Protection Act and the ADEA before a court, the EEOC, the NLRB, or any other&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;&#160;you have seven (7) days following the date you sign this Standard Release to revoke it by delivering written notice to the Company&#8217;s General Counsel at the address below or by facsimile&#58;</font></div><div style="padding-left:144pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mark A. Wilson, Senior Vice President &#38; General Counsel</font></div><div style="padding-left:108pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nektar Therapeutics</font></div><div style="padding-left:108pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">455 Mission Bay Boulevard South</font></div><div style="padding-left:108pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">San Francisco, CA 94158</font></div><div style="padding-left:108pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(415) 339-5322 (facsimile)</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the revocation period expires on a weekend or holiday, you will have until the end of the next business day to revoke it.  This Standard Release will become effective on the eighth day after you sign this Standard Release, provided you do not revoke this Standard Release (&#8220;the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Standard Release Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) prior to the expiration of the seven (7) day revocation period as provided above. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;Entire Agreement&#59; Modification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Standard Release is governed by California law.  The Agreement, the Standard Release and your Employee Agreement, if any, constitute the complete and only agreement between you and the Company on these subjects.  In entering this Standard Release, you are not relying on any promise or representation, written or oral, other than those expressly contained in the Agreement and this Standard Release.  Any prior agreements between or directly involving you and the Company are superseded by the Agreement and this Standard Release, except for your Employee Agreement with the Company, the Equity Plans, and Award Agreements.  This Standard Release may not be modified except in a writing signed by both you and a Senior Vice President of the Company.  This Standard Release shall bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Released Parties, their heirs, successors and assigns.  Any determination that a provision of this Standard Release is invalid or unenforceable, in whole or in part, will not affect any other provision of this Standard Release, and the provision in question shall be modified by the court so as to be rendered enforceable in accordance with the intent of the parties to the extent possible. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The headings in this Standard Release are provided for reference only and shall not affect the substance of this Standard Release.  This Standard Release may be signed in counterparts.  This Standard Release may be executed by electronic means and such signatures shall be deemed to bind each Party with the same force and effect as a handwritten signature.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Remainder of Page Intentionally Blank&#93;</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;padding-left:216pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.705%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If this Standard Release is acceptable to you, please sign below and return the original to Human Resources no later than August 14, 2022.  The Company&#8217;s offer to enter this Standard Release will automatically expire if we do not receive your executed Standard Release by the aforementioned time period.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PLEASE READ THIS STANDARD RELEASE AND CAREFULLY CONSIDER ALL OF ITS PROVISIONS BEFORE SIGNING IT.  THIS STANDARD RELEASE CONTAINS A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS, INCLUDING CLAIMS UNDER TITLE VII, THE CALIFORNIA FAIR EMPLOYMENT AND HOUSING ACT AND OTHER FEDERAL, STATE AND LOCAL LAWS PROHIBITING DISCRIMINATION IN EMPLOYMENT, TO THE EXTENT PERMITTED BY LAW.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I acknowledge and agree that I have read and understand this Standard Release, am signing this Standard Release knowing I could be waiving valuable rights, and acknowledge that this Standard Release is final and binding.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JOHN NORTHCOTT&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Position&#58; SVP &#38; Chief Commercial Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dated&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;      the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Standard Release Signature Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nektar Therapeutics</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Dated&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Howard W. Robin<br>President and Chief Executive Officer</font></div><div style="margin-bottom:24pt"><font><br></font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;padding-left:216pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.705%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>nktr2022-06x30xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idd4b9035edaa4908be84c4b152aff4d2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Howard W. Robin, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended June&#160;30, 2022 of Nektar Therapeutics&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:48.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; HOWARD W. ROBIN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin<br>Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>nktr2022-06x30xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i425fa6fbf3444c50b0815e66d59c2082_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jillian B. Thomsen, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended June&#160;30, 2022 of Nektar Therapeutics&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:49.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JILLIAN B. THOMSEN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jillian B. Thomsen</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President, Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>nktr2022-06x30xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib941c08443684a549b4e814f8722fd55_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATIONS*</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#8220;Company&#8221;), and Jillian B. Thomsen, Senior Vice President,  Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the three months ended June&#160;30, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; HOWARD W. ROBIN</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; JILLIAN B. THOMSEN</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Howard W. Robin</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer, President and Director</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jillian B. Thomsen<br>Senior Vice President, Chief Financial Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nktr-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:29a4b4dc-8cca-4a2c-8b00-1653a7b25685,g:4140688d-8727-4745-9ca5-400c87633167-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nktr="http://www.nektar.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nektar.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.nektar.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecurities" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities">
        <link:definition>2104102 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesTables" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail">
        <link:definition>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
        <link:definition>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.nektar.com/role/Inventory">
        <link:definition>2109103 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.nektar.com/role/InventoryTables">
        <link:definition>2310302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.nektar.com/role/InventoryDetails">
        <link:definition>2411405 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability">
        <link:definition>2112104 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables">
        <link:definition>2313303 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails">
        <link:definition>2414406 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails">
        <link:definition>2415407 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoSalesofFutureRoyalties" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties">
        <link:definition>2116105 - Disclosure - Liabilities Related to Sales of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoSalesofFutureRoyaltiesTables" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables">
        <link:definition>2317304 - Disclosure - Liabilities Related to Sales of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails">
        <link:definition>2418408 - Disclosure - Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails">
        <link:definition>2419409 - Disclosure - Liabilities Related to Sales of Future Royalties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.nektar.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2421410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements">
        <link:definition>2122107 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetails" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>2423411 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgram" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram">
        <link:definition>2124108 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramTables" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables">
        <link:definition>2325305 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails">
        <link:definition>2426412 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails">
        <link:definition>2427413 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails">
        <link:definition>2428414 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails">
        <link:definition>2429415 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>2430416 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.nektar.com/role/StockBasedCompensation">
        <link:definition>2131109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.nektar.com/role/StockBasedCompensationTables">
        <link:definition>2332306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2433417 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2434418 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationActivityDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail">
        <link:definition>2435419 - Disclosure - Stock-Based Compensation - Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.nektar.com/role/NetLossPerShare">
        <link:definition>2136110 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.nektar.com/role/NetLossPerShareTables">
        <link:definition>2337307 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetail" roleURI="http://www.nektar.com/role/NetLossPerShareDetail">
        <link:definition>2438420 - Disclosure - Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nktr_DebtInvestmentMaximumMaturityPeriod" abstract="false" name="DebtInvestmentMaximumMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_SFJPharmaceuticalsMember" abstract="true" name="SFJPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OtherPartnerMember" abstract="true" name="OtherPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LegalMattersMember" abstract="true" name="LegalMattersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_AccruedClinicalTrialExpensesCurrent" abstract="false" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" abstract="false" name="GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2020Member" abstract="true" name="PurchaseAndSaleAgreement2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" abstract="true" name="RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PotentialDevelopmentAndRegulatoryMilestones" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" abstract="false" name="LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInProductionCosts" abstract="false" name="PercentageOfSharingInProductionCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_RoyaltiesLiabilityMeasurementInput" abstract="false" name="RoyaltiesLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsAbstract" abstract="true" name="LicenseAndCollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" abstract="true" name="SubleaseOperatingLeaseRightOfUseAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PercentageOfSharingInDevelopmentCosts" abstract="false" name="PercentageOfSharingInDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember" abstract="true" name="TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LongTermInvestmentMaturityPeriod" abstract="false" name="LongTermInvestmentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" abstract="false" name="PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_SubleasePropertyPlantAndEquipmentMember" abstract="true" name="SubleasePropertyPlantAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PotentialDevelopmentMilestones" abstract="false" name="PotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EmployeeSeveranceWithNoServicePeriodMember" abstract="true" name="EmployeeSeveranceWithNoServicePeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LicenseCollaborationAndOtherRevenueMember" abstract="true" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_PartialRepaymentOfRoyaltySaleProceeds" abstract="false" name="PartialRepaymentOfRoyaltySaleProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ReimbursementOfExpenses" abstract="false" name="ReimbursementOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" abstract="false" name="PercentageOfSharingInPhaseTwoDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" abstract="false" name="UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementCommittedFunding" abstract="false" name="CollaborativeArrangementCommittedFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_Nektar214Member" abstract="true" name="Nektar214Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_BuildingAndLeaseholdImprovementsMember" abstract="true" name="BuildingAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" abstract="true" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_Nektar358Member" abstract="true" name="Nektar358Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OrganizationPolicyTextBlock" abstract="false" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SaleOfStockConsiderationReceived" abstract="false" name="SaleOfStockConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCollaborationAgreementMember" abstract="true" name="BristolMyersSquibbCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" abstract="false" name="PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DevelopmentDerivativeLiabilityTextBlock" abstract="false" name="DevelopmentDerivativeLiabilityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_EmployeeSeveranceWithServicePeriodRequirementMember" abstract="true" name="EmployeeSeveranceWithServicePeriodRequirementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_RoyaltyMonetizationProceeds" abstract="false" name="RoyaltyMonetizationProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCompanyMember" abstract="true" name="BristolMyersSquibbCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2012Member" abstract="true" name="PurchaseAndSaleAgreement2012Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_DebtInvestmentMaturityTerm" abstract="false" name="DebtInvestmentMaturityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" abstract="true" name="TwoThousandSeventeenPerformanceIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" abstract="false" name="ScheduleOfPurchaseAndSaleAgreementTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_OpdivoMember" abstract="true" name="OpdivoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>nktr-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:29a4b4dc-8cca-4a2c-8b00-1653a7b25685,g:4140688d-8727-4745-9ca5-400c87633167-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_18836d77-2500-4c55-a28e-0b9a0cd93501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca5d0520-8445-4f69-b205-deb0fb3d4d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18836d77-2500-4c55-a28e-0b9a0cd93501" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca5d0520-8445-4f69-b205-deb0fb3d4d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b9944adb-8978-46b3-9964-758626fb41c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18836d77-2500-4c55-a28e-0b9a0cd93501" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b9944adb-8978-46b3-9964-758626fb41c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_89b0be14-0dcd-4079-a0bd-36716af8b054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18836d77-2500-4c55-a28e-0b9a0cd93501" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_89b0be14-0dcd-4079-a0bd-36716af8b054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f826b810-d3fb-48da-ad0f-485d2890116a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18836d77-2500-4c55-a28e-0b9a0cd93501" xlink:to="loc_us-gaap_InventoryNet_f826b810-d3fb-48da-ad0f-485d2890116a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2e648a19-0b5b-4680-ac1d-afb280c8bb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18836d77-2500-4c55-a28e-0b9a0cd93501" xlink:to="loc_us-gaap_OtherAssetsCurrent_2e648a19-0b5b-4680-ac1d-afb280c8bb7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca66f533-7a7f-415b-94b1-eadae268a4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9b10d3d2-38dc-4f8b-98a5-6033de7ba442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca66f533-7a7f-415b-94b1-eadae268a4c2" xlink:to="loc_us-gaap_PreferredStockValue_9b10d3d2-38dc-4f8b-98a5-6033de7ba442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_068f6562-1823-4a0d-addc-a08f46fb91c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca66f533-7a7f-415b-94b1-eadae268a4c2" xlink:to="loc_us-gaap_CommonStockValue_068f6562-1823-4a0d-addc-a08f46fb91c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f0059c22-5e45-4035-a1c5-e2593d29f501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca66f533-7a7f-415b-94b1-eadae268a4c2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f0059c22-5e45-4035-a1c5-e2593d29f501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56bf7b98-e5d0-4ef5-badd-1cedc9b38e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca66f533-7a7f-415b-94b1-eadae268a4c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56bf7b98-e5d0-4ef5-badd-1cedc9b38e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_351d9d2a-396d-413c-af54-f9cadc22a138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca66f533-7a7f-415b-94b1-eadae268a4c2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_351d9d2a-396d-413c-af54-f9cadc22a138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d2683349-23ff-4e50-a895-ee762b0be0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_33eb55d4-667d-4f93-a204-8550db762d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d2683349-23ff-4e50-a895-ee762b0be0b6" xlink:to="loc_us-gaap_LiabilitiesCurrent_33eb55d4-667d-4f93-a204-8550db762d2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ce03c7c3-ff73-4374-9685-c6e7c301ef21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d2683349-23ff-4e50-a895-ee762b0be0b6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ce03c7c3-ff73-4374-9685-c6e7c301ef21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_290868c6-b365-48b5-9669-f747bf16e0fa" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d2683349-23ff-4e50-a895-ee762b0be0b6" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_290868c6-b365-48b5-9669-f747bf16e0fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_04e90bb7-e8ca-4222-804e-aa7195277d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d2683349-23ff-4e50-a895-ee762b0be0b6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_04e90bb7-e8ca-4222-804e-aa7195277d47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_fb1179ce-5630-4644-94b0-97749fe7c2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d2683349-23ff-4e50-a895-ee762b0be0b6" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_fb1179ce-5630-4644-94b0-97749fe7c2a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_680e9500-b633-4ceb-98dd-04864c9ed514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a49b1722-f7d8-4567-bc25-26ef49973b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_680e9500-b633-4ceb-98dd-04864c9ed514" xlink:to="loc_us-gaap_Liabilities_a49b1722-f7d8-4567-bc25-26ef49973b3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7cbb2240-79ea-49e3-bc17-e6f7a4c245b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_680e9500-b633-4ceb-98dd-04864c9ed514" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7cbb2240-79ea-49e3-bc17-e6f7a4c245b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_59da2c69-b661-4f6a-bcf8-519278379e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_680e9500-b633-4ceb-98dd-04864c9ed514" xlink:to="loc_us-gaap_StockholdersEquity_59da2c69-b661-4f6a-bcf8-519278379e1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_26b4e6fc-5525-48af-93c9-82e6165229f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0784b571-249f-40a0-a1a4-10bff5bccd66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26b4e6fc-5525-48af-93c9-82e6165229f6" xlink:to="loc_us-gaap_AssetsCurrent_0784b571-249f-40a0-a1a4-10bff5bccd66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6ac425fc-aa1b-41e4-a9fb-aa8f17fdecb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26b4e6fc-5525-48af-93c9-82e6165229f6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6ac425fc-aa1b-41e4-a9fb-aa8f17fdecb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0b61ac63-6d6b-41b7-a1f8-2a7a27682644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26b4e6fc-5525-48af-93c9-82e6165229f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0b61ac63-6d6b-41b7-a1f8-2a7a27682644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_61306046-8afd-4816-aa80-bb8f4470a6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26b4e6fc-5525-48af-93c9-82e6165229f6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_61306046-8afd-4816-aa80-bb8f4470a6ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4a7f70f2-7210-4872-88a4-24cacfd85f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26b4e6fc-5525-48af-93c9-82e6165229f6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4a7f70f2-7210-4872-88a4-24cacfd85f7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d1e793ca-d71c-44d5-ac22-2cc4e97e77f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26b4e6fc-5525-48af-93c9-82e6165229f6" xlink:to="loc_us-gaap_Goodwill_d1e793ca-d71c-44d5-ac22-2cc4e97e77f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d7f2ce18-e731-4215-bf0d-37840a631863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0b3cbeeb-6323-4b42-bdd4-6d4fb209e904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d7f2ce18-e731-4215-bf0d-37840a631863" xlink:to="loc_us-gaap_AccountsPayableCurrent_0b3cbeeb-6323-4b42-bdd4-6d4fb209e904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c4f5b61d-50be-4cf0-8321-bf23b2975c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d7f2ce18-e731-4215-bf0d-37840a631863" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c4f5b61d-50be-4cf0-8321-bf23b2975c00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_4899ed7d-72b2-429e-92e9-3c9a2328413d" xlink:href="nktr-20220630.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d7f2ce18-e731-4215-bf0d-37840a631863" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_4899ed7d-72b2-429e-92e9-3c9a2328413d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1b9e558f-919c-4cb8-b848-55b9ad7e3444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d7f2ce18-e731-4215-bf0d-37840a631863" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1b9e558f-919c-4cb8-b848-55b9ad7e3444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a87d9d16-ee8b-47e8-b920-b73342ded470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d7f2ce18-e731-4215-bf0d-37840a631863" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a87d9d16-ee8b-47e8-b920-b73342ded470" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c3297f63-b210-4601-80ea-66ce22c8a7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83d28300-b0c0-4b9d-af8c-952a8affe2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c3297f63-b210-4601-80ea-66ce22c8a7f2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83d28300-b0c0-4b9d-af8c-952a8affe2bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0bb8c178-e72a-4eb3-8b6e-78b0cf315125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c3297f63-b210-4601-80ea-66ce22c8a7f2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0bb8c178-e72a-4eb3-8b6e-78b0cf315125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f073c6dd-4cd8-4554-a976-af8e02caf720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_954aa453-0734-472a-bc06-39f6000cafa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f073c6dd-4cd8-4554-a976-af8e02caf720" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_954aa453-0734-472a-bc06-39f6000cafa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6f601729-2f4a-4f7a-a8de-61af5ebb5bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f073c6dd-4cd8-4554-a976-af8e02caf720" xlink:to="loc_us-gaap_CostsAndExpenses_6f601729-2f4a-4f7a-a8de-61af5ebb5bb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7eeadbf0-7e96-46ae-91e6-357fa466ac97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_0508ffa7-757d-4655-a967-b1284abf5b01" xlink:href="nktr-20220630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7eeadbf0-7e96-46ae-91e6-357fa466ac97" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_0508ffa7-757d-4655-a967-b1284abf5b01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_83d05890-8352-444b-a39e-a45ad4068dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7eeadbf0-7e96-46ae-91e6-357fa466ac97" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_83d05890-8352-444b-a39e-a45ad4068dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_0448ee3d-da95-4fdf-8447-4e455acfa32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7eeadbf0-7e96-46ae-91e6-357fa466ac97" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_0448ee3d-da95-4fdf-8447-4e455acfa32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_229eb482-7395-4f16-a975-57b899e6f3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_144d9c3f-2061-4a10-a53a-645819282aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_229eb482-7395-4f16-a975-57b899e6f3fa" xlink:to="loc_us-gaap_OperatingIncomeLoss_144d9c3f-2061-4a10-a53a-645819282aa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_455eb113-3127-4827-b821-ac9e69f2cf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_229eb482-7395-4f16-a975-57b899e6f3fa" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_455eb113-3127-4827-b821-ac9e69f2cf13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4c6476c6-5954-4e0d-a3c1-24e9e9338e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_436f7773-72d1-4d9d-8f8f-397b2cfe1d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4c6476c6-5954-4e0d-a3c1-24e9e9338e74" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_436f7773-72d1-4d9d-8f8f-397b2cfe1d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_20311dc2-2f6f-4214-8749-90f4c91fbb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4c6476c6-5954-4e0d-a3c1-24e9e9338e74" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_20311dc2-2f6f-4214-8749-90f4c91fbb81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_94884137-0c60-4b6e-8268-07c768b01a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4c6476c6-5954-4e0d-a3c1-24e9e9338e74" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_94884137-0c60-4b6e-8268-07c768b01a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f5b4b855-df76-4d8f-9971-ff36a3c2c945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4c6476c6-5954-4e0d-a3c1-24e9e9338e74" xlink:to="loc_us-gaap_RestructuringCharges_f5b4b855-df76-4d8f-9971-ff36a3c2c945" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1c744eff-07f1-47df-8baa-316961c9bbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a8fc1642-e2e2-4538-9302-fecd26835b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1c744eff-07f1-47df-8baa-316961c9bbb0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a8fc1642-e2e2-4538-9302-fecd26835b01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_814153c0-0fff-4a91-bbdb-62fea5030531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1c744eff-07f1-47df-8baa-316961c9bbb0" xlink:to="loc_us-gaap_NetIncomeLoss_814153c0-0fff-4a91-bbdb-62fea5030531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aae574d4-4d19-4ec8-a8af-df77d6d6a3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ce29a6e2-3432-4a03-93a1-24ca8b05c1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aae574d4-4d19-4ec8-a8af-df77d6d6a3c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ce29a6e2-3432-4a03-93a1-24ca8b05c1ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e00561a8-2900-4163-aec3-3f50914cc873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aae574d4-4d19-4ec8-a8af-df77d6d6a3c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e00561a8-2900-4163-aec3-3f50914cc873" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_310a4b58-324e-480c-81c6-bad5d00cd98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_708b5d13-6331-42d1-a308-7ac702266a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_310a4b58-324e-480c-81c6-bad5d00cd98c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_708b5d13-6331-42d1-a308-7ac702266a01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_56ce95d3-c2b7-4fa9-a099-85a6fdf16ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_310a4b58-324e-480c-81c6-bad5d00cd98c" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_56ce95d3-c2b7-4fa9-a099-85a6fdf16ca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_d8473379-eb1f-42a0-b12a-b8a9818dd797" xlink:href="nktr-20220630.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_d8473379-eb1f-42a0-b12a-b8a9818dd797" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ede64cc5-75eb-4b81-b169-4812c7142b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_AssetImpairmentCharges_ede64cc5-75eb-4b81-b169-4812c7142b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_13a394bf-ecbd-4aff-adbf-1f3d06a5e862" xlink:href="nktr-20220630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_13a394bf-ecbd-4aff-adbf-1f3d06a5e862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b7d89abe-8677-40f4-be96-8b31e2b33d68" xlink:href="nktr-20220630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b7d89abe-8677-40f4-be96-8b31e2b33d68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_96997975-1a07-49a1-af6a-2e7b791e28c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_96997975-1a07-49a1-af6a-2e7b791e28c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6b81432f-fa91-4fbc-a115-af2c77197676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_DepreciationAndAmortization_6b81432f-fa91-4fbc-a115-af2c77197676" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_57b4c309-7e09-4186-8561-2400cb807e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_57b4c309-7e09-4186-8561-2400cb807e72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c12500bb-c6a9-4969-83b9-b442e00e584c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c12500bb-c6a9-4969-83b9-b442e00e584c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_69731ed9-2b05-42bd-93c8-f7a1aa9e4954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_ProfitLoss_69731ed9-2b05-42bd-93c8-f7a1aa9e4954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0aa6b9ef-9609-4dd9-a005-3ecbbbac68c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0aa6b9ef-9609-4dd9-a005-3ecbbbac68c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_641ed0ad-3c3d-49bd-a4ce-71a5f9d1ab56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_641ed0ad-3c3d-49bd-a4ce-71a5f9d1ab56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_d610f911-75fe-4065-a28c-daccaa76f42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_d610f911-75fe-4065-a28c-daccaa76f42f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_20c32186-0adb-426d-b6ae-4157bea7e327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_20c32186-0adb-426d-b6ae-4157bea7e327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_9881162f-62a6-4feb-b56f-c1dadb41cd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_9881162f-62a6-4feb-b56f-c1dadb41cd6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_29bf4081-e3ce-4fc6-b092-15a164a76bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_29bf4081-e3ce-4fc6-b092-15a164a76bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d05e8057-2675-4b2b-acbe-6fd106d8ce97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bccecbe7-0794-4b2a-8695-c11538e3b193" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d05e8057-2675-4b2b-acbe-6fd106d8ce97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cce0a987-07ef-4394-b7dc-9d0395db11f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_956abac3-c777-495b-986e-1e489e13a818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cce0a987-07ef-4394-b7dc-9d0395db11f2" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_956abac3-c777-495b-986e-1e489e13a818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9c4e94c0-9434-4ed7-8d8c-2978f7a9da1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cce0a987-07ef-4394-b7dc-9d0395db11f2" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9c4e94c0-9434-4ed7-8d8c-2978f7a9da1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17878368-020e-4894-a9df-3e5e143c6b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cce0a987-07ef-4394-b7dc-9d0395db11f2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17878368-020e-4894-a9df-3e5e143c6b27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f6f445c3-2b2c-4341-a7a3-387a06cee46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cce0a987-07ef-4394-b7dc-9d0395db11f2" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f6f445c3-2b2c-4341-a7a3-387a06cee46b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a019aeb4-bac9-4e5c-99ed-3cdd7b7b4f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_afd4b19b-2250-4388-99a5-baf67f3d7f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a019aeb4-bac9-4e5c-99ed-3cdd7b7b4f42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_afd4b19b-2250-4388-99a5-baf67f3d7f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18745ffa-325a-4fe5-8bb7-5dcf5ec07970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a019aeb4-bac9-4e5c-99ed-3cdd7b7b4f42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18745ffa-325a-4fe5-8bb7-5dcf5ec07970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47ca39a4-1364-4db2-92d7-6a78b6183a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a019aeb4-bac9-4e5c-99ed-3cdd7b7b4f42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47ca39a4-1364-4db2-92d7-6a78b6183a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37efbd95-849e-469f-a6e0-61190e37f3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a019aeb4-bac9-4e5c-99ed-3cdd7b7b4f42" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37efbd95-849e-469f-a6e0-61190e37f3b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c940d64f-d5c6-4150-ae7e-67eefac41585" xlink:href="nktr-20220630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1ad3fa6-7051-4433-a32f-1c63bc6c0da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c940d64f-d5c6-4150-ae7e-67eefac41585" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1ad3fa6-7051-4433-a32f-1c63bc6c0da0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b6141d57-50b7-459b-85c1-d41bfeff3e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c940d64f-d5c6-4150-ae7e-67eefac41585" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b6141d57-50b7-459b-85c1-d41bfeff3e64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_584acdf9-4895-4fd8-9615-ba8b228faafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_c940d64f-d5c6-4150-ae7e-67eefac41585" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_584acdf9-4895-4fd8-9615-ba8b228faafb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8f2ef06d-8b33-4cce-bbc5-c48739911a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c5427238-f7fb-4ebe-8ddb-b1ab141ceef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8f2ef06d-8b33-4cce-bbc5-c48739911a61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c5427238-f7fb-4ebe-8ddb-b1ab141ceef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_26e570aa-d84d-4d2e-adde-48577f9160cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8f2ef06d-8b33-4cce-bbc5-c48739911a61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_26e570aa-d84d-4d2e-adde-48577f9160cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e910351e-4795-4715-97b6-d9921fa43928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8f2ef06d-8b33-4cce-bbc5-c48739911a61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e910351e-4795-4715-97b6-d9921fa43928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_895538ce-b85d-48e1-a891-9cef8376f3cf" xlink:href="nktr-20220630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2097b1e9-8f6a-467e-8ed0-fdba29300e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_895538ce-b85d-48e1-a891-9cef8376f3cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2097b1e9-8f6a-467e-8ed0-fdba29300e0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_0e3447dc-b083-4c97-b429-cfa570d0ee3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_895538ce-b85d-48e1-a891-9cef8376f3cf" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_0e3447dc-b083-4c97-b429-cfa570d0ee3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_cd294cc4-8c49-43a9-9572-8dc6e5b6e2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_895538ce-b85d-48e1-a891-9cef8376f3cf" xlink:to="loc_us-gaap_Cash_cd294cc4-8c49-43a9-9572-8dc6e5b6e2e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_74033a47-34c9-47fe-9df6-2228e90258e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_fec973bc-5cf7-496d-bc05-58723b5063a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_74033a47-34c9-47fe-9df6-2228e90258e3" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_fec973bc-5cf7-496d-bc05-58723b5063a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a5b3d609-6333-4c5c-9641-a4d4d7d76301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_74033a47-34c9-47fe-9df6-2228e90258e3" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a5b3d609-6333-4c5c-9641-a4d4d7d76301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8daa001f-6d35-4ca1-92d2-149bd97110cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_74033a47-34c9-47fe-9df6-2228e90258e3" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8daa001f-6d35-4ca1-92d2-149bd97110cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_cbe6465a-47ed-451a-b125-763b19a5e511" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_63a44787-bcce-4171-9d3a-bd262cf77485" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_cbe6465a-47ed-451a-b125-763b19a5e511" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_63a44787-bcce-4171-9d3a-bd262cf77485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_77447c58-d1b9-476d-a9b9-1a83df85ef1a" xlink:href="nktr-20220630.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_cbe6465a-47ed-451a-b125-763b19a5e511" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_77447c58-d1b9-476d-a9b9-1a83df85ef1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_54cc6215-f612-4f0a-9c61-2ad6a2160c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_124074db-c2c7-4035-8950-2c3060faea45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_54cc6215-f612-4f0a-9c61-2ad6a2160c14" xlink:to="loc_us-gaap_AssetImpairmentCharges_124074db-c2c7-4035-8950-2c3060faea45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_8e54d303-93ae-42f3-8c6e-680a190b0d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_54cc6215-f612-4f0a-9c61-2ad6a2160c14" xlink:to="loc_us-gaap_SeveranceCosts1_8e54d303-93ae-42f3-8c6e-680a190b0d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_ec87349f-f28b-4937-9099-efdad929d720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_54cc6215-f612-4f0a-9c61-2ad6a2160c14" xlink:to="loc_us-gaap_BusinessExitCosts1_ec87349f-f28b-4937-9099-efdad929d720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_58484869-07be-4120-8175-8fdc64eeb6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_54cc6215-f612-4f0a-9c61-2ad6a2160c14" xlink:to="loc_us-gaap_LossOnContractTermination_58484869-07be-4120-8175-8fdc64eeb6f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_dc78dabf-b60f-479a-a2bb-9b25611e2a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_96f99d38-d86d-46ba-a46e-ad5427c3e812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetImpairmentCharges_dc78dabf-b60f-479a-a2bb-9b25611e2a87" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_96f99d38-d86d-46ba-a46e-ad5427c3e812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_17afc0e0-c2cd-4c18-843c-39ff0438f4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetImpairmentCharges_dc78dabf-b60f-479a-a2bb-9b25611e2a87" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_17afc0e0-c2cd-4c18-843c-39ff0438f4b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4a08cb26-07e5-4ba9-ac1a-83441c8c9a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55e4c477-9dc7-4fc8-b351-ed957026b57a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4a08cb26-07e5-4ba9-ac1a-83441c8c9a28" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55e4c477-9dc7-4fc8-b351-ed957026b57a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_140839b1-853f-4af0-831f-bd9b441f36b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4a08cb26-07e5-4ba9-ac1a-83441c8c9a28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_140839b1-853f-4af0-831f-bd9b441f36b2" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>nktr-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:29a4b4dc-8cca-4a2c-8b00-1653a7b25685,g:4140688d-8727-4745-9ca5-400c87633167-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="iaf72d627cb5e4fc590a2ffb4fbe2309e_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a6153d7d-58b9-4871-833b-62bbb878dbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_RevenuesAbstract_a6153d7d-58b9-4871-833b-62bbb878dbfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3dd9e5ef-a69d-4182-889c-ba9781fd1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a6153d7d-58b9-4871-833b-62bbb878dbfc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3dd9e5ef-a69d-4182-889c-ba9781fd1a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6b734a9c-6037-473f-8b8c-54a8747d6f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6b734a9c-6037-473f-8b8c-54a8747d6f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5ae04f0e-3e14-4486-8e97-0b280066d4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5ae04f0e-3e14-4486-8e97-0b280066d4e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_81d73178-92c0-4c86-b8f7-d204fb919cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_81d73178-92c0-4c86-b8f7-d204fb919cc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1d6b591e-b7d4-4d85-9131-c2875381d88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:to="loc_us-gaap_RestructuringCharges_1d6b591e-b7d4-4d85-9131-c2875381d88d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8130992e-0bde-4837-9719-c03c135b0afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:to="loc_us-gaap_CostsAndExpenses_8130992e-0bde-4837-9719-c03c135b0afb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aa800cb9-4636-402a-a666-5ba4fb0cd3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_OperatingIncomeLoss_aa800cb9-4636-402a-a666-5ba4fb0cd3f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_b62c6e8f-b8e1-4ca7-8da7-21af271b0926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_b62c6e8f-b8e1-4ca7-8da7-21af271b0926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_afc62b30-e65f-4dae-a35f-d3372a6eff1e" xlink:href="nktr-20220630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_afc62b30-e65f-4dae-a35f-d3372a6eff1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3f2405c4-8bbe-4c38-b95a-fd060718c195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3f2405c4-8bbe-4c38-b95a-fd060718c195" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d647f8d9-d3cb-40ca-bb25-4348955963e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d647f8d9-d3cb-40ca-bb25-4348955963e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b16d8849-b01c-4306-8529-0535ca288c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b16d8849-b01c-4306-8529-0535ca288c44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_80c98453-72a3-4126-abb8-e84d6fb0b8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_80c98453-72a3-4126-abb8-e84d6fb0b8f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_faf6d1d1-33bb-4cc7-a537-0178a639322a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_NetIncomeLoss_faf6d1d1-33bb-4cc7-a537-0178a639322a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e65ba605-0c63-4058-9587-12bd6d244812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_EarningsPerShareBasic_e65ba605-0c63-4058-9587-12bd6d244812" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e425eb69-5a6b-4726-a880-b5441e686e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e425eb69-5a6b-4726-a880-b5441e686e81" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_616d8bca-102e-45fc-bb7e-d4ef71a8ac3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_616d8bca-102e-45fc-bb7e-d4ef71a8ac3d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_473c162e-193f-4ee8-b8d7-344b651cd981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_473c162e-193f-4ee8-b8d7-344b651cd981" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e76fd5f8-b397-419a-94c5-0e307f98b3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_StatementTable_e76fd5f8-b397-419a-94c5-0e307f98b3d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_56d40ef7-a512-4051-b34f-80eaca8b5351" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e76fd5f8-b397-419a-94c5-0e307f98b3d8" xlink:to="loc_srt_ProductOrServiceAxis_56d40ef7-a512-4051-b34f-80eaca8b5351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56d40ef7-a512-4051-b34f-80eaca8b5351_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_56d40ef7-a512-4051-b34f-80eaca8b5351" xlink:to="loc_srt_ProductsAndServicesDomain_56d40ef7-a512-4051-b34f-80eaca8b5351_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddbdb341-e637-4837-ad65-bef88658d649" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_56d40ef7-a512-4051-b34f-80eaca8b5351" xlink:to="loc_srt_ProductsAndServicesDomain_ddbdb341-e637-4837-ad65-bef88658d649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_523b6682-3a9c-4465-9abb-5dafb4bd3144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddbdb341-e637-4837-ad65-bef88658d649" xlink:to="loc_us-gaap_ProductMember_523b6682-3a9c-4465-9abb-5dafb4bd3144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_3e5b31cc-98e8-4cee-92e5-21f94c9cb93a" xlink:href="nktr-20220630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddbdb341-e637-4837-ad65-bef88658d649" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_3e5b31cc-98e8-4cee-92e5-21f94c9cb93a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_5eba5618-4db3-4549-82ee-e3e0902c264e" xlink:href="nktr-20220630.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ddbdb341-e637-4837-ad65-bef88658d649" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_5eba5618-4db3-4549-82ee-e3e0902c264e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="idf59daefe9584393bccca94fdf3aaf87_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a79ee8c0-4f1c-41fb-a318-14e5fd693185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a79ee8c0-4f1c-41fb-a318-14e5fd693185" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_af7e7565-c0fa-4810-bdb4-1576814c3ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_SharesOutstanding_af7e7565-c0fa-4810-bdb4-1576814c3ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6826112b-cbb9-4b74-87aa-759d69d31e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_StockholdersEquity_6826112b-cbb9-4b74-87aa-759d69d31e6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_82d2fe3c-7987-4783-838d-07b8896968cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_82d2fe3c-7987-4783-838d-07b8896968cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9762bfe8-6082-4d53-8b53-2dbeb7e7a5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9762bfe8-6082-4d53-8b53-2dbeb7e7a5f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7d1d9a63-39a0-4f7f-83ed-b4ed4623f40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7d1d9a63-39a0-4f7f-83ed-b4ed4623f40d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9e6204a2-a3a6-4c58-899d-de03117e6fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9e6204a2-a3a6-4c58-899d-de03117e6fe9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0bd17237-5b00-450e-a153-8f22d43a86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a099a131-05e6-41d1-bc26-be5263039458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_feb0bc43-375b-420f-8dae-642a837a6a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a79ee8c0-4f1c-41fb-a318-14e5fd693185" xlink:to="loc_us-gaap_StatementTable_feb0bc43-375b-420f-8dae-642a837a6a5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_486e3ad3-3a0e-4067-a226-be9fb617ba36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_feb0bc43-375b-420f-8dae-642a837a6a5b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_486e3ad3-3a0e-4067-a226-be9fb617ba36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_486e3ad3-3a0e-4067-a226-be9fb617ba36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_486e3ad3-3a0e-4067-a226-be9fb617ba36" xlink:to="loc_us-gaap_EquityComponentDomain_486e3ad3-3a0e-4067-a226-be9fb617ba36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_486e3ad3-3a0e-4067-a226-be9fb617ba36" xlink:to="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bd3668e6-2fdd-451c-b100-703bbbd582f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:to="loc_us-gaap_CommonStockMember_bd3668e6-2fdd-451c-b100-703bbbd582f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_838de474-dd31-484a-9182-16b7190e594e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_838de474-dd31-484a-9182-16b7190e594e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9194b0d7-fb97-440c-9885-8805a5e77b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9194b0d7-fb97-440c-9885-8805a5e77b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_34d30b33-6690-4ce8-b2e9-bf714c8f4ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:to="loc_us-gaap_RetainedEarningsMember_34d30b33-6690-4ce8-b2e9-bf714c8f4ecc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i4fea874754244ec78ed2b3d65b8473b0_OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:href="nktr-20220630.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_6263c496-a5b9-42f4-8330-ffaca2bc67d6" xlink:href="nktr-20220630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_6263c496-a5b9-42f4-8330-ffaca2bc67d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_e829daf2-5e2c-42b7-88ba-231897ebdaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_e829daf2-5e2c-42b7-88ba-231897ebdaa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_18e414b0-0c31-4b0e-84d9-423793aaaad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_18e414b0-0c31-4b0e-84d9-423793aaaad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_ae968bb8-a53d-48a2-9c9b-3f899ff87535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_ae968bb8-a53d-48a2-9c9b-3f899ff87535" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_95f1c721-1ad7-4bff-851e-8c24c9b9a1ef" xlink:href="nktr-20220630.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_95f1c721-1ad7-4bff-851e-8c24c9b9a1ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3453bcd6-d847-4dbc-92d1-2db4c5ac63a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_95f1c721-1ad7-4bff-851e-8c24c9b9a1ef" xlink:to="loc_srt_CounterpartyNameAxis_3453bcd6-d847-4dbc-92d1-2db4c5ac63a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3453bcd6-d847-4dbc-92d1-2db4c5ac63a9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3453bcd6-d847-4dbc-92d1-2db4c5ac63a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3453bcd6-d847-4dbc-92d1-2db4c5ac63a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8e25479-cbee-48c4-972e-c58b2f7d86f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3453bcd6-d847-4dbc-92d1-2db4c5ac63a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8e25479-cbee-48c4-972e-c58b2f7d86f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_4b007fc7-3f86-4c73-bd32-23866ce84955" xlink:href="nktr-20220630.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8e25479-cbee-48c4-972e-c58b2f7d86f9" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_4b007fc7-3f86-4c73-bd32-23866ce84955" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_4a86ff36-70bb-4b8f-9d16-c09efcecde94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_95f1c721-1ad7-4bff-851e-8c24c9b9a1ef" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_4a86ff36-70bb-4b8f-9d16-c09efcecde94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4a86ff36-70bb-4b8f-9d16-c09efcecde94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_4a86ff36-70bb-4b8f-9d16-c09efcecde94" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4a86ff36-70bb-4b8f-9d16-c09efcecde94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_5ee943bc-542f-4b11-95fe-eedc6b5a4f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_4a86ff36-70bb-4b8f-9d16-c09efcecde94" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_5ee943bc-542f-4b11-95fe-eedc6b5a4f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_72b7c33e-725d-48bb-bdae-be611c1303e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5ee943bc-542f-4b11-95fe-eedc6b5a4f33" xlink:to="loc_us-gaap_EmployeeSeveranceMember_72b7c33e-725d-48bb-bdae-be611c1303e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" id="ife9f2f3510a04863b3992cc75da17b31_CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:href="nktr-20220630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_c4cb8b31-cb56-47a7-bb52-17d81011db93" xlink:href="nktr-20220630.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_c4cb8b31-cb56-47a7-bb52-17d81011db93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_c7cb76ad-050c-4d40-ab3f-8a86b4cb9d43" xlink:href="nktr-20220630.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_c7cb76ad-050c-4d40-ab3f-8a86b4cb9d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_097ddac3-0786-42c8-a325-f6a0bfde4072" xlink:href="nktr-20220630.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_097ddac3-0786-42c8-a325-f6a0bfde4072" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ad294611-2be4-43ee-bdc9-dd64cd6dda22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ad294611-2be4-43ee-bdc9-dd64cd6dda22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_70030f2c-38d5-4fa9-af6a-b16bfd7eea28" xlink:href="nktr-20220630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_70030f2c-38d5-4fa9-af6a-b16bfd7eea28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_772cfae2-485e-4988-9f20-5838bfabe6a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_70030f2c-38d5-4fa9-af6a-b16bfd7eea28" xlink:to="loc_srt_RangeAxis_772cfae2-485e-4988-9f20-5838bfabe6a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_772cfae2-485e-4988-9f20-5838bfabe6a1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_772cfae2-485e-4988-9f20-5838bfabe6a1" xlink:to="loc_srt_RangeMember_772cfae2-485e-4988-9f20-5838bfabe6a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9264bcfc-5114-440c-ad36-6982890c170c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_772cfae2-485e-4988-9f20-5838bfabe6a1" xlink:to="loc_srt_RangeMember_9264bcfc-5114-440c-ad36-6982890c170c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_053684df-9296-4ece-be66-d1bae1cadfb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9264bcfc-5114-440c-ad36-6982890c170c" xlink:to="loc_srt_MinimumMember_053684df-9296-4ece-be66-d1bae1cadfb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d6677b83-cd3a-4b97-9756-d4341055913d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9264bcfc-5114-440c-ad36-6982890c170c" xlink:to="loc_srt_MaximumMember_d6677b83-cd3a-4b97-9756-d4341055913d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended" id="i42fe2650583442358893aedce89f8ba6_CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e76db2b4-d513-4e76-b975-7a6257312aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e76db2b4-d513-4e76-b975-7a6257312aea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab14796a-6ad3-4f6a-a9ae-09cddde8d885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab14796a-6ad3-4f6a-a9ae-09cddde8d885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8de3a813-8d92-483e-beb9-b2aa6d7ba7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8de3a813-8d92-483e-beb9-b2aa6d7ba7e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45544daa-4f99-447f-bfde-7fb365b5b769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45544daa-4f99-447f-bfde-7fb365b5b769" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4fbd56b9-71bc-4176-9f9b-b5712977d28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4fbd56b9-71bc-4176-9f9b-b5712977d28e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_acdb9064-c8ff-4a32-ade8-88bc2b08737b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_Cash_acdb9064-c8ff-4a32-ade8-88bc2b08737b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f8f1944b-6c5b-491c-b136-cdfa2c9d2dc6" xlink:href="nktr-20220630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f8f1944b-6c5b-491c-b136-cdfa2c9d2dc6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7735d5d5-7072-4516-904d-bac8cea4ad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7735d5d5-7072-4516-904d-bac8cea4ad6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3849f3bc-6603-4453-b342-91f740cc1edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7735d5d5-7072-4516-904d-bac8cea4ad6c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3849f3bc-6603-4453-b342-91f740cc1edf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3849f3bc-6603-4453-b342-91f740cc1edf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3849f3bc-6603-4453-b342-91f740cc1edf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3849f3bc-6603-4453-b342-91f740cc1edf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae971c25-6701-4cb4-80cf-e273ceaae0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3849f3bc-6603-4453-b342-91f740cc1edf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae971c25-6701-4cb4-80cf-e273ceaae0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7feb2c8e-d5dd-4738-8ac6-4c131d76a878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae971c25-6701-4cb4-80cf-e273ceaae0cd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7feb2c8e-d5dd-4738-8ac6-4c131d76a878" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_442b0db5-41e7-4cc8-a620-368ac7172c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae971c25-6701-4cb4-80cf-e273ceaae0cd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_442b0db5-41e7-4cc8-a620-368ac7172c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_54373af7-eec2-4c00-b058-7639d7450dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7735d5d5-7072-4516-904d-bac8cea4ad6c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_54373af7-eec2-4c00-b058-7639d7450dc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54373af7-eec2-4c00-b058-7639d7450dc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_54373af7-eec2-4c00-b058-7639d7450dc5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54373af7-eec2-4c00-b058-7639d7450dc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_54373af7-eec2-4c00-b058-7639d7450dc5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_60b1405b-cf00-43a7-a544-6aa2f9932cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_60b1405b-cf00-43a7-a544-6aa2f9932cc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_47b1047a-4d14-448e-a5b7-3718f35ec67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:to="loc_us-gaap_CommercialPaperMember_47b1047a-4d14-448e-a5b7-3718f35ec67f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_79559767-dbf1-4146-9433-d06837f90bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_79559767-dbf1-4146-9433-d06837f90bfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_95522f26-deef-409b-933f-6e5b28ec85c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_95522f26-deef-409b-933f-6e5b28ec85c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_60b1a3e9-d329-4c02-bf19-d8e9bd291081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:to="loc_us-gaap_CertificatesOfDepositMember_60b1a3e9-d329-4c02-bf19-d8e9bd291081" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="extended" id="iccfd315c7013468fb34c7a035e9c4b26_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c209c2a-ef9f-4d95-8814-06680bbdda72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_018c867e-ef8e-49a4-9146-7bbad070e5cd" xlink:href="nktr-20220630.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c209c2a-ef9f-4d95-8814-06680bbdda72" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_018c867e-ef8e-49a4-9146-7bbad070e5cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_640769ba-6efc-46d6-baf0-3dd493a13cb6" xlink:href="nktr-20220630.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c209c2a-ef9f-4d95-8814-06680bbdda72" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_640769ba-6efc-46d6-baf0-3dd493a13cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_b4b1120f-948e-4976-bd33-8316b4388721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c209c2a-ef9f-4d95-8814-06680bbdda72" xlink:to="loc_us-gaap_DerivativeLiabilities_b4b1120f-948e-4976-bd33-8316b4388721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f891cfc-e6df-4b21-a7bb-5ce25b907f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c209c2a-ef9f-4d95-8814-06680bbdda72" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f891cfc-e6df-4b21-a7bb-5ce25b907f59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_678e3520-e47f-4b6a-8bc4-36feb303193a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f891cfc-e6df-4b21-a7bb-5ce25b907f59" xlink:to="loc_srt_CounterpartyNameAxis_678e3520-e47f-4b6a-8bc4-36feb303193a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_678e3520-e47f-4b6a-8bc4-36feb303193a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_678e3520-e47f-4b6a-8bc4-36feb303193a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_678e3520-e47f-4b6a-8bc4-36feb303193a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74a53083-9af1-417e-8704-3dabe4d7dbb5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_678e3520-e47f-4b6a-8bc4-36feb303193a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74a53083-9af1-417e-8704-3dabe4d7dbb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_99e643bf-0321-4dad-b846-ea81f5989746" xlink:href="nktr-20220630.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74a53083-9af1-417e-8704-3dabe4d7dbb5" xlink:to="loc_nktr_SFJPharmaceuticalsMember_99e643bf-0321-4dad-b846-ea81f5989746" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="extended" id="i55606ef0a5e842e8a5cb1552e1b2c307_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89502ce9-4db7-4219-a78d-b2c8e84522e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89502ce9-4db7-4219-a78d-b2c8e84522e1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7ac406d0-6dbe-4cab-90fc-131a413d4864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7ac406d0-6dbe-4cab-90fc-131a413d4864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_e14deccf-233c-4dc6-9d61-d5045c48e40d" xlink:href="nktr-20220630.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_e14deccf-233c-4dc6-9d61-d5045c48e40d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_98cacef1-cd92-47b0-abf0-f95d500c2411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_98cacef1-cd92-47b0-abf0-f95d500c2411" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_9f0e1668-883f-4245-97d3-d0465ca69e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_9f0e1668-883f-4245-97d3-d0465ca69e66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ea77e740-6514-492c-9d71-3bf2bd3d46eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca7c530-d56c-4354-ad02-de82b9a99119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89502ce9-4db7-4219-a78d-b2c8e84522e1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca7c530-d56c-4354-ad02-de82b9a99119" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_dbad52fe-5af8-43ea-ac21-7c79930078ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca7c530-d56c-4354-ad02-de82b9a99119" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_dbad52fe-5af8-43ea-ac21-7c79930078ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dbad52fe-5af8-43ea-ac21-7c79930078ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_dbad52fe-5af8-43ea-ac21-7c79930078ba" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dbad52fe-5af8-43ea-ac21-7c79930078ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_de885275-5d39-42d6-bbaf-8462053f3544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_dbad52fe-5af8-43ea-ac21-7c79930078ba" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_de885275-5d39-42d6-bbaf-8462053f3544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_ddb70e75-d665-4e5e-9585-c759af9a112d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_de885275-5d39-42d6-bbaf-8462053f3544" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_ddb70e75-d665-4e5e-9585-c759af9a112d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a520373-ff77-4942-b209-5239eaa51e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca7c530-d56c-4354-ad02-de82b9a99119" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a520373-ff77-4942-b209-5239eaa51e17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a520373-ff77-4942-b209-5239eaa51e17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a520373-ff77-4942-b209-5239eaa51e17" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a520373-ff77-4942-b209-5239eaa51e17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5124967-83bf-4e6a-84cb-f9695c987950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a520373-ff77-4942-b209-5239eaa51e17" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5124967-83bf-4e6a-84cb-f9695c987950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bcdb6918-e857-4803-89a3-454d45f3f63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5124967-83bf-4e6a-84cb-f9695c987950" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bcdb6918-e857-4803-89a3-454d45f3f63d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="extended" id="i9aa6cc72cd2a45bba2c8b1c048ec3ce5_LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds_bba4c9d4-db19-4b3a-a9a1-230974ce7734" xlink:href="nktr-20220630.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_RoyaltyMonetizationProceeds_bba4c9d4-db19-4b3a-a9a1-230974ce7734" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_9974e4c4-87c7-4b25-a921-e2ef7a7e7c3f" xlink:href="nktr-20220630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_9974e4c4-87c7-4b25-a921-e2ef7a7e7c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_92ba6e94-de7e-4cd5-a9b0-68f59943057f" xlink:href="nktr-20220630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_92ba6e94-de7e-4cd5-a9b0-68f59943057f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_3dce98ad-2629-4377-a3b1-5e6fefe0118f" xlink:href="nktr-20220630.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_3dce98ad-2629-4377-a3b1-5e6fefe0118f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_7a6035a8-468d-4257-8440-f94045cfca1f" xlink:href="nktr-20220630.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_7a6035a8-468d-4257-8440-f94045cfca1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_e1087df8-9a63-4b75-a821-57938a9d3f87" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_e1087df8-9a63-4b75-a821-57938a9d3f87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_febf9c86-3bc3-4421-8ca0-e89b26cf4863" xlink:href="nktr-20220630.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_febf9c86-3bc3-4421-8ca0-e89b26cf4863" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_997b49ac-995a-41eb-91dc-b89da5a34667" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_997b49ac-995a-41eb-91dc-b89da5a34667" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3f7d271-2f16-4629-8625-2af79cf37934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3f7d271-2f16-4629-8625-2af79cf37934" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bedf5d48-e0d5-45be-af3f-ffa0e7935beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3f7d271-2f16-4629-8625-2af79cf37934" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bedf5d48-e0d5-45be-af3f-ffa0e7935beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bedf5d48-e0d5-45be-af3f-ffa0e7935beb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bedf5d48-e0d5-45be-af3f-ffa0e7935beb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bedf5d48-e0d5-45be-af3f-ffa0e7935beb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c64ec47-c9a1-4dd7-ac43-447c5bf269ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bedf5d48-e0d5-45be-af3f-ffa0e7935beb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c64ec47-c9a1-4dd7-ac43-447c5bf269ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_66ce3307-78f3-4839-9aef-4682590232c3" xlink:href="nktr-20220630.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c64ec47-c9a1-4dd7-ac43-447c5bf269ed" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_66ce3307-78f3-4839-9aef-4682590232c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_e9f451ba-79a9-4189-a401-89cdfc5b38fc" xlink:href="nktr-20220630.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c64ec47-c9a1-4dd7-ac43-447c5bf269ed" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_e9f451ba-79a9-4189-a401-89cdfc5b38fc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="extended" id="i3080f9e0f45a40ca9cbe664c48255c6e_LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_9c9fc2d8-fcf4-4fe5-a0c5-f74af6426f95" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput_df761151-26ce-45a0-a421-65d3c99a33ce" xlink:href="nktr-20220630.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_9c9fc2d8-fcf4-4fe5-a0c5-f74af6426f95" xlink:to="loc_nktr_RoyaltiesLiabilityMeasurementInput_df761151-26ce-45a0-a421-65d3c99a33ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_592efd78-a18f-4ebd-923d-f97bdf5483ee" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_9c9fc2d8-fcf4-4fe5-a0c5-f74af6426f95" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_592efd78-a18f-4ebd-923d-f97bdf5483ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cbcf4918-c94d-41c8-97f7-ae0f8f71507b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_592efd78-a18f-4ebd-923d-f97bdf5483ee" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cbcf4918-c94d-41c8-97f7-ae0f8f71507b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cbcf4918-c94d-41c8-97f7-ae0f8f71507b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cbcf4918-c94d-41c8-97f7-ae0f8f71507b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cbcf4918-c94d-41c8-97f7-ae0f8f71507b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34376f0c-541d-4cc9-b129-312d1c45fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cbcf4918-c94d-41c8-97f7-ae0f8f71507b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34376f0c-541d-4cc9-b129-312d1c45fa62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_80bc7bac-0543-4525-b212-818da46981c4" xlink:href="nktr-20220630.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34376f0c-541d-4cc9-b129-312d1c45fa62" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_80bc7bac-0543-4525-b212-818da46981c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_5e817b7c-7ec7-4401-a50d-0c539377ba79" xlink:href="nktr-20220630.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34376f0c-541d-4cc9-b129-312d1c45fa62" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_5e817b7c-7ec7-4401-a50d-0c539377ba79" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="ib23ce032b59f4763b28e9cd19b16e66c_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f72ec3b8-4970-42b2-9c8b-aa8a129fdc81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_16a97e6b-74a1-4455-a5df-7fb5d60c1460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f72ec3b8-4970-42b2-9c8b-aa8a129fdc81" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_16a97e6b-74a1-4455-a5df-7fb5d60c1460" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bd9745b0-54c2-4862-8e7b-d513f9d45937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_f72ec3b8-4970-42b2-9c8b-aa8a129fdc81" xlink:to="loc_us-gaap_LossContingenciesTable_bd9745b0-54c2-4862-8e7b-d513f9d45937" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_fd5d1f83-5335-4818-ab8c-1c504737ed91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bd9745b0-54c2-4862-8e7b-d513f9d45937" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_fd5d1f83-5335-4818-ab8c-1c504737ed91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_fd5d1f83-5335-4818-ab8c-1c504737ed91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_fd5d1f83-5335-4818-ab8c-1c504737ed91" xlink:to="loc_us-gaap_LossContingencyNatureDomain_fd5d1f83-5335-4818-ab8c-1c504737ed91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_da507e21-e006-4bb2-9a0b-b9b305e335fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_fd5d1f83-5335-4818-ab8c-1c504737ed91" xlink:to="loc_us-gaap_LossContingencyNatureDomain_da507e21-e006-4bb2-9a0b-b9b305e335fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember_fe8ed419-7d82-4655-8c4e-50e1e06eede9" xlink:href="nktr-20220630.xsd#nktr_LegalMattersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_da507e21-e006-4bb2-9a0b-b9b305e335fd" xlink:to="loc_nktr_LegalMattersMember_fe8ed419-7d82-4655-8c4e-50e1e06eede9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended" id="i6e44b93582e349c2899f88b11e18dae5_LicenseandCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_f8d26dd9-f55e-4c03-9ce1-77b37c928539" xlink:href="nktr-20220630.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_f8d26dd9-f55e-4c03-9ce1-77b37c928539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_74e2f451-331c-46c2-981d-769259936fe7" xlink:href="nktr-20220630.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_74e2f451-331c-46c2-981d-769259936fe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_00f60037-689e-421c-824d-0288884fce65" xlink:href="nktr-20220630.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_00f60037-689e-421c-824d-0288884fce65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_0978c691-83d8-4712-9879-6fd0c9b81d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_us-gaap_SharesIssued_0978c691-83d8-4712-9879-6fd0c9b81d9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_afd4e123-52bf-4f5f-b53b-9da3b97ca8b2" xlink:href="nktr-20220630.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_afd4e123-52bf-4f5f-b53b-9da3b97ca8b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_22c61f79-128b-4d8f-b035-7f1780cc9f98" xlink:href="nktr-20220630.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PotentialDevelopmentMilestones_22c61f79-128b-4d8f-b035-7f1780cc9f98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_183726af-74db-48dd-ac02-c3dacbf56279" xlink:href="nktr-20220630.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_ReimbursementOfExpenses_183726af-74db-48dd-ac02-c3dacbf56279" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7515a399-c8ce-472d-8e6c-a2e24ba5f120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7515a399-c8ce-472d-8e6c-a2e24ba5f120" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_50884c80-b098-4410-81f8-3a85deb6c988" xlink:href="nktr-20220630.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_50884c80-b098-4410-81f8-3a85deb6c988" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_741a9a95-6906-4132-8f25-a3b2a3c9757d" xlink:href="nktr-20220630.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_741a9a95-6906-4132-8f25-a3b2a3c9757d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_620dcf9d-e3ec-4fe2-ae89-7d153af31e4c" xlink:href="nktr-20220630.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_620dcf9d-e3ec-4fe2-ae89-7d153af31e4c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_871e90b0-d881-4cd8-85eb-2bb21cb9043a" xlink:href="nktr-20220630.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_871e90b0-d881-4cd8-85eb-2bb21cb9043a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_9a8d6d33-66e6-4fda-9866-2d306d532a52" xlink:href="nktr-20220630.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_9a8d6d33-66e6-4fda-9866-2d306d532a52" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_f4d99279-aebd-47da-a895-18eab452ce09" xlink:href="nktr-20220630.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_f4d99279-aebd-47da-a895-18eab452ce09" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7560b1d7-17dd-4310-910d-396ff00cceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7560b1d7-17dd-4310-910d-396ff00cceb4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7e407f0c-aa13-43df-a2ea-c52eb56c3e01" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_srt_ProductOrServiceAxis_7e407f0c-aa13-43df-a2ea-c52eb56c3e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e407f0c-aa13-43df-a2ea-c52eb56c3e01_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7e407f0c-aa13-43df-a2ea-c52eb56c3e01" xlink:to="loc_srt_ProductsAndServicesDomain_7e407f0c-aa13-43df-a2ea-c52eb56c3e01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_24ab9a4d-5b77-4378-9be0-667fd871fc96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7e407f0c-aa13-43df-a2ea-c52eb56c3e01" xlink:to="loc_srt_ProductsAndServicesDomain_24ab9a4d-5b77-4378-9be0-667fd871fc96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_ee42bb25-48f9-446d-85d4-15b530e52745" xlink:href="nktr-20220630.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_24ab9a4d-5b77-4378-9be0-667fd871fc96" xlink:to="loc_nktr_Nektar214Member_ee42bb25-48f9-446d-85d4-15b530e52745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_e44ffe28-eb94-4ab2-bed0-921f7de4b27d" xlink:href="nktr-20220630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_24ab9a4d-5b77-4378-9be0-667fd871fc96" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_e44ffe28-eb94-4ab2-bed0-921f7de4b27d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1f1b5d41-9931-463c-854d-b323fcc0c52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1f1b5d41-9931-463c-854d-b323fcc0c52b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1f1b5d41-9931-463c-854d-b323fcc0c52b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1f1b5d41-9931-463c-854d-b323fcc0c52b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1f1b5d41-9931-463c-854d-b323fcc0c52b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05e9f3a8-e4d6-4bf0-952c-2c1cfdb73844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1f1b5d41-9931-463c-854d-b323fcc0c52b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05e9f3a8-e4d6-4bf0-952c-2c1cfdb73844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_d87142b9-52cd-4d92-b1d9-f72c6910d627" xlink:href="nktr-20220630.xsd#nktr_OpdivoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05e9f3a8-e4d6-4bf0-952c-2c1cfdb73844" xlink:to="loc_nktr_OpdivoMember_d87142b9-52cd-4d92-b1d9-f72c6910d627" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_db15af03-2dd3-4273-9beb-42619e50a2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_us-gaap_TypeOfArrangementAxis_db15af03-2dd3-4273-9beb-42619e50a2e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db15af03-2dd3-4273-9beb-42619e50a2e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_db15af03-2dd3-4273-9beb-42619e50a2e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db15af03-2dd3-4273-9beb-42619e50a2e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28fb701e-273a-46e5-8899-979b218c14f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_db15af03-2dd3-4273-9beb-42619e50a2e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28fb701e-273a-46e5-8899-979b218c14f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_0cde5400-18b9-4728-8bfb-4a458132f9d5" xlink:href="nktr-20220630.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28fb701e-273a-46e5-8899-979b218c14f4" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_0cde5400-18b9-4728-8bfb-4a458132f9d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_1e61762d-2f61-4964-a7ac-6b3203822b74" xlink:href="nktr-20220630.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28fb701e-273a-46e5-8899-979b218c14f4" xlink:to="loc_nktr_Nektar358Member_1e61762d-2f61-4964-a7ac-6b3203822b74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_14036947-2ab9-43d5-b403-492c192abbea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_dei_LegalEntityAxis_14036947-2ab9-43d5-b403-492c192abbea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_14036947-2ab9-43d5-b403-492c192abbea_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_14036947-2ab9-43d5-b403-492c192abbea" xlink:to="loc_dei_EntityDomain_14036947-2ab9-43d5-b403-492c192abbea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_14036947-2ab9-43d5-b403-492c192abbea" xlink:to="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_fa467d40-0f6a-4cdd-9102-cd79a6a42017" xlink:href="nktr-20220630.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_fa467d40-0f6a-4cdd-9102-cd79a6a42017" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_0b3a5390-066e-477a-a6e2-4fe31618883b" xlink:href="nktr-20220630.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:to="loc_nktr_EliLillyAndCompanyMember_0b3a5390-066e-477a-a6e2-4fe31618883b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_8855000d-e44d-457c-bafb-24f5be307e55" xlink:href="nktr-20220630.xsd#nktr_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:to="loc_nktr_EliLillyMember_8855000d-e44d-457c-bafb-24f5be307e55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_7c14e6fc-78ee-4b2f-9571-8e9300065fe5" xlink:href="nktr-20220630.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:to="loc_nktr_OtherPartnerMember_7c14e6fc-78ee-4b2f-9571-8e9300065fe5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_391af8a3-8a9f-40a0-a30d-366d87621111" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_srt_ConsolidatedEntitiesAxis_391af8a3-8a9f-40a0-a30d-366d87621111" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_391af8a3-8a9f-40a0-a30d-366d87621111_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_391af8a3-8a9f-40a0-a30d-366d87621111" xlink:to="loc_srt_ConsolidatedEntitiesDomain_391af8a3-8a9f-40a0-a30d-366d87621111_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8d7620c6-fbe2-4f38-969b-8dca42bb5a1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_391af8a3-8a9f-40a0-a30d-366d87621111" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8d7620c6-fbe2-4f38-969b-8dca42bb5a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_a099308a-8ac7-4596-ad0a-10af5a2adf92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8d7620c6-fbe2-4f38-969b-8dca42bb5a1b" xlink:to="loc_srt_ParentCompanyMember_a099308a-8ac7-4596-ad0a-10af5a2adf92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_67910d5e-c461-4e0f-9019-bbe2ddb105b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_67910d5e-c461-4e0f-9019-bbe2ddb105b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_67910d5e-c461-4e0f-9019-bbe2ddb105b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_67910d5e-c461-4e0f-9019-bbe2ddb105b4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_67910d5e-c461-4e0f-9019-bbe2ddb105b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e1d237bb-8c74-4b99-ad83-a924d1b217d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_67910d5e-c461-4e0f-9019-bbe2ddb105b4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e1d237bb-8c74-4b99-ad83-a924d1b217d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_20b5e969-2d24-4878-afb5-0b92746981f6" xlink:href="nktr-20220630.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e1d237bb-8c74-4b99-ad83-a924d1b217d3" xlink:to="loc_nktr_SharePurchaseAgreementMember_20b5e969-2d24-4878-afb5-0b92746981f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_970a2fd9-01e4-47b5-91c3-03c2959cddd9" xlink:href="nktr-20220630.xsd#nktr_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_nktr_MilestoneAxis_970a2fd9-01e4-47b5-91c3-03c2959cddd9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_970a2fd9-01e4-47b5-91c3-03c2959cddd9_default" xlink:href="nktr-20220630.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nktr_MilestoneAxis_970a2fd9-01e4-47b5-91c3-03c2959cddd9" xlink:to="loc_nktr_MilestoneDomain_970a2fd9-01e4-47b5-91c3-03c2959cddd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_d7061206-dad6-4f93-ac02-b362c69cc0b5" xlink:href="nktr-20220630.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nktr_MilestoneAxis_970a2fd9-01e4-47b5-91c3-03c2959cddd9" xlink:to="loc_nktr_MilestoneDomain_d7061206-dad6-4f93-ac02-b362c69cc0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_4e3774f0-20b1-4b92-acc3-160f0e257a5a" xlink:href="nktr-20220630.xsd#nktr_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_d7061206-dad6-4f93-ac02-b362c69cc0b5" xlink:to="loc_nktr_MilestoneOneMember_4e3774f0-20b1-4b92-acc3-160f0e257a5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_af8a1b19-a19f-46d2-86ab-179b8f4f2d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_af8a1b19-a19f-46d2-86ab-179b8f4f2d3f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_af8a1b19-a19f-46d2-86ab-179b8f4f2d3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_af8a1b19-a19f-46d2-86ab-179b8f4f2d3f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_af8a1b19-a19f-46d2-86ab-179b8f4f2d3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b3a13eb6-6271-4487-be1b-661f6d22a709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_af8a1b19-a19f-46d2-86ab-179b8f4f2d3f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b3a13eb6-6271-4487-be1b-661f6d22a709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_58d4fd57-e275-40c5-9a9d-e17031169a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b3a13eb6-6271-4487-be1b-661f6d22a709" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_58d4fd57-e275-40c5-9a9d-e17031169a97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6d07362b-c15c-47f9-b4bc-43da2fe6782b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_srt_CounterpartyNameAxis_6d07362b-c15c-47f9-b4bc-43da2fe6782b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d07362b-c15c-47f9-b4bc-43da2fe6782b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6d07362b-c15c-47f9-b4bc-43da2fe6782b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d07362b-c15c-47f9-b4bc-43da2fe6782b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_981dce2b-36af-4943-8e20-0cf7347c52c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6d07362b-c15c-47f9-b4bc-43da2fe6782b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_981dce2b-36af-4943-8e20-0cf7347c52c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_7e2a6597-c26a-40c6-b115-28fca277f812" xlink:href="nktr-20220630.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_981dce2b-36af-4943-8e20-0cf7347c52c0" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_7e2a6597-c26a-40c6-b115-28fca277f812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d197f467-6a4b-4f78-987d-5111e644225c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_srt_RangeAxis_d197f467-6a4b-4f78-987d-5111e644225c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d197f467-6a4b-4f78-987d-5111e644225c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d197f467-6a4b-4f78-987d-5111e644225c" xlink:to="loc_srt_RangeMember_d197f467-6a4b-4f78-987d-5111e644225c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1fbafbf6-d5cd-4d6a-b0e1-f7bb2a9bea9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d197f467-6a4b-4f78-987d-5111e644225c" xlink:to="loc_srt_RangeMember_1fbafbf6-d5cd-4d6a-b0e1-f7bb2a9bea9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87d809ce-58da-4b1f-83c2-efa5ba3013b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1fbafbf6-d5cd-4d6a-b0e1-f7bb2a9bea9d" xlink:to="loc_srt_MaximumMember_87d809ce-58da-4b1f-83c2-efa5ba3013b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails" xlink:type="extended" id="ic2a94d20d643403c9398ebf85d3ac632_RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2b9e23e7-e4ad-4f8a-b908-aa2e03c503b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_93ba0bcd-c48a-479d-90fe-40879c4563d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2b9e23e7-e4ad-4f8a-b908-aa2e03c503b4" xlink:to="loc_dei_EntityNumberOfEmployees_93ba0bcd-c48a-479d-90fe-40879c4563d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_8cbba79d-8794-4d52-a026-31d52125ffbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2b9e23e7-e4ad-4f8a-b908-aa2e03c503b4" xlink:to="loc_us-gaap_LossOnContractTermination_8cbba79d-8794-4d52-a026-31d52125ffbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_44fe3117-3b34-428f-a686-11e2fb21e713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2b9e23e7-e4ad-4f8a-b908-aa2e03c503b4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_44fe3117-3b34-428f-a686-11e2fb21e713" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6a62dec4-29af-413d-bbd8-fd08ba972cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2b9e23e7-e4ad-4f8a-b908-aa2e03c503b4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6a62dec4-29af-413d-bbd8-fd08ba972cd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6c86de8d-ace6-4e42-b40b-abeb4942d53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6a62dec4-29af-413d-bbd8-fd08ba972cd3" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6c86de8d-ace6-4e42-b40b-abeb4942d53b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6c86de8d-ace6-4e42-b40b-abeb4942d53b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6c86de8d-ace6-4e42-b40b-abeb4942d53b" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6c86de8d-ace6-4e42-b40b-abeb4942d53b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_17b1e929-c51a-47a0-9919-6ad5adfc042c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6c86de8d-ace6-4e42-b40b-abeb4942d53b" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_17b1e929-c51a-47a0-9919-6ad5adfc042c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_673b82e9-c9b1-4b3f-9a93-11f2c46008f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_17b1e929-c51a-47a0-9919-6ad5adfc042c" xlink:to="loc_us-gaap_EmployeeSeveranceMember_673b82e9-c9b1-4b3f-9a93-11f2c46008f1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails" xlink:type="extended" id="i907afbecd1c64688b172cdadd2e7efdf_RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6919eacb-c1b1-498a-883c-18d74a06f7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c8164c3-f0f2-46c6-9c60-b91f99d78199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6919eacb-c1b1-498a-883c-18d74a06f7c3" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c8164c3-f0f2-46c6-9c60-b91f99d78199" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6919eacb-c1b1-498a-883c-18d74a06f7c3" xlink:to="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_d44ec4ea-c124-48b7-8d45-b48b7c34cbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:to="loc_us-gaap_RestructuringReserve_d44ec4ea-c124-48b7-8d45-b48b7c34cbbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d3b90934-5c8e-43c2-ad52-e5c08577bf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:to="loc_us-gaap_RestructuringCharges_d3b90934-5c8e-43c2-ad52-e5c08577bf6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_d24c7c70-cbfb-4da0-ae38-e170a3131cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:to="loc_us-gaap_PaymentsForRestructuring_d24c7c70-cbfb-4da0-ae38-e170a3131cf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_0ab6e7d4-dc1e-47f4-860d-025d2ceefd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2d0acaee-99ac-4ea2-a5fd-f369ee124298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6919eacb-c1b1-498a-883c-18d74a06f7c3" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2d0acaee-99ac-4ea2-a5fd-f369ee124298" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_26b062b9-5d7f-4154-bffd-423998c6bbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2d0acaee-99ac-4ea2-a5fd-f369ee124298" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_26b062b9-5d7f-4154-bffd-423998c6bbc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_26b062b9-5d7f-4154-bffd-423998c6bbc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_26b062b9-5d7f-4154-bffd-423998c6bbc1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_26b062b9-5d7f-4154-bffd-423998c6bbc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0bc8550f-cc72-42d1-8acb-a18b5970bdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_26b062b9-5d7f-4154-bffd-423998c6bbc1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0bc8550f-cc72-42d1-8acb-a18b5970bdc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e1c9d471-f509-4494-a0fd-d4c225d18e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0bc8550f-cc72-42d1-8acb-a18b5970bdc1" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e1c9d471-f509-4494-a0fd-d4c225d18e92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember_2bba9c3a-a776-4553-896b-9a209e36be5b" xlink:href="nktr-20220630.xsd#nktr_EmployeeSeveranceWithNoServicePeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeSeveranceMember_e1c9d471-f509-4494-a0fd-d4c225d18e92" xlink:to="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember_2bba9c3a-a776-4553-896b-9a209e36be5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_dd8580ef-61a7-4272-823b-15b28b859cb6" xlink:href="nktr-20220630.xsd#nktr_EmployeeSeveranceWithServicePeriodRequirementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeSeveranceMember_e1c9d471-f509-4494-a0fd-d4c225d18e92" xlink:to="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_dd8580ef-61a7-4272-823b-15b28b859cb6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="extended" id="iff11260b90594ec1b62758c2874622d8_RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_5a33b87a-c2bf-4206-adbc-3a3095329583" xlink:href="nktr-20220630.xsd#nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:to="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_5a33b87a-c2bf-4206-adbc-3a3095329583" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_29df4b04-544b-469e-ad01-4bf77afd5665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_29df4b04-544b-469e-ad01-4bf77afd5665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_52b9dbec-76dc-448c-982b-86363cba6b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_52b9dbec-76dc-448c-982b-86363cba6b44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1383d2da-e3fa-4778-98f8-f72c4ef84684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:to="loc_us-gaap_AssetImpairmentCharges_1383d2da-e3fa-4778-98f8-f72c4ef84684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7817a0c5-efc2-420e-a9fd-98c2777586bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7817a0c5-efc2-420e-a9fd-98c2777586bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7817a0c5-efc2-420e-a9fd-98c2777586bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7817a0c5-efc2-420e-a9fd-98c2777586bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7817a0c5-efc2-420e-a9fd-98c2777586bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a39282b-3de7-491e-b0c1-ad2eecfb8f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7817a0c5-efc2-420e-a9fd-98c2777586bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a39282b-3de7-491e-b0c1-ad2eecfb8f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8e8c2846-9a53-4113-af50-17b760ad317e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a39282b-3de7-491e-b0c1-ad2eecfb8f43" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8e8c2846-9a53-4113-af50-17b760ad317e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b9160259-578f-4e86-8d9b-9ce5d6ef6075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b9160259-578f-4e86-8d9b-9ce5d6ef6075" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b9160259-578f-4e86-8d9b-9ce5d6ef6075_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b9160259-578f-4e86-8d9b-9ce5d6ef6075" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b9160259-578f-4e86-8d9b-9ce5d6ef6075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e6685993-ab2b-46b6-96c4-426f443c5597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b9160259-578f-4e86-8d9b-9ce5d6ef6075" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e6685993-ab2b-46b6-96c4-426f443c5597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember_ac1a79c0-dcf0-43d0-bbd1-a39677ba5892" xlink:href="nktr-20220630.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e6685993-ab2b-46b6-96c4-426f443c5597" xlink:to="loc_nktr_SubleasePropertyPlantAndEquipmentMember_ac1a79c0-dcf0-43d0-bbd1-a39677ba5892" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_e6636a11-9d91-4292-bb67-a6e07e9e3eb5" xlink:href="nktr-20220630.xsd#nktr_SubleaseOperatingLeaseRightOfUseAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e6685993-ab2b-46b6-96c4-426f443c5597" xlink:to="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_e6636a11-9d91-4292-bb67-a6e07e9e3eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_7d747a17-2d02-459e-beb7-9e739cce9330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_7d747a17-2d02-459e-beb7-9e739cce9330" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_7d747a17-2d02-459e-beb7-9e739cce9330_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7d747a17-2d02-459e-beb7-9e739cce9330" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_7d747a17-2d02-459e-beb7-9e739cce9330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d8b788cf-7d61-410b-b5b8-a2ce034b4320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7d747a17-2d02-459e-beb7-9e739cce9330" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d8b788cf-7d61-410b-b5b8-a2ce034b4320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_90037dd4-b2b4-4dfd-802e-fd3977051792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d8b788cf-7d61-410b-b5b8-a2ce034b4320" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_90037dd4-b2b4-4dfd-802e-fd3977051792" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_33e0d7fd-d6a8-4cda-89e1-3001bfee8d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_90037dd4-b2b4-4dfd-802e-fd3977051792" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_33e0d7fd-d6a8-4cda-89e1-3001bfee8d14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3dd3b324-bd27-4b9f-bdfc-db495dd755ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_90037dd4-b2b4-4dfd-802e-fd3977051792" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3dd3b324-bd27-4b9f-bdfc-db495dd755ba" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i132ce68425974d56a21297c6492bb53f_RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_177bca82-95b0-45f3-bbe2-eddea28d1063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2536e92e-66d2-4939-9f9b-842f847d8f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_177bca82-95b0-45f3-bbe2-eddea28d1063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2536e92e-66d2-4939-9f9b-842f847d8f59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a7344f35-71dc-4952-98ca-fc629d00ce45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_177bca82-95b0-45f3-bbe2-eddea28d1063" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a7344f35-71dc-4952-98ca-fc629d00ce45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_78946828-fd6b-4368-a61b-a29c44593016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_177bca82-95b0-45f3-bbe2-eddea28d1063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_78946828-fd6b-4368-a61b-a29c44593016" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ffc1184-12c0-4c60-9365-4a25bc40ef30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_177bca82-95b0-45f3-bbe2-eddea28d1063" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ffc1184-12c0-4c60-9365-4a25bc40ef30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22aa4972-b7c9-45f0-a6ed-02739216eba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ffc1184-12c0-4c60-9365-4a25bc40ef30" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22aa4972-b7c9-45f0-a6ed-02739216eba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22aa4972-b7c9-45f0-a6ed-02739216eba4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22aa4972-b7c9-45f0-a6ed-02739216eba4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22aa4972-b7c9-45f0-a6ed-02739216eba4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22aa4972-b7c9-45f0-a6ed-02739216eba4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember_5e064e8f-3676-4ddd-9121-1af045ff3009" xlink:href="nktr-20220630.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_nktr_BuildingAndLeaseholdImprovementsMember_5e064e8f-3676-4ddd-9121-1af045ff3009" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember_c7fcee66-4c7c-41a8-9415-96b1a671ad9b" xlink:href="nktr-20220630.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_nktr_LaboratoryEquipmentMember_c7fcee66-4c7c-41a8-9415-96b1a671ad9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerEquipmentAndSoftwareMember_a75653eb-a9b3-4a52-9d4f-e2e39e299573" xlink:href="nktr-20220630.xsd#nktr_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_nktr_ComputerEquipmentAndSoftwareMember_a75653eb-a9b3-4a52-9d4f-e2e39e299573" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_7f877244-0ade-4e1d-b65c-7b40fe844a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_us-gaap_EquipmentMember_7f877244-0ade-4e1d-b65c-7b40fe844a7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2e31d410-ce57-4298-b1f6-b69622518eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2e31d410-ce57-4298-b1f6-b69622518eeb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember_88d851b3-878d-4f6f-8b64-49a2df0a5de3" xlink:href="nktr-20220630.xsd#nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember_88d851b3-878d-4f6f-8b64-49a2df0a5de3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_616c1ed7-1263-42a5-bf93-9d592751ab2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_us-gaap_ConstructionInProgressMember_616c1ed7-1263-42a5-bf93-9d592751ab2e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i4669f52ad15c437697dd085c495c272d_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de69ea60-2db0-450e-8c4c-b98ba170ebf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b4daf8b4-e3b7-4a08-a15c-1eebfa773e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de69ea60-2db0-450e-8c4c-b98ba170ebf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b4daf8b4-e3b7-4a08-a15c-1eebfa773e34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d75cb61-9178-4428-916e-9ec0eadf785f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de69ea60-2db0-450e-8c4c-b98ba170ebf3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d75cb61-9178-4428-916e-9ec0eadf785f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1c1a3b52-54fd-4dc9-b1df-4834ead4de78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d75cb61-9178-4428-916e-9ec0eadf785f" xlink:to="loc_us-gaap_PlanNameAxis_1c1a3b52-54fd-4dc9-b1df-4834ead4de78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1c1a3b52-54fd-4dc9-b1df-4834ead4de78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1c1a3b52-54fd-4dc9-b1df-4834ead4de78" xlink:to="loc_us-gaap_PlanNameDomain_1c1a3b52-54fd-4dc9-b1df-4834ead4de78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6f6bd63d-99d2-4d24-9320-999a4b9aed77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1c1a3b52-54fd-4dc9-b1df-4834ead4de78" xlink:to="loc_us-gaap_PlanNameDomain_6f6bd63d-99d2-4d24-9320-999a4b9aed77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_85029996-f1f5-48be-881b-33e803beea7b" xlink:href="nktr-20220630.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6f6bd63d-99d2-4d24-9320-999a4b9aed77" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_85029996-f1f5-48be-881b-33e803beea7b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" id="i24952d4b7e03425eadc44644d67721b5_StockBasedCompensationStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_46ad7242-8132-4d1a-b635-6990b0f7859b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_edf160d5-8937-41a3-bfad-3e82c0f157c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_46ad7242-8132-4d1a-b635-6990b0f7859b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_edf160d5-8937-41a3-bfad-3e82c0f157c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_65a2752c-2a7b-4623-a2e7-e36638d6761a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_46ad7242-8132-4d1a-b635-6990b0f7859b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_65a2752c-2a7b-4623-a2e7-e36638d6761a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_810938c2-9ae3-4d13-86f2-72c865ba75bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_65a2752c-2a7b-4623-a2e7-e36638d6761a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_810938c2-9ae3-4d13-86f2-72c865ba75bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_810938c2-9ae3-4d13-86f2-72c865ba75bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_810938c2-9ae3-4d13-86f2-72c865ba75bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_810938c2-9ae3-4d13-86f2-72c865ba75bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_810938c2-9ae3-4d13-86f2-72c865ba75bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f5a1457c-0d24-45d1-8bf5-90f21ce4bc48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:to="loc_us-gaap_CostOfSalesMember_f5a1457c-0d24-45d1-8bf5-90f21ce4bc48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cc0602a3-5013-4bd9-b33c-dff8984c6b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cc0602a3-5013-4bd9-b33c-dff8984c6b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dc0e9ef4-0db8-4194-81ce-70691da4e84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dc0e9ef4-0db8-4194-81ce-70691da4e84e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_4630eb52-5175-4281-80fe-d460106824d9" xlink:href="nktr-20220630.xsd#nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:to="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_4630eb52-5175-4281-80fe-d460106824d9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#StockBasedCompensationActivityDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended" id="i43516139e86e48aabc190b6983b7a2a5_StockBasedCompensationActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a4e7d98a-5c5a-4eb5-a9e2-8bfc38cf89c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a4e7d98a-5c5a-4eb5-a9e2-8bfc38cf89c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6d5b627-f456-4db8-88fd-e328bdd73d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6d5b627-f456-4db8-88fd-e328bdd73d7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9f03465c-02b6-48b4-8a4e-323dae1c91bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9f03465c-02b6-48b4-8a4e-323dae1c91bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_42bf2e1c-82e1-4557-b722-98c0ae837126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_42bf2e1c-82e1-4557-b722-98c0ae837126" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c830e5f7-b974-4752-825a-0b8d0de76d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c830e5f7-b974-4752-825a-0b8d0de76d73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_afd3afc7-8e65-4908-aba6-ef0ebaf28d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_afd3afc7-8e65-4908-aba6-ef0ebaf28d5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f14d6077-4240-4932-b7d5-b1e59bfa72f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_afd3afc7-8e65-4908-aba6-ef0ebaf28d5b" xlink:to="loc_us-gaap_AwardTypeAxis_f14d6077-4240-4932-b7d5-b1e59bfa72f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f14d6077-4240-4932-b7d5-b1e59bfa72f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f14d6077-4240-4932-b7d5-b1e59bfa72f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f14d6077-4240-4932-b7d5-b1e59bfa72f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd76ace-7a26-44c5-83c8-d66876b5de82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f14d6077-4240-4932-b7d5-b1e59bfa72f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd76ace-7a26-44c5-83c8-d66876b5de82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_74886365-0670-4e2f-9127-32eb42002c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd76ace-7a26-44c5-83c8-d66876b5de82" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_74886365-0670-4e2f-9127-32eb42002c63" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>nktr-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:29a4b4dc-8cca-4a2c-8b00-1653a7b25685,g:4140688d-8727-4745-9ca5-400c87633167-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_64a88a83-b36c-4149-9a18-cc440a4dafd0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4a1bf66d-1a67-4fb9-b137-26da08f910c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b1a6094c-4ab7-41bc-bf9e-0baafaf6be0e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7694044b-e079-4e6c-8e3a-ec11df22b71f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a10dfe83-a1e1-46cf-abfe-e47a00ff020f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_f8c49cba-8c2c-4b50-a857-a247bb1e360d_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, credit loss expense (reversal)</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7362bce0-f29c-47fa-95be-e0b313518b8a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4fc3a23c-8654-404f-a81a-f109f6cfc338_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d28795c1-a00c-4778-ae66-ebd0293a5cf2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a5d74c52-395c-4b66-8ad0-bc44fa6a2da8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_086071a3-ec89-444e-91b8-c2cb6ccf22a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3eb8f123-5235-4a24-9b46-161c0d129efc_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of other property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9a99ed58-ff0b-43ad-b90e-7193b42fe42d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_c8c0bcc2-c7d2-40e9-80ff-0af0692c2672_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum maturity term for debt securities investment</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Investment Maximum Maturity Period</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt investment maximum maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:href="nktr-20220630.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:to="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8554e4c4-26c7-48c4-8aa6-b8a93ed1d2a9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e397d59d-f4fe-4ee8-ab13-f4adfe754d2c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_c91d6889-7441-4ca5-9f73-65abfd2044ef_terseLabel_en-US" xlink:label="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_label_en-US" xlink:label="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Operating Lease Right of Use Assets [Member]</link:label>
    <link:label id="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_documentation_en-US" xlink:label="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Operating Lease Right of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:href="nktr-20220630.xsd#nktr_SubleaseOperatingLeaseRightOfUseAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:to="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_419b3378-58ca-4fd8-9e4f-e6b06287701d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88a6c43c-1f0c-4693-96d0-1c7e9a99704e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_65c0f428-b207-4ccb-b6bb-e8459b5501e7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_51906662-df41-4e45-b066-612cc33ccacc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_9d01f8a8-b5db-4622-94f8-ada7fba829a3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_21647678-a624-4d74-91ae-f0c5da35f405_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_42baf1bc-487b-4b90-8e38-8d6fb89f2e3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_7fd1db01-2d90-46e9-9163-c88380f0198b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember_cc3b803c-c8bb-4ce2-af82-d5f364fe3bcb_terseLabel_en-US" xlink:label="lab_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property, plant and equipment, net</link:label>
    <link:label id="lab_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember_label_en-US" xlink:label="lab_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Property Plant And Equipment Excluding Construction In Progress [Member]</link:label>
    <link:label id="lab_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember_documentation_en-US" xlink:label="lab_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Property Plant And Equipment Excluding Construction In Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember" xlink:href="nktr-20220630.xsd#nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember" xlink:to="lab_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_440c4aa7-4234-4d80-a360-591349cc97ff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property, plant and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_d67a2707-5020-4199-9fc3-f38f9dac1260_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional development and regulatory milestones (up to)</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20220630.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_e9a0ed3c-8ba4-4620-be77-07eb8dcff484_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed55f06a-e2cf-463e-9070-c7c92b95e766_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_65152b5b-78d8-43b8-b412-e964aa2d3b34_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from development derivative liability</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_d9f5c052-807b-4e60-b7e7-2b7f9058d54c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_65f6f32e-4c63-4237-bd71-dd288a6d4fb4_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability balance as of March 31, 2022</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_72426b71-8797-4794-95a2-0de41e021f12_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability balance as of June 30, 2022</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneDomain_ffe157e9-efa3-4c62-9660-2163249ff8fd_terseLabel_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_label_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_documentation_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain" xlink:href="nktr-20220630.xsd#nktr_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneDomain" xlink:to="lab_nktr_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a6e457d2-4e32-472c-a20c-3ff9f4639f1c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 shares authorized; 187,405 shares and 185,468 shares outstanding at June 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c44aa5bc-b775-45f1-837a-bc196b68aa4f_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_eedffbd2-ac29-4e76-99f1-ff494e8395ba_terseLabel_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember" xlink:href="nktr-20220630.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyAndCompanyMember" xlink:to="lab_nktr_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_ead92e30-6cc3-47b8-8139-59eb9012eb92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d39efd7c-89a1-423f-9583-c92a03485e36_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4358450e-518f-43ac-a927-c49405cf32c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value, of RSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_07023901-5047-468f-85c6-7048e2b0dfae_terseLabel_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period required</link:label>
    <link:label id="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_label_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance With Service Period Requirement [Member]</link:label>
    <link:label id="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_documentation_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance With Service Period Requirement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:href="nktr-20220630.xsd#nktr_EmployeeSeveranceWithServicePeriodRequirementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:to="lab_nktr_EmployeeSeveranceWithServicePeriodRequirementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d461d007-a98e-4576-9975-708fb3b7a038_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d6b6f19d-d4e6-4bde-afa0-8ab68edaf952_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79e27462-0a68-4166-9311-7b5250bfb938_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OpdivoMember_88b1381d-d6a7-43cc-8198-c3e209f3a248_terseLabel_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo</link:label>
    <link:label id="lab_nktr_OpdivoMember_label_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo [Member]</link:label>
    <link:label id="lab_nktr_OpdivoMember_documentation_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember" xlink:href="nktr-20220630.xsd#nktr_OpdivoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoMember" xlink:to="lab_nktr_OpdivoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3fc53768-c1b1-42a3-b816-9f2af551ef11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c5be2b3e-a50f-4c9a-bb09-09bd374bb82d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SubleasePropertyPlantAndEquipmentMember_d2ba88cf-10ff-487d-bc09-f0be5c60024c_terseLabel_en-US" xlink:label="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_nktr_SubleasePropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Property, Plant And Equipment [Member]</link:label>
    <link:label id="lab_nktr_SubleasePropertyPlantAndEquipmentMember_documentation_en-US" xlink:label="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Property, Plant And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:href="nktr-20220630.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:to="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_f2a87d10-949a-462d-9bd9-2719403d467b_terseLabel_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</link:label>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_label_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability [Text Block]</link:label>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_documentation_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:href="nktr-20220630.xsd#nktr_DevelopmentDerivativeLiabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:to="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_36a9e8ff-6b9e-4bf4-a8ac-a61ec8d6c528_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c4fc7f1-8a72-4944-ab06-188bab928b94_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4b2f2ed-014b-44a1-bf60-7c3800062523_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_758694c5-d859-48cf-ab05-7da237612bc7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_e48596f3-ae25-4a94-b8d8-43576c7eaebe_terseLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ac13e84b-4758-4c84-b8ef-cf883ef204ba_totalLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Restricted Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, restricted cash, cash equivalents, and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="nktr-20220630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_7d85fbc6-8a31-4839-a097-e09350b0b11b_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums (discounts), net and other non-cash transactions</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3b4e18da-8067-481c-b497-22c7c0fb8010_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_49a15e82-46c4-4e75-8712-a2b9a299cd45_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_916161be-8069-48d3-8404-c93fb6c4fcc9_terseLabel_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:href="nktr-20220630.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:to="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f7b47cab-83bf-4aaa-92e0-60bc3ce7176d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_20ececd1-2417-4568-8593-5b967e629c6b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_32c14500-4384-4220-b2de-1128baacf901_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_label_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:href="nktr-20220630.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:to="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_31994b5c-196f-4f82-b79a-5effedb2834b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ae276cb0-b5c6-4987-806b-4fec2224e387_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_424d0ca1-996a-4582-b6a7-9237b75ef946_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ffabd073-777d-4850-817b-1cda9b1f62f0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c1f4982a-d306-4e22-85ec-ceefc5f870aa_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_39c8669b-1da4-492c-aa94-ef4bca2bfc57_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_8896b919-0e5e-4469-a9df-03c4c860791a_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:href="nktr-20220630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5b83f28e-d91f-45f2-98e5-e4678d86c2a8_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4e0da039-bf31-4f4b-8b47-5d041977f184_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6ddb90ca-86f9-499c-bbdb-e69f2c44bcf3_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_9cd72f9a-43d6-40ff-ba0b-01816407c0cf_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Phase Two Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:href="nktr-20220630.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b12e783f-44a3-499c-bab8-559237814ad2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_58eaff53-a39c-4dfd-b7ac-05c7a8f7786c_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b74cece9-d623-4284-b090-75d9c77b02f5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c88f96cc-bbf7-4cc6-8eed-1014e0506ad8_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0ce14496-c1d1-434d-8937-b6354cff73c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b6b538cc-de20-411c-ab88-e586bef9de42_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_583fc63c-ceb3-4c89-ad4c-53f5def1d5b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_9e2e98c9-2c42-4fe4-a6e7-07c84094e173_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2a77153c-3f87-42a2-a7d9-0b802c51a471_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_565b9d29-f180-48a2-b0b1-c38ede39c5a0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_c48e1709-3944-44d4-bd5c-822e59988440_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing production costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Production Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in production costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts" xlink:href="nktr-20220630.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInProductionCosts" xlink:to="lab_nktr_PercentageOfSharingInProductionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_cd4d10bf-d75a-4944-964c-d36a5abcc812_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_f89389eb-22e0-4663-9852-2c7a3ad95bd0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_3059e537-ff4d-49fb-aeab-f17fcd1733b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_f8a6607e-094b-4824-b73f-f9430f932b72_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment expense for facilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_66e81e26-8280-4fe6-98ec-27a1032d408c_negatedTerseLabel_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized transaction costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_label_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities On Sale Of Future Royalties Unamortized Transaction Costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_documentation_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities On Sale Of Future Royalties Unamortized Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:href="nktr-20220630.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:to="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_02cbf0c4-8d4a-4342-996e-1959db7e90fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d29897db-420d-4e65-90ad-852cd861fa02_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_ea3db9fb-eb0c-49a3-bf89-a6e0098031a8_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced under certain conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received Under Certain Conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received under certain conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:href="nktr-20220630.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7bc01a39-1ceb-4115-bc2a-c2d5e7f81a6a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OtherPartnerMember_06e2e98d-bbae-49f4-9164-bb6226037709_terseLabel_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_label_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner [Member]</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_documentation_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember" xlink:href="nktr-20220630.xsd#nktr_OtherPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OtherPartnerMember" xlink:to="lab_nktr_OtherPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_0520c538-440a-4db7-8c5c-43dd816890c7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d3e8b0f3-689e-4a84-b685-aec8ecf943df_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_4e97cf38-e28e-4134-891a-000c06541f87_negatedLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_ff77cf4d-3811-41f3-97ba-aaf4a4ac89ff_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash royalty revenue related to sale future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20220630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5a54ae94-4f10-4cd4-b704-d729f58d9d1f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_15b4ff87-32c2-4237-842f-6032effb6ac9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e041a4b0-0dd3-43d0-9f61-da50338a64c0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_771b2e40-7ee4-4e3d-8318-6e57ab878a0d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_afac7c61-915d-4651-a220-32b0f468c2bf_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_748e475f-e3be-4f07-a355-5215f89c4fc1_terseLabel_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_label_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investment Maturity Period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:href="nktr-20220630.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:to="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4bd9995f-bcea-4b10-b4b1-bb14a95d70b1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b27db05e-2021-46b1-aad2-63920d4680e0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_70111c95-1066-42b5-b6d3-0c914a50fc5e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9a23c731-d5b3-4d12-b1b0-c8ca0ec486fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_8755d794-958f-4050-a126-fd4cd0ab32cb_terseLabel_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_label_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</link:label>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_documentation_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:href="nktr-20220630.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:to="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_8a5a0ee3-e3c3-4b2c-9368-9f7ab1c078cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_a7168509-9c0e-4781-adf3-33207ee52b18_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_7fef086f-06da-445a-a64a-56503242a533_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed funding (up to)</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:href="nktr-20220630.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:to="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_87061f48-5b0c-421e-94d6-f8b2fae23391_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nktr-20220630.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_8e843e3e-2b87-4f7d-b526-b2fa00a97e17_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total severance and other termination benefits, at fair value</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_4a9857a9-6623-444d-8ef4-c63215568777_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_e44d9862-182b-4c6d-8fe6-031e5074911f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_259db01a-3675-4b33-91bb-78f01b4e92c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_b8bb3fe4-7b97-4293-9aa8-a4871d365942_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:href="nktr-20220630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_27b748b6-1273-48e1-b318-418ba4787de7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ded34dff-7d65-4482-ada6-ac53036b55df_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_ac889834-5b16-42a6-a213-64bcb0724ad1_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_a3c5c61d-2ac8-4e44-a635-e5ea7d81bb0b_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:href="nktr-20220630.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:to="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_04953a57-298f-4ba6-8ff6-43e26051916a_negatedLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liabilities related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_028e6984-b379-40d5-9bc1-39fa9d2d1eea_terseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liabilities related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_6c1c3bed-a63c-46d2-ade4-84c8082b051c_verboseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_label_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:href="nktr-20220630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a292c187-65a2-4b9f-9f34-89cc65b02b05_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_07101386-10bb-4a43-b996-454373b89581_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional payments for development milestones (up to)</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones" xlink:href="nktr-20220630.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestones" xlink:to="lab_nktr_PotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_562059b3-602f-4cd8-8ae8-d6591932801b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df1704af-7b9c-4498-9883-2169770d314f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ComputerEquipmentAndSoftwareMember_2d221ea3-9194-42bb-8275-1d66d262bea9_terseLabel_en-US" xlink:label="lab_nktr_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_nktr_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_nktr_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_nktr_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_nktr_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerEquipmentAndSoftwareMember" xlink:href="nktr-20220630.xsd#nktr_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ComputerEquipmentAndSoftwareMember" xlink:to="lab_nktr_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_f7036035-6c63-40ee-b4a7-11fca2faeb1c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db87bef5-a651-4d04-976f-a83a7cce4496_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5a7ac2b2-7dbe-44d7-8a15-249102b285dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_3ab2b40f-944c-4328-90f1-b85a1e1045e7_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_ca457ce6-6cf6-4737-8ade-76a4bcf7a983_totalLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties non current net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1e50b46f-8dc3-40ad-b47d-99ad79d0dd24_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ec85aee-56b5-4d52-a537-a7e9921db5f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1285b86e-b7d2-4be0-bf1d-55b85cef11c4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_db418949-3840-4e44-99e5-1a3b884daafa_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment and other costs of terminated program</link:label>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_4a2cda72-aa4f-45b3-8c06-2cfafd8fce1c_verboseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received From License Agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:href="nktr-20220630.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f74db5f2-b041-4068-8a86-34b36e7ce49e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9dd7e659-ac59-423d-a1ac-65e45ac0c8e7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_8360b7bd-dcc1-4a10-8325-1c2932dd80b9_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember" xlink:href="nktr-20220630.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCompanyMember" xlink:to="lab_nktr_BristolMyersSquibbCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_805bac89-31a4-48c6-92cc-1ba544e03129_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_98dfc31b-b8df-4f99-ac58-02d67f437747_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_4a473fb4-a08e-40af-b30a-154c3ae61b7b_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:href="nktr-20220630.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_24009cd4-be5c-4648-a7cf-23abd89e0cf5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c0108258-8eb1-47a7-ab6f-b1e27cf52060_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_90b3935c-b4a2-4400-8905-961b2625fd2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_34e7cbbc-5046-46fc-b28c-382ba6cb4caa_terseLabel_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember" xlink:href="nktr-20220630.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SharePurchaseAgreementMember" xlink:to="lab_nktr_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_e7f045cb-5197-4191-954d-2e9763ea3f1d_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_db27c213-08a2-472b-8dc4-3813cc6466a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_349d5fd8-eb2e-4985-8a42-10dc5702bd30_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_19150609-f3c5-4751-bfb4-3bb96c868ae2_terseLabel_en-US" xlink:label="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment and other costs of terminated program</link:label>
    <link:label id="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_label_en-US" xlink:label="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment And Other Costs Of Terminated Program [Member]</link:label>
    <link:label id="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_documentation_en-US" xlink:label="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment And Other Costs Of Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:href="nktr-20220630.xsd#nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:to="lab_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_b66bad48-cac9-4e86-a842-511de25dbb49_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_8a886548-8059-482a-b6c5-a7ee63397645_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and benefit expense</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_566810c0-0c7e-40c5-8de5-1551a4985aff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Portfolio of Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_40e52e38-cf6e-48fe-a676-cc791a7f41c5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5b618d88-2541-466a-adbe-0f18c3d91a39_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_33d9bbf8-aefb-41da-8183-7afb94fbc486_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_2f9a57a8-8194-41e9-8246-054f183a2567_negatedTerseLabel_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to RPI</link:label>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_label_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial Repayment Of Royalty Sale Proceeds</link:label>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_documentation_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial Repayment Of Royalty Sale Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:href="nktr-20220630.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:to="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar214Member_8f7f4ce3-5c93-4ffa-ab8e-69f76dd93bb5_terseLabel_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214</link:label>
    <link:label id="lab_nktr_Nektar214Member_label_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214 [Member]</link:label>
    <link:label id="lab_nktr_Nektar214Member_documentation_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member" xlink:href="nktr-20220630.xsd#nktr_Nektar214Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar214Member" xlink:to="lab_nktr_Nektar214Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_3b893eb8-ab3e-4753-856e-5d914b29360f_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Related to Sales of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_0a32f7b1-f9fc-42ab-985c-8c56ed29d0de_terseLabel_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_label_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Policy [Text Block]</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock" xlink:href="nktr-20220630.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationPolicyTextBlock" xlink:to="lab_nktr_OrganizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_06ded2ce-4934-4a88-bbdf-75536ca72db1_terseLabel_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember" xlink:href="nktr-20220630.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LaboratoryEquipmentMember" xlink:to="lab_nktr_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f38943a-3df1-472b-8be7-b87fc0cae9ff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_039b5703-eaff-4efd-b49d-0f0d8970a1bd_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7f3a0105-84c3-477d-8956-ab3deb93ed25_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_898ab5c4-36d9-4827-b455-b03357b562cd_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_cba4a96a-f47a-41d8-8d02-737f1bcd91b2_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:href="nktr-20220630.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_d146cbcc-cca4-4d9d-a87c-a9a23e569d85_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a3aa5233-ce05-4e82-a0ab-db5806a0aea8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_e82fc9f7-64aa-497a-b4df-1afd30a3c27c_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_label_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Consideration Received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_documentation_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived" xlink:href="nktr-20220630.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockConsiderationReceived" xlink:to="lab_nktr_SaleOfStockConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_1c7a89cb-3e33-43c1-ae6a-c99693413a38_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_a68c91e3-04f9-46c5-8fbb-82832de7fb45_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Other Costs of Terminated Program</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6fc05a32-934f-404f-b242-6ea0b75386bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7aa10e09-360d-4d52-9df3-68f47929cfba_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_c3ebed84-0b04-4af3-95dd-ccfde6159caf_terseLabel_en-US" xlink:label="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment and Operating lease right-of-use assets</link:label>
    <link:label id="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_label_en-US" xlink:label="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure</link:label>
    <link:label id="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_documentation_en-US" xlink:label="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:href="nktr-20220630.xsd#nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:to="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_11d29dcc-dc7c-47f8-9d0d-ccd5905c3772_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations of U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3805c277-4c40-4a50-b026-99d189405a8e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_b4f32175-662e-4913-bdbd-5dac355b8e70_terseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received upfront and milestone payment</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="nktr-20220630.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9fb91fd0-c067-43db-a201-e35816f3d3b2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PreferredStockShareDesignated_ba25c719-eca3-470e-b496-969bfc1dcb25_terseLabel_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated (in shares)</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_label_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated" xlink:href="nktr-20220630.xsd#nktr_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PreferredStockShareDesignated" xlink:to="lab_nktr_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_9a3ecc89-d6ef-425b-b391-b794a2743d2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_019787d8-38c4-4063-96c5-45af92bc0b9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_3e0d5808-c2bc-434d-a738-a70ebcd9f39e_terseLabel_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_label_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses Current</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:href="nktr-20220630.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:to="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9763ae55-a1ae-4428-8a39-fea21d3efea0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c24aca8d-2d9a-4029-88ad-831094fdf4f9_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_a33ce478-1ec4-4d7e-8481-08aa4b578faa_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0b912b23-1d83-4d1c-ac2c-ec0c1a5c7b50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0f2c9df0-41e3-46e6-af96-b567dfeeb8e1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6f47d7ed-958f-46e2-b1ca-fa7168f596e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_9f87acfc-f494-4ce7-9d21-1d89491f1bb6_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa4b95f1-7c24-4fbe-b439-6a792ea008db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_a77ab9d6-65c2-439a-96ef-2cbe3f4c30a2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_64daa5d9-89f7-4dd2-a8ed-036a5b0f06f1_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_78328ae5-2cc2-4762-80e2-21c9d59ad22d_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average maturity term for debt securities investment (or less)</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Investment Maturity Term</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt investment maturity date description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm" xlink:href="nktr-20220630.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaturityTerm" xlink:to="lab_nktr_DebtInvestmentMaturityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c6a3bf3e-4f1a-45a9-b3ee-398984c0b806_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b7bb4f3b-ddeb-4aed-8f2d-8f82a6da0237_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_8d9ee27a-f01c-4801-96db-189fd7910813_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment and other costs of terminated program</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_54dbb442-91de-415a-9518-3987a3c7f63e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_dfc98c2e-e9af-4653-93fe-40dd8118f67b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_647f0b98-598d-4130-9bad-fa331e03b2dd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6fc2a81f-2fde-4ed9-b1b5-2b723d0950f7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_5046d815-1cd1-414d-8c95-825d2318f680_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3173083e-d1f5-438a-8afb-38045f986261_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07bbffb3-ad3d-49f9-8ecb-53219f0f2a2b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86c86512-b1d1-4b01-9db8-021fd9a99a9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneAxis_b32bb83f-498c-4d2f-bcc8-5660b9622642_terseLabel_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_label_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_documentation_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis" xlink:href="nktr-20220630.xsd#nktr_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneAxis" xlink:to="lab_nktr_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_09bf0052-356a-496c-b914-1bcc096d398c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation matters, liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7b16c110-a3bd-44b8-8625-d157c861f05a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_df5ddb79-0b73-46f6-8a4c-7c96a075a3f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_adc4ac03-9a3c-47ae-b53a-e52dad4ed7b5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_00423a45-f0cf-4f49-b565-eae233ff8076_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_dbc2297e-df9a-4e52-8960-006fd0cc1756_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_98417885-6ed8-4a51-ba67-e943bcb19aeb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at June 30, 2022 or December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_d3a5569e-c0a4-4312-8d86-8bea65897d10_negatedLabel_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, net</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:href="nktr-20220630.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:to="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_5c6abbf6-9258-4382-a8f5-dce9352a876d_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties &#8211; ending balance</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_51a7eaf4-2717-45ed-b218-ae935e453d63_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_c1c5de35-57b9-4874-b52f-1d414979a94e_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination and other restructuring costs</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_bcd81acb-1b0e-4a42-bbbd-98e4c25aaa99_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_399caac3-7ef8-4def-aa8a-9febced181cd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_27542223-ad7f-4656-90e7-7576a30d4173_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4eafa7e8-886f-490c-828d-58a5c97bca24_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6a4063b-b47e-46b0-b3e4-d63b0c4159ce_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, excluding assessed tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_07dd96f7-98f0-48c2-8fb4-c10c9603709c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ce93edca-ff18-4c98-99dd-b3063185af1a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LegalMattersMember_03820dde-b4c2-4c92-8c76-fcef43653f0c_terseLabel_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_nktr_LegalMattersMember_label_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters [Member]</link:label>
    <link:label id="lab_nktr_LegalMattersMember_documentation_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember" xlink:href="nktr-20220630.xsd#nktr_LegalMattersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LegalMattersMember" xlink:to="lab_nktr_LegalMattersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c2e72faf-507c-4498-b696-bdc32c020b4c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e1c66bff-4149-4452-8991-05f232337f3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_fe74e757-52a0-476d-b543-74782d59988c_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Results of Bempegaldesleukin Program and Reorganization and Restructuring Plans</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_7ac613f5-8f85-4f8f-b3e6-91759efa3b5d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_17a5e198-30f3-439e-8d1a-c33148046c70_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_49108def-b5c2-4a22-80e0-f9a8650143dd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_44b5f279-cabd-4897-8bf9-b3467b3edc69_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c4bafa7-4dbd-4726-a4b2-d8bb971449d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5f92714f-9336-4d1e-95c7-2eecde1c20e8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a27bcbd6-269d-4903-8140-b9d889190741_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_29451688-0cdd-4fc2-97d4-9c5d400cc786_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2fb84775-3a05-4c4c-8df4-47c54c9535b9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_06578c03-d146-4aea-9ed7-cc79dbaaea42_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_776d2341-7636-45bf-8ce5-2c7647e2943c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_de364d58-92de-4cbc-97d3-3e7608d38af9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_cbedbb12-57a5-4a26-9d18-4384c4b86d59_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f5f049da-a1c3-44ba-bcaf-1278c8dbf350_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_54798355-fa19-496d-9706-058501b4a3c6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_eef80348-49ea-4a64-8050-55e1951ff980_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_841a0713-03b0-4149-b645-1d433fa06743_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_90c58978-62b8-4a77-affc-b081c71f64dc_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c54e20f5-0b75-4894-acd1-f8334cf8ef4a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_c44a232c-5e3c-4819-8e43-dee91cad028f_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:href="nktr-20220630.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:to="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7676d309-952f-452a-9467-d76dc208abcf_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_fd22eec1-6f6f-4910-8f7e-2b2019432e04_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_70182bc0-4e20-4b06-a712-93a2ac7fcac0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8ed3cc41-bfff-4606-9fd3-b06580c40ee1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from SFJ</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_90653f4f-df3b-4c1f-bb1e-6106ec929a20_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2ff629ce-8764-439e-9d64-cbe9b44c42fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_48aa250c-1bbf-4a94-917c-3d034815c3d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_bb4b918f-ce19-4239-8e2f-09b8af8b98fd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f694d825-94ae-4624-a017-27069002c711_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b0f0ae30-4256-4558-9379-1a00ae1e7d4c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_13404b77-30a8-4b12-9c94-260c6c1d1fb1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d6291206-4c8e-4947-bb0c-69dda9266c08_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember_aeb462bc-c11c-41c6-b3d8-db9e62e14d94_terseLabel_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No service period</link:label>
    <link:label id="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember_label_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance With No Service Period [Member]</link:label>
    <link:label id="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember_documentation_en-US" xlink:label="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance With No Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:href="nktr-20220630.xsd#nktr_EmployeeSeveranceWithNoServicePeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:to="lab_nktr_EmployeeSeveranceWithNoServicePeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_e16e14e7-eb00-426f-8e08-92904f18189a_terseLabel_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_label_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals [Member]</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_documentation_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember" xlink:href="nktr-20220630.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SFJPharmaceuticalsMember" xlink:to="lab_nktr_SFJPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_b643fab0-d75b-4cf8-9f0b-236a1168e4a5_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar's</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_deaf5c42-f513-4170-9163-513339e2bb88_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_9844ece4-0f6f-4153-a782-98b077d0905e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e94f8305-96a8-4032-8d02-715477a52061_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6865f1bf-4951-4c0e-91c0-93821a2d3387_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_957926a9-a9c8-49af-b9d6-98eec802ed9a_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_13d1a52d-2d61-49a7-90f7-9ef3b9329537_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payments (up to)</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Amount</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:href="nktr-20220630.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_2b3a1a7b-24db-4d3c-a8ce-76767d16554a_terseLabel_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and leasehold improvements</link:label>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Leasehold Improvements [Member]</link:label>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Leasehold Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember" xlink:href="nktr-20220630.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BuildingAndLeaseholdImprovementsMember" xlink:to="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_91c0f79c-9b78-4790-b3c2-c8ee07136aa6_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8816b094-38e1-4099-8431-9c800d7a184b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_68b9bfd8-e29f-4e15-99e7-78d945f2f77c_terseLabel_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty monetization proceeds</link:label>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_label_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetization Proceeds</link:label>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_documentation_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetization Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds" xlink:href="nktr-20220630.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltyMonetizationProceeds" xlink:to="lab_nktr_RoyaltyMonetizationProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_be6e950e-1809-4497-b6b6-0337dfd28326_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_d9df47fc-d4a4-4c52-afad-2278e4dec28e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_62a8de81-a4fe-4443-a63b-fdfc693c13fa_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_797780f5-e9ec-482f-a3ae-8fa4ecfcd4a5_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:href="nktr-20220630.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_364add1e-06a7-437a-af78-0bcff51c3252_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_44f646d8-84ec-4667-93d3-20c8acf7fae0_terseLabel_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Performance Incentive Plan</link:label>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_label_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Performance Incentive Plan [Member]</link:label>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_documentation_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Performance Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:href="nktr-20220630.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:to="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ecb6edef-2eda-4ed7-b5f0-4358a5d0ef23_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyMember_c62a2100-8f62-48ee-8f28-03b5efba4fc7_terseLabel_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_nktr_EliLillyMember_label_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_nktr_EliLillyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember" xlink:href="nktr-20220630.xsd#nktr_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyMember" xlink:to="lab_nktr_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_d54342c1-2c92-4012-8846-77a58e1acbf2_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nktr-20220630.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_19ca5f02-2eb4-4e01-b3cd-921f2606b2e5_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2963ef29-4e33-4455-960a-2a66079e3188_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ab2fe12a-f5c2-49fa-aff0-1bddca844b43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_05a21d90-2c0d-46fa-a644-55872c0ca209_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7ff420de-f4c1-4fcb-9339-c58bf981a548_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ecafe179-2e99-4419-ae8b-a856f952ccdc_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_13834757-0b7e-44dd-b0c5-ea2ecb34cff8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_60687cd5-b09f-43c0-af18-d804468dca7f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_2c1595bc-4d1a-4d7f-aedf-d097d8613c08_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced if conditions occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received If Conditions Occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received, if conditions occur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:href="nktr-20220630.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_e22294ee-de06-4fc7-b4d0-a43c586bd4c0_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_a4674e57-6882-4b6b-b76a-df779dea9ba0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1c52692d-758b-4046-aa31-d08f567a7aa5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5bd0fe66-de28-430f-b70e-ff2ef9fd0217_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneOneMember_b36175ea-d60f-4303-a5f6-99b4af22328c_terseLabel_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_label_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_documentation_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember" xlink:href="nktr-20220630.xsd#nktr_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneOneMember" xlink:to="lab_nktr_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dfa10523-0868-40ca-91e7-e22cf716e9c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac34a575-a90e-42bc-9948-f2df3767a19e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_92bfecf5-7d4d-4725-8ee5-ee4dab0637a6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_565834b9-51c8-4fee-8639-da8b8d89a387_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_9f32a686-18f7-48bd-8614-00bb3c1b6865_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_f8f980f6-8453-42a1-88a4-9f214b91772e_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7ad92e70-545c-44a0-98ac-cf36fc99bd2a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_4493fb03-2ec3-4a98-9861-8af3fd63f594_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:href="nktr-20220630.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_c9047b2a-f28b-41e7-97ff-501ff34519d8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_db6a27e3-db2a-427e-8cb0-654ed76eafe7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ecedf539-b26b-4a1f-b8df-007dfdfb8219_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_8c331d4f-bc0d-41d8-a295-1a9fdd850480_terseLabel_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties liability discount rate</link:label>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_label_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Liability, Measurement Input</link:label>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput" xlink:href="nktr-20220630.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltiesLiabilityMeasurementInput" xlink:to="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_79d9a745-30f2-41ea-b3f9-beb491e09fa4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4907ee81-5768-4ddc-ae91-32b3e72c3c1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_db68b754-6dce-4f49-ab6e-7b6b5fce1ee2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_41933b5b-8f07-4818-9969-9f9b37b181d3_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ReimbursementOfExpenses_2dcb396a-de30-480f-a5cc-ab361ce214a4_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_label_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_documentation_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses" xlink:href="nktr-20220630.xsd#nktr_ReimbursementOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementOfExpenses" xlink:to="lab_nktr_ReimbursementOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d1991a58-5d09-46d5-9738-86d94c9edb7a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_275dd582-b64b-4dc9-bf6f-c70963a156fa_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_ed8f7eae-17bc-46c8-ab1a-c55cf26900bb_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_396c29b5-3405-466e-b2bb-92aaf8f80d92_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures, and other</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_4daa7a0e-a8e3-4e38-b891-87d81a44dab6_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:href="nktr-20220630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4ecd9baf-4217-45c4-8167-547fca957782_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1454a322-d6bd-4cac-88c6-3ca73e624a81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_397b2c9c-113d-475a-bc13-785fa9e5f2bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_80eac3f6-aa0f-4a05-8ef5-de7b760ca61e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e9c92cf-0202-41d6-a870-61fe93e24629_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1fc7b5d3-9cb3-44e2-92c3-177b3b9b9c41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring, Impairment and Other Costs of Terminated Program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9539db05-eb39-46af-8989-06bad09157ed_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8aa757f2-bd3c-49bf-933f-a529a4a18a41_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_67be4c24-4dfd-408c-86ac-fead659cd505_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c36d71c6-d1ab-4552-8973-a2410a9ea108_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9943020c-37c0-44ad-ae64-985878a77985_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17b56783-9de0-45f2-a288-44be397569f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7c753799-04a4-455a-be7b-1c34ecdb6597_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_391f00f2-181c-46b0-8cae-6a487afaa5b8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_75dea3d2-5160-4a54-bd25-2985342e5ec6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1f140ea5-6117-4f43-9418-18f250c125f5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_51fbe039-0322-46d0-8570-7d5c29e325d6_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_31ab39e9-773b-451f-bd3f-fce29d998543_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d5064e3-eb20-4b7c-8c1e-160851c098be_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d43ef783-d591-4f1c-a7bf-57d36bede81c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3b865ce9-3e9e-4f51-9dde-cc1f9ec6bf01_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_59598ba5-d6ef-4076-8d3c-446e4c9e5a52_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_f3830958-7415-4973-9c93-7e263622f493_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock_d7f3c860-37aa-482b-ba42-b2b809e52b5a_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock_label_en-US" xlink:label="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Purchase and Sale Agreement [Table Text Block]</link:label>
    <link:label id="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock_documentation_en-US" xlink:label="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Purchase and Sale Agreement [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:href="nktr-20220630.xsd#nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:to="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_cbe6fef0-8f9b-4e41-acc4-69b6469c9ff9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_c5212e40-ec07-46d3-bb8a-b617599790e4_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding phase 3 development costs on an indication by indication basis borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_label_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_documentation_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding Phase three development costs on an indication by indication basis borne.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:href="nktr-20220630.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:to="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_249fce7b-72c6-4f9d-b2e9-ff04871fe8ef_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b501e6a5-4365-422a-bfe9-8751b5bf4c86_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_80d2525c-b382-4028-b774-a0a83e83ca57_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c898dbe8-f280-4af2-bf63-115fcd69f8e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d98646ab-d346-45f2-9da9-35128a604379_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_5f7fdfd9-1067-470a-bb94-a2872d28d1e9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c1c320d3-b196-446c-87a4-868a028278ea_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06f846a0-b7d4-474a-a7a4-5b04851b96c8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8c2e3da-aa4c-4bb9-8e61-39b604bb9291_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_b2029e4b-d104-48a9-b11e-20a5e8ed91ef_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_cfead6aa-45f7-401a-a7c4-5ca68143fead_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f718746a-b863-48c3-9cb5-06315016b575_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c1b90220-1760-4b0c-9a52-0e18426e7089_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1db11705-06dc-4c9b-b3a1-21403e7c3b0f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f6567f8d-930d-4ed5-b5d4-6830c88c9f5c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Asset Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b81feb76-e588-4e3f-975d-260bd61faf2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_169a66cf-aa67-472d-8b91-a704a18ad86c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_5e135cfa-203b-44ae-8280-a35d27253fc7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0db72c32-8be5-4ab8-8de3-d98710be5dfa_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5da0154f-9901-409c-9d7e-c56256b16465_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar358Member_52e4489d-761d-436f-9316-ff92637a8e01_terseLabel_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:label id="lab_nktr_Nektar358Member_label_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358 [Member]</link:label>
    <link:label id="lab_nktr_Nektar358Member_documentation_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member" xlink:href="nktr-20220630.xsd#nktr_Nektar358Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar358Member" xlink:to="lab_nktr_Nektar358Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5f1e191e-eeec-472d-8790-aad255e5d04d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_fc4003ef-7e3e-45e6-9b6d-ed88111de755_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of right-of-use assets and property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_52bb2ea8-fc81-4e68-88a8-b0352b0bd64c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of right-of-use assets and property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e544b0c9-1601-4b61-acf6-65e325cf3a29_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_29f9d058-cae1-44f8-9b53-f93d7b014842_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2060c706-3764-4b6b-b0fd-f12fa320e767_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0b8c835f-f540-4477-89bd-c33849cc3886_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_34f9e1f1-c8f8-4514-8e49-452f356113cb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_94aa5949-7608-401f-a17c-d89aaf79de53_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset recognized in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_11df830c-cc20-4177-a37a-a5b08e189fc2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8f838669-a16d-457b-b77a-864349ac6920_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_f2fef1c9-fefa-42d1-afa0-b238b491a7a3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce termination, percentage</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_b96b3067-1956-40fd-9313-1f7ba75906ea_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_eb6c4d95-2fa1-46f4-8583-dd88ef1054a9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>nktr-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:29a4b4dc-8cca-4a2c-8b00-1653a7b25685,g:4140688d-8727-4745-9ca5-400c87633167-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d76c093b-0f9d-4bbf-95fe-8d1c453f3df5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_DocumentType_d76c093b-0f9d-4bbf-95fe-8d1c453f3df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_bdfc4d0b-fdf5-4f5b-984b-3f6174d9501a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_DocumentQuarterlyReport_bdfc4d0b-fdf5-4f5b-984b-3f6174d9501a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_587251de-5717-40dc-8784-45704783df33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_DocumentPeriodEndDate_587251de-5717-40dc-8784-45704783df33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7e64df46-de5b-4acd-9701-71b632b7100e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_DocumentTransitionReport_7e64df46-de5b-4acd-9701-71b632b7100e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_45d5d4eb-289c-4345-9227-5387749f3bb1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityFileNumber_45d5d4eb-289c-4345-9227-5387749f3bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d5cffe59-2301-4947-828f-afe585829676" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityRegistrantName_d5cffe59-2301-4947-828f-afe585829676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_521695e5-5897-4bdc-8a19-b83a25f48c5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_521695e5-5897-4bdc-8a19-b83a25f48c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_91fffc74-48c3-42d8-85a6-37db57a628b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityTaxIdentificationNumber_91fffc74-48c3-42d8-85a6-37db57a628b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6ee66369-5cd1-4b6a-8351-b0c9c553abb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityAddressAddressLine1_6ee66369-5cd1-4b6a-8351-b0c9c553abb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_896db5e1-1005-4059-97a4-57e1b2efe985" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityAddressCityOrTown_896db5e1-1005-4059-97a4-57e1b2efe985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6ad4cde9-4e09-4764-8020-69b5e83b8dbe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityAddressStateOrProvince_6ad4cde9-4e09-4764-8020-69b5e83b8dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_49108257-33d3-4da4-a3e0-88b12b539197" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityAddressPostalZipCode_49108257-33d3-4da4-a3e0-88b12b539197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_90465588-7fc7-4e5f-8128-0ef6adf06afc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_CityAreaCode_90465588-7fc7-4e5f-8128-0ef6adf06afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3d25d839-3726-436f-9cd7-e69ceffed76b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_LocalPhoneNumber_3d25d839-3726-436f-9cd7-e69ceffed76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6f9c3c4d-65d4-422d-bd33-eea0cf5f196a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_Security12bTitle_6f9c3c4d-65d4-422d-bd33-eea0cf5f196a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7382aebb-7b84-4c6e-823c-9f85910bde9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_TradingSymbol_7382aebb-7b84-4c6e-823c-9f85910bde9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_19cbb589-1d39-4c50-94c6-b9c4f7cb5d97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_SecurityExchangeName_19cbb589-1d39-4c50-94c6-b9c4f7cb5d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e95452e3-597e-4ccd-95f9-7bc1ecc5ef88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityCurrentReportingStatus_e95452e3-597e-4ccd-95f9-7bc1ecc5ef88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6945c2b7-820e-4149-b45b-6763639688f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityInteractiveDataCurrent_6945c2b7-820e-4149-b45b-6763639688f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_78dbd382-93d7-41e5-9859-93def2a1bf72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityFilerCategory_78dbd382-93d7-41e5-9859-93def2a1bf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c1f9a1cd-b46a-4449-8361-24a78c23cfcb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntitySmallBusiness_c1f9a1cd-b46a-4449-8361-24a78c23cfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e7e7b117-42f4-41f7-b6ad-f78a1e00e8ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityEmergingGrowthCompany_e7e7b117-42f4-41f7-b6ad-f78a1e00e8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_97e40844-f00e-423a-83ed-b45f81a4df7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityShellCompany_97e40844-f00e-423a-83ed-b45f81a4df7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5f22e536-3438-4e95-970e-6b2ea3c4fab5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5f22e536-3438-4e95-970e-6b2ea3c4fab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cbdebccb-365e-4701-8f8f-ccbfbc981c69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_AmendmentFlag_cbdebccb-365e-4701-8f8f-ccbfbc981c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8b678dcc-39ce-490c-83de-c5d88ef7df70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_DocumentFiscalYearFocus_8b678dcc-39ce-490c-83de-c5d88ef7df70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fdd3d92f-8087-43f6-b508-a4939457b774" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fdd3d92f-8087-43f6-b508-a4939457b774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cd41045f-d2c6-4a09-877a-54b04ea9fa16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_EntityCentralIndexKey_cd41045f-d2c6-4a09-877a-54b04ea9fa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_791665a0-a91f-42fc-983e-6e254a8308c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37bebc29-c86f-480a-8532-5d8d8416b1f1" xlink:to="loc_dei_CurrentFiscalYearEndDate_791665a0-a91f-42fc-983e-6e254a8308c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b74c4dda-e733-4eed-865f-0a8025532f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_45904c11-c8ab-4f90-bf1a-7ba161dd702d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b74c4dda-e733-4eed-865f-0a8025532f92" xlink:to="loc_us-gaap_AssetsAbstract_45904c11-c8ab-4f90-bf1a-7ba161dd702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_234ca5a0-9ac2-4b38-b852-5dbf3d5865d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45904c11-c8ab-4f90-bf1a-7ba161dd702d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_234ca5a0-9ac2-4b38-b852-5dbf3d5865d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b963c9d0-d306-4200-a21a-9a0aaab8e6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_234ca5a0-9ac2-4b38-b852-5dbf3d5865d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b963c9d0-d306-4200-a21a-9a0aaab8e6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5dd733ba-aff0-4c63-a1b7-7d5026a8c3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_234ca5a0-9ac2-4b38-b852-5dbf3d5865d6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5dd733ba-aff0-4c63-a1b7-7d5026a8c3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b9c8e980-b9b8-4bd6-832e-202711493795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_234ca5a0-9ac2-4b38-b852-5dbf3d5865d6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b9c8e980-b9b8-4bd6-832e-202711493795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5b2e7317-a54e-4886-82c3-ec39b8476453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_234ca5a0-9ac2-4b38-b852-5dbf3d5865d6" xlink:to="loc_us-gaap_InventoryNet_5b2e7317-a54e-4886-82c3-ec39b8476453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5d8ff908-c379-40e7-93e6-9806294e5dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_234ca5a0-9ac2-4b38-b852-5dbf3d5865d6" xlink:to="loc_us-gaap_OtherAssetsCurrent_5d8ff908-c379-40e7-93e6-9806294e5dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5feacda1-03ac-44fd-aa4e-49d1fc4b9ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_234ca5a0-9ac2-4b38-b852-5dbf3d5865d6" xlink:to="loc_us-gaap_AssetsCurrent_5feacda1-03ac-44fd-aa4e-49d1fc4b9ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_17c41573-18e6-4805-be06-bd4df689cac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45904c11-c8ab-4f90-bf1a-7ba161dd702d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_17c41573-18e6-4805-be06-bd4df689cac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8af245b3-884c-46e6-b3e1-fc4e4eb0b765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45904c11-c8ab-4f90-bf1a-7ba161dd702d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8af245b3-884c-46e6-b3e1-fc4e4eb0b765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3c54b77b-7097-403c-ae61-196f9ba32a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45904c11-c8ab-4f90-bf1a-7ba161dd702d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3c54b77b-7097-403c-ae61-196f9ba32a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_be41001e-ac60-4dfb-99d0-c84ff32820f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45904c11-c8ab-4f90-bf1a-7ba161dd702d" xlink:to="loc_us-gaap_Goodwill_be41001e-ac60-4dfb-99d0-c84ff32820f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_24e68b0f-a054-4e1d-82e4-3aed12460382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45904c11-c8ab-4f90-bf1a-7ba161dd702d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_24e68b0f-a054-4e1d-82e4-3aed12460382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_917c5807-1380-452b-96e5-9f5063bed092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45904c11-c8ab-4f90-bf1a-7ba161dd702d" xlink:to="loc_us-gaap_Assets_917c5807-1380-452b-96e5-9f5063bed092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b74c4dda-e733-4eed-865f-0a8025532f92" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26733d01-ba50-4e96-af6c-20a92b535182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_26733d01-ba50-4e96-af6c-20a92b535182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4c1741ab-244e-4647-96a9-576b0182c6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26733d01-ba50-4e96-af6c-20a92b535182" xlink:to="loc_us-gaap_AccountsPayableCurrent_4c1741ab-244e-4647-96a9-576b0182c6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fce1ce4c-263e-4e9d-866a-4cd5be623e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26733d01-ba50-4e96-af6c-20a92b535182" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fce1ce4c-263e-4e9d-866a-4cd5be623e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_6d407649-3446-4236-bcc8-689667d9cd3d" xlink:href="nktr-20220630.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26733d01-ba50-4e96-af6c-20a92b535182" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_6d407649-3446-4236-bcc8-689667d9cd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9846a758-af37-495f-8c91-a841fe733219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26733d01-ba50-4e96-af6c-20a92b535182" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9846a758-af37-495f-8c91-a841fe733219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b9be7004-2c0c-4f8d-acbe-589554fea14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26733d01-ba50-4e96-af6c-20a92b535182" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b9be7004-2c0c-4f8d-acbe-589554fea14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aa9efebb-66fb-4a65-a826-34947e8412ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26733d01-ba50-4e96-af6c-20a92b535182" xlink:to="loc_us-gaap_LiabilitiesCurrent_aa9efebb-66fb-4a65-a826-34947e8412ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4968c581-9e73-4fa8-afec-3a19f5e3fb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4968c581-9e73-4fa8-afec-3a19f5e3fb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_65b996ff-1a13-4c60-a870-4547baa82da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_65b996ff-1a13-4c60-a870-4547baa82da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_5582715c-32a3-4fd2-9998-865014d09034" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_5582715c-32a3-4fd2-9998-865014d09034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f938cd4f-9efe-4ae7-82b1-2f2d3293fafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f938cd4f-9efe-4ae7-82b1-2f2d3293fafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e7d739fa-ded6-4bad-88a7-a182d0dd7fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:to="loc_us-gaap_Liabilities_e7d739fa-ded6-4bad-88a7-a182d0dd7fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5f3c1daf-2e31-4f82-92ad-9c71e2d13ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5f3c1daf-2e31-4f82-92ad-9c71e2d13ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_bd6194e5-f5b9-4923-af24-0645fb21b8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_bd6194e5-f5b9-4923-af24-0645fb21b8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8671e1aa-ad52-4c1b-bb11-b57b9f7bfb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd6194e5-f5b9-4923-af24-0645fb21b8dc" xlink:to="loc_us-gaap_PreferredStockValue_8671e1aa-ad52-4c1b-bb11-b57b9f7bfb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a482f7c9-f089-4572-a0ea-71d81cd2264f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd6194e5-f5b9-4923-af24-0645fb21b8dc" xlink:to="loc_us-gaap_CommonStockValue_a482f7c9-f089-4572-a0ea-71d81cd2264f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57737a6e-ae29-4afd-bf09-04059722edd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd6194e5-f5b9-4923-af24-0645fb21b8dc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57737a6e-ae29-4afd-bf09-04059722edd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53639cf4-9ea9-46b5-856b-c7c241b7d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd6194e5-f5b9-4923-af24-0645fb21b8dc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53639cf4-9ea9-46b5-856b-c7c241b7d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2661feb1-9a33-49de-bdde-66ef80cb0c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd6194e5-f5b9-4923-af24-0645fb21b8dc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2661feb1-9a33-49de-bdde-66ef80cb0c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_274fb1fb-8fe2-4cc3-bcd7-3c3b9e655386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bd6194e5-f5b9-4923-af24-0645fb21b8dc" xlink:to="loc_us-gaap_StockholdersEquity_274fb1fb-8fe2-4cc3-bcd7-3c3b9e655386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bd3bbd88-286d-46e9-9179-57d8bce5cb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5eebabe-8902-46e4-bdb0-11650a23c0e0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_bd3bbd88-286d-46e9-9179-57d8bce5cb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_034fb7e6-59f1-483b-baee-9d0d68f81af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6dc31056-92de-40a6-bf28-2d93918a4775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_034fb7e6-59f1-483b-baee-9d0d68f81af3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6dc31056-92de-40a6-bf28-2d93918a4775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_35ba5a3b-e777-4df2-aa1f-f9309cae5832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_034fb7e6-59f1-483b-baee-9d0d68f81af3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_35ba5a3b-e777-4df2-aa1f-f9309cae5832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated_51df2e02-cbf3-4cdd-bb9e-d010f8bfda6f" xlink:href="nktr-20220630.xsd#nktr_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_034fb7e6-59f1-483b-baee-9d0d68f81af3" xlink:to="loc_nktr_PreferredStockShareDesignated_51df2e02-cbf3-4cdd-bb9e-d010f8bfda6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cf9c898c-a588-415c-b6b4-c77e9f20c299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_034fb7e6-59f1-483b-baee-9d0d68f81af3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cf9c898c-a588-415c-b6b4-c77e9f20c299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4d469a17-5117-4d51-9980-4a9c443133d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_034fb7e6-59f1-483b-baee-9d0d68f81af3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4d469a17-5117-4d51-9980-4a9c443133d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1d73f1ba-0c87-4318-b76e-21dce37218d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_034fb7e6-59f1-483b-baee-9d0d68f81af3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1d73f1ba-0c87-4318-b76e-21dce37218d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e3a088be-39e5-4e73-bcfe-bb250e0f0b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_034fb7e6-59f1-483b-baee-9d0d68f81af3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e3a088be-39e5-4e73-bcfe-bb250e0f0b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_be26f314-5d77-4b53-a910-3ef214eacba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e76fd5f8-b397-419a-94c5-0e307f98b3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be26f314-5d77-4b53-a910-3ef214eacba7" xlink:to="loc_us-gaap_StatementTable_e76fd5f8-b397-419a-94c5-0e307f98b3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_56d40ef7-a512-4051-b34f-80eaca8b5351" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e76fd5f8-b397-419a-94c5-0e307f98b3d8" xlink:to="loc_srt_ProductOrServiceAxis_56d40ef7-a512-4051-b34f-80eaca8b5351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddbdb341-e637-4837-ad65-bef88658d649" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_56d40ef7-a512-4051-b34f-80eaca8b5351" xlink:to="loc_srt_ProductsAndServicesDomain_ddbdb341-e637-4837-ad65-bef88658d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_523b6682-3a9c-4465-9abb-5dafb4bd3144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddbdb341-e637-4837-ad65-bef88658d649" xlink:to="loc_us-gaap_ProductMember_523b6682-3a9c-4465-9abb-5dafb4bd3144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_3e5b31cc-98e8-4cee-92e5-21f94c9cb93a" xlink:href="nktr-20220630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddbdb341-e637-4837-ad65-bef88658d649" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_3e5b31cc-98e8-4cee-92e5-21f94c9cb93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_5eba5618-4db3-4549-82ee-e3e0902c264e" xlink:href="nktr-20220630.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ddbdb341-e637-4837-ad65-bef88658d649" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_5eba5618-4db3-4549-82ee-e3e0902c264e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e76fd5f8-b397-419a-94c5-0e307f98b3d8" xlink:to="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a6153d7d-58b9-4871-833b-62bbb878dbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_RevenuesAbstract_a6153d7d-58b9-4871-833b-62bbb878dbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3dd9e5ef-a69d-4182-889c-ba9781fd1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a6153d7d-58b9-4871-833b-62bbb878dbfc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3dd9e5ef-a69d-4182-889c-ba9781fd1a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6b734a9c-6037-473f-8b8c-54a8747d6f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6b734a9c-6037-473f-8b8c-54a8747d6f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5ae04f0e-3e14-4486-8e97-0b280066d4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5ae04f0e-3e14-4486-8e97-0b280066d4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_81d73178-92c0-4c86-b8f7-d204fb919cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_81d73178-92c0-4c86-b8f7-d204fb919cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1d6b591e-b7d4-4d85-9131-c2875381d88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:to="loc_us-gaap_RestructuringCharges_1d6b591e-b7d4-4d85-9131-c2875381d88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8130992e-0bde-4837-9719-c03c135b0afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c6ce6628-4e37-42ef-a7dd-219c68891638" xlink:to="loc_us-gaap_CostsAndExpenses_8130992e-0bde-4837-9719-c03c135b0afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aa800cb9-4636-402a-a666-5ba4fb0cd3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_OperatingIncomeLoss_aa800cb9-4636-402a-a666-5ba4fb0cd3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_b62c6e8f-b8e1-4ca7-8da7-21af271b0926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_b62c6e8f-b8e1-4ca7-8da7-21af271b0926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_afc62b30-e65f-4dae-a35f-d3372a6eff1e" xlink:href="nktr-20220630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_afc62b30-e65f-4dae-a35f-d3372a6eff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3f2405c4-8bbe-4c38-b95a-fd060718c195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3f2405c4-8bbe-4c38-b95a-fd060718c195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d647f8d9-d3cb-40ca-bb25-4348955963e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9949a387-dead-47f3-be2e-abb8efe4dac5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d647f8d9-d3cb-40ca-bb25-4348955963e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b16d8849-b01c-4306-8529-0535ca288c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b16d8849-b01c-4306-8529-0535ca288c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_80c98453-72a3-4126-abb8-e84d6fb0b8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_80c98453-72a3-4126-abb8-e84d6fb0b8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_faf6d1d1-33bb-4cc7-a537-0178a639322a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_NetIncomeLoss_faf6d1d1-33bb-4cc7-a537-0178a639322a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e65ba605-0c63-4058-9587-12bd6d244812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_EarningsPerShareBasic_e65ba605-0c63-4058-9587-12bd6d244812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e425eb69-5a6b-4726-a880-b5441e686e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e425eb69-5a6b-4726-a880-b5441e686e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_616d8bca-102e-45fc-bb7e-d4ef71a8ac3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_616d8bca-102e-45fc-bb7e-d4ef71a8ac3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_473c162e-193f-4ee8-b8d7-344b651cd981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_620b285c-c288-4516-b9e8-7f356df3c1bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_473c162e-193f-4ee8-b8d7-344b651cd981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e63f6f74-b747-4a17-b83d-c74f3d28e1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c57a0c5c-dd0d-41dc-82a6-f02da462b7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e63f6f74-b747-4a17-b83d-c74f3d28e1c2" xlink:to="loc_us-gaap_NetIncomeLoss_c57a0c5c-dd0d-41dc-82a6-f02da462b7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f18ac960-e953-43e1-aa2d-d86c18f2573f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e63f6f74-b747-4a17-b83d-c74f3d28e1c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f18ac960-e953-43e1-aa2d-d86c18f2573f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_104e1225-7bb8-4b26-98c7-867fb294d57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f18ac960-e953-43e1-aa2d-d86c18f2573f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_104e1225-7bb8-4b26-98c7-867fb294d57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d377e637-015f-487c-9e41-1e4479737f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f18ac960-e953-43e1-aa2d-d86c18f2573f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d377e637-015f-487c-9e41-1e4479737f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2b20a127-908e-497f-bf49-b3318323e582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f18ac960-e953-43e1-aa2d-d86c18f2573f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2b20a127-908e-497f-bf49-b3318323e582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_98c3bb01-475a-48a2-8849-0af48356eabe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e63f6f74-b747-4a17-b83d-c74f3d28e1c2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_98c3bb01-475a-48a2-8849-0af48356eabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f0953b51-f324-4ae6-8439-82d5fb4c89d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_feb0bc43-375b-420f-8dae-642a837a6a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f0953b51-f324-4ae6-8439-82d5fb4c89d2" xlink:to="loc_us-gaap_StatementTable_feb0bc43-375b-420f-8dae-642a837a6a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_486e3ad3-3a0e-4067-a226-be9fb617ba36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_feb0bc43-375b-420f-8dae-642a837a6a5b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_486e3ad3-3a0e-4067-a226-be9fb617ba36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_486e3ad3-3a0e-4067-a226-be9fb617ba36" xlink:to="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bd3668e6-2fdd-451c-b100-703bbbd582f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:to="loc_us-gaap_CommonStockMember_bd3668e6-2fdd-451c-b100-703bbbd582f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_838de474-dd31-484a-9182-16b7190e594e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_838de474-dd31-484a-9182-16b7190e594e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9194b0d7-fb97-440c-9885-8805a5e77b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9194b0d7-fb97-440c-9885-8805a5e77b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_34d30b33-6690-4ce8-b2e9-bf714c8f4ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_614040e1-56fb-4f6a-8b41-c65b6b0d40cb" xlink:to="loc_us-gaap_RetainedEarningsMember_34d30b33-6690-4ce8-b2e9-bf714c8f4ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a79ee8c0-4f1c-41fb-a318-14e5fd693185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_feb0bc43-375b-420f-8dae-642a837a6a5b" xlink:to="loc_us-gaap_StatementLineItems_a79ee8c0-4f1c-41fb-a318-14e5fd693185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a79ee8c0-4f1c-41fb-a318-14e5fd693185" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_af7e7565-c0fa-4810-bdb4-1576814c3ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_SharesOutstanding_af7e7565-c0fa-4810-bdb4-1576814c3ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6826112b-cbb9-4b74-87aa-759d69d31e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_StockholdersEquity_6826112b-cbb9-4b74-87aa-759d69d31e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_82d2fe3c-7987-4783-838d-07b8896968cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_82d2fe3c-7987-4783-838d-07b8896968cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9762bfe8-6082-4d53-8b53-2dbeb7e7a5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9762bfe8-6082-4d53-8b53-2dbeb7e7a5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7d1d9a63-39a0-4f7f-83ed-b4ed4623f40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7d1d9a63-39a0-4f7f-83ed-b4ed4623f40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9e6204a2-a3a6-4c58-899d-de03117e6fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9e6204a2-a3a6-4c58-899d-de03117e6fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0bd17237-5b00-450e-a153-8f22d43a86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_SharesOutstanding_0bd17237-5b00-450e-a153-8f22d43a86c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a099a131-05e6-41d1-bc26-be5263039458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aac10a1b-fd72-4e36-b390-d8549d3504c6" xlink:to="loc_us-gaap_StockholdersEquity_a099a131-05e6-41d1-bc26-be5263039458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nktr-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_93410c16-5061-4a05-b706-639ec2498852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1fe58e9-e07b-4ed9-a8dd-6e34f28b7293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_93410c16-5061-4a05-b706-639ec2498852" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1fe58e9-e07b-4ed9-a8dd-6e34f28b7293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_17b2a9c2-a1a9-4375-be1c-aa7b8978bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1fe58e9-e07b-4ed9-a8dd-6e34f28b7293" xlink:to="loc_us-gaap_ProfitLoss_17b2a9c2-a1a9-4375-be1c-aa7b8978bfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1fe58e9-e07b-4ed9-a8dd-6e34f28b7293" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_638a7090-6a7e-495f-985a-43b51c85891a" xlink:href="nktr-20220630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_638a7090-6a7e-495f-985a-43b51c85891a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b53d7f31-de89-4117-8185-473f0504af3a" xlink:href="nktr-20220630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b53d7f31-de89-4117-8185-473f0504af3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_e2784cbd-365c-4ff0-b52f-c56a91e6ad8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_e2784cbd-365c-4ff0-b52f-c56a91e6ad8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_4688882b-acfc-4b1a-b182-8faee4ee1f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_4688882b-acfc-4b1a-b182-8faee4ee1f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0d00aec4-e5d6-492d-b926-66674413f28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0d00aec4-e5d6-492d-b926-66674413f28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_3ae551d3-1048-47ef-89c0-15b1b66a79ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:to="loc_us-gaap_DepreciationAndAmortization_3ae551d3-1048-47ef-89c0-15b1b66a79ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6b47a03f-5250-4f50-956d-c45e82903b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:to="loc_us-gaap_AssetImpairmentCharges_6b47a03f-5250-4f50-956d-c45e82903b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5b5b250b-7593-4416-9cc6-b5d482994bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5b5b250b-7593-4416-9cc6-b5d482994bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25261689-edf0-42a9-85c9-826a5239fced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f27d3dcb-1ca6-49f6-8f08-a2c6232657d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25261689-edf0-42a9-85c9-826a5239fced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f9ecbb2a-4580-497e-91ee-56fc2a50bd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25261689-edf0-42a9-85c9-826a5239fced" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f9ecbb2a-4580-497e-91ee-56fc2a50bd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_64bf6ee2-d996-405e-b87c-88a2e7205492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25261689-edf0-42a9-85c9-826a5239fced" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_64bf6ee2-d996-405e-b87c-88a2e7205492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_6820b869-028a-43a9-98ac-316089c2230f" xlink:href="nktr-20220630.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25261689-edf0-42a9-85c9-826a5239fced" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_6820b869-028a-43a9-98ac-316089c2230f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6e57f07a-2da3-48dd-b87c-fbd50628410e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25261689-edf0-42a9-85c9-826a5239fced" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6e57f07a-2da3-48dd-b87c-fbd50628410e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_493ed40c-4096-4899-8d8f-a80cdea7efbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25261689-edf0-42a9-85c9-826a5239fced" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_493ed40c-4096-4899-8d8f-a80cdea7efbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d33db8d9-5b9a-4786-9745-eaf78254e7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25261689-edf0-42a9-85c9-826a5239fced" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d33db8d9-5b9a-4786-9745-eaf78254e7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_00a08f5b-fb88-4c66-83a6-d3391f5e85ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25261689-edf0-42a9-85c9-826a5239fced" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_00a08f5b-fb88-4c66-83a6-d3391f5e85ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c6d6e0ee-e01f-4b7a-9913-11d330183bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1fe58e9-e07b-4ed9-a8dd-6e34f28b7293" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c6d6e0ee-e01f-4b7a-9913-11d330183bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d4199a2-cac0-4d78-bd53-4d96dfd04a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_93410c16-5061-4a05-b706-639ec2498852" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d4199a2-cac0-4d78-bd53-4d96dfd04a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1ec91b96-6a28-4b60-86f8-3d66ebb4a659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d4199a2-cac0-4d78-bd53-4d96dfd04a71" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1ec91b96-6a28-4b60-86f8-3d66ebb4a659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3b9d1e92-ea8e-42ca-9efa-2736ddc3107f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d4199a2-cac0-4d78-bd53-4d96dfd04a71" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3b9d1e92-ea8e-42ca-9efa-2736ddc3107f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8b3a44b4-c3ad-42bd-a3c7-71ab60f3cd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d4199a2-cac0-4d78-bd53-4d96dfd04a71" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8b3a44b4-c3ad-42bd-a3c7-71ab60f3cd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2c0f4cc0-b896-4e60-9eee-7bff871c7982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d4199a2-cac0-4d78-bd53-4d96dfd04a71" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2c0f4cc0-b896-4e60-9eee-7bff871c7982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe626fe5-0aa0-45ee-8f53-facf791cdb47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d4199a2-cac0-4d78-bd53-4d96dfd04a71" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe626fe5-0aa0-45ee-8f53-facf791cdb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e09ee876-aea8-4a75-8252-bcbe0d3b9ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_93410c16-5061-4a05-b706-639ec2498852" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e09ee876-aea8-4a75-8252-bcbe0d3b9ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_32050afe-2198-46ca-9859-148c85996e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e09ee876-aea8-4a75-8252-bcbe0d3b9ced" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_32050afe-2198-46ca-9859-148c85996e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_bc6bc2c4-2677-49af-8b84-cfcc53696209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e09ee876-aea8-4a75-8252-bcbe0d3b9ced" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_bc6bc2c4-2677-49af-8b84-cfcc53696209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7af5dc4d-e378-4f30-aeea-44e08271e4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e09ee876-aea8-4a75-8252-bcbe0d3b9ced" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7af5dc4d-e378-4f30-aeea-44e08271e4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02640a50-9f14-46fe-a96c-5560206c1100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_93410c16-5061-4a05-b706-639ec2498852" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02640a50-9f14-46fe-a96c-5560206c1100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be7649c5-9c49-4e27-afb1-2304dd310b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_93410c16-5061-4a05-b706-639ec2498852" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be7649c5-9c49-4e27-afb1-2304dd310b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb5d8dc5-02d0-49e5-9221-d46db807591a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_93410c16-5061-4a05-b706-639ec2498852" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb5d8dc5-02d0-49e5-9221-d46db807591a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0b4275c3-a349-4a1d-afd9-00f07e64cf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_93410c16-5061-4a05-b706-639ec2498852" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0b4275c3-a349-4a1d-afd9-00f07e64cf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_50ccc194-a70f-4831-9dc4-f9d8ccc3c106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_93410c16-5061-4a05-b706-639ec2498852" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_50ccc194-a70f-4831-9dc4-f9d8ccc3c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f080632d-545e-4595-9680-eff899e5c1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_50ccc194-a70f-4831-9dc4-f9d8ccc3c106" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f080632d-545e-4595-9680-eff899e5c1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20220630.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_548e2dfc-7603-4234-bc86-e70a2ef2c43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_31ebe230-8228-4a26-b0c4-cbcef502d59f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_548e2dfc-7603-4234-bc86-e70a2ef2c43f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_31ebe230-8228-4a26-b0c4-cbcef502d59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20220630.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4a3afe1-a887-47a2-a028-7878f74df25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock_3b276971-14c9-4da8-98e4-2fd4b7c76b5d" xlink:href="nktr-20220630.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4a3afe1-a887-47a2-a028-7878f74df25c" xlink:to="loc_nktr_OrganizationPolicyTextBlock_3b276971-14c9-4da8-98e4-2fd4b7c76b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_836f0948-2ca7-4561-855d-4e291c696e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4a3afe1-a887-47a2-a028-7878f74df25c" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_836f0948-2ca7-4561-855d-4e291c696e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1db79542-2fc9-4719-8132-6080f64f4a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4a3afe1-a887-47a2-a028-7878f74df25c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1db79542-2fc9-4719-8132-6080f64f4a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_9425ebd5-2049-41ca-b97d-ba3fc0b0dcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4a3afe1-a887-47a2-a028-7878f74df25c" xlink:to="loc_us-gaap_UseOfEstimates_9425ebd5-2049-41ca-b97d-ba3fc0b0dcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_35a5424f-c373-46b9-8768-731abf82b99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4a3afe1-a887-47a2-a028-7878f74df25c" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_35a5424f-c373-46b9-8768-731abf82b99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_fc89dc80-afc0-4ad3-b12e-ccd6f125de7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4a3afe1-a887-47a2-a028-7878f74df25c" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_fc89dc80-afc0-4ad3-b12e-ccd6f125de7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1a683871-9509-4960-96b2-5268ea2184a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4a3afe1-a887-47a2-a028-7878f74df25c" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1a683871-9509-4960-96b2-5268ea2184a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_3ef88fc3-23f1-40a7-8630-343c0fff4f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4a3afe1-a887-47a2-a028-7878f74df25c" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_3ef88fc3-23f1-40a7-8630-343c0fff4f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b41f3afc-79b5-4f68-a2c4-337c7645a9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_95f1c721-1ad7-4bff-851e-8c24c9b9a1ef" xlink:href="nktr-20220630.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b41f3afc-79b5-4f68-a2c4-337c7645a9d6" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_95f1c721-1ad7-4bff-851e-8c24c9b9a1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3453bcd6-d847-4dbc-92d1-2db4c5ac63a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_95f1c721-1ad7-4bff-851e-8c24c9b9a1ef" xlink:to="loc_srt_CounterpartyNameAxis_3453bcd6-d847-4dbc-92d1-2db4c5ac63a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8e25479-cbee-48c4-972e-c58b2f7d86f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3453bcd6-d847-4dbc-92d1-2db4c5ac63a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8e25479-cbee-48c4-972e-c58b2f7d86f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_4b007fc7-3f86-4c73-bd32-23866ce84955" xlink:href="nktr-20220630.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8e25479-cbee-48c4-972e-c58b2f7d86f9" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_4b007fc7-3f86-4c73-bd32-23866ce84955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_4a86ff36-70bb-4b8f-9d16-c09efcecde94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_95f1c721-1ad7-4bff-851e-8c24c9b9a1ef" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_4a86ff36-70bb-4b8f-9d16-c09efcecde94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_5ee943bc-542f-4b11-95fe-eedc6b5a4f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_4a86ff36-70bb-4b8f-9d16-c09efcecde94" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_5ee943bc-542f-4b11-95fe-eedc6b5a4f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_72b7c33e-725d-48bb-bdae-be611c1303e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5ee943bc-542f-4b11-95fe-eedc6b5a4f33" xlink:to="loc_us-gaap_EmployeeSeveranceMember_72b7c33e-725d-48bb-bdae-be611c1303e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:href="nktr-20220630.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_95f1c721-1ad7-4bff-851e-8c24c9b9a1ef" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_6263c496-a5b9-42f4-8330-ffaca2bc67d6" xlink:href="nktr-20220630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_6263c496-a5b9-42f4-8330-ffaca2bc67d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_e829daf2-5e2c-42b7-88ba-231897ebdaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_e829daf2-5e2c-42b7-88ba-231897ebdaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_18e414b0-0c31-4b0e-84d9-423793aaaad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_18e414b0-0c31-4b0e-84d9-423793aaaad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_ae968bb8-a53d-48a2-9c9b-3f899ff87535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_af55663d-fd8d-450e-9172-c7396f3799da" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_ae968bb8-a53d-48a2-9c9b-3f899ff87535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20220630.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_298488b3-28b7-4697-8786-94d5421897ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_e5e9e79e-a2e8-4fd7-984e-8078f833d1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_298488b3-28b7-4697-8786-94d5421897ea" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_e5e9e79e-a2e8-4fd7-984e-8078f833d1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20220630.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fe6c9c71-487f-4e8f-a4c8-f9921c418298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_9492b219-bc37-4ef0-aa4c-00ddd7bce507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fe6c9c71-487f-4e8f-a4c8-f9921c418298" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_9492b219-bc37-4ef0-aa4c-00ddd7bce507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_99bfa60a-1d47-4bbb-9d4d-33c6bc7d9687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fe6c9c71-487f-4e8f-a4c8-f9921c418298" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_99bfa60a-1d47-4bbb-9d4d-33c6bc7d9687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bf04f8f2-8271-490e-8d3d-cfdff3e1c13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_30b13606-749d-4de2-a732-1daaa4fe58d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bf04f8f2-8271-490e-8d3d-cfdff3e1c13a" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_30b13606-749d-4de2-a732-1daaa4fe58d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7ccb7749-6c10-4116-a511-bd931dda7b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_30b13606-749d-4de2-a732-1daaa4fe58d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7ccb7749-6c10-4116-a511-bd931dda7b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b38e832b-0c0a-46ed-afd1-be6ae6c2a34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_30b13606-749d-4de2-a732-1daaa4fe58d2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b38e832b-0c0a-46ed-afd1-be6ae6c2a34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ca21d2df-f48b-43bc-bcfe-701a40a9a37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_30b13606-749d-4de2-a732-1daaa4fe58d2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ca21d2df-f48b-43bc-bcfe-701a40a9a37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a688ac24-3d78-4cad-ad1d-1683fa156194" xlink:href="nktr-20220630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_30b13606-749d-4de2-a732-1daaa4fe58d2" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a688ac24-3d78-4cad-ad1d-1683fa156194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_89f89793-00c2-408b-aad7-674c6b69ca54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_70030f2c-38d5-4fa9-af6a-b16bfd7eea28" xlink:href="nktr-20220630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_89f89793-00c2-408b-aad7-674c6b69ca54" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_70030f2c-38d5-4fa9-af6a-b16bfd7eea28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_772cfae2-485e-4988-9f20-5838bfabe6a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_70030f2c-38d5-4fa9-af6a-b16bfd7eea28" xlink:to="loc_srt_RangeAxis_772cfae2-485e-4988-9f20-5838bfabe6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9264bcfc-5114-440c-ad36-6982890c170c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_772cfae2-485e-4988-9f20-5838bfabe6a1" xlink:to="loc_srt_RangeMember_9264bcfc-5114-440c-ad36-6982890c170c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_053684df-9296-4ece-be66-d1bae1cadfb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9264bcfc-5114-440c-ad36-6982890c170c" xlink:to="loc_srt_MinimumMember_053684df-9296-4ece-be66-d1bae1cadfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d6677b83-cd3a-4b97-9756-d4341055913d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9264bcfc-5114-440c-ad36-6982890c170c" xlink:to="loc_srt_MaximumMember_d6677b83-cd3a-4b97-9756-d4341055913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:href="nktr-20220630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_70030f2c-38d5-4fa9-af6a-b16bfd7eea28" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_c4cb8b31-cb56-47a7-bb52-17d81011db93" xlink:href="nktr-20220630.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_c4cb8b31-cb56-47a7-bb52-17d81011db93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_c7cb76ad-050c-4d40-ab3f-8a86b4cb9d43" xlink:href="nktr-20220630.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_c7cb76ad-050c-4d40-ab3f-8a86b4cb9d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_097ddac3-0786-42c8-a325-f6a0bfde4072" xlink:href="nktr-20220630.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_097ddac3-0786-42c8-a325-f6a0bfde4072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ad294611-2be4-43ee-bdc9-dd64cd6dda22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_4eb23963-42bb-4576-83a1-b29871191eb1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ad294611-2be4-43ee-bdc9-dd64cd6dda22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a3b856a3-b6b2-477f-9b6a-06c722fb1bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7735d5d5-7072-4516-904d-bac8cea4ad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a3b856a3-b6b2-477f-9b6a-06c722fb1bd0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7735d5d5-7072-4516-904d-bac8cea4ad6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3849f3bc-6603-4453-b342-91f740cc1edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7735d5d5-7072-4516-904d-bac8cea4ad6c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3849f3bc-6603-4453-b342-91f740cc1edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae971c25-6701-4cb4-80cf-e273ceaae0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3849f3bc-6603-4453-b342-91f740cc1edf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae971c25-6701-4cb4-80cf-e273ceaae0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7feb2c8e-d5dd-4738-8ac6-4c131d76a878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae971c25-6701-4cb4-80cf-e273ceaae0cd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7feb2c8e-d5dd-4738-8ac6-4c131d76a878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_442b0db5-41e7-4cc8-a620-368ac7172c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae971c25-6701-4cb4-80cf-e273ceaae0cd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_442b0db5-41e7-4cc8-a620-368ac7172c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_54373af7-eec2-4c00-b058-7639d7450dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7735d5d5-7072-4516-904d-bac8cea4ad6c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_54373af7-eec2-4c00-b058-7639d7450dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_54373af7-eec2-4c00-b058-7639d7450dc5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_60b1405b-cf00-43a7-a544-6aa2f9932cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_60b1405b-cf00-43a7-a544-6aa2f9932cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_47b1047a-4d14-448e-a5b7-3718f35ec67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:to="loc_us-gaap_CommercialPaperMember_47b1047a-4d14-448e-a5b7-3718f35ec67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_79559767-dbf1-4146-9433-d06837f90bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_79559767-dbf1-4146-9433-d06837f90bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_95522f26-deef-409b-933f-6e5b28ec85c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_95522f26-deef-409b-933f-6e5b28ec85c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_60b1a3e9-d329-4c02-bf19-d8e9bd291081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f617f26e-4562-4d0a-8500-d6af3e6fee3e" xlink:to="loc_us-gaap_CertificatesOfDepositMember_60b1a3e9-d329-4c02-bf19-d8e9bd291081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7735d5d5-7072-4516-904d-bac8cea4ad6c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e76db2b4-d513-4e76-b975-7a6257312aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e76db2b4-d513-4e76-b975-7a6257312aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab14796a-6ad3-4f6a-a9ae-09cddde8d885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab14796a-6ad3-4f6a-a9ae-09cddde8d885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8de3a813-8d92-483e-beb9-b2aa6d7ba7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8de3a813-8d92-483e-beb9-b2aa6d7ba7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45544daa-4f99-447f-bfde-7fb365b5b769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45544daa-4f99-447f-bfde-7fb365b5b769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4fbd56b9-71bc-4176-9f9b-b5712977d28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4fbd56b9-71bc-4176-9f9b-b5712977d28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_acdb9064-c8ff-4a32-ade8-88bc2b08737b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_us-gaap_Cash_acdb9064-c8ff-4a32-ade8-88bc2b08737b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f8f1944b-6c5b-491c-b136-cdfa2c9d2dc6" xlink:href="nktr-20220630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8cc548e-330b-4e82-a754-272399d71b38" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f8f1944b-6c5b-491c-b136-cdfa2c9d2dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20220630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_77ecab87-b36d-4f32-9940-08e1fbbc92a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_9f0b5a62-4e43-4269-ac84-aa49f68e873f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_77ecab87-b36d-4f32-9940-08e1fbbc92a2" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_9f0b5a62-4e43-4269-ac84-aa49f68e873f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20220630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9127b1e2-9ec3-41d7-a8e9-e6f50b4ddc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1b8c6ea0-87c7-45cc-8f39-e541edd85bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9127b1e2-9ec3-41d7-a8e9-e6f50b4ddc98" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1b8c6ea0-87c7-45cc-8f39-e541edd85bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9e680fcb-0c85-4096-be25-46c00561f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3d644f09-90f0-4bb4-97a0-97322f0e5334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9e680fcb-0c85-4096-be25-46c00561f5e4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3d644f09-90f0-4bb4-97a0-97322f0e5334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7a5d49a3-e240-473f-80fa-3f7855c8be6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9e680fcb-0c85-4096-be25-46c00561f5e4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7a5d49a3-e240-473f-80fa-3f7855c8be6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_79e476ee-2106-42cd-a5fe-274e92c2cb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9e680fcb-0c85-4096-be25-46c00561f5e4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_79e476ee-2106-42cd-a5fe-274e92c2cb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bf8cbabb-0124-4bbd-8164-e080e5339c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9e680fcb-0c85-4096-be25-46c00561f5e4" xlink:to="loc_us-gaap_InventoryNet_bf8cbabb-0124-4bbd-8164-e080e5339c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="simple" xlink:href="nktr-20220630.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_68969359-7b8e-421f-b299-6bb32fbcbec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentDerivativeLiabilityTextBlock_941ac621-2f3f-46ab-b4e4-fc3974a5b962" xlink:href="nktr-20220630.xsd#nktr_DevelopmentDerivativeLiabilityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_68969359-7b8e-421f-b299-6bb32fbcbec9" xlink:to="loc_nktr_DevelopmentDerivativeLiabilityTextBlock_941ac621-2f3f-46ab-b4e4-fc3974a5b962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="simple" xlink:href="nktr-20220630.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1d8ff598-c0bb-4ef9-a872-2333d6456b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_651ee979-dd2c-4480-aee1-27cef5477378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1d8ff598-c0bb-4ef9-a872-2333d6456b05" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_651ee979-dd2c-4480-aee1-27cef5477378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2f5d353d-3dbf-45e3-afac-8ff7cf1b58cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f891cfc-e6df-4b21-a7bb-5ce25b907f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2f5d353d-3dbf-45e3-afac-8ff7cf1b58cf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f891cfc-e6df-4b21-a7bb-5ce25b907f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_678e3520-e47f-4b6a-8bc4-36feb303193a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f891cfc-e6df-4b21-a7bb-5ce25b907f59" xlink:to="loc_srt_CounterpartyNameAxis_678e3520-e47f-4b6a-8bc4-36feb303193a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74a53083-9af1-417e-8704-3dabe4d7dbb5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_678e3520-e47f-4b6a-8bc4-36feb303193a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74a53083-9af1-417e-8704-3dabe4d7dbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_99e643bf-0321-4dad-b846-ea81f5989746" xlink:href="nktr-20220630.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74a53083-9af1-417e-8704-3dabe4d7dbb5" xlink:to="loc_nktr_SFJPharmaceuticalsMember_99e643bf-0321-4dad-b846-ea81f5989746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c209c2a-ef9f-4d95-8814-06680bbdda72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f891cfc-e6df-4b21-a7bb-5ce25b907f59" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c209c2a-ef9f-4d95-8814-06680bbdda72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_018c867e-ef8e-49a4-9146-7bbad070e5cd" xlink:href="nktr-20220630.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c209c2a-ef9f-4d95-8814-06680bbdda72" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_018c867e-ef8e-49a4-9146-7bbad070e5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_640769ba-6efc-46d6-baf0-3dd493a13cb6" xlink:href="nktr-20220630.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c209c2a-ef9f-4d95-8814-06680bbdda72" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_640769ba-6efc-46d6-baf0-3dd493a13cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_b4b1120f-948e-4976-bd33-8316b4388721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4c209c2a-ef9f-4d95-8814-06680bbdda72" xlink:to="loc_us-gaap_DerivativeLiabilities_b4b1120f-948e-4976-bd33-8316b4388721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fe56b7df-313a-4e01-bb66-7f4bd14be7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca7c530-d56c-4354-ad02-de82b9a99119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fe56b7df-313a-4e01-bb66-7f4bd14be7c8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca7c530-d56c-4354-ad02-de82b9a99119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_dbad52fe-5af8-43ea-ac21-7c79930078ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca7c530-d56c-4354-ad02-de82b9a99119" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_dbad52fe-5af8-43ea-ac21-7c79930078ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_de885275-5d39-42d6-bbaf-8462053f3544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_dbad52fe-5af8-43ea-ac21-7c79930078ba" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_de885275-5d39-42d6-bbaf-8462053f3544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_ddb70e75-d665-4e5e-9585-c759af9a112d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_de885275-5d39-42d6-bbaf-8462053f3544" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_ddb70e75-d665-4e5e-9585-c759af9a112d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a520373-ff77-4942-b209-5239eaa51e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca7c530-d56c-4354-ad02-de82b9a99119" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a520373-ff77-4942-b209-5239eaa51e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5124967-83bf-4e6a-84cb-f9695c987950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a520373-ff77-4942-b209-5239eaa51e17" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5124967-83bf-4e6a-84cb-f9695c987950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bcdb6918-e857-4803-89a3-454d45f3f63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5124967-83bf-4e6a-84cb-f9695c987950" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bcdb6918-e857-4803-89a3-454d45f3f63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89502ce9-4db7-4219-a78d-b2c8e84522e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca7c530-d56c-4354-ad02-de82b9a99119" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89502ce9-4db7-4219-a78d-b2c8e84522e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89502ce9-4db7-4219-a78d-b2c8e84522e1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7ac406d0-6dbe-4cab-90fc-131a413d4864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7ac406d0-6dbe-4cab-90fc-131a413d4864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_e14deccf-233c-4dc6-9d61-d5045c48e40d" xlink:href="nktr-20220630.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_e14deccf-233c-4dc6-9d61-d5045c48e40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_98cacef1-cd92-47b0-abf0-f95d500c2411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_98cacef1-cd92-47b0-abf0-f95d500c2411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_9f0e1668-883f-4245-97d3-d0465ca69e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_9f0e1668-883f-4245-97d3-d0465ca69e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ea77e740-6514-492c-9d71-3bf2bd3d46eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a95c97f-7c12-44f5-9568-f9282cf71efa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ea77e740-6514-492c-9d71-3bf2bd3d46eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20220630.xsd#LiabilitiesRelatedtoSalesofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a7ba071f-6d10-40a3-967a-f6739c7f8f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_6f0180ac-3f11-406e-a1a2-8cba43cd8198" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a7ba071f-6d10-40a3-967a-f6739c7f8f10" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_6f0180ac-3f11-406e-a1a2-8cba43cd8198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables" xlink:type="simple" xlink:href="nktr-20220630.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e5ce5320-4422-4625-96c6-dade4aaf7061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock_796a14d7-4b6b-403a-8954-dd113b0e8c27" xlink:href="nktr-20220630.xsd#nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e5ce5320-4422-4625-96c6-dade4aaf7061" xlink:to="loc_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock_796a14d7-4b6b-403a-8954-dd113b0e8c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_21c98621-4c2f-4e48-9566-483350d327f6" xlink:href="nktr-20220630.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e5ce5320-4422-4625-96c6-dade4aaf7061" xlink:to="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_21c98621-4c2f-4e48-9566-483350d327f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8bf59508-a5b6-4d86-bad7-413f32cd0b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3f7d271-2f16-4629-8625-2af79cf37934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8bf59508-a5b6-4d86-bad7-413f32cd0b56" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3f7d271-2f16-4629-8625-2af79cf37934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bedf5d48-e0d5-45be-af3f-ffa0e7935beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3f7d271-2f16-4629-8625-2af79cf37934" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bedf5d48-e0d5-45be-af3f-ffa0e7935beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c64ec47-c9a1-4dd7-ac43-447c5bf269ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bedf5d48-e0d5-45be-af3f-ffa0e7935beb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c64ec47-c9a1-4dd7-ac43-447c5bf269ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_66ce3307-78f3-4839-9aef-4682590232c3" xlink:href="nktr-20220630.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c64ec47-c9a1-4dd7-ac43-447c5bf269ed" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_66ce3307-78f3-4839-9aef-4682590232c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_e9f451ba-79a9-4189-a401-89cdfc5b38fc" xlink:href="nktr-20220630.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c64ec47-c9a1-4dd7-ac43-447c5bf269ed" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_e9f451ba-79a9-4189-a401-89cdfc5b38fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3f7d271-2f16-4629-8625-2af79cf37934" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds_bba4c9d4-db19-4b3a-a9a1-230974ce7734" xlink:href="nktr-20220630.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_RoyaltyMonetizationProceeds_bba4c9d4-db19-4b3a-a9a1-230974ce7734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_9974e4c4-87c7-4b25-a921-e2ef7a7e7c3f" xlink:href="nktr-20220630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_9974e4c4-87c7-4b25-a921-e2ef7a7e7c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_92ba6e94-de7e-4cd5-a9b0-68f59943057f" xlink:href="nktr-20220630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_92ba6e94-de7e-4cd5-a9b0-68f59943057f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_3dce98ad-2629-4377-a3b1-5e6fefe0118f" xlink:href="nktr-20220630.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_3dce98ad-2629-4377-a3b1-5e6fefe0118f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_7a6035a8-468d-4257-8440-f94045cfca1f" xlink:href="nktr-20220630.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_7a6035a8-468d-4257-8440-f94045cfca1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_e1087df8-9a63-4b75-a821-57938a9d3f87" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_e1087df8-9a63-4b75-a821-57938a9d3f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_febf9c86-3bc3-4421-8ca0-e89b26cf4863" xlink:href="nktr-20220630.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_febf9c86-3bc3-4421-8ca0-e89b26cf4863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_997b49ac-995a-41eb-91dc-b89da5a34667" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c14576f-76b8-4a0a-bc73-60a544bde491" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_997b49ac-995a-41eb-91dc-b89da5a34667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b69f9c8d-0846-4b56-b0d4-de8756bd559f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_592efd78-a18f-4ebd-923d-f97bdf5483ee" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b69f9c8d-0846-4b56-b0d4-de8756bd559f" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_592efd78-a18f-4ebd-923d-f97bdf5483ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cbcf4918-c94d-41c8-97f7-ae0f8f71507b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_592efd78-a18f-4ebd-923d-f97bdf5483ee" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cbcf4918-c94d-41c8-97f7-ae0f8f71507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34376f0c-541d-4cc9-b129-312d1c45fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cbcf4918-c94d-41c8-97f7-ae0f8f71507b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34376f0c-541d-4cc9-b129-312d1c45fa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_80bc7bac-0543-4525-b212-818da46981c4" xlink:href="nktr-20220630.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34376f0c-541d-4cc9-b129-312d1c45fa62" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_80bc7bac-0543-4525-b212-818da46981c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_5e817b7c-7ec7-4401-a50d-0c539377ba79" xlink:href="nktr-20220630.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34376f0c-541d-4cc9-b129-312d1c45fa62" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_5e817b7c-7ec7-4401-a50d-0c539377ba79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_9c9fc2d8-fcf4-4fe5-a0c5-f74af6426f95" xlink:href="nktr-20220630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_592efd78-a18f-4ebd-923d-f97bdf5483ee" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_9c9fc2d8-fcf4-4fe5-a0c5-f74af6426f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput_df761151-26ce-45a0-a421-65d3c99a33ce" xlink:href="nktr-20220630.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_9c9fc2d8-fcf4-4fe5-a0c5-f74af6426f95" xlink:to="loc_nktr_RoyaltiesLiabilityMeasurementInput_df761151-26ce-45a0-a421-65d3c99a33ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ec62251b-a788-4091-8a8c-3d1a430caafd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7802956e-d525-4df8-8141-53cdf58b760f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ec62251b-a788-4091-8a8c-3d1a430caafd" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7802956e-d525-4df8-8141-53cdf58b760f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_065c381a-4c40-499c-af0a-459527503e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bd9745b0-54c2-4862-8e7b-d513f9d45937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_065c381a-4c40-499c-af0a-459527503e37" xlink:to="loc_us-gaap_LossContingenciesTable_bd9745b0-54c2-4862-8e7b-d513f9d45937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_fd5d1f83-5335-4818-ab8c-1c504737ed91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bd9745b0-54c2-4862-8e7b-d513f9d45937" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_fd5d1f83-5335-4818-ab8c-1c504737ed91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_da507e21-e006-4bb2-9a0b-b9b305e335fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_fd5d1f83-5335-4818-ab8c-1c504737ed91" xlink:to="loc_us-gaap_LossContingencyNatureDomain_da507e21-e006-4bb2-9a0b-b9b305e335fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember_fe8ed419-7d82-4655-8c4e-50e1e06eede9" xlink:href="nktr-20220630.xsd#nktr_LegalMattersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_da507e21-e006-4bb2-9a0b-b9b305e335fd" xlink:to="loc_nktr_LegalMattersMember_fe8ed419-7d82-4655-8c4e-50e1e06eede9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f72ec3b8-4970-42b2-9c8b-aa8a129fdc81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bd9745b0-54c2-4862-8e7b-d513f9d45937" xlink:to="loc_us-gaap_LossContingenciesLineItems_f72ec3b8-4970-42b2-9c8b-aa8a129fdc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_16a97e6b-74a1-4455-a5df-7fb5d60c1460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f72ec3b8-4970-42b2-9c8b-aa8a129fdc81" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_16a97e6b-74a1-4455-a5df-7fb5d60c1460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20220630.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_d672287e-ffb9-440c-8141-0aabc4da5ccd" xlink:href="nktr-20220630.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3c28999d-9cba-47fd-b23f-6d157dc22f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_d672287e-ffb9-440c-8141-0aabc4da5ccd" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3c28999d-9cba-47fd-b23f-6d157dc22f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_7338247b-e0cb-47a7-8c69-c35064241a67" xlink:href="nktr-20220630.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_7338247b-e0cb-47a7-8c69-c35064241a67" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7e407f0c-aa13-43df-a2ea-c52eb56c3e01" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_srt_ProductOrServiceAxis_7e407f0c-aa13-43df-a2ea-c52eb56c3e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_24ab9a4d-5b77-4378-9be0-667fd871fc96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7e407f0c-aa13-43df-a2ea-c52eb56c3e01" xlink:to="loc_srt_ProductsAndServicesDomain_24ab9a4d-5b77-4378-9be0-667fd871fc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_ee42bb25-48f9-446d-85d4-15b530e52745" xlink:href="nktr-20220630.xsd#nktr_Nektar214Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_24ab9a4d-5b77-4378-9be0-667fd871fc96" xlink:to="loc_nktr_Nektar214Member_ee42bb25-48f9-446d-85d4-15b530e52745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_e44ffe28-eb94-4ab2-bed0-921f7de4b27d" xlink:href="nktr-20220630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_24ab9a4d-5b77-4378-9be0-667fd871fc96" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_e44ffe28-eb94-4ab2-bed0-921f7de4b27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1f1b5d41-9931-463c-854d-b323fcc0c52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1f1b5d41-9931-463c-854d-b323fcc0c52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05e9f3a8-e4d6-4bf0-952c-2c1cfdb73844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1f1b5d41-9931-463c-854d-b323fcc0c52b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05e9f3a8-e4d6-4bf0-952c-2c1cfdb73844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_d87142b9-52cd-4d92-b1d9-f72c6910d627" xlink:href="nktr-20220630.xsd#nktr_OpdivoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05e9f3a8-e4d6-4bf0-952c-2c1cfdb73844" xlink:to="loc_nktr_OpdivoMember_d87142b9-52cd-4d92-b1d9-f72c6910d627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_db15af03-2dd3-4273-9beb-42619e50a2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_us-gaap_TypeOfArrangementAxis_db15af03-2dd3-4273-9beb-42619e50a2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28fb701e-273a-46e5-8899-979b218c14f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_db15af03-2dd3-4273-9beb-42619e50a2e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28fb701e-273a-46e5-8899-979b218c14f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_0cde5400-18b9-4728-8bfb-4a458132f9d5" xlink:href="nktr-20220630.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28fb701e-273a-46e5-8899-979b218c14f4" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_0cde5400-18b9-4728-8bfb-4a458132f9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_1e61762d-2f61-4964-a7ac-6b3203822b74" xlink:href="nktr-20220630.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28fb701e-273a-46e5-8899-979b218c14f4" xlink:to="loc_nktr_Nektar358Member_1e61762d-2f61-4964-a7ac-6b3203822b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_14036947-2ab9-43d5-b403-492c192abbea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_dei_LegalEntityAxis_14036947-2ab9-43d5-b403-492c192abbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_14036947-2ab9-43d5-b403-492c192abbea" xlink:to="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_fa467d40-0f6a-4cdd-9102-cd79a6a42017" xlink:href="nktr-20220630.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_fa467d40-0f6a-4cdd-9102-cd79a6a42017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_0b3a5390-066e-477a-a6e2-4fe31618883b" xlink:href="nktr-20220630.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:to="loc_nktr_EliLillyAndCompanyMember_0b3a5390-066e-477a-a6e2-4fe31618883b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_8855000d-e44d-457c-bafb-24f5be307e55" xlink:href="nktr-20220630.xsd#nktr_EliLillyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:to="loc_nktr_EliLillyMember_8855000d-e44d-457c-bafb-24f5be307e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_7c14e6fc-78ee-4b2f-9571-8e9300065fe5" xlink:href="nktr-20220630.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a307bf82-8ddb-42a2-8378-a3a2866974ad" xlink:to="loc_nktr_OtherPartnerMember_7c14e6fc-78ee-4b2f-9571-8e9300065fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_391af8a3-8a9f-40a0-a30d-366d87621111" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_srt_ConsolidatedEntitiesAxis_391af8a3-8a9f-40a0-a30d-366d87621111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8d7620c6-fbe2-4f38-969b-8dca42bb5a1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_391af8a3-8a9f-40a0-a30d-366d87621111" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8d7620c6-fbe2-4f38-969b-8dca42bb5a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_a099308a-8ac7-4596-ad0a-10af5a2adf92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8d7620c6-fbe2-4f38-969b-8dca42bb5a1b" xlink:to="loc_srt_ParentCompanyMember_a099308a-8ac7-4596-ad0a-10af5a2adf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_67910d5e-c461-4e0f-9019-bbe2ddb105b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_67910d5e-c461-4e0f-9019-bbe2ddb105b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e1d237bb-8c74-4b99-ad83-a924d1b217d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_67910d5e-c461-4e0f-9019-bbe2ddb105b4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e1d237bb-8c74-4b99-ad83-a924d1b217d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_20b5e969-2d24-4878-afb5-0b92746981f6" xlink:href="nktr-20220630.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e1d237bb-8c74-4b99-ad83-a924d1b217d3" xlink:to="loc_nktr_SharePurchaseAgreementMember_20b5e969-2d24-4878-afb5-0b92746981f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_970a2fd9-01e4-47b5-91c3-03c2959cddd9" xlink:href="nktr-20220630.xsd#nktr_MilestoneAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_nktr_MilestoneAxis_970a2fd9-01e4-47b5-91c3-03c2959cddd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_d7061206-dad6-4f93-ac02-b362c69cc0b5" xlink:href="nktr-20220630.xsd#nktr_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneAxis_970a2fd9-01e4-47b5-91c3-03c2959cddd9" xlink:to="loc_nktr_MilestoneDomain_d7061206-dad6-4f93-ac02-b362c69cc0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_4e3774f0-20b1-4b92-acc3-160f0e257a5a" xlink:href="nktr-20220630.xsd#nktr_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_d7061206-dad6-4f93-ac02-b362c69cc0b5" xlink:to="loc_nktr_MilestoneOneMember_4e3774f0-20b1-4b92-acc3-160f0e257a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_af8a1b19-a19f-46d2-86ab-179b8f4f2d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_af8a1b19-a19f-46d2-86ab-179b8f4f2d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b3a13eb6-6271-4487-be1b-661f6d22a709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_af8a1b19-a19f-46d2-86ab-179b8f4f2d3f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b3a13eb6-6271-4487-be1b-661f6d22a709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_58d4fd57-e275-40c5-9a9d-e17031169a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b3a13eb6-6271-4487-be1b-661f6d22a709" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_58d4fd57-e275-40c5-9a9d-e17031169a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6d07362b-c15c-47f9-b4bc-43da2fe6782b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_srt_CounterpartyNameAxis_6d07362b-c15c-47f9-b4bc-43da2fe6782b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_981dce2b-36af-4943-8e20-0cf7347c52c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6d07362b-c15c-47f9-b4bc-43da2fe6782b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_981dce2b-36af-4943-8e20-0cf7347c52c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_7e2a6597-c26a-40c6-b115-28fca277f812" xlink:href="nktr-20220630.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_981dce2b-36af-4943-8e20-0cf7347c52c0" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_7e2a6597-c26a-40c6-b115-28fca277f812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d197f467-6a4b-4f78-987d-5111e644225c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_srt_RangeAxis_d197f467-6a4b-4f78-987d-5111e644225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1fbafbf6-d5cd-4d6a-b0e1-f7bb2a9bea9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d197f467-6a4b-4f78-987d-5111e644225c" xlink:to="loc_srt_RangeMember_1fbafbf6-d5cd-4d6a-b0e1-f7bb2a9bea9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87d809ce-58da-4b1f-83c2-efa5ba3013b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1fbafbf6-d5cd-4d6a-b0e1-f7bb2a9bea9d" xlink:to="loc_srt_MaximumMember_87d809ce-58da-4b1f-83c2-efa5ba3013b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3d6cb78-60a0-4908-b33e-393860cea776" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_f8d26dd9-f55e-4c03-9ce1-77b37c928539" xlink:href="nktr-20220630.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_f8d26dd9-f55e-4c03-9ce1-77b37c928539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_74e2f451-331c-46c2-981d-769259936fe7" xlink:href="nktr-20220630.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_74e2f451-331c-46c2-981d-769259936fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_00f60037-689e-421c-824d-0288884fce65" xlink:href="nktr-20220630.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_00f60037-689e-421c-824d-0288884fce65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_0978c691-83d8-4712-9879-6fd0c9b81d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_us-gaap_SharesIssued_0978c691-83d8-4712-9879-6fd0c9b81d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_afd4e123-52bf-4f5f-b53b-9da3b97ca8b2" xlink:href="nktr-20220630.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_afd4e123-52bf-4f5f-b53b-9da3b97ca8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_22c61f79-128b-4d8f-b035-7f1780cc9f98" xlink:href="nktr-20220630.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PotentialDevelopmentMilestones_22c61f79-128b-4d8f-b035-7f1780cc9f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_183726af-74db-48dd-ac02-c3dacbf56279" xlink:href="nktr-20220630.xsd#nktr_ReimbursementOfExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_ReimbursementOfExpenses_183726af-74db-48dd-ac02-c3dacbf56279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7515a399-c8ce-472d-8e6c-a2e24ba5f120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7515a399-c8ce-472d-8e6c-a2e24ba5f120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_50884c80-b098-4410-81f8-3a85deb6c988" xlink:href="nktr-20220630.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_50884c80-b098-4410-81f8-3a85deb6c988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_741a9a95-6906-4132-8f25-a3b2a3c9757d" xlink:href="nktr-20220630.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_741a9a95-6906-4132-8f25-a3b2a3c9757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_620dcf9d-e3ec-4fe2-ae89-7d153af31e4c" xlink:href="nktr-20220630.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_620dcf9d-e3ec-4fe2-ae89-7d153af31e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_871e90b0-d881-4cd8-85eb-2bb21cb9043a" xlink:href="nktr-20220630.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_871e90b0-d881-4cd8-85eb-2bb21cb9043a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_9a8d6d33-66e6-4fda-9866-2d306d532a52" xlink:href="nktr-20220630.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_9a8d6d33-66e6-4fda-9866-2d306d532a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_f4d99279-aebd-47da-a895-18eab452ce09" xlink:href="nktr-20220630.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_f4d99279-aebd-47da-a895-18eab452ce09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7560b1d7-17dd-4310-910d-396ff00cceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9bd60b0b-5aab-4dfd-b9cf-43da0de87512" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7560b1d7-17dd-4310-910d-396ff00cceb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgram"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cbbf66d9-df32-43c3-856d-91f4683c4a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_0f03c276-b6d6-4665-8334-4fc4219db71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cbbf66d9-df32-43c3-856d-91f4683c4a8a" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_0f03c276-b6d6-4665-8334-4fc4219db71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_45c70f39-7238-456d-a8e7-b03d9ab708c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_47b8da1b-739e-4437-92b4-29aef06b0a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_45c70f39-7238-456d-a8e7-b03d9ab708c4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_47b8da1b-739e-4437-92b4-29aef06b0a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b427a2fe-34c7-4326-835a-49864f611e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_45c70f39-7238-456d-a8e7-b03d9ab708c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b427a2fe-34c7-4326-835a-49864f611e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_05d24716-14b4-4d48-bae4-7e3cf1d860ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6a62dec4-29af-413d-bbd8-fd08ba972cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_05d24716-14b4-4d48-bae4-7e3cf1d860ef" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6a62dec4-29af-413d-bbd8-fd08ba972cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6c86de8d-ace6-4e42-b40b-abeb4942d53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6a62dec4-29af-413d-bbd8-fd08ba972cd3" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6c86de8d-ace6-4e42-b40b-abeb4942d53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_17b1e929-c51a-47a0-9919-6ad5adfc042c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6c86de8d-ace6-4e42-b40b-abeb4942d53b" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_17b1e929-c51a-47a0-9919-6ad5adfc042c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_673b82e9-c9b1-4b3f-9a93-11f2c46008f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_17b1e929-c51a-47a0-9919-6ad5adfc042c" xlink:to="loc_us-gaap_EmployeeSeveranceMember_673b82e9-c9b1-4b3f-9a93-11f2c46008f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2b9e23e7-e4ad-4f8a-b908-aa2e03c503b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6a62dec4-29af-413d-bbd8-fd08ba972cd3" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_2b9e23e7-e4ad-4f8a-b908-aa2e03c503b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_93ba0bcd-c48a-479d-90fe-40879c4563d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2b9e23e7-e4ad-4f8a-b908-aa2e03c503b4" xlink:to="loc_dei_EntityNumberOfEmployees_93ba0bcd-c48a-479d-90fe-40879c4563d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_8cbba79d-8794-4d52-a026-31d52125ffbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2b9e23e7-e4ad-4f8a-b908-aa2e03c503b4" xlink:to="loc_us-gaap_LossOnContractTermination_8cbba79d-8794-4d52-a026-31d52125ffbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_44fe3117-3b34-428f-a686-11e2fb21e713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2b9e23e7-e4ad-4f8a-b908-aa2e03c503b4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_44fe3117-3b34-428f-a686-11e2fb21e713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_262ef1a6-f4e7-47e4-a5df-b4da5233b129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_04c3adc1-bc10-45bb-a145-45bf00763082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_262ef1a6-f4e7-47e4-a5df-b4da5233b129" xlink:to="loc_us-gaap_BusinessExitCosts1_04c3adc1-bc10-45bb-a145-45bf00763082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_e66588b5-f9f6-4b97-8e99-d0b2a7b93d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_262ef1a6-f4e7-47e4-a5df-b4da5233b129" xlink:to="loc_us-gaap_SeveranceCosts1_e66588b5-f9f6-4b97-8e99-d0b2a7b93d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_57d00e7e-9e27-4eac-bf14-224875fde5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_262ef1a6-f4e7-47e4-a5df-b4da5233b129" xlink:to="loc_us-gaap_AssetImpairmentCharges_57d00e7e-9e27-4eac-bf14-224875fde5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_436976b1-ff0a-451b-a2f4-cf6c468851a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_262ef1a6-f4e7-47e4-a5df-b4da5233b129" xlink:to="loc_us-gaap_LossOnContractTermination_436976b1-ff0a-451b-a2f4-cf6c468851a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_689d0b30-6813-4f99-9709-36ce75ac24fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_262ef1a6-f4e7-47e4-a5df-b4da5233b129" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_689d0b30-6813-4f99-9709-36ce75ac24fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_27914e50-cf92-432a-8900-859d5e3841ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2d0acaee-99ac-4ea2-a5fd-f369ee124298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_27914e50-cf92-432a-8900-859d5e3841ee" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2d0acaee-99ac-4ea2-a5fd-f369ee124298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_26b062b9-5d7f-4154-bffd-423998c6bbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2d0acaee-99ac-4ea2-a5fd-f369ee124298" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_26b062b9-5d7f-4154-bffd-423998c6bbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0bc8550f-cc72-42d1-8acb-a18b5970bdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_26b062b9-5d7f-4154-bffd-423998c6bbc1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0bc8550f-cc72-42d1-8acb-a18b5970bdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e1c9d471-f509-4494-a0fd-d4c225d18e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0bc8550f-cc72-42d1-8acb-a18b5970bdc1" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e1c9d471-f509-4494-a0fd-d4c225d18e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember_2bba9c3a-a776-4553-896b-9a209e36be5b" xlink:href="nktr-20220630.xsd#nktr_EmployeeSeveranceWithNoServicePeriodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeSeveranceMember_e1c9d471-f509-4494-a0fd-d4c225d18e92" xlink:to="loc_nktr_EmployeeSeveranceWithNoServicePeriodMember_2bba9c3a-a776-4553-896b-9a209e36be5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_dd8580ef-61a7-4272-823b-15b28b859cb6" xlink:href="nktr-20220630.xsd#nktr_EmployeeSeveranceWithServicePeriodRequirementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeSeveranceMember_e1c9d471-f509-4494-a0fd-d4c225d18e92" xlink:to="loc_nktr_EmployeeSeveranceWithServicePeriodRequirementMember_dd8580ef-61a7-4272-823b-15b28b859cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6919eacb-c1b1-498a-883c-18d74a06f7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2d0acaee-99ac-4ea2-a5fd-f369ee124298" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6919eacb-c1b1-498a-883c-18d74a06f7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c8164c3-f0f2-46c6-9c60-b91f99d78199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6919eacb-c1b1-498a-883c-18d74a06f7c3" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c8164c3-f0f2-46c6-9c60-b91f99d78199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6919eacb-c1b1-498a-883c-18d74a06f7c3" xlink:to="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_d44ec4ea-c124-48b7-8d45-b48b7c34cbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:to="loc_us-gaap_RestructuringReserve_d44ec4ea-c124-48b7-8d45-b48b7c34cbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d3b90934-5c8e-43c2-ad52-e5c08577bf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:to="loc_us-gaap_RestructuringCharges_d3b90934-5c8e-43c2-ad52-e5c08577bf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_d24c7c70-cbfb-4da0-ae38-e170a3131cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:to="loc_us-gaap_PaymentsForRestructuring_d24c7c70-cbfb-4da0-ae38-e170a3131cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_0ab6e7d4-dc1e-47f4-860d-025d2ceefd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c9494e15-50db-49fc-9a57-b10550029f7c" xlink:to="loc_us-gaap_RestructuringReserve_0ab6e7d4-dc1e-47f4-860d-025d2ceefd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_47bf198e-c7ac-47f0-9ba7-0f39c1af302c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_47bf198e-c7ac-47f0-9ba7-0f39c1af302c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7817a0c5-efc2-420e-a9fd-98c2777586bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7817a0c5-efc2-420e-a9fd-98c2777586bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a39282b-3de7-491e-b0c1-ad2eecfb8f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7817a0c5-efc2-420e-a9fd-98c2777586bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a39282b-3de7-491e-b0c1-ad2eecfb8f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8e8c2846-9a53-4113-af50-17b760ad317e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a39282b-3de7-491e-b0c1-ad2eecfb8f43" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8e8c2846-9a53-4113-af50-17b760ad317e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b9160259-578f-4e86-8d9b-9ce5d6ef6075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b9160259-578f-4e86-8d9b-9ce5d6ef6075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e6685993-ab2b-46b6-96c4-426f443c5597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b9160259-578f-4e86-8d9b-9ce5d6ef6075" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e6685993-ab2b-46b6-96c4-426f443c5597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember_ac1a79c0-dcf0-43d0-bbd1-a39677ba5892" xlink:href="nktr-20220630.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e6685993-ab2b-46b6-96c4-426f443c5597" xlink:to="loc_nktr_SubleasePropertyPlantAndEquipmentMember_ac1a79c0-dcf0-43d0-bbd1-a39677ba5892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_e6636a11-9d91-4292-bb67-a6e07e9e3eb5" xlink:href="nktr-20220630.xsd#nktr_SubleaseOperatingLeaseRightOfUseAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e6685993-ab2b-46b6-96c4-426f443c5597" xlink:to="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_e6636a11-9d91-4292-bb67-a6e07e9e3eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_7d747a17-2d02-459e-beb7-9e739cce9330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_7d747a17-2d02-459e-beb7-9e739cce9330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d8b788cf-7d61-410b-b5b8-a2ce034b4320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7d747a17-2d02-459e-beb7-9e739cce9330" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d8b788cf-7d61-410b-b5b8-a2ce034b4320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_90037dd4-b2b4-4dfd-802e-fd3977051792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d8b788cf-7d61-410b-b5b8-a2ce034b4320" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_90037dd4-b2b4-4dfd-802e-fd3977051792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_33e0d7fd-d6a8-4cda-89e1-3001bfee8d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_90037dd4-b2b4-4dfd-802e-fd3977051792" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_33e0d7fd-d6a8-4cda-89e1-3001bfee8d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3dd3b324-bd27-4b9f-bdfc-db495dd755ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_90037dd4-b2b4-4dfd-802e-fd3977051792" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3dd3b324-bd27-4b9f-bdfc-db495dd755ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ab7fd98e-cfd9-44e7-b274-848f0f4ef9b5" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_5a33b87a-c2bf-4206-adbc-3a3095329583" xlink:href="nktr-20220630.xsd#nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:to="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_5a33b87a-c2bf-4206-adbc-3a3095329583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_29df4b04-544b-469e-ad01-4bf77afd5665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_29df4b04-544b-469e-ad01-4bf77afd5665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_52b9dbec-76dc-448c-982b-86363cba6b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_52b9dbec-76dc-448c-982b-86363cba6b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1383d2da-e3fa-4778-98f8-f72c4ef84684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d0264f8f-4dd5-41dc-978b-4e6ece4928b8" xlink:to="loc_us-gaap_AssetImpairmentCharges_1383d2da-e3fa-4778-98f8-f72c4ef84684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20220630.xsd#RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e2645be1-8003-4712-98fe-a3f13dd0547c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ffc1184-12c0-4c60-9365-4a25bc40ef30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e2645be1-8003-4712-98fe-a3f13dd0547c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ffc1184-12c0-4c60-9365-4a25bc40ef30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22aa4972-b7c9-45f0-a6ed-02739216eba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ffc1184-12c0-4c60-9365-4a25bc40ef30" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22aa4972-b7c9-45f0-a6ed-02739216eba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22aa4972-b7c9-45f0-a6ed-02739216eba4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember_5e064e8f-3676-4ddd-9121-1af045ff3009" xlink:href="nktr-20220630.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_nktr_BuildingAndLeaseholdImprovementsMember_5e064e8f-3676-4ddd-9121-1af045ff3009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember_c7fcee66-4c7c-41a8-9415-96b1a671ad9b" xlink:href="nktr-20220630.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_nktr_LaboratoryEquipmentMember_c7fcee66-4c7c-41a8-9415-96b1a671ad9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerEquipmentAndSoftwareMember_a75653eb-a9b3-4a52-9d4f-e2e39e299573" xlink:href="nktr-20220630.xsd#nktr_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_nktr_ComputerEquipmentAndSoftwareMember_a75653eb-a9b3-4a52-9d4f-e2e39e299573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_7f877244-0ade-4e1d-b65c-7b40fe844a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_us-gaap_EquipmentMember_7f877244-0ade-4e1d-b65c-7b40fe844a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2e31d410-ce57-4298-b1f6-b69622518eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2e31d410-ce57-4298-b1f6-b69622518eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember_88d851b3-878d-4f6f-8b64-49a2df0a5de3" xlink:href="nktr-20220630.xsd#nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember_88d851b3-878d-4f6f-8b64-49a2df0a5de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_616c1ed7-1263-42a5-bf93-9d592751ab2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5cf09f27-5d6b-49ca-b146-e41ada169d41" xlink:to="loc_us-gaap_ConstructionInProgressMember_616c1ed7-1263-42a5-bf93-9d592751ab2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_177bca82-95b0-45f3-bbe2-eddea28d1063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ffc1184-12c0-4c60-9365-4a25bc40ef30" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_177bca82-95b0-45f3-bbe2-eddea28d1063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2536e92e-66d2-4939-9f9b-842f847d8f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_177bca82-95b0-45f3-bbe2-eddea28d1063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2536e92e-66d2-4939-9f9b-842f847d8f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a7344f35-71dc-4952-98ca-fc629d00ce45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_177bca82-95b0-45f3-bbe2-eddea28d1063" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a7344f35-71dc-4952-98ca-fc629d00ce45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_78946828-fd6b-4368-a61b-a29c44593016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_177bca82-95b0-45f3-bbe2-eddea28d1063" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_78946828-fd6b-4368-a61b-a29c44593016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20220630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2b3704b-c2f4-486b-bab5-8a4f5951f2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6b5517cc-2a46-431f-a43d-1905e74e1e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2b3704b-c2f4-486b-bab5-8a4f5951f2fe" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6b5517cc-2a46-431f-a43d-1905e74e1e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20220630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6fb56b30-7ddd-40a9-9ea6-8f19467b80b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9f0d1a4e-0be6-408c-9088-a554f06850da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6fb56b30-7ddd-40a9-9ea6-8f19467b80b1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9f0d1a4e-0be6-408c-9088-a554f06850da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_2849ede7-2aa9-4ce6-9fed-141fe1a1cda9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6fb56b30-7ddd-40a9-9ea6-8f19467b80b1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_2849ede7-2aa9-4ce6-9fed-141fe1a1cda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d4d5d40-1884-44be-83d7-b248af556d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d75cb61-9178-4428-916e-9ec0eadf785f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d4d5d40-1884-44be-83d7-b248af556d7f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d75cb61-9178-4428-916e-9ec0eadf785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1c1a3b52-54fd-4dc9-b1df-4834ead4de78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d75cb61-9178-4428-916e-9ec0eadf785f" xlink:to="loc_us-gaap_PlanNameAxis_1c1a3b52-54fd-4dc9-b1df-4834ead4de78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6f6bd63d-99d2-4d24-9320-999a4b9aed77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1c1a3b52-54fd-4dc9-b1df-4834ead4de78" xlink:to="loc_us-gaap_PlanNameDomain_6f6bd63d-99d2-4d24-9320-999a4b9aed77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_85029996-f1f5-48be-881b-33e803beea7b" xlink:href="nktr-20220630.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6f6bd63d-99d2-4d24-9320-999a4b9aed77" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_85029996-f1f5-48be-881b-33e803beea7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de69ea60-2db0-450e-8c4c-b98ba170ebf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d75cb61-9178-4428-916e-9ec0eadf785f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de69ea60-2db0-450e-8c4c-b98ba170ebf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b4daf8b4-e3b7-4a08-a15c-1eebfa773e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de69ea60-2db0-450e-8c4c-b98ba170ebf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b4daf8b4-e3b7-4a08-a15c-1eebfa773e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_612d2b37-b324-473b-9be2-cd05fbae28d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_65a2752c-2a7b-4623-a2e7-e36638d6761a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_612d2b37-b324-473b-9be2-cd05fbae28d8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_65a2752c-2a7b-4623-a2e7-e36638d6761a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_810938c2-9ae3-4d13-86f2-72c865ba75bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_65a2752c-2a7b-4623-a2e7-e36638d6761a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_810938c2-9ae3-4d13-86f2-72c865ba75bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_810938c2-9ae3-4d13-86f2-72c865ba75bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f5a1457c-0d24-45d1-8bf5-90f21ce4bc48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:to="loc_us-gaap_CostOfSalesMember_f5a1457c-0d24-45d1-8bf5-90f21ce4bc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cc0602a3-5013-4bd9-b33c-dff8984c6b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cc0602a3-5013-4bd9-b33c-dff8984c6b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dc0e9ef4-0db8-4194-81ce-70691da4e84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dc0e9ef4-0db8-4194-81ce-70691da4e84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_4630eb52-5175-4281-80fe-d460106824d9" xlink:href="nktr-20220630.xsd#nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d0b0f10e-4b77-4020-ba13-c8c0a1ecea78" xlink:to="loc_nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember_4630eb52-5175-4281-80fe-d460106824d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_46ad7242-8132-4d1a-b635-6990b0f7859b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_65a2752c-2a7b-4623-a2e7-e36638d6761a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_46ad7242-8132-4d1a-b635-6990b0f7859b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_edf160d5-8937-41a3-bfad-3e82c0f157c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_46ad7242-8132-4d1a-b635-6990b0f7859b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_edf160d5-8937-41a3-bfad-3e82c0f157c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#StockBasedCompensationActivityDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea5a255e-4852-4511-bd0b-45ecbf970aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_afd3afc7-8e65-4908-aba6-ef0ebaf28d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea5a255e-4852-4511-bd0b-45ecbf970aed" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_afd3afc7-8e65-4908-aba6-ef0ebaf28d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f14d6077-4240-4932-b7d5-b1e59bfa72f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_afd3afc7-8e65-4908-aba6-ef0ebaf28d5b" xlink:to="loc_us-gaap_AwardTypeAxis_f14d6077-4240-4932-b7d5-b1e59bfa72f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd76ace-7a26-44c5-83c8-d66876b5de82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f14d6077-4240-4932-b7d5-b1e59bfa72f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd76ace-7a26-44c5-83c8-d66876b5de82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_74886365-0670-4e2f-9127-32eb42002c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdd76ace-7a26-44c5-83c8-d66876b5de82" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_74886365-0670-4e2f-9127-32eb42002c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_afd3afc7-8e65-4908-aba6-ef0ebaf28d5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a4e7d98a-5c5a-4eb5-a9e2-8bfc38cf89c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a4e7d98a-5c5a-4eb5-a9e2-8bfc38cf89c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6d5b627-f456-4db8-88fd-e328bdd73d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6d5b627-f456-4db8-88fd-e328bdd73d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9f03465c-02b6-48b4-8a4e-323dae1c91bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9f03465c-02b6-48b4-8a4e-323dae1c91bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_42bf2e1c-82e1-4557-b722-98c0ae837126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_42bf2e1c-82e1-4557-b722-98c0ae837126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c830e5f7-b974-4752-825a-0b8d0de76d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a32cc2b-f0b5-4569-964d-0be824121643" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c830e5f7-b974-4752-825a-0b8d0de76d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20220630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4649f66a-6922-45ea-9df1-520fba572b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d3085174-8699-4bf6-b099-7e828f731db1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4649f66a-6922-45ea-9df1-520fba572b4a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d3085174-8699-4bf6-b099-7e828f731db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="nktr-20220630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b9aea1ba-fe23-4139-a765-08f2c1904a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ab9e1e23-81d4-45d8-91a4-2e06c6336859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b9aea1ba-fe23-4139-a765-08f2c1904a40" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ab9e1e23-81d4-45d8-91a4-2e06c6336859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="simple" xlink:href="nktr-20220630.xsd#NetLossPerShareDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_91b24375-861f-4a3b-805e-138148f1155d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fbb95f02-02c0-4482-84b6-f06bafc82c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_91b24375-861f-4a3b-805e-138148f1155d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fbb95f02-02c0-4482-84b6-f06bafc82c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M8\+_(AL7:29[YT.F^S22+7L0\Z]'QXE9".U^&8X-O\'1)3_ @7G/8O_\9W&
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MF\+/0WO/*ELY>CF?'LFC5_+JBGQS8SBZ?TC_+_\\SR]?DBR$%"1QD+(JR8'
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MV/<MYS"F-!A+W$F':R)<I/CK;2*G66QFGH;0IA^AX_ ;LNJ183/S0#K.2FJ
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M%3P'B"=<2D2A+.M0^BQ$02^/I9Q*H=A=)2(%Z5K4D= XYWX*WI5?1]/VY\C
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M<R6J*/GR TBKL)O1W;J2QFHEO4ZX6,E[\CAE4"BG^U@^Y0;)__>M? EU>]Y
MAV\Y8G6[D.DDJ.FL1*RS ;&( FIQNI.V^:?G8.XZD'NM\E_KW,=RUP UY^5Q
MJ1_JD+G+US%.CEI"&HEUF#G,/.^C--]C,N?5[WA^\+J8CA!HM!XDQV\1*C?\
M N[YC]":>H>"A-*+:)\\'^&2<^CZJ%QMI06O]E9?X2?(1N4<Q@T'4%#1YX <
M"$X09X]SS]T$\CZN1USW,QI;,Y&JW4705R[UB)EXBRKZ9%"05.+3O9>??%#H
M#19R^U&XBR]&1<DU!,T/P[_B)=3L_#?:/>_2/#U(0.J7J%0\VHIHI(/&F!I?
M1HZ\FN\Q^CYT76D]9>ONQ3*]&->!IG0S/"57;Z1\9TO5IVR*E.JD/2Z?@>=G
MG/VW2 OB7>3+<1I>1Q"IEC+:,SY U+L2K?M*4;OQ-03>^1:<LS]+<_\V5#BN
ME!-^GZSE)YXZ9T0] T4T5_2<X<[S?BVPHX0"N'B:)9A90>UBN"=?3^OXO:A8
M]"0"&WZ-V@/3T!'>1&/5K]*/")!X#4@EHF;:D3(CO2BIY.Q-M;Z4%C!0D!"/
MQTQ8,*Z=0 +O>V<3*!@W)F#J;>O3#MUMD'/.F!0YI]?%TE^.:^"<<A<";S^-
MFO6_0 O+4H6Y&.<H;0IAZ5['BW%"6KY'K=!-0MV<M+FXG.X%YD0@81B#@L,*
MV85TR$XZ;TH.\15P3[\%@<5?1O7[/T73/@>Z N\AV7I4-L#N5#NZTQ&57Y[6
M()=E.0YD7E./9TS+?CRKXV\??Y]UHGU2W\/6A9B+D\BX#P@;%R]:EM"ZX?;&
M+3%= &RH(:@4NT0BUDM$8;"@D L+O><T#SKUB(4'3/&!I'FM4K9KI%*4DKIH
M.:[ALEW2C5*=?B2:#Z,SN(X<[YFHW?$G!%=^&][YGX.;BVZ++E5I&JRM7ZAD
M2U6S1RW7;#/+Z1^=;7F^OVE&BJ4I!SU.8(35E+Q%W,WT4NF@6R&YK8\CL.IE
M5&_[*YH/$R0$WT>L83]]AX!$2!4@D%-$$)3N96ZH,62-J9[/Z>NQOO_>:EZG
MQI<"4G8P.N1$,M'B0JQJ!]J.S$;=IM\@M)3&V!P+%%1WX/&JWX$CVQ$:$"@X
M+%"H+#9RD)5(0@4WYYQR(\KG?A8^NI9U'TTB9VT-XAS^CU1*.D\\VJY.YW5C
MSM[G>2IGCA_O6N6;^T:-C3;]/![3*N<XIJZCL3^E8JJ1&*?,LAA'+$*F#@N2
M=*U9VK<[V4)KI1/1JBU29Q-<]5TX9]U/#O4--,\NE 9K @GD;(>+=4%GD='4
MCP%!6< &"0&'/:I@Z\]A*"$566;LVP._A[W7*)C.LWRF H$%GB,B#5PZ$>[9
MY.PN?Q'U'_X77:QR6/^1JE5@H09I:!75!<WI?L!"_WJP?'Q!0?6C\!1?!&?)
MU? 0* 16?A>U'_P'[=Y5B#<=4='H>*M$K*)1'F.&S&S"3'VQLBTLZ\ZQ_ IT
MAD^2H769+)6A<:U^LH1G;V:?+RG=]\988Q@8DASUX"A25Q4R-/Y3=7L0\1 L
M')B*FLVOP[?L&W#.>1@5W"FY\&):#\XQQ_4)^S0Y<\9JB#E6]V+AJ,4$&J_G
M$9P1U+)JX[0[X%SP& )K?XR:/6^BW;=:HG^96+7L2^K 1<.!KI55EC(A(6U;
M;ZV&H0FS/B%EWQ.Y%D]#PE#V4%"@4&3?^$Y@P>['P,UKQWG?WHNHQI@+6%!"
M/^-U*_++Z.;< ,_LA^!]^^NHV?)GM)4MHD5T!U)M+D5QW.8ZWF7F>:H*\YA4
MD*=3PUW]Z.,)"CV;FHS1<F(3X)U\.3F,-Q/<?0E5ZWZ"QKU%Z.3ZDI:C4J#7
MG>X@B]+W2J+G@MY_:<S!;0BG\3W2F:S%HJ?9G9N>3K1]+'"HTP2%6@(%YU"!
M0G_'Q6! P1C/<?/D119+@:4D;2))Q.())8,LCT65O!S!D;Q65PC1^GWH\*]%
MX\&IJ-K\&@(KO@7O@L\3J-ZF'-BB"\4A,5)BY#OGA0/[)FZOK=*6JZAA[[3,
MI[>%H^5U_=*,;((4W7%.J[/D&KAFW OW@D<16OU]U.W\)UJ.SD,DM!')IL-T
M7?PJ(L3R>G+";:18]+5F]34N!S>NC?%GA<,95+MD;4FT>1&KW86V8_-0M_FW
M""][!GX-"IQZY'><JY6/3AP4<H$A;#2RDXBEED2==A.<\SX'_^I74+^O"!W!
MM>0<'4!&&A$V*RE"G7;:6Z3JQ*Y5'^NSS=1ZG1:X34K=G((%U6DX9J;&&JD&
M:L^B:TQ.'7_^[G@=8G4?H;5\J42>?$N?A7/ZG?!,OEI?XPDP.E2'M,QX*&\Q
M9[: 2$"G_O+ACA2!<C18%X(&>/Q.&F76$ZH#/JM1VXG4F_0 !7+$?.*,&0T'
M:9XP*'"T;>J]<"Y\$N%-KZ/IV%QT56Y&NM,M7>C9@12%-TGC.)[D>5K/'<.&
M>M\_/<7,V<"ETX]8W[_T*I&8#:[Z'NIVO8$.[VHIKDUU58K3RNNEJGTQ>E%D
MIWP.[OITTW@G2VN3_V?RF/7[3(_YH0[#$B(?VDGCG_L"T1R(U"#3X4.2@#$:
M>A_-!Z:A<L-OX5WR-51,OP?E15=(+:O1*R37U^P_>/5,IS;&IU\?_*@.\.>*
M8(.'I9&GWBHRJ7S-:W?^ ^VN)4AQM@2#+1]@I=4:WNLA8H_U-G?O3^>L6V0"
M":<"% ;H".1>Z'[#PB !Q7 ^5 C_'*$XOCFN:7>B8C;=G-4_0L-NVAS<*Y"4
MW@HA=>K IUX:%BQ0T#0W3"(*)V;#&!1HT0\6C4+N28=/0.$F#0JOVD#AF T4
M8B=I(3_3K#>'3D.$='S\F(."K4&-T8DU3H 0$XLK&>2$"E4G^5 @6H]D1P#Q
MYB,*$@[-0-76W\.__!MPTZ;IFGX[7)S+S;FL1>?IACVJ5X)\7QL$\!IE]'4)
M&Y+-A:.S11B*C$Z[E@2?D=;A8Y.0M:'0HPXX.)+ $J).6K>\"Q]#<,5+J-W^
M5[0>LR A$PD+Y''O!Y6Z$I=[>KKGA1T6U(D8G^;2M6_W(UZW&^UE\U&WY36$
MWR%0F'N?.+ ,"DJV<+QV8 <!"F8TQ]A#"J0C,SMA;M:.GWZS-"(,K/D^&O8[
MT!E:1Z!PD/:!&M7]E%,J3G$^>VZTF(&!3U$Y+2.19-B-98&"REO6394X,LC1
MA!CW1*E'=S2$KO 6U'\T%:%UOX"'Q@_W%O*47B;KJX!8/_99*UJO4GL-(1&5
M,CI6IXQJ_7B&W$FC33G?H DB8P>U/MCW#SZQY;0HE2+%4#U>U,?<CBM15G(K
MRFA_]Z_Y$6KW3D*[;R52;4=HOPA)"DU2TLCB.'[3M3,;%.QK+C<:9%#P+?@L
M0JM>EFA,IV\-DLVL-E0I]5MI226,9>7&#UT36E9KA,VZ\Z17=YN/]5QG4B9,
M&YV,N:< -R#KIGG<37,AS;#0?!@=GA6HWST)H34_5/*I)==+C8;?H?N(Y,R#
M_OBO?=5=^G5ME$2@I3_,!-E+O"672YT"I[6&5GP+==O^(.LAR_JJM.HV=$LZ
MUU"I;>I(CX:$$5#(,BN,[^<0?O'%\$RY$>Z9]R&X['G4;/H=6H@P8T2:F=:C
MZ.X*T\!JDP&6-AM7),Z :((U4(8C* 1[!87+-"@\9H&"SP"%*H*$SA%0.&%3
M"ZY:[,\,4.!T#*.QD@$**J*0T!:5XFT+$LAA;3Q SM1&-!^>A>IM?Y;T#,_"
M+\ UXT[:/*^17@5*=WN""A_KT]>@<3IJIA6ID^LL]2*)#HS6$0C5;3E4/%8+
M+A388&&4 @4Q+=]I0@)+H-Y+D/ HPJN_A[KM?U:%R\'U2#:RVI=?00)'1U)1
M$Q*&PWJ5'19/:'G*KAQ0^&T.*%Q\UH)"OMHS"Q12"A222FC#$-LP<K@5*,15
MI(S&=W>T"NATH=.["M4[_@W_N]\EQ^@AN"9?)[KYY@EJOZ^MD1IJ@:X!"D$]
MID4.DB-ADU0!/COP <G/'J]3Z8P.N(,Y_#- 04??9&[QZZNL@?+BB2B?\0!]
MWQ=0N^,O:'<N1+II+S+D?*5XW>"HELR1XSFY9P\HL RY6T#A80L4O+F@T#6,
M02$MJG<&3 LL)&+:A^N4SN3I2 U2[5Y$PELE$EN[]0_P+WT:[AD<8;M*"RB,
MA]%8<,"@8(IZC,KR;;(5.<<**' TSTOWV#UYH@@+A)9_G7RLU]!^;#:2]1\0
MU+BE]G)H04'9J0.% 0[&DY5Z-)#745V;QTO(QTN;D7?Z;?"_]2B1W(NHW_%7
M=%6\A53M3F3:7 #+(XI" A>;Z<*G85+(/#@;7J!@-4T:98*"M7C90>%&"Q3V
M,"BLI06L; 043MBR>VZ<<:"0,ARIA D*\F]QI")2!)K2Z4:)YB.T<6Q$6_D"
MU'WP=PD!>Q=]22#!67JU0()[T@21)?5+Z%@Y^B&S$5A.F-IA0,)H$Q*,TR2)
M1(A>]W@16PCJ0ET#%-@9D&[DG#/,.=?%W"?A6KBFWZ4C"2^B;MN?T'9D)J*!
M]Y B2."B6TZ9S(A22$07_PV?3O+9H&!TO;:#PCP;*'Q*-FP+%%3._-D""KT)
M5'":A0D*= WC1EU1#U!0N=HB YIH07>7']UM!]%>L1"A#;^%Y^UG!#C=)5?2
M][] (&%@.=DZG==(,;+!0I8<).^SA>?H-+WS:5R?9Z8Y*8=^K'9V3SQEQ@2%
MHC$F*+!,L:^(.Y1?A8JI=R*P^$G4;/@YVH],1;IN*S+MY;1NU"G920T*?=^3
MLP,4@@(*7-]Q)?P$"N&\H-"N02&JBV.'(RBDK?EAU.<E5+$S"P*D8\WT76H0
MKS] /L1J-.U]$U5KO@O__ ?AG7:#%#5[Y3!H[,!!P:S+&:7K9D?E@,)H&RB,
MUY*^EQ H7 ?/[$\A1.M?[>9?HNWH="3JMM,>[!1%I^Z,X=L,W;@S(&'H06$0
MCN"IZ-)X_,W"BBIP;BH7RWFG7 <OW2!12%C[([1\]"8BWG>)YO9JV;I&-;B2
MNI/C<<.4^1?\?MVXM+*3O1$-%U!08R1;"6<$%$Z?Y06%FH& @KV/0A]S_C@
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M<-6)8)72NDB, (5/#5#H1?]A9I5-YV21"CY5==DYKR:$%^+76I%L]4HVLNW
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M&%4/]0>%T6@L@><S4$YQ9'G1Q:+7)0Q=\[Z&T-+'4+WI#VC<E8?V\@6:%>P
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M_NG7T3ZD];'H 52O?A)U;_]>YFJ8FK\KL!KQNAU(MA!(Z(KJP>5VBD^9%8R
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M&>ZY3CLI0Y-9HJ%IMT_)!@H&++B 0I>Z[AT'R3^N1<.N_\"__''Y?LI*KB*
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M,-F$WJX@DHV[T$Y?9.W6%Q%9\;A4%7APB9D.N&]8>C^Y=YE;$?)-W[+>E ,
MA8&&>-R/R1&'QRT.P4+FX9V(P/2;$9K[5=2N^Q5:";1T^U<@Q>J/K,PJ@\U=
M*GL85V#!M!P9!J13!2@8L#!\I]T?*-A#GS8[C 44BL;+FN"R7X"O'0$M5KSV
M3[D&@6G7PT^!GV_Z#11@W2B#=Q53;X1WZDUB%6QTF]=AZC$W]7N,];BIQLQ]
M]#@QQ_]G/]^ MPWG-6X<_#6&>H^.URR?=K,XS\/3[L2A:5_$X3D/HGS14PBM
M_ROJ=L] FW\#>AH.4)!9IS)@J9X!@8(:1!RL]<@!%,A)^PK/41F]CQHH6-1X
M)FND3(&%7/4SRUFJK&"N5)Y\>3P#P "+ O"2ZQ":=1>J%WP=M4L?1,.J[Z)V
MV3<1G4\!XANW4A!V%0)%$W00-D[V_\! P9YA,@-^+J!@,74XG9+Y;*>1PZ5@
M1DP/H=-[#N2/@2^?SKT"'J"\$N53;D%XR:-"Y]RZ?SIBE3J3V\F<W*U(21D[
MIK+2CJ!,?:\):Y:A=P0HG%) (9-V@P6KG52J/XKQAS/UJ:ZHM/BP(G#SCI=I
M[SV&\)Q[$)Q\E<RZ*3 [1@5S1],FZ0 *(0LPV$JV9L[)2Z]1,>DJ^&;>A>CJ
MI]"T\U5T^98@U;1/-#Z$35#HO&-V@..L>"=31P44;+"@ !.W"_>FNY064GL%
MG4/;T+R[$,'E/X)O]CWP36)??;: FI#5?G04#&G.8-0""KJUU9HK'"=TF'Y.
M1!5?AL#L>X6QL&'[?^E[V8!T2QE=BUKI5N 9@W3&@ $G4$C:0$'345LZ$@P2
M3IF*@ETM-5GZB,>T]>AV'P8+16-U=M_.\$<\3J P6BH)ENGJPH 5A?P!*@KY
MHUS?BU,$SBFF9HNPZ38F>9[/.*H5SGD=)U"PNT%,&ZC=MC3&\7FX:C'64JEV
MOWZN11PBE?S""71F7X:**12#O'$O_ L?1N6Z9U&W_16TELZ1*ER2P"Z#!6E#
MDOG:F*KZIA.:Y7($*)P"0($MI2@&4Q0$Q?206&0#V@Y.$Z&,T(('*."\&=ZB
MR\AAGR<\YR%AE*" (8]091Y+V^>(#70@]^]Y[+\19="& Y!"1J,7(#"9 EWZ
M?)7+OH^Z=YZG@&":</"RD(W5@L1EZ$1<2K)F:,JFFCMU@,)Q'4X#M![)P>T
M"X+@.8L]>2*"TRC@>^,.5"[X*JJ6/H3HLN\ANN('J"1G&EG^0SK,'T=DV>.$
M[A^7WXU%EKO_#@_RF,AP_W\ &_ QRP9^W/&\1^??(7)>H>5/(K#\*?B7_Q2!
M-;]%:./?4;6]&$VER]$9W8%XBU=ZBFVFCH0#(#A+Y ,/,S<34*@BH!":[08*
MX8\(*"BPX!RFT^!1#ZNQ4V>+LCGZ4PVW-@-\KCY)EIZ%DR;? /^L>R@0?00-
M&W^%YLV_1]OV%]#XWJ]1O8:NX\*O(S!3#8D&N*VC8+RT'[A8D;*R4<99N3)8
M?!T,-WOA0)_+$<QH15A5LL^E]SL6OH(S4%YX 0X742 T1PLT;GL)'>4+D:A]
M'ZG6"F1H/Z9Z6I&(=1-8X)YVG9TVK1V._3Q243AU@$(O#R<Z@((BJ##4UPHH
M]-+>R\0;D6KWBZIK>]D\\GW/([3P6[0^;T6@9*)4I3F(M=?DT5P'[6_S#9>\
M.6?'Z#TSGH UBXU=+-4$_[ROHF;C;]!V8#+YRW5(M5%P3/Y3?%.J1\_2#084
M;.I7JZ4BF7*! S-\KY(4#K KK(7<M]^*# =8+?O043J;WLOO:*]^B[ZOSPF8
M$7I8K4H], '"$*#! :Z4;U<^7LTFJ0X !F1^SSGT6A?!.^,V>.=_&U5,0E+&
M<U^["+A3+))J$U C0,^J*CA,GZM&+T/MS;14%)2=_&%FN[)OE(ISLEY##PV;
MEFQ]+F:W7?/,6K9EMP*YNR],ZY>SBF#/A%G)PT(G!;UBJ+()8VSP(7,/UO.;
M:MDH"Q0[Z;'-H'25&90NS-7)H%P'&!IC?5;W_&2.:H,6L'"6 M;D.\HG?Q9E
M,^Z";\&#"*WZ*6JW_A-MAV8)B4ZJY2#%GM4RJ,]G7\;L'TN-/>$8=#8D ,<Z
MASH"%(X1*&2$7K O$Y.#G_L+4XT?(AY>C9:=_T'UJA\A-/?+\$W^'"H*+H:?
MP$*(#LQ0'@5#K]-!]#HMTKP<L4A^?Z PG*'3J.Z#K.3>4@ZT..":="V"=!B'
M5SZ%^O=?0J=O,9+"H>XC)]6H:6"U8K/E_,T@\R<?*%2Z@D%W^X@"5F,$7(6*
MSB(G.0&AZ=<B//?SB"YY$+5K?X+&=WZ/QLU_0>.V?Z*! JJZ;2^3O:+M5=1J
MJW/88+?5#6#'^O\?YVO4TF?EGS7;_H.JK?]%]8XBU.Z>@<9#R] 6VH*>^D-(
M=D253H=P?\<D4'-G+AQ (34 4-A"0&&9 @I>6K?<FA#Z&(""G4U2^@.*F8@!
M QNKLXYU9+S4(2]GB&>L/L!9O^0Z^ @D!!<]@MI-OT/;GCQT'BI!MW<FVO;G
MHV[SGQ%9]00"M/^]!-ZYU< OLR]CK(&];&$>,VAG0*X9WE..G $ T_OU#U+,
MT&#$XZ@J"$^W&IAC/9?R@C-1FG\^RKB:-.\;B*Y[%BU[BM 37$UGPX?(=%8B
MU=V(1$\GXK$8XO$DX@GFX,\&"ZGC3"B, (6/!"AH<& !!68XX3DZ 0IMDLCB
MZE%7:*W,!52M^Z7*HG.+0]'YUAS=L0SQ.MMM5-(K5X;^*S4KF#__=)3EG4U
M]3)4S+P3P24/HW[+7]'E?5-$2].= 0$R&4=65,W$Z(JWTUP@00\Q.^[+2!4E
M:67=T]9L35P_=X]*6L1JT-=9@5A@&5JV_PO5*W\(_XQ;44'!.P?Q0:G^Y3JN
MA9-2^0C7Q559R+&M(%?/Q8T7,,(MH3P;43KS2PB]]2P:]TZC-?(. ;IR4"!!
MWUV[)E=)6$"A5YM\QK2JE"AA+1LH*):DDTN/:IC:["%>W8J6;UO$$#LXV80*
M-"UOWBAKN)EGUD)%=)_3LK2EW&0QN=9 LAF8SAXB5G%AKC8=O!>-L01NG<D:
MUXR% RA8<SCYSMD+-2A=Y3 G8#! H=(,2<L:&67M'_G\6N24_45% >T;SP4X
M5'0Y#C,[U^S[$%[%B9Y_HIW.MWCM9O1V>NE,J:'UTJ$4S9,]$M\E1631S)N-
M (63"A34O$)2!*=Z.;O:1H%0W39TE<Y$TWO/HWKY#Q"8]04*A)BC^F($Z, ,
MYIV!D  %55500"&G_Z8<1OE7]5?G2G 3*3Q#!IO]3',W\P[XYS^(J@W/H75?
M"6+A-4@U[16I^-Z$IK-,Q1Q]QY]&H."HQEB#JNK ELQ.,5<3+D&8F0:6?A-U
M&YY&RXZ_H^- ,3K+9J'+MPB=_J5D*Z2GN]._2JS#80/]W>D;X#:''?'_/X[7
M&.#_.URV$AV^%6CWKD!;!?WTK45[<)-4$F(-I4BVJ]YV*9&S\S6.O1^5H<KH
M#5A1.$E 066M<C4;T5CU,W^,!@QC-5@88V6 F DE2.='@(._8CH_)E'@3WLZ
MM.3[J-[X>S3OSD=/8 GBE:N0K%F/[L!""L8*4//.'Q!>^CWX9MX.W^0KZ?PY
MAX*0\:+L:8$%%P=]MAJI,U/&6:W/*,!0,(A95851+K 0),?C]RBG4S[I*I3/
MH&!MZ:.H?>\%M!Z8)E705,MAI#JC2,;:A&\_'H^3)10'OP$+!BB,##.?,D#!
M:CU*I1U[SM8/8/K;7LXV]D20:/J0]O)"U&Y[">$53Y ?O(T [^5:B=EDT)T@
MX5B @JIR1ST*>+/8FB_O=!S..Q=E)5?#/_=+J%S](S3O>H7VRW+R2:SN'J+W
MV$!GB<JB]])W*$;G2B^W"V5;VF$#WM^#/O[<;.R7DVS<<L3&>BZMZ*/ JJ_'
MAV3T+73OS4?#NJ?)3W\>Y867RIR: DYCC@THF#7ES#8;O16M=\)D$7P>'"ZY
M$@>FTOFP_$G4;/\/VGS+1.N$#A+TI5IH?=#9FHE;[(N] X$%"\ ;D-![TH&"
MG+6.-K20==Z:,W>LL+,%Y5J,4UH]G$G/'R=$##XR?SX'R]RV1O<7CA<+9EG(
M86J^;9SZVV,;#Y +.0?3\VKS6S9.*.S=9!YCU=R F 8PA8XVH2P*>[O=3H.%
M;(T&JWJ<ZV99$@K6'#LVR=. 09[+9@KS>;B"?8&<W653;Z:XCC6SGI;YFO:R
M^8C5;"-P64'KI4GVD( %W;YG428;GWQ<%/@C0.$8@8*QM 8+]/\4B/>U'4(B
MM!J=>SUHW/0;A!=\$]XI-],&O8(VP+D$%LXDH$ +V@(*N1HH9,TJ# LHZ&O@
M42U(0<]9M+'.AW?RM100?![A98^A<=O?T56FN)K1':1#LEXQ/*652-:G'BB8
M8(S71I[*\@A0*"&',/5R5"[X(FK?>APMV_^*[O)I2%:_A7335F3:]U-@6TI6
M0>;['S/ZS.WE!'S+D&8JS58*\-N\2/.P'??0QENDI8&=M0T2;$JV;':2@684
M3@90J-0.40YB%H'*9\:K,6)&/5; @FY1DX%W 0EGBWIKQ>2K43Y=G1\,PAMW
MY0N83#?M1(9%DSH.(EF_A8#8(C3N_"^B:W\&_[S[X)U^ \J+)] 91/M3G&2.
M9-O,L)T*L!R]K8Z9!9L-Z3-BW#?+-CA0("L:)18IHO\O8G$?34]9="$%)U=+
M !M9]2/)3'64+T"B82=]O\R"U(1DO /Q6 ]B A;('#,+2F]E!"B<2D!!/K\#
M*"23:3'.HJN>_ ;:LWX"^%O1=' Z*C?^ ?Y%WY9L-J\'O[!RY62Q_!P;4 CG
MV>N8VVY"K^?"^_H9*,T['V63/HO@P@=0L^E9M!\L1*I^ YTQ+  8!OT!I%M
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M\EEX;N%PX4243[L%7BVD6;_]-8JA"%PV[*9U7DMKIEG3_/?H.19;7\50[8X
MA9,(% 3Q<Q:$@O"^S@ %0UO1XUU(3_TRJE;_&($Y7X9ORN?@+9A 2)D6<=XX
MK5BI^/LC!4>J* SV^4UP; \V!UC4A7O;)GT.@7E?0_7:GZ/Y@_^@Q[\<&3HT
M6%RNCSFE62U7J@IQ:Q#U5-)1.%8S_,:N(-,:;!HM94\^N((EYR,P]4I$%GP9
M->M^3-?H7^BF]9!JV$(!\G[TQ0A4Q2+D6*I5!HH<_/^,<6D^1I^[IQJ]W55*
MN(\  O-\<T:N-]FI,GYFR-7!CN.D,K1ZA(>840A^C#,*SL%D2RS-@ 2'">&
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M)[Q_$(GH6VC?7XBJ];] ^>PO"_L0 V _!6^A@C&:M46WRQ2Z@8* A6$ !3O
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M93IWOP7__._ ._\15"SX/BH6/B;F773L5N$P[^+'X5_\!'QLBYZ@^Y^@VY]
M^2+^^W$$%O\0D<6/H'KQ0XC,N4?F$[R>BX4>->2B1SU*&ZBB4,1QB $*AJ)3
MB=%Q2PXG#KQ3;R 0]2#JMSR/CK+9B)-_[$WP6FE1S')"/.($"PZ@T->+=*]2
M94[* "O/%)U<H!#1!"N18MISDR]&U9R;4;_L:VA]^RGT[/X+4F4%Z W. JJ6
MH*]Z!?IJWQ*#V!J@9A50O9)LE?Y]]3!LE</H[QI^'GJ^FK5DZ\C6T^WKT5>U
M#GW1-<A$5B(=6HJD_TW$R"=U'IR,5@+U33O^@X:M+Z*6@&SUNF<)P#U%H.$[
M\-&ZK2"@759R+<H*+Y69!I_LHS-T'#?&6O^*X4J+R!4I\3B;F,(&"E9E05-C
M6W[.>:YH$,[/&V0F*/)3/%]47G0YRJ?>BB"MXZJWGT?+H=E(T-F=HK,[S=HX
MB38R\D],F7K<<Z@C0,$%%/HRO98-[[!.J[YL+L\G58L&MR#T,5UJ>P"INAWH
M\2U!\P>OH&K-3Q'FH2D6GN&^369Z8<<EA[5:&$>E2.S:F%H[H- (NXR3JH6_
M^"(1D^&R6IB0<N/VE]#M6RA#F)E./SFN!A4,B+C+L3JNCQ(H#"YZ,R X,,)4
MNG=;4949 2U5$I=R:/$$^*?PC,+]J%K_2S3NSD=7Z"TD6PXAW1U%'U>&9(8C
MX>J_M_OP^]M0CSG>__\X7\,\CBDQ4UH%-&4)&#E @@,4I%RB1[8ZLPSZGPI
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M6/ 1R/05G.-J)75JXL@:XJ1E48ZKVM1?S$T+N3GC5TL<--?2HY"SN^ ,I;'
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M=IW,-L1JMJ*]?*$XR\JW?@[_FU^'E]M!F'J/]B=7%NW!9C.3D&.?"8YSP2C
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M11.D=U*4,@VMEBG#6H?:T$#!V>NF*+A&Z8# 9%#/D7[!\BDW(K"0T.?ZWU&
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MQQ& PJ#OE8% 09^^%Y\G.8!WQBV(+'L8=1M_CO:#TY"JV8IT6SG2/0UJ[E%
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M8,&.I*.'O__*@I&24Z#0=/I!H5B!@G_&=00*]Q H?(M 01FNB>J1"Q3L]VE
M@4W6&!(8$+9NW8K5JU=CTZ9-V+ES)T*A$.+Q>)ZD-NT"!;ML'9?G1FER$S#$
MZ?F(-4L+$I\"]40VH?G@#%1M>1ZAU8_#2\F@=_H-XKC+)U26ZV?!>#E5"FM
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M"&UZCD!A!H'"%GIM82!#>W%OMP:%]"@HG'F@T$]D>B6)3ELG[T:JS0PX)_1
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M[>BM-4#AJZ)![1)0N(#RJ#D[O;//@4)6@4*B1T%! F<4#% (!8-D@U(SSKU
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MDCKO5/F1HV(&W&\\"%_-T^C85X@!5XW**O1Y)*L0"_:1#PHH7V0,D9/W%+:
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M'8.^:D2[#R,ZV""RH$KM2&42V(PRL%&=6Y]JX#?\/DNG;F.=5FO(82H%PHB
M1#S:CU.1=D3H,^JGY]>^^R5:MW/HC+U%@G9;T23)*JA!6\F@9^ZMI#UQNN=F
M-+(6)$RR%%S:-$$R3_;2JV10GFWQ'6A<\V\X6?,-M*^]';Z*J^0YJ]*EO"&6
MT1[/\#(@>T A]?FG6P,CQ5V&_[5:FK5AF*E"J7QNJ'47N@^7HWGK<W"O^39L
MBVZ3RQE53CA!/Y.Q.EMH@0733E,&FOIG9AE9@6IJ)I_'@RT9_-T;?HC672^+
M_P\T<5:A#O'!-D0#!/_2^Q74V1'C#&$(2LP4B>I!E\F?D_Y,3RG+-3-?@$#
MJ(<;C<.-F;<@*A4J]<D\N"<ZJ ZD8"L%:'720.RWKT3+KC_!ON91U"W^,FI+
MKI6L@KMH/*PJ#)E__LGJ!T,:KMAY<5:!G47I%V0@C+-J)M'M;+2L_QJZJQ]
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;Y;X^$U__!\;-AK0[D+8#     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228556432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,404,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230308272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,545<span></span>
</td>
<td class="nump">$ 25,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">541,771<span></span>
</td>
<td class="nump">708,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">10,006<span></span>
</td>
<td class="nump">22,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">16,969<span></span>
</td>
<td class="nump">15,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">19,245<span></span>
</td>
<td class="nump">23,333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">665,536<span></span>
</td>
<td class="nump">795,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">8,928<span></span>
</td>
<td class="nump">64,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">39,792<span></span>
</td>
<td class="nump">60,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">68,996<span></span>
</td>
<td class="nump">117,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,234<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">861,987<span></span>
</td>
<td class="nump">1,117,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,346<span></span>
</td>
<td class="nump">9,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">30,323<span></span>
</td>
<td class="nump">15,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">29,234<span></span>
</td>
<td class="nump">26,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">13,035<span></span>
</td>
<td class="nump">15,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">20,047<span></span>
</td>
<td class="nump">17,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">104,985<span></span>
</td>
<td class="nump">85,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">119,415<span></span>
</td>
<td class="nump">125,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">176,775<span></span>
</td>
<td class="nump">195,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,080<span></span>
</td>
<td class="nump">3,592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">403,255<span></span>
</td>
<td class="nump">437,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at June 30, 2022 or December 31, 2021, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized; 187,405 shares and 185,468 shares outstanding at June 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,549,360<span></span>
</td>
<td class="nump">3,516,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(8,191)<span></span>
</td>
<td class="num">(4,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(3,082,456)<span></span>
</td>
<td class="num">(2,832,995)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">458,732<span></span>
</td>
<td class="nump">679,508<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 861,987<span></span>
</td>
<td class="nump">$ 1,117,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228517456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">187,405,000<span></span>
</td>
<td class="nump">185,468,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230429840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 21,585<span></span>
</td>
<td class="nump">$ 28,330<span></span>
</td>
<td class="nump">$ 46,407<span></span>
</td>
<td class="nump">$ 51,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">5,115<span></span>
</td>
<td class="nump">7,667<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
<td class="nump">13,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">42,740<span></span>
</td>
<td class="nump">101,313<span></span>
</td>
<td class="nump">149,993<span></span>
</td>
<td class="nump">196,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,521<span></span>
</td>
<td class="nump">29,555<span></span>
</td>
<td class="nump">47,860<span></span>
</td>
<td class="nump">61,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="nump">106,045<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">107,520<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">174,421<span></span>
</td>
<td class="nump">138,535<span></span>
</td>
<td class="nump">315,803<span></span>
</td>
<td class="nump">271,574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(152,836)<span></span>
</td>
<td class="num">(110,205)<span></span>
</td>
<td class="num">(269,396)<span></span>
</td>
<td class="num">(219,597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,713)<span></span>
</td>
<td class="nump">33,427<span></span>
</td>
<td class="num">(4,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liabilities related to the sales of future royalties</a></td>
<td class="num">(7,228)<span></span>
</td>
<td class="num">(13,089)<span></span>
</td>
<td class="num">(14,757)<span></span>
</td>
<td class="num">(26,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">2,257<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income (expense), net</a></td>
<td class="num">(6,132)<span></span>
</td>
<td class="num">(14,957)<span></span>
</td>
<td class="nump">20,161<span></span>
</td>
<td class="num">(28,440)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(158,968)<span></span>
</td>
<td class="num">(125,162)<span></span>
</td>
<td class="num">(249,235)<span></span>
</td>
<td class="num">(248,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (159,068)<span></span>
</td>
<td class="num">$ (125,519)<span></span>
</td>
<td class="num">$ (249,461)<span></span>
</td>
<td class="num">$ (248,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding used in computing basic net loss per share (in shares)</a></td>
<td class="nump">186,800<span></span>
</td>
<td class="nump">182,698<span></span>
</td>
<td class="nump">186,323<span></span>
</td>
<td class="nump">182,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding used in computing diluted net loss per share (in shares)</a></td>
<td class="nump">186,800<span></span>
</td>
<td class="nump">182,698<span></span>
</td>
<td class="nump">186,323<span></span>
</td>
<td class="nump">182,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,312<span></span>
</td>
<td class="nump">$ 7,846<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 12,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">16,264<span></span>
</td>
<td class="nump">20,456<span></span>
</td>
<td class="nump">33,825<span></span>
</td>
<td class="nump">39,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 1,582<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230238864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (159,068)<span></span>
</td>
<td class="num">$ (125,519)<span></span>
</td>
<td class="num">$ (249,461)<span></span>
</td>
<td class="num">$ (248,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(988)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(3,079)<span></span>
</td>
<td class="num">(830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="num">(671)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="num">(955)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,659)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="num">(4,034)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (160,727)<span></span>
</td>
<td class="num">$ (125,798)<span></span>
</td>
<td class="num">$ (253,495)<span></span>
</td>
<td class="num">$ (249,591)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682229372864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,077,295<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 3,388,730<span></span>
</td>
<td class="num">$ (2,295)<span></span>
</td>
<td class="num">$ (2,309,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">17,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">23,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">(123,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(826)<span></span>
</td>
<td class="num">(122,967)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">994,506<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,429,734<span></span>
</td>
<td class="num">(3,121)<span></span>
</td>
<td class="num">(2,432,125)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,077,295<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,388,730<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
<td class="num">(2,309,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">3,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (249,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">904,975<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,466,001<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="num">(2,557,644)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">$ 994,506<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,429,734<span></span>
</td>
<td class="num">(3,121)<span></span>
</td>
<td class="num">(2,432,125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">1,483<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 12,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">23,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">(125,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="num">(125,519)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">904,975<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,466,001<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="num">(2,557,644)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">679,508<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">3,516,641<span></span>
</td>
<td class="num">(4,157)<span></span>
</td>
<td class="num">(2,832,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">(92,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,375)<span></span>
</td>
<td class="num">(90,393)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">607,889<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">3,537,790<span></span>
</td>
<td class="num">(6,532)<span></span>
</td>
<td class="num">(2,923,388)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 679,508<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">3,516,641<span></span>
</td>
<td class="num">(4,157)<span></span>
</td>
<td class="num">(2,832,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">1,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (253,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">458,732<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">3,549,360<span></span>
</td>
<td class="num">(8,191)<span></span>
</td>
<td class="num">(3,082,456)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">$ 607,889<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">3,537,790<span></span>
</td>
<td class="num">(6,532)<span></span>
</td>
<td class="num">(2,923,388)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">(160,727)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,659)<span></span>
</td>
<td class="num">(159,068)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 458,732<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 3,549,360<span></span>
</td>
<td class="num">$ (8,191)<span></span>
</td>
<td class="num">$ (3,082,456)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682225629952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">126 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (249,461)<span></span>
</td>
<td class="num">$ (248,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,825)<span></span>
</td>
<td class="num">(39,254)<span></span>
</td>
<td class="nump">$ 367,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liabilities related to the sales of future royalties</a></td>
<td class="nump">$ 7,228<span></span>
</td>
<td class="nump">$ 13,089<span></span>
</td>
<td class="nump">14,757<span></span>
</td>
<td class="nump">26,385<span></span>
</td>
<td class="nump">259,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,713<span></span>
</td>
<td class="num">(33,427)<span></span>
</td>
<td class="nump">4,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,951<span></span>
</td>
<td class="nump">5,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">11,103<span></span>
</td>
<td class="nump">23,714<span></span>
</td>
<td class="nump">32,064<span></span>
</td>
<td class="nump">47,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,171<span></span>
</td>
<td class="nump">7,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="nump">57,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,321<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Amortization of premiums (discounts), net and other non-cash transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,486<span></span>
</td>
<td class="nump">10,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,168)<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities', window );">Operating leases, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,627<span></span>
</td>
<td class="nump">11,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,833<span></span>
</td>
<td class="num">(2,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,588<span></span>
</td>
<td class="nump">14,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,520)<span></span>
</td>
<td class="num">(4,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,417)<span></span>
</td>
<td class="num">(159,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(247,014)<span></span>
</td>
<td class="num">(527,887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,423<span></span>
</td>
<td class="nump">612,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,983)<span></span>
</td>
<td class="num">(6,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,426<span></span>
</td>
<td class="nump">83,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="nump">28,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities', window );">Cash receipts from development derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">30,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,327<span></span>
</td>
<td class="num">(46,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,218<span></span>
</td>
<td class="nump">198,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 77,545<span></span>
</td>
<td class="nump">$ 152,345<span></span>
</td>
<td class="nump">77,545<span></span>
</td>
<td class="nump">152,345<span></span>
</td>
<td class="nump">$ 77,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset recognized in exchange for lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682312580832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We (individually or with a partner) are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in oncology and immunology.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of June&#160;30, 2022, we had approximately $628.2 million in cash and investments in marketable securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Bempegaldesleukin Program and the Restructuring Plan</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans for the Company&#8217;s future:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 14, 2022, BMS and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 7 for additional information on our BMS Collaboration Agreement.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we decided to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 4 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, subject to activities required for an orderly wind down of the studies, there will be no ongoing clinical development activities of bempegaldesleukin.    </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the Restructuring Plan), which were reviewed and approved by our Board of Directors on April 14, 2022. Pursuant to the Restructuring Plan, on April 26, 2022, our duly authorized officers implemented certain strategic, operational and organizational steps, including the prioritization of key Phase 2 development programs to advance our early stage research pipeline. In addition, we announced our plan to reduce our workforce by approximately 70% and to close our research facility in India.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and expect to incur significant costs resulting from these decisions and plans. See Note 8 for additional information on the effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three and six months ended June&#160;30, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2021 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 filed with the SEC on March 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of June&#160;30, 2022 and December&#160;31, 2021, our accounts receivable includes $7.4&#160;million and $21.4&#160;million, respectively, for unbilled net expense reimbursements from BMS. The remaining accounts receivable relate primarily to product sales. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable. We have not recorded reserves for credit losses for the three and six months ended June&#160;30, 2022 and 2021, nor have recorded such an allowance as of June&#160;30, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual employee termination benefits provided that the obligations result from services already rendered based on vested rights to such benefits when the payment of benefits becomes probable and the amount can be reasonably estimated,</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn, </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract termination costs when we cancel the contract in accordance with its terms, and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 for additional information on the severance expense that we recognized for employees terminated in connection with our reduction-in-force.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Asset Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. See Note 8 for additional information regarding the impairment charge we recorded in connection with our leased facilities and certain property and equipment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228509504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash and Investments in Marketable Securities</a></td>
<td class="text">Cash and Investments in Marketable Securities<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,545&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,218&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,771&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,828&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628,244&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in liquid, high quality debt securities which are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of June&#160;30, 2022 and December&#160;31, 2021, all of our long-term investments had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTM5_574175bf-cc3f-4a3a-8666-7dacd922de94"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTM5_b6cfd8b2-81fb-4e7c-b623-4b4795c2fc57">one</span></span> and two years.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,416&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,505)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,911&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,121&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,402&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,742)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,660&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,625&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December&#160;31, 2021, our gross unrealized losses totaled $0.7&#160;million, and our gross unrealized gains were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230829216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,969&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,801&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230752384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DevelopmentDerivativeLiabilityTextBlock', window );">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</a></td>
<td class="text">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ has primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we are the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $637.5&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin for the metastatic melanoma, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to $0 as of March 31, 2022, and we recognized a corresponding gain in the Change in fair value of development derivative liability. As discussed in Note 1, on April 14, 2022, BMS and we decided to end the development for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and that all other ongoing studies in the bempegaldesleukin program would be discontinued. We also announced that SFJ and we agreed to discontinue the SCCHN Clinical Trial. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presented the SFJ Agreement as a Development derivative liability in our Condensed Consolidated Balance Sheets, which we remeasured to fair value at each reporting date. As SFJ conducted the SCCHN Clinical Trial, we recorded non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remitted funding to us to support our internal costs of conducting the trial, we also recorded a corresponding increase to the development derivative liability. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the development derivative liability:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of March 31, 2022 and 2021, respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DevelopmentDerivativeLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Derivative Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DevelopmentDerivativeLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230709008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to Sales of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liabilities Related to Sales of Future Royalties</a></td>
<td class="text">Liabilities Related to Sales of Future Royalties<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.968%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Drug</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty under Purchase and Sale Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Sold</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (naloxegol tablets) and  MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca AB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (certolizumab pegol)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Continuous Erythropoietin Receptor Activator)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F. Hoffmann-La Roche Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our ongoing manufacturing obligations in both arrangements, we account for the proceeds as imputed debt (Royalty Obligations) and therefore continue to recognize these non-cash royalties as revenue. As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. Additionally, to the extent that the amount or timing of the royalty payments is materially different from our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the applicable Royalty Obligation. As of June 30, 2022, our imputed interest rates for the arrangements with RPI and HCR were 16% and 15%, respectively.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account of each arrangement (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,489&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,786&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,275&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,286&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,775&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Loss recognized from Settlement Agreement to resolve UCB&#8217;s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230673872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018, about the clinical trials of bempegaldesleukin. The Mulquin complaint was amended in May 2019. The defendants moved to dismiss and the court granted the motion without prejudice in July 2020. The Mulquin plaintiffs again amended their complaint and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice. The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument occurred on December 10, 2021. On May 19, 2022, the Ninth Circuit affirmed the district court's dismissal of all claims against the defendants. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A derivative action was also filed against certain of the Company&#8217;s current and former officers and directors, purportedly on the Company&#8217;s behalf. This derivative action is based on the allegations in the Mulquin action and on the premise that the Company&#8217;s officers and directors breached their fiduciary duties to the Company. The complaint for this derivative action was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF). Following a stay in the proceedings during the pendency of the appeal in the Mulquin action, the Company received an amended complaint on July 29, 2022, and the defendants will have until September 12, 2022 to respond to the amended complaint. Given the nature and status of the derivative action, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at either June&#160;30, 2022 or December&#160;31, 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div>To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230788160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License And Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our collaboration agreements in the three and six months ended June&#160;30, 2022, other than as described below for our Strategic Collaboration Agreement with BMS and Note 4 regarding SFJ.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing and commercialization of bempegaldesleukin, 35% of the costs to BMS and 65% to Nektar. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million. In 2020, we received non-refundable milestone payments of $50.0&#160;million in aggregate for the first patient, first visit in the registrational trials in muscle-invasive bladder cancer and adjuvant melanoma.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, on March 14, 2022, we announced our registrational trial in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the trials in metastatic melanoma and adjuvant melanoma. On April 14, 2022, we announced that our registrational trials in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided that these studies and all other ongoing studies in the program will be discontinued. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. However, without further development of bempegaldesleukin, we will no longer be eligible for the development, regulatory and sales milestones under the arrangement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognized BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. As discussed in Note 8, beginning in the three months ended June 30, 2022, we began reporting clinical trial, other third-party costs and employee costs for the bempegaldesleukin program in Restructuring, impairment and other costs of program. Accordingly, during the three months ended June 30, 2022, we recorded $7.6&#160;million, as a reduction of such expense for the net reimbursement from BMS. During the six months ended June 30, 2022, we recorded $24.9&#160;million as a reduction of research and development expense for the net reimbursement from BMS, reflecting the reimbursement recorded in the three months ended March 31, 2022. For the three and six months ended June 30, 2021, we recorded $24.8&#160;million and $51.4&#160;million, respectively, as a reduction of research and development expense for the net reimbursement from BMS. As of June&#160;30, 2022, we have recorded an unbilled receivable of $7.4&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">): NKTR-358 </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop NKTR-358, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0&#160;million and are eligible for up to $250.0&#160;million in additional development and regulatory milestones. We are currently in Phase 1B and Phase 2 development, where we share costs with 75% of the costs borne by Lilly and 25% of the costs borne by us. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to 25% of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the costs of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 development on an indication-by-indication basis in order for us to achieve the maximum royalty level under the Lilly Agreement, and further</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, we will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales.  Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lilly Agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The Lilly Agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are entitled to significant development milestones under this arrangement, through June&#160;30, 2022, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 5, we have sold our rights to receive royalties from these other collaboration agreements. Our non-cash royalty revenue which totaled $16.3&#160;million and $33.8&#160;million for the three and six months ended June&#160;30, 2022 and totaled  $20.5&#160;million and $39.3&#160;million for the three and six months ended June 30, 2021, respectively, represents revenue for granting licenses which we had satisfied in prior periods.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $40.0&#160;million of regulatory milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230779872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Restructuring, Impairment and Other Costs of Terminated Program</a></td>
<td class="text">Restructuring, Impairment and Other Costs of Terminated ProgramAs discussed in Note 1, because our registrational trials in bempegaldesleukin did not meet their primary endpoints, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors, and, during April 2022, we announced the Restructuring Plan to prioritize key Phase 2 development programs, to advance our early stage research pipeline and to reduce our workforce by approximately 70% from approximately <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735 to approximately 225 employees. In connection with these events, we reported the following costs in Restructuring, impairment and other costs of terminated program in the three months ended June 30, 2022:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Severance and related benefit costs pursuant to the Restructuring Plan;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impairment of right-of-use assets and property, plant and equipment resulting from the Restructuring Plan, primarily reflecting excess office and laboratory leased spaces in San Francisco, CA; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract termination and other costs associated with these plans. Previously, during the three months ended March 31, 2022, we recognized an initial $1.5&#160;million in cancellation fees related to certain manufacturing activities for bempegaldesleukin.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In prior periods, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin primarily in research and development expense. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,520&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program for the three and six months ended June 30, 2022 includes a reduction of $7.6&#160;million for the net reimbursement from BMS. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and Benefit Expense</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the reduction in force under our Restructuring Plan are entitled to receive severance payments and certain Company funded benefits. We recognized severance and benefit expense in full for employees who were notified of their termination in April 2022 and have no requirements for future service, and we are recognizing expense for employees who are required to render services to receive their severance and benefits over the service period ratably over the service period. This service period began in April 2022 and all will end during 2022. The following table provides details regarding the severance and other termination benefit expense and a reconciliation of such liability for the three months ended June 30, 2022, which we report within Accrued compensation on our Condensed Consolidated Balance Sheet (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">No service period</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service period required</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total severance and other termination benefits, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,869&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability as of June 30, 2022 for employees terminated with no requirements for future service primarily relates to final severance paid in July 2022. We may record adjustments to severance and benefit expense in future periods as our estimates of the costs of benefits change or when an employee terminates before the end of their requisite service period. However, we do not expect that such adjustments will have a material effect on our results of operations or financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Right-of-Use Assets and Property, Plant and Equipment</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our Restructuring Plan, we have consolidated our operations by exiting all of the office space from our leased facility at 360 Third St. and certain laboratory and office spaces at our leased facility at 455 Mission Bay Blvd. South, both in San Francisco, CA. We are seeking to sublease these spaces, while still maintaining sufficient office and laboratory space to allow our team to develop our proprietary programs. We have also terminated all research and development activities at our owned facility in India, which we plan to sell. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these plans, we reviewed each of our excess spaces for impairment as of May 31, 2022, when management had determined which spaces we would retain and which spaces we may sublease. As part of our impairment evaluation of each excess space, we separately compared the estimated undiscounted income for each sublease to the net book value of the related long-term assets, which include right-of-use assets and certain property, plant and equipment, primarily for leasehold improvements (collectively, sublease assets). We estimated sublease income using market participant assumptions, including the length of time to enter into a sublease and lease payments, which we evaluated using current real estate trends and market conditions. If such income exceeded the net book value of the related assets, we did not record an impairment charge. Otherwise, we recorded an impairment charge by reducing the net book value of the assets to their estimated fair value, which we determined by discounting the estimated sublease income using the estimated borrowing rate of a market participant subtenant, which we estimated to be 6.4%. For our India site, we recorded no impairment charge because the estimated net proceeds from the sale exceed the net book value of the site. We have classified the India facility as an asset held for sale as of June 30, 2022 and report this in other current assets in our Condensed Consolidated Balance Sheet. Additionally, we recorded an impairment expense primarily for software which we plan to abandon and certain excess equipment based on the estimated income from selling such assets. We recorded impairment charges as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease Right-of-Use Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of impaired facilities before write-off</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Fair value of impaired facilities &#8212; Level 3 of Fair Value Hierarchy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment expense for facilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of other property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total impairment of right-of-use assets and property, plant and equipment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our property, plant and equipment as of June 30, 2022 and December 31, 2021, reflecting the effects of the impairment charges and held-for-sale reclassification.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,158&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,385&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,348&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,386&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,039)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,044&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,347&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>We may record adjustments to impairment expense in future periods as we enter into sublease or sale agreements or change our estimates when additional information becomes available to us.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230785728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2022, the stockholders of Nektar approved an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 5,000,000 shares.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our Restructuring Plan, we recorded the benefit for the forfeitures of stock awards from employees who were terminated as part of our reduction-in-force during the three months ended June 30, 2022. We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,714&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards of our common stock as follows (shares in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230377968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. Potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,543&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,352&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,435&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,870&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228483792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We (individually or with a partner) are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in oncology and immunology.</span></div>Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Results of Bempegaldesleukin Program and Reorganization and Restructuring Plans</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Bempegaldesleukin Program and the Restructuring Plan</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans for the Company&#8217;s future:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 14, 2022, BMS and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 7 for additional information on our BMS Collaboration Agreement.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we decided to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 4 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, subject to activities required for an orderly wind down of the studies, there will be no ongoing clinical development activities of bempegaldesleukin.    </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the Restructuring Plan), which were reviewed and approved by our Board of Directors on April 14, 2022. Pursuant to the Restructuring Plan, on April 26, 2022, our duly authorized officers implemented certain strategic, operational and organizational steps, including the prioritization of key Phase 2 development programs to advance our early stage research pipeline. In addition, we announced our plan to reduce our workforce by approximately 70% and to close our research facility in India.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and expect to incur significant costs resulting from these decisions and plans. See Note 8 for additional information on the effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three and six months ended June&#160;30, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2021 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 filed with the SEC on March 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Significant Concentrations</a></td>
<td class="text">Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements.We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual employee termination benefits provided that the obligations result from services already rendered based on vested rights to such benefits when the payment of benefits becomes probable and the amount can be reasonably estimated,</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn, </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract termination costs when we cancel the contract in accordance with its terms, and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 for additional information on the severance expense that we recognized for employees terminated in connection with our reduction-in-force.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Asset Impairment</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Asset Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. See Note 8 for additional information regarding the impairment charge we recorded in connection with our leased facilities and certain property and equipment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228639216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,545&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,218&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,771&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,828&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628,244&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,416&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,505)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,911&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,121&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,402&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,742)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,660&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,625&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682231699664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,969&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,801&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682225616048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the development derivative liability:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of March 31, 2022 and 2021, respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230773040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to Sales of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock', window );">Schedule of Purchase and Sale Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.968%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Drug</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty under Purchase and Sale Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Sold</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (naloxegol tablets) and  MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca AB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (certolizumab pegol)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Continuous Erythropoietin Receptor Activator)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F. Hoffmann-La Roche Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock', window );">Schedule Of Liability Related To Sale Of Potential Future Royalties</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account of each arrangement (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,489&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,786&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,275&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,286&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,775&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Loss recognized from Settlement Agreement to resolve UCB&#8217;s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability Related To Sale Of Potential Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Purchase and Sale Agreement [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682312527056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring, Impairment and Other Costs of Terminated Program</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,520&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The following table provides details regarding the severance and other termination benefit expense and a reconciliation of such liability for the three months ended June 30, 2022, which we report within Accrued compensation on our Condensed Consolidated Balance Sheet (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">No service period</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service period required</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total severance and other termination benefits, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,869&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>Additionally, we recorded an impairment expense primarily for software which we plan to abandon and certain excess equipment based on the estimated income from selling such assets. We recorded impairment charges as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease Right-of-Use Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of impaired facilities before write-off</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Fair value of impaired facilities &#8212; Level 3 of Fair Value Hierarchy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment expense for facilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of other property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total impairment of right-of-use assets and property, plant and equipment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our property, plant and equipment as of June 30, 2022 and December 31, 2021, reflecting the effects of the impairment charges and held-for-sale reclassification.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,158&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,385&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,348&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,386&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,039)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,044&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,347&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230768224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,714&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-based Compensation, Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards of our common stock as follows (shares in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230907456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">Potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,543&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,352&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,435&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,870&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682229326416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 628,244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 628,244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 798,783,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,492,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Accounts receivable, credit loss expense (reversal)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce termination, percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228329680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,545<span></span>
</td>
<td class="nump">$ 25,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">541,771<span></span>
</td>
<td class="nump">708,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">8,928<span></span>
</td>
<td class="nump">64,828<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 628,244<span></span>
</td>
<td class="nump">$ 798,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230402192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaximumMaturityPeriod', window );">Maximum maturity term for debt securities investment</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaturityTerm', window );">Weighted average maturity term for debt securities investment (or less)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Investments in Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maturity date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maximum maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LongTermInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LongTermInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228415152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 18,726<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">628,244<span></span>
</td>
<td class="nump">798,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">561,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">557,660<span></span>
</td>
<td class="nump">762,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">141,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">139,911<span></span>
</td>
<td class="nump">278,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">415,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">412,874<span></span>
</td>
<td class="nump">478,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Obligations of U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,875<span></span>
</td>
<td class="nump">5,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">9,516<span></span>
</td>
<td class="nump">10,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">$ 42,342<span></span>
</td>
<td class="nump">$ 23,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682233006464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,099<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">13,837<span></span>
</td>
<td class="nump">9,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">3,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 16,969<span></span>
</td>
<td class="nump">$ 15,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228465904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember', window );">SFJ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementCommittedFunding', window );">Committed funding (up to)</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount', window );">Success payments (up to)</a></td>
<td class="nump">$ 637,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementCommittedFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Committed Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementCommittedFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-Based Payments, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682229537600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details) - Development Derivative Liability - Fair Value, Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at beginning of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,597<span></span>
</td>
<td class="nump">$ 27,726<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense', window );">Non-cash research and development expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,547<span></span>
</td>
<td class="nump">4,951<span></span>
</td>
<td class="nump">5,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Cash receipts from SFJ</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in the fair value of development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,713<span></span>
</td>
<td class="num">(33,427)<span></span>
</td>
<td class="nump">4,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,607<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682224967664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">126 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,825<span></span>
</td>
<td class="nump">$ 39,254<span></span>
</td>
<td class="num">(367,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">$ 7,228<span></span>
</td>
<td class="nump">$ 13,089<span></span>
</td>
<td class="nump">14,757<span></span>
</td>
<td class="nump">$ 26,385<span></span>
</td>
<td class="nump">259,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">179,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">176,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,775<span></span>
</td>
<td class="nump">$ 195,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(297,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">69,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">69,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">109,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">$ 107,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities On Sale Of Future Royalties Unamortized Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Potential Future Royalties Non Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PartialRepaymentOfRoyaltySaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Partial Repayment Of Royalty Sale Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PartialRepaymentOfRoyaltySaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltyMonetizationProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Monetization Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltyMonetizationProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682232994448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liabilities Related to Sales of Future Royalties - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability discount rate</a></td>
<td class="nump">0.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability discount rate</a></td>
<td class="nump">0.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltiesLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltiesLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228634544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember', window );">Legal Matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682223625968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th"><div>Jul. 23, 2017</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,330,000<span></span>
</td>
<td class="nump">46,407,000<span></span>
</td>
<td class="nump">$ 51,977,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol Myers Squibb Company | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfStockConsiderationReceived', window );">Sale of stock consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly And Company | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly And Company | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions', window );">Percentage of regulatory milestones payments will be reduced under certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur', window );">Percentage of regulatory milestones payments will be reduced if conditions occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly And Company | Nektar's | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Company | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="nump">$ 24,900,000<span></span>
</td>
<td class="nump">24,800,000<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="nump">51,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Opdivo | Bristol Myers Squibb Collaboration Agreement | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Opdivo | Bristol Myers Squibb Collaboration Agreement | Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,456,000<span></span>
</td>
<td class="nump">$ 33,825,000<span></span>
</td>
<td class="nump">$ 39,254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received, if conditions occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received under certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of funding Phase three development costs on an indication by indication basis borne.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in Phase 2 development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in production costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received from license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682230427392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>employee</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Contract termination and other restructuring costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 2,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce termination, percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682232961168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</a></td>
<td class="nump">$ 20,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and benefit expense</a></td>
<td class="nump">27,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="nump">57,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,321<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Contract termination and other restructuring costs</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="nump">$ 106,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682229421728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="nump">$ 106,045<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 107,520<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total severance and other termination benefits, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of March 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="nump">27,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="num">(12,881)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of June 30, 2022</a></td>
<td class="nump">14,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithNoServicePeriodMember', window );">No service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total severance and other termination benefits, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of March 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="nump">23,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="num">(12,881)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of June 30, 2022</a></td>
<td class="nump">10,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithServicePeriodRequirementMember', window );">Service period required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total severance and other termination benefits, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of March 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="nump">4,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance as of June 30, 2022</a></td>
<td class="nump">$ 4,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithNoServicePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithNoServicePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithServicePeriodRequirementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=nktr_EmployeeSeveranceWithServicePeriodRequirementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228560304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expense for facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of other property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="nump">$ 57,321<span></span>
</td>
<td class="nump">57,321<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">87,268<span></span>
</td>
<td class="nump">87,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expense for facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of other property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment | Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">16,348<span></span>
</td>
<td class="nump">16,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember', window );">Operating Lease Right-of-Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expense for facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember', window );">Operating Lease Right-of-Use Assets | Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">70,920<span></span>
</td>
<td class="nump">70,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3 | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">35,067<span></span>
</td>
<td class="nump">35,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3 | Property, Plant and Equipment | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">6,976<span></span>
</td>
<td class="nump">6,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3 | Operating Lease Right-of-Use Assets | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">$ 28,091<span></span>
</td>
<td class="nump">$ 28,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682229370576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 39,792<span></span>
</td>
<td class="nump">$ 60,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember', window );">Building and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">83,158<span></span>
</td>
<td class="nump">97,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">36,738<span></span>
</td>
<td class="nump">42,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">28,391<span></span>
</td>
<td class="nump">28,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">23,743<span></span>
</td>
<td class="nump">22,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures, and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">7,318<span></span>
</td>
<td class="nump">10,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember', window );">Depreciable property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">179,348<span></span>
</td>
<td class="nump">201,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(143,304)<span></span>
</td>
<td class="num">(148,039)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">36,044<span></span>
</td>
<td class="nump">53,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 3,748<span></span>
</td>
<td class="nump">$ 7,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682233044112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember', window );">2017 Performance Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682228388032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 11,103<span></span>
</td>
<td class="nump">$ 23,714<span></span>
</td>
<td class="nump">$ 32,064<span></span>
</td>
<td class="nump">$ 47,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">649<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">4,751<span></span>
</td>
<td class="nump">13,479<span></span>
</td>
<td class="nump">16,793<span></span>
</td>
<td class="nump">27,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">4,781<span></span>
</td>
<td class="nump">9,519<span></span>
</td>
<td class="nump">13,032<span></span>
</td>
<td class="nump">18,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 922<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 922<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682223537680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Activity (Detail) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="nump">$ 9.78<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 10.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
<td class="nump">3,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="nump">626<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, of RSUs granted (in dollars per share)</a></td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="nump">$ 18.20<span></span>
</td>
<td class="nump">$ 6.10<span></span>
</td>
<td class="nump">$ 19.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139682233091168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">20,543<span></span>
</td>
<td class="nump">18,352<span></span>
</td>
<td class="nump">21,435<span></span>
</td>
<td class="nump">18,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>nktr-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktr="http://www.nektar.com/20220630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktr-20220630.xsd" xlink:type="simple"/>
    <context id="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia4e3b25b44f741e29bebfd8f823ae5ab_I20220729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="i207fe7daf0ce450ab750e00dde6b86c4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5776247877d44fa1a76a034a60ca9a45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab10c83366854752a16f76890719307a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i841d22063d474fa5b3b392a4925ca344_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id98ac0fa001e4daab8a52e2248b1146c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie9530c36c4b448839ff7ef902cfd13dc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibaa02756dcbe4a1a871ce1cb0480648d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i957bd179292a4a5f8bea0ec87a04ddac_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2e6059c3a6a244129de957ee89ff70fc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i82df606601154dc1ad7096a861539bf7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i51c7b009052b4c3db8cb98c20f670ac9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5a6d564c98e44ea1bb8b4ec60494b8bb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i134972093bfc48989eb2da3ed230985f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib60cd739b0c941a290a478c66b5d7ae8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i04be0f98fd20499e95230b26650d671c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia6c832ade51b45958d331545ae3e5dc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i207702fa8b624c6685cbfa6fc0824271_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e9a5d5deddf468b87ac44df66d21b86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93c37c43548a4597827bc1c98a494182_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec541b07f4024b509da17efe3def4f82_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19adf3d7365740b8858300248f7a335e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8a50cc46191d4f39bb966fafeb0e21e3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icafc13b8f8e341f385a8e18d347395f3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iafa6f15b9c6c42eb988d570abd03ec38_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic71c4e96623541daac88b34839da139e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b44eabefa5748f3b2039c96188a4ea4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i13345764e6d142fba76c8c33e9ce581f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id81e115f70424914b18921a48b6334c6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id9463547a4e54c51a8dae165b31e8443_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3d42324a1f854a268dd508881663f4b2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie0e5f79481a6422383f5010e8d560526_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id3c21ab7235041cd9295a6a01131a511_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia46078182c6d4bf9b8244c13bb5ada0c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id92ad17e88394b29b2c99010d4cfde2b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2d89fcb27e2e40da9712016c38d184da_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0352e962dc144389a178d00a7ff496fb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6c2e13b9ea7a4dcf8081838f1ac66a94_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4bfcf4e2d4804d659adca4c109ad23d1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i332b83a475bf4c03a2f3b3c3d925e70a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib6abdeb335de487c9793e2cad1674f4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5e39b9fd4534db1890613d6cbab71a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida61f606d16e4a479dbd86a2a2078bcb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if034602e638345f8a92708bdd04f4ae4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74a11ce6ef2f4211a0e058edcf0f297a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i16f9f7814fe344ab965d049b1bf8498d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6cf30f1f3976425f9ae1a9658814d0a2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i24276f68c0f648ce93afcce8e8ccb424_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5b081e4b21eb44e3937cc738e930511a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i947f1c275a9b45f0a3c9254c3b4831ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2d041e6febc8402f9919661245a523c4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i47859d4a9c7d444ea3fc5298c02e72eb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i021df6170fef4aa0940cfaf057de5391_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6863c3c60a704766bc19dbf81c2dcb5b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i741af916cbcf43e186ee1732ed353f02_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i73b2f1f3796c48159ef8f2ec154733e9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5340ad5b6f0045e68f5d19b34ed7b610_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5db06ec5739d430ab6e1129243313c23_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i93db7cc57e114d759dc91e2753b81b55_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i86e75a96d7ae4fb5941842c8f737bbc8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia2b9522e14ad475e9d048da16aa5b505_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1443f9bb2a2a449b8e75120a43351e1e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6844748a7747471187efa284c70c9b40_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i2fb960f7e2be4ba7b0f30d51ecbfb755_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8729a4959d1742a08e7c7a9e6181f0a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia518ccd858fb499086a0d1804fb52ded_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id2f38983ece7482091edcf1be3b8181d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66e409cb85994a9abd0992f91c81602e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b4fb75e85ef4d1da810d56d536e5949_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0737ddba317b4605a758d1342bb280e1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icd6d6cf71b0b4e4cb1bd7a9a8a889eaa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63723a98759b4da988fffbbea0791b9d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i22f239069b834dec8cbd03936544ce8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5873fdec0d5484a8a91ad052ca94c7b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id98fd41da4fd448aa47ed43c6f62a705_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie76220fe2fa146ab81b848b799537428_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5c9aa8ae8ab44df7bce7acd7e0dd79d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b0f9be97ef3499ea6911ba085621ae3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie8ed5efbb1774febb2171044acdc2732_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice3a2c19d2b5444eaed3f904cc22980b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id459719606054ed78ab057269952a7b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i751eb150d22f4b73820c3eb0fdd04e8d_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="i6b68ac442765412db42b3953906b0388_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i95ace3aff3a44be7928b81e09398f163_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icde60c2bb5d4479b97cd2cd805d5a6bb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie6ef03c0e8b845309927dbe4dfbda529_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3a1586d1667c4181ab22d8c15f8e9bca_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie21c1fe452b344cea3b108885a4d4a8b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i57c770143f6e43cc8285c4e87e608f39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec257d9c2a4f4ca29ba184473f2f37bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id755a03fdc2b4e99b02634a338a1d47e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0fd48c3f03db4bea80b8a4775bd85320_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7c3682511cdc470e8b31f4be9255bc51_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9ffcae4931614a41b546c5604b6e9e1a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i07faaf6c80274e79b161089c13725a99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80ddb5385d944743a6830e905272b6dc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if11fbbe66ec44a33844d1df024a81f34_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="ib0f61ce40f5741b1bd39e0dce462d66f_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i434d1fce8cc349169ce2249b32af62e5_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i5b4e6c90ab19450e859fb50421c353c0_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i689d7549c612490aa4442f5f5348ccf0_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="id4bfcb6279024241948e7bd08d4d1b15_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="ie055df71b6fe4ad78a3fae8b679f8f1b_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="id5048bfc963648bd9dd0de98c3c9f77f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i545e1ec1c15e497d8d84331994a8de35_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8cb09da3230846e4ab889acaf256b09a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6a74c1627d594a4e9983b68d9cb5016a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i55a25cbb90084904aaa526c771ddf88f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2710a7259237431b952f8e9e2f6ca813_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i06b66ce62bc84a1e8198557985db717e_D20170723-20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-23</startDate>
            <endDate>2017-07-23</endDate>
        </period>
    </context>
    <context id="i709e2f46181a4b05a3abc2e27c2e31e3_I20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-23</instant>
        </period>
    </context>
    <context id="ic5ed1fb4aeaf4781a0044453513572b1_D20170723-20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-23</startDate>
            <endDate>2017-07-23</endDate>
        </period>
    </context>
    <context id="i4c14708c9dc14478a8d5ecaefcbb0ee5_D20170723-20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-23</startDate>
            <endDate>2017-07-23</endDate>
        </period>
    </context>
    <context id="id60d7ddcd1e843edacbce13b2a891386_D20170723-20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-23</startDate>
            <endDate>2017-07-23</endDate>
        </period>
    </context>
    <context id="i4e937e61c4a04a74b304ed91d94164d3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i615612becd454568aed79f306f2b522e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic87a58d05dff437199600e83c801a439_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="ia2f06c20fdeb4692aecab09bd5ba73dc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iac52ca5498ce49769a17fcd39f41a8fe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i30a2d694cc3e4307a91fcd4094b87e05_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia3a1676fb6a54c20884fa6fd60c2e2c7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia26bb03096c94a0cb77035930f749cab_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia0541e02c0b140788f808cb99a415cce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithNoServicePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifaeb6b4f62ff443a849137f15836e9cf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">nktr:EmployeeSeveranceWithServicePeriodRequirementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5ce6c1dda32f4aad9544682d143fc875_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i497fa308a3a645399b2e66b525053f40_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1540676709064b73bec30295a78b402b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6a99a4cd3e9046998329b115338a1fcf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifbf30fbd9d0b453c90b68fbde9485002_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3d93efed2f4445efbb3ddeb1f2270dee_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i575b5f648bf14d37af112b07599ee280_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i90314768134649a19db482bb55a94126_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic166b3669ca64e7781374dbce5ce7ae2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i79e0f4b9899445bfb9f7c130223aa7e0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib642b7862a8f41ebaf418619e6c1e3a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73b2d39f16fe45808af4224f9bb7e64a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9cdb1245c2a242b295b7228ac4ac5bfd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i278bdb80843a4d15829b02b5f7e5db58_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4699c5afe4c64c4dab6ccd99e97a4420_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1e3d5e8c9da41acba432436d90e144e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2392ef5c8b944214b18e26ee24b8b8f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i597b24d94a354403bcb197617d6325c3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idcf4331b31d34c4b8595b0bf92ffe39c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13e1155ab7ba47dfa1bb5c48d087629a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie29cf24f92e945298307779be936b4b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0c160117d32471bba70bb96f864292d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3143ddecf7734d3da635d16bd5e504a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8529e0af2b847e992427d335aa69816_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i33ecfd9df5834d09abbc58af261ebf32_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9c21bdadf59b4c48a135191cd5c2ec54_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i27d1141edbfe4feb8e6950e0879e5c18_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3cb0b12b5faa4aaba9bdc2b06745202f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6659ab393074492bbe414ddb56231ee4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iecfbea4ad565429885a50c6fba0cc5b8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1cecbd4c604b48409676aa9a35884b89_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i34088cc50d6948ccbe3650a776356dc9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b3fe74ae0994a9b8a3cb73f23feba72_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib91712b5e54b4334b079f6d3036b9a32_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2f2c5502b65c4bc38990dea8219187f9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id493f1b7c27c408ea3daa0171ccfbdbd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifa4c735c57bc4b3cbe3c2e99a3d9895e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i34db7c40bdc449ff8d949f1f5970651c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i58da4c5a8eb049b2ae0fe612bc3870d4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4a9af591eefe4df68e2c4f1f5bd76bca_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e718894f1c9465093719bbd74467c63_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9172d4dea5534ee5a60b8140527f533b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifd2b36e57d474f11a75428893dd08b02_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7f5070c46f774b5ba4d6c3752a1c61f0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="employee">
        <measure>nktr:employee</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80L2ZyYWc6YmMyMGE0ZmEwYjVjNDdjM2EwZjllNzc1MDNjMjA2YjcvdGFibGU6NDg3NzZiNjk5Y2MxNDhkYTk5ODMzM2ExZWE3YTMxODcvdGFibGVyYW5nZTo0ODc3NmI2OTljYzE0OGRhOTk4MzMzYTFlYTdhMzE4N18yLTEtMS0xLTMwNTUy_80de16ce-8abf-435e-808c-8a22aff7ecbe">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80L2ZyYWc6YmMyMGE0ZmEwYjVjNDdjM2EwZjllNzc1MDNjMjA2YjcvdGFibGU6NDg3NzZiNjk5Y2MxNDhkYTk5ODMzM2ExZWE3YTMxODcvdGFibGVyYW5nZTo0ODc3NmI2OTljYzE0OGRhOTk4MzMzYTFlYTdhMzE4N180LTEtMS0xLTMwNTUy_c00ae5d7-f2df-45dc-99dc-9584dea2f118">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80L2ZyYWc6YmMyMGE0ZmEwYjVjNDdjM2EwZjllNzc1MDNjMjA2YjcvdGFibGU6NDg3NzZiNjk5Y2MxNDhkYTk5ODMzM2ExZWE3YTMxODcvdGFibGVyYW5nZTo0ODc3NmI2OTljYzE0OGRhOTk4MzMzYTFlYTdhMzE4N181LTEtMS0xLTMwNTUy_5671b4d6-cfc7-4515-a253-4c62ac66f9a6">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80L2ZyYWc6YmMyMGE0ZmEwYjVjNDdjM2EwZjllNzc1MDNjMjA2YjcvdGFibGU6NDg3NzZiNjk5Y2MxNDhkYTk5ODMzM2ExZWE3YTMxODcvdGFibGVyYW5nZTo0ODc3NmI2OTljYzE0OGRhOTk4MzMzYTFlYTdhMzE4N184LTEtMS0xLTMwNTUy_0e06e235-4a21-4f75-8c51-fd9e18f9cd5c">0000906709</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80L2ZyYWc6YmMyMGE0ZmEwYjVjNDdjM2EwZjllNzc1MDNjMjA2YjcvdGFibGU6NDg3NzZiNjk5Y2MxNDhkYTk5ODMzM2ExZWE3YTMxODcvdGFibGVyYW5nZTo0ODc3NmI2OTljYzE0OGRhOTk4MzMzYTFlYTdhMzE4N185LTEtMS0xLTMwNTUy_4efc2c62-fb9c-4282-b390-0f58dda6f9f6">--12-31</dei:CurrentFiscalYearEndDate>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="ia518ccd858fb499086a0d1804fb52ded_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTM5_574175bf-cc3f-4a3a-8666-7dacd922de94">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="id2f38983ece7482091edcf1be3b8181d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTM5_b6cfd8b2-81fb-4e7c-b623-4b4795c2fc57">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <dei:DocumentType
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjU5_e27a9ff5-0d69-42cd-a929-3b8df74f4e56">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6YWEwNDczNTJlNjM0NGQyNWFlZjFlNTZmNjI5YjY3ZTgvdGFibGVyYW5nZTphYTA0NzM1MmU2MzQ0ZDI1YWVmMWU1NmY2MjliNjdlOF8wLTAtMS0xLTMwNTUy_b9232417-d1d1-4e3b-abd7-cdddee9016fb">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yNjY_c7eb90ce-f581-4e70-914a-466f5ff09587">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6NzE1YWExMjNkZjYwNDAyYmI0ZWU5NDFmZmU0MzgzNWYvdGFibGVyYW5nZTo3MTVhYTEyM2RmNjA0MDJiYjRlZTk0MWZmZTQzODM1Zl8wLTAtMS0xLTMwNTUy_849aebed-99cc-4d10-ae44-539aa8d4a50b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjU2_3930c1e5-2dc1-4f89-98c9-cdb721a078a2">0-24006</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjYw_d831eb3d-a949-4cb9-b62f-ffacaaadc718">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6MDRlOGY4MzZjMjkxNDRkOGI4NTU5MGJkYzIzZjAzMTkvdGFibGVyYW5nZTowNGU4ZjgzNmMyOTE0NGQ4Yjg1NTkwYmRjMjNmMDMxOV8wLTAtMS0xLTMwNTUy_9408f402-20d4-4046-b0eb-d9996c61b4e5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6MDRlOGY4MzZjMjkxNDRkOGI4NTU5MGJkYzIzZjAzMTkvdGFibGVyYW5nZTowNGU4ZjgzNmMyOTE0NGQ4Yjg1NTkwYmRjMjNmMDMxOV8wLTItMS0xLTMwNTUy_cdfeccca-b11a-434a-9f68-473479c7bf95">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjU3_c6ad1ecc-23a5-44eb-a07c-0357fe674786">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjYx_2cf5a1dd-4402-43c7-9cba-bca2031c43c7">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjYy_b3287541-fbff-4d41-8758-8ca626e2b9b1">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjYz_697492f3-5fbc-4fdd-a400-4421cbdbc291">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjY0_52189eae-acde-4278-9ba7-19672b6a494a">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjY1_706587f4-a21d-429c-9cf5-d541e6335319">482-5300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6M2YzYzg1YmExZjE0NDFiYzgzMzNkMTI2ZmQ0YTIwYTcvdGFibGVyYW5nZTozZjNjODViYTFmMTQ0MWJjODMzM2QxMjZmZDRhMjBhN18yLTAtMS0xLTMwNTUy_e5e618fd-56aa-45bd-bebb-fb52f2db4589">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6M2YzYzg1YmExZjE0NDFiYzgzMzNkMTI2ZmQ0YTIwYTcvdGFibGVyYW5nZTozZjNjODViYTFmMTQ0MWJjODMzM2QxMjZmZDRhMjBhN18yLTEtMS0xLTMwNTUy_76bc7a11-5d1c-4173-8f6b-2e15b1bb9369">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6M2YzYzg1YmExZjE0NDFiYzgzMzNkMTI2ZmQ0YTIwYTcvdGFibGVyYW5nZTozZjNjODViYTFmMTQ0MWJjODMzM2QxMjZmZDRhMjBhN18yLTItMS0xLTMwNTUy_4cd819ca-fe9b-4710-ae55-b5fa217740bf">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjY2_19913785-0053-4553-a534-276064232d66">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjU4_11f7fd39-f7ee-4f25-ac27-0deae14e20c9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6OGVjYTJkOTY5M2RiNGVkOGFkNWVjMDJjNjVmN2E0YTUvdGFibGVyYW5nZTo4ZWNhMmQ5NjkzZGI0ZWQ4YWQ1ZWMwMmM2NWY3YTRhNV8wLTAtMS0xLTMwNTUy_65ab7958-be63-497e-ac08-233401b13652">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6OGVjYTJkOTY5M2RiNGVkOGFkNWVjMDJjNjVmN2E0YTUvdGFibGVyYW5nZTo4ZWNhMmQ5NjkzZGI0ZWQ4YWQ1ZWMwMmM2NWY3YTRhNV8yLTYtMS0xLTMwNTUy_05a3e35a-7571-40e3-a889-d5e6ee2e5f1c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGFibGU6OGVjYTJkOTY5M2RiNGVkOGFkNWVjMDJjNjVmN2E0YTUvdGFibGVyYW5nZTo4ZWNhMmQ5NjkzZGI0ZWQ4YWQ1ZWMwMmM2NWY3YTRhNV80LTItMS0xLTMwNTUy_cee88d5b-1e9e-4a15-94cc-b4e4a504e979">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV82MDQ3MzEzOTU1MDM3_ad55be6e-ded3-4a3b-85ee-b6742e1eae2e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia4e3b25b44f741e29bebfd8f823ae5ab_I20220729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8xL2ZyYWc6NjE5YTE3NWE2MmJmNDIyZjlmZThjZmU0YWJkMzAwNWUvdGV4dHJlZ2lvbjo2MTlhMTc1YTYyYmY0MjJmOWZlOGNmZTRhYmQzMDA1ZV8yMjQ4_242640bf-1161-4271-ab2a-7351857249d1"
      unitRef="shares">187404772</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMy0xLTEtMS0zMDU1Mg_dcd163d5-54a1-44b7-a656-e987ac93e282"
      unitRef="usd">77545000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMy0zLTEtMS0zMDU1Mg_c4f9d1cb-70ab-4443-b687-e88b7c87bfff"
      unitRef="usd">25218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNC0xLTEtMS0zMDU1Mg_ee93cde0-5e8d-4dfe-a339-d89091c9c5d9"
      unitRef="usd">541771000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNC0zLTEtMS0zMDU1Mg_de700be2-6bf3-457c-8c38-71d8775de90e"
      unitRef="usd">708737000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNS0xLTEtMS0zMDU1Mg_6de34cd1-f2b4-49f7-b754-15275321291e"
      unitRef="usd">10006000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNS0zLTEtMS0zMDU1Mg_5917ebc4-8a06-41d8-957e-6da0229f3260"
      unitRef="usd">22492000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNi0xLTEtMS0zMDU1Mg_7a907a61-df8f-46ef-9771-b859c5ba82a7"
      unitRef="usd">16969000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNi0zLTEtMS0zMDU1Mg_f91f0336-69f0-4bbd-8883-6faad5154476"
      unitRef="usd">15801000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNy0xLTEtMS0zMDU1Mg_6fcf7335-8b01-4d95-96b4-b4de7867cf5f"
      unitRef="usd">19245000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfNy0zLTEtMS0zMDU1Mg_471915c3-8a8d-4497-a978-673cd548135c"
      unitRef="usd">23333000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfOC0xLTEtMS0zMDU1Mg_47db0078-b318-4058-aea4-60440636ca36"
      unitRef="usd">665536000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfOC0zLTEtMS0zMDU1Mg_28ad6e77-7f22-431f-b860-e8dc84418674"
      unitRef="usd">795581000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfOS0xLTEtMS0zMDU1Mg_ff8578ff-e41d-429a-9029-23510ca96f13"
      unitRef="usd">8928000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfOS0zLTEtMS0zMDU1Mg_1d2c509b-9021-4604-a566-07e6bacbbe6e"
      unitRef="usd">64828000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTAtMS0xLTEtMzA1NTI_fbd6dfa1-2d16-403c-843e-07350ceaa411"
      unitRef="usd">39792000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTAtMy0xLTEtMzA1NTI_6a99fb72-dc51-4382-bcf2-cdcb84e295cf"
      unitRef="usd">60510000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTEtMS0xLTEtMzA1NTI_bd87f6fd-94a8-4421-b495-8eb2a4090c63"
      unitRef="usd">68996000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTEtMy0xLTEtMzA1NTI_aeb09127-3326-409a-8ace-1ac5343d14b7"
      unitRef="usd">117025000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTItMS0xLTEtMzA1NTI_675461d7-04e9-4899-8c50-ac7b8994bae8"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTItMy0xLTEtMzA1NTI_97988f5b-7051-4415-8fa3-fdbbc137d3ea"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTMtMS0xLTEtMzA1NTI_0ff46da2-a725-4cf2-b5a8-2f60264df902"
      unitRef="usd">2234000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTMtMy0xLTEtMzA1NTI_84450b41-1a34-4a92-b65b-69b8f2fba0ad"
      unitRef="usd">2744000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTQtMS0xLTEtMzA1NTI_e5daaba4-8b00-4e1a-9d6d-6e1a00663094"
      unitRef="usd">861987000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTQtMy0xLTEtMzA1NTI_a75f7054-665f-41f3-88ed-fe0f91bacfd3"
      unitRef="usd">1117189000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTctMS0xLTEtMzA1NTI_5337cc1a-c1cc-4475-96ba-72f676a86314"
      unitRef="usd">12346000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTctMy0xLTEtMzA1NTI_d3b290f0-43d7-489a-841c-6f92a37584c4"
      unitRef="usd">9747000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTgtMS0xLTEtMzA1NTI_6d54e137-b9e3-4e56-b22f-79a74dfa6752"
      unitRef="usd">30323000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTgtMy0xLTEtMzA1NTI_35afd38e-29ad-4eab-894e-2c67490d3320"
      unitRef="usd">15735000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTktMS0xLTEtMzA1NTI_26a6a34c-07da-4c88-bd48-2b7398b3ccc8"
      unitRef="usd">29234000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMTktMy0xLTEtMzA1NTI_1ba566bc-257f-42dd-bd72-0d57ff94f96f"
      unitRef="usd">26809000</nktr:AccruedClinicalTrialExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjAtMS0xLTEtMzA1NTI_ce809f16-018e-4ee5-aeb7-03895b5781a1"
      unitRef="usd">13035000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjAtMy0xLTEtMzA1NTI_99db9cc6-d9e7-423b-9760-018c4ea56aa8"
      unitRef="usd">15468000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjEtMS0xLTEtMzA1NTI_4ad2c85b-547d-4d4a-bbfa-f1df05ce1a33"
      unitRef="usd">20047000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjEtMy0xLTEtMzA1NTI_30fd90ea-f2e4-47b4-8f40-21701578b730"
      unitRef="usd">17441000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjItMS0xLTEtMzA1NTI_7a14245f-2245-489b-8299-44fc0f6ac322"
      unitRef="usd">104985000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjItMy0xLTEtMzA1NTI_2e5c8dde-f2a2-41c3-af04-8dcb4c206daf"
      unitRef="usd">85200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjMtMS0xLTEtMzA1NTI_7565ce8c-1354-459c-acee-921c3431dfe5"
      unitRef="usd">119415000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjMtMy0xLTEtMzA1NTI_544e207c-2a72-4aef-ac6a-b39789b4c1a5"
      unitRef="usd">125736000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjQtMS0xLTEtMzA1NTI_952debfd-a12d-4705-8bd9-71ef49b7b545"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjQtMy0xLTEtMzA1NTI_60fe333c-4dd7-4b70-adfc-08b20165a8ec"
      unitRef="usd">27726000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjUtMS0xLTEtMzA1NTI_6d80247d-1a13-46c6-a6ef-7a53db5017a0"
      unitRef="usd">176775000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjUtMy0xLTEtMzA1NTI_444691ca-e175-4681-b3f9-3f8615e28c4c"
      unitRef="usd">195427000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjYtMS0xLTEtMzA1NTI_0ad0926e-8e21-4628-8995-98f049c5f9ee"
      unitRef="usd">2080000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjYtMy0xLTEtMzA1NTI_aa4ea691-7173-4979-915d-42c3a348117d"
      unitRef="usd">3592000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjctMS0xLTEtMzA1NTI_a6c28877-dae2-4f0b-a749-cda3c0364923"
      unitRef="usd">403255000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjctMy0xLTEtMzA1NTI_67c82a0b-fca5-412d-9885-bc0e18c6c7f0"
      unitRef="usd">437681000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjgtMS0xLTEtMzA1NTI_9cba38e4-84db-471e-b5e0-fb6c377e86cb"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMjgtMy0xLTEtMzA1NTI_6391881b-9b17-46e0-9253-462cba33cb36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV8yMQ_78e6db7d-534b-468d-a510-dfd37b451f73"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV8yMQ_97b0e455-0cb0-4e15-8486-02673684c988"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV8zNQ_2798f712-b8e7-42ba-9c3c-535f17c64dad"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV8zNQ_2c359ca9-a4ba-4a79-9d0d-0832df3a19c1"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV81Nw_1fc04ece-6ffc-4be8-8d11-b1ca12a3826e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV81Nw_3d677712-d5b7-40e8-ac8e-60a1fe88a7d3"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <nktr:PreferredStockShareDesignated
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV81Nw_54e30853-9a85-4e80-9152-0d3baad556cb"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjphYzkyZDNlYzM5MzI0OTY4OWJmYjJkOTdkOGU2NDhhZV81Nw_fe7c4b4f-cb2c-45fc-bbab-95252598c5fa"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMS0xLTEtMzA1NTI_6fdd578a-90b4-4cdc-94da-5bae9a795850"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzAtMy0xLTEtMzA1NTI_dd0b9f07-1e1a-4e1a-bbfc-5bf5fa8ebc83"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF8xOA_b05c0ddd-5f0f-41c1-88aa-7332f1e6c96c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF8xOA_df717e02-f832-4132-8c0f-0905e2445efa"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF8zMg_4d39ee6e-2303-41d1-88e5-faf3820c416d"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF8zMg_645421e7-5653-4a35-a406-0effd4035cdf"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF81NA_ed948156-60b5-4060-a2a7-e6475e96326c"
      unitRef="shares">187405000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMC0xLTEtMzA1NTIvdGV4dHJlZ2lvbjo5YzA5NTBjZmQ1ZTA0YTU0YjliY2JlZjUwMTQ4ZDA1OF82OA_d8fd9694-e40c-4455-ab53-0632a89ac84d"
      unitRef="shares">185468000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMS0xLTEtMzA1NTI_6f505fb4-7b8b-414d-9cc4-db3663809b1e"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzEtMy0xLTEtMzA1NTI_81d93896-41af-46ad-ab7f-02e0ac8b6920"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzItMS0xLTEtMzA1NTI_2527e7a9-4291-4b6e-b458-9e94096dd74e"
      unitRef="usd">3549360000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzItMy0xLTEtMzA1NTI_944af5a8-18ab-4c45-b056-159a34387da9"
      unitRef="usd">3516641000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzMtMS0xLTEtMzA1NTI_fae4df6e-244b-4f5c-8471-c2197681d210"
      unitRef="usd">-8191000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzMtMy0xLTEtMzA1NTI_4b11cc99-a1e6-4bfb-b174-5409b3e1652f"
      unitRef="usd">-4157000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzQtMS0xLTEtMzA1NTI_cc36f779-a5ac-4fc1-b0b2-662d15fce412"
      unitRef="usd">-3082456000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzQtMy0xLTEtMzA1NTI_35e49a24-8d2d-4ea9-b1c1-491bf4b72a95"
      unitRef="usd">-2832995000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzUtMS0xLTEtMzA1NTI_c1a7001b-1a8b-4224-8435-f54d687b1337"
      unitRef="usd">458732000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzUtMy0xLTEtMzA1NTI_aa93c94e-b1c5-41aa-b666-7397fa4280b2"
      unitRef="usd">679508000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzYtMS0xLTEtMzA1NTI_548dbe7b-ffc7-412e-b247-8b2adfa0edd0"
      unitRef="usd">861987000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yMi9mcmFnOjlkZTRiM2Y5NmIzYzQ5MWVhMGVkMDYzZWM0YmU0MzAyL3RhYmxlOjA5NzY2Yzc2ZmJjNTRhNmI4YmRhOTcxYTczMzJlNzE5L3RhYmxlcmFuZ2U6MDk3NjZjNzZmYmM1NGE2YjhiZGE5NzFhNzMzMmU3MTlfMzYtMy0xLTEtMzA1NTI_1cd03fdb-7ef2-4c8b-9b6b-c0da4bfe148c"
      unitRef="usd">1117189000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab10c83366854752a16f76890719307a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMy0xLTEtMS0zMDU1Mg_f90e137b-a902-4181-a193-d244d50f5674"
      unitRef="usd">5312000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i841d22063d474fa5b3b392a4925ca344_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMy0zLTEtMS0zMDU1Mg_77e18abb-b763-4499-ae06-6272644e15ca"
      unitRef="usd">7846000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id98ac0fa001e4daab8a52e2248b1146c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMy01LTEtMS0zMDg0NA_4d343171-a04c-49c0-ad11-e68336775aa9"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9530c36c4b448839ff7ef902cfd13dc_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMy03LTEtMS0zMDg0NA_e8d466ba-876b-4a4c-a3f6-5ab0dcc140a4"
      unitRef="usd">12641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaa02756dcbe4a1a871ce1cb0480648d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNC0xLTEtMS0zMDU1Mg_dbd7ca35-f921-43e3-902e-2f5e898fc132"
      unitRef="usd">16264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i957bd179292a4a5f8bea0ec87a04ddac_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNC0zLTEtMS0zMDU1Mg_56f2d597-20fc-4d4f-89d0-5e5a86f6e784"
      unitRef="usd">20456000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e6059c3a6a244129de957ee89ff70fc_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNC01LTEtMS0zMDg0NA_5557ad72-37db-432f-91a2-a843cde7ab22"
      unitRef="usd">33825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82df606601154dc1ad7096a861539bf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNC03LTEtMS0zMDg0NA_c5ff6273-bf68-4191-b2ed-4ff5e2a87507"
      unitRef="usd">39254000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51c7b009052b4c3db8cb98c20f670ac9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNS0xLTEtMS0zMDU1Mg_633c7635-43a4-42db-99f7-2582f5326448"
      unitRef="usd">9000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a6d564c98e44ea1bb8b4ec60494b8bb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNS0zLTEtMS0zMDU1Mg_fe05a08c-50ea-4f14-9d9d-53d8c6dbcb57"
      unitRef="usd">28000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i134972093bfc48989eb2da3ed230985f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNS01LTEtMS0zMDg0NA_6edd588d-cb48-48d2-881e-f6b42bee9b75"
      unitRef="usd">1582000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib60cd739b0c941a290a478c66b5d7ae8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNS03LTEtMS0zMDg0NA_0a021325-6c76-4bae-8f01-291dbc862962"
      unitRef="usd">82000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNi0xLTEtMS0zMDU1Mg_3cf2abc6-493e-4eac-8df2-86458c84e49e"
      unitRef="usd">21585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNi0zLTEtMS0zMDU1Mg_3b87a048-d05b-4fa2-9b49-25541daefee6"
      unitRef="usd">28330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNi01LTEtMS0zMDg0NA_79e11a23-9331-4e9b-af94-02e45a0bddf7"
      unitRef="usd">46407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfNi03LTEtMS0zMDg0NA_97b58364-50b1-4249-a33e-d03305359ed3"
      unitRef="usd">51977000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOC0xLTEtMS0zMDU1Mg_6ea798c9-4c1f-48b5-a3ae-f47c901d66d2"
      unitRef="usd">5115000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOC0zLTEtMS0zMDU1Mg_b6607496-37de-4839-ad17-c007f803cc52"
      unitRef="usd">7667000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOC01LTEtMS0zMDg3NA_9b3fdeaf-bfdf-492a-9e29-472d4a831b71"
      unitRef="usd">10430000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOC03LTEtMS0zMDg3NA_9a89ec78-3863-4f23-8dab-cc170116dd28"
      unitRef="usd">13423000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOS0xLTEtMS0zMDU1Mg_b70bba5b-5d16-4c44-9873-54acdb61ca91"
      unitRef="usd">42740000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOS0zLTEtMS0zMDU1Mg_29cf8813-9a5f-4e0b-a44b-63f9ec27eb41"
      unitRef="usd">101313000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOS01LTEtMS0zMDg3NA_60c51cc5-9197-427e-adcd-2592de8b9f1a"
      unitRef="usd">149993000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfOS03LTEtMS0zMDg3NA_a34ab3e9-012e-46d2-8830-928d27adb861"
      unitRef="usd">196917000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTAtMS0xLTEtMzA1NTI_04827bd5-c532-4469-94cc-d77793411bed"
      unitRef="usd">20521000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTAtMy0xLTEtMzA1NTI_7827055a-dc0b-4255-94da-cb69201f420f"
      unitRef="usd">29555000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTAtNS0xLTEtMzA4NzQ_20d6bf77-451d-4db3-820c-ffa3808b51bf"
      unitRef="usd">47860000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTAtNy0xLTEtMzA4NzQ_f8ce5a2a-aace-4984-b1d8-753545692766"
      unitRef="usd">61234000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTEtMS0xLTEtMzA1NTI_78f6443b-5d68-4d31-9920-b56aa576c72a"
      unitRef="usd">106045000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTEtMy0xLTEtMzA1NTI_f97c82a7-9d37-464e-b0a8-797432914783"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTEtNS0xLTEtMzA4NzQ_784b74da-b555-4b12-8d19-1ffe44478357"
      unitRef="usd">107520000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTEtNy0xLTEtMzA4NzQ_4e92ce63-c929-4fb8-9226-e960572bb9ee"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:CostsAndExpenses
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTItMS0xLTEtMzA1NTI_54dcced9-6fdd-4695-bb9e-e36b73a89bcb"
      unitRef="usd">174421000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTItMy0xLTEtMzA1NTI_7753823b-1a03-406d-b925-1a30f393582a"
      unitRef="usd">138535000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTItNS0xLTEtMzA4ODY_f940a333-cce1-42f6-be08-7aa0e3a95095"
      unitRef="usd">315803000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTItNy0xLTEtMzA4ODY_4d50f9b2-e274-4641-bb10-71b66a546eb4"
      unitRef="usd">271574000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTMtMS0xLTEtMzA1NTI_c5c1101b-cf62-476d-b68e-5a98c92e22b4"
      unitRef="usd">-152836000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTMtMy0xLTEtMzA1NTI_518b3346-6f69-4cfd-b918-2390f8a734d7"
      unitRef="usd">-110205000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTMtNS0xLTEtMzA4ODY_d5c15c45-d098-403b-8254-1682ef484b2e"
      unitRef="usd">-269396000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTMtNy0xLTEtMzA4ODY_0bb6ac6a-bb99-4d02-9ccd-42373da8cc5a"
      unitRef="usd">-219597000</us-gaap:OperatingIncomeLoss>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTUtMS0xLTEtMzA1NTI_79d03c49-9678-4163-8f36-ee11ac576bf1"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTUtMy0xLTEtMzA1NTI_38df5220-d4e4-41e1-806b-a2e4f1397959"
      unitRef="usd">-2713000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTUtNS0xLTEtMzA5MTc_52c81acb-0ca6-4c55-b08f-c6f77aabdd21"
      unitRef="usd">33427000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTUtNy0xLTEtMzA5MTc_18552a5e-3cbc-483b-9696-2b21bd29cd80"
      unitRef="usd">-4312000</us-gaap:LiabilitiesFairValueAdjustment>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTYtMS0xLTEtMzA1NTI_c6ae1263-fd1b-4b8e-885a-2295d9580bc5"
      unitRef="usd">7228000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTYtMy0xLTEtMzA1NTI_efe53f33-4875-4e23-b37b-5a7d327d35af"
      unitRef="usd">13089000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTYtNS0xLTEtMzA5MTc_1670922b-8380-4049-a98f-7ad0c6767f0c"
      unitRef="usd">14757000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTYtNy0xLTEtMzA5MTc_b9f8bcdd-8c42-4fd8-ad5e-8d46b5ee761e"
      unitRef="usd">26385000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTctMS0xLTEtMzA1NTI_8edf2522-3501-4372-b42d-0d7b9f82b81a"
      unitRef="usd">1096000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTctMy0xLTEtMzA1NTI_cf4f8c3a-1e8d-4dba-86b6-5d05b2329aea"
      unitRef="usd">845000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTctNS0xLTEtMzA5MjQ_14d34ae6-0f58-43e4-9956-0acf800edfd3"
      unitRef="usd">1491000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTctNy0xLTEtMzA5MjQ_c015b718-c40f-4420-ba5f-40f337fb9672"
      unitRef="usd">2257000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTgtMS0xLTEtMzA1NTI_89b64abe-7628-418b-93df-38db0624693d"
      unitRef="usd">-6132000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTgtMy0xLTEtMzA1NTI_4c10f9df-0909-499f-8362-eaccc39b9d2e"
      unitRef="usd">-14957000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTgtNS0xLTEtMzA5MzM_a7023557-11f3-457e-b4c9-985a847d71af"
      unitRef="usd">20161000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTgtNy0xLTEtMzA5MzM_ea7a810c-ef32-4928-b798-f1f7bf4ddd71"
      unitRef="usd">-28440000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTktMS0xLTEtMzA1NTI_b7ff777d-9616-48d2-adac-babd423a1def"
      unitRef="usd">-158968000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTktMy0xLTEtMzA1NTI_d4615117-d801-4ed0-a9d6-a9269fe9b032"
      unitRef="usd">-125162000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTktNS0xLTEtMzA5MzM_d7286771-1272-4f87-93a8-f699464cf768"
      unitRef="usd">-249235000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMTktNy0xLTEtMzA5MzM_7fcca9a6-9214-4837-b876-df9e57ca0bcb"
      unitRef="usd">-248037000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjAtMS0xLTEtMzA1NTI_d6b82b25-d7c4-4e55-9a54-c7103a5c939f"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjAtMy0xLTEtMzA1NTI_92f99c93-877c-4295-a77c-9f5c2ad52b48"
      unitRef="usd">357000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjAtNS0xLTEtMzA5MzM_81f6883d-614f-489a-b648-acce8fce05a7"
      unitRef="usd">226000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjAtNy0xLTEtMzA5MzM_6a40b781-0d47-4afc-8d2f-a493b16bad95"
      unitRef="usd">449000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjEtMS0xLTEtMzA1NTI_ab1417ff-daa6-4a3c-8fed-3e0333aa30c6"
      unitRef="usd">-159068000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjEtMy0xLTEtMzA1NTI_4b7516bc-01c9-46c9-8b6f-85938ed37a4c"
      unitRef="usd">-125519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjEtNS0xLTEtMzA5MzM_42db699f-24c4-403e-a77e-4f37d531cf40"
      unitRef="usd">-249461000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjEtNy0xLTEtMzA5MzM_8d9bcf09-1909-46cb-b6de-517c132cfee8"
      unitRef="usd">-248486000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtMS0xLTEtMzA1NTI_3128f977-28b1-4c77-aa84-f32aba0e43b6"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtMS0xLTEtMzA1NTI_c26928c6-5d4f-4553-8be0-b986b0eb1b23"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtMy0xLTEtMzA1NTI_a6c56bed-bdaa-48fb-940b-f3da31533e92"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtMy0xLTEtMzA1NTI_fe17880a-cbbe-4bdc-963d-b35b6e89577a"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtNS0xLTEtMzA5NDM_24d2f03e-61aa-46ac-98e8-674ddeb00df6"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtNS0xLTEtMzA5NDM_a1793020-00b6-4c54-bfb4-3beb980ca5dc"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtNy0xLTEtMzA5NDM_34672dfc-7315-4b46-80ac-aed0c81df9f9"
      unitRef="usdPerShare">-1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjMtNy0xLTEtMzA5NDM_7f1e6dac-95ca-494c-b511-6c2432a8a5b8"
      unitRef="usdPerShare">-1.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtMS0xLTEtMzA1NTI_9bc9ebf4-fe87-48c6-b4a5-f1a2d53ed7e5"
      unitRef="shares">186800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtMS0xLTEtMzA1NTI_fde463f0-37b1-42da-9fb4-403cf73ef182"
      unitRef="shares">186800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtMy0xLTEtMzA1NTI_911d45e6-2556-4bad-a3b4-ba83478f8a70"
      unitRef="shares">182698000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtMy0xLTEtMzA1NTI_b1486c95-76d1-4245-8e95-1506b8894199"
      unitRef="shares">182698000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtNS0xLTEtMzA5NTA_02cf4277-918c-48a2-928a-9c5101678749"
      unitRef="shares">186323000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtNS0xLTEtMzA5NTA_392cf590-1876-4f4f-9333-4ad595236a0f"
      unitRef="shares">186323000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtNy0xLTEtMzA5NTA_22db53a2-b591-457d-bbef-0c58b59aa2e9"
      unitRef="shares">182038000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yNS9mcmFnOmJjZmFkNDYzNThhYjQ1M2Y4M2YxM2IyNGM4YTEyN2E1L3RhYmxlOjViMWYwYTZmZGU1YzQzNDViMmQzZTFhZmFjZWY0OTZlL3RhYmxlcmFuZ2U6NWIxZjBhNmZkZTVjNDM0NWIyZDNlMWFmYWNlZjQ5NmVfMjQtNy0xLTEtMzA5NTA_fef81653-e4c2-4e90-bb08-da6009861971"
      unitRef="shares">182038000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfMi0xLTEtMS0zMDU1Mg_16b7afcf-2ad8-44d9-a755-ef992d0629d0"
      unitRef="usd">-159068000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfMi0zLTEtMS0zMDU1Mg_6616d01e-37a5-46bf-a2aa-e6de339bc3d5"
      unitRef="usd">-125519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfMi00LTEtMS0zMTAzMw_f4276e00-6cca-413d-af95-78b8244f0b9c"
      unitRef="usd">-249461000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfMi02LTEtMS0zMTAzMw_be3276cf-5b99-4df2-95fb-e859aadec3c7"
      unitRef="usd">-248486000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNC0xLTEtMS0zMDU1Mg_b4398460-b9f6-412e-a99c-c5f942ba27f9"
      unitRef="usd">-988000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNC0zLTEtMS0zMDU1Mg_dd4a7146-c835-4aac-a305-b75290bd7d6b"
      unitRef="usd">-64000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNC01LTEtMS0zMTA0Ng_a9d637da-0ae3-49a2-a98d-ae701bb727af"
      unitRef="usd">-3079000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNC03LTEtMS0zMTA0Ng_83c8bbbe-0721-4bf5-bbd1-bfd21a0eadb2"
      unitRef="usd">-830000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNS0xLTEtMS0zMDU1Mg_af1077fc-b75a-4db7-8f23-7a8563ec61e2"
      unitRef="usd">-671000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNS0zLTEtMS0zMDU1Mg_ced8818a-790e-4fb0-b1f8-c797c002d331"
      unitRef="usd">-215000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNS01LTEtMS0zMTA0Ng_5cdfdf3e-fb63-4d33-8771-ce99ec192b37"
      unitRef="usd">-955000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNS03LTEtMS0zMTA0Ng_b9776085-a47a-4e91-af75-448b9b8386d3"
      unitRef="usd">-275000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNi0xLTEtMS0zMDU1Mg_d3567cac-e00c-49a4-a8d0-082241ca17b0"
      unitRef="usd">-1659000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNi0zLTEtMS0zMDU1Mg_576d746f-9b50-4a9d-81bb-852d616ee650"
      unitRef="usd">-279000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNi01LTEtMS0zMTA0Ng_9098930a-e725-49d8-b497-05956462b633"
      unitRef="usd">-4034000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNi03LTEtMS0zMTA0Ng_f216393b-bf31-4379-9f2c-575c8d8ca785"
      unitRef="usd">-1105000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNy0xLTEtMS0zMDU1Mg_a0820572-8181-404c-a417-529d65c971b2"
      unitRef="usd">-160727000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNy0zLTEtMS0zMDU1Mg_66a5239e-7f94-42cd-87bc-38e6c476b6f9"
      unitRef="usd">-125798000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNy01LTEtMS0zMTA0Ng_3e33bd70-e3fc-42c9-a601-640dd0152f5e"
      unitRef="usd">-253495000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8yOC9mcmFnOjAxODFiMWFhYzliNTQ1ZGU5NDY4MDE4ODlhYzgxMWQxL3RhYmxlOjQ2OTJkYjRkMDcyYjRiNGQ5YzAwMzExMGYzNWZmYTY1L3RhYmxlcmFuZ2U6NDY5MmRiNGQwNzJiNGI0ZDljMDAzMTEwZjM1ZmZhNjVfNy03LTEtMS0zMTA0Ng_35dafbd0-5707-4941-9fcd-63222a58c2a4"
      unitRef="usd">-249591000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ia6c832ade51b45958d331545ae3e5dc3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS0xLTEtMS0zMDU1Mg_d9f2e287-f2a7-4907-99d3-dbd81474dcfd"
      unitRef="shares">180091000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia6c832ade51b45958d331545ae3e5dc3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS0zLTEtMS0zMDU1Mg_89e5eb60-c353-4770-b627-350141b0a93b"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i207702fa8b624c6685cbfa6fc0824271_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS01LTEtMS0zMDU1Mg_948d5ca0-fe5a-4e08-a338-4c37983d2ff4"
      unitRef="usd">3388730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e9a5d5deddf468b87ac44df66d21b86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS03LTEtMS0zMDU1Mg_1b12c503-8704-4126-8b24-04230a69b834"
      unitRef="usd">-2295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i93c37c43548a4597827bc1c98a494182_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS05LTEtMS0zMDU1Mg_911b11f3-4885-47ea-83ce-ab0ad49d838c"
      unitRef="usd">-2309158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec541b07f4024b509da17efe3def4f82_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMS0xMS0xLTEtMzA1NTI_0a5e88fe-fa0d-41de-82da-3a3f29e7c0ff"
      unitRef="usd">1077295000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i19adf3d7365740b8858300248f7a335e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMi0xLTEtMS0zMDU1Mg_fce0ccbb-a991-4095-8c6f-0133d3a4a5fb"
      unitRef="shares">2199000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8a50cc46191d4f39bb966fafeb0e21e3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMi01LTEtMS0zMDU1Mg_bbb135c0-34fa-4539-ab5b-4e26c741e30f"
      unitRef="usd">17106000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icafc13b8f8e341f385a8e18d347395f3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMi0xMS0xLTEtMzA1NTI_029720c6-f92f-4341-a339-d3cf21fe90d9"
      unitRef="usd">17106000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8a50cc46191d4f39bb966fafeb0e21e3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMy01LTEtMS0zMDU1Mg_dd80a55c-32ef-4265-8cdc-2143cd0536bf"
      unitRef="usd">23898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icafc13b8f8e341f385a8e18d347395f3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfMy0xMS0xLTEtMzA1NTI_046cead0-daa4-4196-871f-23eab8ff5655"
      unitRef="usd">23898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iafa6f15b9c6c42eb988d570abd03ec38_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNC03LTEtMS0zMDU1Mg_8b74b527-428a-4575-9dc8-ac859d1b02ab"
      unitRef="usd">-826000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic71c4e96623541daac88b34839da139e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNC05LTEtMS0zMDU1Mg_779c2085-b61d-47e8-9c6e-388348a79653"
      unitRef="usd">-122967000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icafc13b8f8e341f385a8e18d347395f3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNC0xMS0xLTEtMzA1NTI_e3c87811-943c-4bf9-ad25-439670e70f09"
      unitRef="usd">-123793000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i4b44eabefa5748f3b2039c96188a4ea4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS0xLTEtMS0zMDU1Mg_06c1cc11-ba7e-429f-b8f8-f4c0a4fbf00f"
      unitRef="shares">182290000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4b44eabefa5748f3b2039c96188a4ea4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS0zLTEtMS0zMDU1Mg_1c83bb2d-511b-413d-bcfe-3d22e0843e0b"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i13345764e6d142fba76c8c33e9ce581f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS01LTEtMS0zMDU1Mg_4434b9ab-3dc0-40a7-ae91-c4bf605b8848"
      unitRef="usd">3429734000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id81e115f70424914b18921a48b6334c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS03LTEtMS0zMDU1Mg_4a8f19cf-2552-4849-9df8-2056b29b85fc"
      unitRef="usd">-3121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9463547a4e54c51a8dae165b31e8443_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS05LTEtMS0zMDU1Mg_5bca68e9-c3cd-4b9a-8a4a-40cffb19da3a"
      unitRef="usd">-2432125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d42324a1f854a268dd508881663f4b2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNS0xMS0xLTEtMzA1NTI_7322324b-0b3a-40ab-84a9-7aefd7b9cfa9"
      unitRef="usd">994506000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie0e5f79481a6422383f5010e8d560526_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNi0xLTEtMS0zMTA5Nw_7485969a-f421-40cd-9c87-9e59a7d81be8"
      unitRef="shares">1483000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id3c21ab7235041cd9295a6a01131a511_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNi01LTEtMS0zMTA5Nw_a46743d1-2a16-4519-8692-c3c48785d588"
      unitRef="usd">12553000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNi0xMS0xLTEtMzEwOTc_ab607331-0018-47cb-9456-0ea1596dc194"
      unitRef="usd">12553000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id3c21ab7235041cd9295a6a01131a511_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNy01LTEtMS0zMTA5Nw_be64ec23-4833-4d0c-baa0-4c5f9ad58666"
      unitRef="usd">23714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfNy0xMS0xLTEtMzEwOTc_f4c37870-3af7-47b5-b24c-f57f99c17cfd"
      unitRef="usd">23714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia46078182c6d4bf9b8244c13bb5ada0c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOC03LTEtMS0zMTA5Nw_a987286f-89e2-4586-a73e-6b3474d1c976"
      unitRef="usd">-279000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id92ad17e88394b29b2c99010d4cfde2b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOC05LTEtMS0zMTA5Nw_ddcad5ea-a345-4734-8db3-dea47ce82405"
      unitRef="usd">-125519000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOC0xMS0xLTEtMzEwOTc_33663d71-3581-4964-a77d-763efb0d5fc6"
      unitRef="usd">-125798000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i2d89fcb27e2e40da9712016c38d184da_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS0xLTEtMS0zMTA5Nw_a2dc8282-4c2d-41f0-9275-e051e4d687c6"
      unitRef="shares">183773000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2d89fcb27e2e40da9712016c38d184da_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS0zLTEtMS0zMTA5Nw_c30a45e0-9884-4c4c-be01-3b633c22da19"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0352e962dc144389a178d00a7ff496fb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS01LTEtMS0zMTA5Nw_236d219e-8579-47d3-b3f5-b2ec905c7031"
      unitRef="usd">3466001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c2e13b9ea7a4dcf8081838f1ac66a94_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS03LTEtMS0zMTA5Nw_f13909ec-db55-4642-a955-96d91dc1061d"
      unitRef="usd">-3400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4bfcf4e2d4804d659adca4c109ad23d1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS05LTEtMS0zMTA5Nw_d53193c8-2514-4198-920d-cf1bf6e3d7ba"
      unitRef="usd">-2557644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i332b83a475bf4c03a2f3b3c3d925e70a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFiOGE4MTI0YWM3MzQ0ZGQ5NTcwMmQzZTQ4YjUwN2Q3L3RhYmxlcmFuZ2U6YWI4YTgxMjRhYzczNDRkZDk1NzAyZDNlNDhiNTA3ZDdfOS0xMS0xLTEtMzEwOTc_328506b2-99f4-46f2-91ac-27537a18b661"
      unitRef="usd">904975000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib6abdeb335de487c9793e2cad1674f4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS0xLTEtMS0zMDU1Mg_e0e27040-2a85-4e6c-9e78-90cb3e4dc6db"
      unitRef="shares">185468000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib6abdeb335de487c9793e2cad1674f4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS0zLTEtMS0zMDU1Mg_5bdaa61e-2632-4863-a399-96d4c5cbca93"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if5e39b9fd4534db1890613d6cbab71a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS01LTEtMS0zMDU1Mg_1523ba40-49f9-4936-a6de-3ae97c263036"
      unitRef="usd">3516641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida61f606d16e4a479dbd86a2a2078bcb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS03LTEtMS0zMDU1Mg_921eba21-2268-4338-a544-2a72f4310e0c"
      unitRef="usd">-4157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if034602e638345f8a92708bdd04f4ae4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS05LTEtMS0zMDU1Mg_86943c55-2542-477c-a176-c2b6e015dea9"
      unitRef="usd">-2832995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMS0xMS0xLTEtMzA1NTI_044af9d2-ab76-4927-9531-08cc7fa4e9be"
      unitRef="usd">679508000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i74a11ce6ef2f4211a0e058edcf0f297a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMi0xLTEtMS0zMDU1Mg_524a10f5-9ea5-495e-82a6-cbf08c1fbb0f"
      unitRef="shares">806000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i16f9f7814fe344ab965d049b1bf8498d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMi01LTEtMS0zMDU1Mg_458f252b-8295-4164-aaae-3315b9ba1abf"
      unitRef="usd">188000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6cf30f1f3976425f9ae1a9658814d0a2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMi0xMS0xLTEtMzA1NTI_08729052-d43a-4671-aa09-057415830019"
      unitRef="usd">188000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i16f9f7814fe344ab965d049b1bf8498d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMy01LTEtMS0zMDU1Mg_7129b87e-d4dd-4113-8a4a-d496c5ce830e"
      unitRef="usd">20961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6cf30f1f3976425f9ae1a9658814d0a2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfMy0xMS0xLTEtMzA1NTI_17459d81-a986-4fe2-8ac0-6ab1b14870ee"
      unitRef="usd">20961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i24276f68c0f648ce93afcce8e8ccb424_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNC03LTEtMS0zMDU1Mg_46411152-886f-4cfa-825d-54aa9357ad0e"
      unitRef="usd">-2375000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5b081e4b21eb44e3937cc738e930511a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNC05LTEtMS0zMDU1Mg_f0c56ddd-cce1-4d97-8158-869ff2a1695c"
      unitRef="usd">-90393000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6cf30f1f3976425f9ae1a9658814d0a2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNC0xMS0xLTEtMzA1NTI_4daf565a-ca88-4f26-a80b-b99557aaedd5"
      unitRef="usd">-92768000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i947f1c275a9b45f0a3c9254c3b4831ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS0xLTEtMS0zMDU1Mg_989f9c68-7947-4c1a-a452-dca72d7093af"
      unitRef="shares">186274000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i947f1c275a9b45f0a3c9254c3b4831ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS0zLTEtMS0zMDU1Mg_c9a54d81-6af9-46c2-8895-411316eeb581"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d041e6febc8402f9919661245a523c4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS01LTEtMS0zMDU1Mg_036183e1-9635-45d7-a3eb-fc2b3181f1c4"
      unitRef="usd">3537790000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47859d4a9c7d444ea3fc5298c02e72eb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS03LTEtMS0zMDU1Mg_bdd66494-2770-4b3d-a860-7d1c92066cbe"
      unitRef="usd">-6532000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i021df6170fef4aa0940cfaf057de5391_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS05LTEtMS0zMDU1Mg_245d0714-8270-409b-92b3-dc45d8946658"
      unitRef="usd">-2923388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6863c3c60a704766bc19dbf81c2dcb5b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNS0xMS0xLTEtMzA1NTI_c70c866f-7b6a-42ba-95ce-1cffc0a33d85"
      unitRef="usd">607889000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i741af916cbcf43e186ee1732ed353f02_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNi0xLTEtMS0zMTEyMw_5f0dee10-93db-4cc7-84b5-4fbacaf953f4"
      unitRef="shares">1131000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i73b2f1f3796c48159ef8f2ec154733e9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNi01LTEtMS0zMTEyMw_c9621658-95f0-4b38-938b-61440127b64b"
      unitRef="usd">467000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNi0xMS0xLTEtMzExMjM_f0c24947-175a-4460-b03c-ff6320618ef2"
      unitRef="usd">467000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i73b2f1f3796c48159ef8f2ec154733e9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNy01LTEtMS0zMTEyMw_c2e5ef2b-d075-4433-9d5f-dc23e3cb494f"
      unitRef="usd">11103000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfNy0xMS0xLTEtMzExMjM_7f88a1cf-f5d3-46b9-a01f-4810d7ad9a00"
      unitRef="usd">11103000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5340ad5b6f0045e68f5d19b34ed7b610_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOC03LTEtMS0zMTEyMw_1e7567bf-ff43-4c52-b160-551ca95c2726"
      unitRef="usd">-1659000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5db06ec5739d430ab6e1129243313c23_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOC05LTEtMS0zMTEyMw_7a5e7537-1569-456b-93a6-bedccfe74405"
      unitRef="usd">-159068000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOC0xMS0xLTEtMzExMjM_26a96814-30ce-4135-ab01-4415243209fe"
      unitRef="usd">-160727000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i93db7cc57e114d759dc91e2753b81b55_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS0xLTEtMS0zMTEyMw_3cece348-1cf9-4344-809c-b11d4f916f8c"
      unitRef="shares">187405000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i93db7cc57e114d759dc91e2753b81b55_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS0zLTEtMS0zMTEyMw_d16f81fc-4232-4599-838b-78fbf2d05d91"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86e75a96d7ae4fb5941842c8f737bbc8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS01LTEtMS0zMTEyMw_812bded5-3de9-41a1-93cf-e41ed31b1b97"
      unitRef="usd">3549360000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2b9522e14ad475e9d048da16aa5b505_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS03LTEtMS0zMTEyMw_55a917c3-1e4a-4d97-88de-3cfe0aa1283d"
      unitRef="usd">-8191000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1443f9bb2a2a449b8e75120a43351e1e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS05LTEtMS0zMTEyMw_f0d7bdfd-ac95-4ef7-9bef-f5474b6ed03b"
      unitRef="usd">-3082456000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zMS9mcmFnOmQ0MmI3MjE4ZjU4NzQ3MGRiNGQ5ZGM0OTlkNGYzZmRlL3RhYmxlOmFjODg3OTY2NTkxNzQ5NDY5Y2Y0MjRlZmFmOWE1ZGU3L3RhYmxlcmFuZ2U6YWM4ODc5NjY1OTE3NDk0NjljZjQyNGVmYWY5YTVkZTdfOS0xMS0xLTEtMzExMjM_77cf48df-2793-4be8-a7f6-3aeb82e1a08f"
      unitRef="usd">458732000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMy0xLTEtMS0zMDU1Mg_156d3cd2-ec7b-42a0-8018-aecd53406133"
      unitRef="usd">-249461000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMy0zLTEtMS0zMDU1Mg_cd5c6ce2-bdbd-4968-8f51-76ef47f0f295"
      unitRef="usd">-248486000</us-gaap:ProfitLoss>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNS0xLTEtMS0zMDU1Mg_7fb04e0b-e4e6-425f-b4e3-8ec1dde5a2cd"
      unitRef="usd">33825000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNS0zLTEtMS0zMDU1Mg_e980d1c6-f290-4e19-b605-fd6d520ca118"
      unitRef="usd">39254000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNi0xLTEtMS0zMDU1Mg_428fd31f-7e28-453b-8635-da2717aa86d8"
      unitRef="usd">14757000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNi0zLTEtMS0zMDU1Mg_1b6aadbd-9315-40ae-a79e-af858850b3be"
      unitRef="usd">26385000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNy0xLTEtMS0zMDU1Mg_48dc8591-f0c7-4938-b5ef-f951d668b1de"
      unitRef="usd">33427000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfNy0zLTEtMS0zMDU1Mg_029e8144-0484-4058-b9ab-3ea73df38460"
      unitRef="usd">-4312000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfOC0xLTEtMS0zMDU1Mg_db36d27a-2c9c-4a40-852c-a50bb3b178e4"
      unitRef="usd">4951000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfOC0zLTEtMS0zMDU1Mg_ec2b8fc6-cb8f-4d61-8e05-7479288ee394"
      unitRef="usd">5795000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfOS0xLTEtMS0zMDU1Mg_e0cc3fca-0c48-4b23-9d03-662f96749573"
      unitRef="usd">32064000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfOS0zLTEtMS0zMDU1Mg_f6418d02-0dcd-47d3-be5b-879b04fcf0c4"
      unitRef="usd">47612000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTAtMS0xLTEtMzA1NTI_be88672e-5e77-4db5-8c6e-8c55cf193b8a"
      unitRef="usd">7171000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTAtMy0xLTEtMzA1NTI_5c7948f1-ec08-42a4-926e-2233b1626e66"
      unitRef="usd">7090000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTEtMS0xLTEtMzQwOTU_fb251e96-0ebf-4973-9f13-8349a5802977"
      unitRef="usd">57321000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTEtMy0xLTEtMzQwOTU_7b6c4afd-3ec0-4101-99ab-0b85af98cb3b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTEtMS0xLTEtMzA1NTI_bc6720f0-a2f9-423c-be93-fe8957cfb72f"
      unitRef="usd">-700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTEtMy0xLTEtMzA1NTI_c7566f73-f6a7-482d-ac51-daad58f8539c"
      unitRef="usd">-4090000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTMtMS0xLTEtMzA1NTI_4fb3371d-0aaa-4cb0-b52b-58cd51e18db6"
      unitRef="usd">-12486000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTMtMy0xLTEtMzA1NTI_e5e8c9b2-90bb-424e-b210-f8f3a333894a"
      unitRef="usd">-10018000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTQtMS0xLTEtMzA1NTI_dfad6bf1-5f2b-40a4-bd7e-9074e27fd91d"
      unitRef="usd">1168000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTQtMy0xLTEtMzA1NTI_958e7390-f212-4613-9a24-22b80b422aa8"
      unitRef="usd">-676000</us-gaap:IncreaseDecreaseInInventories>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTUtMS0xLTEtMzA1NTI_ede55972-29ac-4576-9fbf-bdab30ff4b46"
      unitRef="usd">-1486000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTUtMy0xLTEtMzA1NTI_b5f5a4e2-11dd-45c3-ba20-bc1181d3aa94"
      unitRef="usd">-2260000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTYtMS0xLTEtMzA1NTI_b54a7b98-1bb0-4833-af66-ebea19e9a57c"
      unitRef="usd">-7627000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTYtMy0xLTEtMzA1NTI_108b96fc-e519-4a85-a8d7-453c8e4f5b02"
      unitRef="usd">-11585000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTctMS0xLTEtMzA1NTI_78e50e1b-aaed-4afd-8368-7bcd4072077a"
      unitRef="usd">2833000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTctMy0xLTEtMzA1NTI_67596fc3-b179-44d9-acc3-fd56e1109e40"
      unitRef="usd">-2101000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTgtMS0xLTEtMzA1NTI_7f5f8977-c702-46bf-9805-7cf4a9d1c613"
      unitRef="usd">14588000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTgtMy0xLTEtMzA1NTI_79b2fb3f-8cc9-4932-ad8c-6ef3a8696da6"
      unitRef="usd">14133000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTktMS0xLTEtMzA1NTI_d8441658-3577-48a7-8866-840121d7d7c9"
      unitRef="usd">-1520000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMTktMy0xLTEtMzA1NTI_28666c86-8f62-4471-bbad-2b5851ecaefe"
      unitRef="usd">-4101000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjAtMS0xLTEtMzA1NTI_fc36820f-2e32-4759-80e2-159b5e465f3c"
      unitRef="usd">-163417000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjAtMy0xLTEtMzA1NTI_de4204a5-0107-4924-b6a9-c45a7e199a48"
      unitRef="usd">-159986000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjItMS0xLTEtMzA1NTI_0c1e1f74-a4ee-4d68-bd8f-f482e341db10"
      unitRef="usd">247014000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjItMy0xLTEtMzA1NTI_08fd4b10-41f0-4bf6-b5ec-f00db8416071"
      unitRef="usd">527887000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjMtMS0xLTEtMzA1NTI_dd2b3b71-9f56-4fb4-bf13-16017a2e055a"
      unitRef="usd">466423000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjMtMy0xLTEtMzA1NTI_26549be6-5ff6-41de-a21f-a4c4e21fe39c"
      unitRef="usd">612419000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjQtMS0xLTEtMzA1NTI_25dc7080-6c79-4c08-ba81-3362c98a5d8d"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjQtMy0xLTEtMzA1NTI_f94a5c7e-a76d-4c82-979c-0187c8a4867a"
      unitRef="usd">5035000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjUtMS0xLTEtMzA1NTI_8b32bb62-0341-4b72-8225-e4ecd57eec8a"
      unitRef="usd">4983000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjUtMy0xLTEtMzA1NTI_7e9c604e-693c-429e-90dd-9e8639435a9e"
      unitRef="usd">6157000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjYtMS0xLTEtMzA1NTI_36909e45-de09-4d07-a830-0fa4ef0566e0"
      unitRef="usd">214426000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjYtMy0xLTEtMzA1NTI_9daa42e2-f6e1-4c22-abf7-1fda2e138713"
      unitRef="usd">83410000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjgtMS0xLTEtMzA1NTI_9e26ded8-f46a-405f-8316-6f62b82d07a1"
      unitRef="usd">655000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjgtMy0xLTEtMzA1NTI_e9334e01-dfda-4c87-b04e-5f6853dd1d1e"
      unitRef="usd">28523000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjktMS0xLTEtMzA1NTI_b539a882-48e0-4437-830e-e79b945e70df"
      unitRef="usd">750000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMjktMy0xLTEtMzA1NTI_04c96094-adcc-44a9-9b1a-dd967fb00a2f"
      unitRef="usd">1500000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzAtMS0xLTEtMzA1NTI_1f9e242c-252a-454f-b71b-fbade7d42b50"
      unitRef="usd">1405000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzAtMy0xLTEtMzA1NTI_53207339-4cb4-41be-9bf0-dae27bf9099d"
      unitRef="usd">30023000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzEtMS0xLTEtMzA1NTI_1ef704b2-d8eb-4a70-b42b-3334530288ca"
      unitRef="usd">-87000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzEtMy0xLTEtMzA1NTI_b621ef39-1842-43f1-9cd4-bde8e2dad1c3"
      unitRef="usd">-57000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzItMS0xLTEtMzA1NTI_2cef1a6e-5644-4140-99e3-164e64560ee9"
      unitRef="usd">52327000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzItMy0xLTEtMzA1NTI_e2d896ca-64cb-40d9-a5b4-154c0b18fbe2"
      unitRef="usd">-46610000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzMtMS0xLTEtMzA1NTI_f6402ad5-1539-494c-bf5b-5a7f4363324b"
      unitRef="usd">25218000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iec541b07f4024b509da17efe3def4f82_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzMtMy0xLTEtMzA1NTI_e485d6c3-5e08-462f-9a24-ae11cb0b5424"
      unitRef="usd">198955000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzQtMS0xLTEtMzA1NTI_aff60e5c-f855-4bf6-a2b3-d77d3e8cb955"
      unitRef="usd">77545000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i332b83a475bf4c03a2f3b3c3d925e70a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzQtMy0xLTEtMzA1NTI_616f2a7c-c927-4b75-a1ab-28c48cf1bdc3"
      unitRef="usd">152345000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzYtMS0xLTEtMzA1NTI_911126f9-a62d-426a-80cf-48a395210849"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF8zNC9mcmFnOjMwZjliZmM4MTIwMjQ2NjJiOWY3OWFjNzRkZWJkNTFhL3RhYmxlOjU3Nzc1NjhhY2I3ODQzZjlhNDdkMzkxZTY0OWY5Y2IyL3RhYmxlcmFuZ2U6NTc3NzU2OGFjYjc4NDNmOWE0N2QzOTFlNjQ5ZjljYjJfMzYtMy0xLTEtMzA1NTI_7afc0b09-0d42-4cc6-95f0-15b5bb01f140"
      unitRef="usd">1057000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3MTM_a24122d3-34d9-4019-a60c-6a9beab99b62">Organization and Summary of Significant Accounting Policies&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We (individually or with a partner) are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in oncology and immunology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of June&#160;30, 2022, we had approximately $628.2 million in cash and investments in marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Results of Bempegaldesleukin Program and the Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans for the Company&#x2019;s future:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On March 14, 2022, BMS and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 7 for additional information on our BMS Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we decided to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 4 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, subject to activities required for an orderly wind down of the studies, there will be no ongoing clinical development activities of bempegaldesleukin.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the Restructuring Plan), which were reviewed and approved by our Board of Directors on April 14, 2022. Pursuant to the Restructuring Plan, on April 26, 2022, our duly authorized officers implemented certain strategic, operational and organizational steps, including the prioritization of key Phase 2 development programs to advance our early stage research pipeline. In addition, we announced our plan to reduce our workforce by approximately 70% and to close our research facility in India.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have incurred and expect to incur significant costs resulting from these decisions and plans. See Note 8 for additional information on the effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three and six months ended June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2021 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 filed with the SEC on March 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers are primarily pharmaceutical companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of June&#160;30, 2022 and December&#160;31, 2021, our accounts receivable includes $7.4&#160;million and $21.4&#160;million, respectively, for unbilled net expense reimbursements from BMS. The remaining accounts receivable relate primarily to product sales. We generally do not require collateral from our customers. We perform a regular review of our customers&#x2019; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable. We have not recorded reserves for credit losses for the three and six months ended June&#160;30, 2022 and 2021, nor have recorded such an allowance as of June&#160;30, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contractual employee termination benefits provided that the obligations result from services already rendered based on vested rights to such benefits when the payment of benefits becomes probable and the amount can be reasonably estimated,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contract termination costs when we cancel the contract in accordance with its terms, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 8 for additional information on the severance expense that we recognized for employees terminated in connection with our reduction-in-force.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Asset Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. See Note 8 for additional information regarding the impairment charge we recorded in connection with our leased facilities and certain property and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <nktr:OrganizationPolicyTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3MjY_09f22e6f-ee68-49ff-b5cf-da6c64c16f86">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We (individually or with a partner) are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in oncology and immunology.&lt;/span&gt;&lt;/div&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</nktr:OrganizationPolicyTextBlock>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTAyNA_136b38be-1db2-4713-aa04-76d92cf4f341"
      unitRef="usd">628200000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3MTk_e68328d5-687d-400e-bbf0-0cd349a99327">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Results of Bempegaldesleukin Program and the Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans for the Company&#x2019;s future:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On March 14, 2022, BMS and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 7 for additional information on our BMS Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we decided to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 4 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, subject to activities required for an orderly wind down of the studies, there will be no ongoing clinical development activities of bempegaldesleukin.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the Restructuring Plan), which were reviewed and approved by our Board of Directors on April 14, 2022. Pursuant to the Restructuring Plan, on April 26, 2022, our duly authorized officers implemented certain strategic, operational and organizational steps, including the prioritization of key Phase 2 development programs to advance our early stage research pipeline. In addition, we announced our plan to reduce our workforce by approximately 70% and to close our research facility in India.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have incurred and expect to incur significant costs resulting from these decisions and plans. See Note 8 for additional information on the effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i6844748a7747471187efa284c70c9b40_D20220401-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfNDAxNg_054c1d37-a98c-440d-a472-dedaffd996e7"
      unitRef="number">0.70</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3MTY_663f0d25-0bc4-46fe-a32c-7fd6ff0a099d">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three and six months ended June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2021 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 filed with the SEC on March 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3MTU_bcd6ab24-1a4c-4eec-9759-5037436989b5">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjI3Mjg_1ea8ec61-0a9d-4297-8730-8caa2f79227b">Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements.We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2fb960f7e2be4ba7b0f30d51ecbfb755_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfODQxMg_8196590a-9a40-4580-b56b-e2c5d6e36d21"
      unitRef="usd">7400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8729a4959d1742a08e7c7a9e6181f0a3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfODQxOQ_bdb879ab-ddde-4ff0-ab5d-5eeecee10623"
      unitRef="usd">21400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTY0OTI2NzQ2NDQ4OA_11c1a750-11cf-4ef3-b5ff-52336a3ad929"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTY0OTI2NzQ2NDQ4OA_22d8c169-1d30-4205-84d6-5d0bca59c37d"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTY0OTI2NzQ2NDQ4OA_7d063a50-8ca5-4502-9a5e-256459ce5875"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTY0OTI2NzQ2NDQ4OA_a94fe1f7-7701-419e-b828-83e4db9d2b54"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMTY0OTI2NzQ4MDY5NQ_22a44aaf-ec28-4a14-a77f-24f93320faec">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contractual employee termination benefits provided that the obligations result from services already rendered based on vested rights to such benefits when the payment of benefits becomes probable and the amount can be reasonably estimated,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contract termination costs when we cancel the contract in accordance with its terms, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 8 for additional information on the severance expense that we recognized for employees terminated in connection with our reduction-in-force.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80MC9mcmFnOmM5MWU0MWIxZDEzZTRjNDk5MTQ2NmI0ODhkMzQ0NDIwL3RleHRyZWdpb246YzkxZTQxYjFkMTNlNGM0OTkxNDY2YjQ4OGQzNDQ0MjBfMjE5OTAyMzMxMjQ3Ng_09c0610c-1326-48e6-9bc9-e3778ef0faab">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Asset Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. See Note 8 for additional information regarding the impairment charge we recorded in connection with our leased facilities and certain property and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfODYw_0155fffc-903d-44b5-aed5-3fc6724132ba">Cash and Investments in Marketable Securities&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest in liquid, high quality debt securities which are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of June&#160;30, 2022 and December&#160;31, 2021, all of our long-term investments had maturities between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTM5_574175bf-cc3f-4a3a-8666-7dacd922de94"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTM5_b6cfd8b2-81fb-4e7c-b623-4b4795c2fc57"&gt;one&lt;/span&gt;&lt;/span&gt; and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June&#160;30, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December&#160;31, 2021, our gross unrealized losses totaled $0.7&#160;million, and our gross unrealized gains were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfODU0_e0f44ed9-c952-4854-bb81-fce19bd4b626">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfMi0xLTEtMS0zMDU1Mg_3d8ae68e-ece7-4156-9ddd-00ca930291c9"
      unitRef="usd">77545000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfMi0zLTEtMS0zMDU1Mg_03669afa-0dd5-4492-b25b-4281c57ee901"
      unitRef="usd">25218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfMy0xLTEtMS0zMDU1Mg_c9bd8a1c-fc97-4d80-98ec-d2a47da420a9"
      unitRef="usd">541771000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfMy0zLTEtMS0zMDU1Mg_da03a5bf-538e-4d72-b080-37dc066acb5a"
      unitRef="usd">708737000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfNC0xLTEtMS0zMDU1Mg_b8514ad4-a325-44fe-b608-1b96dff1a0cc"
      unitRef="usd">8928000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfNC0zLTEtMS0zMDU1Mg_c8e0f097-3b4e-4849-bc68-7a5ea1c6a2b4"
      unitRef="usd">64828000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfNS0xLTEtMS0zMDU1Mg_ef480b9a-ba5e-44c5-bdf4-d531e5fadfa3"
      unitRef="usd">628244000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOjBjNTZlNmU2YzAzYTQ5NDY4MTNiODk2ZGE5NzJmMmRhL3RhYmxlcmFuZ2U6MGM1NmU2ZTZjMDNhNDk0NjgxM2I4OTZkYTk3MmYyZGFfNS0zLTEtMS0zMDU1Mg_f826e0f5-6906-40c9-bb84-58f7b5f1ead6"
      unitRef="usd">798783000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:DebtInvestmentMaximumMaturityPeriod
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfMzk5_ac6e01cd-4b6b-47a1-9714-029b9740291f">P2Y</nktr:DebtInvestmentMaximumMaturityPeriod>
    <nktr:DebtInvestmentMaturityTerm
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNDU0_d39d7a30-938d-4de3-971a-f234492ed947">P1Y</nktr:DebtInvestmentMaturityTerm>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i66e409cb85994a9abd0992f91c81602e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTQ2_8b91c342-db01-4db0-86c7-8f13c6041b88">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i2b4fb75e85ef4d1da810d56d536e5949_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfNTQ2_92bb9f8a-fa1c-45b0-9f23-466324216bba">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfODU2_83b35634-587e-4d3f-bab1-a39de9ee83e3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0737ddba317b4605a758d1342bb280e1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMi00LTEtMS0zMDU1Mg_ff37acd6-8ed1-4402-b136-83bafcd0d3fc"
      unitRef="usd">141416000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0737ddba317b4605a758d1342bb280e1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMi02LTEtMS0zMDU1Mg_79e3da13-ca1a-4da9-b00f-245faa621211"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0737ddba317b4605a758d1342bb280e1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMi04LTEtMS0zMDU1Mg_5b2ee916-c2f3-42f1-a853-8277026b0250"
      unitRef="usd">1505000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0737ddba317b4605a758d1342bb280e1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMi0xMC0xLTEtMzA1NTI_c6441fbf-a7e6-4f65-bd4a-8559090f99ea"
      unitRef="usd">139911000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd6d6cf71b0b4e4cb1bd7a9a8a889eaa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMi0xMi0xLTEtMzA1NTI_97f96262-264b-414c-8093-7c88671d1545"
      unitRef="usd">278121000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i63723a98759b4da988fffbbea0791b9d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMy00LTEtMS0zMDU1Mg_d40a60d9-4dab-4dbe-a0cf-4140ae2629ae"
      unitRef="usd">415106000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i63723a98759b4da988fffbbea0791b9d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMy02LTEtMS0zMDU1Mg_855c8d52-b4b0-46d2-a782-a4e838c3377f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i63723a98759b4da988fffbbea0791b9d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMy04LTEtMS0zMDU1Mg_73c2e891-aea0-4c2b-828b-efb11735641a"
      unitRef="usd">2232000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63723a98759b4da988fffbbea0791b9d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMy0xMC0xLTEtMzA1NTI_598ac761-7c91-45f9-988a-e208fa0e1415"
      unitRef="usd">412874000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22f239069b834dec8cbd03936544ce8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfMy0xMi0xLTEtMzA1NTI_d381d43a-87ce-472b-9b3c-8dbe66008f3a"
      unitRef="usd">478629000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if5873fdec0d5484a8a91ad052ca94c7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNC00LTEtMS0zMDU1Mg_cf8e610d-29d4-4e81-b896-82537b003aab"
      unitRef="usd">4880000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if5873fdec0d5484a8a91ad052ca94c7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNC02LTEtMS0zMDU1Mg_f88b63a6-64bc-4a65-b69f-f8a0bcd5c8a5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if5873fdec0d5484a8a91ad052ca94c7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNC04LTEtMS0zMDU1Mg_91cecd99-de08-4eba-9878-02279c98361b"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5873fdec0d5484a8a91ad052ca94c7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNC0xMC0xLTEtMzA1NTI_bdb4024f-0d1d-4001-89ed-157f81392d95"
      unitRef="usd">4875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id98fd41da4fd448aa47ed43c6f62a705_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNC0xMi0xLTEtMzA1NTI_a36a2b6d-97d5-4e26-94d4-def7c98b7590"
      unitRef="usd">5875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie76220fe2fa146ab81b848b799537428_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNS00LTEtMS0zMDU1Mg_be09783b-3d9b-4677-9b0e-f7078bcf9454"
      unitRef="usd">561402000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie76220fe2fa146ab81b848b799537428_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNS02LTEtMS0zMDU1Mg_c11365c7-c012-4755-bf73-64833c94e354"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie76220fe2fa146ab81b848b799537428_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNS04LTEtMS0zMDU1Mg_64d4c13b-e667-4cd3-b813-212b913e9e18"
      unitRef="usd">3742000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie76220fe2fa146ab81b848b799537428_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNS0xMC0xLTEtMzA1NTI_635017bb-8446-41c4-afb9-0b859bc0906f"
      unitRef="usd">557660000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c9aa8ae8ab44df7bce7acd7e0dd79d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNS0xMi0xLTEtMzA1NTI_c5c7c284-d896-4b84-8111-8a5eed8ee946"
      unitRef="usd">762625000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0b0f9be97ef3499ea6911ba085621ae3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNi0xMC0xLTEtMzA1NTI_c42ed84d-620c-449b-aa91-5241e1c13dc2"
      unitRef="usd">42342000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie8ed5efbb1774febb2171044acdc2732_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNi0xMi0xLTEtMzA1NTI_ace8b1f0-1f40-4c09-aae1-909b30531f69"
      unitRef="usd">23968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ice3a2c19d2b5444eaed3f904cc22980b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNy0xMC0xLTEtMzA1NTI_ca1d3ce4-a788-46e2-9dc4-3f5d0f9279df"
      unitRef="usd">9516000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id459719606054ed78ab057269952a7b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfNy0xMi0xLTEtMzA1NTI_12f7c785-83b9-4fff-b96d-0d03c438d41b"
      unitRef="usd">10940000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfOC0xMC0xLTEtMzA1NTI_c4539cc9-e98e-441f-bb37-f064a12010ce"
      unitRef="usd">18726000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfOC0xMi0xLTEtMzA1NTI_6bf3bd37-9acf-4bdb-a670-97115afdc939"
      unitRef="usd">1250000</us-gaap:Cash>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfOS0xMC0xLTEtMzA1NTI_8c14b41b-735e-422c-b2ca-59be72f54808"
      unitRef="usd">628244000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RhYmxlOmQ5NzQ4MzAzYzk3MTRmOWE5YzU0NmM3YWQ3ZTQwY2QwL3RhYmxlcmFuZ2U6ZDk3NDgzMDNjOTcxNGY5YTljNTQ2YzdhZDdlNDBjZDBfOS0xMi0xLTEtMzA1NTI_b318a45b-67c3-41cb-ae85-eaa87ab531bc"
      unitRef="usd">798783000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80My9mcmFnOmI0ZTdkYWIwY2Y5ODQ2YjM5ZGQ0MDQ3NWM4MWRiMzg4L3RleHRyZWdpb246YjRlN2RhYjBjZjk4NDZiMzlkZDQwNDc1YzgxZGIzODhfODAx_7d7ea293-fe4e-418f-8ba2-bd75668f1f02"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RleHRyZWdpb246NzY1ODM1ODY1NTdjNDQ3NThiNGY1ODhmMDIyZDgzZDVfODQy_172e3a10-99f9-437c-88bf-97b6a205d7ca">Inventory&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RleHRyZWdpb246NzY1ODM1ODY1NTdjNDQ3NThiNGY1ODhmMDIyZDgzZDVfODQ0_d500e198-f701-4721-aab3-a605f385545e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMS0xLTEtMS0zMDU1Mg_a4814f80-a0d8-4a0d-9055-e4cdbd724add"
      unitRef="usd">2099000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMS0zLTEtMS0zMDU1Mg_efcd7da9-884b-455a-80c8-c4abf8fcd27d"
      unitRef="usd">3166000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMi0xLTEtMS0zMDU1Mg_d6c2e19c-fc39-4379-924c-633a933c7392"
      unitRef="usd">13837000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMi0zLTEtMS0zMDU1Mg_075ea139-ad94-4e41-9faf-7b88fffa8f8a"
      unitRef="usd">9342000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMy0xLTEtMS0zMDU1Mg_996d90b2-d0c9-490e-bb95-4e60f6cbf744"
      unitRef="usd">1033000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfMy0zLTEtMS0zMDU1Mg_8f00bd0a-f195-4389-97a5-68863d7d5b70"
      unitRef="usd">3293000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfNC0xLTEtMS0zMDU1Mg_4fb8c3fa-8ffc-4ef0-be4a-e93b4b6ac77f"
      unitRef="usd">16969000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RhYmxlOmY3NDZlYmFhYTE5MDQxZTBhODg5MTg4NTQ0ZGI1N2ZjL3RhYmxlcmFuZ2U6Zjc0NmViYWFhMTkwNDFlMGE4ODkxODg1NDRkYjU3ZmNfNC0zLTEtMS0zMDU1Mg_9ba6f4e8-1950-4304-ae19-eac07924e3c3"
      unitRef="usd">15801000</us-gaap:InventoryNet>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80Ni9mcmFnOjc2NTgzNTg2NTU3YzQ0NzU4YjRmNTg4ZjAyMmQ4M2Q1L3RleHRyZWdpb246NzY1ODM1ODY1NTdjNDQ3NThiNGY1ODhmMDIyZDgzZDVfODQ2_0fcb9c71-9a43-4e3b-b200-d43b79d86561">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</us-gaap:InventoryPolicyTextBlock>
    <nktr:DevelopmentDerivativeLiabilityTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RleHRyZWdpb246NGE1MzM0YzRjMzNkNDMxYTliYzVkMTM4OTE1ZjVlZDFfMzI2Ng_ee569094-dd8c-455c-9e5f-a6adb2aedfee">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ has primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we are the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $637.5&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin for the metastatic melanoma, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to $0 as of March 31, 2022, and we recognized a corresponding gain in the Change in fair value of development derivative liability. As discussed in Note 1, on April 14, 2022, BMS and we decided to end the development for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and that all other ongoing studies in the bempegaldesleukin program would be discontinued. We also announced that SFJ and we agreed to discontinue the SCCHN Clinical Trial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We presented the SFJ Agreement as a Development derivative liability in our Condensed Consolidated Balance Sheets, which we remeasured to fair value at each reporting date. As SFJ conducted the SCCHN Clinical Trial, we recorded non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remitted funding to us to support our internal costs of conducting the trial, we also recorded a corresponding increase to the development derivative liability. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the development derivative liability:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of March 31, 2022 and 2021, respectively&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nktr:DevelopmentDerivativeLiabilityTextBlock>
    <nktr:CollaborativeArrangementCommittedFunding
      contextRef="i751eb150d22f4b73820c3eb0fdd04e8d_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RleHRyZWdpb246NGE1MzM0YzRjMzNkNDMxYTliYzVkMTM4OTE1ZjVlZDFfMzAz_9e3761ee-0816-4e2e-bbd6-5e76dd362b33"
      unitRef="usd">150000000</nktr:CollaborativeArrangementCommittedFunding>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsAmount
      contextRef="i751eb150d22f4b73820c3eb0fdd04e8d_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RleHRyZWdpb246NGE1MzM0YzRjMzNkNDMxYTliYzVkMTM4OTE1ZjVlZDFfODE4_a039ab93-7e3f-4ce9-b069-e4786e9887ba"
      unitRef="usd">637500000</nktr:CollaborativeArrangementSuccessBasedPaymentsAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i6863c3c60a704766bc19dbf81c2dcb5b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RleHRyZWdpb246NGE1MzM0YzRjMzNkNDMxYTliYzVkMTM4OTE1ZjVlZDFfNjU5NzA2OTc3MDcwMQ_ca78fbc6-23f9-408a-967a-7e51d45c205d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RleHRyZWdpb246NGE1MzM0YzRjMzNkNDMxYTliYzVkMTM4OTE1ZjVlZDFfMzI2NQ_2dc01f81-8a36-4ce8-a980-13fb66d2263f">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the development derivative liability:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of March 31, 2022 and 2021, respectively&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6b68ac442765412db42b3953906b0388_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfMi00LTEtMS0zMDU1Mg_11035c1c-7111-4232-b2bf-5ef12dd4be5d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i95ace3aff3a44be7928b81e09398f163_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfMi02LTEtMS0zMDU1Mg_424ec540-bfd2-4535-be9b-dacaa928c02a"
      unitRef="usd">4597000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="icde60c2bb5d4479b97cd2cd805d5a6bb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfMy00LTEtMS0zMDU1Mg_f1727eb5-e054-43cc-8a30-e01acca67409"
      unitRef="usd">0</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="ie6ef03c0e8b845309927dbe4dfbda529_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfMy02LTEtMS0zMDU1Mg_d1dd4b19-e70a-4c01-aec6-82c89e385ec9"
      unitRef="usd">3547000</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="icde60c2bb5d4479b97cd2cd805d5a6bb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNC00LTEtMS0zMDU1Mg_22e4781b-7811-496c-b21f-16a76d339c1b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ie6ef03c0e8b845309927dbe4dfbda529_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNC02LTEtMS0zMDU1Mg_43f217a1-971d-4efb-8ebc-9c279bf0f0f4"
      unitRef="usd">750000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="icde60c2bb5d4479b97cd2cd805d5a6bb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNS00LTEtMS0zMDU1Mg_79d8310a-f623-49fa-b481-6a84461c2561"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="ie6ef03c0e8b845309927dbe4dfbda529_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNS02LTEtMS0zMDU1Mg_fbc4a288-9293-4c61-ad24-24617c7aa7a7"
      unitRef="usd">2713000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3a1586d1667c4181ab22d8c15f8e9bca_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNi00LTEtMS0zMDU1Mg_b8cea9a2-280b-4dd5-9c6a-bf15e2a3296e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie21c1fe452b344cea3b108885a4d4a8b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjZhYzZiODUxNWNhMjRhNzU5ZGZkZTcxZDE4Y2QzMGQyL3RhYmxlcmFuZ2U6NmFjNmI4NTE1Y2EyNGE3NTlkZmRlNzFkMThjZDMwZDJfNi02LTEtMS0zMDU1Mg_73de5abd-a8c6-4020-8360-3669f4ac5189"
      unitRef="usd">11607000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i57c770143f6e43cc8285c4e87e608f39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMS00LTEtMS0zMzkwMg_5eb49037-36a4-4f63-a8be-c2ff2aff7031"
      unitRef="usd">27726000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iec257d9c2a4f4ca29ba184473f2f37bd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMS02LTEtMS0zMzkxMg_2a40840b-1920-4574-b938-ddc15357f893"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="id755a03fdc2b4e99b02634a338a1d47e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMi00LTEtMS0zMzkwMg_bcddef3a-beb8-4a50-b813-dadbf164004c"
      unitRef="usd">4951000</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="i0fd48c3f03db4bea80b8a4775bd85320_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMi02LTEtMS0zMzkxMg_afe09693-71fb-41a8-98df-d35efc9d5555"
      unitRef="usd">5795000</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="id755a03fdc2b4e99b02634a338a1d47e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMy00LTEtMS0zMzkwMg_1620f034-1dd8-415a-b779-4c75e76ced45"
      unitRef="usd">750000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i0fd48c3f03db4bea80b8a4775bd85320_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfMy02LTEtMS0zMzkxMg_e60e1c61-a062-4a3e-b8e6-73156ab4f9ce"
      unitRef="usd">1500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="id755a03fdc2b4e99b02634a338a1d47e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfNC00LTEtMS0zMzkwMg_fb70df94-821e-40a0-9014-1609a2cb7b99"
      unitRef="usd">-33427000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i0fd48c3f03db4bea80b8a4775bd85320_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfNC02LTEtMS0zMzkxMg_d5ff28e2-b59b-4a45-a5c1-41260632a984"
      unitRef="usd">4312000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3a1586d1667c4181ab22d8c15f8e9bca_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfNS00LTEtMS0zNDA1MQ_6c2a3cfc-1aa4-4c39-aae2-67699b3c3aac"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie21c1fe452b344cea3b108885a4d4a8b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF80OS9mcmFnOjRhNTMzNGM0YzMzZDQzMWE5YmM1ZDEzODkxNWY1ZWQxL3RhYmxlOjA4ZDRlZmEwNTk1MzQzOTk5MDA2Nzg1MTU2MTIxZmMwL3RhYmxlcmFuZ2U6MDhkNGVmYTA1OTUzNDM5OTkwMDY3ODUxNTYxMjFmYzBfNS02LTEtMS0zNDA1NQ_681f087a-297d-42d3-819d-d47448d69657"
      unitRef="usd">11607000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RleHRyZWdpb246NDhhZTA3NWYzM2JkNGU5NWEyNjlmZjVhOTFlYjA4NTJfMTY5MQ_4c7b8e4e-fd12-4cb1-a532-e3578d2dcf2b">Liabilities Related to Sales of Future Royalties&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Drug&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Manufacturer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty under Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; and ADYNOVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (brand name for ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; in Europe)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (naloxegol tablets) and  MOVENTIG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (brand name for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; in Europe)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca AB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (certolizumab pegol)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UCB Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RPI Finance Trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 24, 2012&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (Continuous Erythropoietin Receptor Activator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;F. Hoffmann-La Roche Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RPI Finance Trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 24, 2012&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to our ongoing manufacturing obligations in both arrangements, we account for the proceeds as imputed debt (Royalty Obligations) and therefore continue to recognize these non-cash royalties as revenue. As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. Additionally, to the extent that the amount or timing of the royalty payments is materially different from our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the applicable Royalty Obligation. As of June 30, 2022, our imputed interest rates for the arrangements with RPI and HCR were 16% and 15%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account of each arrangement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period from inception to June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty monetization proceeds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(367,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to RPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1) Loss recognized from Settlement Agreement to resolve UCB&#x2019;s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
    <nktr:ScheduleOfPurchaseAndSaleAgreementTableTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RleHRyZWdpb246NDhhZTA3NWYzM2JkNGU5NWEyNjlmZjVhOTFlYjA4NTJfMTY5Mg_1a898fae-de5b-44c5-b5b0-2bc6bf5bdefe">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Drug&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Manufacturer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty under Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; and ADYNOVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (brand name for ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; in Europe)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (naloxegol tablets) and  MOVENTIG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (brand name for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; in Europe)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca AB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (certolizumab pegol)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UCB Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RPI Finance Trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 24, 2012&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (Continuous Erythropoietin Receptor Activator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;F. Hoffmann-La Roche Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RPI Finance Trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 24, 2012&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nktr:ScheduleOfPurchaseAndSaleAgreementTableTextBlock>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="i7c3682511cdc470e8b31f4be9255bc51_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RleHRyZWdpb246NDhhZTA3NWYzM2JkNGU5NWEyNjlmZjVhOTFlYjA4NTJfNjU5NzA2OTc2OTIxMA_b66cd3a9-b3e5-4d2b-bec8-71d1d960c1da"
      unitRef="number">0.16</nktr:RoyaltiesLiabilityMeasurementInput>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="i9ffcae4931614a41b546c5604b6e9e1a_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RleHRyZWdpb246NDhhZTA3NWYzM2JkNGU5NWEyNjlmZjVhOTFlYjA4NTJfNjU5NzA2OTc2OTIxOA_956c7920-d8c2-4e11-bf26-fa45026c6fde"
      unitRef="number">0.15</nktr:RoyaltiesLiabilityMeasurementInput>
    <nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RleHRyZWdpb246NDhhZTA3NWYzM2JkNGU5NWEyNjlmZjVhOTFlYjA4NTJfMTY5Mw_4fce65a4-e47d-48ad-8bb3-a6f66de90b67">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account of each arrangement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period from inception to June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty monetization proceeds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(367,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to RPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1) Loss recognized from Settlement Agreement to resolve UCB&#x2019;s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMi0xLTEtMS0zMDU1Mg_22658a73-38a8-4e13-97b3-68a2ac739047"
      unitRef="usd">124000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMi0zLTEtMS0zMDU1Mg_c2753cc8-1188-4475-9461-91557ad39874"
      unitRef="usd">150000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMi01LTEtMS0zMDU1Mg_c87f018c-dd35-4e4f-bfb7-a74441c918fc"
      unitRef="usd">274000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMy0xLTEtMS0zMDU1Mg_c4f301f7-83c5-46e1-b45e-33d898b50b63"
      unitRef="usd">-297507000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMy0zLTEtMS0zMDU1Mg_67d90f3c-9d99-41bd-9de8-48a65a0734fd"
      unitRef="usd">-69770000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfMy01LTEtMS0zMDU1Mg_3426c57d-85d6-4e5e-9fe2-eaf9e68f4a4d"
      unitRef="usd">-367277000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNC0xLTEtMS0zMDU1Mg_227f8abe-3772-46c8-8c01-e5d891365aea"
      unitRef="usd">229474000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNC0zLTEtMS0zMDU1Mg_f7337315-d63d-4c44-a064-71a150508cb9"
      unitRef="usd">29556000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNC01LTEtMS0zMDU1Mg_fc3fd73a-14e5-4fe1-8d09-a667f59b2aa0"
      unitRef="usd">259030000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNS0xLTEtMS0zMDU1Mg_fe53bc28-6fa9-4cb9-b8f1-23093ba03b1c"
      unitRef="usd">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNS0zLTEtMS0zMDU1Mg_f4ea5f1c-7f2b-46e7-a504-0165f67d4d54"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNS01LTEtMS0zMDU1Mg_78b1db04-9e64-48c0-a0d1-94363faa6b16"
      unitRef="usd">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i57c21698e5224eabb781dee4b47e571c_D20120101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNi0xLTEtMS0zMDU1Mg_782af0a0-1677-4092-b81b-849ceac61937"
      unitRef="usd">23522000</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i1e6ef773bfe64cd093008612e64df65e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNi0zLTEtMS0zMDU1Mg_84aaf2b5-965d-44c4-8e29-dafd625522e5"
      unitRef="usd">0</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i16be06e4152e4ce481549b23d09556ad_D20120101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNi01LTEtMS0zMDU1Mg_ec5806be-a761-43dd-9c8b-b2c1d857f7be"
      unitRef="usd">23522000</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i7c3682511cdc470e8b31f4be9255bc51_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNy0xLTEtMS0zMDU1Mg_97d94938-a46e-429b-814f-3ada27ac1ab3"
      unitRef="usd">69489000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i9ffcae4931614a41b546c5604b6e9e1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNy0zLTEtMS0zMDU1Mg_cfdb5b2d-6232-4a14-b053-fb4f902b2187"
      unitRef="usd">109786000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfNy01LTEtMS0zMDU1Mg_136c8acb-b16f-4fce-bd7d-a184571b7989"
      unitRef="usd">179275000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i7c3682511cdc470e8b31f4be9255bc51_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOC0xLTEtMS0zMDU1Mg_eb74965a-ff4d-4257-98c7-a6547efed7ed"
      unitRef="usd">0</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i9ffcae4931614a41b546c5604b6e9e1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOC0zLTEtMS0zMDU1Mg_e0f41bff-effa-46f7-b04e-9c6f449ba8f4"
      unitRef="usd">2500000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOC01LTEtMS0zMDU1Mg_ed034880-42f6-4aab-8ed0-453803c9a9e5"
      unitRef="usd">2500000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i7c3682511cdc470e8b31f4be9255bc51_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOS0xLTEtMS0zMDU1Mg_c454d56e-fb8a-4a41-b678-2fa441d0e6a7"
      unitRef="usd">69489000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i9ffcae4931614a41b546c5604b6e9e1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOS0zLTEtMS0zMDU1Mg_b03ee524-1b86-4d27-b887-1827d0c6efe0"
      unitRef="usd">107286000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81Mi9mcmFnOjQ4YWUwNzVmMzNiZDRlOTVhMjY5ZmY1YTkxZWIwODUyL3RhYmxlOjg4YzcxNWFmYzdmMTQyNzhiZWFiMzBkZWNhNjVkOGQ2L3RhYmxlcmFuZ2U6ODhjNzE1YWZjN2YxNDI3OGJlYWIzMGRlY2E2NWQ4ZDZfOS01LTEtMS0zMDU1Mg_9c64ba96-ec61-4aa0-9c8f-aad6adf8e62d"
      unitRef="usd">176775000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81NS9mcmFnOmI0M2UzYmQyY2U0ZTQ0MzQ4MjBlYzcyZjlmOTg2N2MzL3RleHRyZWdpb246YjQzZTNiZDJjZTRlNDQzNDgyMGVjNzJmOWY5ODY3YzNfNjcyNQ_0db1f95c-f8ba-48f9-acda-b380d8d6a758">Commitments and Contingencies&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018, about the clinical trials of bempegaldesleukin. The Mulquin complaint was amended in May 2019. The defendants moved to dismiss and the court granted the motion without prejudice in July 2020. The Mulquin plaintiffs again amended their complaint and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice. The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument occurred on December 10, 2021. On May 19, 2022, the Ninth Circuit affirmed the district court's dismissal of all claims against the defendants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A derivative action was also filed against certain of the Company&#x2019;s current and former officers and directors, purportedly on the Company&#x2019;s behalf. This derivative action is based on the allegations in the Mulquin action and on the premise that the Company&#x2019;s officers and directors breached their fiduciary duties to the Company. The complaint for this derivative action was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF). Following a stay in the proceedings during the pendency of the appeal in the Mulquin action, the Company received an amended complaint on July 29, 2022, and the defendants will have until September 12, 2022 to respond to the amended complaint. Given the nature and status of the derivative action, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at either June&#160;30, 2022 or December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnifications in Connection with Commercial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.&lt;/span&gt;&lt;/div&gt;To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i07faaf6c80274e79b161089c13725a99_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81NS9mcmFnOmI0M2UzYmQyY2U0ZTQ0MzQ4MjBlYzcyZjlmOTg2N2MzL3RleHRyZWdpb246YjQzZTNiZDJjZTRlNDQzNDgyMGVjNzJmOWY5ODY3YzNfNDU3MQ_37144bfd-9f6d-494f-af29-5f1a954fee31"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i80ddb5385d944743a6830e905272b6dc_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81NS9mcmFnOmI0M2UzYmQyY2U0ZTQ0MzQ4MjBlYzcyZjlmOTg2N2MzL3RleHRyZWdpb246YjQzZTNiZDJjZTRlNDQzNDgyMGVjNzJmOWY5ODY3YzNfNDU3MQ_f8831c74-26b1-46ce-b4c8-d137ec3fef98"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNzQ5NQ_7d685a2a-946a-4ffe-aaea-d45d38159b6d">License and Collaboration Agreements&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our collaboration agreements in the three and six months ended June&#160;30, 2022, other than as described below for our Strategic Collaboration Agreement with BMS and Note 4 regarding SFJ.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb Company (BMS)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: Bempegaldesleukin, also referred to as NKTR-214 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#x2019;s Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#x2019;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing and commercialization of bempegaldesleukin, 35% of the costs to BMS and 65% to Nektar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million. In 2020, we received non-refundable milestone payments of $50.0&#160;million in aggregate for the first patient, first visit in the registrational trials in muscle-invasive bladder cancer and adjuvant melanoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 1, on March 14, 2022, we announced our registrational trial in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the trials in metastatic melanoma and adjuvant melanoma. On April 14, 2022, we announced that our registrational trials in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided that these studies and all other ongoing studies in the program will be discontinued. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. However, without further development of bempegaldesleukin, we will no longer be eligible for the development, regulatory and sales milestones under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognized BMS&#x2019; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#x2019; expenses as research and development expense. As discussed in Note 8, beginning in the three months ended June 30, 2022, we began reporting clinical trial, other third-party costs and employee costs for the bempegaldesleukin program in Restructuring, impairment and other costs of program. Accordingly, during the three months ended June 30, 2022, we recorded $7.6&#160;million, as a reduction of such expense for the net reimbursement from BMS. During the six months ended June 30, 2022, we recorded $24.9&#160;million as a reduction of research and development expense for the net reimbursement from BMS, reflecting the reimbursement recorded in the three months ended March 31, 2022. For the three and six months ended June 30, 2021, we recorded $24.8&#160;million and $51.4&#160;million, respectively, as a reduction of research and development expense for the net reimbursement from BMS. As of June&#160;30, 2022, we have recorded an unbilled receivable of $7.4&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eli Lilly and Company (Lilly&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;): NKTR-358 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop NKTR-358, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0&#160;million and are eligible for up to $250.0&#160;million in additional development and regulatory milestones. We are currently in Phase 1B and Phase 2 development, where we share costs with 75% of the costs borne by Lilly and 25% of the costs borne by us. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to 25% of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the costs of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Phase 3 development on an indication-by-indication basis in order for us to achieve the maximum royalty level under the Lilly Agreement, and further&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if approved, we will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales.  Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lilly Agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The Lilly Agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we are entitled to significant development milestones under this arrangement, through June&#160;30, 2022, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 5, we have sold our rights to receive royalties from these other collaboration agreements. Our non-cash royalty revenue which totaled $16.3&#160;million and $33.8&#160;million for the three and six months ended June&#160;30, 2022 and totaled  $20.5&#160;million and $39.3&#160;million for the three and six months ended June 30, 2021, respectively, represents revenue for granting licenses which we had satisfied in prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $40.0&#160;million of regulatory milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="if11fbbe66ec44a33844d1df024a81f34_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMTg5OA_1d526572-081a-45e6-b033-ea56fda40e7c"
      unitRef="number">0.675</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="ib0f61ce40f5741b1bd39e0dce462d66f_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMTkyMQ_d2406ce3-8e27-4161-ad44-46cf392f3779"
      unitRef="number">0.325</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i434d1fce8cc349169ce2249b32af62e5_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjAyNQ_4562dea7-69c1-44be-a5e8-e15b9f009332"
      unitRef="number">0.35</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i5b4e6c90ab19450e859fb50421c353c0_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjA1Mg_e698f168-6f51-4cd2-b605-b9a3640db0da"
      unitRef="number">0.65</nktr:PercentageOfSharingInProductionCosts>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="i689d7549c612490aa4442f5f5348ccf0_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjE5NA_4e541515-17d7-4986-99d7-a604d788becf"
      unitRef="usd">1000000000</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <us-gaap:SharesIssued
      contextRef="id4bfcb6279024241948e7bd08d4d1b15_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjIxMQ_0245cd20-1a06-4562-9ecf-416fde07f86b"
      unitRef="shares">8284600</us-gaap:SharesIssued>
    <nktr:SaleOfStockConsiderationReceived
      contextRef="ie055df71b6fe4ad78a3fae8b679f8f1b_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjMyNQ_3aba27e8-1962-4074-9c5b-1ed8720aa2f7"
      unitRef="usd">850000000</nktr:SaleOfStockConsiderationReceived>
    <nktr:PotentialDevelopmentMilestones
      contextRef="id5048bfc963648bd9dd0de98c3c9f77f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjM4Nw_cdd502ab-84bc-409c-8aa0-d7804c397b98"
      unitRef="usd">50000000</nktr:PotentialDevelopmentMilestones>
    <nktr:ReimbursementOfExpenses
      contextRef="i545e1ec1c15e497d8d84331994a8de35_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjE5OTAyMzI2NDg4MQ_56e7f53e-8523-44ea-9174-d46fdae284d9"
      unitRef="usd">7600000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i8cb09da3230846e4ab889acaf256b09a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjE5OTAyMzI2NDg4MQ_87c03267-3a0b-4491-b60c-50577b1393cc"
      unitRef="usd">7600000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i6a74c1627d594a4e9983b68d9cb5016a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDA1Mg_ccde7678-612e-4683-abd2-5232574eea36"
      unitRef="usd">24900000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i55a25cbb90084904aaa526c771ddf88f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjE5OTAyMzI2NDg1MA_75b34390-af41-4845-9c8e-3c0b9c169e1f"
      unitRef="usd">24800000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i2710a7259237431b952f8e9e2f6ca813_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfMjE5OTAyMzI2NDg2NQ_e07693d2-540f-4316-8eeb-e18ef620f580"
      unitRef="usd">51400000</nktr:ReimbursementOfExpenses>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2fb960f7e2be4ba7b0f30d51ecbfb755_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDI0MA_8196590a-9a40-4580-b56b-e2c5d6e36d21"
      unitRef="usd">7400000</us-gaap:AccountsReceivableNetCurrent>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i06b66ce62bc84a1e8198557985db717e_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDYxMw_1aa9ec69-c43a-4ed9-ba6e-f7b7bab6ecbd"
      unitRef="usd">150000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="i709e2f46181a4b05a3abc2e27c2e31e3_I20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDY0Mw_23cb9299-93da-46e3-bfcd-e811e2a8aba5"
      unitRef="usd">250000000</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="ic5ed1fb4aeaf4781a0044453513572b1_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDc3OQ_0d2cdcc4-e939-4339-8b3b-bb0810a7bd58"
      unitRef="number">0.75</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="i06b66ce62bc84a1e8198557985db717e_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDgxNA_4785d94d-0d65-4f9e-bb6b-a6cff7d6babb"
      unitRef="number">0.25</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i4c14708c9dc14478a8d5ecaefcbb0ee5_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNDk0Nw_4e596389-9eb3-446d-8016-4cf43fc6a465"
      unitRef="number">0.25</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
      contextRef="id60d7ddcd1e843edacbce13b2a891386_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNTUwOQ_31ba2324-84f7-4227-86fd-ade51f9d37c9"
      unitRef="number">0.50</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
      contextRef="id60d7ddcd1e843edacbce13b2a891386_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNTc0NA_fcd2484d-49ff-4daf-b929-41549bd2d75e"
      unitRef="number">0.75</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaa02756dcbe4a1a871ce1cb0480648d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNjU5NzA2OTc3NjE4Ng_552f5966-7aa8-43bf-8802-dc39c7303641"
      unitRef="usd">16300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e6059c3a6a244129de957ee89ff70fc_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNjU5NzA2OTc3NjE5NA_8018bdfd-d45a-4bfc-a6b9-3b6bb173860d"
      unitRef="usd">33800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i957bd179292a4a5f8bea0ec87a04ddac_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNjU5NzA2OTc3NjI0MA_02ccf7cc-f1f5-4231-9fdd-677af2ea0f29"
      unitRef="usd">20500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82df606601154dc1ad7096a861539bf7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNjU5NzA2OTc3NjI0OA_a6938617-5ab2-4010-b789-041cb6ce760f"
      unitRef="usd">39300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i4e937e61c4a04a74b304ed91d94164d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF81OC9mcmFnOjEzNGJiYjkxOGY5YzRmZDZhNGQxNzYyMWVjNTJiMDRmL3RleHRyZWdpb246MTM0YmJiOTE4ZjljNGZkNmE0ZDE3NjIxZWM1MmIwNGZfNzA0MQ_ce561293-edf4-4914-be7c-dc8712f4e68f"
      unitRef="usd">40000000</nktr:PotentialDevelopmentMilestones>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfMjU3_2dc1e985-7573-4b91-aa79-e50b505eec40">Restructuring, Impairment and Other Costs of Terminated ProgramAs discussed in Note 1, because our registrational trials in bempegaldesleukin did not meet their primary endpoints, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors and tyrosine kinase inhibitors, and, during April 2022, we announced the Restructuring Plan to prioritize key Phase 2 development programs, to advance our early stage research pipeline and to reduce our workforce by approximately 70% from approximately &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;735 to approximately 225 employees. In connection with these events, we reported the following costs in Restructuring, impairment and other costs of terminated program in the three months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Severance and related benefit costs pursuant to the Restructuring Plan;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Impairment of right-of-use assets and property, plant and equipment resulting from the Restructuring Plan, primarily reflecting excess office and laboratory leased spaces in San Francisco, CA; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Contract termination and other costs associated with these plans. Previously, during the three months ended March 31, 2022, we recognized an initial $1.5&#160;million in cancellation fees related to certain manufacturing activities for bempegaldesleukin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In prior periods, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin primarily in research and development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, impairment and other costs of terminated program includes the following (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance and benefit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of right-of-use assets and property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract termination and other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and other costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program for the three and six months ended June 30, 2022 includes a reduction of $7.6&#160;million for the net reimbursement from BMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Severance and Benefit Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees affected by the reduction in force under our Restructuring Plan are entitled to receive severance payments and certain Company funded benefits. We recognized severance and benefit expense in full for employees who were notified of their termination in April 2022 and have no requirements for future service, and we are recognizing expense for employees who are required to render services to receive their severance and benefits over the service period ratably over the service period. This service period began in April 2022 and all will end during 2022. The following table provides details regarding the severance and other termination benefit expense and a reconciliation of such liability for the three months ended June 30, 2022, which we report within Accrued compensation on our Condensed Consolidated Balance Sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the three months ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;No service period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Service period required&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total severance and other termination benefits, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognized during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The liability as of June 30, 2022 for employees terminated with no requirements for future service primarily relates to final severance paid in July 2022. We may record adjustments to severance and benefit expense in future periods as our estimates of the costs of benefits change or when an employee terminates before the end of their requisite service period. However, we do not expect that such adjustments will have a material effect on our results of operations or financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Right-of-Use Assets and Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our Restructuring Plan, we have consolidated our operations by exiting all of the office space from our leased facility at 360 Third St. and certain laboratory and office spaces at our leased facility at 455 Mission Bay Blvd. South, both in San Francisco, CA. We are seeking to sublease these spaces, while still maintaining sufficient office and laboratory space to allow our team to develop our proprietary programs. We have also terminated all research and development activities at our owned facility in India, which we plan to sell. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of these plans, we reviewed each of our excess spaces for impairment as of May 31, 2022, when management had determined which spaces we would retain and which spaces we may sublease. As part of our impairment evaluation of each excess space, we separately compared the estimated undiscounted income for each sublease to the net book value of the related long-term assets, which include right-of-use assets and certain property, plant and equipment, primarily for leasehold improvements (collectively, sublease assets). We estimated sublease income using market participant assumptions, including the length of time to enter into a sublease and lease payments, which we evaluated using current real estate trends and market conditions. If such income exceeded the net book value of the related assets, we did not record an impairment charge. Otherwise, we recorded an impairment charge by reducing the net book value of the assets to their estimated fair value, which we determined by discounting the estimated sublease income using the estimated borrowing rate of a market participant subtenant, which we estimated to be 6.4%. For our India site, we recorded no impairment charge because the estimated net proceeds from the sale exceed the net book value of the site. We have classified the India facility as an asset held for sale as of June 30, 2022 and report this in other current assets in our Condensed Consolidated Balance Sheet. Additionally, we recorded an impairment expense primarily for software which we plan to abandon and certain excess equipment based on the estimated income from selling such assets. We recorded impairment charges as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Lease Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net book value of impaired facilities before write-off&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Fair value of impaired facilities &#x2014; Level 3 of Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment expense for facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment of other property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total impairment of right-of-use assets and property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our property, plant and equipment as of June 30, 2022 and December 31, 2021, reflecting the effects of the impairment charges and held-for-sale reclassification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We may record adjustments to impairment expense in future periods as we enter into sublease or sale agreements or change our estimates when additional information becomes available to us.</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i6844748a7747471187efa284c70c9b40_D20220401-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfNjU5NzA2OTc3MDM1NQ_054c1d37-a98c-440d-a472-dedaffd996e7"
      unitRef="number">0.70</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <dei:EntityNumberOfEmployees
      contextRef="i615612becd454568aed79f306f2b522e_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfMTY0OTI2NzQ2NjI0Nw_9ea6766e-4dc5-4c42-ac86-79fd8d05b40b"
      unitRef="employee">735</dei:EntityNumberOfEmployees>
    <dei:EntityNumberOfEmployees
      contextRef="ic87a58d05dff437199600e83c801a439_I20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfMTY0OTI2NzQ2NjI1Mg_dd6668b5-f7d8-4ad1-8ec5-5a971c9bf5c1"
      unitRef="employee">225</dei:EntityNumberOfEmployees>
    <us-gaap:LossOnContractTermination
      contextRef="i6cf30f1f3976425f9ae1a9658814d0a2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfMTY0OTI2NzQ2NjI1Nw_50532fed-a1b1-4e2f-87ad-0b1abf3301bc"
      unitRef="usd">1500000</us-gaap:LossOnContractTermination>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfODc5NjA5MzA0NjYyNw_760e5161-3f21-49fa-9623-0db087a6dda9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, impairment and other costs of terminated program includes the following (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance and benefit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of right-of-use assets and property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract termination and other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and other costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The following table provides details regarding the severance and other termination benefit expense and a reconciliation of such liability for the three months ended June 30, 2022, which we report within Accrued compensation on our Condensed Consolidated Balance Sheet (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the three months ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;No service period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Service period required&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total severance and other termination benefits, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognized during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;Additionally, we recorded an impairment expense primarily for software which we plan to abandon and certain excess equipment based on the estimated income from selling such assets. We recorded impairment charges as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Lease Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net book value of impaired facilities before write-off&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Fair value of impaired facilities &#x2014; Level 3 of Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment expense for facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment of other property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total impairment of right-of-use assets and property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:BusinessExitCosts1
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfMi01LTEtMS0zMTM2OA_146d788b-9a41-4f26-afdf-6f621bffa005"
      unitRef="usd">20408000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfMi03LTEtMS0zMTM2OA_33c77449-0d15-4eb8-9f8a-76ecab957d59"
      unitRef="usd">20408000</us-gaap:BusinessExitCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfMy01LTEtMS0zMTM2OA_ab3f8180-acfc-448d-bf6d-4fa8f3e058ea"
      unitRef="usd">27750000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfMy03LTEtMS0zMTM2OA_4c5c6339-712f-4578-a51d-112749b6d066"
      unitRef="usd">27750000</us-gaap:SeveranceCosts1>
    <us-gaap:AssetImpairmentCharges
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNS0yLTEtMS0zMzI0MQ_2a55b8f0-51b5-4997-bbb3-fb89e2d85ab8"
      unitRef="usd">57321000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNS00LTEtMS0zMzI0Mw_06ffba70-3e9e-45c1-b37b-e1f01b2bbd8c"
      unitRef="usd">57321000</us-gaap:AssetImpairmentCharges>
    <us-gaap:LossOnContractTermination
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNC01LTEtMS0zMTM2OA_6c379e80-ed09-48e0-a3f1-44904866e0bc"
      unitRef="usd">566000</us-gaap:LossOnContractTermination>
    <us-gaap:LossOnContractTermination
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNC03LTEtMS0zMTM2OA_193a8427-09ca-48ec-9e57-7269c695a20f"
      unitRef="usd">2041000</us-gaap:LossOnContractTermination>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNS01LTEtMS0zMTM2OA_a8f96a2d-f5c8-431f-9e13-2858e3008eb4"
      unitRef="usd">106045000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOmQzODUyNmUyODczMjRiZTE4OGM4MGZhMDg1ZGRhMjkzL3RhYmxlcmFuZ2U6ZDM4NTI2ZTI4NzMyNGJlMTg4YzgwZmEwODVkZGEyOTNfNS03LTEtMS0zMTM2OA_a23e14a0-e3cf-4b49-9331-8b545ca38787"
      unitRef="usd">107520000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <nktr:ReimbursementOfExpenses
      contextRef="i545e1ec1c15e497d8d84331994a8de35_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfNjU5NzA2OTc5MzAyNw_56e7f53e-8523-44ea-9174-d46fdae284d9"
      unitRef="usd">7600000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i8cb09da3230846e4ab889acaf256b09a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfNjU5NzA2OTc5MzAyNw_87c03267-3a0b-4491-b60c-50577b1393cc"
      unitRef="usd">7600000</nktr:ReimbursementOfExpenses>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ia2f06c20fdeb4692aecab09bd5ba73dc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMS0yLTEtMS0zMzYyOQ_852b4d19-2961-4c83-98ad-3e3290e20219"
      unitRef="usd">23588000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="iac52ca5498ce49769a17fcd39f41a8fe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMS00LTEtMS0zMzYzMQ_f8300eb4-95c2-4907-a9b5-8dd4774a5c68"
      unitRef="usd">8829000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i615612becd454568aed79f306f2b522e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMS02LTEtMS0zMzYzMw_496a12ad-5716-479c-b185-c6089991416b"
      unitRef="usd">32417000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringReserve
      contextRef="ia2f06c20fdeb4692aecab09bd5ba73dc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMi0yLTEtMS0zMzYyOQ_94f1a750-bdbf-4b2e-a8c9-e40277a531a9"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iac52ca5498ce49769a17fcd39f41a8fe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMi00LTEtMS0zMzYzMQ_587bb617-379b-4956-8c02-d85a60f1adda"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i615612becd454568aed79f306f2b522e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMi02LTEtMS0zMzYzMw_02986932-d2e2-4020-a8f4-e7ab398f7b6b"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i30a2d694cc3e4307a91fcd4094b87e05_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMy0yLTEtMS0zMzYyOQ_b7f6c54c-0c83-46b3-80c2-9c9c8dcb4fc3"
      unitRef="usd">23588000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia3a1676fb6a54c20884fa6fd60c2e2c7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMy00LTEtMS0zMzYzMQ_10d35f9d-0735-429c-b037-f0a3fbbf9193"
      unitRef="usd">4162000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia26bb03096c94a0cb77035930f749cab_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfMy02LTEtMS0zMzYzMw_5e4aa123-4e87-4329-8a7a-d7db905584cf"
      unitRef="usd">27750000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i30a2d694cc3e4307a91fcd4094b87e05_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNC0yLTEtMS0zMzYyOQ_9ac32293-214d-44e9-b60d-39c4817a5113"
      unitRef="usd">12881000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ia3a1676fb6a54c20884fa6fd60c2e2c7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNC00LTEtMS0zMzYzMQ_77f8efac-34ec-471c-af65-5792977718e3"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ia26bb03096c94a0cb77035930f749cab_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNC02LTEtMS0zMzYzMw_8b2a5502-7ff2-4ab0-b00d-4c3564851167"
      unitRef="usd">12881000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="ia0541e02c0b140788f808cb99a415cce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNS0yLTEtMS0zMzYyOQ_f2327e08-f12a-4ed4-84f1-04af3f45f29b"
      unitRef="usd">10707000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ifaeb6b4f62ff443a849137f15836e9cf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNS00LTEtMS0zMzYzMQ_fdcd03e1-e11a-41e8-8338-1174001e6ebe"
      unitRef="usd">4162000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i5ce6c1dda32f4aad9544682d143fc875_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjBiZjg0NjNkM2VkNzRmOGNiMGJhZDkwZTM2ZTc1NGFlL3RhYmxlcmFuZ2U6MGJmODQ2M2QzZWQ3NGY4Y2IwYmFkOTBlMzZlNzU0YWVfNS02LTEtMS0zMzYzMw_33a6ce7b-760f-4eaf-b0cb-268469bffc8d"
      unitRef="usd">14869000</us-gaap:RestructuringReserve>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i497fa308a3a645399b2e66b525053f40_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMS0xLTEtMS0zMzYzNQ_dfacee2e-7c1b-4b72-8699-6c0f89c16e3f"
      unitRef="usd">16348000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i1540676709064b73bec30295a78b402b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMS0zLTEtMS0zMzYzNw_c3f535d0-a287-4a58-965d-86d02f8b2289"
      unitRef="usd">70920000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i6a99a4cd3e9046998329b115338a1fcf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMS01LTEtMS0zNDI0NQ_b6c41fa0-6d99-47c8-a306-c50c163ecda6"
      unitRef="usd">87268000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="ifbf30fbd9d0b453c90b68fbde9485002_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMi0xLTEtMS0zMzYzNQ_b8725cba-b1d4-4893-bff0-939e1a55cc29"
      unitRef="usd">6976000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i3d93efed2f4445efbb3ddeb1f2270dee_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMi0zLTEtMS0zMzYzNw_d1b91211-f80d-406f-85ff-bcd91599a251"
      unitRef="usd">28091000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i575b5f648bf14d37af112b07599ee280_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMi01LTEtMS0zNDI0NQ_4f3e7d2c-eb0a-4a11-91cf-01362329f376"
      unitRef="usd">35067000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i90314768134649a19db482bb55a94126_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMy0xLTEtMS0zMzYzNQ_a09a926d-2f10-4d35-a48c-d254b2161ca7"
      unitRef="usd">9372000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ic166b3669ca64e7781374dbce5ce7ae2_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMy0zLTEtMS0zMzYzNw_2e7b5c0c-55cd-440c-a5b5-f875f39b416c"
      unitRef="usd">42829000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfMy01LTEtMS0zNDI0NQ_54be68b2-8557-406c-987f-b4a39cb541ba"
      unitRef="usd">52201000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i90314768134649a19db482bb55a94126_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfNC0xLTEtMS0zMzYzNQ_6963006d-74fe-4c7c-830a-c0f2e9e0c2ec"
      unitRef="usd">5120000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfNC01LTEtMS0zNDI0NQ_70c8dc83-aab3-420d-848e-74d2a7af2756"
      unitRef="usd">5120000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:AssetImpairmentCharges
      contextRef="i90314768134649a19db482bb55a94126_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfNS0xLTEtMS0zMzYzNQ_5b24eab7-571b-4ca9-906d-987807db3470"
      unitRef="usd">14492000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic166b3669ca64e7781374dbce5ce7ae2_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfNS0zLTEtMS0zMzYzNw_657caad9-45cf-4c13-b096-069331da07cb"
      unitRef="usd">42829000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjQzNDczZTNlNTdkNzQ1NGZhZTcyNjYzOGMwYjZmNDU1L3RhYmxlcmFuZ2U6NDM0NzNlM2U1N2Q3NDU0ZmFlNzI2NjM4YzBiNmY0NTVfNS01LTEtMS0zMzYzOQ_cf56e42c-b620-48d5-9110-89cfcee52c2d"
      unitRef="usd">57321000</us-gaap:AssetImpairmentCharges>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RleHRyZWdpb246YTQ5MDhiMjg1OGMwNDQ5Y2E1NTE0ZWZmMDg5YmQ4NWNfMTY0OTI2NzQ3MDY1OA_299d0f71-4b90-45dc-87be-f3adb6291460">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our property, plant and equipment as of June 30, 2022 and December 31, 2021, reflecting the effects of the impairment charges and held-for-sale reclassification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i79e0f4b9899445bfb9f7c130223aa7e0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMS0xLTEtMS0zNTg5Mg_bd00b37e-f7e5-4248-877e-851881d7db40"
      unitRef="usd">83158000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib642b7862a8f41ebaf418619e6c1e3a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMS0zLTEtMS0zNTgyMA_99f5ca82-2036-4f13-89f6-988bcaef2819"
      unitRef="usd">97385000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i73b2d39f16fe45808af4224f9bb7e64a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMi0xLTEtMS0zNTg5Mg_529611be-66e2-4f40-bcda-264fb559b126"
      unitRef="usd">36738000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9cdb1245c2a242b295b7228ac4ac5bfd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMi0zLTEtMS0zNTg5NA_b2c94b05-d540-4450-ac18-953b775b0b37"
      unitRef="usd">42704000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i278bdb80843a4d15829b02b5f7e5db58_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMy0xLTEtMS0zNTg5Mg_2e0b80c7-7560-4048-bcb0-fc7d07380e59"
      unitRef="usd">28391000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4699c5afe4c64c4dab6ccd99e97a4420_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMy0zLTEtMS0zNTg5NA_1fd3927e-a70a-4a2e-86f3-35c0b48c638d"
      unitRef="usd">28829000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if1e3d5e8c9da41acba432436d90e144e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNC0xLTEtMS0zNTg5Mg_0bdf5439-2756-414f-8cb5-8030251104fd"
      unitRef="usd">23743000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2392ef5c8b944214b18e26ee24b8b8f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNC0zLTEtMS0zNTg5NA_28b28bc3-efbe-4e7c-a4ee-e4aff8a26346"
      unitRef="usd">22374000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i597b24d94a354403bcb197617d6325c3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNS0xLTEtMS0zNTg5Mg_e31d9f32-a645-4a5e-ba9e-006b3a69824c"
      unitRef="usd">7318000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idcf4331b31d34c4b8595b0bf92ffe39c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNS0zLTEtMS0zNTg5NA_6107b44b-4a31-4f3b-a943-3696e0b5987f"
      unitRef="usd">10094000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i13e1155ab7ba47dfa1bb5c48d087629a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNi0xLTEtMS0zNTg5Mg_3b4f901d-f19b-403a-979d-b6119b052fa0"
      unitRef="usd">179348000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie29cf24f92e945298307779be936b4b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNi0zLTEtMS0zNTg5NA_c221e975-45e9-4dbf-b15c-888ceed49b04"
      unitRef="usd">201386000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i13e1155ab7ba47dfa1bb5c48d087629a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNy0xLTEtMS0zNTg5Mg_7fb0bdf0-510c-4861-b6b3-aa5c4bb4d98d"
      unitRef="usd">143304000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie29cf24f92e945298307779be936b4b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfNy0zLTEtMS0zNTg5NA_1cbdacc7-8e71-4660-81c4-582dd30c05be"
      unitRef="usd">148039000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i13e1155ab7ba47dfa1bb5c48d087629a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfOC0xLTEtMS0zNTg5Mg_d4b9a9af-93b3-46df-8531-46f67be225ad"
      unitRef="usd">36044000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie29cf24f92e945298307779be936b4b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfOC0zLTEtMS0zNTg5NA_20884252-e364-4847-84b2-134754b0bbff"
      unitRef="usd">53347000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie0c160117d32471bba70bb96f864292d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfOS0xLTEtMS0zNTg5Mg_93b23a6b-9f32-45ed-9672-13092582251b"
      unitRef="usd">3748000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3143ddecf7734d3da635d16bd5e504a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfOS0zLTEtMS0zNTg5NA_8002cdcc-48d6-479a-90a4-3194dd5965a5"
      unitRef="usd">7163000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i207fe7daf0ce450ab750e00dde6b86c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMTAtMS0xLTEtMzU4OTI_f86acf4c-94cc-461e-b9b8-7b1cce0596fe"
      unitRef="usd">39792000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5776247877d44fa1a76a034a60ca9a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82MS9mcmFnOmE0OTA4YjI4NThjMDQ0OWNhNTUxNGVmZjA4OWJkODVjL3RhYmxlOjViMTM4YmJmNzcwZTQwYzBhYjU1ZDdhN2U1MDhlMjI3L3RhYmxlcmFuZ2U6NWIxMzhiYmY3NzBlNDBjMGFiNTVkN2E3ZTUwOGUyMjdfMTAtMy0xLTEtMzU4OTQ_079a3c82-14af-4719-add1-6603a7e25b2c"
      unitRef="usd">60510000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGV4dHJlZ2lvbjpmMThhMjIxZTIwZGU0MWZhYjlhOWQ4OTRiY2ZiZDE5Y18yMTk5MDIzMjU1ODEy_e5d53ccb-5114-4aaa-9f39-1d7e00d3e02b">Stock-Based Compensation&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2022, the stockholders of Nektar approved an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 5,000,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our Restructuring Plan, we recorded the benefit for the forfeitures of stock awards from employees who were terminated as part of our reduction-in-force during the three months ended June 30, 2022. We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and other costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued stock-based awards of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issued under equity compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if8529e0af2b847e992427d335aa69816_I20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGV4dHJlZ2lvbjpmMThhMjIxZTIwZGU0MWZhYjlhOWQ4OTRiY2ZiZDE5Y182NTk3MDY5NzY3NjQw_21f62a21-2266-44aa-a8a9-7d4d059b4ffe"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGV4dHJlZ2lvbjpmMThhMjIxZTIwZGU0MWZhYjlhOWQ4OTRiY2ZiZDE5Y18yMTk5MDIzMjU1ODEz_aebf58a1-2f7a-4037-aec9-e3c265fe7fd2">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and other costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i33ecfd9df5834d09abbc58af261ebf32_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8yLTEtMS0xLTMxODIw_ae92be32-fb5e-4e06-b635-e1c685a1f505"
      unitRef="usd">649000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c21bdadf59b4c48a135191cd5c2ec54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8yLTMtMS0xLTMxODIw_284c3552-0bef-4228-b058-3d50c81aa41a"
      unitRef="usd">716000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i27d1141edbfe4feb8e6950e0879e5c18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8yLTUtMS0xLTMxODIw_eccf2979-687f-468a-ba4b-8029be8a17bf"
      unitRef="usd">1317000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3cb0b12b5faa4aaba9bdc2b06745202f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8yLTctMS0xLTMxODIw_28d6ca0f-db9e-46ed-821a-79978e4275c7"
      unitRef="usd">1443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6659ab393074492bbe414ddb56231ee4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8zLTEtMS0xLTMxODIw_ff78b5ea-56d4-459d-a907-594293aeaa89"
      unitRef="usd">4751000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iecfbea4ad565429885a50c6fba0cc5b8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8zLTMtMS0xLTMxODIw_94469622-9482-447c-aff0-9ed513d3e0d1"
      unitRef="usd">13479000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1cecbd4c604b48409676aa9a35884b89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8zLTUtMS0xLTMxODIw_24f27e81-4aff-4ac8-a6db-c85cc260d8bf"
      unitRef="usd">16793000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34088cc50d6948ccbe3650a776356dc9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV8zLTctMS0xLTMxODIw_fca22ab0-dbf3-4cbe-ba0e-cd1bce56bf83"
      unitRef="usd">27641000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b3fe74ae0994a9b8a3cb73f23feba72_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV80LTEtMS0xLTMxODIw_a5da0c8a-e384-460d-9b8d-cbd5685d8350"
      unitRef="usd">4781000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib91712b5e54b4334b079f6d3036b9a32_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV80LTMtMS0xLTMxODIw_9879a1a5-6310-4b0f-8be3-93c71309788b"
      unitRef="usd">9519000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f2c5502b65c4bc38990dea8219187f9_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV80LTUtMS0xLTMxODIw_b0ac699b-b09f-4f83-9c0d-757e00ea71bf"
      unitRef="usd">13032000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id493f1b7c27c408ea3daa0171ccfbdbd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV80LTctMS0xLTMxODIw_b650dccb-0f60-4c3f-afbf-d6035ba9a2f0"
      unitRef="usd">18528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa4c735c57bc4b3cbe3c2e99a3d9895e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTEtMS0xLTMzNzY1_09ab1809-6f58-4144-a5db-86b29adea25b"
      unitRef="usd">922000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34db7c40bdc449ff8d949f1f5970651c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTMtMS0xLTMzNzY1_5db1a74c-fb00-4095-8ac1-c6c1993641aa"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i58da4c5a8eb049b2ae0fe612bc3870d4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTUtMS0xLTMzNzY1_b09e327c-ae21-4c10-b184-ffc25b5d7a52"
      unitRef="usd">922000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4a9af591eefe4df68e2c4f1f5bd76bca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTctMS0xLTMzNzY1_6985f39e-c74b-4995-9c9f-e2bfdc4c2b11"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTEtMS0xLTMxODIw_c8c498ef-a0e9-410f-a01f-3c2fdeb76ecc"
      unitRef="usd">11103000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTMtMS0xLTMxODIw_c08ef01d-f746-4eec-a6a5-d182f689d9a3"
      unitRef="usd">23714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTUtMS0xLTMxODIw_8ca73c24-917e-4699-9644-6d108aad1505"
      unitRef="usd">32064000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6MDcyMWJhMDYyNzVlNGVmZTgxNWY5NjkxN2IwM2Y3MTEvdGFibGVyYW5nZTowNzIxYmEwNjI3NWU0ZWZlODE1Zjk2OTE3YjAzZjcxMV81LTctMS0xLTMxODIw_06249410-23fb-48a2-88b7-d9a10e60beaa"
      unitRef="usd">47612000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGV4dHJlZ2lvbjpmMThhMjIxZTIwZGU0MWZhYjlhOWQ4OTRiY2ZiZDE5Y18yMTk5MDIzMjU1ODE0_da206dca-0549-4ca0-be1b-57554f9ea4d7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued stock-based awards of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issued under equity compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8yLTEtMS0xLTMxODIw_00617f3c-ca53-454e-98dd-e64f05c34c4d"
      unitRef="shares">85000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8yLTMtMS0xLTMxODIw_c63de360-70c3-42d7-aad4-dafa93176e03"
      unitRef="shares">157000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8yLTUtMS0xLTMxODIw_7a43e46c-4b59-4f1c-a3a2-7e9f7ba8f996"
      unitRef="shares">107000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8yLTctMS0xLTMxODIw_092623e2-872f-4982-b1f7-df66415f7ab5"
      unitRef="shares">278000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8zLTEtMS0xLTMxODIw_6aad3c31-3ca5-45a4-bdc3-52b15d7c44ab"
      unitRef="usdPerShare">2.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8zLTMtMS0xLTMxODIw_52bd5e97-5dd0-4631-bdb9-3e02d073e24b"
      unitRef="usdPerShare">9.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8zLTUtMS0xLTMxODIw_4237cef2-a863-42a5-9707-1fbab9392877"
      unitRef="usdPerShare">3.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl8zLTctMS0xLTMxODIw_834fd10f-40f2-44f9-a596-41bda29d170f"
      unitRef="usdPerShare">10.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3e718894f1c9465093719bbd74467c63_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl80LTEtMS0xLTMxODIw_185563f5-785e-4edb-813b-15b9b9c34d1b"
      unitRef="shares">626000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9172d4dea5534ee5a60b8140527f533b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl80LTMtMS0xLTMxODIw_3d4cf821-c99d-43eb-9ccb-dcd7d524f2fb"
      unitRef="shares">520000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifd2b36e57d474f11a75428893dd08b02_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl80LTUtMS0xLTMxODIw_2e807c0d-eadb-4eec-85bd-347bfa739bdf"
      unitRef="shares">1031000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7f5070c46f774b5ba4d6c3752a1c61f0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl80LTctMS0xLTMxODIw_e39361d1-f424-44b8-ba4b-a1e872fcc2b8"
      unitRef="shares">887000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3e718894f1c9465093719bbd74467c63_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl81LTEtMS0xLTMxODIw_38e7a5c8-b2f1-442b-a469-957fc9cd9144"
      unitRef="usdPerShare">3.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9172d4dea5534ee5a60b8140527f533b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl81LTMtMS0xLTMxODIw_45d1f9e4-bf60-48ad-b847-17beafb30c01"
      unitRef="usdPerShare">18.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifd2b36e57d474f11a75428893dd08b02_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl81LTUtMS0xLTMxODIw_d8be19d7-a8c7-48c3-a2bd-85f6af11f67f"
      unitRef="usdPerShare">6.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7f5070c46f774b5ba4d6c3752a1c61f0_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl81LTctMS0xLTMxODIw_511a75d4-6eac-4a39-93de-01c13b4994fa"
      unitRef="usdPerShare">19.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl82LTEtMS0xLTMxODIw_8b949853-95ae-4db2-b967-03a35c1d1f34"
      unitRef="shares">1131000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl82LTMtMS0xLTMxODIw_cd1f7886-cfc9-4683-a9c0-9c082eb14527"
      unitRef="shares">1483000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl82LTUtMS0xLTMxODIw_a8f7c8d7-1490-45c0-b452-f53e83b49e88"
      unitRef="shares">1937000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NTk3MDY5NzY3Njg3L2ZyYWc6ZjE4YTIyMWUyMGRlNDFmYWI5YTlkODk0YmNmYmQxOWMvdGFibGU6OGFiMDYzZThmMzVjNDg0MmI0MmNlYTIzODVkNzQyMzIvdGFibGVyYW5nZTo4YWIwNjNlOGYzNWM0ODQyYjQyY2VhMjM4NWQ3NDIzMl82LTctMS0xLTMxODIw_20d3064c-6b54-4c5a-b079-bc507b708be1"
      unitRef="shares">3682000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RleHRyZWdpb246MjgwYTQxMzFhZjY4NDliOGJlMTc5NmI4ZTgyM2Q2NmZfOTE4_da847aa1-0a0d-4118-950b-ca85ed8ceb8e">Net Loss Per Share&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. Potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RleHRyZWdpb246MjgwYTQxMzFhZjY4NDliOGJlMTc5NmI4ZTgyM2Q2NmZfOTE5_4c49dc40-fec5-48f8-9d80-ae597f1c2a68">Potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RhYmxlOmQ0OGI2OWRmMDM2NjQyNDA4NjVkOTQzYjY1MTI0ODJjL3RhYmxlcmFuZ2U6ZDQ4YjY5ZGYwMzY2NDI0MDg2NWQ5NDNiNjUxMjQ4MmNfMi0xLTEtMS0zMDU1Mg_21ac27d6-054c-49fe-b9b2-b72ef01d21a8"
      unitRef="shares">20543000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i04be0f98fd20499e95230b26650d671c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RhYmxlOmQ0OGI2OWRmMDM2NjQyNDA4NjVkOTQzYjY1MTI0ODJjL3RhYmxlcmFuZ2U6ZDQ4YjY5ZGYwMzY2NDI0MDg2NWQ5NDNiNjUxMjQ4MmNfMi0zLTEtMS0zMDU1Mg_b760e043-5e5b-4b08-96b4-962d3cb7486b"
      unitRef="shares">18352000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RhYmxlOmQ0OGI2OWRmMDM2NjQyNDA4NjVkOTQzYjY1MTI0ODJjL3RhYmxlcmFuZ2U6ZDQ4YjY5ZGYwMzY2NDI0MDg2NWQ5NDNiNjUxMjQ4MmNfMi01LTEtMS0zMTQ3NA_7d903375-bfc3-4a73-a9c0-547d7e10aecb"
      unitRef="shares">21435000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i900c983989714ea88eae1b8f36f7016b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE0MDM4M2M4ZmNiMzQ4NzdiN2FhMjUxMmJjYjAwYjAwL3NlYzoxNDAzODNjOGZjYjM0ODc3YjdhYTI1MTJiY2IwMGIwMF82NC9mcmFnOjI4MGE0MTMxYWY2ODQ5YjhiZTE3OTZiOGU4MjNkNjZmL3RhYmxlOmQ0OGI2OWRmMDM2NjQyNDA4NjVkOTQzYjY1MTI0ODJjL3RhYmxlcmFuZ2U6ZDQ4YjY5ZGYwMzY2NDI0MDg2NWQ5NDNiNjUxMjQ4MmNfMi03LTEtMS0zMTQ3NA_40f64452-1766-4ed0-9334-99b1a460bfab"
      unitRef="shares">18870000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M]2VVKL+&E6X%#_,H"OS@;/:P'XYI10*"X\[J *??X?2=.)<;+M218J*$N?;
MI"K'0+9^@KW'!SZ.(CQ :9I%7AS1R XSZ& &3I@76<9K  ;-+&.0RKN"V3 &
MQL.Q!RUV -&T(L1/B!UAV"$,G0C?0?8JQ<63#5=HX@J3,!G@LE@%L8?MN*(.
M5^3$]5%MF(#FME]Z-HB1^?"$&'/0M"(4_NP0XPYB[(1XRU5:O !B;#P\#(.
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M^#8!.SF=W=V&T>UC%!+X]'CWY7/XZ0DN'I_@S]?H]NF1W/U&[NZCAT]/GP%
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M]Z3UQU=\<U:*^HEV+=8RT'PC)*M:8UA!5=#FC;^U.NP9 (_>P&D-G+Z!=\3
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MTRGMK +BZQ7THI'V%)A0H#4!;(, EIA (*0QP3"7R"2=&"?L&64F<4I_[\F
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M*H"BQ1W:,$_P0D>5Q1<F0Y^$412J"_$UI #22P'$+@5\HGQ?M8\93V &5!
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MOGK??N'EKGE5_*[DO-PVEQM&104G#<3?UV7)G[_(#@[_ <+L_U!+ P04
M" !TK 15 /DPZZ 3  "A-P  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;+5;;7/<-I+^*RQM;BNN&HTLV8ESB>TJV4YVO1NOM5%V\^'J/F!(S PBDF
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M(@%8"J+U[7%LZ#RBH'IH-TE+P&0\2CTM,ZH8Y@"S0(*_)I@X [ C=A6E@/T
M'8/(&T?02XR>3"'YJ@@-V/0&( JB '5WT_4]6/F0[ YX\-E7!SV82OECR??+
MWJ/B -6+>W#9HUSAW)"S8*^=O;%J]P(@KUGX[321>)@G.7D#H94"*^Z(>EE<
M#"$.1A'_X2,7T[*SKS._/* ::"%#OT40^9ULKU$ $&>YIJM%N?@27_0&%C7*
M8S$!<<B?A,_%@Z]B;[L]JR)9.-X3VOX^6OZ5W>5PM%]T*;:-8CQJOD(MZB.0
M"P/>V*E<RA6:(*KLYP>T2>UHN5,-:3]VTV"(^ 1Y[X/W9X__0V$&JAP4,C9E
MX'0FJ@;4M[T$S[>H?,U4KT@=%)(^IU(IE4>S$HL&%%.*HX@DR*MS,7I'J7*X
MB9C5+*)]\PD$0EG;]9H')SSRVC-G,+],_1Y\.-3:$2SMQ'OV.D':&@(7#G8A
MC_=;1^\_[YA<,6O)-[[0 2VK^L)4^\R*/G&\J83$PW_8*Y3XQ<_P-]-)7-:W
M1+U;8+#=,:(*BV54I@Z:"E):96W!<AH&4JMX 1C$AMQB,=JU27!S5@3FQ#YR
M+_MUP78F)&/['%&L0:6_R5Z2(F2*JQH,+\>B4&CY_@/;&!NK.3]*\_C+R^]?
M/Q+#$!Y<@XTZ'VA94K-"A@(/JI16X?$$6$-MM4QJS(X\"=',%!YOCXZ_]KX'
MBJ/>0\)4D\[FUB>8E;V&EE\Q^XP!'Q[VK^7E,A7HDIA0<78B^:D]UDTF]N5?
MSL\O'J5$@719DP?G*RV=*!9VHU(D02F/H$"A+9(/303&NU9'72N)(E!%)]($
M /+/A;DP ]%0U8XR RI!B4S F@NLM0&@[6YU3*G_NR:M5JFFC(.2?2\_VW&T
M+0:HGLP6ZA&Y5JPW6%>RV2B8IMXM"C44L5B;K29(FVYE^QMK59 (?36"$H$:
M.+,(4H7"M7(W]A=FAV@V-AIB^$R<HQX%($5+WFCTNUD9.O*5O1PVZ_?8$ EW
M0X#T--J,UJP=B;F8[FPG[C@&F!EM&QBSNE#J33G.3,JA&6K924V;_A_LEGTC
M1 B^F7M3L??E%8(*C"$F;@K:-Q)!3".8I/][-/K*U)+,+CG, )T_:XN.: DB
M2X1(GRR+?T[^W#@E>K&R6E&)\[P"27Y$1-D<U? .L"K6'E/D'6CTO3[H:H!V
ML>W;)O)1$?-/E@*F%H!QYSGYNC:NIO4=8^OC:&ZUP7Y6!&@EK.RQ"K^M#>(?
M/VID]D.OK=T'*#6AI5EXV$\VE>(G,? M2@&A.KH/1:,3'A9BU7XG4%[!'Z="
MM00VR25:H'V>DP^M 7;"*[K70RR*QH0*7AAY@V#5K,#YDU.A[;2XP0-8KKO.
MS5%Q?3WC/G.9"6?JRB?7DMA#@SC7\/R3N"@5RF%B<?KX^.]CH-Q9Z<QST5W"
MUJ[&]S>IN"B0R;A)ZDQED$L9S%/-G(A^"\3R3YV&(+'<)>2?1=SZH:Y80G"N
MFS+XKT"'4PW%LS\MAAP/]W2KR5$,RM^3>]C.O;8HPA>""J%))%X8KV5_0_S!
MF15!);,\K+NX9J))-B@1-8U[,BB@2%4L.8HJ3H&4<\"2CJ.B@<^U/H:6G._8
M9.>(J-38E,[/IX+KU6RX,*;& 3E"U"X)?)?\4'/XLOA7E(V^C[T@[BB,*(0:
M\\BGE:%JI%$P!HL6_Q#(2"@ESG $^6K,%3@;290*+<:AZ31 *-J9TJ#F*)[5
M*'!D)!(-WU&PS'A<9&DQ!)N8)7%2Q-ZS1D^1F4[2P</-]1!M00URK%1HD_.H
M-^7<K+79(/-^L6B(8-!N>VB %9C 2"[OAUG6+\4E*P<)AH)[L:.)%2DXT9/N
M/47'4BS9H$U)H2SXF%'B;)'XC1*_*(9.1 ?.&JT#U[PW4>3&U"RXJ$-.1I1?
MI1G/$=5X3L('>A(4$2+V8YL.J8D!?#X,AO^5>)*SC*1AN03!LINRFR9;!V>_
MXVB3[[+)T^<@F$":E @#!*.:%:] *=3HE H.W+#B/!;?-"&0G12A2,M8]2"Y
M6G<MH'"5D@QM5/(W;+).)>[0I@_@J+*S56F ! VAWNX+IG5$N@:Q'LRV5AHE
M6JM^Z,7?TI!AIT0*KH'ZG+W.S1$B7YCKF+N$4!LXIMX]4IWE9#_Z4F=VPAQC
M+01 W$K67+,:0A3FM Z736<CPNM9A^'.0':<%!X<!\K[=[*<]EL.27<<'G_Q
M;/ET'!=RDR\ ),9O%K/..:']6GJL2?A$:<F%1^YR>4G.7KV[S+F"UYBDU#E
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M_ 7ZOM14<+N-5]!/X[._ %!+ P04    " !TK 15YB -=[X#  !3"   &0
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M0=/)FXL([-#"AA=OVM V-L93$PI#SC&TO("^5\;XPPMO,/Z/6/\+4$L#!!0
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ML^A[DPNV#7(:4NQXP/'MYJ1,TF"U'<\]UH@!#R+X2C'>.1F$V=&>#SASDL]
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M)_,!?)]K[:H7%E#_5W+Y)U!+ P04    " !TK 15I8"\C=P)  "Z%P  &0
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MQ(2PQ<(R@J#''5YAVS(0T?@V8@9[EVQX.']$?^]BIU@VPN"5:K\VI:W/@SR
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M&0GI9"6>9<1MC&TQ069LS-VZ,+$U+BDM;NAIQ+0_%&_'"?>A2L\G4\CF#-B
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M<4<98KB4%P,1#[>62(I;/U;04RU2WHU7"4%&XOVIG7J2+C 35X:5B#@Z0D4
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M-)X?X#UO6.1?N,#PAWJO_@=02P,$%     @ =*P$503ZJ@88!   ^@D  !D
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MA"7FQB)P^JSQ LO2 A&-'UM,IP]I'7?']^COV]PIEQG7>"'+/T1AEB,G<Z#
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M"U&[ EK/E;+;P&W0OZ[SOU!+ P04    " !TK 15((:/\W(#  !Y"   &0
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MLAOP?B%!/^6#-5!]=PW_ U!+ P04    " !TK 15#CF77<P%  !D#@  &0
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M:A= ^[DB<:WC#NBF?_('4$L#!!0    ( '2L!%6ZUVJZ; 0  /@:   9
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MR86!0G]O"T:UUD'[6K:6G.H9S: ?8+'0H.80I._?Q=WH0YL0&R);D>6@D>7
MQYY>T4=6E 7FB+&^/Q$#JB"X4S&Y1X;H%TE8HUN;(/Y5$O($5+5MZX$7^$;G
M#QOG#[UFW;NJ!3FA<U!8A==2@6SC, >M=]KT\"\<.SW:Y/#BWBA'MY&CZ[5J
MN.KK+LJ"1<JFQAY*L:<IY@C-LK(H.;6J3934FI0"ST/.?F('Q_8N&0'.!F+H
M8YLP7A/6S9R*+(X<FSV"YVFT?]0+YRTJ'#4J'/DS@@F;$6VV>X'KVKXALA4?
MCQL?C_]C,3S>I"P;(EN1Y:21Y<0;^DLI)E7J+Z5Y4Q-FH)AL.UK/_:RO)_OZ
MN!6WXNCEUA+]395OO59XD>M&;U-LJWXNW<[B_[BOZ\4V)<V&V%:E25ZD2?[)
MWOX#K>=D?PNR<BY<NJ 7H";NW:)))DMAJKMZT]N\C<[<BR!\F5X]K##R$R8T
M'M1CA.+A@ >LJMXJ5</(F;ONCZ3!QX/[G.+[#I2=@.-C*<USPR[0O!C37U!+
M P04    " !TK 15\14V[ZD%  #I(0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R.2YX;6S-FFUOVS80Q[\*X15#"S2Q2#TZ<PPT"=IU2+8@:;H7PU[0,FT3
ME42/I)UVV(<?*2NB+<I,;,A $""69-[Q_B?R_//)PT?&OXDY(1)\S[-"G/?F
M4B[.^GV1SDF.Q2E;D$*],V4\QU*=\EE?+#C!D](HS_K(\Z)^CFG1&PW+:[=\
M-&1+F=&"W'(@EGF.^8\+DK''\Q[L/5VXH[.YU!?ZH^$"S\@]D0^+6Z[.^K67
M"<U)(2@K "?3\]X'>';IA]J@'/&5DD>Q<0RTE#%CW_3)Y\EYS],1D8RD4KO
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M/4"]/V5,/IWHI_WUKSM&_P-02P,$%     @ =*P$5<^VCBB' @  Q08  !D
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MT>B#8&O^M\[EU3A&^G$4-Y\COJ%S=C*0=Q?.\FLVF+YXAEWKG<X@D# ?$A9
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MSP;.04I'1#)^=)Q!?Z0#[H_OV2^]=_*RY!;.M?PJ"BQGP;N %;#BC<2%WGZ
MSL_8\>5:6O_+MEUL%+"\L:BK#DP**J':+[_K[F$/$(\> 20=(/&ZVX.\R@N.
M/$N-WC+CHHG-#;Q5CR9Q0KFDW*"A74$XS*X%7PHI4(!E"Y <H6"HV0V7M*!7
M[++!Q@!;Z!V7/N@M.RT*X6Z42W:EVK)P]_OJ I +:5^G(9(P1Q_FG8BS5D3R
MB(B/C1JP8?2&)5&2_ X/R4]O*NE-)9YO] A?$L4)FS<F+RE?C*O"^V&G:P-
M!86'%!YE='^-$UOS'&8!U;X%LX$@>_DBGD3OC^@=]GJ'GGWX1!)V#U-P, /?
MK@G.KA J^_V0D^$S.!GU3D9';_Z72ME[*H3-=:.0&;)V2'!+&;<EZKK()HL&
M\20--P>4C'LEXR=J((G^M :.,O[ES4UZO9/_6 .39W R[9U,_WT-3 _6P/A!
M#81[C<Z]&9^X60M%!\&*8-%@2ADT;1]N)ZAKW_N6&JF3^F%)3Q<8%T#[*ZWQ
M?N+::?\89C\!4$L#!!0    ( '2L!%78M6=X1P(   (&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;*U4WVO;,!#^5X0V1@M=[=AI.CK'T":,9;00
M6KH]C#TH]L41U0]/4N+NO]])=DPRDK"'OM@ZZ;Y/]]WI+FNT>;$K $=>I5!V
M3%?.U3=19(L52&8O=0T*3Y;:2.;0-%5D:P.L#" IHB2.1Y%D7-$\"WMSDV=Z
M[017,#?$KJ5DYL\="-V,Z8!N-QYYM7)^(\JSFE7P!.ZYGANTHIZEY!*4Y5H1
M \LQO1W<3(;>/SA\Y]#8G37Q2A9:OWAC5HYI[ ," 87S# Q_&YB $)X(P_C=
M<=+^2@_<76_9OP3MJ&7!+$RT^,%+MQK33Y24L&1KX1YU\Q4Z/5>>K]#"AB]I
M6M_K(27%VCHM.S!&(+EJ_^RUR\,.8' ,D'2 Y'\!:0=(@] VLB!KRAS+,Z,;
M8KPWLOE%R$U HQJN?!6?G,%3CCB73[24W&%9G"5,E62BE>.J E5PL.0CN2U+
M[O/-!)FI]M'X[)]-P3$NSM'C^6E*SMZ?9Y'#<#QI5'17W[57)T>N_K96ER2-
M+T@2)\D!^.0T? H%P@<!/MB'1YB$/A-)GXDD\ V/\-U#A2(?F'-@["$U)^&^
MVVYLS0H84VPG"V8#-/_P;C"*/Q_2]D9D>TK37FD:V--C2K6U_Q3ZYSWZD)D#
M:7\=TIZ^I?8W(MO3/NRU#T]7&5]SU;YAV9;Z@@C.%ES@ 1RL>TLX"H1^*&[R
M.(LVNX).>;111CL=ZJ?C S,55Y8(6"(FOKR^HL2T$Z<UG*Y#TRZTPQ$0EBL<
MTF"\ YXOM79;P\^!?NSG?P%02P,$%     @ =*P$55882"5.#0  T;L  !D
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MWX]J4O ^7T1C^:%7'O5SF=W)WL7?_J(-^_]H*PX2LTC,)C&'Q%P2\TC,)[&
MQ$((:Y2FN2U-4Z5?7(['Z;(JQ$R.97P772>RK:Z42->Z(C&+Q.PU-EQAU2G
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M0Z":A6HVJCFHYJ*:AVH^J@6H%E):LTSK#(:F#F%<I459<'&4B)MEL<RDB.I
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M 1M4LU#-1C4'U5Q4\U#-1[4 U4)*:Y9I'; QOR=@<] O^6WDZKG9N[/2YRM
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M4PA"&^#[+>?J,- .VC8S_ 902P,$%     @ =*P$52N.AP;? P  ZPT  !D
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M0F47F,^74NK]09:@>CAJ\A]02P,$%     @ =*P$56AG"FR[!0  ERP  !D
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MS0I?,M N /?W2MFCXZ9K>!O3/U!+ P04    " !TK 15_'!I<V@$  #2&0
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M>6S]G<,W"ENU-T<VDJ40MW;QH1A[OMT0,,BU92!FV, 4&+-$9AN_.DZOE[3
M_?F._9V+W<2R) JF@GVGA2['WH6'"EB1ANEKL7T/73R)Y<L%4^Z+MJUO<NZA
MO%%:5!W8[*"BO!W)79>'/8#A&0:$'2!\"(@? 40=('JJ0MP!XJ<J)!W A8[;
MV%WB9D23+)5BBZ3U-FQVXK+OT"9?E-M[<J.E^4L-3F>?S57\))1""Y#HIB02
MT,D,-*'L%7J#E#6HW4 Y^E**1A%>J!1KHVXY<-XI35JE\!&E"%T)KDN%YKR
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M"#R-.((I  T8$L?V/;CS/HI6[ZEH_1^^T6]02P,$%     @ =*P$59>*NQS
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M)S/D0,8 9-PAY*_8@4P R*03R.S!7.YF2P<R!2#3#B%;D1P D(,N(1,'<@A
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M*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>EMGLX1 ;T.]C4!O0[V-0&]#O8U
M;T.]C4!O0[V-0&]#O8U ;X]Z>P*]/>KM"?3VJ+<GT-NCWIY ;]_9[";0VZ/>
M_IUZQW2M0GSV/-;X_'=2G6[WAN?C[\O'R<X+=<?9P>^QQ2]02P,$%     @
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M_I.L[UJO_OHW3[O&M2J;HS_K_J7-/P%02P$"% ,4    " !TK 15!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( '2L!%7-7Q5![P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( '2L!%697)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M=*P$5;UY0D;8!0  TQX  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( '2L!%68.[;6VP8  'H<   8
M          " @1P.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " !TK 15S8)??@$#  "V"0  &               @($M%0  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ =*P$51IQ0O;'!P  -RD
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M6"X  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( '2L!%4
M^3#KH!,  *$W   8              " @3@X  !X;"]W;W)K<VAE971S+W-H
M965T."YX;6Q02P$"% ,4    " !TK 15US?$P (%  "9"P  &
M    @($.3   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M=*P$5>8@#7>^ P  4P@  !D              ("!1E$  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " !TK 15L%GJ>@L'   M$P  &0
M            @($[50  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( '2L!%7/@7PD!P<  #<1   9              " @7U<  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ =*P$5:6 O(W<"0
MNA<  !D              ("!NV,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " !TK 151_&WDFL-  "$)@  &0              @('.
M;0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( '2L!%7_
M5TMS>0P  &PC   9              " @7![  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ =*P$53!Q\L6P!   ?0H  !D
M     ("!((@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '2L!%4@AH_S<@,  'D(   9              "
M@1FK  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ =*P$
M5?1UF8O+!0  @PT  !D              ("!PJX  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " !TK 15#CF77<P%  !D#@  &0
M        @('$M   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( '2L!%7;YH>9!00  &\)   9              " @<>Z  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ =*P$54FD/O.X @  "08
M !D              ("! [\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " !TK 15NM=JNFP$  #X&@  &0              @('RP0
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( '2L!%4_C:F;
MW@(  *8'   9              " @97&  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ =*P$51P9?^)M P  /0X  !D
M ("!JLD  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !T
MK 15\14V[ZD%  #I(0  &0              @(%.S0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( '2L!%7/MHXHAP(  ,4&   9
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M970S-"YX;6Q02P$"% ,4    " !TK 15V+5G>$<"   "!@  &0
M    @($#YP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M '2L!%56&$@E3@T  -&[   9              " @8'I  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ =*P$59N\:+)^ P  <@X  !D
M             ("!!O<  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " !TK 15*XZ'!M\#  #K#0  &0              @(&[^@  >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( '2L!%40</\"$@8
M "@U   9              " @='^  !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ =*P$56AG"FR[!0  ERP  !D              ("!
M&@4! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !TK 15
M)M]?>[ $  !7&@  &0              @($,"P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( '2L!%5#K*HZ3@(  "<%   9
M      " @?,/ 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ =*P$5?QP:7-H!   TAD  !D              ("!>!(! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !TK 15DH,8KN0#  "]#P
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M+G)E;'-02P$"% ,4    " !TK 15?,4_R, #  !^'@  #P
M@ %9(@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ =*P$5;@VQ-RI 0
M+AL  !H              ( !1B8! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ =*P$55/9*RFR 0  4QL  !,              ( !
M)R@! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #4 -0!J#@  "BH!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>174</ContextCount>
  <ElementCount>210</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Liabilities Related to Sales of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties</Role>
      <ShortName>Liabilities Related to Sales of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124108 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Inventory</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Liabilities Related to Sales of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables</Role>
      <ShortName>Liabilities Related to Sales of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/NetLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/InventoryTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails</Role>
      <ShortName>Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Liabilities Related to Sales of Future Royalties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails</Role>
      <ShortName>Liabilities Related to Sales of Future Royalties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Stock-Based Compensation - Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nktr-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/NetLossPerShareTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nktr-20220630.htm">nktr-20220630.htm</File>
    <File>nktr-20220630.xsd</File>
    <File>nktr-20220630_cal.xml</File>
    <File>nktr-20220630_def.xml</File>
    <File>nktr-20220630_lab.xml</File>
    <File>nktr-20220630_pre.xml</File>
    <File>nktr2022-06x30xexx101ar201.htm</File>
    <File>nktr2022-06x30xexx102north.htm</File>
    <File>nktr2022-06x30xexx311.htm</File>
    <File>nktr2022-06x30xexx312.htm</File>
    <File>nktr2022-06x30xexx321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="489">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktr-20220630.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "contextCount": 174,
   "dts": {
    "calculationLink": {
     "local": [
      "nktr-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktr-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nktr-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 365,
   "entityCount": 1,
   "hidden": {
    "http://www.nektar.com/20220630": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 7
   },
   "keyCustom": 37,
   "keyStandard": 173,
   "memberCustom": 26,
   "memberStandard": 27,
   "nsprefix": "nktr",
   "nsuri": "http://www.nektar.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.nektar.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Inventory",
     "role": "http://www.nektar.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DevelopmentDerivativeLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DevelopmentDerivativeLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Liabilities Related to Sales of Future Royalties",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties",
     "shortName": "Liabilities Related to Sales of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.nektar.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124108 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Stock-Based Compensation",
     "role": "http://www.nektar.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Net Loss Per Share",
     "role": "http://www.nektar.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables",
     "shortName": "Cash and Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Inventory (Tables)",
     "role": "http://www.nektar.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfPurchaseAndSaleAgreementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Liabilities Related to Sales of Future Royalties (Tables)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables",
     "shortName": "Liabilities Related to Sales of Future Royalties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfPurchaseAndSaleAgreementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program (Tables)",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.nektar.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.nektar.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ProvisionForDoubtfulAccounts",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
     "shortName": "Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DebtInvestmentMaximumMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DebtInvestmentMaximumMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i5776247877d44fa1a76a034a60ca9a45_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
     "shortName": "Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Inventory (Details)",
     "role": "http://www.nektar.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i6863c3c60a704766bc19dbf81c2dcb5b_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i6863c3c60a704766bc19dbf81c2dcb5b_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i6b68ac442765412db42b3953906b0388_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i6b68ac442765412db42b3953906b0388_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i16be06e4152e4ce481549b23d09556ad_D20120101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:RoyaltyMonetizationProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
     "shortName": "Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i16be06e4152e4ce481549b23d09556ad_D20120101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:RoyaltyMonetizationProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i7c3682511cdc470e8b31f4be9255bc51_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "nktr:RoyaltiesLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Liabilities Related to Sales of Future Royalties - Additional Information (Details)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails",
     "shortName": "Liabilities Related to Sales of Future Royalties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i7c3682511cdc470e8b31f4be9255bc51_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "nktr:RoyaltiesLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i80ddb5385d944743a6830e905272b6dc_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i80ddb5385d944743a6830e905272b6dc_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "id4bfcb6279024241948e7bd08d4d1b15_I20180430",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossOnContractTermination",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ic87a58d05dff437199600e83c801a439_I20220430",
      "decimals": "0",
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessExitCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details)",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program - Summary of Restructuring Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessExitCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program - Restructuring Reserve Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i615612becd454568aed79f306f2b522e_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details)",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program - Sublease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i207fe7daf0ce450ab750e00dde6b86c4_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details)",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Restructuring, Impairment and Other Costs of Terminated Program - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i79e0f4b9899445bfb9f7c130223aa7e0_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if8529e0af2b847e992427d335aa69816_I20220608",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if8529e0af2b847e992427d335aa69816_I20220608",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i33ecfd9df5834d09abbc58af261ebf32_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Stock-Based Compensation - Activity (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationActivityDetail",
     "shortName": "Stock-Based Compensation - Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Net Loss Per Share (Detail)",
     "role": "http://www.nektar.com/role/NetLossPerShareDetail",
     "shortName": "Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ia6c832ade51b45958d331545ae3e5dc3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "i19adf3d7365740b8858300248f7a335e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "if7cb3e8c05fa4ec587b0d40b348fb5d7_D20220401-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Cash and Investments in Marketable Securities",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities",
     "shortName": "Cash and Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220630.htm",
      "contextRef": "ib05d4e783215472a8bf9190a4f6f2d89_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 54,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktr_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_BristolMyersSquibbCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb collaboration agreement.",
        "label": "Bristol Myers Squibb Collaboration Agreement [Member]",
        "terseLabel": "Bristol Myers Squibb Collaboration Agreement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol Myers Squibb Company"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BuildingAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building and Leasehold Improvements",
        "label": "Building and Leasehold Improvements [Member]",
        "terseLabel": "Building and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndLeaseholdImprovementsMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Line Items]",
        "label": "Cash And Investments In Marketable Securities [Line Items]",
        "terseLabel": "Cash and Investments in Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesLineItems",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Table]",
        "label": "Cash And Investments In Marketable Securities [Table]",
        "terseLabel": "Cash And Investments In Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesTable",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments.",
        "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments",
        "terseLabel": "Cash and investments in marketable securities",
        "totalLabel": "Total cash and investments in marketable securities"
       }
      }
     },
     "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementCommittedFunding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Committed Funding",
        "label": "Collaborative Arrangement, Committed Funding",
        "terseLabel": "Committed funding (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementCommittedFunding",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-Based Payments, Amount",
        "label": "Collaborative Arrangement, Success-Based Payments, Amount",
        "terseLabel": "Success payments (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsAmount",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment And Software",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_DebtInvestmentMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt investment maturity date description.",
        "label": "Debt Investment Maturity Term",
        "terseLabel": "Weighted average maturity term for debt securities investment (or less)"
       }
      }
     },
     "localname": "DebtInvestmentMaturityTerm",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DebtInvestmentMaximumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt investment maximum maturity period.",
        "label": "Debt Investment Maximum Maturity Period",
        "terseLabel": "Maximum maturity term for debt securities investment"
       }
      }
     },
     "localname": "DebtInvestmentMaximumMaturityPeriod",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DevelopmentDerivativeLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Derivative Liability",
        "label": "Development Derivative Liability [Text Block]",
        "terseLabel": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability"
       }
      }
     },
     "localname": "DevelopmentDerivativeLiabilityTextBlock",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly And Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EmployeeSeveranceWithNoServicePeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance With No Service Period",
        "label": "Employee Severance With No Service Period [Member]",
        "terseLabel": "No service period"
       }
      }
     },
     "localname": "EmployeeSeveranceWithNoServicePeriodMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EmployeeSeveranceWithServicePeriodRequirementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance With Service Period Requirement",
        "label": "Employee Severance With Service Period Requirement [Member]",
        "terseLabel": "Service period required"
       }
      }
     },
     "localname": "EmployeeSeveranceWithServicePeriodRequirementMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross",
        "label": "Gain (Loss) On Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross",
        "terseLabel": "Loss on revaluation of liability related to the sale of future royalties"
       }
      }
     },
     "localname": "GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "negatedLabel": "Operating leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LegalMattersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Matters",
        "label": "Legal Matters [Member]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails": {
       "order": 2.0,
       "parentTag": "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities On Sale Of Future Royalties Unamortized Transaction Costs",
        "label": "Liabilities On Sale Of Future Royalties Unamortized Transaction Costs",
        "negatedTerseLabel": "Less: unamortized transaction costs"
       }
      }
     },
     "localname": "LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Line Items]",
        "terseLabel": "Liability Related to Sale of Future Royalties [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesLineItems",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails": {
       "order": 1.0,
       "parentTag": "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To Sale Of Potential Future Royalties Non Current",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current",
        "terseLabel": "Liabilities related to the sales of future royalties \u2013 ending balance"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties non current net of issuance costs.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs",
        "terseLabel": "Liabilities related to the sales of future royalties, net",
        "totalLabel": "Liabilities related to the sales of future royalties, net"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Text Block]",
        "terseLabel": "Liabilities Related to Sales of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Abstract]",
        "terseLabel": "License And Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "nsuri": "http://www.nektar.com/20220630",
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LongTermInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investment maturity period.",
        "label": "Long Term Investment Maturity Period",
        "terseLabel": "Long term investment maturity period"
       }
      }
     },
     "localname": "LongTermInvestmentMaturityPeriod",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar214Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar 214.",
        "label": "Nektar 214 [Member]",
        "terseLabel": "Nektar 214"
       }
      }
     },
     "localname": "Nektar214Member",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar358Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar-358",
        "label": "Nektar-358 [Member]",
        "terseLabel": "Nektar-358"
       }
      }
     },
     "localname": "Nektar358Member",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense related to sale of royalties.",
        "label": "Non Cash Interest Expense Related To Sale Of Royalties",
        "negatedLabel": "Non-cash interest expense on liabilities related to the sales of future royalties",
        "terseLabel": "Non-cash interest expense on liabilities related to the sales of future royalties",
        "verboseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash royalty revenue related to sale future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedLabel": "Non-cash royalty revenue related to the sales of future royalties",
        "terseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash royalty revenue related to sale of future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]",
        "terseLabel": "Non-cash royalty revenue related to the sales of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OpdivoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opdivo.",
        "label": "Opdivo [Member]",
        "terseLabel": "Opdivo"
       }
      }
     },
     "localname": "OpdivoMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization.",
        "label": "Organization Policy [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_OtherPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other Partner [Member]",
        "terseLabel": "Other Partner"
       }
      }
     },
     "localname": "OtherPartnerMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PartialRepaymentOfRoyaltySaleProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partial Repayment Of Royalty Sale Proceeds",
        "label": "Partial Repayment Of Royalty Sale Proceeds",
        "negatedTerseLabel": "Payments to RPI"
       }
      }
     },
     "localname": "PartialRepaymentOfRoyaltySaleProceeds",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received, if conditions occur.",
        "label": "Percentage Of Development Milestones Payments To Be Received If Conditions Occur",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced if conditions occur"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received under certain conditions.",
        "label": "Percentage Of Development Milestones Payments To Be Received Under Certain Conditions",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced under certain conditions"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of funding Phase three development costs on an indication by indication basis borne.",
        "label": "Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne",
        "terseLabel": "Percentage of funding phase 3 development costs on an indication by indication basis borne"
       }
      }
     },
     "localname": "PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in development costs.",
        "label": "Percentage Of Sharing In Development Costs",
        "terseLabel": "Percentage of sharing development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in Phase 2 development costs.",
        "label": "Percentage Of Sharing In Phase Two Development Costs",
        "terseLabel": "Percentage of sharing in Phase 2 development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInProductionCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in production costs.",
        "label": "Percentage Of Sharing In Production Costs",
        "terseLabel": "Percentage of sharing production costs"
       }
      }
     },
     "localname": "PercentageOfSharingInProductionCosts",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development and regulatory milestones.",
        "label": "Potential Development And Regulatory Milestones",
        "terseLabel": "Potential future additional development and regulatory milestones (up to)"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development milestones.",
        "label": "Potential Development Milestones",
        "terseLabel": "Potential future additional payments for development milestones (up to)"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestones",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure",
        "label": "Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure",
        "terseLabel": "Property, plant and equipment and Operating lease right-of-use assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PurchaseAndSaleAgreement2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2012",
        "label": "Purchase and Sale Agreement 2012 [Member]",
        "terseLabel": "2012 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2012Member",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PurchaseAndSaleAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2020",
        "label": "Purchase and Sale Agreement 2020 [Member]",
        "terseLabel": "2020 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2020Member",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring, Impairment And Other Costs Of Terminated Program",
        "label": "Restructuring, Impairment And Other Costs Of Terminated Program [Member]",
        "terseLabel": "Restructuring, impairment and other costs of terminated program"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherCostsOfTerminatedProgramMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_RoyaltiesLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Liability, Measurement Input",
        "label": "Royalties Liability, Measurement Input",
        "terseLabel": "Royalties liability discount rate"
       }
      }
     },
     "localname": "RoyaltiesLiabilityMeasurementInput",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nktr_RoyaltyMonetizationProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Monetization Proceeds",
        "label": "Royalty Monetization Proceeds",
        "terseLabel": "Royalty monetization proceeds"
       }
      }
     },
     "localname": "RoyaltyMonetizationProceeds",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SFJPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SFJ Pharmaceuticals",
        "label": "SFJ Pharmaceuticals [Member]",
        "terseLabel": "SFJ"
       }
      }
     },
     "localname": "SFJPharmaceuticalsMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SaleOfStockConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock consideration received.",
        "label": "Sale Of Stock Consideration Received",
        "terseLabel": "Sale of stock consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceived",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Liability Related To Sale Of Potential Future Royalties",
        "label": "Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]",
        "terseLabel": "Schedule Of Liability Related To Sale Of Potential Future Royalties"
       }
      }
     },
     "localname": "ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Purchase and Sale Agreement [Table Text Block]",
        "label": "Schedule of Purchase and Sale Agreement [Table Text Block]",
        "terseLabel": "Schedule of Purchase and Sale Agreement"
       }
      }
     },
     "localname": "ScheduleOfPurchaseAndSaleAgreementTableTextBlock",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SubleaseOperatingLeaseRightOfUseAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Operating Lease Right of Use Assets",
        "label": "Sublease Operating Lease Right of Use Assets [Member]",
        "terseLabel": "Operating Lease Right-of-Use Assets"
       }
      }
     },
     "localname": "SubleaseOperatingLeaseRightOfUseAssetsMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SubleasePropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Property, Plant And Equipment",
        "label": "Sublease Property, Plant And Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "SubleasePropertyPlantAndEquipmentMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Property Plant And Equipment Excluding Construction In Progress",
        "label": "Total Property Plant And Equipment Excluding Construction In Progress [Member]",
        "terseLabel": "Depreciable property, plant and equipment, net"
       }
      }
     },
     "localname": "TotalPropertyPlantAndEquipmentExcludingConstructionInProgressMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_TwoThousandSeventeenPerformanceIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Seventeen Performance Incentive Plan",
        "label": "Two Thousand Seventeen Performance Incentive Plan [Member]",
        "terseLabel": "2017 Performance Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenPerformanceIncentivePlanMember",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received from license agreements.",
        "label": "Upfront And Milestone Payments Received From License Agreements",
        "verboseLabel": "Upfront and milestone payments received from license agreements"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received under license agreement.",
        "label": "Upfront And Milestone Payments Received Under License Agreement",
        "terseLabel": "Received upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "nsuri": "http://www.nektar.com/20220630",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r96",
      "r230",
      "r234",
      "r239",
      "r326",
      "r327",
      "r332",
      "r333",
      "r368",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r96",
      "r230",
      "r234",
      "r239",
      "r326",
      "r327",
      "r332",
      "r333",
      "r368",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r43",
      "r94",
      "r95",
      "r242",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r221",
      "r223",
      "r224",
      "r225",
      "r241",
      "r248",
      "r265",
      "r266",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r402",
      "r436",
      "r438",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r221",
      "r223",
      "r224",
      "r225",
      "r241",
      "r248",
      "r265",
      "r266",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r402",
      "r436",
      "r438",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Nektar's"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r149",
      "r223",
      "r224",
      "r254",
      "r255",
      "r406",
      "r435",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r149",
      "r223",
      "r224",
      "r254",
      "r255",
      "r406",
      "r435",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r198",
      "r221",
      "r223",
      "r224",
      "r225",
      "r241",
      "r248",
      "r256",
      "r265",
      "r266",
      "r296",
      "r297",
      "r298",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r402",
      "r436",
      "r438",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r198",
      "r221",
      "r223",
      "r224",
      "r225",
      "r241",
      "r248",
      "r256",
      "r265",
      "r266",
      "r296",
      "r297",
      "r298",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r402",
      "r436",
      "r438",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r42",
      "r43",
      "r94",
      "r95",
      "r242",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r371"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r11",
      "r193"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r48",
      "r49",
      "r50",
      "r424",
      "r443",
      "r444"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r57",
      "r58",
      "r59",
      "r98",
      "r99",
      "r100",
      "r331",
      "r367",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r306",
      "r307",
      "r308",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r268",
      "r310",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r85",
      "r190"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of right-of-use assets and property, plant and equipment",
        "totalLabel": "Impairment of right-of-use assets and property, plant and equipment"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r14",
      "r91",
      "r138",
      "r141",
      "r147",
      "r168",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r326",
      "r332",
      "r353",
      "r369",
      "r371",
      "r409",
      "r423"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r31",
      "r91",
      "r168",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r326",
      "r332",
      "r353",
      "r369",
      "r371"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses",
        "terseLabel": "Debt securities, available-for-sale accumulated gross unrealized loss, before tax"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r158",
      "r176"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r155",
      "r159",
      "r176",
      "r411"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r157",
      "r176"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r157",
      "r176"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Reported Value Measurement"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r8",
      "r371",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r8",
      "r87"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r82",
      "r87",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r82",
      "r354"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r321",
      "r322",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Corporate commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r412",
      "r428"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r226",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r371"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 187,405 shares and 185,468 shares outstanding at June 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r64",
      "r416",
      "r431"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive income (loss)",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r128",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Significant Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r257",
      "r264",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r69",
      "r406"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "auth_ref": [
      "r206",
      "r207",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "terseLabel": "Results of Bempegaldesleukin Program and Reorganization and Restructuring Plans"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r207",
      "r208",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r85",
      "r191"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Development Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r39",
      "r40",
      "r43",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Development derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r270",
      "r271",
      "r302",
      "r303",
      "r304",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r111",
      "r113",
      "r115",
      "r116",
      "r117",
      "r121",
      "r122",
      "r339",
      "r340",
      "r417",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r65",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r113",
      "r115",
      "r116",
      "r117",
      "r121",
      "r122",
      "r339",
      "r340",
      "r417",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r57",
      "r58",
      "r59",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r125",
      "r169",
      "r251",
      "r252",
      "r306",
      "r307",
      "r308",
      "r317",
      "r318",
      "r338",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r367",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r243",
      "r245",
      "r246",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r341",
      "r342",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Portfolio of Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r341",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r243",
      "r245",
      "r246",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r342",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r243",
      "r245",
      "r246",
      "r341",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r243",
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r243",
      "r257",
      "r258",
      "r263",
      "r264",
      "r342",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r243",
      "r245",
      "r246",
      "r257",
      "r258",
      "r263",
      "r264",
      "r342",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r243",
      "r245",
      "r246",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r342",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r343",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "terseLabel": "Change in the fair value of development derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Cash receipts from SFJ"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value at end of period",
        "periodStartLabel": "Fair value at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r243",
      "r245",
      "r246",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r244",
      "r250",
      "r337",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture, fixtures, and other"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r12",
      "r185",
      "r186",
      "r187",
      "r188",
      "r371",
      "r408"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r85",
      "r190",
      "r195"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of other property, plant and equipment"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r189",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Asset Impairment"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r138",
      "r140",
      "r143",
      "r146",
      "r148",
      "r407",
      "r413",
      "r418",
      "r433"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r196",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r109",
      "r110",
      "r137",
      "r316",
      "r319",
      "r320",
      "r434"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r23",
      "r183"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r29",
      "r371"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r27",
      "r90",
      "r124",
      "r181",
      "r182",
      "r184",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r25",
      "r183"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r24",
      "r183"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments, fair value disclosure"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r91",
      "r142",
      "r168",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r327",
      "r332",
      "r333",
      "r353",
      "r369",
      "r370"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r91",
      "r168",
      "r353",
      "r371",
      "r410",
      "r426"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r35",
      "r91",
      "r168",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r327",
      "r332",
      "r333",
      "r353",
      "r369",
      "r370",
      "r371"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "negatedTerseLabel": "Change in fair value of development derivative liability",
        "terseLabel": "Change in fair value of development derivative liability"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Litigation matters, liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Contract termination and other restructuring costs"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r82",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r51",
      "r54",
      "r59",
      "r62",
      "r86",
      "r91",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r109",
      "r110",
      "r114",
      "r138",
      "r140",
      "r143",
      "r146",
      "r148",
      "r168",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r340",
      "r353",
      "r414",
      "r429"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r138",
      "r140",
      "r143",
      "r146",
      "r148"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment expense for facilities"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r97",
      "r134",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r30",
      "r371"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r45",
      "r46",
      "r48"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r52",
      "r55",
      "r57",
      "r58",
      "r60",
      "r63",
      "r251",
      "r355",
      "r360",
      "r361",
      "r415",
      "r430"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Amortization of premiums (discounts), net and other non-cash transactions"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r79",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payments during the period"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r73",
      "r75",
      "r156"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r371"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at June 30, 2022 or December 31, 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Proceeds from Derivative Instrument, Financing Activities",
        "terseLabel": "Cash receipts from development derivative liability"
       }
      }
     },
     "localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r77",
      "r305"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued under equity compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r73",
      "r74",
      "r156"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r73",
      "r74",
      "r156"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r51",
      "r54",
      "r59",
      "r80",
      "r91",
      "r101",
      "r109",
      "r110",
      "r138",
      "r140",
      "r143",
      "r146",
      "r148",
      "r168",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r325",
      "r329",
      "r330",
      "r334",
      "r335",
      "r340",
      "r353",
      "r418"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r10",
      "r192"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Depreciable property, plant and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r194",
      "r371",
      "r420",
      "r427"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r67",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Accounts receivable, credit loss expense (reversal)"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r313",
      "r405",
      "r452"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r200",
      "r203",
      "r211",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Total severance and other termination benefits, at fair value"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Workforce termination, percentage"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r85",
      "r199",
      "r207",
      "r211"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring, impairment and other costs of terminated program"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs and Asset Impairment Charges",
        "totalLabel": "Restructuring, impairment and other costs of terminated program"
       }
      }
     },
     "localname": "RestructuringCostsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring, Impairment and Other Costs of Terminated Program"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgram"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r201",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Liability balance as of June 30, 2022",
        "periodStartLabel": "Liability balance as of March 31, 2022"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r252",
      "r371",
      "r425",
      "r442",
      "r444"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r169",
      "r306",
      "r307",
      "r308",
      "r317",
      "r318",
      "r338",
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r135",
      "r136",
      "r139",
      "r144",
      "r145",
      "r149",
      "r150",
      "r151",
      "r253",
      "r254",
      "r406"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue, excluding assessed tax",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset recognized in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r300",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r204",
      "r205",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Restructuring, Impairment and Other Costs of Terminated Program"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r282",
      "r289",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r267",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail",
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance and benefit expense"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, of RSUs granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail",
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Aggregate number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r57",
      "r58",
      "r59",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r125",
      "r169",
      "r251",
      "r252",
      "r306",
      "r307",
      "r308",
      "r317",
      "r318",
      "r338",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r367",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r125",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r252",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r91",
      "r154",
      "r168",
      "r353",
      "r371"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r244",
      "r250",
      "r337",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r200",
      "r201",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandOtherCostsofTerminatedProgramRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r93",
      "r257",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Obligations of U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r112",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding used in computing diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r111",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding used in computing basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54681-109401"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r453": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r454": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r455": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r456": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r457": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r458": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r459": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r461": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r462": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r463": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r464": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r465": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3505-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0000906709-22-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000906709-22-000014-xbrl.zip
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M1.0Q(LT5^.!_#3KAO_\+"_0;1>NU-.\/BO7,.?2KHEMR:+=8P8\5_'A"MZ>
M_N4I[O4P_HBFU5MD -*XV@;0L'U1/VE\AC<!&-D$G;.##C]]Y(VM-^WT7/WJ
MZ*KQZ> 6 .G2>O-OZ,_V99WL 5#9A#%"OT[V6H?-SZC^Z1#>^P'&4,>'K7L
MB&+:! LSJ+5S&?/@19G 6,:I-D9Y9C@: 1"VU "DN;?9V-\I84:%0/97$.06
M!.F/!7&$06+1;5?&[,M_U_K=Q]Q6_3T_]N]QT_.ZVV[GO;1 5'N3@_T#Z;"A
M>/F4T&R[7!M*;ZM>MI":[X>B0N2?M#_1X< SXAW K:ATII73X#I92;!!4AFR
M]@IE! R7^-D#0U^2)?H<LD3HHX;]Y#*S%X[*E.5./]7 ^.GDYN#\'Z\H#I:F
M&"K3&7-69U:0F,5HG#'&.XG5VJO&]K^;FWO)ONUMOM_^V-QYO3]',O1(S?S+
M]H5Q_9('TJIG,:9]S?1JO=/@4AJ K^6=6M[OU=QQZ6'_^I.IAH5QVIC<P))/
MW6LC&TQ/WQ>$SB+*GM@7K+CP.3#T5^7MJ9W!2GNGM-;B=)@%46:WODYGLA67
MK\&7O>$7PA!<2H7IAU26/K6SH#&IRC^L;^V!1C]@]:O#D_K)9WCOWN?=MSL,
M?#A>?_O7YX.K';BR>55O?K[M'YXWWGYDAR?@.[;KE[O-[13<9@<G1[C1_'Q^
MT-Z#]N#*5OUB]^][_$/-D(H,$2"*9QE#3&06!9MYK;5P EL6^-JKK= RJ9SR
M#SB(-Y(D5I+P-4EHFHN=82);E=J]P([ <[/XSDT6=SX&YYS)+,8F8Y293$>A
M,B8ID]I)( ^PN&89Q92!/'R1R:>MS"OC^>Q HV3B7TH-6P/OOYNV!-1.!D7>
M\WE9N _PU.^V>/$JG]3(Y:W%D>GD5^7W7V<L_S.=O)V]_=KPR.FBG*J;\EIK
M=#=^7?S8T),KNDWO4WG(X3_OH -X(97<#T4[Z#].&(]!366$&IXQ!B;8(.DR
M1+F,04@FE5A[Q3BOU8>QJ#_-9>W/[J 5SDSA:_O=0?]X\3RXYV*OU_!QMP!+
MLI@@\8=" A?_$!>YP=X#7P'28]3)3#L+!M$9@BAVZ9>U5_M _C?@/;N\Y[JW
M66G]Z<.=0U*51FFW> ^P'HS/DJ+^'R+HY3^6$B4YPUFT,6;,PR?XKC+EC" B
M$*LM7GOU&@0<)J^3F[N*X9F(^;X+U&H=YJ>5 _>S4>KJ'Z$ETR32C$?K,A9!
M" U#*$OGB#CKK2,:)_")N9HC[?VX0-4O0R*GV-MI <*:GYI6+5P$-T@5(^!G
M $.A]W# [>?#/,D.;1;!_)SB@/[A!"L=3,B,\R%C1*I,6R,SK(4D5ACPOPS
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M(T.$]POCQ3>^=:J:8))%&]W:>#_6,NFO),@@P^V\WP?1+_5_T>TD -*ZK 4
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M0:\*;L- JYK&]]09[!;ENUJ7Z>7G.;P:7EOKP-BZ*5Y]EO=**-])NU-!IP#
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M?;DOC]=OF*Z]VA^T058NR]3DO/?Y/OTV_2#M_8JGW$0VJR2C^^CWA&^\0S_
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MJ!=$4;.5HEY8D9.KA=1EQK] WH^=JOYX2*>][YM659=\N-]B/[A!D??S4,7
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MM#+PR/@W79M+$W6_==T?M*%KI9Y(R/.Q-G9&@EJ[]=^G4&J\Y*;DX[A$[+8
M+E=!J$'BL30^?UUD,@5.)J#Y^DUH7WDW$RYTJ5<GO+;*Q6J%,_ U1P$L.^A!
M7WNE?J\B"6&,_-/SR<S#7.9^4'I%W6)D0,S140HL)%AVGC1WWOD\]*6@[\FO
MAL9ON5KPR@?\K,K/"Q7,F BOCIX<AZZ^X&W!C (&"<.(R&@,L>SQ68J IOA*
M+T6) *3T*_ ]#!O7)B+&-\+$$Z'EVH-1Z12*&+T )N<^H]L['LX,Z(E!&C58
M3D"QH1B[6Y,.4>4TV9""'3!5GZL8R' 8I?4%+90GCMBH'70'H]9+?00SDGR2
M1/D<_N^5N SL6B\O'?MN"K#ZW)7!NF% Y!*,>:ORMX>SME'6E :W JZW+M=K
ME]<O2<U-=#Y/_F$U/Y6O;4J[W@I B)N,F]YQ'=VLA@Q]N,G!XUA70OE]4]X+
MLY4#4DA=OL&O=9@=\/&+DO\JY[GT(*L>A'X^+F((=,A]FO1$V#29H7.6%]U.
MFLJ-4L!'W *\5 #I*]\?Q+]$,_!OM<CPY0DM XO#CE;#K;AE@AG33$R,8?W>
ML$"WN#\JL%%[C(:[8Q[$S%1>J95OZYG*Q4Z,70G";:X' I:I93N;8^@[X;F>
M'^? I17S#'UX($V[FV*;"53V7CYVCF[DK-#;LY9A-3.[5KK.XID<D/NZ<'-N
M,$LV_DM K*+SWLV%D;W)U86MB=6%[9B"2;W9#6_MU?<QB20_QB2;R> ]U''R
M*(GZ[__2$I$9^J:W6(.6&29KKZY7[-*2T^1:$HBOJ;5"YZA_?'DS&)F@3[G4
M,@RJ):V?5&NR(4/->A0ZE5:?6*$:K=" ]KBSP!7+I8O1JDR*[O\V$TI/58O.
M&\W9!BM-RGF%%8_AOE*-GX9RKI*-*U<$KQ?2&O]N[F64JY*,Y1?"^1C2C0U#
M6D!)U.^!4YU'8*>$/6K'IBBC[;$6\C)L,&ZM6UPW-HS(CM>M@'F,/TLK@<F*
MC-FSUQ]X@!DKKG@RKDBD[P[Z::FR5\&H23#6[;AJE:U$4^WV8+CHUB^Q\N5]
MRXV^"L(#E$Q8[_+.8C7P5P?&<XTLO_R.!#(K+^78)'0X]D0JY\G#.WK7,*YB
MY3/3&H31BO!I?EK&"5<\]&0\-*$ KKD':)'4>TF";NNR7080.R>#Y($"L ]M
M<!J!/?K!'0\)?@IX)"WN7WN/P_AU]<-MXU%Q!7A;E>LZ;JA<,RMO'C\._;C]
M=#<%#$.U>@XF[IKG5WSR9'P"CE=:<"B#)*6PISALWDXK=J;2/66FQ2WE?WO!
MU,"OE:-_EOH&MU8I&>/BRY536K%'Y9@EFS+6&U6T8!Q73QY=J^I"E:$T=#O+
M)<72[SF%%Y0^?+K'AC*KPYR9O)5@3[F.]C66&<:K*4S=BHE^D(EN9RK%ZRR#
MQ#WW:PE *1[<G<M0+6L;,!%%'JHUB^'*\]>]]4=2<4:^Z4-47 ;?]*&S>5X/
M,__VJ@7U&]FY/X^?^E.(_=![R5.H,M&Y#+$^G,V9,K9 U-T@Y566UB'OI@#P
M57KN<[A\.)DR5.&.FRD]#V6&KG^W5S0.-5;I?7G*G[OVE'][=.APQ4G?P4FE
M*S$1L1XE?8TRB8L)?3)R:1+S)4XHUW,FPA^56U+YSJ"N>H,(1"_QPJ@U^+4=
M0A4-=X.B3/8:LTLB_PIR/AFQTYP/$^L3^<*%:\',@[2G"$@!'_P$\+R9.WQ4
MA-%*U4ZL#?7/H#.*=8$N@(]Y[W@(&_,RL^*!/.'C_+17;J2HF3ZHK"HW8B+R
ME?(W;R3H3+I4D]IIO#=@E$CR@!9+^BKK@=8ITP9OKF'<NUA1I?S=L[I1 :C$
MUJ&HDL96W/J$JJE:6$T,-AD; \88%#<T5@<42JO;ZXVB-K<H.=).QAV7*\EE
MIGQO%,:-H)=LWDKE.T=>4*D '[]BM4*\3XMX7]]0(^^':F2%;9=5[!^*S&^W
M\MJ[/*V[EO[.,/GWX1TII7L[BKA7][6"N1T\6Y_</[(^S."KDAS*?-$J=W2(
MF.]L*KGQC@H>=4=[>1) !_B<S%8::ID2<V-?V'"?U<,[<;X#4I>APFK\XY->
MS7"_'<SF]4!&6R?*+.ST_"B!L<Q7O+'V\:BXSHKE?VC9X=IDW;M[:[S)JH38
M-@1@$T AKG^]'^CU[M\[6QG6<"_,==IA-K1GIZ;7G\P!N<[_&&V$N?MHR6;5
M&VK?U+\;-G24\W ^D5I5QI[*^T8;V5+^0S'*O"F_=4KV+ ..M^4M[YQU6V>C
M_6"W(ER/2JE?F>RG-=DW&.K]D*'FPEK/)'5RE>X]F@JV2O>>@[X\=[KW"@]\
M3YQFC/?&:S;#Y?V$?F\9_E!^KXH[!-/J']?":5YJW1MAE-*,#S<SWS'X&[5/
MQWDK/( &CDUO&-_S-[(.AAD'50=&":*CL-[DEM#)=[MCTTI)52ELT^MU75X:
MCC(@5*&5ZJ6WNUYEMZ:DF&'61%JV,A-5'8#7 6"?Y<5@' \:5$^,44EGT+:A
M&*;5]JNB#WDG#NM15!BI=YPP^W!1M##GX^%6K:9HZ#5XKS8#]0:GIU6&+CSB
M\UXQ.!TV>'^VQG@;\W6JQLTLTR'HOXE]RES>Q$*+!7.6-4]TOR)ZHE5]LI+'
M7""=E5*>ME+.R[#W,(DGA2-3Y'JBADM9 *,(5:!Q&!:?N%IZ*M?)-\/HY5 U
M3:R3_&>08IH3VPG28LG$]FJX7H8JRYT2ID@U7KZ>E/_@7OUKZU(%$%:._E/'
MMDX'!9@)L)EE]8^AY2H+T"0[-[80<<@H]V=[E4%N0)3P2"NU!&V6K&G&>YB'
MA@[:+VU3'HJ)?,3DJY?)AL7U=I<4/B]YHQ.NEV/'S][8&U4Y\.OC1T9+2E4P
M:R@8K7P85%_9JCFP53L WENINLF@.KNWW*.\7GMWLZ3-WG59H]=51:;Y"++/
ME]N^TH(_K@5'N;"CH.%HA:YKRU6Y>^MK#9^YD[N:]LR5R/BR9DTO[Y5%F]*6
M_%9KE4OP=.FKIC^N5E26D^GU!N$Z?:"Z/ (N%=9X@(+KM5%;)> I?:6R-3^Y
MJR:D4Q)<J*HK)0)?+ZCDD\IM7( !WALZXQ7A_G%>^,KPA:K3=EQZQH^BU).;
M>$8IK<-R9>7:_VB=IG4Y4>NI2E=8 :<GY;9[MK2.<N#*Y8"JU$BK/)K^]/IH
M^O'J_]V4@8EJ;BD]I+IU!%K&Z+N"/;<C+S^"N!\+AV;$ #N=L62-0OG&=L]"
M5J89=E--EW+_ZDVO(RTJ32:E3\#/"3FM-KZ"/U1%KD8/0^>KK7(@5U_(N?CI
MHN5\*D6AQ:HH]!*&V)^?1^^'Z.\W]YJUG9>U-SN-S<;KG<UWM9W&F]V]^F9S
M9[?QW85<]%<*N20#^34CFGZ9T:1,5!?<J/Z]^W=*W4_PQ)>U*KJM$@KYB=S^
M_1NEES'Y[6.GW.L3_#TQOL?-*R&/F==Y8:W&]K^;FWNUYK^V]S;?;W]L[KS>
M?] VS$N?7^\VMK8;^]M;-?BTO_MN9VNS"5_^W'P'TK%=V__7]G9S_D?QRTY:
M+.D.H(T47AP6?@3L7.TE_77^!S"6E7%?RS,JKD%! 9HZ*Q-83GOAY>C#;S[O
MG;;,Y<N\4S9:/O3;S0U/]Q3?*X==7;XVDANH,I3#<VN&;QY>WB@OC0X\N7%-
MH@V*U(.7T09^\-J7FL5D0U'Q7<U^^1K'3]39QS7[R,/64#HV9J*];SMCIF+F
M!T^9F2J+JZ]Q>,E6?PTZH4;1>HT@<GUXR-<'MVSSL!5<*#T-BLNYP#?FXBO,
M88W[?%1T ;9EP^XZ<!P!,4[WN*&9JL+-_?T[)N<+Q']P2H8J,Z$$E*+/M1*S
MU-( ?OL&YOKJE/](&]_<QV_FCUC^]R/\,1M7\O4P(\. M]V_767JFZ;ZU@Q\
M%[F>NHT9BOT-IX2P88&AV=#<#'=CN?0A13H!O=T]L>>6A7W4Y*#:MT[1,T]
M:1O^]VV[^$U#G!Q:>6#<7(WM]_PBG>3VIJ@R^VN#3M[?2R&'0<^OC8JLES_D
M!,D8I#<1N< X,E9R%!#R/@BKA&/_["0,@01%:V5AQK9I]?Y8RT!>4J'LU&)V
M9,SIR\1/FQV?_MF^9J;-_FM3%.F<B[^3;[ V/) $WGO1?]D9M#/?+6,DJ5F0
M0)B^4,IBZ;%Z^O>EW>J>O2-[9P>T/O GVV>';_7)[LDVJF_569W4V6&[D=>O
M/K#&E<\;Y,UQ_>3C1;W]U\G!R>9Y^O..-EH'5]V+QM;FU>Y6XV3W[2%<JZ/=
M+4</3OSQ07,'UYM_Y0=DY[S^%OZ\49?U7+==^TUG]Z3U^;"YE]?) 6^T=ZX.
MKC[P^J>_C^MO__Y<WSJX.OQ41P?MCZA^M7GYCNX='[0O6KLGF[QQ=4 .KAPY
MA'XTFGO'\"P[:.\=[S;=Q4'37=6O_FHUKK;YZ!EXU^"0?!3UK<^T<7)XTK@Z
M;!^TZ[CQ=IL<G!SGAV^WH<TWQPUXLM[^2.O-5JQ?HHMWS>U^?1]=U;<^XOK1
M/]YY+*CG&6<&9XQ9F1G!11:TDL9I&H@"#U_*=<[X[R]N<LBK*NSP(R(!\E[[
M1M&8)A)8*:@E55!<2D&85%)ZQJ+!1@J#*#,".:,-XZ6"PIA0O%)0\Z6@KFXI
M*,>B]MC93(*9 07%:&:%DEE0RDJGI 7(MO:*\'6"U1PIJ!FX 7.(%_=3VG.6
M%K,G2C4_ !;'LT2^;9;NU<L+K;RFA:XV1_D&;[K%/NB@ZQK=6\'VK[\-/;F5
M&IN6&FN\OH.S0M#4^8 R'I3/F(\A,Y3JS"N--';:<9^.*V=X74K\HWKL?EWR
MI$#KL?[W3R_<TT(F*^&>G7#?QB@^2(1L()FPD6:,2Y<I1U4FL0<Z<Q\T"N!$
M(;4NJ9PCX5X%M<IPMBN/=$I'-KD $!]DZ@<0RF,]QX568E-#*,.IWQO/?"/T
M5QIKVAIK_PX<$3Y0YCS.(K$L8SK*#&C(,LR)Y)1@HC%H+(S6$1)SY%5->P'H
MIQ?DJ:&1E2 _CR#?AAY<8QFL8YDR2&0, $>FN0R9\ 8TL(Z4"+3VBI!UILD<
M"?(J/%(E1I^!?'2+RU5$Y'GPQGC"03NMU-+4U%)^!U](HY$T F<^JI@Q$6*F
MI<2955P[;HTB1@*^$.M:Z#ERB%;1CCG%%RO!?2+!O8TGHL8142HRH2/*F+4^
M4TK13$1C/,><,2E </FZ0O,4IEQ%,I)@[E:G2-](S%J%,IX'6I1SOUE.^<KO
MF;:>NINW(J*+DE*>*8MPQKSFF1:699;Y()60+O((>DJODV7,6UF)[[0!QDI\
MGU1\;\,,)K'&W-%,F;0<RK3,C)8J$Y(ZSYG"E+NU5X2N4TKG2'SG)6R!\0:9
M'<QH=M.A&U.#&<,Y>DRF_7+JL*FMIJS4UU.HK]V[V1Q,>HL0Z"M+L<H8XBHS
MP;!,(,: 3L(9"EZ2$'R=TQ]>/_E&^5B@V,?/*_)36W=9B?P3B?QMQ$*4\2)(
MF<E(2,8HCADH9Y0%Y9UB#(//P=9>20TBKZ85&7EJD9]!U&0VB.5=%Y#3%--0
M?PK7ZKG34!O=CELILBDKLKNI'S$J+E6,66 87"^B3:81T1FA'"?K(R*F:Z_4
MNB;SE$^_"IS,*P)92?<LI?LV3,&>.(ZT33*-,P8.26:X$!F2H+6-LS:( )X)
M6U=S)=X_S:[YZSJYZ5S2_LWJ_^OIT,%5+LCSP)(1)=XG.FQV_/:("JLEYFGN
MZ&MN)O54@9"K3=QH[OP3K1<>3$Y&/!890]1EBM$ .HIR(*HQ#..U5U2ORQ_/
M65LEA\RO)$\+@JPD^=DD^?*F) NC=;229-YQ0!M4D<RZ2#+GG54L$,U=!+2!
MUL&UF"-)_FGB'KM5B>#.43JCM!=JY=QDW9BE(Q=6^2'/FA\R(L6[1(F]U)G=
M^+$7R@CN2DM-3TMMW\$;UBL91?299D9EC(%C9)GFF0J6&(8T<H*"EE+K6J\V
MNRRQ*$\M5V0ERL\FRK< APD6:4QD1BE)KH,VF3(N9-@X3AGUF-F45X[E.B+S
ME/?UT\0WWG:[/AWSO(IB/ ^L&,WW2NU,3^WLW$$00G(FL)<98D%G3&F=*<=1
M9IRT\(59$]3:*RG6^5QEQ:\B%G.*(%92^R12>PLL:*F5BCR5#DO1"88!\D=#
ML^BM=9A*3X.90ZE][NC$+&2NVJER*P*Q<EB>?F_*:AGV*71/_0YB0#$RX0W)
MC"0\8RDH:KE1&8D"$<%\U(BLO2+KA+(Y<E-6(8<Y!0PK"7YZ";Z%'A0#E6L9
MSK"A+&-&@P0+ !-"6Q5)M 89GR18LGF2X)\FT%!M0OG2&L:39I_/':)Z?.'G
M;QW^TBCCZ>ZS66G?Z6G?#W?P4^#>&&M8VM^+,A:PR;07/A/P"2$!--)L[942
M>%VK:9547) =-BN]MM)K3[B9:*77IJK7;B]@21XEXBP3@L>,X4@SI8+/8D!1
M8V#JZ.G:*[R>EK"PFE9MI"7<2#1J>UX.17NWL_GGSKN=YL[V?FVSL57;;^Z^
M_O>_=M]M;>_MEZ>MRM]JVQ\^[C0/IGIP&@6*^>X@'40YK^>F/:J+/XW?,CHV
M;>)8^-79:3]#<:9QF>E3<_EPC>G5B41+"M*F73+[?<5%JZW?4P=M[HXSRBF5
MSH$+ZK!S&6.R+#9E,DFB *RM!,7@C&*R3MD2)A"N5-*2JJ1I%_]>J:0G5$FW
M_$A/+=$HE>BD7J:,)),IAETFHB:&2JZ8 Y6DUR7[X>C88J].S"<2+ 8AS4#[
M-'1Z)A%EE2_Y//!INWW:ZEZ&L!=:IA_\NVLO;*6VIJZVCNXF4GK. J;R_V?O
M2YO:2+*U_XJ"N?'&3(32G<O)S3U!!&-PC_LVT+9Q=]A?'+D:V2#Y2L(V_O7O
MR1+86/("5@E*D#$]6" H5>7)YSE+GH5XFP2!)!7QG&>BK=,0LU-:\HU-0?N"
M+]WWKR92=A?.;9D>%<[7"^<Y*T1(EZ,PB7#K(L+9>6(LX+=!:; T"L%ITRU<
MBZ6K,=8XP[+C9@B^5>ZZ-QT/\&OZ4(R25 M#5VR1#-],Q_?/9/#@3 0'10([
M9P*H#-8Z@[U9,$BX<LH)"(2B* D$8XB/8 CW6ECC10C!;&QR6Q,U;S>:ES5(
M*IIO!,US]@CSI=F5#X1+G0GP&!'-FA,:\?ML(5M5AL6KOJ%+'ZW7L,A*II>X
M,ZND!3/D3GA2[=:(S!:_NE$KI*W7BPVQ0D(^RDP1RM"7@I0D<<EK0H6QTDMM
MF&/H1HD^[90;5:,B'3-"*I9O ,OS1:<V>AN"(M$FC2:(\,1J10NT R0T3YPS
M34@$U-(-.&M(9,7]LBXD:?4_#3QY.QHO>6)S)SRJU33..J>STTIFK9/98N<L
M<)$'(SV1H".!"(YXGQW)+&8J0V)."/2G:)]VZIBY1D>Z:IA4+%\?EN?/:FB.
MEB8$+T] 0'L@)@,EG&G*T,?P6I2S&MT'6+H;QBV,C71IY-H%LZ3.7;MY"Z6Z
M6*MDLL5N7-HQX" SX?BUY+YY8KBU!%53H%FY(#A')J/0MZ:M>,F:U(96X%^G
M.5.!OV+@SYDP/,E@D)[1A'&<  N"('FC'1.#AX!,C5R^L6EDG].VVHW?PLK)
M#H96CM)D4N,KG8JOU#9#J^"TQ49A6BH9D@F$"8ENF;2!.-R^Q'*D-Q LYB1+
M1V/;!]:ECL8UQM)1HZ3B^7KQ/&>C2("$U!P(=QIM%)<RXEDYXH75Z*E 8*[@
MF9><V"X5"UYWG.4FT+B=WJ6C43,:""$T'KQ#G+S[;(J<_E0GTCMQ,MV6L;']
M:=4O^$[?HJ8\^) B^9C&H\I*5V*EQ79:5O*8?([$,1X):"J)\=$2S5(&Z[67
M@*S4]"GAOW;H6+JFF'34RK@2D*N-L22:Y\>NT9R$$(% +,6_7E/B8@Z$&L\I
M4]*9%#8VN>YKOK2)L<8Y)C<1YKB AMYX5I36FXYZT\/4F^">G_1&N9=/IB?C
MU!N/3MW1+/YQ<>QK=8Q646CSR0\ZJQ0\&)5AU?OYS]$4Z6K@CAXV0GER+A.D
MLK.0[EZ:[N='D\F)&X;T8#2I'?+:)+=G7RD1-I27=!/FF""@@B).H1>EG131
M2\JT:\ZI55_K&A"YQ;AOI22GXKZSN)\S:@! 618<24Q+Q+UAQ(MLB<A&,9FX
M"8!&#;.R#[Q+R69W(7 R*\TY&@U?D6D:'W\U :6Z6JNLS*E>UHH)Z?GB"!<7
MJ>4J$9,X0T+BAAAK);$F4[!!9IM2&0!!39=F6]>(2<?,D KC:X;Q?,=M!\FA
M94$TT^A/6&V)93(2X$$X 88Q'3<V15]:WB$8=Z4>IPMIK^VDNRXVIKYC66\K
M2'>MS-4><RVVG74J<(-ZAT27.(%,/7$:+ G1B4"% LO%QB90T>>RK4A(5_)<
M6XR2W%W$KR#/M2*^5<3/'^SH8+A#G.?@)(%R5FN-D<0'FI@)*NA,$?%"]Y5I
MJTBG<QFNRQ?PW-!DA]'Q\6!:DDLF/3>,#13Q =(P_-APN<1Z7$9.YS3Y]?DH
MC;#.6&OSWW[\RV8W!D^L_LE68R1]F SN#P='>"?CDS3/F1=VP]8P/KBX%RHY
M7H(<%WO'VN"=, F(@>@):):(EXF2[%406B<4CR\[<(X5[UB>_8K,@[K75[O7
MYPT!89DQS!/KF2:@<)M;+LMQ*"\H$,$+]96]_G0Z"F\.1T=(IY/SH5/I_TX&
MT]-E9@RU.!9J9=?H2IGPS?8O^7.<<AJ/4['Z<"?T>__S/3KX,XV?'KIQ:L5K
M>+3W<)X6/MU-LRW_=./]\=-I.83]RQV=I,^??N8TT,H5/^:*CUO3W0=?<,6[
M^-M?$/_[^]$+?O3.OWY[^/SCF],7V^7Y=^7NQT=T_^ Y[/_]^_'SU[^_V3^(
M;_9_>\;WM@\/7_R%S_SXI39)1:\CD0)\.7>-Q$E&2<Q1: ^292V^KU:^L8]^
M+MY4]]&:[B.K/44Y2T*#;R;V2C34C"*4*RV4@8">[,8FO8<,N.BZ+OR@]]:-
M>^^*?'_M?7/O38K<)]>S[9H]-MDZF1Z.QLC(L09".KH7/^X]?LFU-5DS3KQI
MFK!Y1VP0 2E.9J:#@NCB=SCMJ_MJ16JQ[JMUVE=!2(OB)@YP2X$K9XF11D*-
MX#$+QVPHC3IIGWZE 'V1XV;[K.<^";]37+=_,IU,W;#8MC^LRZDZ]]KW(]M[
M_Y+E0"&%1%3.@8!/AIC(&/$L.,:=,%REJ_+<TGNJR;O\RH;:3A-TH8K=5K=3
M-[>3B$KKHC:C]*@V*6XG%PSN+NI83L8X';_G"JQ&;=;MM*[;24(2U$A!K#,2
M/0)#2^9-Z<8OO'-1REG MCM66-5XG=]3J)H">,@D>(X:3Z+:\]YY8B7'_UD3
M9'8;F\/1CZVOR]MG\1/3]$;CWNCS)NFY:>_WDV'J"=KO%:U8WM]&?7SLT[@G
M6/-#_(H7>9M"*98\.JWS#*XG2^E+?#>1HEI=WA:FYTNV<HQ2&W2RJ0<"(09B
MT<4FTKMDT4F21M):77X'P-M6PE$%[PK!.S]).E)O,]6$)>9*W+;I\1T0O!EU
MJ4D^&-%%\'8E0_IF3_S*T?MHN,QQ7VLQI-FMU#.:]L"Z\P/K>22??\1[.?C/
MZQ?'C]F+@RWZ_. 9??[Z")\5?^?UL_>[!X_AQ?86VW]H/NQOO?14!I1L)#+3
M7!IH,H)>O2-:")Y94L&J\%-G?:VY9743=7X3Q:R93I23;$3IPHI?3,#M1"V5
MB0/(5%RPU1_TK6+/U=.8-=F('W=?O80H;$HJ$2ZHP(T8"YLEB8HV"\-I *:N
M?,JW"FU8-]4:;2H%$CA+FDA5\NV<D,0!582B[1B!"AEBWM@4M.-G?(L^U<*&
M_&:TL^[(SNQ(MK?U,D4+ADE%%/62X%ZDQ'&G25*@9;)*\&*T,:/[0!?+P#YM
MP&&\%OU:-]ZMV'B\&'HF1ZLLD 0T$"BY7<XC*2+7<&>L"P9BV7A?GV5XOO&^
M&R\ONW)U ?,[T29I!?KA+.!6T7<U]"U$Q265V0/1WG@T3R$2&P*0Z(52PE#K
M62H-C3K4RZCV,.MH0+R"<UEPSD6]#8M6&*L0ERX34"ZB;M.94)XH*C:O+*<=
M V<M<6D"WN[MH#0%&0Q[Z4,H<V-&^7,,J9ZN7X^QL(6+5#[+'?WI!O'1\$PJ
M%VBJ6O;MT=?B"#PNN4[:60+<,@)>)>)!&F*3!6I5C!I2T]0(;%^HVI_L%D.Z
M+1.C0OJ:(3UGD5@ EZ4SA!F'[D( 23R5BC!IG0!AD+5M VFF^FKY$;W=.XEO
M/IO+QKCH=#?4K1!.CD]FO=U'36?4,#I^.TZ':3AIYLF,)C_7%G5]7:)_7HL-
M4M(P\=4"<WV61]-D\<%%:3P:HG#2'RB2IJ'S@?M0::P]&EN<9Y==@IC+H1R4
M<N(L S&@&0F<6:W0[>(,'2O39W:1POY58QZW > _;Y%4@'<0X/-]VCUC(5A+
M'$L*78_LB6<:B$3'PXO$E.1Y8Q/Z3"YV:;\1@->XR;S1$E,>A,'T3@9+;M12
M>9*F#N\H[KCQ$-=M<D$HVS.95.YJC[L6Q^"%(%36&KE+NH#&26#H8WE.E.*1
MR8Q29KSX6-3P/LC%V5F7YZ\:,>DPKELW4"JNKQG7<S:)D FLXT!,+.,MD[.E
M!)X1L,QG\)H[*\NH!B-XW]K%))D;P757"ABZT.)]\LW&=;7C^\V?]EQL*[C3
M2*7267MTMC@"+Z!&HI1YPES)'.&%V$!(DB5$9;1G0FATL:3I:['TT(K:^/WV
M ;^M,Z$*_!4#?V%6C17!0BK62^G_[ASQ2BFBA=79 3?HK&QL*FW[DBYF7'83
M^'>F__O"L)HFN_6JELTEFZ7/'O>^0*'$T8D_2C.!+45YG3MH^Y^KFN4M+<ZM
MT0,K&/FS-8Q5*ZQ2*RP.(I1@HD_:DYR#+E-!4#^@=B?&<Q>SHRG&<J2F6-^:
MI2>CMHJD&PYY52ZM7-HYF[IRZ;5RZ9R%S4*D(D=/=,J<0#!EQ(+R)-#HP.?$
MP)1BNCYCNL_,TNG?G6#3Q@+_9>KP \^MS0NQP&,W?C48-I_>@.;"M4/"_3^^
MJ<#@8>JY4#*KW/"T%(\-1]-B4X_QQ\/> ._LU1CM[;=N/"TIX-/#-$F(7W<2
M!^6,$[$;TW R>]4L:'/TF0=#-PR#)N2(/VAFEMS[TA*_L#9G-P0E(^WM:-+D
M1]X?ETGR@W?IU_>#.#T\)Y(+?W4F9OKY3YS'.SB9?OM/NK+H:LXIN?"UW&U#
M.0RH,"*8'+P I$.OG>.2<1\\I?C?2RXWSO_H</PYY/P*S99Q<F^(R_B ]]W1
M>W<ZV?CER\V(._%\T?DL$W!^R;ZY,#FO;&%FH$ .'HU=(U"$>!J7W\)[<IVY
ME][AN*BJ?_Q81!KQ5?B@(*?,ZRDP^/<O;GX@V#P>KG^;ZJ]NT[V=_SW8>M([
M^._.DZT_=YX=/'KP])L8[LH]/]C?V][9>[JSW<-73_?_>+2]=8#?/#W ?W9W
M]@Z>]O8?]O;_Q"<Z>(2_T/GG^>>C(9+NZ 2O$2?]IA@']=/;-)X5_B)#S^P8
MW*+_ZO[#/#M7')_NM=&7GRF]4=%X.T?N[23=/W_Q:QQ,WAZYT_N#87/1YH]^
M/5.I9WJ@D-B<?FX>>_;V9WXK#7,*QYW%RLX^^>SM>\U;<_;&[#V0]S2WWWR;
MWF/??.][EV4,+PL_==GOOR?YMS^T<S<KM*HWR_6E+ON#2.\/CW3LPJ]^Q;&>
MT<3U.)'F1]Q!9X;J.*7>+O[>X:274!G'3TT.OED%</M7Y>G@P_F:['Q[39;=
M,A>"0Y=WHKJ]<"4B>XE]<Y6AJ7=DV5@;<+N=2U-W5 L[ZL[,D'V2WJ7A26IA
M9FA;>VJ5\T3K/=[0/7:E,.-F$R#_'(_B2<#5<D??&A._=+KV^I]&W<XS)><9
M#48(I8P$+;EC*FME+-7,"JK=R^WF?!XH(Y<[J#]C[H?CT7$)ZY5;^'LP/7QP
M,L'U2..=#^'HI*SCUF22\+^X-M5R>T_/SIOP.B^.'[[9VW[^<>_@\/#YZ\=L
MES_'SWW^89<_.MW[;1>>'^R<[O$=]OF\Z:_![M_/WS\_>''\XK=G[/G'QQ_W
MMO%GQX\_OCAX>(C7>_WB[^=T_^#%T?QYT][?CSZ\>/V?P[WC%V]>'/SU>F][
ME^+/FI$UNW\_/'[^]][1B]>/Y=[Q7_G36=-3^G%W^QG;??4R6YJ8T)XX2TNO
M9,.(0]&2R &BI%DJ#1N;LB_8TGF<W:LXJ;1U2VG+ (L-&T70D)WTP@O+'5@N
M@Q, #6VQ<]IBE;:Z3EL?YVA+ZU2ZD'CBM1($H%3[)JJ(XIHK*+.=@]O8U'T#
MBS5RE;8J;763MJ(U+M#L*&4)HG/>.,D3YV \8Z#"F;7%JK6U)K3%/M/6*[JW
M508"@& :;2P*@8 -E+@R#C>I8F-K+5UIH<385UNW5]ZJO-5-WDI6"AJ$*H,O
MP1AA<]8)/0L><F0BAC-SBU5S:TUX2\SQ5C(1E/*.&*T\ 8?DY4161#I/8P@,
MJ$,OD?%;W/>-\28&UU4ZFF4=C88DN,EA;SPZ=4?3T]YXAJ->DQ&88F\Z*FF(
MLTA>R:S*)].3<3K[]4&Z:TWAKD!QWCG*M50Q^ 2..:-92"QX"H8J,+$&PM:)
MXO8>+ 3"HH\ZE&$ZV7)&0"1!4($EPK-,QIH<F.!(<:J/_F6'>F[7YG M ]U*
M[2/3EI=XD9/9^.1H"D:CR1ZC"S5TM&9 GP\=295YE%:C^#+Z8!$R,392(I-T
M1F65M(%RMO[5_DH5Z+<&Z#PI*FT03CD.P+B-Z,;HA&2/W@MNC1IL63.@SP=;
MI)3:1<V)T!&=%L$SL<QQX@R($)-VGI=>:J)O^&+#I0KT6P-TPV-65"G*F(08
M&.X):A5R/9/"^JQK=&+-@#X?G0@R9\6U(#XK0X!91CQ/D4!&VYVCJR:I1J#;
M/I==,MUK=E$!\A^#4*H@^[VF8L6?U8PUG4EFK>O/8AAWLA?L5:J_6=">EA'7
MW$,0T9O@K0EHY"I-7;#7$Z"H1'9Y(GNZ$(-00@2MA$1CQ0$!CF:+M1D]%6EX
MEJ*<;)N-S;9JOCMT,E1A_ G&3D6I(%B3 ))CWAL/*2@*%O"EOY[P0X7Q56 \
M'V'(B4I'32"2)H=6" -BHXU$BFB"BCYXB?8(7[H_6L5Q=W',!%C-J14^!S#6
MV.1Y=")%+J@U,M?HPIJ!?#ZZH%*,TAC<U1[0Z3"1$V-8(EEYX#XEZ[4L?5I0
M=5><WUZ<>T5#U,)Z&BPPQRUUH)'EE9=1NV2N)[A0H7P5*,_'#ZA#R0@NB4+K
MFX!WB9A<!&89*FNCN%5\8[-3.+XSE7ZSGJ7+QP#N?,?EK(,7R00JLT.'0AKM
M:01:VN_DPE4U@6&M6&RP$#P0(7/G Q*8%:F,F C$Q(Q6B0)I@H$$-J'742R2
MMHX[NM)EL[9D;X$@*/A$LS4Y(@M8FZQ$5\5SI22-2K.:^+!N!#$?EA"^26(Q
M)%)9!E\Z3JP'2[B4P*)+.255PA)](99./J\$<?L(PE,9(6DC.).@N3,^6U;\
MG5PR:HRM(8TU(XCYD(:VB:$+*X@5@J$%83UQV0*A/(%TU,>8RU07U0>Z=!?O
M2A"WCR LI<$:88W5#.U/8Y)+S)M<1AI2IGQ-M%@S@I@/E%CMI1$*B*0>"8*C
M\> $.AN1HLD@A;0IBHU-R?I6KPM!W)GA+_MO4TFM&+["QYQ,9Z-?TH>W)?=B
MLDP?I2\;B+??_^>RD>AZC]V]QSI(LNFOC+@K15>O1J,X*6L6EX]GWFZ#HO68
M91'!?OZM"*",MDCC=X.0)D]1%-5N:,MNV%^LK5+):6N")1!8)F"\1+O!)9)!
M!TM95"KRTF2(L9J(?8OAW'J$L<+Y6N \'TCT2E$-5I7"BH1P%K9TL= D4*JS
MH2($R4OS':7:\@(JG#L(Y];C@17.UP+GBV$_4;QZ+W),+A.?(VIGRQVQB:.R
MUCR",X)YS38V&>U#:^<"%<\=Q'/KX;N*YVO!LYC'LS,V!6V(,*4W7N:"F.@\
M"8&A')F*D1O$L^@#%QW"<RV'FG4VGR0W#H=-?"ZF=^EH]+;,@*OE3]>>WC03
M!#+7]F<Q[,PBII6_6N.OQ2HHKZGW3GHB(U,$ @"Q1@LBP87H%0O.HCT"O*_A
M%C;)JY!>84)2A?3U0'H^8L!MR,8P0:R3Z&(DZHD#\$2)C*8*U\E#XV*POF!+
MVR05T]W%] IRB"JFKP?3\V$#18-D(4B" M0$$,3$Q1 )EY;'9+S-S"&FP?:M
MK9B^Q9A>0=I/Q?3U8'H^=. $.'2C+*&,)P*J*6H4E%AN(M<N>J.*GK:J;]G2
ML?WU+H?J8.S@MS1,9>)\"1VX>#P8#B;3<3,)OB8:7'/TX$P4R&!;7PBBDEC;
MS:H/M@J!S6(('[?8WL&CEQ0,USY*$J3@!$!98B$$$K765@!C/L6FPZ/D2W>K
MK@<:W45UZP&$BNKK1/7IEZC6"&HJI2,Q4(_^AD3/ Z(CP2N+'F,&3C.BVO:E
MK%E$MQC5K8<0*JJO$=5[GW4U/O_CEQRIV&>M"4@6"40OB.$TD)R=,-1XR3RB
M&G3?J)I\<(M1W7H0H:+Z.E%]^B6JLPE).NZ(<R$1L :(9]$0+84$B?I:*[6Q
MJ5B?BUO8D74=YL70LV2#Z?@D3$_&>/?]WN#XK1N,2ZSM0OO56;70*/>F:8PX
M:L;(O!V/7HW=\4]-B[D3(=%59"-\EM2#0S=^E2:5PMJCL)V%(((V60&(DH50
MFDI'P8A%/X-XJ9R36@4T/<N1I>I36-K?J,<;W<7R*M(0?H#E//B0(OF8QJ,*
MXZO">"YJD*T.ACM-;!3H9"A(Q%.'EHC5(+AE@([D!L+5<,9_K3"^O3!>1>9!
M5<DKQ?)\K$ ;\+J$_+R4DH!GG)C(+&$Y)X""Y-)7F5'=E[QF!MYB+*\BXZ"J
MY)7!>"XX ,GRD)0@P98JH^P-L9PKDJRB4G/O;4I=5,EWK.?JZ#L-0VHCU@[%
M!DJ952FP.HML5B.D1?9ZM! 7*"/$0HJ6J!PC.A16DL)8) GEM7#&^N#1"-'0
MA]:R"VJ7M%N$_Y5T0:CX7QG^Y],0M!2&"T^8HX( 59%XRR5^*V@65DC3Q 6%
MZ4M1^RQ7_%]/VX2*_U7A_V(08G_[^<ML@3HAT'L)J?1 S(H@GQNBG:-)."NI
ME1N;@LF^H6V55U?\WR+\KZ3-0L7_RO!_^B7^(4JTWCPGB6LH!PH,[7]&B69>
M*2=!)5_&QVO6E[JMW(8U:8*Z#GD/LYFSH\FDE\>CX_,@QV@X62:9X9:1V3^O
M-YHQP0?&5_.T]JEA[:-A&!VG(K/*;.TQV^Y"9"/(P%#K>!*RX@1T\6R4242Z
MTKN1)\X+LS')^T:H!6;[UU5#LETQ:EH\=;G#/-!"5*/RP WQP%R$0S+CA0!%
M5%:E96LN$0YF"!>69N.T@%B.61GM<[H8X:@\<*=YH(7H1N6!F^&!^4A'1'M
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M._][L/6D=_#?G2=;?^X\.WCTX.DW,=R5>WZPO[>]L_=T9[N'KY[N__%H>^L
MOWEZ@/_L[NP=/.WM/^P]V'KZW][#/_;_[O[S_//1$!EY=(+7B!?*OSI[N\_.
M]<:G>[T)=NV=?WBC\C^KB\;&P)LX<F\GZ?[YBU_C8/+VR)W>'PR;2S5_].N9
M.C_3,84CYTR,9LUG;W^FSWMT1J%G&79GGWSV]KWFK3F#:?:>%O>4,=]\F]YC
MWWSO>Y=E[!Z3XJ<N^_WW)(75W*R\U&5_D,7XPVQDNU3%Z QBU^.TF1_A;M;
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MF[XTUG&T<WFP\X7%J8YS[0BSFA.1L9@H107)4BNY\<+' L\BX/D6GXO,1@!
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M2D224Z*35!/'36)3%Z>6LXWM;$M<TZBX[HF!$G.7A<\S#G>4B;0L$US1W&4
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M3KV!F&H+=0%/U$CS(Z/BU.*6J4H!FK#(%2/&[3KON/QT66T(=BU$DX/Q0V'
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M_WZTQY]\[!#N6*GGODM5/,V\RRSF@3J14*6SA#I*K76ISE,CKJF*CQ<Y>4"
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MDQZ,L(MM$")UXKIF0;/Q^TS'_:H?;IS29Q.MO>UT_? XBOGI>G[6P2=Y%GM
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M/_$:+SZOA&KJI78R<SX6V+8PE8QI1?,DY4RY^+9NR_@X\_[HC-[=5M^T>WA
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M\XWME.>;7"RKM?@R=&P]LJX;A&T0]G$I>(.P*X>P,]1=QRR'A=0DS4R,M2M
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M31MUL.B3$SC[[-<^H?>/]H0EM0#(J'9E?@?7U!6E'OU+K<Q8HM,"3>9_W1Q
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M]!Y%1C^:4V>'02J'A3E5?;?3M3@=.R>%"[;N"('E18OFR1>F<IE[Y<!")YH
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M,1:TT4Y@)QE@FU%ML8:VOFD[^$OH^BV$9(VN;YZN+\=L4@6#$_/(!&,0)R[
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M_![:X5$O9J]Z_OW*IF?)-4S#[^XPE,_/%I+2.<-=<N;C:59Y.G'Y>;XW+I1
M\!80Q9W,V;;?RJSFR*(DB*N=TFP"OY8[_ZL\OMM/.4ZJ<L47Y>4GJP"P4;9E
M<ZYY[74E*"P+!-/KSEKC22*TK%Z8;==6LU!%EK H1_6KE5S^@H:T!JXWW5.
MV\_F'IYX',OCRZ8!Q @Y'LQ689*8'/179JP\,6]LS-^I/X 1'G5/Z@?6L>0T
MZIFE].OXYWC2Z^(TU@%.2>]#%#FLWK%L-!10O?RE'EIN>/UF47$=LE ,Z@V"
MLJL0#[I^7LU'>;/#YE14V2K*DUD)2!WDY7A]=J)HE-,KN=BF".\TC5OMD"Q-
M]C >P[W@(7.[3Z?@5<.7)YI<UN,D7PQ? N')7G;VUDJ,?59!T"0SY <0;%=I
ML#\&69YL3N.5-\TYWNEUZ[5@>3#EAHL8G[5@4I;PW^=O%UZ[#;A1!]99$,M<
MS\GG:1V@PEO,T";?:UG=<P*CRO3,:]>: :,*#B^9P[SG=6QSVG4[9V<+'N1=
MGWK'+,2LQR NH4I'G<99FFDIX7;)@\J:U/-?37>%)).]GB)$,Z'*E]?WC]_R
MC4<KZK:TOV;!2L!'KE[12H7+3A[<W(U.;*7WRW>91^40CVLJMAHN8)7@MW:=
MG*DR#S/@F(Z[RKEN7R,2^!X*W.>F\7JG[G(G;0^,)2!#>RK'.3DUMXUZ5G$U
MS(SJ=.,YKW2UL3E)72\Z"=_'V78+GC2<4XKJ;-:R+,(E%XCB=NM9]'9<TJW9
MHH $'I0DVL(JS\S&Q6/)ZI+?VE9;2!-!N2Q;5[:XOQ:;!6KQK7LT/EHG8HNV
M95FTUJ3UKUBXI#>[<$G]O,*EJ1/[-3X=EC1I1J+-JUK:?3ZI^WQYWGD%GWW^
M\FWWU4?Q\?SMT?Z+_</.JS??.N<?SW8^_/.Y ]_=>?'V:#E1L[.W@S\>_=G=
MW7O)]S_W/G=>[7_I'+W$^R]>LL[GU]_V/^R0G:/7I_#WU#E_(SIO/JD@M;#4
M(L.E13REB*R-%@4N M-$&"?#<G#'/!/":ZD]35Q$;;DD25MO,.9>8+)<M?17
MY5'6%4OS4<5\R'3MXJ7+A[$X;&64UA%[%JG@AD>7E!#$1)T 86BDWXM)-P?*
M)RGOXL25O1L U*\0> S&HXMCMEGHT9LLQNS#4BTPKRC9,8EVZ \70KCZNDF\
MVSU?'QE.QG*<8RGKX[B4LY8ON^Y@&K.=%5_.]KLYC_]^SOU>>H>9SHZFE4X9
MM$]ZDYJ:LNLS?:\4<^ W/H:8#88\\?XA_.Q"7'<RZ,>YPA@_2>_.7SAW\K<Z
M%#S[YNRBLE<QB2PF.\H71[C+D>O:.!>^\F^XTS!VCUPNB2ISGLI?JM6H8MSY
M!9G&AV4K9!8D5<L=ZSA^5&V\U&YTO=$VRN4>PUP[5)RU"Y]1-R1OPP\^'E<#
MJFZ9JNV;$LA6,U5'C(LK.(VBIT'!9'3=BNHIC^U@, BC7*,=RIO8ONV=G5?C
MGY.OXF;4GFLN "N+"#<<'1:OT'I?#.QD/98DL]Y"''EPI$M!P+OG+8UU64P(
MSA,\OBZ>J1[^_0=D$QY[]>VK\#'?4&+Y@[OQ]PDJ59Q=<*54RO4'LST_?VCG
MJ[>_ S&5;WV8LRQ%_+O?\I;=R>&H56V0KB;@V[4B0A#2+[$F&(YAU^5\! C@
M:9GH_-!WTP#U OM10<^SG7?ER<7'X*WL\PT+Z+W[X\\KA>Z;E'U\-NP"ZO30
MSEE6GG<00SLWW>O^#5YU2A/QL\>[7H9^!Y=[J12J715TE%JN.@$ B]SY__;>
M(DKXE=1DHVSO[ER=1'4@H:ZW6S#&]@KB^EM6E2RN%UQ0Y?O@3H?9WOT]!F3.
M]7*K\MZNJE\!SBIX=1#V'$TVZ+-=S'<%N]-KU>/=SG>;)FHN&<:TF#!?4^#A
M\Z!;2D#G,H?+JU[A^I'K]NTLAP(WF!:Z[![#6@_N1'IEEH[+]U16=^FRK"%6
MOKU\ @<FOMKZ >Q2_#]WK'7?%<"Z4BX7ZL)-1T4X)@G>8;_VLG+BM_PR;\9G
M)OO2]0+8A#'WYQ+O)2U5LMW3-9Q,7&MPFHW[8?>X&@1X2A-+D/V[? !JXGW.
M"D<G3RBYJ6Q4AZ%LV19)64J:GZR\\ ^^5KGY'8J>V-8WDSVRX<+7OKBZIC_.
M6^A+E1B)D.1<E#)ZSBUCFO- 0L*46TT2XZ63B<:44%3_P"XHR:B:,D+8D5,_
M!W$W95@$N_ZZ_V(F"_49S[KN M%'%L_O[!V(W:>?2!!4"D41U@3B>1$E<I@Q
M%*V0*5B.H_);3Z3:7CV$^7^R%9GF\R:^U/76W.$DB8\<)Z$X<<0%9B(.\!=)
M@Y2I6?/;7?,O9SMO/@7*L?21Y8Y1"G$B";*!\UQVDYBAB2EEMIXPNG;-8:FK
M@OAUMF4&KXOQ;=F]6YL-6%<1?UW@X R (OFHO6?<$&E\I)0;QZA-DD9Q&T+T
M=Q6XSKCP'JT,?7Z:3R]R 0H:K4(PVP1QGKL1B:A1),*9A+%AC((,78 :E;F_
M$7((QZ/T!EM'#!<X:F&2$YA3XIE@'C>+?KN+7D@*I=&)2(UD$K#H/E#D)!;(
M&<LDQ\'A8,%87 (;#R[;\?ZXW@><14FAKF>_)![*/F45356A7[[TV'9#J9UH
MP0PAB'7!Y2VU5I,<9#EH5B<+\S/^]S6J6:4V00ENO"2 @-A:SCE-(@G& 1W3
M1"MXV0+)/UQ8UEJTXGTUI*?]L#-):OY=9S'?UM7SN62@3MC/LO-7H\XPCTZ+
M7HK.TT\\"DX$$8BH .;7:(D,K!JR$O.@M(:0/&T](=NK1)]5,LQU>[W)69'C
M.M+_#GH6RSQ:DI/ 7?).4F7 O:8<(%1'Y0+6 4RI(R)7/7]7/"8;9B7A,,J\
M*3%<;=7ON\+YYZ_ZZV_@=,$\"P!,C(C%$F7SB0PL=':_4HA8)2W=UA/=IIJW
MY1J2U\K#&LVJ[8Z.!AD)!_[+0BE-.6YS41:H>&:#DW(RHSIND1.V&6_* >Y0
MG[2X+NI$+$1(BCB9(K<@PY8E&[63RB0P&.X2U$%B 70JQIYW^<V>SX]J@CA7
M$S/YZ,1L)_MES#I+%3ABQ("$<:PX,EXX1&+0BH)!H$F!F E\(;P<5?!2<BW5
MX<QRO+8^*[5DLU;WNJXK.P%\-@U@9"2X$-H%$P(.T6C/O$E*I7+^ G_G6$WE
MODTJ,^:"O:G)NJ(Y>H02PSNGGWR ):"9;YH[G_N'>Z0S'1.H,>:>&>7RT8O+
M!::4<$T+9R8Q8.H.1WFW%(+$G)VK?LWU6B?SR;U1S3@Q.RF=#PZ/1[X7P0/\
M:D?9YW(] *V\"UO.%D[)$KYFX#N*/=L'3^_'"B[OT[E\6@[O^G$Y\@QO7?:B
M2.$RVBD;K(1/]KY*;KT_&,/KAV($UDU=F;EX8G/U4==/)P8>$DI=TE&,N:IO
MU *W]"AO3,1^.,Y)^LG!<7LRC<A.8U&Y,#V_/2F0J';N9BNUYGGKER>?=*X<
MX@M>JSS_HG<K#YO4/ YC,5XQ'W:&B>I.G^J[H^.<*>W#^L9>]Z!;:@%[ U]5
M=8>OMIK X?RXQ\.\L]@K&YB5?"U,6'66MJZ_S,*X,GO;K1?C."M6JP\PMM?.
M97VB-V^IGXS#I(8UEWY5VYN#_L$@ITPFG\Y.P!X,[5%UZM3%^04)$UH 7THA
MRSC*OO>DMFSRW3"(=7U:=21S$HFC417TSI=33HN<OQ?BS)T4G? *I''A<EA(
MO*_/\YS&ZF5RD3:\=,QI^=9DS:88LG L .1B#*L[&%95^$LE%_.#GBL%>7BP
M\"&N%-U>%FLF$*#O5BYLMP!L\J7PO5R8Z 9?8R6@M6\Y*;4]GB9#BCE?W4"9
MEG3.C@&4JH>2 _R1FS2GY[YS>DXUI^<V8"P_\?3<#U<>WM_)$4"14HDUB2-K
M^S:K.*MJ[^IZ[*7RP;FK9I51 %@38)GR2=9U]KD(;,Y>99:.["6<Q,E1CXH8
MHI2OE8WB.E-7+6;A!IC4LI5!S_%5SNH.E@KKIK1(I;QM5,@HX9(Z/UPY)-\O
MB:L*"<?+%7OPS;F'SM__LAL6/%]U'G5F*0*)Z,]1VU155BO55:U9854^T@'6
M.6_GE_F$[RZR%\UJK[K#@*JS;!60ER*"PN<6E[> 5G?9)XX(_/@6;/9P7.\/
MM0M'5Z:X6:"$FU4C5M^#=R[[__"-WEE[G@CD2J\X)7ZX3H@JN(@D>N*)B-RH
MH(/FC!%CN-4A,K&VKOS"],;;^=7?32_K!6]BU(M2IKM[3\]VSE_3SHL#OO/F
MDY!1)<$BTH(RQ'FTR!#%4>!YPSI2S8.Y'@,$X+8)EE&&-9>16Z>UL=XF*B1\
M8NOEY<WR_HSEU<IC1J5"S&('RVMRSQ/LD< "3"UAAGF_]41MKU+P?S\]T5Z#
MV,6:3-!Y EG]>+)<4YU/118#]V(&-VNK56\!;*15W!-)51" +SP:HYF3.ACO
M!";2+H,-6TR,-=)X@R,N+\HNI_<AJMQF1Q(:$9>:(>L"10 W5"@>HV5RZPGE
MVQ?UW)DDQ'[ 1;A<"-L35M")("Y>-I6YBPU_E5:JF4MH=0CV"I78$]DF-S"D
M AQE[YS!@+0&<VNMH-(K14)(6I=J'THF2$L:I+TSI"4[3S\I ?$+,QCB14X0
MUUQD"OZ(F,?.  292%*1<WV9G/>O)P94$6P5%88RQ1EQ1M"DHXDT26\U8;48
MD$8,[EH,:.?-IXB5-"SC&\<)P7I(I&-T*!(=DZ0X"8VWG@BRS2\SL+/T:';-
M[P3]2L@#MUIW-.1TF=RM,-?EW?)R_CUO8$VB\FM):W)&XJ0B=9$[JQQ.# <!
M 8%+#N+R"_J2B.6=\J?58:"Z<"*/I!-/ZN8CC;"NM\>O,>"4)D8*@\'-MSPW
M1-48.?#,4:1>!!F9#)1DC_ 2^9S*4-FHJA=C7BYFY&"A(C2YF";LP1T.>MGK
MMO[J]FJ.\>FIH/*GS3H6]*_?JP,_3.@'>>"G(@VM#L^H=8=]3@?#7CCMAKAZ
MM+8ZYE.MT]S1GI+2^MX*_BLGU_P U9@ZG<!V*3*#O[6Z1T?CBOHHYW,6>8^F
ME!Z9Y#]S1;?7<[/,\Z5V 2_S7MD/EJEAZ:3T45+G-;<D@HIK(13\$YPB*I:"
M$845!/B3'VY8IE9.#"_7J36PNQYV/W[;.?U$K#712X,\9Q;Q& QR-O<B54XY
MZR38O]RAZ0J% 65S<[BTL3<^SL)U':%1.+N(7!)-+'=86&9=SH8K^(>1R$K-
MVJ6RLJY2! 3G[71;L2D;N50\,(@'9=X9:@P"WQ'$ ^PP<LD'!+I,(K7:.IL;
MEE^Q;F16C;9,(#"WWSO;Y:T.?>?-QLI_*D?86W^7:C?RK**&*[_0Q<WCTW)N
M>;9569++!5ZO5WSN10PD.6XCQ$X*Y!%CSKE@@C"AJ"/7Q*_UQ>?Y!?9.!\WQ
ME9GD>;:;&R=1'[SG*!IF(&"!?[1C#CF'=0XL7<AT-FNZQBT=/7"#8;_03\W,
MZO6DX):M6",%5Y2"@V^YBEH5RN: <) "\60B" !$!5;ZE%208*)<QI\K2\%X
MM%U+0G=44[:/%LI0IEM1%;2P16AQXY/*22K%#X7.Z?BD+L7)4C/LPA6Q-GO7
M/-_D"5=8>Q/@!WAOJX.(WL;D0>1C?;[IQ^3LCW$A.JND+.?_EN5LM_^T_QJN
MJ7BNGIW-_6Q'W=&S/'N/61:_X,YIKN@WDFFPA='E+2D9D,9$(NX39\E+RZ6X
M4!;7A5\7MK#\68',@L#?38!(KS:0C9R>-0C0*HYN)H:K]0.Y,S3[+1^.[U8$
MY+G-:.4"EZ((ZP^[\6NL3TQ6S&\5I]!9JY?O/U?2MA0:5KQ"=;G=_1[U[I:>
M.\/<ZV=6UE=1618HS#4%&>7.YCF8[/1%,_]%C8V%$7APVCHYC15/7T4K,#ZN
M&7W7S7VI")FB["3F*'<J,U@H]/J9%O.@-W 5.^:,AVB[54_LI+!R&?U+0YT)
M^M=W6#G*VIY4J\Q>'19BW@@@>.I1KM"8[S=4+>Z,F[1N@P&#>MJJ"UMF+4!F
M;SQ7\7ADSZI!PQO5U737,B]!XJ!"\ $\&,YBL-[Y2)@#)]X0IN4-S,O::OQ)
M:+XW>!87PO/GU20\G\[!(S8L>^]/P=5EQ%G**$>:)X4XI0IIF0*R(0J23&#*
MFUR;O\:P7"17[67V[4S/VRN1[KAGY\5MHL]399GH5$6'6A7E=+-ZE OA)K]U
M"U7EORIB@*/C>-*MBZ7+#>I0R[9&<(/<-O H9K*H[J@P1$^[VI1\4\7;6LGT
MI(G#ZEF3!RGKK]-,PG=S7[#'+.8>@R^??*!<\]S/)27$@TTHYQ80)X(;%VA0
M(EX0T8'$%4*CF8!7O=8>7L7WWJI]KTS)]-!%U6.JNF96,9^IFTL[J]J43E.R
M<]SJ@V&QT-$.>]TI]71]/F!>X^?/+2_S[.0S(_D[-;'[\E!K*S0]=1!FD75%
M 9B3R]T(MZL,9;Z^L'TM?FD1MNH:P-P"[RA3-_LXFJ?%GW+.5:2_#V_-G_;R
MB8F#PW5$E:/N044P#)-[@>6?.(;=T?QAA[R\PW+7[^V2QF\UQU(I@IJ[:=DF
MJ\[W3&G+,]"#'(3I"9>%T>63.V6]3JK#*G5;X8IT?5)#.O<*=<TMBF SQI,#
M*JM/RYUX\EF?64'J7%-6.YH]=M*@MB*/'U5/STR E?34?(39"LX+TC5P8I-V
M\G;G??T'LS$V8:&=%/5>P E9=J+J3?Q\?JJJ8YIWM6?NR&C*]KAPN]%< XIY
MFMC94VJF_[/6*)\=NQ+5:A6M31SWT<RCF3K]%]',3MEA9^QHN;JA.K8T9>Z?
MOI+-?2=@5/#_RR>;+JCV%C.5SG2H58%YGOG1^F%,U'MTV6)LMW;A5OF\;SD@
M/HW4LK*-8^VFE</DUZP"<]9BJH0,WD5NB=6*@ _F'>8:2Z[#E>MM)Y45;ZLA
M92:*?-PB#^$#8,_S,4P<",[+;[6]>)H[&\+<[=EOS=;.6G?L\WO1.7]*=_<\
M?/:2=PX^"4&3,%(B9:U&G+F$M,84!<^,5PPSR4EN\+7-;KM(+$HLC&=66LHY
MH29$(U2,&EQ$A9._<M%](R5W*R69TD1CHEV P#1P85'F%D%6.H.8D\X1!8$5
M#EM/&+NTE#!=K19UJ2U?"4QK)+J6D(%$N4 4Q!K4<BN2=M'BZ+6RF <(#J]<
MD-H(V9T*6:D#P]3[I+Q'B22!.&4$F10"DDK91&'A$C5;3RA>0UMW,RC2-"29
M&\X3B$>#)S8H;*35D@AF7%)7KE=MI.2.I63WZ2<K#< -44A8EPE0"$9.:8,P
M!Q=#^J@D3@!%YE*#=44HFBN+7ZQ_G1YV'$U]IGS+@])^9M9888[G_M#F\^PG
MW5'J5@Y>E5ZKHIX?["5VK]'MM*HCS\?$2[47>9Q5JGV:;:R"VX4]UNI/"\W"
MYGWN:O_ U@Q'URQ)X]$P%27Q'+#?*NX8SC5/)!A.) _LTC[ #0_-#W>6>8IW
MWGSR44AP\QB*(7'$#>'(1>7!TX0 @28>I0;%Y9?7$Y5*\S5%0^WO15?5_E*]
M%S<I::SWC.IF%:!EL3[M>EE4=T'$6FV3]<_F.#,.IIW?ZU*FW =E%)<9$^H$
MW:P!U:*6E!30!6HUWWEJH=T4W,)-VDEFK)MF]:M9F/7]6)C"W/LBQXT11#FV
MEW))>:/L@ES5=])*%=+F)-:45.0J?!!7:VTER6:WMM(_J[75PFGKU].SUD_[
MH:24GD[/X&]<KRNZ,VU*_A+O[CWE'S^_YIV]P\\[+][@W0^=P\[>^V^=5_\<
M[7]^RG<__/EE]\4_GU>:DN^]$3LO#KL[GP_([JN=T\Z+-^(C?4DZ>X!*'_:/
M=EX<B(]',.X/G01C9I\H>'K1:(&44 QB&D.0M<J@*+ 36,3H.5YN&27 ![4T
MD!"$YX$RFS+[I@B$T0#QA%KN=+5T O[UX@GXLBZMYY.-Y[U9EOSOZC#\]YM@
M/8"TX'KZB\MG<7'6<6*6*,X\3X1;"8Z?PTYBHX/@TC)U,<F6JYO^?9=P:I7#
M8 TUU H?5/L[[%F%Z:GBDYA0/2UR+8S6\B6M[5#@#Z/_4AX)'Q]V71>L7DWE
M=38<C'+G(_BJ+<G+R<<UC-?D"1."VC5<7'&1HZ'U=\^66H;BF )8G,/-X]FZ
M6ML)7P,\*_MD%>E6Q:!AA[VSW!SQ8-8WK'7</2Y]"^I0?K+QFZ\_'0R_@(7P
MI4BO;#5_*S:L=]V]7ZDY5UQ;I>#_%"%:Q62IYEYA;QS'RWG')99*^EU +27D
M95\]ZVNG/'\W_5V3#8U>YAZO17?_+MY\O7&\,3N_/QUBYR,W>"_2>?,)"^Y)
M8 I9HSWB' =DP=:!?QQL2L$8&4&5U;IBAZKA]J)LK#H-%Z'CXV.4T@VCU :,
MY2<R2EUJ(I=,:I28)PU7&P,F6#L7,:.<ZR 9C=38[_6^O$=?8JTQF% 3+9L#
MDN--\  "%UQ(;6-0)C$L<X=C2F,=\"_Q:TS=ZA"[O[_,R8>S"=B_K)\SVA2J
MZY_O-^]]A.>\IIWS-S2GXSJGGTRT4DD9$0]>(.XY1=9KB6"J@PY8@-UU .IK
M&D44O^%JYOZ"%<YY?)$?$E+B3!&P(!C'K&B86,Y,O<)+=KY9X:NO<*9+"4%*
MJ9U 206-N T$Z0AK+:Q1!!RK)#R$X'1-]?N4-*QJ[ 5KUX]^YME6R8>JMJ/F
M',F%(+5CF@:]WN"TN,XUF^3U^,3F:H[F*,FN0B3V^U7#K.-\K*U_@'HQ09RU
MG)I%1-\;5N:4 Y7WV!UL<6X(KV+0YPM!T*R5[ \0SX%DA%88G$YKVRYDHFN7
MU%U]U7K6B?\T*WY'*_XN9T%+:%B=]:PJDUWLQ]2=\,0N=S=8#4F;];FK]9G+
M2.6T>KX:#1+*.1,[&DW2X;E^*H):MEO'/5O#;?R?<?>XIJ3*I5QYK:8YX-4E
M;-<9%'BM>8*KW$1ZE/$Z=6L9J5/<.;7?BR7Y#G-5-Z5^!Y/V1Q:GG&MIMYX_
M_4_^2B,<=P77]=[U0BGQLJD%,1GX;E'K.:N>Y02L_M_#^#4W?[^<RG.1M*R]
MP J[P$AQ+:X]#_Y^(HD9)3D5R=A(K)%":\(#MO3*7'N3E-!?@]%HMS^9E[W9
MM#R(G;][]R8A7A!8,)IB0)8X@GBD"8$7'Q!VQ+K$&";.Y^9(E]5XY%1IMBN]
MNI8S@9<Y?_)E4CJ\U*-P1D2\MD?LP]N#?[U41;#J2"]FGBNMO9;+M72>:)VC
M-4'V;O\*I,8WFN.[W4-[YP]C&.?V1-])_HX>Z[89C$5T/C\5.^=/<>?SQS-0
M9R5Q%+G!*$N4Y.,]%AE)&<J] D&O90C6K.2>(%P7/ $08\4=5ZXT%XP2$YVT
M-VQY$^U>].KFL6;9,A\MQ;*_=?L5CN5S(3"^,/K7--P\*1G :?8Y'R-&9<__
M>!1_G_SPGU"ZGYS]WNV709<O_:?6G#IEO:9O=-&EZN-9!G<;5UG<DR'\+TR>
M7'^\73[Z]TE8_4SQ;:[XA1_C;?*#GPFB?^B;WQLLP=O,/*C!RBO=]M]EU:J5
M ^'((O3_;H'N3)/[Q:'[';=(P<W)_6[G4GK\+5_\GY4-CY5^Y47D;EN']67E
M%[@Z<+?L94XMSZU,1JVBDWVB;*!:A4^PE5_M/P]JKMXME3XNS-1/%#6S/+O9
M&7C84[N06[S.O*ZR8'@?8TK?>_T<O_V<E[^B';UZRN]6DGU7T/!+IW59."_[
MWE4E%;<V?,&*N/[OY2F\M=>??^V2:=JH][Y&6B$I[UC4'HMD>?1"*X<#QWEO
M-SD1U&4'W-ARV/%LG.MX1J.7W[H5*Q.Y6CZ!/<P Y/#CT;?>[M$;>,[[L\[1
M^S-XQOG.Y[?=_;V7'((0OO-J_Q "#[+_ZBV,\\OYY#OPK/$^?2_WX9TZ>Z_I
M_AX\[WSGK//JS][.W@'_>'YPNG_T\A2>\V7_U<NSW;U.VNEB\M?>RY.==_A\
M9V^'[C[]1+@L?9@SX3 $+8E*9%-(2"9)B4O)8ISIG'";XXO.,]V5D@ ZM*ZI
M+#\"=5<93@.##0Q^_YSOC^1;&AB\-QAD2S#(F%>*<X-P( +QZ#0R25ND9/36
M&9$[U#PP&+RV1UWSRCTDCWIQ2W6RE5H[UC_D_RY-PH7!&;W>1*X%^@>->+?N
M^$W7LH&[6X:[LQ6OSSJ6--$869]R^;$.R"49P/^S.K&(A8X6X$ZUU1J^M6O"
MW7I8N5//KE'B^W);&B6^.R5>]EFX%UYF1O!\9!1QH32R@@1$"%7<.!FPE!NH
MQ+]XIJ^HX"V4$MU%]NY*P+=FNG\]X+MU[R735YS,EOWY83Y!?<5#\ W^78Y_
MG7?X;(I_YZ_S(7IJA7 Z822(@YC-&(6<<PPEITT$ZR6LTUM/A&J#=;NEF.T>
MTE.-+O]T)Z;1Y3O79;R@RZ>?L$S)6841BR:"+^,)<DSEQHP)$T>="]IOH"X_
MAAS+)96OPX7RYK)7V21>'I3K\IU"W@;4K@YJSU>R+-(S9:+&* 9L$-<1(\L2
MR8W>,==21ISK>X5<;>_>I%A^&76]=>_DAG7WC2Y?29>7DRW$,*LY50@;;[,N
M>V2B4$A1:;PTPM),M4?;F-_8/]F\7$NEE&QS'15\"V7*]U@N59=-P@2WPF"<
M*Y\GLS6W24@6M@@?5R7!;4S0+V-1;MT!7%"<DKA_V@]-$'SG0?#*KIQ.1EH:
M4!(^\X^3!#:&,$2UT)%AK*/C6T\(EF!E+CH3=G\*=L_YL 9J&ZC=?.>]@=K[
M@=IE=]Y2%@FW$)HSGQ!W//?V9@1I)[CPEFFE589:U1;TQING&P.U)1SX=SDF
M]V253_.A'//=6SW(>]='*:Y+D$YG9QYMQ>\X:3UVG2/[((J11$\\$9$;%730
M'(34&&YUB$Q<N2U(H>M^.T_WLIM>5E/V,'BZ[Y.R,1_QS<=[A8PJ"1:1%C0W
M/HX6&:(X"ERF8"/5/)AK&1?M'3;!,LJPYC)RZ[0VUMM$A81/[)5[ S7+>PO+
MJY7'C$J%F,4NIV@)<A)[)+!0RA%FF/=;3]3V:K+VBKT5,O/2>LJEJ]$ ;%)C
MML6ZVV=UW>W+I;K;A\+,/*6Z:]F4HJ_[.58461/H[I:%]+$FH<]DO6OH@B_J
MC#::SM>TG6N>N DQQ_,!.'_]LU8:%TM2US&/ZMZ!4^:7T?>JG<L(Q[W2W79&
M-M<Z/1RT3B,,JS\XZ99>&Y6MZPX7]O/@RS-JY'+[0G;?SZ_P/^/NL.Y9E^^=
MQO#&^96&7[N3!I=U@XK)6"LVHVI8J\.IKBQWK2>I3&E]PX56;M5 U[[WJ#7X
M6G<*K[\Y:9DXM-G#.;OH\]S2LSM:_I(#N[]N&C)]=>E,&K.O4"UU_G"[M9Y\
M]')"AT4"".HUQX8)E2SGTC.MP<(+"_XGIA934;D[,]*$BA@A]R#N9N\B1!"@
M7N8E.;##,.$46IRPVB>:6^UET2DO6E:O[[N][K1/:FF7";_7C1,6G:"+G9_V
MK&U)Q;Y2V)#RW'H_A!>O^B7W1_5SJE;GN4]P'DS(/Q77MR1GG]E>>9%WAYE_
M_+="6SC'%G%EWN,5(%V[>I>NQC)]A]$V6/C/2[ 8X)9)Y3W#@A#P##S+[1@>
M#).%I-M4TH=$#O&@F"P>U& WCG:#B(?)N_''%2'SOC@F5A@\'C['1&>P9-NO
MLK'W V> ?^4Y?+?D4=7>6C.3UR?>R?W9'AW327GKJ[JAN44+!,,6//W<)/W'
MSFW>'F\)><S'];_W\K_,KHZE"4M/<0K1<6FHS6>\L7%!.*M8\.N[(5RRF;/(
MBYA3(;[^^3&<@OO\K+O_^0!W/G>^[-!_OG3.WQ[MOH(QOOKS</_%E]/]O1VZ
MO^=)Y]4?O>6='+CF:/?%&[I#WYSO?WC#.J\^\CRNCT=_?-G=>];;.=_O=<[?
MXX\?_DD["Z= /I[MOOFD!74\$(.HD01QKQG*01EBD5&#8^Y6FD_NL[;0=W!R
M_SOZ\C#VPQO$>Q2(YP7U5G"C?=Y)DL82E7Q@)G%B=;J@_TN#>!N!>'-G93Z>
M[[SYE#3#&"P7,L)3Q W.7<2<0#H$KA2WPDN]]42W-34-X#6 ]R@![\<:7C6
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MSHO7&+Q$)STGR6(D _B&7'F-($20R L,+B*+/EBY]42K-I4/PTO\Q8^/EMS
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M6/D-</*_D9%;6;^OK%\?(C8"]WC@#JS.P!7#CCT4=L?QP'4>]AT+.,"U;>&
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M'(X]>PPF@B7&0[L/YL+ \WH3I]=_N.*SO<7!4\.%>#A9T8CW].6D-\99=E*
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MW\!S @J&:+[5BTDENL7 TZ&/%$*KX!AMFC)D:Y9JO:K=*EW!2@JE*Y#:*-S
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M2B]1B47V#ZCHVIUK,"P#@RJ@59-\68@"EVWW !?1UD<6]9&#MC[R -;RP$"
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M_P>9PBN!2TP= L9F<B5S"[[%P$FU^)_.2IET6IH6:U7M& I5!6R7$(X]*S/
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M TJ JO1.&1;(T7$$VZ4L($/BX6L7"'0D&((G;>(!5U>PCF,4QM&L P];;$=
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M^9-#@MES^X<-SM'OF6 P[HM;M!\)[AU%IGX==X<M:AGYA!AY:@Z'PR?-R$^
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MK I]K8_8?6Z\6(JD=#GV>8#5-;;[->7:*E!YX4JOE!_TL,O=]=SO[YCIB9M
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MZHQ1OWG*%DY!E>#UF\,Y$""3P-> <Q@@.!RL((]0Q46P</T-D^T"8MEEIA_
MMOWZ]TOX*]Y["HM)_962B3,\:PU8%-3E+_Y$(="!DH:-I<H6\>0B*O'!2J"Z
M8S1!2"!$H"+ XP@RY$\&*D.#(EII^<GV-LIA8,Y%D*&J5N8)NU[B0@2A!CDC
MDA-[P!<NP*2-\U19O81W%L(O(^J-9094"JS 1-3R"NY=F@EJTP31YTDX?N*_
M!:Y,HQ.5Y\4X5JXKN6'2AQ4A5 4:J:ADJS)9&2NI1EQ9!DMJQ+UN,YLWP5(<
MU\3@&-MUE?RF@<&2]0N25K;(/:K828SZEV4"Z>%H%JOOZVM12)(T SH@2=6E
MQ<NIU(76NG19%8W\/*3M;]3L.8B3A+:O=+RRN[^@5B?K6\&1H/PHI 49.\ @
M,B$3KC@,LAD1*!;.H>Y?P/T#Y1H6MBX_&R^G%Y2>-@*>+$%[@@5S-3L5MC*N
M!.0%W V%P$*X)UJFHX3&18-+ T+BV&ZMTNHIG%"FP1-E 0)8R#YV*H@0! I3
M@(&]?/_O\U<=:PI<@:(,W#LR*1G#IH#X*J !^8:P/J-G5%Q6O&:%Q:X[WQ4V
M6;DF/N2L?C%*B$*^&@DZ<@GS(>/=L+JA=^L? /<JC@&!0 W/#$,&U\!951D8
MXS!)P+J&GC/+P8Q#6BH,BS+44X6;#-#&2Y<Q MFHZ),F4M?X.VB8"]2% ;J]
MH5BE!K7!T[LW$Q:-;+P/BE/138X2N//X+SBC0#NT9$7I>YPA^8FV+=I-@79C
M-5*T+=K-8ZSE(=%N'D_ LBF=Y!%>[)KZ+.$Q!(L =<-!@FBP#)0<=(%-CN_5
M%'"!A5S%@P77BLSU39XUBHQ2HRI$K:J=_ZRB@)\K9X)=.9&FL<N O1N\-\(0
M"],89"#OY/@07%_EI9"NP7D(#\0TX=(7%E^J;4MEYQ8VC()30]\B"0@WE;"-
M@6AA$7PFCQ;U@G8"M3&6)[M%)M&J)."3\K-U53:7#(,"RA>_HR'#"4$3X8L3
MCV(VM)#Z6V'K8>"N" VV1 #)+F/*AJ1UK57X06!$I6PM\2Y).2/&6[EH8 P?
MPS>5):V1"K%)&(M;/X9@W10R7A%O0!N@_!:;RB5U@S1%W=XD,O-YE8B?46&'
M"/E"*AQ<R OT24.P(32V<\D'>S^_<!2UW;/-6,(;3>9U::1JB[VTA0K^8OM%
M ^#M%=!FL\S!D_'!: I4, ^!>3CT5+JY_."(H(5WB 4?VTV'DU=Q&;PK9*=&
M%:C#%*X/>I&S@%(?9((6"-?PCS=QLC ^=@;&,X4I9!D?Z2L?JE\I L[/\3LD
ME8M8Z,<ZF[S^I@ [7Z(WG*:$W\S1%N!S<&7I4-^*!'X K[/9K;SVQ95-PF59
M!!D'XV-$$Z5(/;(R"0(:<8#@F0[!X@.O<N .@Q^S&5""0_S\/<S<N"2POA_T
MJG$]Y<X3N6+WJPD?E/ 5],35#RB[T[@CEQ3R5'9K)<ZK7Z>C)'3-X?E.$-$^
M30U0S(1"4>*H;Z'O2-?4XYT1UE-DH+;L]UZ(K -DZ/ =H9]9+U3\BYQ"P?<"
M68)S4![2-G#R1FR43O,EB$,.9+W$/&L$<NW77U\R9[SFK[^J?KU )WV.$U"J
MM"@]"%HOAT-W8C!#)56N?%]Q1^_VPO5W P,[-N2HEPUO4OFHZ'2AC AJDS3W
M21=;W8=(?V\^A<JF<I5$V[2O_>HK@//5]!.@+6+56J-!5XVBKT*VP<]!5M1^
M;FK]N0< \9H6>4R"-HHVW-WH2\!B*L:H4C-FQ:0NTTR5D')A9^N4D8JTK\QM
M91^-PA<ZHPV#9G3\2V650'* &\ 3*BH<X<G4!9&"\M0!S^#H@.":UYG-I2._
MSJ_*02+[W%0.JRHS7"OA G&UX8,48R26"F<;?E+<]+XUW7C3)]/NZ(J+7IE?
M1-=D6TD4IL^V+?/*)5*)%N=OO&MH9!33FW8M%#/*JA-'P5;"1O2[O:I&A_L/
M/A-87TQVK@'3RVGD:+GB@8=Y%)45UR&<ZSH/ HZG<@NO*'-!VP4\?G8.L[6Y
M,KV;V>R/+&V7(@#^&C;00+\?=?MU-M0:3!\+6DB8>B?IIDQ5C-?+!!U1S'R4
M14><T5'N_7X7:W]U=LA"LI(2.5XA^;E2_U&_8(7STW!;JI/4"9EZL0SCE<02
MATQS''^PX"XNFD*'J-<=UUFS/ZE,7KD#ICKS.$: 81[S6O&V]:&7%;+ HB?U
M15OEFINBFTCW\<T_:JX2%VUTJAE1L>9W[%U:.KV^M/21ZDA?HH#'U,I9.0KL
M-XR;%0Z]1C,_NOORB09 2-"#HN!V^'>*7;9:<I9AJ2(LDG+@.@+!NRA"G/_J
M?NPR!Y:12>$BIBX:DB7IEL#$;K!$U?[LE[.SWY[K##Z&E2.AJJ$HG/E55I#B
M*4T.MWBQY*@9:4,U1X@'16!-$KZ+4)SIAN)L#%7+52G3X!%S7%VH<OP5XWO;
M=[):^6,]8%>AC X$;EI.+3=9E+!4KC5_B:A$(SZ.4FT[I(+K*/^1,0] C"9T
MCRHQ8%43I/T2]H363OFR$KNEG /7L5/$LXR<N$'BY@NL^7#)<"5Z%GEGMD*1
M8SF;+]* ?5]@,R3XE]R;J1-TXER57HHD6>$O>>#>=H9B7DPX6 V+\[ .6RS1
MOM05>+5:&.X X-EG&V@EHJ)4@]8)B@#<-!$6^\'PEYH3I,Q'S#F5SV"BZ'%N
M68VB<5(KD/@(NHZ*:RVN$[MIG6U17%B]ZE4I6:ZNHG))EV&&H0A,%L/'"N1W
M,-.#1%>]4@=0)_8[:(I73N-*^ZZK<, YNT&A^VM720R4R$J@+HK+\@:.X!:C
M2%VM(J[??&TF-G[W+(IRZDO JU\$G*U>YY^%8>O#=^ CF)-I#(Y4*O_:4:]/
M+^7?WY[RW]TJF?2_:^L$3KI.X/',RG,0G,8 VQ-J__<[FME!1A>31 ?\(-3_
M?E48+5I-O>62MP]!^O7HK$\.^=#Z5>USMLF/*;+ :E9L=8YD1?O5!"L1=WRF
M8UP[R-AKA>N&O-[KES?V=R;#'5KI5#]L!_O*?QSW&V?7P9\\(O,R>6QE]*__
M%R]D$H>L ']#;]Q#QCVV0$EYYXS;[>AP+AX5Q081ENY6_2"WNKUEL;W2NO4D
MUF"RY09F(7Z'?A>0)ZB[7%0Y-EOJM28NO(J59'B1"#_CB@EK.K!Q2$OYT^?*
M(Z)&B@1UA8?)$%H;7G6L\EY@V^-?NEB_<+OPENI904 [Y5"E!H8W C\HZ\63
M/%1&&FZBJ'.%RZW+_V&'5-Y2W2:.3W;!W<C9E-655CD682K;MO1FJWT!9%;/
M ^G#]H$4)-;?8X4&.CZ86*;?E1:V^IW9*#LV*6F-U2MZH!&HTB E"Q\S^(G'
MQ;#J,,I3/CZ7\JPX$RIO5_,PZ3B!YA=8 , UM,0C>/P4\4+G+: ^V8RR^\6D
M:;/B,Z8Y/.B"Z,;E"5JV\^1AK(^IE(#?\8GJ7>E2E*@L=U=7C?UCG24INOZN
MO[+5>%WMFGT ;C>L@>A8PZ[Q,^4P\B655U!XI7@]ASE,IFJ5=C?<+:Y4Y2R*
MEO<=]D'9CH) QY>)5&XB6B01-1J$6HD8-$*^I-,''?HY1FVB6D3C/ VQB5M^
M1;X#QQT+2S6/4PV:RRTQ:RQ?("!$W#9)S("%3T%:!#VHO-Z'UQ>3S+0>2'7/
MNP[<J.J<2OTB._.8*L1VI=K Y.9[#90IE>!>&91CSG6IT*K0'UO@+!I&K&H;
M2->'H*/F AN4-JJB6EC@^!5E>A:O?][<;]%=XR-K/%<E$62Z##(^%>R"XI4M
ML"! G4-,-[;#0W]U/H1K3G5S>2(7,77=>V45[5JM8[6QI%IZR5$BFD!<G.0<
M]-@E/Y_M_<JV,0!$31H;F>2*C9>,28N$(PJR.-&!9"YWK5;_\HNVUFZ:E=@N
M:_UJS35VB>!2(HI48<,(A;2:[2)<IW9%IXBI>V;6=\JYJ"3@,.@BB(*%GI*L
ME[Z%H]>U"1QB[1(>G6C]%4<IBEH![>NF5-'V^M&)U/=W;VQXL4R+6NHJ\,P.
M6EA%=G<7E%2EM*1T1T:%FS))],V#?_F)R+VN<58\*%VEX%":*L2*7< L$!BK
M0#?T%]R+(M,55$-Q$7A@J$3AJI(3,+F7384J38I^)^5MK,$3%!9/?2DD[18R
M*Z>5ZL'BT9Q#ZF&%_P(J)&\\(J7ME*:33C,1@:NKUPMMKK/Z2%6&SK6Q*L5!
MR3FD9+4ZK'!Z7%:!%=GCR8P'>Q8-!1NW0E::$G.BFM\H,R3H-BIOHZ/2)[@A
M!S4*J.I5Q7&B."EB?_">27D6I32$S(#M+\P?Q&B+ +;WE0!@:LGO&ND<G>VY
MX,X[U4('5S< DN84B.>T#W5; -.DU#;NK*AI-M=]G=CIH"N0ES+&E< _X5.5
M3"0R>4)<5F,4KLI6@C4F^FO>J1XT=<F ;F=M&C"$!9G<ANK_KR5GRMP360#!
M/([)Y5&]P72ATD(1X95E:@"G-;DG6NG5T6VD=EI> H^^);@-(!+E+E%Y8=L@
M>T;(>96F&'YW-6E$MBOZG95SX9)L:C4&B>"!YXD^1.6HW=(8+I]EZG)F3V(-
M@2K/6(9!V;+"2EHE4[!-HQ1,E >3:"E@%%GN?ENI K)3-@$T!1'6Y9>I+67E
ML!##KE6\=?1RYF<\#K9RRDO6IF**5,S@3E(QDS85<]JI&&NR"??[D0+<OYU]
M^&2<G_]HO/_T]]<?C/-W;]Y_>'OVZ?S]NYM&_*?6B43\K:T1_U\1U(L#XQ*W
M<7R&]P=)%1.(<)4:J#O(%O"D3O1[E01<V6/$^W[+,"^ZQXA5*=53C&Y23T%V
M'*SB]QPL!HF%Q>OIJ]_+*HE*;+H,;\ZQ% 7T_%7K#,CHBY,EJ5 %A:"I@"0(
M;@X8.;5/A>?/MC(]IEZ--XPG<W3\_ID1F-@5T55H?JR[8L&8(@L\6>GTJC*<
M,5];PE&M8UE=5<*%+P1[!SRCLIY4@ZMHWP0_HS%ZN%VWM.U#PA=2;D[1L$C1
M)O1^OH(QEX>>H0Q!JDBJ%4_!*U7M5#.1S*ZQ<C4K!6OZFQI2!*[:I4B\3AC'
MY/RD%;3!SY2KUIWV>@]^K!LM\%\(C4DMFNJ^?91<I]ZW7FO+M1:TIUX _1G.
M:C?Z2N%3QY?8.2\(@@"/\FLF$CS^1"PEL)V;(D@-GR0(I!Q/20/JL7M*-0-E
MLQ+P5WQ9-IY_9="4:K>[=EJ[QA]QKI].TA)=:N6Q!AF*1#3GP=1. X5-ML3.
M?Y>:+P.D7."OR$VBQ* ZY2Y)=7!\J O7-%;E2ZA\H5P\PL*I\^0TJ= X$+)Q
MT>JN&&\9UE"_<1S"!7>DCGFE@X*U^_46J!-32!P!GCB<HEVBQ5)F05%X N<0
M>$AT9$0*&$8701)'7%&'/*"Y&W@_F2F@64JV8DPS4"#&5].S&KST=8]O_>ZH
MH*;>@EF).!5^I!%O 1EB-WTSJR#%E-M&,2&,(L61+E D::BKW54Z@?(1_!AN
M#RAP3]'=WE0=2#%;3#*"TE?PJ-7OJYM<%:=5Z(T"LJ%$;$W <^<\2RVU7E55
M=UGU<@"-+5>JZ ]TLA_J31P_*VKMJHYK%@BZ(0<3Y5;Z&?$-"Q [A4M0 ZSS
M]X:"5?;,>15=K?)] L#;"O-:8\D":*+$YR*@A62Q(RK, :%L8^!=X_ IVJ(C
ML(7\)7A>>0XW@>4EK%75-6%R+D[UK#(T)%*?P>_*!P58; )4F7'NZ;SS?NT(
M23>!K;$%"+3>ZE,DZAA]7H$"\7N[U/I")27X48X\8@6, 8H$Y)X4B$^"D( D
MR,K40F-!Q"GXEDHPL@;VVP QJT.7@!A5@JS\Q@;4HU1Q]AN&D:;@. '*FAO@
M9A6R4@TOU=3X;.Q7@7X16L5HL"95BW'%TAF2"3,2*5:@I"J S"N@6*/.^A;T
M(%!%$_7E)=D,%>L4+Y.J0*%RR4H]!FR:CG&+7N2:J$V*45$)T9>_"=R6N164
MMX&"H:BIH6'#8$9:';>\#0%8%+'\FAQIP-<6;?&IQC9FK%GP2-%*X8=3<!S+
MGBXE6S].4<5"2_^-FO0&ZRC*1/<"V$/YS82!R_%[4I:S,'80C;"*:=\UWF\Z
M:041NNW6JU/\(N,E5F/])561&/ZP1 )3>%&FAM$B-&R,5D<JPTP=0\<&N5-/
MW0 Q%V!W4]T <R)[6R(!AS#1-T9;8]HR3($((354^^(".)%BBQK?&"B'MB[;
MVNH)7:/&S-Q6$NK3891P#7O*?4?<8M.\NFIZ!_H.*FX"MR;JP'V0H0Z:T$=5
M?@6DXQ6?K#\=+SR*C4L2H4Y<5)L1FF,%W DE/^SF:X1Y4(7(6OUDH,$AM-.^
M26&4W$AL%7!W550"R=;$O(*%=:43HYN ^$^KI2X;*3>V1J\,IY:0\;S#.ABA
M9R$S8C?*WR D&I9^E^U*'M9S,SHUW+WM;V8\V@)>6W>159,]A6L$?#&;L;>#
MMGI6^ID:LPN]\BJJYM7O%9=4$%-#OJZ<",C^3+4>;7^.0C&J;$%H1M+G[ 2B
MB-0QTQ1K7.(XU( +K(+$2%>+918ON)P&D[ZJ_@H4"7RM5JL#GZ;EZSJ)<MW$
M'%A;B6NGA1;[."^E^)7LL&%3Q?6H\?;ZUKB0GVMS-.0I^COR4G/Y<KX"SQBL
M'GIC(0YT:G;K.14-@ 7UZL,"BGW2.Q<$S0C:%V11MA9>52^CKV#B-(E!,9%J
MT()J9<RP"H4=?;S"H?1F"AZZ)@)%C<U80E2\4B4*U10%G8>M"Q3]/-+,!+J]
M61O5(-UUEE]<P>;,VPP+[>D( 5DN" =2B06H5VO90>#?M:SJSD[ X?IAK]@B
MK/I#"C";F$PA"E#8D*O7$+T, Y#:DL'J@ I^<0G_V7P<X]&C 9=K9.(\74/B
M;IH1Q?,V&<2T@HH=0G'3$D)4 27PJ(\2+)3A&(_,?_N\#EK>0)WTUD]20R:O
M.=&,2J-]!)ZA$:3Z<$A"*7.S3^='EZ_PMJC80TD;NB(??WU=12_'XA/^MN44
MQ[_VI64:P_*P69GX".@-&@O,=!1&69#6TA(U$:WQ,Y4'0Q-1U.OJ7%>N&MQ"
M-M9+B8*AL&7*=FDB_81B5"B@HL[?8V^&LWM"4#QS.#JRD.&;V-MO+%9@?"]$
M#:Z]>/\/_6M64"?!EC5@<HM++Z3[M46[+NLM[!;M^@#6<FI=K)N9+?UOC@ 7
M(!2I6%. \HB4+* E@ E( QHP7U$D]TK,NZ;V*XV?&<6&5)$9X]Z# *E$A,KI
M3H6T0*-2%ID40I9(W3EXV.@/8HTD%55VC9<;@C57F$ZL;$NH:_X\N1LR6[$!
M+=+Z1*@?;V3SK&>_'U&7DFT^*D8]/_P2ZK09]#E562KPJX:/_"5T=DV-4* <
M6TWIO&B/Z-Z/""Z&.R=#J1Y"!-L4#&\2>AL&QP0*!J5I)7"\I3VW^SHWE&M-
MX?>LF45XK@WB(C^IX$LQ1TJ IVOC32KV^(M=\XF/>WI[NH<'>IX[SIEYEDK)
MA>J-7'11@T9P"M:9H8; J6C./6]WZQEL3]T5.<E"9:MI#I5N.TV'REPC\"1"
M8&2Y#(@@M3P;-T*@0;].N<<[;\5RUHOG-PNNM-+P^ML3+(J95)@?*I71'!';
M%1>]>756SG10?%118V8%KU[U"G!K!I7'E%Q&+AC](H@X*ZL:ANHAN?KP+/X9
M+%&FK4Z\+RY(\Q1Q^E0"& >FJ8D$#:9@"X6B=68M &56^01KT[ E9XO1XQ53
M=FD$#66-*W)*J#Q-I*/KQ6 :8H66"1["H'63/*#87PI_D@5;^)\83"UP(U15
M77LR#W0R<W%1&XQ7%%36H3S*0^%P8I8GD9K^DV:=,@_$1="=?-F>W7V=72D[
M T)&3.+EDGN<N1A49]E+C %/9IR:Q-]S4(C^A6G=5@<^P"6#Q^?H&ZB9$8BC
M*\. JL"PV;:,SF&Q5KC:8,+HJJ;VN.[O7I6-MEOLC&H[;0%548G)Z&ZG>BS@
M!1YX>VH/Y:P7=??4G" 2CT=H4SD##X NM16CU1_=:+9S_]HB2Q67I^*/+3.K
M"^CA9NR*BO4K(?OR4338IG3<BOA]49VAAR*I-UPV4@"F*N8KVSU4H&!]"*<"
M*5I[A*[&H!]3](63^-2Q5&;G-\WO7*LOYD=QT*,YB5D[$_6)S%=W4VRO&BUS
M)SHDRUQ;[H(F2\MB@)L>YZWQ]Q3:.:^8_"0]C)06CH8SCUC/E!>L"W(8[$ZW
M8V"C"C6'Q8:CQM2IQQ!F$E7)JE8@0B&JTX@QI9ND+JMPPU6#[INX2R^L*,XM
M)X1O)=_Q5\)@#5-1=T5%3-6^(2Q#5UB(>G*?*K5;->LM2C@E;&2)R89@@Z+2
M9^"3G"L;H.+(Y9IW?BA%6+:P/59+*-8OT9$R&H*EP-SQS'#!./" IBTV7[\,
MEC3U^]BJ8%2=V>9-P<9QTP4!*X7\U9-4A="IG%4GY#A!O$1^%RZ53F)!:^3E
M:89GEV58F4$Q4\D#4APN .?2&JPH3QKCG Q,#U$3DJICH8*;AL7(\U:*"GTL
M$2DSR.565AM:6%Q9;8DK]X=0OB4H/SZCRK X"W2!6Q A8OFOBC)94]UY[/6*
MN>RKP>6U80"ZX)8*59#?$@4  Z),U@OARYH78/8EZA"B&Y=%JD)[$K@: VJM
M4NDL7=M'N235<BNXV8/N%.T)J*\ 62A!WRB#].%C=*V:@E&EUT,:_)N)66U8
MLEGVHE1WB/6D ?5TE.>A4)\C;U,_HZY17&M#7#.'S*(E4Y7.E67^"DXFCJA,
MO)09FM@5'[+"'#@<. XO&IEE/Q$+B0AUI&.*Z0V;.(<9Y4+P] C<9D?--4 ]
MA2C2J5Y:,?I;+XVLE*0^[G1?$0<O<;1B([^L:$_:T">DKMYIJ";*7E6]3M6E
M41B C7ITGJ[,+5XXF@;MOGCK,/5K,)<JYLQ:VQ,7*VQZ\K%IE[-*Z4V1]=6"
M@@?RUFI=<ZR=!FT$-F'1,K.I\E7%>70;K,X[(S@%BH(4M1+AB J7;D@J?(E8
M8SS(FQ,H!;+5,I'%"X#,L8\S0PA+;DE-W)S:N6C48^N6E+6UE:/W4KCIJ:]*
M$+F!@V)3"V:0N%*POMGY7C.A"VN*>9%5<1ZIXF_RQ\L^ZK*'FABN-D&9C>/F
MTEEV4#MG-?>D,:T404U%SM(GPO17@I*Z<I<0A %G-%/DM-B<0IE6  AK1>[5
MH\C4($YL1Z'>G@U%N*)Y1YN=05GE#7PPJ@.5[QA7JZ-R@F.F@M,-+R&[L_8:
MA&XH<C4F(P>4'9_G$2P\RU53RP<Z8^/G&-20\?^S]ZY-;EM9ENA?84SW]$@1
MR"Q)=ODQOM$16;)EJZMDZ5IR^T9_ TDP"0L$:(#(-.O7W[/7?IQ] )"9DDMR
MILT;<V=<*1(\.(]]]F/MM1X\_^%O#T=?*'9KHC"@,()X'HKPL6^>/LSB_-X,
M@>&.?BH_+6\U3WYYR=QI/\P8G1:^"S:.%<]?;"F)J7)J,:WY$+IN"D:G%[]N
M&]'R/,%N#7;[UQ/L]@Z,Y<\!N^UKEM;#^ 5V8.0@4^7C\]EK[:>$J0HVBSX:
M;%)B9O)A\$4V1<Q",%$><W ^>[Z:NH!N)!*0BPF=SA\C977_'=O7SIM*8ECM
M=6FJ_88Y]G_N+Q&4!(>D1%B^*Q9KX0D(@?2.-2Z4R"@B^51#C2#-H'NBOG_.
M'4RBH2'.2(^PYS/T#U^;@!$V9,8+;D0-P5Y,-&1)'K0F+B<.4B?8:[+I%>9@
M=;PG[IMC_1*\Z%<43RR/KNF[+*3E1:?7DM9!>%;571@D>.A[\[)Q^\B<_G,0
M[6LJ5ANM;[,9N=6) _R_E<UE00()B_-L]AUAM\/6?H5!9+.O-3/T0[%<[JET
M\_CSK[K9/YB<('PX/.@?NV7XYNN^#D\*(V(F.X3Q_PA7:UC'\/=,GO^"Y/G(
MR_YO<N!>):_:Z8>^;ZZ:\'^U2PHF+_[R>O: 9AL<?"(YN"X8 O9]01VK;Y(S
M0,]XR!F [U\^\P,BM45I2F?,+$W,@C@_T@G&&J:K$ ,MSH5WK*[#"1:1&TRF
M'0D@/]U->E8=,[UTVOL<0C@?Q8ZWRR:<VT4/&H371 UB_$QQ2,&*$:NAD/."
MU!J@I/A&5% <PH3#N:?+E_[<B;R0O<W@ZTR?)NSC?7?O^!#>(&\ 3G$IB]BI
M.52[@L@$"DMH[[1$&K,<1*Z2G3TZ'\3E^@MEU%=%LJY+\B,^1V>92]5Y:,!2
M?MGFFT[,]% &*GA@K2KPLA.V-W::0@FQR\T\KY FT31RL[1^]!#Q-/+Q<-Y"
MJ%*@USSZ'&AE5-;Z)K59@ZRKP7X7^QU1\ZF*1?S8@]?[#1VV\M=@'?[Q-)O]
M5UC6K@BVXB)8J/Q_BKI8Y'QXWY ARA-&NH>9C]7><-.3>_B;L/OR?^ZI98DM
MR=/PWLNV#%,?;-!K** 49F;P(Y0S3W[## BY9_\X>\*O<.9^Y6(3[>73HB+B
MH-3L?4O94&?TGO_CS<N79E+_OB>9BGSPHR^*=O%V]A_Y9OM5>!CM*RBJ@"(\
M7X0 /T)A7]$N#?^9/H#>YH<FF+2';HN":,AQ/T:;87LM;G0M641HB=F#@E*_
M!2ZX,">/_TH&$RP ?*\-UL'MA<%NH8IP&C3K+701MMM53LNT2U[K&7UHL#[0
M^=KMW0Q__S9LUWR6?O7[O[_(?YU=!*M<ZI["!/TEK ]%JN$X/?#3K(C1=;GE
M\?Y_!1&SRH9 9N58]O%ZW/L<F=\U>R]SFAW)1VH_W')0 ZW)EC)+E9;J49RS
MPJNE8D;U K<"3>>(D,Q(G<]>N 8\;[UP0UV":\%I360'ZUN95']U$X'!)YL
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MWXCB#*?8#[.3:FY3<-7@KCG<5QJ+IM:"2MMAMQ=B8_N>J]Z2!T<<=X+%#6\
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M[A>;34 \$88I^ D^9;<.'J5"QVGC&YZ=NU$ZEJ<,)S$E> .[%[T^#F';7._
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M$M#&'OHC@=[(_V+0XT0-)49/X^]8ZE$UIMIW33YFB:B8=A%4!PJ1@CU!/AZ
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M(">;#-],A<N/PSYNH!?(ZV73# D-MVB9@$+KXML7KQYZC"O] 4I[#%SUF0N
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M])4F5L7@?;G.>Q9M[."VP$%VTJ/H JA8.$>MB$\!:.* 9F?RZ/L\@B!G!K;
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MR<F+;HDV3R&!2"C+';:S:S>E8XV5YQ]C*D%-U4$9I9'DA8[!"1))8)5Q=PD
M[_ROV*3+8E%V[!G_W,R3MB/ :0FU7VK3OI%M,HBZ6;R=Y==H(0M_V,/J.DHA
MII>IA?M3<W=EZWZ>4P)T"[)^.Z$4"+2EN5N++.=%7:Q*;N%-!%DL0L;K!7?F
M*I=[6(Z'^M618 9N$DX1-S5<QW_C\^8OXRMP<JL@$6>:RBCQRI, K,F4A^Y)
M5^7@VL#<!CS!# QF\.D)9G 'QO+G@!FX"V30(1GIV?2@_U"H&TU&XU4P0]G
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MK$Y,\K;&!K9(?R706Z\L:/E.<9O10:#,)-.\*,XY/73+?AW<K 8$8)$CU/U
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M%>#F.VCR$$BEW1SP$0Y@2U6F[N#S;K*-[N;^O[=U,Y-+YO,G@P4\^QU7$%K
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MI6%.:XR[ZV_/9OI.!$=_C-S\1$N\U$VF;P59TVXV4,^;8,PZB)E+E$6<FJB
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MXTB?T&M]J]\0Y9GP8G71#I,JOXDV^[3T[Y *9E"E+X\:K6 9N17HSWXK*"I
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M"7TE]PJ%2;AB.%YX5L]2 YG=+[&W]( 7)'ZBR5KF@&2?AS,UU9*2LNLZ=3D
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M_[)I+&"@$0;;!.47U(*1*Z7PX/S03.4L8R!#XBC2A1#RJVYD_(7A^'@+1D)
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M C7V#S6T(.21@H@2FE@GBONAMRG[:EEI"7[0A'F\(=5.\(5ZQN[H(E@X&%!
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MSYHV1QEC"9FV#&<%*9\^3;=6V:+$QF]+F/B0N [DJ-J>#VK3PRCP!SV9OS\
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M314'(2+@O3_.(] EQN<)?3XRB:5B^.O-^1\;3!T[#O4$/?\F_&XVLYPQ#;Z
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M\QS"Y/W8U+(,/>B0";;!3#S",I#8U+(,/8C?S=1<7 _5E5\/)=:!5*QVX%C
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MS[#CPMB !F*&IX[6CEQ+.E:07!@\+9M =WAVQUV? Y[-]!6&1(WX#:?0+%!
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ME"[/#\.8/I[@JUGW@7!]P'30C1=CG+_$N/C^TXD8HO=*A1S!>>M F2C!>Z/
M:F>$*5'QU/SUN!O$=2@D'AV%^M13.S*E-#L@9K_'A,1R0OL6%R>(G(\L(E?
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M#JP'GR2.K6L!^QG)D,QQ<Y[>Q2YOB0Q;>:FO[X%P!7ID3!L>' A?SP[A1D+
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M#O:/L%CA>=?AEQ7Z>EQUF$SFN^5Z^"-?S_)2B8%7M<DL9@N.; 0(;UVQP>?
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MRC9;>NE;9]K6@#4$9Z(_FC121WN>O*K'WNY1J%E/SCX/S.40&.,%3)84;Z;
M:ZF; %[[SGC+.4M]^)NWP!J"?]$?3QJIHT=WXDSSCU7;Q<6RM_!\=K$S]:IJ
M\NC/\6)O/%WLG?;&/UJU-=K (>D!Q>8N3=^B:5$+=?J@"XVAW\T6]:2;,+F
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M!N>N$2ES(A,)*)-@DR%"RJ 5B\E5WTTVA/A8^5-%);>$5'>NZKR8_F<?1C
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MZ2F8)GUHIP=7^S/^WDF^!G)9O]0!6$]58VM!':9RK*H*FS[EWT/T;CU !8@
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MW?:;W":7=]],Q80"JU-=LN0F)5?Z?OH!N$C41@$42+.CH^NF;1$XYP?QAW.
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M"8AP$D <9@R&7%#"0I5&RBE*^N0L4Z/S2DBPE=*-@D\#:4>E5\,S,"4>(C.
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MN%)9S)U.9T[.,C4BJ.(0:"EEC]B-(Q#M;*2KH1GX?:]0J02\ 3L1/0=BG$/
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M7'%AF=G'LK^YK1=&,K 5NPYO-I-F)[D#0UF ;;$.^(5P9.;O 0Y4R [PK+&
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M( MX B6-)&<QXDIA]_H^UP$[77&>=[MR/(RNC"?=U7BF08HS+A*-HLFB%?-
M;XQ## 4.$$JQWAQGRK62C@\TQR^#HWOP":2==7P=-".O8FWA_@W4XH';S:98
MLI=-56MFDX.Z=KP_Z[@;$4]V\9D.)K6(NQ4\MH5[GAP2>2L+XV5+'^6]^B!_
MRE7^;-:^WY8KJ?EY+<MM4OWO^3OY57*Y_"G%G7J?K^M*<>4]YR_%(N)A0A+&
M(1(AU?_)E%[#A((B()G ::@9P\I&]BC3W"SHO5;FCKV0CR\K\Z5_!4\[O?95
M5_Y<KE: 2?V8>.%2@*4"?*<>R(U^+J&J?@:YG[S>:.A&9KO6J-TKT%()['7:
ME0LQ^23>2;#5"]PIL-<,W+_-J+D$(4\^>E,%*A_,/=$:Q3.3[\8L8-7<JQ6\
M.3?[?#G!^(6\/_[93U<3QDA[Q>8PCMIOT^['3P]%KIE]<U\TQ5-O_UJ6"QE%
M$4%20B&#U)PT99 AH6UM;7$G.&4"<:NXQ:X.9K<DUC+6Z0-J,<$?1E"'0Z6S
M0%X^/[H6GK&7'7=DG(Z*^M2_XE3H;+.3'0#U*=4^Z^E];F"9XN5:[P^7='6W
M-M'0%77L/JLS/+ZKMY#??DBY^;7(7YY-.,O.V8*B-$,RR6"*<0012QED64JA
M4%E&A*2$4:NI[TN@N5'%3G;04JA*1=A\O,U7VF@%*K7 3B\;[XYQ1M9NRS_E
M>(W,75,,E7OY64_X^JHT>ZTXTQ:5]03>2?U87^U>65O^P[+DJ]Q4L-U/VY G
M44HB ;,$,X@"E$)*XQ"* *LDS6A&[?*-V70V.[+=E94&+6F'4V@?SI;TZ F]
ML:EO,'##ZVGW(.*[+/:YKMZFNG6/TIU%JOO>&>I%>&=N"'5#>GOX@6[H-@M\
MPD2@9)KJC5R$(8H#I:VY0$*E(JF($D$46D437^IH;L31>,BUA 5&VHM)Y-W0
M[:<,GYB-3!=#X1K@3]B/Q14NA1T-3^Q5V*_>J6/AA>>'V1,?9+'\614H;MDS
MMVOQ/Z1X-&4O37=5P,2>B1R7P2MZF-'7?J]%>X=0G74TBH"])JV%=)1UU .D
MGI;9:R29=!7V -GQ(NVCR0&WG[OSWONU;"+I6)R&62(I%&E@7!V"&-)$I9 0
MAJB*HCC"]@7#3MN?VXJ]D]#>U;\+.8OKP>OP&)F6#J 8DASD#"8.EV_783/1
M19HC1FYW8=T(]-YKG7EMNCNJ;ID/[IMZ'AOH1\A_2/%B\K$_%"92:O-JLJ29
MW)O&)Z2ZS&H2'"@:!DD4PP"G>BL2< I)*#,HHXBK+$PEX:'+.89MQW,CNJVT
M-U7RO_IF92>Q6\X)YS&P,^[&0';\:ZHK0'7W G-$R)=OF&VWTWJ,.8)QXD?F
M^O[0@"M>2%K*#[+^]VY]OPWL?$^?EQNZVM^!\1C1)$L@)8&$*&)<6UT(0Q4)
M%6=I1D/B6)G,MNNYD=7['_HWO?=9KL$^8+FN4%C-L5;=9L>P;X?AL&.M<4 >
MF;>V0H-?MF+_S6"]DQPTHH^RXW1'S%OLEW7'$T>#N0)R&A_FW,*5X:/[?>@^
M])%$3$FN$I@))"#*H@1B*1,H)1*4::,UHTXE5/LZFQMC71M&>@Y/6P+R@]+H
ME-.(>7"@-6XH:0\BOL-)SW7U-B&E/4IWAI7VO3.,*$S1YM??:/%/N?GTLA;;
M/$U)FN 8,0*3D.O=F#)I9M.80$$QPP(3&F.KBZ'^;N9&#I64X*D2$Z@7Y]Q7
M'6#:\</U$(U][E2A4TL(*A%'2'/5CX(G-NCH9%(>Z%?TF $N/#UL[F^+M'_2
MPM4U\VY_TN7*;*8^Y87Y9)\[RV326A 51S3%*0RQRB#"3&A6"!$, L9B'C+]
M)R=?$U<!YL871L+2>.HO-4&7F^HRP(TQG(? CDO&!';\HYI*=&"FS*[2[%%^
MO1NPTP>JO(#F,7\<-!0]3^SDW/VDO#44G&-&&]S.0*[+BRK9Z&;G9G/&WZ99
MKQ56! <JA1@E,401#2'&%$&BHE#;1&&614[G.PY]SXWA&M$!U2O^WF?L-[UW
MU2+;U_,<,@J63#<.MF.3W"581["L!B#EB] <>IZ6R]PA.:&Q 4T,K7BYH<NU
M%-L*(]MZPU202&8!3%#"(4(T@ 13#KF*4\4)82*RJE;?W\W<>.F6\Y>GE[HP
M]P>IEGSIR$0=:-J1SO48C<PO6P'!K@J0?S[I!\%;"<JSG4Q<=+)/T=,RD[U/
M#W#^^;SD54;1M7AOZETQD]G84,XV_\_>1QTA$BL6Q#"27!LNE&#-!:FV7JB*
ME4ACE1!D[1-DW>W<N*$1O"KG<"#ZONJS>XR XTCT\\AX^([,*W. UL%5:12(
M)_)@VD)MKE'Y =1T)[ZOX'YGG'K]G.Q;F\[]R5G# Z\H][>]W=KMOO:<!"AC
M)N=S9.*\C&L4R92"21 J%:,D),(IJWQ/7W,C]/-74@.#O/HPMK/^/"$W,E4/
M!<W'+=YH?@'=/;WU'=[EF__+KPP-[OI._[H3NO6J<HXAIB\OM5,O2VF4R1@*
MPQM(_P@Q9P%,$U,\-I542<?HKHZ>YD883;R2EA8<B@MJ>5WCN[H [N<+K["-
MS!:#$1L0XG4!C2MBO+I:GCC(ZX*"IU%>EUX8Z'K=U)^5VFIY,D4I:J.E*(S/
MGC%;WKWN'VGR"-W^20M1]WZOJK^6MR^;'WFQ_$\I%I)+H9*80!:EV@:AH8(,
M"P6#(!-**(:CT"GWO'<)YT9$MX_:1'RL:FI5$E=5ZRJ9 =T)796RKC]UK%_M
M?X3M+* W';>1F; 2#5:2@[9VH*4>8*^@_5RC(JATO&DHTXQUK2?8*^K1QWRL
M,?#EC.Y=OFF]UL>"]\2]?;2.!APU?LU?Z<K<N'YN'+=?6W=2=^OGE\T"\S@.
M!=+,7]4?"06&-"()#"E10N D0-@J 91E?W-C])W$.]_V5R"T26]RL -3<L[A
MS,L";8MS1+\8CGTQL8-O)^W-P;UG);!?#!T.#/UB.=%)X968NAT5VB/4>T9H
MT<QTAX/V.AV<"CJ\-K18[=-3OJ[R:&\O>XD@-$,)C ,5F4- "EFLM#TN&2*A
M#(BB5A<\G3W,C6YK 1L[RK40[3%Z=L;M59B,3)];.(QPH]28[5#=6UW9X_8G
MKB7;H=YI_=BN!Z\-@O[X]+S*7Z5L,GIV&'^K:JCT3_?JJ^3YX]K8=0]5)8GW
M>;DI]Z$GB 29E#B$26:BIH7@D$H2PCABL<PB'O/0R55M-$GG1BQ;1:M=FAGH
M<UN^II;GT&AKWX-MN3F?PQ!.N$G?;;[W6Z:;[<B)ZOJT":TS>MV VZ?*5*]C
MOL<ID3?Z"'B/%_<MYQL%F(\$=W=$^E@=7E&SZZXL7Z3X\%(LUX]U'Y4SXGG1
MS!419EF"8"JXA$@A BE+)<Q8RA+%92AEY+1^.(LPNX6A/K);5CJ E[6&OZGV
M!7A[;7C6;SE:I /&QY+R1T5]"BXO02W^3>T*?7/^>+7-\%3I;P/XE!=*+C=Z
MT^6YAM,@-'W6>'(38/H:4(, .ELC:EA+0[?4FF]ORS+G2^,[_(_EYL?'OY:;
M^^+#LGS.2[K:9W"[+[Y*D^*-;RK)RN,"PB@D<<P2!K$*3#!<B"$A*8%$$19G
M+,2AL"K"[E^TN5'J@;"NFWAOXV6[^W^+41C]V$ K!?9:@3^U6L#HI2</V&K6
M3F:I/SY4;IKBTO[1]W9RX4VPB8\\? -Z>E;BO8<A%U=R^<1>-)49XT#;Y?7V
MKUQ$@K.8F/HD,@XT20<*TH1S;>3&:<AE%"*[ ].^3N9'MRTQS?F&; 1UN5;I
MP-/F/NIZE,:^A#H Z%YM3PM\ .1RV70]4%/=,'5]HWPYH%^ HO\JJ>/=">^/
M^J4_O#2Z\.S0G;_FWE8N33VB(4TP3$1 ($I% DD68XA301 G4K#,*2;PL/FY
M\=U.NH'9,0^QL]UQ#T5D[-VT-1@#]L7G=/:VYSUH?.+][#G%3O>J9Y]R=]K^
MT)#V__U""ST_5J]?Y7->;!91E@B1X BR%#&(!">0J51!G@4DC6F8I,IJUO;T
M,;>INQ43[.0$M:#V'MI=:/;/8T\8C3R9W>%Q<L>^ , @1^RN-B=SP;Z@5-OY
M^M*C[M52W^?K4F]JA-D)5:[=)GE)_D27VA046&622AAFIOQXRK'>A(04\B3A
M*DJ)R:%D6S.UNYNY3?"VI& K*OBC%M:A>FH/L/T3W1]<HY_1#$+*J9KJ92"N
MJ*G:T_ADE54O*]BNKVKQ],""?2_%NKJ4N%V+3\N_S$_;!!,Q27E$6 )C%"2:
M!E()6<08)!&E"BL<".)TX=;=U=RH8"?I#5"-H#?5]7R^^6$;DF4!L)W][@>V
MD2EA)V0%TU;,$?R^+J/AJT)?=T?3UN>[J/!)=;[+;PPXMOR2K]_3\D?M2:K-
MCY]R_2*_RBJOS?>\3HOVZ<5TMG,V;;[F2%":T4!"BF4,D=2[>X9)"'$F<$B1
M2>1LE</Y.C'FQC%:$<BU)J"H50%%K8O^M\X5M,F!9AM0;A,WJDJKYO&ETPG@
M\+&S.$2=9$1&IB^M S!*@$8+T*@!&CW ][S.[WBO0*T+V+NR#RAK-'Q ' YM
M)QF8B8YU;69+V23@/)XHODY^K\:S]VQX>.O3G1Y?C<#!^?+UK0TS>>LJV$U]
MRGU"*LD%851!%(491 E'$(=I!A.4*4Y)DF78R=H]V\O<%J%&O*8.BF/=D_,X
MVAFU5Z,S\H)0RW>S+1L[2C:27@P\6;'G^YC4@.U5\]AV[7]XV'S?U2WY;.J8
M["*@-/WPIOIQB!)$XRB"(F4"(DXYQ)BG,.8TBV4:(8J="KI=['%N/+"OTK.J
M:OBTBB'=Z(_*$C2"@^<ZB:@;4UP> 3O6\(KKR RRA[02]J8=\;@7V!^;6&/C
MB5DN]S<IRUBK?\PX]B\./&#;YMC]O)]33?"EN%]_-8G#C8?1.UHNR]_7.2ME
M\=/<VE51F<8'?\WU6Y5Y_9ZNN$DDJW_\FJ]6G_+"!-<O8I*QB!,.PS V-9(2
M"AD/8YCA1%$B$Q4QY71.-[;$<V._?5[K_2PU&[NMTD#O#G=J@TKO&]#6O Y;
M!H>Z:^-AKSWXP^@/&@ <K_W'_PI9GD3.Z8LQ]H'F?+X3[F>D4XV3KZ/6T>6=
M]L1V*OA/#GXGZ]C]NOFK"8>Y_6M9+G @*8]5"BDUU>!I8$KZJ00*F;$L#3A-
M[>* #UJ=VY)B/'"6Y6;)Z>JP5H(1UN$R>0_;Y;OC06",3*,#<7"Z*C[1^XJ;
MX7U;DUT$GXC?OO<]_>/ 8"):_C#_-W6(?]*5'H*R<G!?\HT4Y@^W:W'X0>O)
M.M+IM" H7[T(S2<?_^)5;=VO=",_*B7Y9H$EX23B"@8:79-Y2<]VG 4P#94D
ML8Q0&I'%)M_0E9U).JWX3F2R4V+$PV^Y <M=>5W1+J];G8E7>;?-#W*OM&/L
MTK1?#SMS<[Z#/C)I&E5NZONHED8W8*\LJ!\Q W_TX>$;-0K@3&WF&[## FS!
M  8-4,/A,5#J38;15S#5M,)/&W#U)@-S$I3U-E)<FQWG(#RL$K&ZMSI*@Q(J
MGK%$Q)!P%D.$9 3ULAC#,,M8S @C'#D=+#OV/SNKN)7)YD !S49/SWKW4MF&
MAM7NC:,5J(-!]</?9?&T7%<7O0]%_EC0IZ&);NS&S6Z!&G$T1EYA#N1MEI'Z
M'KV&?)J4,TZH>4\D8]?[&Z6'<8*F.^F+6S-^BKVUZITUY<X6)(F)8'JC+UEL
M@KRH@IA@ H.441&0,,FDN*;PVVF7<V.^=A$XX:,(W!F4[4C++W:C\]1Q<;A?
MSI33ZTY%?G6EN&YT1JH:=Z;#-ZT@UPW I6IR/6\.SS$J"[ZDJP?Z+(O&(0Y3
MFB69BB 3,8>(, 5)')O8^8A01$-,W4RLL[W,C4[>Y\6SJ>PD3:*G1ESP;.1U
M3SQZ"JGE]OQ:H,;>1>^1J00<*0EI)P0>$Y&>]C%Y,M).-<\E).U^>*#''J^2
MENN-(9?+ZLKBB]PT3D*+-&,2\0A!))2 *, <XI1RJ"05:4*X2(+$R7&OI[.Y
M\<!65E#LA'7TX>M#UHX'?.$U,AWLH-K+N<W,9K(>_DGU5  JUYO.0HKE!GS.
MR[W_GT>G/PNT?/G^]74UK0N@A=(GGH V[PPM0_9>-U+0U=U:R+_^IWQ=\#@5
M6<A3*$+*($J22&]0LAC2"(4!)9*& 5[\E 7+[0N0'?7A,A7:/8TW(VHQ02,G
MJ 0%6E+7DF/'8/;3AA> 1N8*9V0&E!;KT/Z*DF+'+4Y<2JQ#H=,28ET/7IE/
MYF.5^=0D8,S7YFRXNC4G!,5!%' 89SPP)><%I#)%D. $9YAFF?YA4'J9<[W-
MS3JH901[(0=FFSF+K.41J2^\QI[QQU!Y\U!P0L)WAIJS?;U-PIH^M3OSU_2^
M=.T5SL5R5F57/:LZ_5*8L23-< R)D)I;$A5I>P%CS3),QB1+4J(&7NY<*=G<
M>.B@@$&5+)GUUJPK]T7KV&G1NH&IL[P-N^O=T(2#.3))GHYC?^W!LK?XX A9
MOWQC[OW.Z5JYWN@VRA.<W?=4OCH8>K"\TK^:\]3E3]GJ=%__>G\SG/$LB3-"
M8( H,CM%"IG,& QY;")(69H0JT+5 _J>&ZU_7G*3$+*N6[)7PW# 8R'K87,]
MCK8?"-M#ZE'@'?WHNB7U0377O=R:/L=):^T,F+>#;ON>)S[^=H;D]%#<O8FA
M7*9U,OOKRG5_6?ZS/LXT/RUB$JK 5.,+<6CRNK$ 8DXE3"G"&564)@R[<5=G
M7W/CJF_+QW55LES/H0.QG1FJ&UY;1O("VN@,U)(2&.%NM@?C]2_3I-B_")4W
M[NGN:6*NN:CR*;=<?F5@X+QQPKOEO'B1HA52M+T>RA(A:2PBF(2IWO_2!$$F
MH@1&!"<QBF0BN55>)[ONYL8HM8<BK<5US%MO"; =H?B#;61.J1%K)&T'58YP
MS68'BJ]0^/[.IHV#MU+\) C>[JWA":0_:4.'KOZ7I,4G_4FY"%6( DD3F(8F
MVXY",20HQ-HR45$2\#!*E-6Y?$\?<R.,78;D6DY@! 65I.X9I(_AO'SEY@&D
MD>EA #Z#4DAW('!5"NGC-B=/(=VAU+D4TEV/#KU+;W(;)Z%B,H@)#$PB'90*
MO;E(L@!F(N$1D7&4""MKX+CAN4WCYF[8+2_T"5J7)^Q0#,:^*+-4?\"-^,7T
MSK87X5.F<NX2__3:VTNZ9N.5I U^DZ]&KKE>HM^]?J$F1=Z]VG_\6EW0QB%E
M,9$$9EEL?%I"95QD%51<1D3H<4Z04]$_^Z[G-F6-Y* E(ZCE=K/5'9"WL]O'
MP7/DZ=\!I??;<G=P/-GR#AU/:M>[ W)LXP]H81A'&3\]6OYX*/*?2R'%N]??
M2RGNUKM$6_LJ>[NDD:%(@A3)&$H6!1"QC$/,0PG#-,!)R ."F55.D.$BS(VS
MJEANM<K_+('Y,H!\ETZ.[F1WS-<Y8%SLF&Q<M$=F-)-<H0)[*[ZYM/[%: "6
MZ[^!?1J_5LG1,;*!#@?1$_,-$&!2!AP.T#$37M&2^R;IO3;];@M)W^="+@2*
MI3(N0R(A(40JY)!F3,$D$W'*I) XY+:;I';#LV,OLT<PP@$CG?T>Z0"LRWND
MH1",?7EBI[W3%NF<JH.V2 <-3;9%.B=^>XMT]N_#S(]?Y5K/X]7M6MR*I^5Z
M66[J:]>F?N4B9CA-N-X7Q9)(/0>3$!(A).0\5$3RE*G R6WO0G]SFYJ-N)77
M!CT0V,V:N 2SG>G@$;R1)W4;MT-9MS5Y_=D"EJAX6O@O]3;I*F^I^O&2;OO:
ME3$&GY=K>:=_+!<)2?2FA"90I%)!%&0IQ%4 ,DJEJ5N;T,2I7,!I%W,CCE:Y
M5B,CJ(0<6L!V#Z0=3UP'S\C4X(C,\-"!$^5]QPOL.WB;(($3!3LC TZ?O*88
MR&[#JV(<!R3!,$-A I&) 22<Q#"341JG4:00<3HT/6Q^;E/Z]MNWC]^_#:GZ
M,:C<QPQW_[5@(Y;W&+6NQUL6]+"KY''E!KJJ$[1W$W_0P_Z#EJ:PG2D/M',S
MKIS ]Z[!(E,QQVD XXQ2B'#$(*,H,M4K<:"7YH@E5M6I!_4^MSG>#MK8:E 9
ML54]LYT2#L7+G,>CGR-&1WGLU=\.8)><:C[F@'V=N#&QGZ@\W ACX%8;;BB&
MO27AG!N=KA+<4'T/"L -;F28J?=!%LN?U:[PTW)-UR9%S=W:Y,>K(E4.<N97
M:9 XDZF2*H!8$0:11"&DG".8$I:B5)N%2A$76]"Q_[DM)!_D3[G*G^LPE)TJ
M^[)&;F:DZV#8V9DC0CSR*M)"="<Z:,E^6(7$?RJK@<AY,F==>Y_4WAT(S;%!
M/+29 1;S@RQ,2 !]K"IHKDTJY =#K]_U<,G6/*[R@-ZO;]=W^AE>K='O7EL_
MFT(A[_)B+1<\B<)(H@!*'F3&NR^&C&$*61IF"2$9"22R-JF]BS<WJMPK6->C
MK50$SY55$@/1(E)>9SA>:V,%+'>:F2OH]F]&4<",I@XFH_\O@84=_Z9#.S)%
MMT:U*@-=CVJE'JCT ^TELDZD?+\&MVNP5PR\>SWXK1K9=V\^L@Z[A3<=X8FV
M$^?G;SW2FVJDKYG#ONI1CS82O9L2_[U.MVL9#;&#;<UXO0STQ\O7.^^QNS7/
MGW9WM!$BBIOL!5G$4X@4$9!%DD"E H2S4$DLE4N9GLZ>G!;H"2KJ?#=]@'6^
MAGN_NF4E,/BE">7[VPU82\<DW=U(VVU?O. W\BK8EA'<-9@U8GI,Q'T1"E]>
M;YW]3.O<=DG=$Q^VBR]<>=5]K[YM<O[/'_E*OUS6B;AVMSXL"4*9T@2B.-7_
MB2*]$U":.'"6A"QA"G'L%/IKU>O<K/S]M:_)A]02^]] DT[.XEKIBD%PO#GW
M!>UDE^E7H#K\BMT&)=^W[KU]OLU%O T,G7?S5B\/I*<75B[%DA:OYIRXZ:@I
M*RJB)$HX9#&.( HB#%F6(4@#BF.)8TX3I\1,G3W-CH9HDY'-".A48/0RJ)84
MXP.JL6G%!25W^KB$@"_*Z.QG6IJXI.X)-5Q\81@=["H>OWO=_?@_EMHL*OB/
MU\]FJU5]C3DF6#")H8JPR51BJH6H-(9AF"@N4J*P=.(&NV[G1A3[DN9@)VQU
M2?KE]O\96)"^'W8[]O /YLA4TH>C=V9Q0\=W0?;^3M^FJKH5$)VET>W>'L9&
M#T7.I13E)RW\;R:TLKK.>2CD<YVPLKQ=B_=TM2KOU>U/NER9R^U/>6$H\9LI
MSEX]OA $IRBE#(H8I75:82(H@7$21IBF 8HSIVMG+U+-C<OVBIA%?;G^*<O-
M@(23?D;,CN<F'X>QKT,:?>KXU+U&-Z"E4YT<U&AEQNF#9!NP5^8&[!2%*B^@
M4=4?<WK%VQ.Q^I%I4M[U"N,Q+?MMW%-*C3K-=Z(R)90@, S2#*(LH) Q@DR*
M]RP2$1:A=*+A\]W,C5>/\CM4OB9#TJUW@&K'E-=#-3+U#4#I^@P88V0F[^CD
M;3-;].8,O_"TUXP5C9_.V<P(/.1Q%!@WF)"D)NJ+0YQ1!'&*:1#A*,/2RL=\
MN ASHX[CC!5J*[KWC!5]XV)YT38JVF/?P/5GK-@I\489*RQ '#=C19\ <\A8
M80&09<8*FY8&AL4=65O&<M];7*W2OK\6FI!_7Q>2KI;_*86AYW=2&_/R._UK
M$:0*ZZUL %DFD+:A$(74D&3" H23D)&4.R4<]R+5W'BSVA25K4T1/=@4E>;@
MFK:*7C\:W<#+3CFPJBI5LDH_L*%_.<;S>1EIA7DD8Z''ER(.D;:4(99I"&/"
MTL#\&I%PL9:/IJ'O<QQP4@_XB8CCC7LE,MC+7%4<=<T@[6?T[!;-R6??R.NH
MQ6G$#6B7FS\[8KN9][UGYKD'C_K$VE?,J1>9I@U5]0GC282KU\:'K=-?92G-
M&?;M6K0\"^_6U<%*62Z8'D4B$8,B#/0*C"G1&Y90ZL&EB<12D-!X^-D3\H7^
MYK:V?LG7D!M3N6CDKLXCV\Z[\D+NED&HV_&I1RQ'9LJO;?3:3N[+-6BD]4=]
MEK!X(K5+O4U*5Y:J'Q.1[6N#;[7$"]]L@R*5I"(U8?6)RB *0F/2<VW2<YKB
M$,7FSXZW4_O6YT8?C7# V.#N-TLMU*QOB(9A,?Y-3P6#_ZC#LQK[NVMIM3WU
MG<FI6F?N/LX\-+!2S]85^+.DI?RZ?/RQN5>_E[)*PK%068@SO0^'#*>Q-@*X
M26K#$ABD<9@$8<J2S*D(=F]O<YO#^P2N*R,M*(RX,%?PQ:0(J)*4.!;MZ<7:
M;J9[0W#DF;\'KQ+T!GS=HJ>%!96T'FOVV(#BJV1/;U_35NRQ4?ND8(_52P//
M_O8[EZHND"G)6L@?VDQ>_I1UK,'6& @9,0%B,,Q,!3 6<$AH$L% AAA%J<P"
M['1':MWSW$BF?4I0E[DZ$+TZ*' \V+$>!,O#FS&@'9E];N_?WX';S:98LI=-
ME;AEDX,'6E297+S;(LX(^3I6L>YWVJ,35SA.CD><&[C:![ABO_<KO:I7_J>A
M8&&8!<;0$1PB3AAD,0UA%*(@EAF/6>!T^-'9T^SHR$@'*O$&!01T0VI'-EZ
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MF=8@NQZR$T/-0Y/#J/A]7IJZQ":19[-S"4.A3(H/R'FDMXJAWBK2.*.0)BS
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M1KC4VZ1$8:GZ,7_8OM9%*^VQ^ZQ_^N__9?N)_H_QB/SO_^7_ U!+ P04
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M^D?"/OS<&12T8$-(O,/Y>)9?3O,+NHA'FFY&S3."MIQN2%:O5.L4*&V9LHY
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M/QM//_UGF)SB*'HCD\\,LF1DB!$A$ 2QR0<60H@.37HL96L7[&Q$6 ]8V@L
MLT-+HP.(/?L:QO3C";Z:S3_0CLX36L:X>(%Q>?7=Q:NTIF,G90P02F$US4E"
MX-&"S9H)$UR2X;$TH9T4U78D#M,[XW"P.Z2$>@!@2K5\<_$>$]*9HGW^ALN+
MO42?''I'>M]'5ZLY#3@I:A,F83E77EK_V / 3FA[A)YA^G <$%JM>-\!CEY/
MOQ+5L_D9;6&DHR##DEL(6B'YM(YH%TD")DF;J04Z^K&TI%UP<WW]89IS' XG
M._.V UR\77[&^0V6D(9TA8Q)!XDP#(JA!2_1 ('="*^0-&AK8_LN%<.T[C@<
M1O;D<P=(N45\P9!RX,!D2*!4R1!"!;S/O"05?<B/]7+9VR,;IJG' >^:G;F[
M.S1FRS YJI7\VVR:SG?(;5)<6PF<3/X:5M40D3R"F%4NQOD4TF/ODH<TE*^H
M[,%6;N/N'U9 '6BG=_/9%YPOS]Y- IW(::XNZ)<:9JMWL@M%*!TE.*?H.!G:
M4)3(@8X2*HPL6M/:3GZ,GA[LY":P:L;T#@#TEG82:@G"&PP+?%^[!;\MOR]P
MQ:Z13%I%:R-85OOF,)D@H.' O2D^!BF":FX3/490#R9T$PBU8WL'&/K+;);_
M&$\FHXB*,\810C(,2&%&\#7HE9PJ10HG6&D-EXNU>S"<FR!C)V9V ()KEOZU
MZU0H-"ZR H%I!0IY)K<0%<B F0MEF'2MW_;N):0'N[F-XMB;S1U@94W_R).Q
MI1VSP*4CA&M!"#>UD*5H9F3$S)H__*Y7'J;EW<'>L[9B9 =^TYMQB./)RO(F
MZVF5?OQY-B&F+ZHEM3R[9 UJQ$A_'YQGHMI2BNSPR(!SHUD0,C%L[2UM2MNP
M/M+!7],/(J(.-,^U?=T)8QAB4V8<8M"LYKL;",4D@DCPM2./YLVOJH>I&?:5
M]##2?QAB^XBB U!=/)B\"V<UV' 1S2*E;A4GG2Y4C6$994DK!P_:FLAH!\F$
MYK&>>RGI!DQ[R?F!5ZH]F-X!=%Z>?)G,SA#?XZ1.]+G+JU%)R!,J8HJ16'E4
MM7@M]4Q91S1"HFJ-HB>)&O;R.Q"@VHIB0&S5'--Z/.:GF)_3'XY3F'R<DX7P
M\ML7G"ZN]F.R8M8H#U*IFI0B#<24'!CGC;'9IRQOI23>35_==+%A@W^-(7,0
M#G>@C=;.Y7I?]^#?.V6"U8X8)"TH7QO8)<\A.,5+-3(%?ZRL;G=G_B&*A@T'
M'D@/-11"#Y"Z$>B\V,]% YQ1]!$M8PI$8HF<7Y<A)+(GM?-:JX*!J\?:2>X?
M8+Y-T;!QQ$-!JIT0.H#4/8<B!$^TQ C&E#H>QF@Z#Z*6+GMED4Z&2(]U,6[C
MNPT;8SP0=/9D=@?1I@? ?RUZJKQQ23L.GO0GX3]4Y8H)9."^:)0EFL>JO1HJ
MH5[>X(\2 &@KF X4TPN<C[^&VK'K&O^N;<?HZ+TI!7C@LN;@,CHXM@9LE8V!
MSE .K7'V!$G=6.6'0UE+H0SMU%V>D7,?]>.L9K6\+>]F2]H*^1^O3I>G<WP_
M.PN3\VV>*^W?</FVO%XL3NLLW.>SQ7(QTMH)RS6=)A'JX<H"O/>NQH@95YEY
M)F\5PS_@_;6DJAN+OCT@AY5@!^IQY=C<?PB+ERYE5:!:%F128.UO&#F((K(4
M7I;'N\KO[%GNKA2/X0(<\.IM(XH.0'5M$R.TV4I? F3,!E0,&9P+%@+9MYGE
M;$MN'9^XMGPWYO]1GFRV8G8'7D!M=35>GJQJ\Z;Y^6Q:#4^<IKH5763B.100
M*'GU?TF/"MJ/3Y:CR%QB>:PMS$ZED@^3,VQRPE%PU$H8'>B?1S@4L^&UG@$*
MF9B@O)!0<T.!&:5+%#RZW/I2VS-?H7FWF:.BJI$H.@#5NXMU5UM:5Q [0_CG
M(4#(FCB3>(08.8>H;?3%QA)=ZWKN>\@8NHE$&PG?R>?>C]T=(.9:)\<U_4$Y
M46SR4)CS=7BZ@, P@.79\92%,.JQAKJ[WFG7:1@Z1>H@6-F+T1T Y5G.JRRQ
M,'D7QOGU]'GX,B8;Z]JV1MI::8-!""AH1Z%DB(5Y8'7*H14"<VZ>M_(D5<-&
MJ@X$IL;"Z %>*9V>G*Y"&RL?LW8@GN-GG"[&7['.:#[!-[/%8A7,^!B^C70=
M6I"*(F\ST/9,U."TB9!L$HI'\C&P]:VV)8G#1J0.!;P#BJD#%+['91A/,;\,
M\REY%HMKVWV!99S&]4W,\(*1@P\U.=9G)$.3_F4,%L=29(FU-LZ?IFK8R-.!
ML-98&!W ZRZC1L*J$GF)X I6<S%)B'6XGTPR>C1:2]>Z\NDN%<-&H X$GSV9
MW4'HZ2GGE]@C8\S.@7 F5Z?7@^>VYJQF%Q/J%!^=J'6(,H=AAKD/%<S<7RS-
M8';DCJ6_3\,IV:"8WZT$\QF7-9?QYJY:]3%]8*VC=#?=9)_'['G*)*DPBP:T
M+QR4DQ%B0 2?63:N#N5X=$):KSU/;T92B-=OYZME\\I7?H?SU9B)D<E)<J8-
M>$&WO&+!D%,CZ*!E+SUW05G;OC'!)I0-'=YJC)S' UU-Q-.!.79S5^M!)L].
MEY]G\_$_,(^DCD$'8A-::VL=M8 0>('B)?,IH':R=5W7XQ0-'1<[*LCV$L?0
M^3;W;.4%+L:?IO7,C#0GXI'LCA1+S1S*&2+9GY 99\7%DH,I3]V:3R\S=.#K
M0&AIS-].U=#U>4JI^.2\2Q TV92JYNU$$Q4D:]$7P9+PK;,3GB!IZ-#6 (IH
M5X%T@*]K4>$';VZ5E?&!6]"KD7]9<_"U6:<*/BDEN93-V]-M0-;08:T#XZRU
M8/K"VIT+G&<K"X\!6%K-^^$.HC4(@N>$T@KN<FOC_1%RAHYY'0];>PFB1TQ=
MU\4H W,N(DB/&E1-]X^I(%WX0C-DA<7;R<CM0;7MS7BP'*SCHVI747Q'@WH^
M?*1___KRMX\?WKYZ^^[E^V<?7].?-HMT/?#QAPIN;;*;1O&L]7/@)2:O@OHH
M3)%<@<[5D8M:UM%.#"06P16&%)OW_'^ E/W?<\X_\&/M)#%":TK6A;2IK-WW
MN _@5=+ 4#);O(LRMP['WZ1@V"A4"WG??<39F<,#WER+^;+V^LRG:4E6'<Z_
MCA,^^S9>C'2MZ\=2FYUS 8J1-4=*L4Y )#8$MRJIW 0AM, U=-!W5\AX:.U.
M(I0[R''6D*E]@&+U;K3>P>+%["2,IZ.<8R:J.:"IU?F._A6RJ3V$BW-&NVS4
M1D[^9LBX2\ P\&@CT[L V9/!'1B]YQOY%4\BSD=:R&B,$R#)[0.EB&X?8B2-
M&DI4,9-V;6WEWB!@<'3L*]"[C9AWY.[0D>5:UQ<6G]=U?F?O\2M.3_%63>"M
M4L#S74K44?)4IV>B Y6JR2_(4!>\D.[U*7H9GK)@]R-AF/>+]B@ZHB"&AML;
M8M5T@<]G$_J3V7PMK.DZ]^]\SQ>'"&/0AM.&B)^U"-K73K((*)%Y)I(PZDD'
M:;LEAWG@.!"<#L/H#BZR2\N/7%=\35\N1D:P*)Q.D$2-GVMN('HZ"K9(NO=K
M&5=L76)PEXI.'E-WMX<;,;@#B)SC^ZJS<3!<RVPS:%?3_ISEX*2,8$2,T5F7
M8_.J[MLT=.(N[2C3.YFT>S"X'X"\(C[5FL^ZA;^-EY^?GRZ6LQ.<O_R6)J<U
M!%F[6M/_<LT\ESE[U%@@&)_I2)%YYQR9=S%XZWC)/+C6G9UV('-8F.V'B_M!
M=C A[8S#KSB/LV9O$8O5M7_1K_&2<\DD-$;0R<1Z\8NZ)YLS&74^&=H3-[)U
M[.\A6CJYV=JHKB8,[T"%U7V\+75&QW6K\<-LDD<F6EF?<\&PNA,K"[CH$F@5
MG%4VF\):#WA_F)IA%5(;:=\#H0:L[P!$[TD:1$ =&_V"M.UDMAH>=<ZLD0[(
M5&$($KD"I>HD321SLAX^QHS)"EN7DCQ*T+!ZZ"!0:B> #M#T%YSB/$QH+\_R
MR7@ZKORI[<XNMN-JG@"W#KQ(=?(S;2>Z8B$+VF7TQ*[4.M7\"9*&36D\"*):
M"J$#3-$!6<Y/T_)T3I;>\\]A_@D7(YY-U)XC1)OI7&2GP7/)JSE@M:0=.M?Z
M@KN/CF&S%@^EC_9C=P>0N<T8@KQDW@LDO5FK"&H,S5ON(3&R%*6.+)1X8%-Z
MV,3#@UE!.[.Y@V+(RZ:O5U7FHQ#H7DW54S72@&(BD"-I#.@82#FRE&7S_EOW
MD-%)HGT;?VM?-G> E-]FT]G-79QC_O(<>:]\D(YN40R9S/XB(2*=A!"C(YI5
M#JEU)NJ31'624]\&16U%T,$E=:WF]U48SU<YVL_R_WNZ6#6C&T4CDD%7R#9#
M3E9:L. R_4OP4(3ED7G1VO5ZG*)AW?C&XG^X_GI?60S]O'K^B/QZ2I]'IMPY
MEVZ](E^^'X]"249$R0#K.#YB$C%,TE=92BN"P5+X9F^LVZT[K"-_&# =FOW;
M(\NOD37%3ZLI4LT:)S_(OY$L0C&=%+@8R0),TI&&UP%*9H99[A+WK:_!QRD:
MUI(ZK-9J*(L.[L.'-Y(-\<5E3Z<B13(64U@5 ("2JDZ%\49B:YM\/SP=S*8Z
M+)[:2* #<_W*T;AX.AQ/3VE3YY[(;+KX!<ML?MY=[&/XAHN7WXA_)+[Q-,S/
M5M9J[4->'QUGD\F*'VN%/HK<9.>4A\AX(@8P TX+#TQ+G0+9M:EYWN0!M]-)
M.60;%Z$7L7=S FB+YR?X%YQB&2]'CB7OE)9@5V,:N# KS0#H5#;D>$=76A=^
M/T!*)\62+9&W'[M[N()Q>2U&4T(QF6<.4L986YO5U'EI@7'K@I%>"M&Z'^8-
M CHI?&P4OMB9M1UHDXMVB1<EY+^$Q3B-R&6)P3 -+!E9"RH<>$V6!Q<QFRR4
M<KQU,YM["1FVG7QCG.S/Z@[TR.U-O!A/3FL7%51"8S0>=# $>UO5H7,,HE:*
MHW$&7>N6$ ^0,FQ/P0-C9A=V=X":O^'XTV>B^]E7,M<^X6^G-3?];;E3%;X^
M$J8:9)$<$<[(O5&Z)'))+$)66"P/+J3; Z/WQM)6!&X6+F7?"<0.)YM^@7=^
MC.YV)5"6>&5H9]S+ @J)A]'5GJ]*1:-YRKZY&MN2Q,W ][WDFA]2/M]IUXCG
M;W]]]_[E7^EW7O_GRS=O/QRF><3=58[10^*)O;5OC;HVS%?3G^ZTGK]J[VMD
M,<4JB%994+5_4G0R0[*JR"P<\M3:VMV2Q+;>7](VL$0'-F=6\^AS B>"@<)$
M#LJ(:)OO=WOO[QCM3YNCXW'7<!N^=W!W;C*R@>S2\2S3S^=UN/(+7/_WDG>%
MDT'@#0/TFIP;B1Q"$!FR,XF[(K25K6OW]J>ZDXJ((\#SR!+N'-//OH;QI!98
MOIK-ZV/N!TRG\W7C]LM\@<M1)9PIY$)HL#7HIR(Y8-XE"\[8$H576=N#C))M
M0/NPZO?8F-L"\@<#0.? I^V2&7X^ 3J=?9R'Z8+XO*XI7WTW6</C+A>RM'95
MO,YX37)P-H%'Q8&C4M9;:8MJ;4H<9B?#*OV.#\61P-'Y$;G<DXB"!2XL>.80
ME+<%8JEOAU)R)X5$[8X)^*W@>[!<F([ANY/@.GB7N6<[EUNA>T;&R#@HJP.=
MJU#KH&DK+!3EI#9(']>\Y.%!<CI):#^"N=Q*)M_1%)_KP9L/']\^_Q]_??OF
MQ<OW'U[^S]]??_S?!XE,W;/,,4)33^VN?6SJD8%3A9$6C)I#D4(12M& 4[*V
M[LFZ1)6<SP>,2&TZWGN/W:\;V12,+"8E05H=00E6:O(U@E$BN#J/-.C6M5L]
MM4!MCX4G&J)NP^\.#+)+ZM<<J>IW-J5O%ZNFC\H9E"'39@*KXX.,A2#("XOH
M2S3<QB#;ST)\A*!.L+2#I!\"S=YL[P!#M_9PWGC-<,44(QM3FT+L*2: B^29
M)*.CB2PKEEHKGGL)Z00S^POZ=MK"WESO #K7VM>?-].+61KC2 &+DG-]Z4P0
M.6-@&=E^,9,'45I?RW>(&!8R#03[\)" ';C< 4P>F*Y^OADG749%_D;.LLY/
M4 %\;5S%3;3<,]3^=J/+O2'S*$'#QKG:PZ<=]WN TM/STL\WYKE7Q!D+)=86
MD,0A\,YI\CF9#AJMC:8YK#8E;MB P $@=A"I= "WVR/3+SH.JRQ9E!*,\;6)
M3,VQ$>@A%LO)W2@*TZ%GUF\!I(,59+4'4@-^=X":>S+ @O6(KG8<*K6"ILY,
M#W5.%%>H2S:>OFY=&MIYB]XF_M=N#.X (K>C_*^G=^,;[V>3R:O9_(\PSZ,0
M$F>!1RC9BMJNQM36Q@RRT\IGJ9E*K5WY+4GLQ%';$1%W2YH.)IX.T'<W:S04
MBU8;#8F5&ISG#&*."KBVQI&.)3>WN7[:+6_W4 @ZJ,AOZZ^]^+\S@+ZL'ACI
MJ,R7C>ZYVPP:&2<,YR)"BK6_423'PMD0P&I/1XY<##2M+:.[5 Q[SQT52/M)
MH"\DO5XL3C&_6/7>6[^%K\_)12D8KIXMR:E8B7+D1!8%90+KZ]1-ZR149Q:8
MC<YYXXU+K6M@=B!S6%?OZ%@\H Q[N#?OW^*J8](#._36B%C(83',B3IOF'98
M)_:)'#&2S@^ZM#?\MZ5R6#>R Y"VDF '&+W*,EM\G#T0^UOM--[>Z7LD5B_&
M2SQOZ;UFS7M,LT_3U:>LN#2RF6<?##EN/E3CVI+C)C%#5)B5$;*HYNW5#[VG
M81N!'!/_7:&C@]/R:,(2&L%4$.0V!@,J:0?.^PP9F>3<HBG8NEW(ODED!VL9
M<DR,MI))!_"ZZ^BQF+D5TH*.C,Z'9@B!URNE")&5#,ZDUL.:.QNJ/JRCO0W_
M]W2/7D[;=!V\Q\D+S/M0>Y SC:;6R7&(:95YH(613'JEVT_&WLG-/ECKD8'=
M[&TDT!1'1RZU?O;AKZ_>O/W;@4JL+S_]**75]^^E?=IJ[8'Z:C+[XZK1O)>*
ML\0-:&8XJ, T1,L,&.DQ"56?0 ^8K7J'G@;%TO4SW\UG7\?$N5_.?B=C\?7T
MLM?YL[0<?UV7A5U5+Q34#CT@^?9T_+*'X'(&@U(5X:(5OO7PD^VI[.0-8U\$
MW5-C?4AQ=6!GT=;*>+DJ(><VBN 368@\>%#2UF&Q/$$(-CIO72RY-="N5A^X
M3?B!Y7QWZ/<N3.\ +C>\X.K"3M-X@C=:$7R<;<U*8;/,*0)/U37QQ9!1R1P$
MD<CO%4;;W-I=/,0^!FY.?EP(#PZ$3AKF;S-U?62D"Y:1Z6R"K76"NH!WM:2K
MUF DIYWG!QM\/ZR"'1XN]W3;/YCL!FVYO\L\@5AG[1;RR3(ZNH4XM^"XTZLY
ME(P<O%#D5L#\+L8Y=(G)0TBL [OAB4DI**Q3*6:01B=0I=1NDZ) TB9XCB;D
MYB.R&TRM.=CC<S?(/(#X]M6-'P\\P_;UE)B:D$QS91S](R*$5&A7D0>(J[G@
M)2 J1%YTZP933Y T[&MS=ZAL*< .=.2SR>IWSEM3WGE.OQBJP3)C 9,"U+ER
M3&2(7A@PQEBEN"3+O?DK\D:4#?L6W!TZ#R#.#D#Z FGE- [G37J>G<SFR_$_
MUOD>,J#6/$O@3#FR1+" \XD!UY%'0W:S#ZV1^0@YPS[[=@?'5H+K (//%@OB
MX\D7LD0J@R^F#9NH;&"R@!:Z)E#0O[PV&9+2Z(1G,LK63P7W4S+L*W%WR&L@
MK@Y =S$U+:V<M.M3KG34D;80:Z*P!-+9!GQ*ADS@K&@C7L7FE=L/$C/LRW)W
MT&LCM"XF*-Y]M;]DVGGVV27'A!:&&^<!,WEB2@0/3J?:U<4$+:0O"5O?PYM3
M-^P(C>X0>B"Q=J P[^[L64JS4^(\\1W'7]>UC!Y3C"* TH[5SGD(GB/6"M@D
M@JXY1ZV'16U"5V\%56TP\23T]A10IWKR]?0K,7TV7T7Q2:\;1 '9^SI 7B/$
MVCO4N2#0"J;) 3LXWJX1U%O!U9& MJM(AG]8>81E;^KW[^O,D;>%+HV5V;ON
M$7KS5ZX%4VO-&8O.>&#"U;<D8JMW(8'DAI$+)H1DMV*,#SR\M*6KM]JKIK <
M6HZ=JLF5K7QEYJQV/3*H;6$V@,AU$F7-#E@=SA*S9D8XQ5GKAYG-*.NM\.I(
MBG-O(74*O@O+XUTX6YD=RDNL_4[H/JB7@O/$L.P*!,=2QF"QQ-9O+T\2U5NM
MTY&-PEU$TZ4;\O+DRV1VAA=OZ]?5>)8RQSJP7$<?:E6M 6^5!@S%.J$5VL0.
M#KN'Z>NMDNE("&PDL"[!N%+H=,3FIS<WQEA@KNA(2KP.ODO&@*N%6[1ASXM&
MIT/K=A ;$]=;%=0Q[]X]1=4!!C=/%!TEDPTR\O:1\5([8@3PGDO@G/;&N).Q
MM"ZYVYRZ87V4(Z?;'DAH'0RC>&!G-4*P>("1,BON?1"00FU2E:V#6)L+J.Q-
M+IFI8%L/4MV>RDY:QAVI(J:5N#K0CV3G7E3YI_\Z'<_QX=%=+S N1QR3YY%,
M81-$'=9E&#A3',AL#,:H@M&MJQ>V)+'+VIIFB+E=6W- \77A/*^RVS O7A&G
M?PW+\[V\F^.7\YW7*35A,EF\+0]O?22CSQR]($NYCBP2B6X)+ &$E2;G)#FS
MK1WL)H1W661S,"P?7=0]Z-]KFUYGO3]Q@EV40:FHH/;ZH_W%#$$F"Y8'.LU%
MIMR\K<ZV-'9IJQX#M<T%V - ;]\PM&&RPY=G[R9ANJ0C61L=K%*11R*QHA)Q
M,+H:*T.Z7#R2:6YC*<[R9'WSB7Z;4S=L"'UHLZ"-T+JP"#9GY:B@$8;<4&"A
M-IG2M"U7B(4EI&(]3SFJ(WGT]U W;(#]R( \D-#Z]>A?C:=AFNYG)++:<=H:
M"&2CD$=J-3BA!<04D64R8-IGK&U/93?#*(_BT;<25P\7]C6#I':PI'V14;+N
M</7[E,3VFGXPI5W6 9_W5VO46X(L:<$T"P5!<$_[-M62=MH#5R[1?[U!W3I;
MK17M7<8 FF'L$0OT: +O#.@O<#[^&I:K1H#$TM.J.N[A]R@F$Y-("H2Q%I0/
M!5QT9(N7E+0TW@C6/'RU/9E=NOW'@.\AQ-@!4C?GZ,B&HG-2&5"2?:6*9,13
M#* 4,B<L1Y6.%.W?%9?'=NP/A<L#":T#D_5E*9C(LGKY+7T.TT_XGFRMMZM^
M#/7_JVOX-4QPE1E-?!PG\MSJ']#M<?,'UWYSQ(11+-2JIL(5W1UTBP1O$FAM
MF& F<<Y:YY(<8!O#!@D.9O0.+? .5/!>FUWWL+Z;(Y$FI[59['6VKED]BFB-
M\DF#3\J#0F$AE,A!2*;J!$4616L7[[@['#9Z<;"3TC%,.K@X]M,8,>KL,FV6
MB5R+:Y"V+02'K$R.CEE]IQ_8L&=BV/S#/B&^E1"[&1NTYTT7E; Z20BR'M+
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MB2FQ4U.0/0"VE9B.;-FQ*G]R@O:Q\N\ 2*_)%5O<(+['+[@,\W3;,\%8&9U
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M#EE#_?WMPA4MOE$#8C>3V+"[(X[#1U\'0L4]9Q8M\\L<5@<FSF!R@^SI1H6
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MBG\P@';9'PW:Y<7>4P*[//TV/7CR)(4'#YR8E#+<?-Q^YSK\(9?T8'1+>AK
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MCA0?)KN)*T&0"%G#;OS:;E]<0;!8\YI.A?P6C_(4P0Q>1.$!0EV' +6JABE
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MAV0M>&A5="JC,'$A\20YWP.F5G*),@BC&!F*?I@FD&R,ALFO#S%_8/"Z@_L
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M'73Q$*,0S@->%8@\VSPIF<#9)6L7)@$KN27I3[3US 6-4#XBKW'%S!3 T6X
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M"W>,7[*CD-Q\AL/DMAAGX$<X&=M8I* 47+F_PZ@W"PQ*=</9A.MSRMG#34!
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MC]R 4I=!XI,*$V,"&5RYDCUGM//X)DS,@J5I#(#V:1+P&R9<-8:BZ\@75],
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MA\S;.>QMY\F98!VE1(3Q/-@. ;+R*I(4$8KK4<$\.:BY6%5\T\FBRQ7=51Y
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MX5&JMT9MB/.<)3&4\Y.LT6KI6J*R*6.VCH.8$1UCA>U2R 5H$VS).1<\F!N
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M=17'I78 6%/01WJ=*&-QWYU2HB\3HZ/?P\D/VWVB20(D@\@>6%>.8^]$_O3
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M5TUXA'R4=K/),U_.5'_#=SS^BZ*3_P!02P,$%     @ =*P$55Z-WIH5"
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M,#(R,#8S,"YH=&U02P$"% ,4    " !TK 15EN@X*@L0  "WJ   $0
M        @ 'U- ( ;FMT<BTR,#(R,#8S,"YX<V102P$"% ,4    " !TK 15
MSGPH./8:  #5_P  %0              @ $O10( ;FMT<BTR,#(R,#8S,%]C
M86PN>&UL4$L! A0#%     @ =*P$53Y7U6+=/P  ?ZT" !4
M ( !6& " &YK='(M,C R,C V,S!?9&5F+GAM;%!+ 0(4 Q0    ( '2L!%5H
MT-__&JX  ,,:!P 5              "  6B@ @!N:W1R+3(P,C(P-C,P7VQA
M8BYX;6Q02P$"% ,4    " !TK 15%CM!*41E  "8@P0 %0
M@ &U3@, ;FMT<BTR,#(R,#8S,%]P<F4N>&UL4$L! A0#%     @ =*P$58/+
M(02250  >24" !X              ( !++0# &YK='(R,#(R+3 V>#,P>&5X
M>#$P,6%R,C Q+FAT;5!+ 0(4 Q0    ( '2L!%4YF [@F$$  .5R 0 >
M          "  ?H)! !N:W1R,C R,BTP-G@S,'AE>'@Q,#)N;W)T:"YH=&U0
M2P$"% ,4    " !TK 15?K?J*@4(  "L)   &0              @ '.2P0
M;FMT<C(P,C(M,#9X,S!X97AX,S$Q+FAT;5!+ 0(4 Q0    ( '2L!%5>C=Z:
M%0@  "HE   9              "  0I4! !N:W1R,C R,BTP-G@S,'AE>'@S
M,3(N:'1M4$L! A0#%     @ =*P$545-L.+V!0  318  !D
M ( !5EP$ &YK='(R,#(R+3 V>#,P>&5X>#,R,2YH=&U02P4&      L "P#W
) @  @V($

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
